0001023024-24-00008510-Q ANI PHARMACEUTICALS INC 20240806202408060657570657570657757 0 0001023024-24-000085 10-Q 86 20240630 20240806 20240806 ANI PHARMACEUTICALS INC 0001023024 2834 582301143 DE 1231 10-Q 34 001-31812 241177003 210 MAIN STREET WEST BAUDETTE MN 56623 2186343500 210 MAIN STREET WEST BAUDETTE MN 56623 BIOSANTE PHARMACEUTICALS INC 19991228 BEN ABRAHAM TECHNOLOGIES INC 19991027 10-Q 1 anip-20240630.htm 10-Q anip-20240630001023024December 312024Q2falseP7YP1YP3YP3YP3YP3YP3YP3YP3YP3YP3YP3YP3YP3Yhttp://fasb.org/us-gaap/2024#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1http://fasb.org/us-gaap/2024#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1http://fasb.org/us-gaap/2024#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesanip:facilityiso421 01-012024-06-300001023024us-gaap:CommonStockMember2024-07-300001023024anip:ClassCSpecialStockMember2024-07-300001023024anip:ClassCSpecialStockMember2024-06-300001023024anip:ClassCSpecialStockMember2023-12-310001023024us-gaap:ConvertiblePreferredStockMember2024-06-300001023024us-gaap:ConvertiblePreferredStockMember2023-12-310001023024us-gaap:CommonStockMember2023-12-310001023024us-gaap:CommonStockMember2024-06-300001023024anip:ClassCSpecialStockMember2024-06-300001023024anip:ClassCSpecialStockMember2023-12-310001023024anip:ClassCSpecialStockMember2024-04-012024-06-300001023024anip:ClassCSpecialStockMember2023-04-012023-06-300001023024anip:ClassCSpecialStockMember2023-01-012023-06-300001023024us-gaap:ConvertiblePreferredStockMember2023-03-310001023024us-gaap:CommonStockMember2023-03-310001023024us-gaap:AdditionalPaidInCapitalMember2023-03-310001023024us-gaap:TreasuryStockCommonMember2023-03-310001023024us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001023024us-gaap:RetainedEarningsMember2023-03-310001023024anip:ClassCSpecialStockMember2023-03-310001023024us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001023024us-gaap:TreasuryStockCommonMember2023-04-012023-06-300001023024us-gaap:CommonStockMember2023-04-012023-06-300001023024us-gaap:RetainedEarningsMember2023-04-012023-06-300001023024us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001023024us-gaap:ConvertiblePreferredStockMember2023-06-300001023024us-gaap:CommonStockMember2023-06-300001023024us-gaap:AdditionalPaidInCapitalMember2023-06-300001023024us-gaap:TreasuryStockCommonMember2023-06-300001023024us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001023024us-gaap:RetainedEarningsMember2023-06-300001023024us-gaap:ConvertiblePreferredStockMember2024-03-310001023024us-gaap:CommonStockMember2024-03-310001023024us-gaap:AdditionalPaidInCapitalMember2024-03-310001023024us-gaap:TreasuryStockCommonMember2024-03-310001023024us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001023024us-gaap:RetainedEarningsMember2024-03-310001023024us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001023024us-gaap:TreasuryStockCommonMember2024-04-012024-06-300001023024us-gaap:CommonStockMember2024-04-012024-06-300001023024us-gaap:RetainedEarningsMember2024-04-012024-06-300001023024us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001023024us-gaap:CommonStockMember2024-06-300001023024us-gaap:AdditionalPaidInCapitalMember2024-06-300001023024us-gaap:TreasuryStockCommonMember2024-06-300001023024us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001023024us-gaap:RetainedEarningsMember2024-06-300001023024us-gaap:ConvertiblePreferredStockMember2022-12-310001023024us-gaap:CommonStockMember2022-12-310001023024us-gaap:AdditionalPaidInCapitalMember2022-12-310001023024us-gaap:TreasuryStockCommonMember2022-12-310001023024us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001023024us-gaap:RetainedEarningsMember2022-12-310001023024us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001023024us-gaap:TreasuryStockCommonMember2023-01-012023-06-300001023024us-gaap:CommonStockMember2023-01-012023-06-300001023024us-gaap:RetainedEarningsMember2023-01-012023-06-300001023024us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300001023024us-gaap:CommonStockMember2023-12-310001023024us-gaap:AdditionalPaidInCapitalMember2023-12-310001023024us-gaap:TreasuryStockCommonMember2023-12-310001023024us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001023024us-gaap:RetainedEarningsMember2023-12-310001023024us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300001023024us-gaap:TreasuryStockCommonMember2024-01-012024-06-300001023024us-gaap:CommonStockMember2024-01-012024-06-300001023024us-gaap:RetainedEarningsMember2024-01-012024-06-300001023024us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-06-300001023024us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberanip:OakvilleOntarioFormerManufacturingFacilityMember2024-02-160001023024anip:SalesOfGenericPharmaceuticalProductsMember2024-04-012024-06-300001023024anip:SalesOfGenericPharmaceuticalProductsMember2023-04-012023-06-300001023024anip:SalesOfGenericPharmaceuticalProductsMember2024-01-012024-06-300001023024anip:SalesOfGenericPharmaceuticalProductsMember2023-01-012023-06-300001023024anip:SalesOfBrandedRoyaltiesAndOtherPharmaceuticalServicesMember2024-04-012024-06-300001023024anip:SalesOfBrandedRoyaltiesAndOtherPharmaceuticalServicesMember2023-04-012023-06-300001023024anip:SalesOfBrandedRoyaltiesAndOtherPharmaceuticalServicesMember2024-01-012024-06-300001023024anip:SalesOfBrandedRoyaltiesAndOtherPharmaceuticalServicesMember2023-01-012023-06-300001023024anip:SalesOfRareDiseasePharmaceuticalProductsMember2024-04-012024-06-300001023024anip:SalesOfRareDiseasePharmaceuticalProductsMember2023-04-012023-06-300001023024anip:SalesOfRareDiseasePharmaceuticalProductsMember2024-01-012024-06-300001023024anip:SalesOfRareDiseasePharmaceuticalProductsMember2023-01-012023-06-300001023024us-gaap:TransferredAtPointInTimeMember2024-04-012024-06-300001023024us-gaap:TransferredAtPointInTimeMember2023-04-012023-06-300001023024us-gaap:TransferredAtPointInTimeMember2024-01-012024-06-300001023024us-gaap:TransferredAtPointInTimeMember2023-01-012023-06-300001023024us-gaap:TransferredOverTimeMember2024-04-012024-06-300001023024us-gaap:TransferredOverTimeMember2023-04-012023-06-300001023024us-gaap:TransferredOverTimeMember2024-01-012024-06-300001023024us-gaap:TransferredOverTimeMember2023-01-012023-06-300001023024anip:SalesOfContractManufactureProductsMember2024-06-300001023024anip:SalesOfContractManufacturedProductsMember2024-06-300001023024anip:ChargebacksMember2022-12-310001023024anip:GovernmentRebatesMember2022-12-310001023024anip:AllowancesForSalesReturnsMember2022-12-310001023024anip:AdministrativeFeesAndOtherRebatesMember2022-12-310001023024anip:ReservesForCashDiscountMember2022-12-310001023024anip:ChargebacksMember2023-01-012023-06-300001023024anip:GovernmentRebatesMember2023-01-012023-06-300001023024anip:AllowancesForSalesReturnsMember2023-01-012023-06-300001023024anip:AdministrativeFeesAndOtherRebatesMember2023-01-012023-06-300001023024anip:ReservesForCashDiscountMember2023-01-012023-06-300001023024anip:ChargebacksMember2023-06-300001023024anip:GovernmentRebatesMember2023-06-300001023024anip:AllowancesForSalesReturnsMember2023-06-300001023024anip:AdministrativeFeesAndOtherRebatesMember2023-06-300001023024anip:ReservesForCashDiscountMember2023-06-300001023024anip:ChargebacksMember2023-12-310001023024anip:GovernmentRebatesMember2023-12-310001023024anip:AllowancesForSalesReturnsMember2023-12-310001023024anip:AdministrativeFeesAndOtherRebatesMember2023-12-310001023024anip:ReservesForCashDiscountMember2023-12-310001023024anip:ChargebacksMember2024-01-012024-06-300001023024anip:GovernmentRebatesMember2024-01-012024-06-300001023024anip:AllowancesForSalesReturnsMember2024-01-012024-06-300001023024anip:AdministrativeFeesAndOtherRebatesMember2024-01-012024-06-300001023024anip:ReservesForCashDiscountMember2024-01-012024-06-300001023024anip:ChargebacksMember2024-06-300001023024anip:GovernmentRebatesMember2024-06-300001023024anip:AllowancesForSalesReturnsMember2024-06-300001023024anip:AdministrativeFeesAndOtherRebatesMember2024-06-300001023024anip:ReservesForCashDiscountMember2024-06-300001023024anip:FourCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001023024anip:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-04-012024-06-300001023024anip:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-04-012023-06-300001023024anip:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-06-300001023024anip:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-06-300001023024anip:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-04-012024-06-300001023024anip:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-04-012023-06-300001023024anip:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-06-300001023024anip:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-06-300001023024anip:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-04-012024-06-300001023024anip:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-04-012023-06-300001023024anip:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-06-300001023024anip:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-06-300001023024anip:CustomerFourMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-04-012024-06-300001023024anip:CustomerFourMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-04-012023-06-300001023024anip:CustomerFourMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-06-300001023024anip:CustomerFourMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-06-300001023024anip:AlimeraSciencesIncMember2024-06-210001023024anip:AlimeraSciencesIncMemberanip:MilestonePaymentsMember2024-06-210001023024anip:AlimeraSciencesIncMemberanip:A2026MilestonePaymentMember2024-06-212024-06-210001023024anip:AlimeraSciencesIncMemberanip:A2026MilestonePaymentMember2024-06-210001023024anip:AlimeraSciencesIncMemberanip:A2027MilestonePaymentMember2024-06-212024-06-210001023024anip:AlimeraSciencesIncMemberanip:A2027MilestonePaymentMember2024-06-210001023024anip:AlimeraSciencesIncMember2024-06-212024-06-210001023024anip:JPMorganChaseBankN.A.AndBlackstoneCreditInsuranceMemberanip:AlimeraSciencesIncMember2024-06-210001023024anip:AlimeraSciencesIncMember2024-04-012024-06-300001023024anip:AlimeraSciencesIncMember2024-01-012024-06-300001023024anip:OakvilleOntarioCanadaMember2024-04-012024-06-300001023024anip:OakvilleOntarioCanadaMember2024-01-012024-06-300001023024anip:OakvilleOntarioCanadaMember2024-06-300001023024anip:OakvilleOntarioCanadaMember2023-04-012023-06-300001023024anip:OakvilleOntarioCanadaMember2023-01-012023-06-300001023024us-gaap:EmployeeSeveranceMemberanip:OakvilleOntarioCanadaMember2023-01-012023-06-300001023024anip:OakvilleOntarioCanadaMemberus-gaap:FacilityClosingMember2023-01-012023-06-300001023024us-gaap:OtherRestructuringMemberanip:OakvilleOntarioCanadaMember2023-01-012023-06-300001023024anip:OakvilleOntarioCanadaMember2023-12-310001023024us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberanip:OakvilleOntarioFormerManufacturingFacilityMember2024-03-282024-03-280001023024us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberanip:OakvilleOntarioFormerManufacturingFacilityMember2024-03-280001023024anip:CreditAgreementMemberanip:TermLoanMember2021-11-190001023024anip:CreditAgreementMemberus-gaap:LineOfCreditMember2021-11-190001023024anip:CreditAgreementMemberus-gaap:LineOfCreditMember2024-06-300001023024anip:CreditAgreementMemberanip:TermLoanMember2024-06-300001023024anip:CreditAgreementMember2021-11-192021-11-190001023024anip:CreditAgreementMemberus-gaap:LineOfCreditMember2021-11-192021-11-190001023024anip:TermLoanAndDelayedDrawTermLoanMember2024-06-300001023024anip:TermLoanAndDelayedDrawTermLoanMember2023-12-310001023024anip:TermLoanMember2024-06-300001023024us-gaap:InterestRateSwapMember2021-11-210001023024us-gaap:InterestRateSwapMember2024-06-300001023024us-gaap:InterestRateSwapMember2024-01-012024-06-300001023024us-gaap:InterestRateSwapMember2024-04-012024-06-300001023024us-gaap:InterestRateSwapMember2023-04-012023-06-300001023024us-gaap:InterestRateSwapMember2023-01-012023-06-300001023024us-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMemberanip:OneSupplierMember2024-04-012024-06-300001023024us-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMemberanip:OneSupplierMember2024-01-012024-06-300001023024anip:BioSantePharmaceuticalsMember2013-01-012013-12-310001023024anip:WellSpringPharmaServicesIncMember2018-01-012018-12-310001023024anip:NovitiumPharmaMember2021-01-012021-12-310001023024anip:AcquiredAndaIntangibleAssetsMember2024-06-300001023024anip:AcquiredAndaIntangibleAssetsMember2023-12-310001023024anip:ProductRightsMember2024-06-300001023024anip:ProductRightsMember2023-12-310001023024anip:MarketingAndDistributionRightsMember2024-06-300001023024anip:MarketingAndDistributionRightsMember2023-12-310001023024us-gaap:CustomerRelationshipsMember2024-06-300001023024us-gaap:CustomerRelationshipsMember2023-12-310001023024us-gaap:InProcessResearchAndDevelopmentMember2024-06-300001023024us-gaap:InProcessResearchAndDevelopmentMember2023-12-310001023024srt:MinimumMember2024-06-300001023024srt:MaximumMember2024-06-300001023024anip:ClassCSpecialStockMember2024-06-300001023024anip:ClassCSpecialStockMember2023-12-310001023024us-gaap:ConvertiblePreferredStockMemberanip:PrivateInvestmentInPublicEquityMember2021-11-192021-11-190001023024us-gaap:ConvertiblePreferredStockMemberanip:PrivateInvestmentInPublicEquityMember2021-11-190001023024us-gaap:ConvertiblePreferredStockMemberanip:PrivateInvestmentInPublicEquityMember2024-06-300001023024anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember2024-06-300001023024anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember2024-01-012024-06-300001023024anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-04-012024-06-300001023024anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-04-012023-06-300001023024anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-06-300001023024anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-06-300001023024us-gaap:CostOfSalesMemberanip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember2024-04-012024-06-300001023024us-gaap:CostOfSalesMemberanip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember2023-04-012023-06-300001023024us-gaap:CostOfSalesMemberanip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember2024-01-012024-06-300001023024us-gaap:CostOfSalesMemberanip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember2023-01-012023-06-300001023024us-gaap:ResearchAndDevelopmentExpenseMemberanip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember2024-04-012024-06-300001023024us-gaap:ResearchAndDevelopmentExpenseMemberanip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember2023-04-012023-06-300001023024us-gaap:ResearchAndDevelopmentExpenseMemberanip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember2024-01-012024-06-300001023024us-gaap:ResearchAndDevelopmentExpenseMemberanip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember2023-01-012023-06-300001023024anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember2024-04-012024-06-300001023024anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember2023-04-012023-06-300001023024anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember2023-01-012023-06-300001023024us-

gaap:SubsequentEventMemberanip:StockIncentivePlanMember2024-07-122024-07-120001023024anip:StockIncentivePlanMember2024-06-300001023024anip:EmployeesAndConsultantsMemberus-gaap:EmployeeStockOptionMember2024-01-012024-06-300001023024srt:MinimumMemberanip:NonEmployeeDirectorStockOptionMemberus-gaap:EmployeeStockOptionMember2024-01-012024-06-300001023024srt:MaximumMemberanip:NonEmployeeDirectorStockOptionMemberus-gaap:EmployeeStockOptionMember2024-01-012024-06-300001023024anip:NonEmployeeDirectorStockOptionMemberus-gaap:EmployeeStockOptionMember2024-01-012024-06-300001023024us-gaap:EmployeeStockOptionMember2024-06-300001023024us-gaap:RestrictedStockMemberanip:EmployeesAndConsultantsMember2024-01-012024-06-300001023024us-gaap:RestrictedStockMemberanip:NonEmployeeDirectorStockOptionMember2024-01-012024-06-300001023024anip:PerformanceBasedRestrictedStockUnitsMember2024-01-012024-06-300001023024anip:MarketPerformanceBasedRestrictedStockUnitsMember2024-06-300001023024anip:MarketPerformanceBasedRestrictedStockUnitsMember2024-01-012024-06-300001023024anip:MarketPerformanceBasedRestrictedStockUnitsMember2023-02-280001023024anip:MarketPerformanceBasedRestrictedStockUnitsMember2023-02-282023-02-280001023024anip:PerformanceBasedRestrictedStockUnitsMember2024-06-300001023024anip:PerformanceBasedRestrictedStockUnitsMember2023-02-280001023024anip:PerformanceBasedRestrictedStockUnitsMember2023-02-282023-02-280001023024us-gaap:PerformanceSharesMember2024-02-142024-02-140001023024srt:OfficerMemberus-gaap:PerformanceSharesMember2024-02-142024-02-140001023024anip:MarketPerformanceBasedRestrictedStockUnitsMember2024-02-142024-02-140001023024anip:PerformanceBasedRestrictedStockUnitsMember2024-02-142024-02-140001023024us-gaap:SellingGeneralAndAdministrativeExpensesMemberanip:StockIncentivePlanMember2024-04-012024-06-300001023024us-gaap:SellingGeneralAndAdministrativeExpensesMemberanip:StockIncentivePlanMember2023-04-012023-06-300001023024us-gaap:CostOfSalesMemberanip:StockIncentivePlanMember2024-01-012024-06-300001023024us-gaap:CostOfSalesMemberanip:StockIncentivePlanMember2023-01-012023-06-300001023024us-gaap:ResearchAndDevelopmentExpenseMemberanip:StockIncentivePlanMember2024-04-012024-06-300001023024us-gaap:ResearchAndDevelopmentExpenseMemberanip:StockIncentivePlanMember2023-04-012023-06-300001023024us-gaap:ResearchAndDevelopmentExpenseMemberanip:StockIncentivePlanMember2024-01-012024-06-300001023024us-gaap:ResearchAndDevelopmentExpenseMemberanip:StockIncentivePlanMember2023-01-012023-06-300001023024us-gaap:CostOfSalesMemberanip:StockIncentivePlanMember2024-04-012024-06-300001023024us-gaap:CostOfSalesMemberanip:StockIncentivePlanMember2023-04-012023-06-300001023024us-gaap:SellingGeneralAndAdministrativeExpensesMemberanip:StockIncentivePlanMember2024-01-012024-06-300001023024us-gaap:SellingGeneralAndAdministrativeExpensesMemberanip:StockIncentivePlanMember2023-01-012023-06-300001023024anip:StockIncentivePlanMember2024-04-012024-06-300001023024anip:StockIncentivePlanMember2023-04-012023-06-300001023024anip:StockIncentivePlanMember2024-01-012024-06-300001023024anip:StockIncentivePlanMember2023-01-012023-06-300001023024us-gaap:EmployeeStockOptionMember2022-12-310001023024us-gaap:PerformanceSharesMember2022-12-310001023024us-gaap:RestrictedStockMember2022-12-310001023024us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001023024us-gaap:PerformanceSharesMember2023-01-012023-06-300001023024us-gaap:RestrictedStockMember2023-01-012023-06-300001023024us-gaap:EmployeeStockOptionMember2023-06-300001023024us-gaap:PerformanceSharesMember2023-06-300001023024us-gaap:RestrictedStockMember2023-06-300001023024us-gaap:EmployeeStockOptionMember2023-12-310001023024us-gaap:PerformanceSharesMember2023-12-310001023024us-gaap:RestrictedStockMember2023-12-310001023024us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001023024us-gaap:PerformanceSharesMember2024-01-012024-06-300001023024us-gaap:RestrictedStockMember2024-01-012024-06-300001023024us-gaap:PerformanceSharesMember2024-06-300001023024us-gaap:RestrictedStockMember2024-06-3000010230242023-04-300001023024anip:UnapprovedProductsMember2024-04-012024-06-300001023024anip:UnapprovedProductsMember2024-01-012024-06-300001023024anip:UnapprovedProductsMember2023-04-012023-06-300001023024anip:UnapprovedProductsMember2023-01-012023-06-300001023024anip:ProductIntellectualPropertyMemberanip:AlvogenIncMember2023-12-272023-12-270001023024anip:UnapprovedProductsMemberanip:ContractCustomerMember2024-01-012024-06-300001023024anip:UnapprovedProductsMemberanip:ContractCustomerMember2024-04-012024-06-300001023024anip:UnapprovedProductsMemberanip:ContractCustomerMember2023-04-012023-06-300001023024anip:UnapprovedProductsMemberanip:ContractCustomerMember2023-01-012023-06-300001023024anip:NovitiumMember2023-12-012023-12-310001023024anip:NovitiumPharmaMember2024-06-280001023024anip:NovitiumPharmaMember2024-06-300001023024anip:NovitiumPharmaMember2023-12-122023-12-120001023024anip:NovitiumPharmaMember2024-02-222024-02-220001023024us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMemberanip:ProfitBasedMilestonePaymentsMember2024-06-300001023024us-gaap:FairValueInputsLevel1Member2024-06-300001023024us-gaap:FairValueInputsLevel2Member2024-06-300001023024us-gaap:FairValueInputsLevel3Member2024-06-300001023024us-gaap:FairValueInputsLevel1Memberanip:NovitiumPharmaMember2024-06-300001023024us-gaap:FairValueInputsLevel2Memberanip:NovitiumPharmaMember2024-06-300001023024us-gaap:FairValueInputsLevel3Memberanip:NovitiumPharmaMember2024-06-300001023024us-gaap:FairValueInputsLevel1Member2023-12-310001023024us-gaap:FairValueInputsLevel2Member2023-12-310001023024us-gaap:FairValueInputsLevel3Member2023-12-310001023024anip:NovitiumPharmaMember2023-12-310001023024us-gaap:FairValueInputsLevel1Memberanip:NovitiumPharmaMember2023-12-310001023024us-gaap:FairValueInputsLevel2Memberanip:NovitiumPharmaMember2023-12-310001023024us-gaap:FairValueInputsLevel3Memberanip:NovitiumPharmaMember2023-12-310001023024us-gaap:ConvertiblePreferredStockMemberanip:PrivateInvestmentInPublicEquityMember2021-03-082021-03-080001023024us-gaap:ConvertiblePreferredStockMemberanip:PrivateInvestmentInPublicEquityMember2021-03-080001023024us-gaap:RelatedPartyMemberanip:ScitusPharmaServicesMember2024-04-012024-06-300001023024us-gaap:RelatedPartyMemberanip:ScitusPharmaServicesMember2023-04-012023-06-300001023024us-gaap:RelatedPartyMemberanip:ScitusPharmaServicesMember2024-01-012024-06-300001023024us-gaap:RelatedPartyMemberanip:ScitusPharmaServicesMember2023-01-012023-06-300001023024anip:SsPharmaLlcMemberus-gaap:RelatedPartyMember2024-04-012024-06-300001023024anip:SsPharmaLlcMemberus-gaap:RelatedPartyMember2023-04-012023-06-300001023024anip:SsPharmaLlcMemberus-gaap:RelatedPartyMember2024-01-012024-06-300001023024anip:SsPharmaLlcMemberus-gaap:RelatedPartyMember2023-01-012023-06-300001023024us-gaap:RelatedPartyMemberanip:SThreeChemicalsPvtLtdMember2024-04-012024-06-300001023024us-gaap:RelatedPartyMemberanip:SThreeChemicalsPvtLtdMember2023-04-012023-06-300001023024us-gaap:RelatedPartyMemberanip:SThreeChemicalsPvtLtdMember2024-01-012024-06-300001023024us-gaap:RelatedPartyMemberanip:SThreeChemicalsPvtLtdMember2023-01-012023-06-300001023024us-gaap:RelatedPartyMember2024-04-012024-06-300001023024us-gaap:RelatedPartyMember2023-04-012023-06-300001023024us-gaap:RelatedPartyMember2024-01-012024-06-300001023024us-gaap:RelatedPartyMember2023-01-012023-06-300001023024us-gaap:RelatedPartyMemberanip:ScitusPharmaServicesMember2024-06-300001023024us-gaap:RelatedPartyMemberanip:SThreeChemicalsPvtLtdMember2024-06-300001023024us-gaap:RelatedPartyMemberanip:EsjayPharmaLlcMember2024-06-300001023024anip:SsPharmaLlcMemberus-gaap:RelatedPartyMember2024-06-300001023024us-gaap:RelatedPartyMemberanip:Mr.ShanmugamAndEsjayMemberanip:NovitiumPharmaMember2023-12-122023-12-120001023024us-gaap:RelatedPartyMemberanip:ChaliPropertiesLLCMemberanip:NovitiumPharmaMember2023-12-122023-12-120001023024us-gaap:RelatedPartyMemberanip:Mr.ShanmugamAndEsjayMemberanip:NovitiumPharmaMember2024-02-292024-02-290001023024us-gaap:RelatedPartyMemberanip:ChaliPropertiesLLCMemberanip:NovitiumPharmaMember2024-02-292024-02-290001023024us-gaap:OperatingSegmentsMemberanip:GenericsEstablishedBrandsAndOtherMember2024-04-012024-06-300001023024us-gaap:OperatingSegmentsMemberanip:GenericsEstablishedBrandsAndOtherMember2023-04-012023-06-300001023024us-gaap:OperatingSegmentsMemberanip:GenericsEstablishedBrandsAndOtherMember2024-01-012024-06-300001023024us-gaap:OperatingSegmentsMemberanip:GenericsEstablishedBrandsAndOtherMember2023-01-012023-06-300001023024us-gaap:OperatingSegmentsMemberanip:RareDiseaseMember2024-04-012024-06-300001023024us-gaap:OperatingSegmentsMemberanip:RareDiseaseMember2023-04-012023-06-300001023024us-gaap:OperatingSegmentsMemberanip:RareDiseaseMember2024-01-012024-06-300001023024us-gaap:OperatingSegmentsMemberanip:RareDiseaseMember2023-01-012023-06-300001023024us-gaap:CorporateNonSegmentMember2024-04-012024-06-300001023024us-gaap:CorporateNonSegmentMember2023-04-012023-06-300001023024us-gaap:CorporateNonSegmentMember2024-01-012024-06-300001023024us-gaap:CorporateNonSegmentMember2023-01-012023-06-300001023024country:US2024-04-012024-06-300001023024country:US2023-04-012023-06-300001023024country:US2024-01-012024-06-300001023024country:US2023-01-012023-06-300001023024country:CA2024-04-012024-06-300001023024country:CA2023-04-012023-06-300001023024country:CA2024-01-012024-06-300001023024country:CA2023-01-012023-06-300001023024country:CA2023-12-310001023024country:US2024-06-300001023024country:US2023-12-310001023024country:IN2024-06-300001023024country:IN2023-12-31

Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORM 10-QxQUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended June 30, 2024oTRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from Â to Â .Commission File Number 001-31812ANI PHARMACEUTICALS, INC.(Exact name of registrant as specified in its charter)Delaware58-2301143(State or other jurisdiction of incorporation or organization) (IS EmployerIdentification Number)210 Main Street WestBaudette, Minnesota 56623(Address of principal executive offices)(218) 634-3500(Registrantâ€™s telephone number including area code)Securities registered pursuant to Section 12(b) of the Act:Title of each class:Trading Symbol(s)Name of each exchange on which registered:Common StockANIPNasdaq Global MarketIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No oIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No oIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Large accelerated filerxAccelerated fileroNon-accelerated fileroSmaller reporting companyoEmerging growth companyoIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. oIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No xAs of JulyÂ 30, 2024 there were 21,030,069 shares of common stock and 10,864 shares of class C special stock of the registrant outstanding.Table of ContentsANI PHARMACEUTICALS, INC.FORM 10-Q â€” Quarterly ReportFor the Quarterly Period Ended June 30, 2024TABLE OF CONTENTSPagePART I â€”FINANCIAL INFORMATIONItem 1.Condensed Consolidated Financial Statements (unaudited)5Condensed Consolidated Balance Sheets â€” As of June 30, 2024 and December 31, 20235Condensed Consolidated Statements of Operations â€” For the Three and Six Months Ended June 30, 2024 and 20236Condensed Consolidated Statements of Comprehensive (Loss) Income â€” For the Three and Six Months Ended June 30, 2024 and 20237Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholdersâ€™ Equity â€” For the Three and Six Months Ended June 30, 2024 and 20238Condensed Consolidated Statements of Cash Flows â€” For the Six Months Ended June 30, 2024 and 202310Notes to Condensed Consolidated Financial Statements11Item 2.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations37Item 3.Quantitative and Qualitative Disclosures About Market Risk50Item 4.Controls and Procedures50PART II â€”OTHER INFORMATIONItem 1.Legal Proceedings51Item 1A.Risk Factors51Item 2.Unregistered Sales of Equity Securities and Use of Proceeds56Item 3.Defaults upon Senior Securities56Item 4.Mine Safety Disclosures56Item 5.Other Information56Item 6.Exhibits56Signatures582Table of ContentsCAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTSThis Quarterly Report on Form 10-Q and certain information incorporated herein by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the â€œSecurities Actâ€), and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). Such statements include, but are not limited to, statements about future operations, strategies and growth potential, the revenue potential (licensing, royalty and sales) of products we sell, development timelines, expected timeframe for submission of new drug applications, abbreviated new drug applications, or supplemental new drug applications to the U.S. Food and Drug Administration (the â€œFDAâ€), pipeline or potential markets for our products, selling and marketing strategies and associated costs to support the sales of Purified CortrophinÂ® Gel (Repository Corticotropin Injection USP) (â€œCortrophin Gelâ€), the announcement and pendency of the acquisition of Alimera Sciences, Inc. (â€œAlimeraâ€), impact of accounting principles, litigation expenses, liquidity and capital resources, the impact of global pandemics on our business, and other statements that are not historical in nature, particularly those that utilize terminology such as â€œanticipates,â€ â€œwill,â€ â€œexpects,â€ â€œplans,â€ â€œpotential,â€ â€œfuture,â€ â€œbelieves,â€ â€œintends,â€ â€œcontinue,â€ other words of similar meaning, derivations of such words, and the use of future dates. Such forward-looking statements are based on the reasonable beliefs of our management as well as assumptions made by and information currently available to our management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified; therefore, our actual results may differ materially from those described in any forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in our periodic reports filed with the U.S. Securities and Exchange Commission (the â€œSECâ€), including those discussed in the â€œRisk Factorsâ€ section in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023 and the following factors:â€¢our ability to continue to achieve commercial success with Cortrophin Gel, our first rare disease pharmaceutical product, including expanding the market and gaining market share, our business, financial condition, and results of operations will be negatively impacted;â€¢the ability of our approved products, including Cortrophin Gel, to achieve commercialization at levels of market acceptance that will continue to allow us to achieve profitability;â€¢our ability to complete or achieve any, or all of the intended benefits of acquisitions and investments, including the pending acquisition of Alimera, in a timely manner or at all;â€¢the risks that our acquisitions and investments, including the pending acquisition of Alimera, could disrupt our business and harm our financial position and operating results;â€¢delays in production, increased costs and potential loss of revenues if we need to change suppliers due to the limited number of suppliers for our raw materials, active pharmaceutical ingredients (â€œAPIâ€), expedients, and other materials;â€¢our reliance on single source third party contract manufacturing supply for certain of our key products, including Cortrophin Gel, and post consummation of the acquisition, for Alimera's products;â€¢delays or failure in obtaining and maintaining approvals by the FDA of the products we sell;â€¢changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration, and other regulatory agencies, including among other things, drug recalls, regulatory approvals, facility inspections and potential enforcement actions;â€¢our ability to develop, license or acquire, and commercialize new products;â€¢the level of competition we face and the legal, regulatory and/or legislative strategies employed by our competitors to prevent or delay competition from generic alternatives to branded products;â€¢our ability to protect our intellectual property rights;â€¢the impact of legislative or regulatory reform on the pricing for pharmaceutical products;â€¢the impact of any litigation to which we are, or may become, a party;â€¢our ability, and that of our suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries;â€¢our ability to maintain the services of our key executives and other personnel; andâ€¢general business and economic conditions, such as inflationary pressures, geopolitical conditions including, but not limited to, the conflict between Russia and the Ukraine, the conflict

between Israel and Gaza, conflicts related to the attacks on cargo ships in the Red Sea, and the effects and duration of outbreaks of public health emergencies.3Table of ContentsThese factors should not be construed as exhaustive and should be read in conjunction with our other disclosures, including but not limited to our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, including the factors described in â€œItem 1A. Risk Factors.â€ Other risks may be described from time to time in our filings made under the securities laws, including our quarterly reports on Form 10-Q and our current reports on Form 8-K. New risks emerge from time to time. It is not possible for our management to predict all risks. The forward-looking statements contained in this document are made only as of the date of this document. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.The Company may use its investor relations website as a distribution channel of material company information. Financial and other important information regarding the Company is routinely posted on and accessible through the Companyâ€™s investor relations website. We encourage investors and others interested in our Company to review the information we post on our investor relations website in addition to filings with the SEC, press releases, public conference calls and webcasts. Information contained on the Companyâ€™s website is not included as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.4Table of ContentsPart I â€” FINANCIAL INFORMATIONItem 1.Â Â Â Â Condensed Consolidated Financial Statements (unaudited)ANI PHARMACEUTICALS, INC. AND SUBSIDIARIESCondensed Consolidated Balance Sheets(in thousands, except share and per share amounts)(unaudited)Assets June 30,2024December 31,2023Current AssetsCash and cash equivalents$240,110Â $221,121Â Accounts receivable, net of $102,784 and $97,262 of adjustments for chargebacks and other allowances at JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively166,091Â 162,079Â Inventories125,448Â 111,196Â Prepaid income taxes2,867Â â€”Â Assets held for saleâ€”Â 8,020Â Prepaid expenses and other current assets14,001Â 17,400Â Investment in equity securities6,943Â â€”Â Total Current Assets555,460Â 519,816Â Non-current AssetsProperty and equipment, net51,640Â 44,593Â Deferred tax assets, net of deferred tax liabilities and valuation allowance89,506Â 90,711Â Intangible assets, net183,078Â 209,009Â Goodwill28,221Â 28,221Â Derivatives and other non-current assets12,848Â 12,072Â Total Assets$920,753Â $904,422Â Liabilities, Mezzanine Equity, and Stockholdersâ€™ EquityCurrent LiabilitiesCurrent debt, net of deferred financing costs$850Â $850Â Accounts payable48,681Â 36,683Â Accrued royalties20,357Â 16,276Â Accrued compensation and related expenses16,111Â 23,786Â Accrued government rebates12,324Â 12,168Â Income taxes payableâ€”Â 8,164Â Returned goods reserve33,897Â 29,678Â Current contingent consideration841Â 12,266Â Accrued expenses and other6,917Â 5,606Â Total Current Liabilities139,978Â 145,477Â Non-current LiabilitiesNon-current debt, net of deferred financing costs and current component284,394Â 284,819Â Non-current contingent consideration11,092Â 11,718Â Other non-current liabilities4,679Â 4,809Â Total Liabilities$440,143Â $446,823Â Commitments and Contingencies (Note 13)Mezzanine EquityConvertible Preferred Stock, Series A, $0.0001 par value, 1,666,667 shares authorized; 25,000 shares issued and outstanding at JuneÂ 30, 2024 and DecemberÂ 31, 202324,850Â 24,850Â Stockholdersâ€™ EquityCommon Stock, $0.0001 par value, 33,333,334 shares authorized; 21,476,115 shares issued and 21,063,528 outstanding at JuneÂ 30, 2024; 20,730,896 shares issued and 20,466,953 shares outstanding at DecemberÂ 31, 20232Â 2Â Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectivelyâ€”Â â€”Â Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectivelyâ€”Â â€”Â Treasury stock, 412,587 shares of common stock, at cost, at JuneÂ 30, 2024 and 263,943 shares of common stock, at cost, at DecemberÂ 31, 2023(20,042)(10,081)Additional paid-in capital532,497Â 514,103Â Accumulated deficit(65,025)(80,132)Accumulated other comprehensive income, net of tax8,328Â 8,857Â Total Stockholdersâ€™ Equity455,760Â 432,749Â Total Liabilities, Mezzanine Equity, and Stockholdersâ€™ Equity$920,753Â $904,422Â The accompanying notes are an integral part of these condensed consolidated financial statements.5ANI PHARMACEUTICALS, INC. AND SUBSIDIARIESCondensed Consolidated Statements of Operations(in thousands, except per share amounts)(unaudited)Three Months Ended June 30,Six Months Ended June 30,2024202320242023Net Revenues$138,040Â $116,547Â $275,470Â $223,333Â Operating ExpensesCost of sales (excluding depreciation and amortization)57,698Â 42,284Â 106,855Â 79,992Â Research and development7,296Â 7,374Â 17,807Â 13,298Â Selling, general, and administrative52,821Â 38,760Â 100,842Â 75,228Â Depreciation and amortization14,697Â 14,690Â 29,383Â 29,390Â Contingent consideration fair value adjustment359Â 1,035Â 449Â 1,996Â Restructuring activitiesâ€”Â 2Â â€”Â 1,132Â Gain on sale of building â€”Â â€”Â (5,347)â€”Â Total Operating Expenses, net132,871Â 104,145Â 249,989Â 201,036Â Operating Income 5,169Â 12,402Â 25,481Â 22,297Â Other Income (Expense), netÂ Â Unrealized (loss) gain on investment in equity securities (2,712)â€”Â 6,943Â â€”Â Interest expense, net(4,656)(7,100)(9,256)(14,796)Other expense, net(88)(53)(120)(87)(Loss) Income Before Income Tax Expense (Benefit) (2,287)5,249Â 23,048Â 7,414Â Income tax expense (benefit)â€”Â (996)7,128Â (270)Net (Loss) Income $(2,287)$6,245Â $15,920Â $7,684Â Dividends on Series A Convertible Preferred Stock(407)(407)(813)(813)Net (Loss) Income Available to Common Shareholders$(2,694)$5,838Â $15,107Â $6,871Â Basic and Diluted (Loss) Income Per Share:Basic (Loss) Income Per Share(0.14)0.30Â $0.71Â $0.36Â Diluted (Loss) Income Per Share(0.14)0.29Â $0.70Â $0.36Â Basic Weighted-Average Shares Outstanding19,32117,68819,21017,044Diluted Weighted-Average Shares Outstanding19,32117,85519,56117,177The accompanying notes are an integral part of these condensed consolidated financial statements.6ANI PHARMACEUTICALS, INC. AND SUBSIDIARIESCondensed Consolidated Statements of Comprehensive (Loss) Income(in thousands)(unaudited)Three Months Ended June 30,Six Months Ended June 30,2024202320242023Net (Loss) Income $(2,287)$6,245Â $15,920Â $7,684Â Other comprehensive (loss) income, net of tax:Â Â Foreign currency translation adjustment(12)(17)(109)90Â (Loss) Gain on interest rate swap(1,066)2,612Â (420)1,469Â Total other comprehensive (loss) income, net of tax(1,078)2,595Â (529)1,559Â Total comprehensive (loss) income, net of tax$(3,365)$8,840Â $15,391Â $9,243Â The accompanying notes are an integral part of these condensed consolidated financial statements.7ANI PHARMACEUTICALS, INC. AND SUBSIDIARIESCondensed Consolidated Statements of Changes in Mezzanine Equity and Stockholdersâ€™ EquityFor the Three Months Ended June 30, 2024 and 2023(in thousands)(unaudited)Mezzanine EquitySeries A Convertible PreferredStockMezzanine EquitySeries A Convertible Preferred StockSharesCommonStockPar ValueCommonStockSharesClass CSpecialStockAdditionalPaid-inCapitalTreasuryStockSharesTreasuryStockAccumulated OtherComprehensive Income,Net of TaxAccumulatedDeficitTotal MezzanineEquity andStockholdersâ€™EquityBalance, March 31, 2023$24,850Â 25$1Â 18,226$â€”Â $408,395Â 234$(8,643)$11,131Â $(96,252)339,482Â Stock-based Compensation Expenseâ€”Â â€”â€”Â â€”â€”Â 5,249Â â€”â€”Â â€”Â 5,249Â Treasury Stock Purchases for Restricted Stock Vestsâ€”Â â€”â€”Â â€”â€”Â â€”Â 14(537)â€”Â â€”Â (537)Issuance of Common Shares upon Stock Option and ESPP Exerciseâ€”Â â€”â€”Â 40â€”Â 1,289Â â€”â€”Â â€”Â 1,289Â Issuance of Restricted Stock Awardsâ€”Â â€”â€”Â 104â€”Â â€”Â â€”â€”Â â€”Â Restricted Stock Awards Forfeituresâ€”Â â€”â€”Â (18)â€”Â â€”Â â€”â€”Â â€”Â Issuance of Common Stock in Public Offeringâ€”Â â€”1Â 2,184â€”Â 80,555Â â€”â€”Â â€”Â 80,556Â Dividends on Series A Convertible Preferred Stockâ€”Â â€”â€”Â â€”â€”Â â€”Â (407)(407)Other Comprehensive Incomeâ€”Â â€”â€”Â â€”â€”Â â€”Â 2,595Â â€”Â 2,595Â Net Incomeâ€”Â â€”â€”Â â€”â€”Â â€”Â 6,245Â 6,245Â Balance, June 30, 2023$24,850Â 25$2Â 20,536$â€”Â $495,488Â 248$(9,180)$13,726Â $(90,414)$434,472Â Balance, March 31, 2024$24,850Â 25$2Â 21,373$â€”Â $523,628Â 393$(18,742)$9,406Â $(62,331)$476,813Â Stock-based Compensation Expenseâ€”Â â€”â€”Â â€”â€”Â 7,864Â â€”â€”Â â€”Â 7,864Â Treasury Stock Purchases for Restricted Stock Vestsâ€”Â â€”â€”Â â€”â€”Â â€”Â 20(1,300)â€”Â â€”Â (1,300)Issuance of Common Shares upon Stock Option and ESPP Exerciseâ€”Â â€”â€”Â 46â€”Â 1,005Â â€”â€”Â â€”Â 1,005Â Issuance of Restricted Stock Awardsâ€”Â â€”â€”Â 65â€”Â â€”Â â€”â€”Â â€”Â Restricted Stock Awards Forfeituresâ€”Â â€”â€”Â (8)â€”Â â€”Â â€”â€”Â â€”Â Dividends on Series A Convertible Preferred Stockâ€”Â â€”â€”Â â€”â€”Â â€”Â (407)(407)Other Comprehensive Lossâ€”Â â€”â€”Â â€”â€”Â â€”Â (1,078)â€”Â (1,078)Net Lossâ€”Â â€”â€”Â â€”â€”Â â€”Â (2,287)(2,287)Balance, June 30, 2024$24,850Â 25$2Â 21,476$â€”Â $532,497Â 413$(20,042)$8,328Â $(65,025)$480,610Â The accompanying notes are an integral part of these condensed consolidated financial statements.8ANI PHARMACEUTICALS, INC. AND SUBSIDIARIESCondensed Consolidated Statements of Changes in Mezzanine Equity and Stockholdersâ€™ EquityFor the Six Months Ended June 30, 2024 and 2023(in thousands)(unaudited)Mezzanine EquitySeries A Convertible PreferredStockMezzanine EquitySeries A Convertible Preferred StockSharesCommonStockPar ValueCommonStockSharesClass CSpecialStockAdditionalPaid-inCapitalTreasuryStockSharesTreasuryStockAccumulated OtherComprehensive Income,Net of TaxAccumulatedDeficitTotal MezzanineEquity andStockholdersâ€™EquityBalance, December 31, 2022$24,850Â 25$1Â 17,644$â€”Â $403,900Â 149$(5,094)$12,167Â $(97,285)$338,539Â Stock-based Compensation Expenseâ€”Â â€”â€”Â â€”â€”Â 9,587Â â€”â€”Â â€”Â 9,587Â Treasury Stock Purchases for Restricted Stock Vestsâ€”Â â€”â€”Â â€”â€”Â â€”Â 99(4,086)â€”Â â€”Â (4,086)Issuance of Common Shares upon Stock Option and ESPP Exerciseâ€”Â â€”â€”Â 45â€”Â 1,446Â â€”â€”Â â€”Â 1,446Â Issuance of Restricted Stock Awardsâ€”Â â€”â€”Â 624â€”Â â€”Â â€”â€”Â â€”Â Issuance of Performance Stock Unitsâ€”Â â€”â€”Â 67â€”Â â€”Â â€”â€”Â â€”Â Restricted Stock Awards Forfeituresâ€”Â â€”â€”Â (28)â€”Â â€”Â â€”â€”Â â€”Â Issuance of Common Stock in Public Offeringâ€”Â â€”1Â 2,184â€”Â 80,555Â â€”â€”Â â€”Â 80,556Â Dividends on Series A Convertible Preferred Stockâ€”Â â€”â€”Â â€”â€”Â â€”Â (813)(813)Other Comprehensive Incomeâ€”Â â€”â€”Â â€”â€”Â â€”Â 1,559Â â€”Â 1,559Â Net Incomeâ€”Â â€”â€”Â â€”â€”Â â€”Â 7,684Â 7,684Â Balance, June 30, 2023$24,850Â 25$2Â 20,536$â€”Â $495,488Â 248$(9,180)$13,726Â $(90,414)$434,472Â Balance, December 31, 2023$24,850Â 25$2Â 20,731$â€”Â $514,103Â 264$(10,081)$8,857Â $(80,132)$457,599Â Stock-based Compensation Expenseâ€”Â â€”â€”Â â€”â€”Â 14,798Â â€”â€”Â â€”Â 14,798Â Treasury Stock Purchases for Restricted Stock Vestsâ€”Â â€”â€”Â â€”â€”Â â€”Â 149(9,961)â€”Â â€”Â (9,961)Issuance of Common Shares upon Stock Option and ESPP Exerciseâ€”Â â€”â€”Â 77â€”Â 3,596Â â€”â€”Â â€”Â 3,596Â Issuance of Restricted Stock Awardsâ€”Â â€”â€”Â 606â€”Â â€”Â â€”â€”Â â€”Â Issuance of Performance Stock Unitsâ€”Â â€”â€”Â 74â€”Â â€”Â â€”â€”Â â€”Â Restricted Stock Awards Forfeituresâ€”Â â€”â€”Â (12)â€”Â â€”Â â€”â€”Â â€”Â Dividends on Series A Convertible Preferred Stockâ€”Â â€”â€”Â â€”â€”Â â€”Â (813)(813)Other Comprehensive Lossâ€”Â â€”â€”Â â€”â€”Â â€”Â (529)â€”Â (529)Net Incomeâ€”Â â€”â€”Â â€”â€”Â â€”Â 15,920Â 15,920Â Balance, June 30, 2024$24,850Â 25$2Â 21,476$â€”Â $532,497Â 413$(20,042)$8,328Â $(65,025)$480,610Â The accompanying notes are an integral part of these condensed consolidated financial statements.9ANI PHARMACEUTICALS, INC. AND SUBSIDIARIESCondensed Consolidated Statements of Cash Flows(in thousands)(unaudited)Six Months Ended June 30,20242023Cash Flows From Operating ActivitiesNet income $15,920Â $7,684Â Adjustments to reconcile net income to net cash and cash equivalents provided by operating activities:Stock-based compensation14,798Â 9,587Â Deferred taxes1,205Â (137)Depreciation and amortization29,383Â 29,390Â Unrealized gain on investment in equity securities (6,943)â€”Â Non-cash operating lease expense750Â 61Â Non-cash interest 198Â 1,973Â Contingent consideration fair value adjustment449Â 1,996Â Gain on sale of building (5,347)â€”Â Changes in operating assets and liabilities, net of acquisition:Accounts receivable, net(4,012)(7,486)Inventories(14,252)1,032Â Prepaid expenses and other assets1,777Â 1,449Â Accounts payable10,379Â (800)Accrued royalties4,081Â (577)Prepaid income taxes(11,031)(261)Accrued government rebates156Â (1,099)Returned goods reserve4,219Â (3,601)Accrued expenses, accrued compensation, and other(6,047)2,839Â Net Cash and Cash Equivalents Provided by Operating Activities35,683Â 42,050Â Cash Flows From Investing ActivitiesAcquisition of product rights, intangible assets, and other related assetsâ€”Â (4,329)Acquisition of property and equipment, net(9,030)(4,850)Proceeds from the sale of building 13,514Â â€”Â Net Cash and Cash Equivalents Provided by (Used in) Investing Activities4,484Â (9,179)Cash Flows From Financing ActivitiesPayments on borrowings under credit agreements(1,500)(1,500)Series A convertible preferred stock dividends paid(813)(813)Proceeds from stock option exercises and ESPP purchases3,596Â 1,446Â Proceeds from public offeringâ€”Â 80,555Â Treasury stock purchases for restricted stock vests(9,961)(4,086)Payments on contingent consideration(12,500)â€”Â Net Cash and Cash Equivalents (Used in) Provided by Financing Activities(21,178)75,602Â Net Change in Cash, Cash Equivalents, and Restricted Cash18,989Â 108,473Â Cash, cash equivalents, and restricted cash, beginning of period221,121Â 53,234Â Cash and cash equivalents, end of period$240,110Â $161,707Â Reconciliation of cash, cash equivalents, and restricted cash, beginning of periodCash and cash equivalents$221,121Â $48,228Â Restricted cashâ€”Â 5,006Â Cash, cash equivalents, and restricted cash, beginning of period$221,121Â $53,234Â Supplemental disclosure for cash flow information:Cash paid for interest, net of amounts capitalized$16,155Â $15,456Â Cash paid for income taxes$17,204Â $141Â Right-of-use assets obtained in exchange for lease obligations$â€”Â $4,499Â Supplemental non-cash investing and financing activities:Property and equipment purchased and included in accounts payable$1,618Â $539Â The accompanying notes are an integral part of these condensed consolidated financial statements.10NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Tabular Dollars in Thousands, Except Share and per Share Data)(Unaudited)1.Â Â Â Â BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTSOverviewANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, â€œANI,â€ the â€œCompany,â€ â€œwe,â€ â€œus,â€ or â€œourâ€) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. The Company is focused on delivering growth by scaling up the Rare Disease business through the launch of Cortrophin Gel, strengthening its generics business with enhanced development capability, innovation in established brands and leveraging its U.S. based manufacturing capabilities. The Companyâ€™s three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. The Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. This action was part of ongoing initiatives to capture operational synergies following our acquisition of Novitium Pharma LLC (â€œNovitiumâ€) in November 2021. The Company has fully completed the transition of the products manufactured or packaged in Oakville to one of the three U.S. based manufacturing sites. In February 2024, the Company entered into an agreement for the sale of the Oakville site, for a price of $19.2Â million Canadian Dollars, or approximately $14.2Â million, based on the exchange rate at closing. The sale closed on March 28, 2024 (see Note 4).The Companyâ€™s operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, and possible fluctuations in financial results. Basis of PresentationThe accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) for interim financial information. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Companyâ€™s financial position, results of operations, comprehensive (loss) income, and cash flows. The consolidated balance sheet at DecemberÂ 31, 2023 has been derived from audited financial statements as of that date. The unaudited interim condensed consolidated statements of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the U.S. Securities and Exchange Commission (the â€œSECâ€). Therefore, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited financial statements and notes thereto previously distributed in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 (the â€œ2023 Form 10-Kâ€), as filed with the SEC.Principles of ConsolidationThe unaudited interim condensed consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.11Foreign CurrencyThe Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. The Company currently has a subsidiary located in India. The Canada-based subsidiary conducted its transactions in U.S. dollars and Canadian dollars, but its functional currency was the U.S. dollar. The India-based subsidiary generally conducts its transactions in Indian rupees, which is also its functional currency. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net income. The gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the three and six months ended JuneÂ 30, 2024 and 2023. Unless otherwise noted, all references to â€œ$â€ or â€œdollarâ€ refer to the U.S. dollar. The Companyâ€™s asset and liability accounts are translated using the current exchange rate as of the balance sheet date, except for shareholdersâ€™ equity accounts, which are translated using historical rates. Net revenues and expense accounts are translated using an average exchange rate over the period ended on the balance sheet date. Adjustments resulting from the translation of the financial statements of the Companyâ€™s foreign subsidiaries into U.S. dollars are accumulated as a separate component of shareholdersâ€™ equity within accumulated

other comprehensive (loss) income, net of tax.Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the condensed consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, income tax provision or benefit, deferred taxes and valuation allowance, stock-based compensation, revenue recognition, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.Restructuring ActivitiesThe Company defines restructuring activities to include costs directly associated with exit or disposal activities. Such costs include cash employee contractual severance and other termination benefits, one-time employee termination severance and benefits, contract termination charges, impairment and acceleration of depreciation associated with long-lived assets, and other exit or disposal costs. In general, the Company records involuntary employee-related exit and disposal costs when there is a substantive plan for employee severance and related payments are probable and estimable. For one-time termination benefits, including those with a service requirement, expense is recorded when the employees are entitled to receive such benefits and the amount can be reasonably estimated. Expense related to one-time termination benefits with a service requirement is recorded over time, as the service is completed. Contract termination fees and penalties, and other exit and disposal costs are generally recorded as incurred. Restructuring activities are recognized as an operating expense in the condensed consolidated statements of operations.Investment in Equity Securities The Company accounts for its investment in equity securities with a readily determinable fair value in accordance with the guidance in ASC 321, Investments â€" Equity Securities. The Company presents unrealized gains and losses related to the equity securities, within Unrealized gain on investment in equity securities in its unaudited condensed consolidated statements of operations. Fair values are obtained from quoted prices on the NASDAQ Stock Market, Inc. (â€œNASDAQâ€). 12Assets Held-for-SaleThe Company classifies assets held-for-sale if all held-for-sale criteria is met pursuant to ASC 360-10, Property, Plant and Equipment. Criteria include management commitment to sell the disposal group in its present condition and the sale being deemed probable of being completed within one year. Assets classified as held-for-sale are not depreciated and are measured at the lower of their carrying amount or fair value less cost to sell. The Company assesses the fair value of a disposal group, less any costs to sell, each reporting period it remains classified as held-for-sale and reports any subsequent changes as an adjustment to the carrying value of the disposal group, as long as the new carrying value does not exceed the initial carrying value of the disposal group. The Company determined that the Oakville, Ontario, Canada property met the held-for-sale criteria. As of DecemberÂ 31, 2023, approximately $8.0Â million of assets held for sale were recorded on the consolidated balance sheets. The Oakville, Ontario property was sold on March 28, 2024 (see Note 4).Recent Accounting PronouncementsRecent Accounting Pronouncements Not Yet AdoptedFrom time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies and are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.In November 2023, the FASB issued Accounting Standards Update (â€œASUâ€) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures related to significant segment expenses. The guidance in this ASU is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the effect the adoption of this ASU may have on its disclosures in the notes to the consolidated financial statements.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes guidance to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. These amendments are effective for all public entities for fiscal periods beginning after December 15, 2024, with early adoption permitted. These amendments apply on a prospective basis, but entities have an option to apply it retrospectively for all periods presented. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements.Recent Securities and Exchange Commission Final Rules Issued but Not Yet EffectiveOn March 6, 2024, the SEC adopted new rules that will require registrants to disclose certain climate-related information in their annual reports. The final rule requires disclosure of, among other things: material climate-related risks and their material impacts; activities to mitigate or adapt to such risks; information about a registrantâ€™s board of directorsâ€™ oversight of climate-related risks and managementâ€™s role in managing material climate-related risks; and information on any climate-related targets or goals that are material to the registrantâ€™s business, results of operations, or financial condition. In addition, certain disclosures related to severe weather events and other natural conditions will be required in a registrantâ€™s audited financial statements. The required information about climate-related risks will also include disclosure of a registrantâ€™s greenhouse gas emissions. The Company will be subject to the applicable requirements of the final rule in our annual reports for fiscal years beginning on January 1, 2025. In April 2024, the SEC voluntarily stayed the rules pending judicial review. The Company is currently evaluating the potential impact of these rules on its consolidated financial statements and related disclosures.132.Â Â Â Â REVENUE RECOGNITION AND RELATED ALLOWANCESRevenue RecognitionThe Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized using the following steps:â€¢Identification of the contract, or contracts, with a customer;â€¢Identification of the performance obligations in the contract;â€¢Determination of the transaction price, including the identification and estimation of variable consideration;â€¢Allocation of the transaction price to the performance obligations in the contract; andâ€¢Recognition of revenue when we satisfy a performance obligation.Revenues are primarily derived from sales of generic, rare disease, and established brand pharmaceutical products, royalties, and other pharmaceutical services. Revenue is recognized when obligations under the terms of contracts with customers are satisfied, which generally occurs when control of the products sold are transferred to the customer. Variable consideration is estimated after the consideration of applicable information that is reasonably available. The Company generally does not have incremental costs to obtain contracts that would otherwise not have been incurred. The Company does not adjust revenue for the promised amount of consideration for the effects of a significant financing component because our customers generally pay us within 100 days.All revenue recognized in the accompanying unaudited interim condensed consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue:Three Months Ended June 30,Six Months Ended June 30,Products and Services (in thousands)2024202320242023Sales of generic pharmaceutical products$73,964Â $63,317Â $144,181Â $127,030Â Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services14,883Â 28,926Â 45,159Â 55,669Â Sales of rare disease pharmaceutical products49,193Â 24,304Â 86,130Â 40,634Â Total net revenues$138,040Â $116,547Â $275,470Â $223,333Â Three Months Ended June 30,Six Months Ended June 30,Timing of Revenue Recognition (in thousands)2024202320242023Performance obligations transferred at a point in time$138,040Â $116,547Â $275,470Â $222,958Â Performance obligations transferred over timeâ€”Â â€”Â 375Â Total$138,040Â $116,547Â $275,470Â $223,333Â In the three and six months ended JuneÂ 30, 2024 and 2023, the Company did not incur, and therefore did not defer, any material incremental costs to obtain or fulfill contracts. The Company recognized a decrease of $1.5 million to net revenue from performance obligations satisfied in prior periods during the six months ended JuneÂ 30, 2024, consisting primarily of revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales. The Company recognized an increase of $5.0 million to net revenue from performance obligations satisfied in prior periods during the six months ended JuneÂ 30, 2023, consisting primarily of revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales. Additionally, as of JuneÂ 30, 2024, and December 31, 2023, there was no deferred revenue recorded on the condensed consolidated balance sheets. As of JuneÂ 30, 2024, the aggregate amount of the transaction price allocated to the remaining performance obligations for all open contract manufacturing customer contracts was $3.0 million, which consists of firm orders for contract manufactured products. The Company recognizes revenue for these performance obligations as they are satisfied, which is anticipated within six months.14Variable considerationSales of pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative and other rebates, and cash discounts. Estimates for these elements of variable consideration require significant judgment. The following table summarizes activity in the condensed consolidated balance sheets for accruals and allowances for the six months ended JuneÂ 30, 2024 and 2023, respectively:Accruals for Chargebacks, Returns, and Other Allowances(in thousands)ChargebacksGovernmentRebatesReturnsAdministrativeFees and OtherRebatesPromptPaymentDiscountsBalance at December 31, 2022$148,562Â $10,872Â $33,399Â $9,442Â $6,488Â Accruals/Adjustments290,826Â 11,100Â 5,995Â 25,606Â 11,028Â Credits Taken Against Reserve(362,253)(10,001)(9,596)(25,177)(12,653)Balance at June 30, 2023 (1)$77,135Â $11,971Â $29,798Â $9,871Â $4,863Â Balance at December 31, 2023$84,208Â $12,168Â $29,678Â $11,412Â $4,865Â Accruals/Adjustments267,779Â 13,324Â 21,895Â 29,970Â 11,422Â Credits Taken Against Reserve(262,541)(13,168)(17,676)(29,656)(11,243)Balance at June 30, 2024 (1)$89,446Â $12,324Â $33,897Â $11,726Â $5,044Â _____(1)Chargebacks and Prompt Payment Discounts are included as an offset to accounts receivable in the unaudited interim condensed consolidated balance sheets. Administrative Fees and Other Rebates are included as an offset to accounts receivable or as accrued expenses and other in the unaudited interim condensed consolidated balance sheets. Returns are included in returned goods reserve in the unaudited interim condensed consolidated balance sheets. Government Rebates are included in accrued government rebates in the unaudited interim condensed consolidated balance sheets. Credit ConcentrationANIâ€™s customers are primarily wholesale distributors, chain drug stores, group purchasing organizations, and pharmaceutical companies.During the three and six months ended JuneÂ 30, 2024, there were four customers that accounted for 10% or more of net revenues. During the three months ended JuneÂ 30, 2023, there were four customers that accounted for 10% or more of net revenues. During the six months ended JuneÂ 30, 2023, there were three customers that accounted for 10% or more of net revenues. As of JuneÂ 30, 2024, accounts receivable from these customers totaled 79% of Accounts receivable, net. The four customers represent the total percentage of net revenues as follows:Three Months Ended June 30,Six Months Ended June 30,20242023Customer 124Â %32Â %29Â %32Â %Customer 212Â %14Â %12Â %14Â %Customer 313Â %13Â %11Â %13Â %Customer 417Â %10Â %15Â %9Â %153.Â Â Â Â PENDING MERGER AGREEMENTOn June 21, 2024, the Company entered into an Agreement and Plan of Merger (the â€œMerger Agreementâ€) with Alimera Sciences, Inc., a Delaware corporation (â€œAlimeraâ€) and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of the Company (â€œMerger Subâ€), providing for the merger of Merger Sub with and into Alimera (the â€œMergerâ€), with Alimera surviving the Merger as a wholly owned indirect subsidiary of the Company. Capitalized terms used herein, but not otherwise defined, have the meanings set forth in the Merger Agreement.At the effective time of the Merger (the â€œEffective Timeâ€), each outstanding share of common stock, par value $0.01 per share, of Alimera, outstanding immediately prior to the Effective Time will automatically be converted into the right to receive (i) $5.50 in cash, without interest and (ii) one contingent value right (a â€œCVRâ€), which shall represent the right to receive the Milestone Payments (as defined below) subject to the terms and conditions set forth in the CVR Agreement (as defined below) (the consideration contemplated by (i) and (ii), together, the â€œMerger Considerationâ€).At or immediately prior to the Effective Time, the Company will enter into a contingent value rights agreement (the â€œCVR Agreementâ€), pursuant to which each holder of Alimera Common Stock, as well as holders of Alimera Warrants, Alimera Options, Alimera PSUs, Alimera RSAs and Alimera RSUs, may become entitled to contingent cash payments per CVR (each, a â€œMilestone Paymentâ€), such payment(s) being contingent upon, and subject to, satisfaction of the Milestones (as defined below).When issued, each CVR will entitle the holder (the â€œHolderâ€) to receive Milestone Payments for 2026 and 2027, upon satisfaction of the applicable Milestones. The Milestone Payments for each CVR will equal the product (rounded to the nearest 1/100 of $0.01) of $0.25 multiplied by a fraction (which in no case will exceed one), and (i) for 2026, equals the amount, if any, by which the 2026 Net Revenue exceeds $140.0Â million, divided by $10.0Â million (subject to adjustment for the exercise price of Eligible Options), and (ii) for 2027, equals the amount, if any, by which the 2027 Net Revenue exceeds $160.0Â million, divided by $15.0Â million (subject to adjustment for the exercise price of Eligible Options) (the occurrence of the events in clauses (i) and (ii), each, a â€œMilestoneâ€).The Merger Agreement requires Alimera, as promptly as reasonably practicable, and in any event within 25 business days following the date of the Merger Agreement, to prepare and file with the SEC a proxy statement for the purpose of seeking stockholder approval to the Merger Agreement. Alimera filed their preliminary proxy statement on July 24, 2024 with the SEC.Consummation of the Merger is subject to certain conditions, including approval by Alimeraâ€™s stockholders, the absence of any legal restraints restraining, enjoining, preventing, prohibiting or otherwise making illegal the consummation of the Merger, expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and any other specified required regulatory approvals that may be required will have been obtained, and each partyâ€™s performance of its obligations in all material respects under the Merger Agreement.In connection with the Merger, JPMorgan Chase Bank, N.A. and Blackstone Credit & Insurance (the â€œLendersâ€) have committed to provide debt financing for the transaction in an aggregate principal amount equal to $280.0Â million, on the terms and subject to the conditions set forth in a commitment letter, dated June 21, 2024 (the â€œDebt Commitment Letterâ€). The obligations of the Lenders to provide debt financing under the Debt Commitment Letter are subject to customary conditions, including, without limitation, execution and delivery of definitive documentation consistent with the Debt Commitment Letter.During the three and six months ended JuneÂ 30, 2024, the Company incurred approximately $3.5 million in transaction costs related to this pending Merger Agreement, all of which were expensed, and are included in Selling, general, and administrative on the condensed consolidated statements of operations.164.Â Â Â Â RESTRUCTURING On March 31, 2023 the Company ceased operations at the Oakville, Ontario, Canada manufacturing plant. This action was part of ongoing initiatives to capture operational synergies following the acquisition of Novitium in November 2021. ANI has fully completed the transition of the products manufactured or packaged in Oakville to one of the Companyâ€™s three U.S. based manufacturing sites. There were no restructuring activities recorded in the three or six months ended JuneÂ 30, 2024 and as of JuneÂ 30, 2024, there was no severance or other employee benefits accrued on the unaudited interim condensed consolidated balance sheet. For the three months ended JuneÂ 30, 2023, restructuring activities resulted in an immaterial amount of expenses, and for the six months ended JuneÂ 30, 2023, restructuring activities resulted in expenses of $1.1 million. This included $0.2 million of severance and other employee benefit costs and $0.7 million of accelerated depreciation costs and $0.2 million for other miscellaneous costs.In conjunction with the exit of the Canadian facility, the Company determined that the land and building at the Oakville, Ontario, Canada plant (the â€œPropertyâ€) will be sold together and met the criteria to be classified as held for sale as of JuneÂ 30, 2023. The land and building had a net carrying value of approximately $8.0 million, which was presented as assets held for sale on the accompanying condensed consolidated balance sheet at December 31, 2023. These assets were part of the Generics, Established Brands, and Other segment. As of JuneÂ 30, 2024 these assets were sold.On February 15, 2024, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement (the â€œAgreementâ€) with 1540700 Ontario Limited (â€œBuyerâ€) for the sale of the Property for a total purchase price of $19.2Â million Canadian Dollars, or approximately $14.2Â million, based on the exchange rate at closing. On March 28, 2024 the Company completed the sale of the Property. After payment of commissions, real estate taxes, and other related costs of approximately $0.7 million, the Company received a net proceeds of approximately $13.5Â million at closing. The gain on the sale of the Property was approximately $5.3Â million, recorded in the unaudited interim condensed consolidated statements of operations for the six months ended JuneÂ 30, 2024.5.Â Â Â Â INDEBTEDNESSCredit FacilityOn November 19, 2021, the Company completed its acquisition of Novitium pursuant to the terms of the Agreement and Plan of Merger, dated as of March 8, 2021 (the â€œNovitium Merger Agreementâ€), by and among the Company, Novitium, Nile Merger Sub LLC, a Delaware limited liability company, and certain other parties, with Novitium becoming a wholly owned subsidiary of the Company.On NovemberÂ 19, 2021, the Company, as borrower, entered into a credit agreement (the â€œCredit Agreementâ€) with Truist Bank and other lenders, which provides for credit facilities consisting of (i) a senior secured term loan facility in an aggregate principal amount of $300.0 million (the â€œTerm Facilityâ€) and (ii) a senior secured revolving credit facility in an aggregate commitment amount of $40.0 million, which may be used for revolving credit loans, swingline loans and letters of credit (the â€œRevolving Facility,â€ and together with the Term Facility, the â€œCredit Facilityâ€). The Term Facility proceeds were used to finance the cash portion of the consideration under the Novitium Merger Agreement, repay the existing credit facility, and pay fees, costs and expenses incurred in connection with the merger. The Term Facility matures in November 2027 and the Revolving Facility in November 2026. The Credit Facility has a subjective acceleration clause in case of a material adverse effect. In July 2023, the Company amended its Credit Agreement to transition from London Interbank Offered Rate (â€œLIBORâ€) to the Secured Overnight Financing Rate (â€œSOFRâ€) due to the cessation of LIBOR pursuant to the

terms of Amendment No.1 to the Credit Agreement (â€œAmendment No. 1â€). SOFR was applied to the Credit Facility for the interest period (as defined in the Credit Agreement) beginning on August 1, 2023 and replaced all LIBOR terms.The Credit Facility permits both base rate borrowings (â€œABR Loansâ€) and Eurodollar rate borrowings (â€œEurodollar Loansâ€), plus a spread as defined in the Credit Facility. As of JuneÂ 30, 2024, we had not drawn on the Revolving Facility and $40.0 million remained available for borrowing subject to certain conditions. The interest rate under the Term Facility was 11.44% at JuneÂ 30, 2024.17The Company incurred $14.0 million in deferred debt issuance costs associated with the Credit Facility. Costs allocated to the Term Facility are classified as a direct reduction to the current and non-current portion of the borrowings, depending on their nature. Costs allocated to the Revolving Facility are classified as other current and other non-current assets, depending on their nature. A commitment fee of 0.5% per annum is assessed on any unused portion of the Revolving Facility.The Credit Facility is secured by a lien on substantially all of ANI Pharmaceuticals, Inc.â€™s and its principal domestic subsidiaryâ€™s assets and any future domestic subsidiary guarantorsâ€™ assets. The Credit Facility is subject to customary financial and nonfinancial covenants. The carrying value of the current and non-current components of the Term Facility as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are:Current(in thousands)June 30,2024December 31,2023Current borrowing on debt$3,000Â $3,000Â Deferred financing costs(2,150)(2,150)Current debt, net of deferred financing costs $850Â $850Â Non-Current(in thousands)June 30,2024December 31,2023Non-current borrowing on debt$289,500Â $291,000Â Deferred financing costs(5,106)(6,181)Non-current debt, net of deferred financing costs and current component$284,394Â $284,819Â As of JuneÂ 30, 2024, outstanding principal was $292.5 million on the Term Facility. Of the $0.6 million of unamortized deferred debt issuance costs allocated to the Revolving Facility, $0.3 million is included in other non-current assets in the unaudited interim condensed consolidated balance sheets, and $0.3 million is included in prepaid expenses and other current assets in the unaudited interim condensed consolidated balance sheets. The contractual maturity of the Term Facility is as follows for the period ending:(in thousands)Term Facility2024 (remainder of the year)$1,500Â 20253,000Â 20263,000Â 2027285,000Â Total$292,500Â The following table sets forth the components of total interest expense related to the Term Facility during the three and six months ended JuneÂ 30, 2024 and 2023, as recognized in the accompanying unaudited interim condensed consolidated statements of operations for the three and six months ended JuneÂ 30, 2024 and 2023:Three Months Ended June 30,Six Months Ended June 30,(in thousands)2024202320242023Contractual coupon$6,848Â $7,620Â $13,761Â $14,970Â Amortization of finance fees591Â 591Â 1,182Â 1,182Â Capitalized interest(151)(277)(263)(298)$7,288Â $7,934Â $14,680Â $15,854Â 186.Â Â Â Â DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITYIn April 2020, the Company entered into an interest rate swap with Citizens Bank, N.A. to manage its exposure to changes in LIBOR-based interest rates underlying total borrowings under term facilities related to the prior credit agreement, and the interest rate swap matures in December 2026. Concurrent with the termination of the prior credit agreement and entry into the Credit Agreement with Truist Bank, the interest rate swap with a notional value of $168.6 million at origin on NovemberÂ 21, 2021 was novated and Truist Bank is the new counterparty. As described further below, the Company amended its Credit Agreement to transition from LIBOR to SOFR due to the cessation of LIBOR, and accordingly, the interest rate swap transitioned from LIBOR to SOFR. The swap is used to manage changes in SOFR-based interest rates underlying a portion of the borrowing under the Term Facility. The interest rate swap provides an effective fixed interest rate of 2.26% and has been designated as an effective cash flow hedge and therefore qualifies for hedge accounting. As of JuneÂ 30, 2024, the notional amount of the interest rate swap was $139.4 million and decreased quarterly by approximately $4.0 million until December 2023, after which it remains static until maturity in December 2026. As of JuneÂ 30, 2024, the fair value of the interest rate swap asset recorded in other non-current assets in the unaudited interim condensed consolidated balance sheets was $7.4 million. As of JuneÂ 30, 2024, $8.5 million was recorded in accumulated other comprehensive (loss) income, net of tax in the unaudited interim condensed consolidated balance sheets.During the three and six months ended JuneÂ 30, 2024, the loss on the fair value of the interest rate swaps, net of tax recorded in accumulated other comprehensive (loss) income in the unaudited interim condensed consolidated statements of comprehensive income was approximately $1.1 million and $0.5 million, respectively. Differences between the hedged SOFR rate and the fixed rate are recorded as interest expense in the same period that the related interest is recorded for the Term Facility based on the SOFR rate. In the three and six months ended JuneÂ 30, 2024, the Company recorded a reduction in interest expense of $1.6 million and $3.2 million in relation to the interest rate swaps, respectively. In the three and six months ended JuneÂ 30, 2023, the Company recorded a reduction in interest expense of $0.6 million and $1.1 million in relation to the interest rate swaps, respectively. Included in this amount for the three and six months ended JuneÂ 30, 2024 are reclassifications out of accumulated other comprehensive (loss) income of $0.2 million of interest income and $0.4 million, respectively, related to terminated and de-designated cash flow hedges. Included in this amount for the three and six months ended JuneÂ 30, 2023 are reclassifications out of accumulated other comprehensive (loss) income of $0.7 million of interest income and $0.7 million, respectively, related to terminated and de-designated cash flow hedges.In conjunction with the amendment of the Credit Agreement (see Note 5), the Companyâ€™s derivative positions automatically transitioned to SOFR, the designated fallback terms, as determined by the International Swaps and Derivatives Association on August 1, 2023. Concurrently, the Company updated its hedge documentation to reflect the change of the benchmark index, which changed solely as a result of reference rate reform. Under ASC 848, Reference Rate Reform, hedge accounting may continue without de-designation if certain criteria are met. For cash flow hedges in which the designated hedged risk is LIBOR (or another rate that is expected to be discontinued), the guidance allows an entity to assert that it remains probable that the hedged forecasted transaction will occur. The Company applied the optional expedient within ASC 848 to conclude the updates to the hedge relationship due to reference rate reform did not have a material impact on the Companyâ€™s consolidated financial statements.7.Â Â Â Â EARNINGS PER SHAREBasic earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares of common stock outstanding during the period.For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is calculated by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options, shares to be purchased under the 2016 Employee Stock Purchase Plan (â€œESPPâ€), and performance stock units, using the more dilutive of the treasury stock or the two-class method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share.19Unvested restricted shares and Series A convertible preferred stock shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic and diluted earnings (loss) per share excludes from the numerator net income (but not net loss) attributable to the unvested restricted shares and the common shares assumed converted from the preferred shares and excludes the impact of those shares from the denominator. The Companyâ€™s participating securities do not have a contractual obligation to share in the Companyâ€™s losses. As such, the net loss was attributed entirely to common stockholders. As the Company has reported a net loss for the three months ended June 30, 2024, diluted net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders for this period.Earnings per share for the three and six months ended JuneÂ 30, 2024 and 2023 are calculated for basic and diluted earnings per share as follows:BasicDilutedBasicDiluted(in thousands, except per share amounts)Three Months Ended June 30,Three Months Ended June 30,Six Months Ended June 30,Six Months Ended June 30,20242023202420232024202320242023Net (loss) income available to common shareholders$(2,694)$5,838Â $(2,694)$5,838Â $15,107Â $6,871Â $15,107Â $6,871Â Earnings allocated to participating securitiesâ€”Â (589)â€”Â (589)(1,499)(716)(1,474)(716)Net (loss) income available to common shareholders$(2,694)$5,249Â $(2,694)$5,249Â $13,608Â $6,155Â $13,633Â $6,155Â Basic Weighted-Average Shares Outstanding19,32117,68819,32117,68819,210Â 17,04419,210Â 17,044Dilutive effect of common stock options, ESPP, and performance stock unitsâ€”Â 167351Â 133Diluted Weighted-Average Shares Outstanding19,32117,85519,561Â 17,177(Loss) earnings per share(0.14)0.30Â (0.14)0.29Â $0.71Â $0.36Â $0.70Â $0.36Â The number of shares of potentially dilutive securities excluded from the computation of diluted net loss per share attributable to common stockholders was 2.8Â million for the three months ended JuneÂ 30, 2024 because including them would have been anti-dilutive.The number of anti-dilutive shares, which have been excluded from the computation of diluted earnings per share, was 2.3 million for the six months ended JuneÂ 30, 2024. The number of anti-dilutive shares, which have been excluded from the computation of diluted earnings per share, was 2.5 million for the three and six months ended JuneÂ 30, 2023. 8.Â Â Â Â INVENTORIESInventories consist of the following as of:(in thousands)June 30, 2024December 31, 2023Raw materials$62,584Â $62,237Â Packaging materials10,434Â 9,617Â Work-in-progress4,775Â 3,144Â Finished goods47,655Â 36,198Â Inventories$125,448Â $111,196Â 20Vendor ConcentrationRaw materials are sourced for products, including active pharmaceutical ingredients (â€œAPIâ€), from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the cost and time required to validate a second source of supply. As a result, the Company is dependent upon our current vendors to reliably supply the API required for on-going product manufacturing. During the three and six months ended JuneÂ 30, 2024, approximately 27% and 24%, respectively, of our raw material purchases were from one supplier. During the three and six months ended JuneÂ 30, 2023, no single vendor represented more than 10% of our raw material inventory purchases. 9.Â Â Â Â GOODWILL AND INTANGIBLE ASSETSGoodwillAs a result of the 2013 merger with BioSante Pharmaceuticals, Inc., the Company recorded goodwill of $1.8 million. As a result of the acquisition of WellSpring Pharma Services Inc. in 2018, the Company recorded goodwill of $1.7 million. From the acquisition of Novitium in 2021, the Company recorded goodwill of $24.6 million. As of JuneÂ 30, 2024, the Company has two operating segments, which were also deemed the Companyâ€™s two reporting units, Generics, Established Brands, and Other reporting unit and the Rare Disease reporting unit. All of the goodwill is recorded in the Generics, Established Brands, and Other reporting unit. Goodwill is reviewed for impairment at least annually, at October 31, or more frequently if a triggering event occurs between impairment testing dates. The Companyâ€™s impairment assessment begins with a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. Qualitative factors may include, macroeconomic conditions, industry and market considerations, cost factors, and other relevant entity and Company specific events. If, based on the qualitative test, the Company determines that it is â€œmore likely than notâ€ that the fair value of a reporting unit is less than its carrying value, then we evaluate goodwill for impairment by comparing the fair value of our reporting unit to its respective carrying value, including its goodwill. If it is determined that it is â€œnot likelyâ€ that the fair value of the reporting unit is less than its carrying value, then no further testing is required. There have been no events or changes in circumstances that would have reduced the fair value of the Generics, Established Brands, and Other reporting unit below its carrying value during the three and six months ended JuneÂ 30, 2024 and 2023, no impairment charges have been recognized.Intangible AssetsThe components of definite-lived intangible assets and indefinite-lived intangible assets, other than goodwill, are as follows:June 30, 2024December 31, 2023Remaining Weighted Average Amortization Period(1)(in thousands)Gross Carrying AmountAccumulatedAmortizationNet Carrying Amount Gross CarryingAmountAccumulatedAmortizationNet Carrying AmountDefinite-Lived Intangible Assets:Acquired ANDAs intangible assets$209,780Â $(112,742)$97,038Â $209,780Â $(100,660)$109,120Â 4.8 yearsNDAs and product rights244,871Â (196,451)48,420Â 244,871Â (184,861)60,010Â 2.8 yearsMarketing and distribution rights17,157Â (14,752)2,405Â 17,157Â (14,271)2,886Â 2.5 yearsCustomer relationships24,900Â (9,485)15,415Â 24,900Â (7,707)17,193Â 4.3 yearsTotal Definite-Lived Intangible Assets496,708Â (333,430)163,278Â 496,708Â (307,499)189,209Â 4.1 yearsIndefinite-Lived Intangible Assets:In process research and development19,800Â â€”Â 19,800Â 19,800Â â€”Â 19,800Â IndefiniteTotal Intangible Assets, net$516,508Â $(333,430)$183,078Â $516,508Â $(307,499)$209,009Â (1)Weighted average amortization period as of JuneÂ 30, 2024. 21Definite-lived intangible assets arising from business combinations and other asset acquisitions include intangibles such as Abbreviated New Drug Applications (â€œANDAsâ€), New Drug Applications (â€œNDAsâ€) and product rights, marketing and distribution rights, customer relationships, and non-compete agreements. Definite-lived intangible assets are amortized over the estimated period during which the asset is expected to contribute directly or indirectly to future cash flows. Definite-lived intangible assets are stated at cost, net of amortization, and generally amortized over their remaining estimated useful lives, ranging from seven to ten years, based on the straight-line amortization method. In the case of certain NDAs and product rights assets, an accelerated amortization method is used to better match the anticipated economic benefits expected to be provided. Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that these asset might be impaired. Amortization expense for definite-lived intangibles was $13.0 million and $12.8 million for the three months ended JuneÂ 30, 2024 and 2023, respectively. Amortization expense for definite-lived intangibles was $25.9 million and $25.7 million for the six months ended JuneÂ 30, 2024 and 2023, respectively. No impairment losses were recognized in the three and six months ended JuneÂ 30, 2024 and 2023.Indefinite-lived intangible assets other than goodwill include primarily In-Process Research & Development (â€œIPR&Dâ€) projects. IPR&D intangible assets represent the fair value of technology acquired in a business combination or asset acquisition for which the technology projects are incomplete but have substance or alternative future use. When an IPR&D project is completed (generally upon receipt of regulatory approval), then the IPR&D will be accounted for as a definite-lived intangible asset. Indefinite-lived intangible assets are not amortized, and the Company tests for impairment of indefinite-lived intangible assets when events or circumstances indicate that the carrying value of the assets may not be recoverable, and the Company performs an asset impairment analysis annually, as of October 31. No impairment losses were recognized in the three and six months ended JuneÂ 30, 2024 and 2023, respectively. Expected future amortization expense for definite-lived intangible assets is as follows:(in thousands)2024 (remainder of the year)$24,896Â 202547,592Â 202634,107Â 202725,140Â 202818,359Â 2029 and thereafter13,184Â Total$163,278Â 10.Â Â Â Â MEZZANINE AND STOCKHOLDERSâ€™ EQUITYStockholdersâ€™ EquityAuthorized sharesThe Company is authorized to issue up to 33.3 million shares of common stock with a par value of $0.0001 per share, 0.8 million shares of class C special stock with a par value of $0.0001 per share, and 1.7 million shares of undesignated preferred stock with a par value of $0.0001 per share at JuneÂ 30, 2024. There were 21.5 million and 21.1 million shares of common stock issued and outstanding as of JuneÂ 30, 2024, respectively, and 20.7 million and 20.5 million shares of common stock issued and outstanding as of DecemberÂ 31, 2023, respectively. Class C Special Stock There were 11 thousand shares of class C special stock issued and outstanding as of JuneÂ 30, 2024 and DecemberÂ 31, 2023. Each share of class C special stock entitles its holder to one vote per share. Each share of class C special stock is exchangeable, at the option of the holder, for one share of common stock, at an exchange price of $90.00 per share, subject to adjustment upon certain capitalization events. Holders of class C special stock are not entitled to receive dividends or to participate in the distribution of our assets upon liquidation, dissolution, or winding-up the Company. 22The holders of class C special stock have no cumulative voting, preemptive, subscription, redemption, or sinking fund rights.Mezzanine EquityPIPE SharesConcurrently with the execution of the Novitium Merger Agreement, and as financing for a portion of the acquisition, on March 8, 2021, the Company entered into an Equity Commitment and Investment Agreement with Ampersand 2020 Limited Partnership (the â€œPIPE Investorâ€), pursuant to which the PIPE Investor purchased 25,000 shares of Series A Convertible Preferred Stock (the â€œPIPE Sharesâ€), for a purchase price of $1,000 per share and an aggregate purchase price of $25.0 million on NovemberÂ 19, 2021. The PIPE Shares are classified as mezzanine equity because the shares are mandatorily redeemable for cash upon a change in control, an event that is not solely within the Companyâ€™s control. The PIPE Shares accrue dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind, and will also participate, on a pro-rata basis, in any dividends that may be declared with respect to our common stock. The PIPE Shares are convertible into common shares at the conversion price of $41.47 (i) beginning two years after their issuance date, at the election of ANI (in which case the PIPE Investor must convert all of the PIPE Shares), if the volume-weighted average price of the common stock for any 20 trading days out of 30 consecutive trading days exceeds 170% of the conversion price, and (ii) at any time after issuance, at the election of the PIPE Investor. As of JuneÂ 30, 2024, the PIPE shares are currently convertible into a maximum of 602,901 shares of common stock.In case of a liquidation event, the holder of the PIPE Shares will be entitled to receive, in preference to holders of the Companyâ€™s common stock, the greater of (i) the PIPE Sharesâ€™ purchase price plus any accrued and unpaid dividends thereon and (ii) the amount the holder of the PIPE Shares would have received in the liquidation event if it had converted its PIPE Shares into common stock. The PIPE Shares will have voting rights, voting as one series with the holders of common stock, on as-converted basis, and will have separate voting rights on any (i) amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the â€œCertificateâ€) that adversely amends and relates solely to the terms of the PIPE Shares and (ii) issuance of additional Series A convertible preferred stock. In case of a change of control, the PIPE Shares will be redeemed at the greater of (i) the PIPE Sharesâ€™ purchase price plus any accrued and unpaid dividends thereon and (ii) the change of control transaction consideration that the PIPE Investor would have received if it had converted into shares of common stock.There were 25,000 shares of Series A convertible preferred stock outstanding as of JuneÂ 30, 2024.11.Â Â Â Â STOCK-BASED COMPENSATIONEmployee Stock Purchase PlanIn July 2016, the Company commenced administration of the ANI Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan. As of JuneÂ 30, 2024, the Company had 0.1 million shares of common stock available under the ESPP. Under the ESPP, participants can purchase common shares of the Companyâ€™s stock at a 15% discount on the lowest share price on the first day of the purchase period or the last day of the purchase period.The following table summarizes ESPP expense

incurred under the 2016 Employee Stock Purchase Plan and included in our accompanying unaudited interim condensed consolidated statements of operations:(in thousands)Three Months Ended June 30,Six Months Ended June 30,2024202320242023Selling, general, and administrative$137Â $70Â $276Â $143Â Cost of sales30Â 18Â 60Â 30Â Research and development12Â 12Â 23Â 19Â Total$179Â $100Â $359Â $192Â 23Stock Incentive PlanDuring the 2024 Annual Meeting of Stockholders held on May 21, 2024, the stockholders of the Company approved an amendment to the Amended and Restated Stock Incentive Plan (the â€œ2022 Planâ€) (such amendment, the â€œ2024 Stock Plan Amendmentâ€ and the 2022 Plan, after giving effect to the 2024 Stock Plan Amendment, the â€œAmended 2022 Stock Plan†). Subject to adjustment, the 2024 Stock Plan Amendment authorizes the issuance of an additional 1,610,000 shares.As of JuneÂ 30, 2024, 2.0 million shares of common stock were available for issuance under the Amended 2022 Stock Plan.Stock Options Outstanding stock options to purchase shares of common stock are granted to employees and consultants generally vest over a period of four years and have 10-year contractual terms. Outstanding stock options granted to non-employee directors generally vest over a period of one to four years and have 10-year contractual terms. From time to time, stock options are granted to employees through an inducement grant outside of the Amended 2022 Stock Plan to induce prospective employees to accept employment with the Company (the â€œInducement Grantsâ€). The options are granted at an exercise price equal to the fair market value of a share of common stock on the respective grant date and are generally exercisable in four equal annual installments beginning on the first anniversary of the respective grant date. The grants are made pursuant to inducement grants outside of our stockholder approved equity plan as permitted under the Nasdaq Stock Market listing rules.Restricted Stock Awards Restricted stock awards (â€œRSAsâ€) granted to employees generally vest over a period of four years and RSAs granted to non-officer directors generally vest over a period of one year.During the vesting period, the recipient of the RSAs has full voting rights as a stockholder and would receive dividends, if declared, even though the restricted stock remains subject to transfer restrictions and will generally be forfeited upon termination of the officer prior to vesting. The fair value of each RSA is based on the market value of our stock on the date of grant. Upon vesting, unrestricted shares of common stock are delivered to employees and directors.Performance-Based Restricted Stock Units February 28, 2023 Performance-Based Restricted Stock Units GrantAwards may also be issued in the form of Performance Stock Units (â€œPSUsâ€). PSUs represent the right to receive an amount of cash, a number of shares of common stock or a combination of both, contingent upon the achievement of specified performance objectives during a specified performance period. PSUs granted to date vest over a three-year performance period. On February 28, 2023, as part of the Companyâ€™s equity compensation program, we granted PSUs to certain executives. Of these PSUs, 50% were market performance-based restricted stock units (â€œMPRSUsâ€), vesting of which is contingent upon the Company meeting certain total shareholder return (â€œTSRâ€) levels as compared to a select peer group over the over three years starting January 1, 2023. The MPRSUs are also subject to the recipientâ€™s continued employment or service through December 31, 2025. The MPRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (83,942 shares, net of forfeitures) based on TSR performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The estimated grant date fair value per share of the MPRSUs was $68.65 and was calculated using a Monte Carlo simulation model. These MPRSUs are included at 100% of the estimate number of shares at the end of the three-year performance period and are reflected under â€œGrantedâ€ in the table below.24The other 50% of the PSUs were performance based restricted stock units (â€œPRSUsâ€), vesting of which is contingent upon the Company meeting certain adjusted non-GAAP year-on-year EBITDA growth rates over the over three years starting January 1, 2023. The PRSUs are also subject to the recipientâ€™s continued employment or service through December 31, 2025. The PRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (83,942 shares, net of forfeitures) based on adjusted non-GAAP year-on-year EBITDA growth rates. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The Company analyzed progress on the performance goals to assess the likelihood of achievement. The estimated grant date fair value per share of the PRSUs was $41.84 based on the closing price of the stock on the date of grant. These PRSUs are included at 100% of the estimated number of shares at the end of the three-year performance period and are reflected under â€œGrantedâ€ in the table below.February 14, 2024 Performance-Based Restricted Stock Units GrantOn February 14, 2024, the Company granted 73,588 PSUs to officers and employees of the Company under the 2022 Plan (66,433 to officers of the Company). PSU performance will be measured over a three-year performance period from January 1, 2024 through December 31, 2026 and will cliff-vest contingent upon the achievement of specified performance objectives. Of these PSUs, 50% were MPRSUs, vesting of which is contingent upon the Company meeting certain TSR levels as compared to a select peer group over the over three years starting January 1, 2024, and 50% of the PSUs were PRSUs, vesting of which is contingent upon the Company meeting certain adjusted non-GAAP year-on-year EBITDA growth rates over the over three years starting January 1, 2024. Both the MPRSUs and the PRSUs have a maximum potential to vest at 200%. The estimated grant date fair value per share of the MPRSUs was $85.65 and was calculated using a Monte Carlo simulation model. These MPRSUs are included at 100% of the estimate number of shares at the end of the three-year performance period and are reflected under â€œGrantedâ€ in the table below.The estimated grant date fair value per share of the PRSUs was $56.10 based on the closing price of the stock on the date of grant. These PRSUs are included at 100% of the estimated number of shares at the end of the three-year performance period and are reflected under â€œGrantedâ€ in the table below.The following table summarizes stock-based compensation expense incurred under the Amended 2022 Stock Plan and Inducement Grants included in the accompanying unaudited interim condensed consolidated statements of operations:(in thousands)Three Months Ended June 30,Six Months Ended June 30,2024202320242023Selling, general, and administrative$7,069Â $4,766Â $13,301Â $8,673Â Research and development334Â 213Â 606Â 413Â Cost of sales282Â 170Â 532Â 309Â Total$7,685Â $5,149Â $14,439Â $9,395Â 25A summary of stock options (including Inducement Grants), RSA, and PSU activity under the Amended 2022 Stock Plan and Inducement Grants during the six months ended JuneÂ 30, 2024 and 2023 is presented below:(in thousands)OptionsPSUsRSAsOutstanding at December 31, 2022907â€”1,141Granted385624Options Exercised/RSAs Vested(26)â€”(338)(1)Forfeited(24)â€”(46)Outstanding at June 30, 2023860851,381Outstanding at December 31, 2023689841,351Grantedâ€”74606Options Exercised/RSAs Vested(54)â€”(433)(2)Forfeitedâ€”â€”(12)Outstanding at June 30, 20246351581,512

(1)Includes 99 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $4.1 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets.(2)Includes 149 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $10.0 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets.12.Â Â Â Â INCOME TAXESThe Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. As of JuneÂ 30, 2024, a valuation allowance was recorded against consolidated net deferred tax assets of $0.4 million, related solely to deferred tax assets for net operating loss carryforwards in certain U.S. state jurisdictions. The Company uses a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company has not identified any uncertain income tax positions that could have a material impact on the consolidated financial statements. The Company recognizes interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense; the Company did not have any such amounts accrued as of JuneÂ 30, 2024 and DecemberÂ 31, 2023. The Company is subject to taxation in various U.S. jurisdictions, Canada, and India and all of its income tax returns remain subject to examination by tax authorities due to the availability of NOL carryforwards.26For interim periods, the Company recognizes an income tax expense (benefit) based on our estimated annual effective tax rate, calculated on a worldwide consolidated basis, expected for the entire year. The interim annual estimated effective tax rate is based on the statutory tax rates then in effect, as adjusted for estimated changes in estimated permanent differences and excludes certain discrete items whose tax effect, when material, are recognized in the interim period in which they occur. These changes in permanent differences and discrete items result in variances to the effective tax rate from period to period. The Companyâ€™s estimated annual effective tax rate changes throughout the year as our on-going estimates of pre-tax income, and changes in permanent differences are revised, and as discrete items occur. Global Intangible Low-Taxed Income (â€œGILTIâ€), as defined in the Tax Cuts and Jobs Act of 2017, generated from our Canadian and Indian operations is subject to U.S. taxes, with certain defined exemptions, thresholds and credits. For financial reporting purposes the Company has elected to treat GILTI inclusions as a period cost. For the three months ended JuneÂ 30, 2024, the Company recognized an income tax expense of $0.0Â million. The Companyâ€™s effective tax rate was 0.0% after discrete items for the three months ended JuneÂ 30, 2024. The effective tax rate differed from the federal statutory rate of 21% primarily due to state taxes, stock based compensation, and non-deductible expenses related to the pending business combination.For the three months ended JuneÂ 30, 2023, the Company recognized an income tax benefit of $1.0Â million. The Companyâ€™s effective tax rate was (19.0)% for the three months ended June 30, 2023. The effective tax rate differed from the federal statutory rate of 21% primarily due to the recognition of the U.S. federal research and development credit, permanent differences, and discrete tax benefit primarily related to remeasurement of its gross deferred assets due to change in state deferred effective tax rate. For the six months ended JuneÂ 30, 2024, the Company recognized an income tax expense of $7.1 million. The Companyâ€™s effective tax rate was 30.9% after discrete items for the six months ended JuneÂ 30, 2024. The effective tax rate differed from the federal statutory rate of 21% primarily due to state taxes, stock based compensation, tax on the sale of the Oakville, Ontario manufacturing site, and recording of a withholding tax liability on the proceeds of the sale, and non-deductible expenses related to the pending business combination.For the six months ended JuneÂ 30, 2023, the Company recognized an income tax benefit of $0.3Â million. The Companyâ€™s effective tax rate was (3.7)% for the six months ended June 30, 2023. The effective tax rate differed from the federal statutory rate of 21% primarily due to the recognition of the U.S. federal research and development credit, permanent differences, and discrete tax benefit primarily related to remeasurement of gross deferred assets due to change in state deferred effective tax rate.The Company does not expect that any law changes enacted during the period will have a material impact on the provision for income taxes.13.Â Â Â Â COMMITMENTS AND CONTINGENCIESOperating LeasesIn April 2023, the Company entered into an agreement to lease additional warehouse space in East Windsor, New Jersey. The lease has a term of five years, and was classified as an operating lease. The lease was capitalized and included in other non-current assets on the accompanying unaudited condensed consolidated balance sheets. Additionally, during October 2023, the Company entered into an amendment for the Middleton, Wisconsin location which expanded the Companyâ€™s square footage and also extended the termination date to December 2028. Government RegulationThe Companyâ€™s products and facilities are subject to regulation by a number of federal and state governmental agencies, such as the Drug Enforcement Administration (â€œDEAâ€), the Food and Drug Administration (â€œFDAâ€), the Centers for Medicare and Medicaid Services (â€œCMSâ€), the Central Drugs Standard Control Organization (â€œCDSCOâ€), The Narcotics Control Bureau (â€œNCBâ€), and Indiaâ€™s Ministry of Health and Family Welfare (â€œMoHFWâ€). The FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of ANIâ€™s products. The DEA and NCB maintain oversight over products that are considered controlled substances.27Unapproved ProductsFour products, Esterified Estrogens and Methyltestosterone (â€œEEMTâ€), Opium Tincture, Thyroid Tablets, and Hyoscyamine are sold without approved NDAs or ANDAs. If the FDA took enforcement action against the Company, the Company may be required to seek FDA approval for the group of products or withdraw them from the market. During the three and six months ended JuneÂ 30, 2024, net revenues from commercial sales of these products for these products totaled $6.8 million and $10.9 million, respectively. During the three and six months ended JuneÂ 30, 2023, net revenues from EEMT and Opium Tincture totaled $3.5 million and $7.2 million, respectively. On DecemberÂ 27, 2023, the Company acquired from Alvogen, Inc. the rights to Hyoscyamine for total cash consideration of $2.0 million, which product was launched commercially in February 2024. Contract manufacturing revenues for Hyoscyamine, for both the three and six months ended JuneÂ 30, 2024 were less than $0.1 million. Contract manufacturing revenues for Hyoscyamine, for three and six months ended JuneÂ 30, 2023 were $0.5 million and $1.1 million, respectively. Legal proceedings The Company is, and from time to time may become, involved in various disputes, governmental and/or regulatory inquiries, investigations, government reimbursement related actions and litigation. These matters are complex and subject to significant uncertainties. While we believe that we have valid claims and/or defenses in the litigation and other matters described below, litigation is inherently unpredictable, particularly where the damages sought are substantial or indeterminate or when the proceedings, investigations or inquiries are in the early stages, and the outcome of the proceedings could result in losses, including substantial damages, fines, civil or criminal penalties and injunctive or administrative remedies. We intend to vigorously prosecute and/or defend these matters, as appropriate; however, from time to time, we may settle or otherwise resolve these matters on terms and conditions that we believe are in our best interests. Resolution of any or all claims, investigations, and legal proceedings, individually or in the aggregate, could have a material adverse effect on our results of operations and/or cash flows in any given accounting period or on our overall financial condition.Some of these matters with which we are involved are described below and in our 2023 Form 10-K, and unless otherwise disclosed, we are unable to predict the outcome of the matter or to provide an estimate of the range of reasonably possible material losses. We record accruals for loss contingencies to the extent we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.From time to time, we are also involved in other pending proceedings for which, in our opinion based upon facts and circumstances known at the time, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to our results, and therefore remain undisclosed. If and when any reasonably possible losses associated with the resolution of such other pending proceedings, in our opinion, become material, we will disclose such matters.Furthermore, like many pharmaceutical manufacturers, we are periodically exposed to product liability claims. The prevalence of these claims could limit our coverage under future insurance policies or cause those policies to become more expensive, which could harm our business, financial condition, and operating results. Recent trends in the product liability and director and officer insurance markets is to exclude matters related to certain classes of drugs. Our policies have been subject to such exclusions which place further potential risk of financial loss on us.Legal fees for litigation-related matters are expensed as incurred and included in the condensed consolidated statements of operations under the selling, general, and administrative expense line item. 28Commercial Litigation On December 3, 2020, class action complaints were filed against the Company on behalf of putative classes of direct and indirect purchasers of the drug Bystolic. On December 23, 2020, six individual purchasers of Bystolic, CVS, Rite Aid, Walgreen, Kroger, Albertsons, and H-E-B, filed complaints against the Company. On March 15, 2021, the plaintiffs in these actions filed amended complaints. All amended complaints were substantively identical. The plaintiffs in these actions alleged that, beginning in 2012, Forest Laboratories, the manufacturer of Bystolic, entered into anticompetitive agreements when settling patent litigation related to Bystolic with seven potential manufacturers of a generic version of Bystolic: Hetero, Torrent, Alkem/Indchemie, Glenmark, Amerigen, Watson, and various of their corporate parents, successors, subsidiaries, and affiliates. ANI itself was not a party to patent litigation with Forest concerning Bystolic and did not settle patent litigation with Forest. The plaintiffs named the Company as a defendant based on the Companyâ€™s January 8, 2020 Asset Purchase Agreement with Amerigen. Under the terms of the 2020 Asset Purchase Agreement, Amerigen agreed to indemnify ANI for certain liabilities relating to Bystolic, including liabilities that arose prior to closing of the asset purchase. The complaints alleged that the 2013 patent litigation settlement agreement between Forest and Amerigen violated federal and state antitrust laws and state consumer protection laws by delaying the market entry of generic versions of Bystolic. Plaintiffs alleged they paid higher prices as a result of delayed generic competition. Plaintiffs sought damages, trebled or otherwise multiplied under applicable law, injunctive relief, litigation costs and attorneysâ€™ fees. The complaints did not specify the amount of damages sought from the Company or other defendants and the Company. The cases were consolidated in the United States District Court for the Southern District of New York. On April 23, 2021, the Company and other defendants filed motions to dismiss the amended complaints. On January 24, 2022, the court dismissed all claims brought by the plaintiffs without prejudice. The court granted the plaintiffs until February 22, 2022 to file amended complaints, which were filed in federal court in the Southern District of New York, on that date. The newly amended complaints contained substantially similar claims. On April 19, 2022, the Company and other defendants filed motions to dismiss the newly amended complaints. After full briefing and oral argument, on February 21, 2023, the court granted the Company and the defendantsâ€™ motion to dismiss all actions with prejudice. Plaintiffs filed an appeal in the Second Circuit. On May 13, 2024, the Second Circuit affirmed the district courtâ€™s judgment, dismissing plaintiffsâ€™ claims with

prejudice.29On March 4, 2024, ANI commenced a civil action against CG Oncology, Inc. f/k/a Cold Genesys, Inc. (â€œCG Oncologyâ€) in the Superior Court of the State of Delaware (â€œDelaware Actionâ€). ANIâ€™s complaint alleges that, under an Assignment and Technology Transfer Agreement dated as of November 15, 2010 (the â€œNovember 2010 Agreementâ€), CG Oncology is liable to pay ANI a running royalty of 5% of the worldwide net sales of cretostimogene made by CG Oncology or any affiliate or sublicensee thereof; and that in February 2024, CG Oncology wrongfully repudiated its royalty obligation to ANI. On April 2, 2024, CG Oncology filed an answer and counterclaim (the â€œCGON Answer and Counterclaimâ€) and concurrently moved for judgment on the pleadings or, in the alternative, for partial summary judgment (the â€œMotion for Summary Judgmentâ€). CG Oncologyâ€™s Motion for Summary Judgment seeks judgment declaring that the November 2010 Agreement does not â€œoblige CGON to pay royalties after expiration of the latest-running assigned patent.â€ CG Oncology also seeks judgment awarding compensatory damages and punitive damages on counterclaims for alleged breach of the November 2010 Agreement and for alleged misappropriation of trade secrets under federal and Delaware state law. On April 22 and 25, 2024, ANI filed its reply to CG Oncologyâ€™s counterclaims, denying any liability to CG Oncology and asserting additional counterclaims against CG Oncology (â€œReply Counterclaimsâ€) for alleged breach of the November 2010 Agreement and, in the alternative, for unjust enrichment. ANIâ€™s Reply Counterclaims seek judgment (i) declaring that, under Section 3.3 of the November 2010 Agreement, CG Oncology is contractually obligated to pay ANI 5% of the worldwide net sales of cretostimogene made by CG Oncology or any affiliate or sublicensee thereof; (ii) dismissing CG Oncologyâ€™s counterclaims with prejudice; (iii) awarding ANI compensatory damages as provided by law, including damages grounded in restitution and unjust enrichment; (iv) in the event of a judgment in ANIâ€™s favor on ANIâ€™s fourth counterclaim for unjust enrichment, ordering CG Oncology to re-transfer to ANI ownership of all assets that ANI sold to CG Oncology under the November 2010 Agreement, including, without limitation, all data and documentation comprising IND 12154; and (v) in the event of a judgment in ANIâ€™s favor on ANIâ€™s fourth counterclaim for unjust enrichment, imposing a constructive trust on all fruits of CG0070-related assets that ANI sold to CG Oncology under the November 2010 Agreement including, without limitation, all data and documentation comprising IND 12154 and any other IND that CG Oncology may have for CG0070. On May 15, 2024, CG Oncology filed a reply to ANIâ€™s counterclaims, which generally maintains the positions in the CGON Answer and Counterclaim. The parties are currently engaged in pretrial discovery. On June 7, 2024, CG Oncology filed a motion to stay discovery pending a decision by the court on its Motion for Summary Judgment. The court denied CG Oncologyâ€™s motion to stay discovery at the conclusion of an oral hearing held on July 11, 2024. The hearing on CG Oncologyâ€™s Motion for Summary Judgment is currently scheduled for August 22, 2024. ANI intends to vigorously pursue this matter.On March 5, 2024, a complaint was filed against ANI by Acella Pharmaceuticals, LLC, in the United States District Court of Minnesota, asserting, among other things, false advertising under the Lanham Act, and unfair trade practices and false advertising under Minnesota law, relating to ANIâ€™s natural desiccated thyroid tablets USP. The complaint seeks injunctive relief, actual and consequential damages, disgorgement of profits, and attorneysâ€™ fees and costs. On April 16, 2024, ANI filed an answer to Acellaâ€™s complaint, denying all claims, and asserting certain affirmative defenses, and counterclaims against Acella for false advertising of its thyroid product marketed as NP ThyroidÂ® Tablets, under the Lanham Act, common law unfair competition and unfair and deceptive trade practices and false advertising under Minnesota and Georgia law. ANI seeks injunctive relief, compensatory damages, punitive damages and attorneysâ€™ fees and costs. On May 17, 2024, Acella filed a motion to dismiss ANIâ€™s counterclaims. On June 7, 2024, ANI filed an amended answer to Acellaâ€™s complaint and counterclaims. Acella filed a motion to dismiss ANIâ€™s amended counterclaims on July 31, 2024. A hearing date has been set for September 11, 2024 on Acellaâ€™s motion to dismiss. The case is currently in fact discovery until February 1, 2025. ANI disputes any liability in this matter and intends to defend this lawsuit vigorously.Patent LitigationOn November 21, 2023, a complaint was filed against Novitium and certain other defendants in the case of Harmony Biosciences, LLC, Bioprojet Societe Civile de Recherche and Bioprojet Pharma SAS v. AET Pharma US, Inc., Annora Pharma Private Limited, Novitium Pharma LLC, Zenara Pharma Private Limited and Biophore India Pharmaceuticals Private Limited in the United States District Court for the District of Delaware, asserting, among other things, that Novitiumâ€™s proposed pitolisant hydrochloride drug product, which is subject to Novitiumâ€™s Abbreviated New Drug Application, infringes certain U.S. patents. The complaint seeks damages, injunctive relief, attorneysâ€™ fees and costs. On January 29, 2024, Novitium filed its answer, denying all allegations and asserting counterclaims of non-infringement and invalidity. On February 16, 2024, plaintiffs filed their answer, denying Novitiumâ€™s counterclaims and asserting certain affirmative defenses against Novitium. On April 15, 2024, the court consolidated Novitiumâ€™s case and two other cases brought by plaintiffs against Lupin Limited et al, and MSN Pharms. Inc. et al., into one consolidated matter filed in C.A. No. 23-1286-JLH. The case is currently in discovery. The court set a trial date of February 2026. Novitium disputes any liability in this matter.30Ranitidine Related LitigationFederal Court Multi District LitigationANI and Novitium were named as defendants, along with numerous other brand and generic pharmaceutical manufacturers, wholesale distributors, retail pharmacy chains, and repackagers of ranitidine-containing products, in In re: Zantac/Ranitidine NDMA Litigation (MDL No, 2924), filed in the United District Court for the Southern District of Florida (the â€œMDL Courtâ€). Plaintiffs allege that defendants failed to disclose and/or concealed the alleged inherent presence of N-Nitrosodimethylamine (or â€œNDMAâ€) in brand-name Zantac or generic ranitidine and the alleged associated risk of cancer. While ANI was initially a defendant, the lead plaintiff attorneys voluntarily dismissed ANI as a defendant in the Master Complaint. On July 8, 2021, the MDL Court dismissed all claims by all plaintiffs against the generic drug manufacturers with prejudice , on preemption grounds. The MDL Court also dismissed all claims by all plaintiffs against the brand manufacturers on summary judgment. Plaintiffs appealed the MDL Courtâ€™s dismissals to the Eleventh Circuit Court of Appeals. On November 7, 2022, the Eleventh Circuit affirmed the MDL Courtâ€™s dismissal of cases brought by third-party payors. The Eleventh Circuit raised questions in the appeals of the other cases about the finality of the MDL Courtâ€™s judgments, which were resolved in September 2023. Plaintiffs filed opening briefs on April 10, 2024 and generics defendants filed their response on July 25, 2024.ANI and Novitium dispute any liability in this matter.State Court Personal Injury LitigationANI and Novitium have also been named as defendants in various state lawsuits.California. The pending cases in California state court naming generic ranitidine manufacturers were transferred to an existing civil case coordination docket for pretrial proceedings (JCCP) in Alameda County. On September 21, 2023, plaintiffs filed a master complaint in the JCCP alleging strict liability, negligent failure to warn and general negligence, but not naming any generic defendants. In December 2023, the Keller Postman firm filed approximately 200 individual plaintiff short form complaints that name generic defendants. Novitium is named in 28 of the short form complaints which reference the claims for the master complaint, but has not been served. ANI is not named. On February 1, 2024, the generic defendants filed an omnibus demurrer challenging the sufficiency of the Keller Postman complaints, largely on the basis of preemption. On April 23, 2024, the California court granted the demurrer in part, dismissing all design defect claims against the generic defendants with prejudice on preemption grounds, but the court otherwise granted plaintiffs an opportunity for leave to amend their other claims against the generic defendants. Plaintiffs filed an amended master complaint on April 29, 2024. Novitium is named in one case and discovery is currently ongoing. Pennsylvania. In September 2022, two complaints were filed naming Novitium as a defendant in Pennsylvania state court, Philadelphia County. On February 16, 2023, the Pennsylvania plaintiffs filed a consolidated long-form complaint against the generic defendants, Plaintiffs v. Actavis, et. al. Civil Action No. 1364. The long-form complaint names Novitium as a defendant. The long form complaint asserts causes of action for negligence, failure to warn, negligent storage and transportation, breach of express warranties, breach of implied warranties, negligent misrepresentation, fraud, strict products liability, wrongful death and survivor actions, and loss of consortium. The complaint includes a prayer for punitive damages. The generic defendants filed their preliminary objections to Plaintiffsâ€™ consolidated long-form generic complaint on March 20, 2023. The court dismissed all claims related to failure to warn/design defects on preemption grounds. The court also sustained the genericsâ€™ preliminary objections relating to the counts of strict liability-design defect and breach of implied warranty to the extent Pennsylvania substantive law applies, effectively dismissing the generic defendants from the case unless and until a non-resident plaintiff names a generic in a short form complaint. Out of an abundance of caution, however, the generics, including Novitium, all filed answers to the long form complaint in June 2023. In January 2024, plaintiffs filed short form complaints naming generic defendants, including Novitium in one complaint. Generic defendants filed joint preliminary objections to the short form complaints based on preemption. The deadline for filing responses to these objections has passed and no amended complaint or response has been filed by plaintiffs against Novitium.ANI and Novitium dispute any liability in these matters.14.Â Â Â Â FAIR VALUE DISCLOSURESFair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value.31The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of our funds. The fair value of short-term financial instruments (primarily accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current liabilities) approximate their carrying values because of their short-term nature. The Term Facility bears an interest rate that fluctuates with the changes in SOFR and, because the variable interest rates approximate market borrowing rates available to us, we believe the carrying values of these borrowings approximated their fair values at JuneÂ 30, 2024.Financial Assets and Liabilities Measured at Fair Value on a Recurring BasisMoney Market FundsMoney market funds are readily convertible into cash and the net asset value of each fund on the last day of the Â Â Â Â Â Â Â Â reporting period is used to determine its fair value. Money market funds are included in Cash and cash equivalents within the Consolidated Balance Sheet, and is classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company does not adjust the quoted market price for such financial instruments. The fair value of the money market funds as of JuneÂ 30, 2024 was approximately $166.5 million.Interest Rate SwapThe fair value of the interest rate swap is estimated based on the present value of projected future cash flows using the SOFR forward rate curve (see Note 6). The model used to value the interest rate swap includes inputs of readily observable market data, a Level 2 input. As described in detail in Note 6, the fair value of the interest rate swap was $7.4 million as of JuneÂ 30, 2024, and was classified as a non-current asset.CG Oncology Equity SecuritiesThe Company currently holds 219,925 shares of common stock in CG Oncology (Nasdaq: CGON). The Company accounts for its investment in CG Oncology equity securities as an equity investment with a readily determinable fair value, as the securities are publicly traded on the Nasdaq Global Select Market. The fair value of the equity securities is based on its closing price on the Nasdaq and is classified within Level 1 of the fair value hierarchy because the equity securities are valued using quoted market prices. The Company does not adjust the quoted market price for such financial instruments. The fair value of the CG Oncology equity securities as of JuneÂ 30, 2024 was approximately $6.9 million based on a closing market price of $31.57 on June 28, 2024. This amount is classified on the unaudited condensed consolidated statements of operations as Unrealized gain on investment in equity securities. Between 2013 and 2023, CG Oncology securities held by the Company were valued at zero under U.S. GAAP.Contingent ConsiderationIn connection with the acquisition of Novitium, the Company may pay up to $46.5 million in additional consideration related to the achievement of certain milestones, such as milestones on gross profit of Novitium portfolio products over a 24-month period, regulatory filings completed during this 24-month period, and a percentage of net profits on certain products that are launched in the future.The discounted cash flow method used to value this contingent consideration includes inputs which are classified as Level 3 inputs, as the inputs are not based on readily available market data. Pursuant to the terms of the Novitium Merger Agreement, on DecemberÂ 12, 2023, the Company paid $12.5 million of cash consideration to the Company Members, defined as the holders of Novitium ownership interests in the Novitium Merger Agreement, as the holders of Novitium ownership interests, for the achievement of the â€œANDA Filing Earn-Out,â€ as defined in the Agreement (Note 15). Furthermore, on FebruaryÂ 22, 2024, the Company paid $12.5 million to Company Members of Novitium upon the achievement of the â€œGross Profit Earn-Out,â€ as defined in the Agreement (Note 15).The fair value of the contingent consideration was approximately $11.9 million and $24.0 million as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively, and is reflected as a current and non-current accrued contingent consideration liability in the unaudited interim condensed consolidated balance sheets.32The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs as of June 30, 2024:Payment TypeValuation TechniqueUnobservable InputAssumptionsProfit-based milestone paymentsProbability-weighted discounted cash flowDiscount rate13%Projected fiscal year of payment2025-2035The following table presents the changes in contingent consideration balances classified as Level 3 for the three and six months ended JuneÂ 30, 2024 and 2023:Three Months Ended June 30,Six Months Ended June 30,(in thousands)2024202320242023Beginning balance$11,574Â $36,019Â $23,984Â $35,058Â Payment of Gross-Profit earn-outâ€”Â â€”Â (12,500)â€”Â Change in fair value359Â 1,035Â 449Â 1,996Â Ending balance$11,933Â $37,054Â $11,933Â $37,054Â The following table presents our financial assets and liabilities accounted for at fair value on a recurring basis as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, by level within the fair value hierarchy:(in thousands)DescriptionFair Value at June 30, 2024Level 1Level 2Level 3AssetsMoney Market Fund$166,485Â $166,485Â $â€”Â $â€”Â Interest rate swap$7,366Â $â€”Â $7,366Â $â€”Â Â Â Â CG Oncology - Investment in equity securities$6,943Â $6,943Â $â€”Â $â€”Â LiabilitiesÂ Â Â Â Contingent consideration$11,933Â $â€”Â $â€”Â $11,933Â DescriptionFair Value at December 31, 2023Level 1Level 2Level 3AssetsÂ Â Â Money Market Fund$191,841Â $191,841Â $â€”Â $â€”Â Interest rate swap$6,236Â $â€”Â $6,236Â $â€”Â LiabilitiesÂ Â Â Â Contingent consideration$23,984Â $â€”Â $â€”Â $23,984Â Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring BasisThere are no financial assets or liabilities that are measured at fair value on a non-recurring basis.Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring BasisThere are no non-financial assets or liabilities that are measured at fair value on a recurring basis.Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring BasisLong-lived assets, including property, plant, and equipment, right-of-use (â€œROUâ€) assets, intangible assets, and goodwill, are measured at fair value on a non-recurring basis, and no such fair value impairment was recognized in the three and six months ended JuneÂ 30, 2024 and 2023.3315.Â Â Â Â RELATED PARTY TRANSACTIONSPIPE SharesOn MarchÂ 8, 2021, the Company entered into an Equity Commitment and Investment Agreement with the PIPE Investor, pursuant to which 25,000 shares were purchased for $1,000 per share for an aggregate purchase price of $25.0 million on NovemberÂ 19, 2021. The Chairman of the Companyâ€™s board of directors is an operating partner of Ampersand Capital Partners, an affiliate of the PIPE Investor.NovitiumIn connection with the acquisition of Novitium, the Company entered into employment agreements with the two executives and founders of Novitium, Muthusamy Shanmugam, Head of R&D and COO of NJ Operations of ANI, and Chad Gassert, Sr. Vice President, Corporate Development and Strategy of ANI. Both serve as executive officers of the Company and Mr. Shanmugam also serves on the Companyâ€™s board of directors. Mr. Shanmugam holds a minority interest in Scitus Pharma Services (â€œScitusâ€), which provides clinical research services to Novitium, a majority interest in SS Pharma LLC (â€œSS Pharmaâ€), which acquires and supplies API to Novitium, a minority interest in Nuray Chemical Private Limited (â€œNurayâ€), which manufactured and supplied API to Novitium in prior periods, a majority interest in Esjay Pharma LLC (â€œEsjayâ€), which provides research and development and facilities consulting services, and a minority interest in SThree Chemicals Pvt Ltd (â€œSThreeâ€), which acquires and supplies API to Novitium. A summary of payments to related parties is presented below:Three Months Ended June 30,Six Months Ended June 30,20242023202320242023Scitus Pharma Services$580Â $1,188Â $1,081Â $1,905Â SS Pharma LLC176Â 1,978Â 1,245Â 3,579Â SThree Chemicals Pvt Ltd683Â â€”Â 1,069Â â€”Â $1,439Â $3,166Â $3,395Â $5,484Â As of JuneÂ 30, 2024, the outstanding balances due to Scitus, SThree, and Esjay were $0.7 million, $2.2 million, and $46 thousand respectively. There was no outstanding balance due to SS Pharma.On DecemberÂ 12, 2023, the Company paid $12.5 million of cash consideration to the Company Members of Novitium for the achievement of the â€œANDA Filing Earn-Out,â€ as defined in the Novitium Merger Agreement, as discussed in Note 2. The Company paid Mr. Shanmugam and Esjay, and Mr. Gassertâ€™s company Chali Properties LLC, approximately $6.7 million and $1.9 million, respectively, for their portion of the cash consideration due to them as part of the Novitium acquisition.On FebruaryÂ 22, 2024, the Company paid $12.5 million of cash consideration to the Company Members of Novitium for the achievement of the â€œGross Profit Earn-Out,â€ as defined in the Novitium Merger Agreement, as discussed in Note 2. The Company paid Mr. Shanmugam and Esjay, and Mr. Gassertâ€™s company Chali Properties LLC, approximately $6.7 million and $1.9 million, respectively, for their portion of the cash consideration due to them as part of the Novitium acquisition. 16.Â Â Â Â SEGMENT REPORTINGAn operating segment is defined as a component of an entity that engages in business activities from which it may recognize revenues and incur expense, its operating results are regularly reviewed by the entityâ€™s chief operating decision maker (â€œCODMâ€) to make decisions about resources to be allocated to the segment and assess its performance, and its discrete financial information is available. The CODM for the Company is the Chief Executive Officer. The Company is organized into two operating segments as follows:â€¢Generics, Established Brands, and Other â€“ Consists of operations related to the development, manufacturing, and marketing of generic and established brand pharmaceuticals, including those sold through traditional channels, contract manufactured products, product development services, royalties, and other.34â€¢Rare Disease â€“ Consists of operations related to the development, manufacturing and marketing of pharmaceuticals used in the treatment of patients with rare conditions. The rare disease segment currently consists of

operations related to Cortrophin Gel.The CODM evaluates the two operating segments based on revenues and earnings before interest, income taxes, depreciation, and amortization (â€œEBITDAâ€), exclusive of corporate expenses and other expenses not directly allocated or attributable to an operating segment. These expenses include, but are not limited to, certain management, legal, accounting, human resources, insurance, and information technology expenses.The Company does not manage assets of the Company by operating segment, and our CODM does not review asset information by operating segment. Accordingly, the Company does not present total assets by operating segment.Financial information by reportable segment is as follows:Three Months Ended June 30,Six Months Ended June 30,(in thousands)20242023Net RevenuesGenerics, Established Brands, and Other$88,847Â $92,243Â $189,340Â $182,699Â Rare Disease49,193Â 24,304Â 86,130Â 40,634Â Total net revenues$138,040Â $116,547Â $275,470Â $223,333Â Segment earnings before interest, taxes, depreciation and amortization (â€œEBITDAâ€) and reconciliation to income before income taxesGenerics, Established Brands, and Other$31,631Â $39,937Â $76,937Â $78,765Â Rare Disease4,344Â 4,215Â 4,740Â 2,964Â Depreciation and amortization(14,697)(14,690)(29,383)(29,390)Corporate and other unallocated expenses(1)(16,109)(17,060)(26,813)(30,042)Total operating income 5,169Â 12,402Â 25,481Â 22,297Â Unrealized (loss) gain on investment in equity securities (2,712)â€”Â 6,943Â â€”Â Interest expense, net(4,656)(7,100)(9,256)(14,796)Other expense, net(88)(53)(120)(87)(Loss) Income Before Income Tax Expense (Benefit)$(2,287)$5,249Â $23,048Â $7,414Â _____(1)Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our unaudited interim consolidated statement of operations. This amount also includes the gain on the sale of the Oakville, Ontario site of approximately $5.3Â million refer to Note 4 for further information.Geographic InformationOperations are currently located in the United States and India. The Company has ceased operations at our Oakville, Ontario, Canada location as of March 31, 2023. The majority of the assets of the Company are located in the United States.35The following table depicts the Companyâ€™s revenue by geographic operations during the following periods:(in thousands)Three Months Ended June 30,Six Months Ended June 30,Location of Operations20242023United States$138,040Â $116,547Â $275,470Â $222,768Â Canadaâ€”Â â€”Â 565Â Total Revenue$138,040Â $116,547Â $275,470Â $223,333Â The following table depicts the Companyâ€™s property, plant and equipment, net according to geographic location, which excludes the land and building at the Companyâ€™s Canada facility, which was classified as held for sale as of DecemberÂ 31, 2023. These assets had a carrying value of approximately $8.0 million. The land and building at the Canada facility was sold on March 28, 2024, refer to Note 4. The Companyâ€™s property, plant and equipment are as follows: (in thousands)June 30, 2024December 31, 2023United States$49,887Â $43,163Â India1,753Â 1,430Â Total property and equipment, net$51,640Â $44,593Â 17.Â Â Â Â SUBSEQUENT EVENTS On July 12, 2024, the Company filed a Registration Statement on Form S-8 with the SEC, to register under the Securities Act of 1933, as amended, 1,610,000 shares of common stock which may be issued from time to time in accordance with the Companyâ€™s Amended 2022 Stock Plan. 36Item 2.Â Â Â Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsThe following Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited interim condensed consolidated financial statements and the accompanying notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q, the audited consolidated financial statements and the accompanying notes thereto in our Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023 (the â€œ2023 Form 10-Kâ€), as well as the information contained under Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations and â€œRisk Factorsâ€ contained in the 2023 Form 10-K, and Part II, Item 1A â€œRisk Factorsâ€ of this Quarterly Report on Form 10-Q , and other information provided from time to time in our other filings with the SEC. This discussion contains forward-looking statements, based on current expectations and related to future events and our future financial performance, that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many important factors, including those set forth under â€œRisk Factorsâ€ in our 2023 Form 10-K and this Quarterly Report on Form 10-Q.EXECUTIVE OVERVIEWANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, â€œANI,â€ the â€œCompany,â€ â€œwe,â€ â€œus,â€ or â€œourâ€) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by scaling up our Rare Disease business through the launch of our lead asset, Cortrophin Gel, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our U.S.-based manufacturing capabilities. Our three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. We ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. This action was part of ongoing initiatives to capture operational synergies following our acquisition of Novitium Pharma LLC (â€œNovitiumâ€) in November 2021. We have fully completed the transition of the products manufactured or packaged in Oakville to one of our three U.S. based manufacturing sites. In February 2024, our Canadian subsidiary entered into an agreement for the purchase and sale of the Oakville site, for a purchase price of $19.2Â million Canadian Dollars, or approximately $14.2Â million, based on the exchange rate at closing. The sale closed on March 28, 2024 (see Note 4).StrategyOur objective is to build a sustainable and growing biopharmaceutical company serving patients in need and creating long-term value for our investors. Our overall strategy is enabled by an empowered, collaborative, and purposeful team with high performance-orientation that seeks to deliver on our purpose of â€œServing Patients, Improving Lives.â€Our growth strategy is driven by the following key growth drivers:Building a successful Rare Disease platformOn June 24 2024, we announced that we entered into a definitive agreement pursuant to which we will acquire Alimera Sciences, Inc. (â€œAlimeraâ€), which is currently expected to close late during the third quarter of 2024, subject to customary closing conditions, including receipt of required regulatory approvals and approval by Alimeraâ€™s shareholders. The acquisition of Alimera is anticipated to strengthen our Rare Disease business and expand our footprint beyond the U.S. with the addition of Alimeraâ€™s direct marketing operations located in Germany, the United Kingdom, Portugal, and Ireland, as well as its partnerships in Europe, Asia, and the Middle East.Throughout 2023 and the first half of 2024, we continued to build and invest in our infrastructure to support growth in new areas of opportunity, such as pulmonology, ophthalmology, and gout in the ACTH market. On October 2, 2023, we announced FDA approval and commercial availability of a 1-mLvial of Cortrophin Gel, appropriate for adjunctive treatment of certain patients with acute gouty arthritis flares. As a result of the continued investment in our Rare Disease platform, our expenditures were significantly higher during the first half of 2024 as compared to the prior year.We have spent significant time, effort and resources in establishing our Rare Disease platform. We acquired the NDAs for Cortrophin Gel and Cortrophin-Zinc in January 2016 and executed long-term supply agreements with a supplier of our primary raw material for corticotrophin API, a supplier of corticotrophin API with whom we have advanced the manufacture of commercial scale batches of API, and a Cortrophin Gel fill/finish contract manufacturer. During the second quarter of 2021, we submitted a Supplemental New Drug Application (â€œsNDAâ€) to the FDA.37On October 29, 2021, the FDA approved the Companyâ€™s sNDA for Purified Cortrophin Gel (Repository Corticotropin Injection USP) for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis (â€œMSâ€) and rheumatoid arthritis (â€œRAâ€), in addition to excess urinary protein due to nephrotic syndrome. Cortrophin Gel is an adrenocorticotropic hormone (â€œACTHâ€), also known as purified corticotropin.During 2021 and 2022, we invested significantly in leadership, expertise and infrastructure in the areas of commercialization of rare disease therapies and developed a launch strategy and commercial plan for this product. During this timeframe, we hired a significant number of new employees and assembled and trained our Rare Disease field force. On January 24, 2022, we announced the commercial launch of Cortrophin Gel in the U.S as our foundational Rare Disease asset. We plan to continue to expand our Rare Disease business, through a combination of organic growth, as described above, and acquisition. See below for expanded discussion on our pending business combination with Alimera. While we continue to execute against our strategic initiatives that we believe will result in the long-term, sustainable growth and value to our stockholders, we continue to evaluate potential acquisitions and other strategic transactions of businesses that we believe complement our existing portfolio, infrastructure and capabilities or provide us with the opportunity to expand our existing capabilities.Strengthening our Generics, Established Brands, and Other segment through continued investment in our generic research and development capability and increased focus on niche opportunitiesWe have grown our generics business through a combination of market share gains on existing products and new product launches. We have also successfully acquired numerous ANDAs through business and asset acquisitions. Our most recent business acquisition in the Generics, Established Brands, and Other segment was the acquisition of Novitium in 2021, which included its portfolio of commercial and pipeline generic products, manufacturing and development facilities and expert workforce. The Novitium acquisition significantly increased our generic pharmaceutical research and development and manufacturing capabilities. We have begun to increase our focus on niche lower competition opportunities such as injectables, Paragraph IV, and competitive generic therapy (â€œCGTâ€) designation filings. Additionally, we will continue to seek opportunities to enhance our capabilities through strategic partnerships and acquisitions of assets and businesses.During 2023, we acquired two ANDAs and one pipeline product from the Chapter 7 Trustee for the estates of Akorn Holding Company and certain of its affiliates, acquired an ANDA and registered patents and pending patent applications from Slayback Pharma Limited Liability Company, and acquired additional ANDAs and product rights for two products in the second half of 2023. During 2022, we completed an asset acquisition of four ANDAs from Oakrum Pharma, including two that were commercial at the time of acquisition. .We have grown our established brand product offerings through acquisition. We have acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. We are innovating in our go-to-market strategy through creative partnerships. Generic Product Development ConsiderationsWe consider a variety of criteria in determining which products to develop. These criteria include:â€¢Formulation Complexity. Our development and manufacturing capabilities enable us to manufacture pharmaceuticals that are differentiated and include high potency, modified release, combination, and hormonal products. This ability to manufacture a variety of differentiated products is a competitive strength that we intend to leverage in selecting products to develop and commercialize.â€¢Market Size and Patient Need. When determining whether to develop or acquire an individual product, we review the current and expected market size for that product. and competitive environment. We endeavor to pursue products with sufficient market size to enable us to enter the market with a strong likelihood of serving patients in need and thus being able to price our products both competitively and at a profit.â€¢Profit Potential. In determining the potential profit of a product, we forecast our anticipated market share, pricing, competitive environment and the estimated cost to manufacture the products.â€¢Manufacturing. We generally seek to develop and manufacture products at our own manufacturing plants to ensure quality control of our products, supply chain reliability and to more closely control the economic inputs and outputs of our products. 38â€¢Competition. When determining whether to develop or acquire a product, we research existing and expected competition. We seek to develop products for which we can obtain sufficient market share and may decline to develop a product if we anticipate significant competition. Our manufacturing facilities provide a means of entering niche markets, such as hormone therapies, in which fewer generic companies typically compete.Recent DevelopmentsPending merger agreementOn June 21, 2024, the Company entered into an Agreement and Plan of Merger with Alimera and ANIP Merger Sub INC. (â€œMerger Subâ€), providing for the merger of Merger Sub with and into Alimera (the â€œMergerâ€), with Alimera surviving the Merger as a wholly owned indirect subsidiary of the Company. Capitalized terms used herein, but not otherwise defined, have the meanings set forth in the Merger Agreement.At the effective time of the Merger (the â€œEffective Timeâ€), each outstanding share of common stock, par value $0.01 per share, of Alimera, outstanding immediately prior to the Effective Time will automatically be converted into the right to receive (i) $5.50 in cash, without interest and (ii) one contingent value right (a â€œCVRâ€), which shall represent the right to receive the Milestone Payments (as defined below) subject to the terms and conditions set forth in the CVR Agreement (as defined below) (the consideration contemplated by (i) and (ii), together, the â€œMerger Considerationâ€).At or immediately prior to the Effective Time, the Company will enter into a contingent value rights agreement (the â€œCVR Agreementâ€), pursuant to which each holder of Alimera Common Stock, as well as holders of Alimera Warrants, Alimera Options, Alimera PSUs, Alimera RSAs and Alimera RSUs, may become entitled to contingent cash payments per CVR (each, a â€œMilestone Paymentâ€), such payment(s) being contingent upon, and subject to, satisfaction of the Milestones (as defined below).When issued, each CVR will entitle the holder (the â€œHolderâ€) to receive Milestone Payments for 2026 and 2027, upon satisfaction of the applicable Milestones. The Milestone Payments for each CVR will equal the product (rounded to the nearest 1/100 of $0.01) of $0.25 multiplied by a fraction (which is no case will exceed one), and (i) for 2026, equals the amount, if any, by which the 2026 Net Revenue exceeds $140.0Â million, divided by $10.0Â million (subject to adjustment for the exercise price of Eligible Options), and (ii) for 2027, equals the amount, if any, by which the 2027 Net Revenue exceeds $160.0Â million, divided by $15.0Â million (subject to adjustment for the exercise price of Eligible Options) (the occurrence of the events in clauses (i) and (ii), each, a â€œMilestoneâ€).The Merger Agreement requires Alimera, as promptly as reasonably practicable, and in any event within 25 business days following the date of the Merger Agreement, to prepare and file with the SEC a proxy statement for the purpose of seeking stockholder approval to the Merger Agreement.Consummation of the Merger is subject to certain conditions, including approval by Alimeraâ€™s stockholders, the absence of any legal restraints restraining, enjoining, preventing, prohibiting or otherwise making illegal the consummation of the Merger, expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and any other specified required regulatory approvals that may be required will have been obtained, and each partyâ€™s performance of its obligations in all material respects under the Merger Agreement.In connection with the Merger, JPMorgan Chase Bank, N.A. and Blackstone Credit & Insurance (the â€œLendersâ€) have committed to provide debt financing for the transaction in an aggregate principal amount equal to $280.0Â million, on the terms and subject to the conditions set forth in a commitment letter, dated June 21, 2024 (the â€œDebt Commitment Letterâ€). The obligations of the Lenders to provide debt financing under the Debt Commitment Letter are subject to customary conditions, including, without limitation, execution and delivery of definitive documentation consistent with the Debt Commitment Letter.During the three and six months ended JuneÂ 30, 2024, the Company incurred approximately $3.5 million, respectively, in transaction costs related to this pending Merger Agreement, all of which were expensed.39Restructuring On February 15, 2024, ANI Pharmaceuticals Canada, Inc., a wholly owned subsidiary of the Company, entered into an agreement (the â€œAgreementâ€) with 1540700 Ontario Limited (â€œBuyerâ€) for the sale of ANIâ€™s Oakville, Ontario former manufacturing site (the â€œPropertyâ€) for a total purchase price of $19.2Â million Canadian Dollars, or approximately $14.2Â million, based on the exchange rate at closing. During February 2024, and in accordance with the Agreement, the Buyer deposited a total of approximately $1.9Â million Canadian Dollars, or approximately $1.4Â million in refundable deposits in escrow as part of the total purchase price. On March 28, 2024 the Company completed the sale of the Property. After payment of commissions, taxes, and other related costs of approximately $0.6 million, the Company received a net cash amount of approximately $13.5Â million at closing. The gain on the sale of the Property was approximately $5.3Â million, recorded in the unaudited interim condensed consolidated statements of operations.GENERALImpacts to our second quarter 2024 and 2023 results of operations, including to net revenues, operating expenses, interest and other expense, net, and income taxes are described below.The following table summarizes our results of operations for the periods indicated:Three Months Ended June 30,Six Months Ended June 30,(in thousands)20242023Net Revenues$138,040Â $116,547Â $275,470Â $223,333Â Operating ExpensesCost of sales (excluding depreciation and amortization)57,698Â 42,284Â 106,855Â 79,992Â Research and development7,296Â 7,374Â 17,807Â 13,298Â Selling, general, and administrative52,821Â 38,760Â 100,842Â 75,228Â Depreciation and amortization14,697Â 14,690Â 29,383Â 29,390Â Contingent consideration fair value adjustment359Â 1,035Â 449Â 1,996Â Restructuring activitiesâ€”Â 2Â â€”Â 1,132Â Gain on sale of building â€”Â â€”Â (5,347)â€”Â Operating Income 5,169Â 12,402Â 25,481Â 22,297Â Unrealized (loss) gain on investment in equity securities (2,712)â€”Â 6,943Â â€”Â Interest expense, net(4,656)(7,100)(9,256)(14,796)Other expense, net(88)(53)(120)(87)(Loss) Income Before Income Tax Expense (Benefit)(2,287)5,249Â 23,048Â 7,414Â Income tax expense (benefit)â€”Â (996)7,128Â (270)Net (Loss) Income $(2,287)$6,245Â $15,920Â $7,684Â 40The following table sets forth, for all periods indicated, items in our unaudited interim condensed consolidated statements of operations as a percentage of net revenues:Three Months Ended June 30,Six Months Ended June 30,20242023Net Revenues100Â %100Â %100Â %100Â %Operating ExpensesCost of sales (excluding depreciation and amortization)41.8Â %36.3Â %38.8Â %35.8Â %Research and development5.3Â %6.3Â %6.5Â %6.0Â %Selling, general, and administrative38.3Â %33.3Â %36.6Â %33.7Â %Depreciation and amortization10.6Â %12.6Â %10.7Â %13.2Â %Contingent consideration fair value adjustment0.3Â %0.9Â %0.2Â %0.9Â %Restructuring activitiesâ€”Â %0.0%â€”Â %0.5Â %Gain on sale of building â€”Â %â€”Â %(1.9)%â€”Â %Operating Income

3.7Â %10.6Â %9.1Â %9.9Â %Unrealized (loss) gain on investment in equity securities (2.0)%â€”Â %2.5Â %â€”Â %Interest expense, net(3.4)%(6.1)%(3.4)%(6.6)%Other expense, net(0.0)%(0.0)%(0.0)%(0.0)%(Loss) Income Before Income Tax Expense (Benefit)(1.7)%4.5Â %8.2Â %3.3Â %Income tax expense (benefit)â€”Â %(0.9)%2.6Â %(0.1)%Net (Loss) Income (1.7)%5.4Â %5.6Â %3.4Â %41RESULTS OF OPERATIONSRESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30, 2024 AND 2023Net RevenuesThree Months Ended June 30,(in thousands)20242023Change% ChangeGenerics, Established Brands, and Other SegmentGeneric pharmaceutical products$73,964Â $63,317Â $10,647Â 16.8Â %Established brand pharmaceutical products, royalties, and other pharmaceutical services14,883Â 28,926Â (14,043)(48.5)%Generics, established brands, and other segment total net revenues$88,847Â $92,243Â $(3,396)(3.7)%Rare Disease SegmentRare disease pharmaceutical products$49,193Â $24,304Â $24,889Â 102.4Â %Total net revenues$138,040Â $116,547Â $21,493Â 18.4Â %We derive substantially all of our revenues from sales of generic, rare disease, and established brand pharmaceutical products, royalties on net sales of certain products, and other pharmaceutical services. Many of our established brand products as well as our generic products face competition from generic products and we expect them to continue to face competition from generic products in the future. The primary means of competition among generic manufacturers are pricing, contract terms, service levels, and reliability. Increased competition generally results in decreased average selling prices of generic and brand products over time. In addition, due to strategic partnerships between wholesalers and pharmacy chains, we have experienced, and expect to continue to experience, increases in net sales to the wholesalers, with corresponding decreases in net sales to the pharmacy chains.Net revenues for the three months ended JuneÂ 30, 2024 were $138.0 million compared to $116.5 million for the same period in 2023, an increase of 18.4%, primarily as a result of the following factors:â€¢Net revenues for generic pharmaceutical products were $74.0 million during the three months ended JuneÂ 30, 2024, an increase of 16.8% compared to $63.3 million for the same period in 2023, driven by increased volumes and the inclusion of 2023 launches and new product launches in 2024. From a product perspective, the increase was principally driven by revenues from year over year increases in products such as Colestipol, Estradiol, Pentoxifylline, Pirfenidone, Thyroid, and various other products tempered by a decrease in revenues of Famotidine, Paliperidone, Misoprostol, and Nebivolol among others. â€¢Net revenues for branded pharmaceutical products, royalties, and other pharmaceutical services were $14.9 million during the three months ended JuneÂ 30, 2024, a decrease of 48.5% compared to $28.9 million for the same period in 2023, driven by a net decrease in volume. During the three months ended June 30, 2023, we benefited from supplying incremental volume in markets that were experiencing supply chain disruptions for competing products.â€¢Net revenues of rare disease pharmaceutical products, which consists entirely of sales of Cortrophin Gel, were $49.2 million during the three months ended JuneÂ 30, 2024, an increase of $24.9 million from $24.3 million for the same period in 2023. This increase was driven by increased volume in this third year of launch (product was launched in late January 2022).42Cost of Sales (Excluding Depreciation and Amortization)Three Months Ended June 30,(in thousands)20242023Change% Change Cost of sales (excluding depreciation and amortization)$57,698Â $42,284Â $15,414Â 36.5Â %Cost of sales consists of direct labor, including manufacturing and packaging, active and inactive pharmaceutical ingredients, freight costs, packaging components, and royalties payable related to profit-sharing arrangements. Cost of sales does not include depreciation and amortization expense, which is reported as a separate component of operating expenses on our unaudited interim condensed consolidated statements of operations.For the three months ended JuneÂ 30, 2024, cost of sales increased to $57.7 million from $42.3 million for the same period in 2023, an increase of $15.4 million, or 36.5%. The increase is primarily due to significant net growth in sales volumes of pharmaceutical products and significant growth of royalty bearing products, including Cortrophin Gel.Cost of sales, as a percentage of net revenues, increased to 41.8% from 36.3% for the three months ended JuneÂ 30, 2024, compared to the same period in 2023, primarily due to a shift in product mix year over year, increase in sales volume, and increase in sales of products that bear a royalty payable. During the three months ended JuneÂ 30, 2024, approximately 27% of our raw material purchases were from one supplier. During the three months ended JuneÂ 30, 2023, no single vendor represented more than 10% of our raw material inventory purchases.Other Operating Expenses, netThree Months Ended June 30,(in thousands)20242023Change% ChangeResearch and development$7,296Â $7,374Â $(78)(1.1)%Selling, general, and administrative52,821Â 38,760Â 14,061Â 36.3Â %Depreciation and amortization14,697Â 14,690Â 7Â â€”Â %Contingent consideration fair value adjustment359Â 1,035Â (676)(65.3)%Restructuring activitiesâ€”Â 2Â (2)(100.0)%Total other operating expenses, net$75,173Â $61,861Â $13,312Â 21.5Â %For the three months ended JuneÂ 30, 2024, other operating expenses, net increased to $75.2 million from $61.9 million for the same period in 2023, an increase of $13.3 million, or 21.5%, primarily as a result of the following factors:â€¢Research and development expenses decreased from $7.4 million to $7.3 million, a nominal decrease of approximately $0.1 million or 1.1% when comparing the three months ended JuneÂ 30, 2024 to the same period in 2023.â€¢Selling, general, and administrative expenses increased from $38.8 million to $52.8 million, an increase of $14.1 million, or 36.3%, due to increased employment related costs, continued investment in our Rare Disease segment sales and marketing activities, legal expenses, expenses related to the pending acquisition of Alimera, as well as an overall increase in activities required to support the growth of our business. â€¢Depreciation and amortization expense was $14.7 million for the three months ended JuneÂ 30, 2024, compared to $14.7 million for the same period in 2023.43â€¢We recognized losses of $0.4 million and $1.0 million in the three months ended JuneÂ 30, 2024 and 2023, respectively, for the contingent consideration fair value adjustment. The change in the fair value adjustment during the three months ended JuneÂ 30, 2024 is primarily related to changes in the anticipated timing of cash flows (i.e., moving closer to the anticipated payment dates of the consideration for the third milestone in connection with the acquisition of Novitium). Additionally, the fair value measurement adjustment in the three months ended JuneÂ 30, 2024 is related to only the third milestone, whereas the fair value adjustment at June 30, 2023 related to all three milestones.Other Expense, netThree Months Ended June 30,(in thousands)20242023Change% Change Unrealized loss on investment in equity securities$(2,712)$â€”Â $(2,712)(100.0)%Interest expense, net(4,656)(7,100)2,444Â (34.4)%Other expense, net(88)(53)(35)66.0Â %Total other expense, net$(7,456)$(7,153)$(303)4.2Â %For the three months ended JuneÂ 30, 2024, we recognized total other expense of $7.5 million as compared to total other expense of $7.2 million for the same period in 2023, an increase of $0.3 million. â€¢We recorded an unrealized loss on our investment in equity securities held in CG Oncology of approximately $2.7 million is due to the mark to market to fair value of equity securities as of the balance sheet date. There was no comparable loss on investment in the three months ended JuneÂ 30, 2023. â€¢Interest expense, net for the three months ended JuneÂ 30, 2024 consists primarily of interest expense on borrowings under our Term Facility of approximately $8.5 million and amortization of deferred debt issuance costs of approximately $0.6 million, offset by dividend income earned on our money market funds and interest earned on our cash balances of approximately $2.6 million, the effects of the interest rate swap of approximately $1.6 million, and interest capitalized into construction in progress. The decrease in interest expense is primarily related to the increase in the dividend income and interest income earned on our larger cash balances during the current period, as interest expense on borrowing under our Term Facility and amortization of deferred debt issuance costs are consistent with the three months ended JuneÂ 30, 2023.44Income Tax Expense (Benefit)Three Months Ended June 30,Â (in thousands)20242023Change% Change Income tax expense (benefit)$â€”Â (996)996Â (100.0)%Income tax expense (benefit) consists of current and deferred components, which include changes in our deferred tax assets, our deferred tax liabilities, and our valuation allowance.For the three months ended JuneÂ 30, 2024, we recognized an income tax expense of approximately $0.0 million. The Companyâ€™s effective tax rate was 0.0% after discrete items for the three months ended JuneÂ 30, 2024. The effective tax rate differed from the federal statutory rate of 21% primarily due to state taxes, stock based compensation, and non-deductible expenses related to the pending business combination which were treated as a discrete item during the quarter which affects the estimated tax rate.For the three months ended JuneÂ 30, 2023, we recognized an income tax benefit of $1.0 million. The income tax expense resulted from applying an estimated annual worldwide effective tax rate of (19.0)% to pre-tax consolidated income of $5.2 million reported during the period. There were no material discrete items occurring during the three months ended JuneÂ 30, 2023.RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023Net RevenuesSix Months Ended June 30,(in thousands)20242023Change% ChangeGenerics, Established Brands, and Other SegmentGeneric pharmaceutical products$144,181Â $127,030Â $17,151Â 13.5Â %Established brand pharmaceutical products, royalties, and other pharmaceutical services$45,159Â $55,669Â (10,510)(18.9)%Generics, established brands, and other segment total net revenues$189,340Â $182,699Â $6,641Â 3.6Â %Rare Disease SegmentRare disease pharmaceutical products86,130Â 40,634Â 45,496Â 112.0Â %Total net revenues$275,470Â $223,333Â $52,137Â 23.3Â %Net revenues for the six months ended JuneÂ 30, 2024 were $275.5 million compared to $223.3 million for the same period in 2023, an increase of 23.3%, primarily as a result of the following factors:â€¢Net revenues for generic pharmaceutical products were $144.2 million during the six months ended JuneÂ 30, 2024, an increase of 13.5% compared to $127.0 million for the same period in 2023, driven by increased volumes and the inclusion of 2023 launches and new product launches in 2024. From a product perspective, the increase was principally driven by revenues from year over year increases in products such as Colestipol, Estradiol,Lacosamide, Nitrofurantoin, Pentoxifylline, Pirfenidone, Prednisone, Tranexamic Acid, and various other products tempered by a decrease in revenues of Famotidine, Meloxicam, Nebivolol, Paliperidone, and Prochlorperazine among others. â€¢Net revenues for branded pharmaceutical products, royalties, and other pharmaceutical services were $45.2 million during the six months ended JuneÂ 30, 2024, a decrease of 18.9% compared to $55.7 million for the same period in 2023, driven by a net decrease in volume. During the first quarter of 2024, we were successful in supplying incremental volume in markets that were experiencing supply chain disruptions for competing products, which did not continue into the second quarter of 2024.â€¢Net revenues of rare disease pharmaceutical products, which consists entirely of sales of Cortrophin Gel, were $86.1 million during the six months ended JuneÂ 30, 2024, an increase of $45.5 million from $40.6 million for the same period in 2023. This increase was driven by increased volume in this third year of launch (product 45was launched in late January 2022).Cost of Sales (Excluding Depreciation and Amortization)Six Months Ended June 30,(in thousands)20242023Change% ChangeCost of sales (excluding depreciation and amortization)$106,855Â $79,992Â $26,863Â 33.6Â %For the six months ended JuneÂ 30, 2024, cost of sales increased to $106.9 million from $80.0 million for the same period in 2023, an increase of $26.9 million, or 33.6%. The increase is primarily due to significant net growth in sales volumes of pharmaceutical products and significant growth of royalty bearing products, including Cortrophin Gel.Cost of sales, as a percentage of net revenues, increased to 38.8% from 35.8% for the six months ended JuneÂ 30, 2024, compared to the same period in 2023, primarily due to a shift in product mix year over year, increase in sales volume, and increase in sales of products that bear a royalty payable.During the six months ended JuneÂ 30, 2024, approximately 24% of our raw material purchases were from one supplier. During the six months ended JuneÂ 30, 2023, no single vendor represented more than 10% of our raw material inventory purchases.Other Operating Expenses, netSix Months Ended June 30,(in thousands)20242023Change% ChangeResearch and development$17,807Â $13,298Â $4,509Â 33.9Â %Selling, general, and administrative100,842Â 75,228Â 25,614Â 34.0Â %Depreciation and amortization29,383Â 29,390Â (7)â€”Â %Contingent consideration fair value adjustment449Â 1,996Â (1,547)(77.5)%Restructuring activitiesâ€”Â 1,132Â (1,132)(100.0)%Gain on sale of building (5,347)â€”Â (5,347)100.0Â %Total other operating expenses$143,134Â $121,044Â $22,090Â 18.2Â %For the six months ended JuneÂ 30, 2024, other operating expenses, net increased to $143.1 million from $121.0 million for the same period in 2023, an increase of $22.1 million, or 18.2%, primarily as a result of the following factors:â€¢Research and development expenses increased from $13.3 million to $17.8 million, an increase of $4.5 million or 33.9%, primarily due to a higher level of activity associated with ongoing and new projects in the six months ended JuneÂ 30, 2024.â€¢Selling, general, and administrative expenses increased from $75.2 million to $100.8 million, an increase of $25.6 million, or 34.0%, due to increased employment related costs, continued investment in our Rare Disease segment sales and marketing activities, legal expenses, expenses related to the pending acquisition of Alimera, as well as an overall increase in activities required to support the growth of our business. â€¢Depreciation and amortization expense was $29.4 million for the six months ended JuneÂ 30, 2024, compared to $29.4 million for the same period in 2023. 46â€¢We recognized losses of $0.4 million and $2.0 million in the six months ended JuneÂ 30, 2024 and 2023, respectively, for the contingent consideration fair value adjustment. The change in the fair value adjustment during the six months ended JuneÂ 30, 2024 is primarily related to changes in the anticipated timing of cash flows (i.e., moving closer to the anticipated payment dates of the consideration for the third milestone in connection with the acquisition of Novitium) and fluctuations in the discount rates, offset by adjustments recorded upon payment of the Gross Profit Earn-Out during the first quarter. Additionally, the fair value measurement adjustment in the six months ended JuneÂ 30, 2024 is related to only the third milestone, whereas the fair value adjustment at JuneÂ 30, 2023 related to all three milestones.â€¢We recognized restructuring activities expenses of $1.1 million in the six months ended JuneÂ 30, 2023. In 2023 costs included severance and other employee benefits costs of $0.2 million, $0.7 million of accelerated depreciation costs and $0.2 million for other miscellaneous costs accrued in 2022. There were no restructuring expenses recognized in the six months ended JuneÂ 30, 2024.â€¢We recognized a gain related to the sale of the former Oakville, Ontario manufacturing site of approximately $5.3 million during the six months ended JuneÂ 30, 2024. There was no comparable sale in the six months ended JuneÂ 30, 2023.Other Expense, netSix Months Ended June 30,(in thousands)20242023Change% ChangeUnrealized gain on investment in equity securities $6,943Â $â€”Â $6,943Â 100.0Â %Interest expense, net(9,256)(14,796)5,540Â 37.4Â %Other expense, net(120)(87)(33)37.9Â %Total other expense, net$(2,433)$(14,883)$12,450Â 83.7Â %For the six months ended JuneÂ 30, 2024, we recognized total other expense, net of $2.4 million as compared to total other expense of $14.9 million for the same period in 2023, a decrease of $12.5 million. â€¢The unrealized gain on investment in equity securities of approximately $6.9 million is due to the mark to market to fair value of equity securities held in CG Oncology as of the balance sheet date. There was no comparable gain on investment in the six months ended JuneÂ 30, 2023. â€¢Interest expense, net for the six months ended JuneÂ 30, 2024 consists primarily of interest expense on borrowings under our Term Facility of approximately $17.0 million and amortization of deferred debt issuance costs of approximately $1.2 million, offset by dividend income earned on our money market funds and interest earned on our cash balances of approximately $5.4 million, the effects of the interest rate swap of approximately $3.2 million, and interest capitalized into construction in progress. The decrease in interest expense is primarily related to the increase in the dividend income and interest income earned on our larger cash balances during the current period, as interest expense on borrowing under our Term Facility and amortization of deferred debt issuance costs are consistent with the six months ended JuneÂ 30, 2023.47Income Tax Expense (Benefit)Six Months Ended June 30,(in thousands)20242023Change% ChangeIncome tax expense (benefit)$7,128Â (270)7,398Â (2740.0)%For the six months ended JuneÂ 30, 2024, we recognized an income tax expense of $7.1 million. The Companyâ€™s effective tax rate was 30.9% after discrete items for the six months ended JuneÂ 30, 2024. The effective tax rate differed from the federal statutory rate of 21% primarily due to state taxes, stock based compensation, tax on the sale of the Oakville, Ontario manufacturing site, and recording of a withholding tax liability on the proceeds of the sale, and non-deductible expenses related to a planned acquisition.For the six months ended JuneÂ 30, 2023, we recognized an income tax benefit of $0.3 million. The income tax expense resulted from applying an estimated annual worldwide effective tax rate of (3.7)% to pre-tax consolidated income of $7.4 million reported during the period. There were no material discrete items occurring during the six months ended JuneÂ 30, 2023.48LIQUIDITY AND CAPITAL RESOURCESDebt FinancingOn November 19, 2021, the Company, as borrower, entered into a credit agreement (the â€œCredit Agreementâ€) with Truist Bank and other lenders, which provides for credit facilities consisting of (i) a senior secured term loan facility in an aggregate principal amount of $300.0 million (the â€œTerm Facilityâ€) and (ii) a senior secured revolving credit facility in an aggregate commitment amount of $40.0 million, which may be used for revolving credit loans, swingline loans and letters of credit (the â€œRevolving Facility,â€ and together with the Term Facility, the â€œCredit Facilityâ€). The Credit Facility is secured by substantially all our assets and the assets of our domestic subsidiaries. As of JuneÂ 30, 2024, $3.0 million of principal of the loan was recorded as current borrowings in the condensed consolidated balance sheet. As of JuneÂ 30, 2024, we had not drawn on the Revolving Facility and $40.0 million remained available for borrowing subject to certain conditions.On June 21, 2024, in connection with the pending business combination with Alimera, JPMorgan Chase Bank, N.A. and Blackstone Credit & Insurance as Lenders committed to provide debt financing for the Merger in an aggregate principal amount equal to $280.0 million, on the terms and subject to the conditions set forth in the Debt Commitment Letter. Refer to Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations in this Quarterly Report on Form 10-Q for further information regarding the Merger.Equity FinancingIn May 2023, through a public offering, we completed the issuance and sale of 2,183,545 shares of ANI common stock, resulting in net proceeds after issuance costs of $80.6 million. The proceeds are intended to be used to in-license, acquire or invest in additional businesses, technologies, products or assets, to fund our commercialization efforts, including, but not limited to, sales and marketing and consulting expenses related thereto, and for general corporate purposes. We believe that our financial resources, consisting of current working capital, anticipated future operating revenue and corresponding collections from customers, our Credit Facility, under which $40.0 million remains available for borrowing as of JuneÂ 30, 2024, and the anticipated debt financing provided by the Lenders for the Merger in an aggregate principal amount equal to $280.0 million, will be sufficient to enable us to meet our working capital requirements and debt obligations for at least the next 12 months.Cash FlowsThe following table summarizes the net cash and cash equivalents (used in) provided by operating activities, investing activities, and financing activities for the periods indicated:Six Months Ended June 30,(in thousands)20242023Operating

Activities$35,683Â $42,050Â Investing Activities$4,484Â $(9,179)Financing Activities$(21,178)$75,602Â Net Cash Provided by OperationsNet cash provided by operating activities was $35.7 million for the six months ended JuneÂ 30, 2024, compared to net cash provided by operating activities of $42.1 million during the same period in 2023, a decrease of $6.4 million. The decrease in cash provided by operating activities resulted from an increase in non-cash items such as stock-based compensation offset by non-recurring transactions such as gain on the sale of the Oakville, Ontario manufacturing site, and the gain on investment of equity securities as well as significant fluctuations in our assets and liabilities due to increased activities. Net Cash Provided by (Used in) Investing ActivitiesNet cash provided by investing activities for the six months ended JuneÂ 30, 2024 was $4.5 million, principally due to the proceeds received from the sale of the Oakville, Ontario manufacturing site in March 2024 of approximately $13.5 million offset by capital expenditures of approximately $9.0 million. Net cash used in investing activities for the six months ended JuneÂ 30, 2023 was $9.2 million, principally due to $4.9 million of capital expenditures and acquisitions of ANDAs from the estates of Akorn Holding Company for $4.3 million.49Net Cash (Used in) Provided by Financing ActivitiesNet cash used in financing activities for the six months ended JuneÂ 30, 2024 was $21.2 million, principally resulting from $12.5 million paid to the Company Members of Novitium, $10.0 million of treasury stock purchased related to restricted stock vests, $1.5 million maturity payments on the Term Facility, and $0.8 million convertible preferred stock dividends paid, offset by $3.6 million from proceeds from stock option exercises and ESPP purchases. Net cash provided by financing activities for the six months ended JuneÂ 30, 2023 was $75.6 million, principally due to $80.6 million in proceeds from the May 2023 public offering and $1.4 million from proceeds from stock option exercises and ESPP purchases. This is offset by cash used in financing activities related to $4.1 million of treasury stock purchased in relation to restricted stock vests, $1.5 million maturity payments on the Term Facility, and $0.8 million convertible preferred stock dividends paid.CRITICAL ACCOUNTING ESTIMATESA summary of our significant accounting policies is included in Part II, Item 8. Consolidated Financial Statements, Note 1, Description of Business and Summary of Significant Accounting Policies, in our 2023 Form 10-K. Certain of our accounting policies are considered critical, as these policies require significant, difficult or complex judgments by management, often requiring the use of estimates about the effects of matters that are inherently uncertain. There have been no material changes to our critical accounting estimates since the 2023 Form 10-K.CONTRACTUAL OBLIGATIONSAs of JuneÂ 30, 2024, our contractual obligations have not changed materially from the amounts reported in our 2023 Form 10-K.Item 3.Â Â Â Â Quantitative and Qualitative Disclosures About Market RiskMarket risks include interest rate risk, equity risk, foreign currency exchange rate risk, commodity price risk, and other relevant market rate or price risks. Of these risks, interest rate risk, equity risk, and foreign currency exchange rate risk could have a significant impact on our results of operations. There have been no material changes in our exposure to market risks since the end of the most recent fiscal year as reported in Part II, Item 7A of our 2023 Form 10-K.Item 4.Â Â Â Â Controls and ProceduresEvaluation of Disclosure Controls and ProceduresDisclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), is recorded, processed, summarized, and reported within the time periods specified in the SECâ€™s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.Our management has carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of June 30, 2024. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level. In designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.Changes in Internal Control over Financial ReportingThere were no changes in our internal control over financial reporting, during the quarter ended JuneÂ 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.50Part II â€“ OTHER INFORMATIONItem 1.Â Â Â Â Legal ProceedingsPlease refer to Note 13, Commitments and Contingencies, in the unaudited interim condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.Item 1A.Â Â Â Â Risk FactorsIn addition to the other information set forth in this report, please carefully consider the factors described under the heading â€œRisk Factorsâ€ in our 2023 Form 10-K in Part I, Item 1A. The risks described are not the only risks facing us. Additional risks and uncertainties not currently known to us, or that our management currently deems to be immaterial, also may adversely affect our business, financial condition, and/or operating results. The following are new significant risk factors related to the pending acquisition of Alimera that could materially harm our business, financial position, or operating results or could cause our actual results to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statement made in this report.Risks Related to the MergerThe Merger is subject to a number of conditions beyond our control. Failure to complete the Merger within the expected time frame, or at all, could have a material adverse effect on our business, operating results, financial condition and our share price.On June 21, 2024, we entered into an Agreement and Plan of Merger (the â€œMerger Agreementâ€) with Alimera and ANIP Merger Sub INC., a Delaware corporation and wholly owned indirect subsidiary of us (â€œMerger Subâ€), pursuant to which, and on the terms and subject to the conditions set forth therein, (i) Merger Sub will be merged with and into Alimera (the â€œMergerâ€), with Alimera surviving the Merger as a wholly owned subsidiary of ANI and (ii) at the effective time of the Merger, each outstanding share of Alimera common stock, par value $0.01 per share, will automatically be converted into the right to receive (A) $5.50 in cash, without interest and less any applicable withholding taxes, and (B) one contingent value right (a â€œCVRâ€). Capitalized terms used herein, but not otherwise defined, have the meanings set forth in the Merger Agreement.Consummation of the Merger is subject to certain conditions, including approval by Alimeraâ€™s stockholders, the absence of any legal restraints restraining, enjoining, preventing, prohibiting or otherwise making illegal the consummation of the Merger, expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with such waiting period having expired on July 29, 2024 and any other specified required regulatory approvals that may be required will have been obtained, and each partyâ€™s performance of its obligations in all material respects under the Merger Agreement.We cannot predict whether and when the conditions to the Merger will be satisfied. If one or more of these conditions are not satisfied, and as a result, we do not complete the Merger, we would remain liable for significant transaction costs, and the focus of our management would have been diverted from seeking other potential strategic opportunities, in each case without realizing any benefits of the Merger. Certain costs associated with the Merger have already been incurred or may be payable even if the Merger is not consummated. Finally, any disruptions to our business resulting from the announcement and pendency of the Merger, including any adverse changes in our relationships with our partners, suppliers and employees, could continue or accelerate in the event that we fail to consummate the Merger.Our share price may also fluctuate significantly based on announcements by Alimera, other third parties, or us regarding the Merger or based on market perceptions of the likelihood of the satisfaction of the conditions to the consummation of the Merger. Such announcements may lead to perceptions in the market that the Merger may not be completed, which could cause our share price to fluctuate or decline. Other factors outside of our control, such as a governmental entity enacting legislation that prohibits the Merger, could cause us not to satisfy the governmental entity condition and thus the Merger would not be consummated. If we do not consummate the Merger, the price of our common stock may decline significantly from the current market price, which may reflect a market assumption that the Merger will be consummated. Any of these events could have a material adverse effect on our business, operating results and financial condition and could cause a decline in the price of our common stock. 51Actions of activist stockholders or other parties may impair our ability to consummate the Merger.Activist stockholders could also take actions that disrupt the business of Alimera, divert the time and attention of their management and employees away from their business operations, cause them to incur substantial additional expense, create perceived uncertainties among current and potential customers, clients, suppliers, employees and other constituencies as to their future direction as a consequence thereof, which may result in lost sales, impaired supplier relationships or other business arrangements and the loss of potential business opportunities, and make it more difficult to attract and retain qualified personnel and business partners.We have incurred, and will continue to incur, direct and indirect costs as a result of the Merger. We have incurred, and will continue to incur, significant costs and expenses, including fees for professional services and other transaction costs, in connection with the Merger, including costs that we may not currently expect. We must pay substantially all of these costs and expenses whether or not the transaction is completed. Moreover, many of the expenses that will be incurred are, by their nature, difficult to estimate accurately. To the extent these acquisition and integration expenses are higher than anticipated, we may experience liquidity or cash flow issues. Among other termination rights, and subject to certain limitations, each of Alimera and ANI may terminate the Merger Agreement if the Merger is not consummated by December 21, 2024, and each of Alimera and ANI may mutually agree to terminate the Merger Agreement. The obligations and liabilities of Alimera, some of which may be unanticipated or unknown, may be greater than we have anticipated, which may diminish the value of Alimera to us.Alimeraâ€™s obligations and liabilities, some of which may not have been disclosed to us or may not be reflected or reserved for in Alimeraâ€™s historical financial statements, may be greater than we have anticipated. The obligations and liabilities of Alimera could have a material adverse effect on Alimeraâ€™s business or Alimeraâ€™s value to us or on our business, financial condition, or results of operations. Under the Merger Agreement, we have only limited indemnification with respect to obligations or liabilities of Alimera, whether known or unknown. In addition, even in cases where we are able to obtain indemnification, we may discover liabilities greater than the contractual limits or the financial resources of the indemnifying party. In the event that we are responsible for liabilities substantially in excess of any amounts recovered through rights to indemnification or alternative remedies that might be available to us, or any applicable insurance, we could suffer severe consequences that would substantially reduce our earnings and cash flows or otherwise materially and adversely affect our business, financial condition, or results of operations.We will incur substantial debt in order to satisfy our obligations in connection with the acquisition of Alimera.In connection with the acquisition, JP Morgan Chase Bank, N.A. and Blackstone Credit & Insurance have committed to provide debt financing for the transaction in an aggregate principal amount equal to $280.0 million, on the terms and subject the conditions set forth in a commitment letter, dated June 21, 2024 (the â€œDebt Commitment Letterâ€). In order to service the debt we incur under the Debt Commitment Letter, we will require a significant amount of cash. Our ability to make scheduled payments of principal and interest depends on our future performance, which is subject to economic, financial, competitive, and other factors beyond our control. Our business may not continue to generate cash flow from operations in the future sufficient to service our debt. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt, or obtaining additional debt or equity financing on terms that may not be favorable to us or available to us at all. Our ability to refinance any such debt will depend on the capital markets and our financial condition at that time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default under our current or future indebtedness. Any event of default or inability to otherwise satisfy our obligations could have a material adverse effect on our future operating results and financial condition.As a result of the Merger, we will record goodwill in connection with our acquisition of Alimera, and if it becomes impaired, our earnings could be significantly impacted.Under current accounting methods, goodwill is not amortized but, instead, is subject to impairment tests on at least an annual basis and more frequently if an event occurs or circumstances change that reduce the fair value of a reporting unit below its carrying amount. In connection with our acquisition of Alimera we will record goodwill in the fair value amount of such acquisition. Although we do not anticipate impairment charges, if we conclude that some portion of such goodwill is impaired, a non-cash charge for the amount of such impairment would be recorded against earnings.52A goodwill impairment charge could be caused by a decline in our stock price or the occurrence of a triggering event that compounds negative financial results. Therefore, following the Merger, and our recording of goodwill in connection therewith, if such goodwill becomes impaired, our earnings could be significantly and adversely affected.The Merger may become the target of securities class action and derivative lawsuits that could result in substantial costs and may delay or prevent the Merger from being completed. Securities class action lawsuits and derivative lawsuits are often brought against public companies that have entered into merger agreements. The outcome of any litigation is uncertain, but regardless of the outcome of any such lawsuits, they could delay or prevent the Merger or otherwise adversely affect us financially.If the acquisition of Alimera is consummated, the combined company may not perform as we or the market expects, which could have an adverse effect on the price of our common stock.Even if the Merger is consummated, the combined company may not perform as we or the market expects. Risks associated with the combined company following the Merger include:â€¢integrating businesses is a difficult, expensive, and time-consuming process, and the failure to successfully integrate our businesses with the business of Alimera in the expected time frame would adversely affect our financial condition and results of operation;â€¢there may be inconsistencies in standards, controls, procedures and policies that will need to be reconciled;â€¢the Merger will materially increase the size of our operations, and if we are not able to effectively manage our expanded operations, our common stock price may be adversely affected;â€¢it is possible that our key employees or key employees of Alimera might decide not to remain with us after the Alimera acquisition is completed, and the loss of such personnel could have a material adverse effect on the financial condition, results of operations, and growth prospects of the combined company;â€¢the success of the combined company will also depend upon relationships with third parties and Alimeraâ€™s or our pre-existing customers, which relationships may be affected by customer preferences or public attitudes about the Merger. Any adverse changes in these relationships could adversely affect the combined companyâ€™s business, financial condition, and results of operations; andâ€¢if government agencies or regulatory bodies impose requirements, limitations, costs, divestitures or restrictions on the consummation of the Merger, the combined companyâ€™s ability to realize the anticipated benefits of the acquisition may be impaired.Further, we intend to enter into the Merger with the expectation that the acquisition will result in, among other things, benefits relating to enhanced revenues, a strengthened market position for the combined company and operating efficiencies. Achieving the benefits of the Merger is subject to a number of uncertainties, including whether we integrate Alimera in an efficient manner, and general competitive factors in the marketplace. The occurrence of any of these Merger-related events individually or in combination could materially and adversely affect our business, results of operations, financial condition and the market price of our common stock.Following the closing of the Merger, if we fail to successfully manage our international operations, our business, operating results and financial condition could suffer.Alimera has direct operations and markets its products outside the United States, with international operations that cover the United Kingdom and much of Europe and the Middle East. We have not historically conducted any operations or marketed any of our products outside the United States. As a result, following the closing of the Merger, the percentage of our revenues generated outside of the United States will increase materially, and our new international operations will require significant management attention and financial resources.There is a high level of regulation in all markets where Alimeraâ€™s products are sold and great diversity in how those markets operate. Consequently, experience and expertise will be required in understanding the market dynamics of each country, the rules and regulations in place governing the sale of medicines, the codes of practice governing promotion of medicines, different currencies, the financial frameworks applying to taxation (both corporate andvalue-added tax) and the need to communicate in different languages.53Moreover, Alimeraâ€™s international operations rely on distributors in many countries to provide adequate levels of experience and expertise on its behalf. We will need to monitor and manage these relationships appropriately to address risks in these markets.Conducting extensive international operations subjects us to risks that are inherent in international operations, including:â€¢extended collection timelines for accounts receivable and greater working capital requirements;â€¢multiple, conflicting legal systems and unexpected changes in legal requirements such as privacy and data protection laws and regulations, employment laws, regulatory requirements and other governmental approvals, permits and licenses;â€¢tariffs, export restrictions, trade barriers and other regulatory or contractual limitations on our ability to sell or develop our products in certain foreign markets, including China and certain other parts of Asia;â€¢changes in currency exchange rates;â€¢currency transfer and other restrictions and regulations that may limit our ability to sell our products internationally or repatriate profits to the United States;â€¢difficulties adapting to new cultures, business customs, and legal systems;â€¢trade laws and business practices favoring local competition;â€¢potential tax issues, including restrictions on repatriating earnings, resulting from multiple, conflicting and complex tax laws and regulations;â€¢weaker intellectual property protection in some countries;â€¢natural disasters, political, economic, and social instability, including the effects of ongoing U.S.-China diplomatic and trade friction, social unrest in China, the recent conflicts between Russia and Ukraine, Israel and Hamas, and global sanctions imposed in response thereto, the possibility of a wider European or global conflict, or other war or terrorist activities or the threat of war and terrorism; andâ€¢adverse economic conditions, including increasing inflation and the stability and solvency of business financial markets, financial institutions and sovereign nations.In particular, regulatory oversight of pharmaceutical products, including production, marketing and sales, can vary significantly among countries and will require additional oversight by our compliance and marketing teams. We will need to spend significantly more time and

invest in additional resources to ensure compliance with regulatory regimes outside the United States. Similarly, there are often supply chain risks that are specific to a given region, and our expansion outside the United States will expose us to additional risks and expenses related thereto.In addition, compliance with foreign and U.S. laws and regulations that are applicable to our international operations is complex and may increase our cost of doing business in international jurisdictions, and our international operations could expose us to fines and penalties if we fail to comply with these regulations. These laws and regulations include import and export requirements, U.S. laws such as the Foreign Corrupt Practices Act, and local laws prohibiting corrupt payments to governmental officials. Although we intend to implement policies and procedures designed to help ensure compliance with these laws, there can be no assurance that our employees, partners and other persons with whom we do business will not take actions in violation of our policies or these laws. Any violations of these laws could subject us to civil or criminal penalties, including substantial fines or prohibitions on our ability to offer our products in one or more countries, and could also materially and adversely harm our business and financial condition.Following the closing of the Merger, we will need to meet certain additional requirements for our international operations, including adequate levels of reimbursement and various regulatory approvals, and our inability to meet these requirements could adversely affect our results of operations.Following the closing the Merger, we will have certain additional requirements that we will need to meet in order to engage in international operations. For example, in the European Economic Area (â€œEEAâ€) and the United Kingdom, each country has a different reviewing body that evaluates reimbursement dossiers submitted by marketing authorization holders of new 54drugs and then makes recommendations as to whether or not the drug should be reimbursed. Limitations on reimbursement could be imposed at the national, regional or local level or by fiscal intermediaries in each country, either through the initial authorization process or at some point in the future. In addition, due to price referencing within the EEA, the United Kingdom and certain other countries, existing pricing in our current markets could be negatively affected by a change in pricing in a country where Alimera currently has reimbursement or by a new price in a country where we or Alimera obtain reimbursement approval in the future.Following the closing of the Merger, our business could also be adversely affected if governments, private insurers or other reimbursing bodies or payers limit the indications for reimbursement approval to a smaller subset than we believe our products are effective in treating or establish a limit on the frequency with which our products may be administered that is less often than we believe would be effective. Those actions could limit our revenues and harm our business.We will also need to maintain or obtain marketing authorization and commercialization rights in countries outside the United States. Certain countries, such as those in the EEA, require minimum sales within three years or licenses may be revoked if extensions are not negotiated. Alimera does not currently have rights in China and certain other parts of Asia. Following the closing of the Merger, to market our products in foreign jurisdictions, we will be required to obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. We may not receive the necessary approvals to commercialize our products in any additional market.The process of obtaining regulatory approvals and clearances in jurisdictions where our products are not approved will require us to expend substantial time and capital. Despite the time and expense incurred, regulatory approval is never guaranteed. The number of preclinical and clinical tests that will be required for regulatory approval varies depending on the drug candidate, the disease or condition for which the drug candidate is in development, the jurisdiction in which we are seeking approval and the regulations applicable to that particular drug candidate. The applicable regulatory authorities may make requests or suggestions regarding our clinical trials, resulting in an increased risk of difficulties or delays in obtaining regulatory approval. For example, the regulatory authorities may not approve of certain of our methods for analyzing our trial data, including how we evaluate the relationship between risk and benefit. Additionally, the foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. For all of these reasons, following the closing of the Merger, we may not obtain additional foreign regulatory approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or jurisdictions or by the FDA.Following the closing of the Merger, our reliance on third parties to manufacture and test certain of our products will increase, and if any of these third parties is unable to satisfy our demand, our business, operating results and financial condition could suffer.Alimera does not have in-house manufacturing capability and depends entirely on single source third-party manufacturers for the manufacture of its products, including for supply of active pharmaceutical ingredients, the product applicator, the product implants, and the final assembly of the injectors with the implants. In addition, Alimera relies on third parties for the quality release testing. If any of these third-party manufacturers breaches its agreement, is unable to meet its contractual or quality requirements or becomes unwilling to perform for any reason, we may be unable, in a timely manner or at all, to locate alternative acceptable manufacturers or testing facilities, as applicable, enter into favorable agreements with them and ensure that they are approved by the applicable regulatory authorities, such as the FDA. For example, Alimera relies on (subject to certain exceptions) an agreement with an exclusive supplier for the manufacturing and supply of YUTIQ, which has an initial term of two years through May 2025. Following the Merger, if the supplier is unwilling to extend the supply agreement, and we are unable to timely transfer manufacturing to a replacement supplier or make other arrangements to supply product, we may not be able to fulfill demand for YUTIQ. In addition, on July 12, 2024, the supplier of YUTIQ received a warning letter from the FDA alleging violations of current good manufacturing practice (CGMP) requirements in connection with a February 2024 FDA inspection and associated February 2024 Form FDA-483 specifically related to the manufacturing of YUTIQ at the supplierâ€™s facility (the "Warning Letter"). The Warning Letter requires the supplier to implement certain corrective and preventive actions. Any failure by the supplier to remediate to the FDAâ€™s satisfaction these findings or any future findings the FDA may have, could result in the supply of YUTIQ being adversely effected or terminated, and, if such findings remain unresolved following the Merger, our ability to fulfill demand for YUTIQ could be materially impaired. Further, Alimeraâ€™s suppliers and manufacturers rely on additional third parties for the manufacture of component parts. Any inability of Alimeraâ€™s contract manufacturers to acquire sufficient quantities of the active pharmaceutical ingredients and other component parts in a timely manner from these third parties could delay commercial production of YUTIQ or ILUVIEN. 55Any of these events could adversely affect our ability following the Merger to fulfill demand for the acquired products. In addition, any of these events could in turn have a material adverse effect on our business, financial position, and operating results, including an impairment of the acquired assets, or cause a decline in the price of our common stock.Item 2.Â Â Â Â Unregistered Sales of Equity Securities and Use of Proceeds Sales of Unregistered SecuritiesNone. Issuer Purchases of Equity SecuritiesThere were no repurchases of equity securities pursuant to a repurchase plan or program during the three months ended JuneÂ 30, 2024.PeriodTotal Numberof SharesPurchased(1)Average PricePaid per ShareTotal Number ofShares Purchased asPart of PubliclyAnnounced Plans or ProgramsMaximum Number (orapproximate dollarvalue) of Sharesthat may yet bePurchased Under thePlans or ProgramsApril 1 - April 30, 202413,259$66.92Â â€”$â€”Â May 1 - May 31, 20245,816$65.02Â â€”$â€”Â June 1 - June 30, 2024553$62.62Â â€”$â€”Â Total19,628$66.23Â â€”(1)Shares purchased during the period were transferred to the Company from employees in satisfaction of minimum tax withholding obligations associated with the vesting of restricted stock awards during the period.Item 3.Â Â Â Â Defaults Upon Senior SecuritiesNone.Item 4.Â Â Â Â Mine Safety DisclosuresNot applicable.Item 5.Â Â Â Â Other InformationOur directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or may represent a non-Rule 10b5-1 trading arrangement under the Exchange Act. During the quarter ended JuneÂ 30, 2024, no such plans or other arrangements were adopted or terminated.Item 6.Â Â Â Â ExhibitsThe exhibits listed in the Index to Exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report on Form 10-Q.56INDEX TO EXHIBITSExhibit No.Description2.1+Agreement and Plan of Merger dated June 21, 2024, by and among ANI Pharmaceuticals, Inc., ANIP Merger Sub INC. and Alimera Sciences, Inc. (incorporated by reference to Exhibit 2.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 24, 2024)10.1+Voting Agreement, dated June 21, 2024, by and among ANI Pharmaceuticals, Inc., Alimera Sciences, Inc. and Caligan Partners LP, Caligan Partners Master Fund LP and Caligan Partners CV VI LP. (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 24, 2024)10.2**Amended and Restated 2022 Stock Incentive Plan (incorporated by reference to Appendix A to the Companyâ€™s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 5, 2024)31.1Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13(a)-14(a)/15d-14(a).31.2Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13(a)-14(a)/15d-14(a).32.1*Certification of Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.101.INSInline XBRL Instance Document â€“ the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.101.SCHInline XBRL Taxonomy Extension Schema Document101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document101.LABInline XBRL Taxonomy Extension Label Linkbase Document101.PREInline XBRL Taxonomy Extension Presentation Linkbase101.DEFInline XBRL Taxonomy Extension Definition Linkbase104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).* In accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed. **Denotes a management contract or compensatory plan contract or arrangement. + Portions of these Exhibits have been omitted pursuant to Rule 601(b) of Regulation S-K. For more, see the cover page of such Exhibits.57SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.ANI Pharmaceuticals, Inc. (Registrant)Date:August 6, 2024By:/s/ Nikhil LalwaniNikhil LalwaniPresident andChief Executive Officer(principal executive officer)Date:August 6, 2024By:/s/ Stephen P. CareyStephen P. CareySenior Vice President, Finance andChief Financial Officer(principal financial and accounting officer)58 EX-31.1 2 anip-20240630x10qxexx311.htm EX-31.1 DocumentExhibit 31.1CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TOSECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Nikhil Lalwani, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of ANI Pharmaceuticals, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13aâ€“15(e) and 15dâ€“15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13aâ€“15(f) and 15dâ€“15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Date: AugustÂ 6, 2024/s/ Nikhil LalwaniNikhil LalwaniPresident andChief Executive Officer(principal executive officer) EX-31.2 3 anip-20240630x10qxexx312.htm EX-31.2 DocumentExhibit 31.2CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TOSECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Stephen P. Carey, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of ANI Pharmaceuticals, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13aâ€“15(e) and 15dâ€“15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13aâ€“15(f) and 15dâ€“15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Date: AugustÂ 6, 2024/s/ Stephen P. CareyStephen P. CareySenior Vice President, Finance and Chief Financial Officer(principal financial and accounting officer) EX-32.1 4 anip-20240630x10qxexx321.htm EX-32.1 DocumentExhibit 32.1CERTIFICATIONPURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTEDPURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the quarterly report on Form 10-Q of ANI Pharmaceuticals, Inc. (the â€œCompanyâ€) for the quarterly period ended JuneÂ 30, 2024 (the â€œReportâ€) as filed with the Securities and Exchange Commission on the date hereof, the undersigned Chief Executive Officer and Chief Financial Officer of the Company hereby certify that, to such officerâ€™s knowledge:(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.This certification is provided solely pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Dated: AugustÂ 6, 2024/s/ Nikhil LalwaniNikhil LalwaniPresident and Chief Executive Officer(principal executive officer)Dated: AugustÂ 6, 2024/s/ Stephen P. CareyStephen P. CareySenior Vice President, Finance and Chief Financial Officer(principal financial and accounting officer)A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. EX-101.SCH 5 anip-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Consolidated Statements of Comprehensive (Loss) Income link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES

link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - PENDING MERGER AGREEMENT link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - RESTRUCTURING link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - INDEBTEDNESS link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - MEZZANINE AND STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - FAIR VALUE DISCLOSURES link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - SEGMENT REPORTING link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - INDEBTEDNESS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - FAIR VALUE DISCLOSURES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - SEGMENT REPORTING (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Timing (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Allowances (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Concentration (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - PENDING MERGER AGREEMENT (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - RESTRUCTURING (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - INDEBTEDNESS - Credit facility (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - INDEBTEDNESS - Facility components (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - INDEBTEDNESS - Maturity of credit facility (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - INDEBTEDNESS - Interest (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - INVENTORIES - Schedule of inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - INVENTORIES - Concentration (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Components (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Components (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - MEZZANINE AND STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - STOCK-BASED COMPENSATION - Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - STOCK-BASED COMPENSATION - Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - STOCK-BASED COMPENSATION - Option activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - STOCK-BASED COMPENSATION - Non-option activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - FAIR VALUE DISCLOSURES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - FAIR VALUE DISCLOSURES - Level 3 (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - FAIR VALUE DISCLOSURES - Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - SEGMENT REPORTING - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - SEGMENT REPORTING - Geographic (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 anip-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 anip-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 anip-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Performance obligations satisfied in prior periods Contract with Customer, Performance Obligation Satisfied in Previous Period Acquisition of goodwill Goodwill, Acquired During Period Statistical Measurement [Domain] Statistical Measurement [Domain] Work-in-progress Inventory, Work in Process, Gross RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense Maximum percentage of conversion price Percentage of Conversion Price Percentage of conversion price. Cover [Abstract] Cover [Abstract] Net Change in Cash, Cash Equivalents, and Restricted Cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect In process research and development In Process Research and Development [Member] Discount rate Measurement Input, Discount Rate [Member] Trading Symbol Trading Symbol Segment reporting Segment Reporting Information [Line Items] Temporary stock issued (in dollars per share) Temporary Equity, Redemption Price Per Share All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of earnings per share, basic and diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] COMMITMENTS AND CONTINGENCIES Other Commitments [Line Items] Disposal Group Name [Domain] Disposal Group Name [Domain] Pay vs Performance Disclosure [Line Items] Shares conversion price (in dollars per share) Preferred Stock, Convertible, Conversion Price Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Accounts receivable, net Increase (Decrease) in Accounts Receivable Derivative [Table] Derivative [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] FAIR VALUE DISCLOSURES Fair Value Disclosures [Text Block] Proceeds from stock option exercises and ESPP purchases Proceeds from Stock Options Exercised Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Award Timing Disclosures [Line Items] Investment, Name [Domain] Investment, Name [Domain] Current borrowing on debt Long-term Debt, Gross, Current Current portion before unamortized (discount) premium and debt issuance costs, of long-term debt. Other Performance Measure, Amount Other Performance Measure, Amount 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Goodwill [Line Items] Goodwill [Line Items] Common Stock, shares outstanding Beginning Balance, Common (in shares) Ending Balance, Common (in shares) Common Stock, Shares, Outstanding Net (loss) income available to common shareholders, Basic Undistributed Earnings, Basic Prepaid income taxes Increase (Decrease) in Income Taxes Stock-based compensation shares available Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Plan Name [Domain] Plan Name [Domain] United States UNITED STATES Derivatives and other non-current assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Convertible Preferred Stock, shares issued Temporary Equity, Shares Issued Gross Carrying Amount Finite-Lived Intangible Assets, Gross Schedule of carrying value of the current and non-current components of the term loan Schedule of Long-Term Debt Instruments [Table Text Block] Treasury Stock Purchases for Restricted Stock Vests (in shares) Treasury Stock, Shares, Acquired Number of annual installments Number of Annual Installments Number of Annual Installments Operating Segments Operating Segments [Member] Selling, general, and administrative Selling, General and Administrative Expenses [Member] Fair value interest rate derivative assets Interest rate swap Interest Rate Derivative Assets, at Fair Value Prepaid income taxes Prepaid Income Taxes, Net Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer. Supplier [Domain] Supplier [Domain] Net Cash and Cash Equivalents Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Cash Flows From Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Treasury Stock Treasury Stock, Common [Member] CG Oncology CG Oncology [Member] CG Oncology Income taxes payable Taxes Payable, Current Performance obligations period Revenue, Remaining Performance Obligation, Optional Exemption, Remaining Duration Basic and Diluted (Loss) Income Per Share: Earnings Per Share Reconciliation [Abstract] Plan Name [Axis] Plan Name [Axis] Prepaid expenses and other current assets Prepaid Expense, Current Equity Components [Axis] Equity Components [Axis] Award Timing Method Award Timing Method [Text Block] Facility Closing Facility Closing [Member] Business combination, milestone payment multiplier Business Combination, Milestone Payment Multiplier Business Combination, Milestone Payment Multiplier Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Restructuring Type [Axis] Restructuring Type [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Four Customers Four Customers [Member] Four Customers Class C Special Stock Class C Special Stock Class C Special Stock Insider Trading Policies and Procedures [Line Items] Threshold number of trading days Threshold Number of Trading Days Threshold number of trading days. Use of Estimates Use of Estimates, Policy [Policy Text Block] Total Operating Expenses, net Costs and Expenses Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Compensation Amount Outstanding Recovery Compensation Amount Diluted Earnings Per Share, Diluted [Abstract] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Accrued government rebates Increase Decrease, Accrued Government Rebates The increase (decrease) during the reporting period in liabilities related to government rebates. Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Payments of debt issuance costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Credits Taken Against Reserve SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Current contingent consideration Business Combination, Contingent Consideration, Liability, Current Accrued expenses and other Accrued Liabilities, Current Anti-dilutive shares diluted earnings (loss) per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Sales of contract manufacture products Sales of contract manufacture products [Member] Sales of contract manufacture products Convertible, shares issuable Preferred Stock, Convertible, Shares Issuable Assets Held-for-Sale Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Asset Acquisition [Axis] Asset Acquisition [Axis] Credit Facility [Domain] Credit Facility [Domain] Cash, cash equivalents, and restricted cash, beginning of period Cash and cash equivalents, end of period Cash, cash equivalents, and restricted cash, beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents EBITDA Earnings/(loss) before interest, taxes, depreciation and amortization Represents earnings/(loss) before interest, taxes, depreciation and amortization (EBITDA). Closing price Investment Owned, Cost Vote per share Common Stock, Vote Per Share Common Stock, Vote Per Share Current Assets Assets, Current [Abstract] Goodwill Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Other comprehensive (loss) income, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Esjay Pharma LLC Esjay Pharma LLC Represents the information pertaining to Esjay Pharma LLC. SS Pharma LLC SS Pharma LLC Represents the information pertaining to SS Pharma LLC. INVENTORIES Inventory Disclosure [Text Block] JPMorgan, Chase Bank, N.A. and Blackstone Credit & Insurance JPMorgan, Chase Bank, N.A. and Blackstone Credit & Insurance [Member] JPMorgan, Chase Bank, N.A. and Blackstone Credit & Insurance Treasury stock, shares at cost Beginning Balance, Treasury (in shares) Ending Balance, Treasury (in shares) Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Options Share-Based Payment Arrangement, Option [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Total comprehensive (loss) income, net of tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred Stock, shares outstanding Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Basic Earnings Per Share, Basic [Abstract] Inventories Inventory, Gross Non-option Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Payments on borrowings under credit agreements Repayments of Debt Total Liabilities Liabilities Number of reporting units Number of Reporting Units Common Stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Expiration Date Trading Arrangement Expiration Date Cash Flows From Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Earnings allocated to participating securities, Diluted Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted Shares held (in shares) Investment Owned, Balance, Shares Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Total Shareholder Return Amount Total Shareholder Return Amount Debt issuance costs, noncurrent Deferred financing costs Debt Issuance Costs, Noncurrent, Net Common Stock, shares issued Common Stock, Shares, Issued Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively Class C Special Stock Value Aggregate par or stated value of issued nonredeemable Class C Special stock (or common stock redeemable solely at the option of the issuer). Earnings allocated to participating securities, Basic Undistributed Earnings (Loss) Allocated to Participating Securities, Basic Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Concentration risk, percentage Concentration Risk, Percentage Novitium Novitium [Member] Novitium Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Subsequent Event [Line Items] Subsequent Event [Line Items] Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development Research and Development Expense [Member] Basic Undistributed Earnings (Loss)

Available to Common Shareholders, Basic [Abstract] Common Stock, shares authorized Common Stock, Shares Authorized Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted Weighted-Average Shares Outstanding (in shares) Diluted Weighted-Average Shares Outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Derivative liability, notional amount Derivative Liability, Notional Amount Prompt Payment Discounts Prompt Payment Discounts Reserves For Cash Discount MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] 2024 (remainder of the year) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total Stockholdersâ€™ Equity Balance Balance Equity, Attributable to Parent Related Party Related Party [Member] Payments on contingent consideration Payments on contingent consideration Payment for Contingent Consideration Liability, Financing Activities Concentration Risk Type [Domain] Concentration Risk Type [Domain] Sales of generic pharmaceutical products Sales of generic pharmaceutical products Sales of generic pharmaceutical products Selling, general, and administrative Corporate and other unallocated expenses Selling, General and Administrative Expense Contingent consideration fair value adjustment Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Cash Flow Cash flow impact of amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. Accounts receivable, net of $102,784 and $97,262 of adjustments for chargebacks and other allowances at JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively Accounts Receivable, after Allowance for Credit Loss, Current Number of executive founders Number of Executive Founders Number of Executive Founders Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Cost of sales Cost of Sales [Member] Sale of Stock [Domain] Sale of Stock [Domain] Assets held for sale Asset, Held-for-Sale, Not Part of Disposal Group, Current Total Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Employees and Consultants Employees and Consultants [Member] Information related to employees and consultants. Document Fiscal Period Focus Document Fiscal Period Focus Transaction costs Business Combination, Acquisition Related Costs All Executive Categories All Executive Categories [Member] Dilutive effect of common stock options, ESPP, and performance stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Business acquisition, share price (in dollars per share) Business Acquisition, Share Price 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Assets Assets [Abstract] Total other comprehensive (loss) income, net of tax Other Comprehensive Income (Loss) Other Comprehensive Income (Loss), Net of Tax Number of pharmaceutical manufacturing facilities Number of Pharmaceutical Manufacturing Facilities Number of Pharmaceutical Manufacturing Facilities Restricted cash Restricted Cash, Current Document Type Document Type WellSpring WellSpring WellSpring Derivative Contract [Domain] Derivative Contract [Domain] Commitment fee (as a percent) Line of Credit Facility, Commitment Fee Percentage Debt effective interest rate (as a percent) Debt Instrument, Interest Rate, Effective Percentage Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Schedule of financial information by reportable segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Issuance of Restricted Stock Awards (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Contractual coupon Interest Expense, Debt, Excluding Amortization Business combination, number of contingent value rights to be received Business Combination, Number of Contingent Value Rights to be Received Business Combination, Number of Contingent Value Rights to be Received Unapproved Products Unapproved Products Unapproved Products Non-current contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Royalty percentage Loss Contingency, Damages Sought, Royalty Percentage Loss Contingency, Damages Sought, Royalty Percentage Inventory, Current [Table] Inventory, Current [Table] Subsequent Event [Table] Subsequent Event [Table] Gross Carrying Amount Indefinite-Lived Intangible Assets (Excluding Goodwill) Maximum Maximum [Member] Amortization of intangible assets Amortization of Intangible Assets Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Customer 4 Customer four [Member] Customer four Beginning balance, permanent and temporary equity Ending balance, permanent and temporary equity Stockholders' Equity Attributable to Parent and Temporary Equity Total of all stockholders' equity (deficit) items attributable to the parent and temporary equity. Total Finite-Lived Intangible Assets, Net Accruals for Chargebacks, Returns, and Other Allowances SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Convertible Preferred Stock Convertible Preferred Stock [Member] Mezzanine Equity Temporary Equity [Abstract] Accounts payable Outstanding balances Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Dividends on Series A Convertible Preferred Stock Preferred Stock Dividends, Income Statement Impact Returned goods reserve Returned Goods Reserve Represents the reserve for goods returned. PENDING MERGER AGREEMENT Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Adjustments for chargebacks and other allowances Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Discount from market price (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date Non-current Assets Assets, Noncurrent [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] Diluted Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] (Loss) Income Before Income Tax Expense (Benefit) Pre-tax consolidated income (loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Issuance of Performance Stock Units (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Marketing and distribution rights Marketing and distribution rights Marketing and distribution rights Convertible Preferred Stock, shares authorized Temporary Equity, Shares Authorized Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Supplier Concentration Risk Supplier Concentration Risk [Member] Performance obligations transferred over time Transferred over Time [Member] Schedule of components of intangible assets Schedule of Intangible Assets and Goodwill [Table Text Block] Deferred tax assets, net of deferred tax liabilities and valuation allowance Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Title of Individual [Axis] Title and Position [Axis] Remaining estimated useful lives Finite-Lived Intangible Asset, Useful Life Convertible Preferred Stock, par value (in dollars per share) Temporary Equity, Par or Stated Value Per Share Additional Paid-in Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Investment, Name [Axis] Investment, Name [Axis] Customer relationships Customer Relationships [Member] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Diluted (Loss) Income Per Share (in dollars per share) (Loss) earnings per share, Diluted (in dollars per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Title of Individual [Domain] Title and Position [Domain] Temporary stock issued, value Temporary Equity, Stock Issued During Period, Value, New Issues Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Schedule of expected future amortization expense for definite-lived intangible assets Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Non-cash operating lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Canada CANADA Minimum conversion period Preferred Stock, Conversion Period, Minimum Preferred Stock, Conversion Period, Minimum Number of operating segments Number of Operating Segments Cash paid for income taxes Income Taxes Paid Preferred Stock, shares issued Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] Schedule of financial assets and liabilities accounted for at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Employee Severance Employee Severance [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Acquired ANDAs intangible assets Acquired ANDAs intangible assets Acquired ANDAs intangible assets RESTRUCTURING Restructuring and Related Activities Disclosure [Text Block] Unobservable inputs Business Combination, Contingent Consideration, Liability, Measurement Input Debt issuance costs, current Deferred financing costs Debt Issuance Costs, Current, Net Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Summary of stock option and restricted stock activity Share-Based Payment Arrangement, Activity [Table Text Block] Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Value of shares held Investment Owned, Fair Value Gain on sale of property Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Rare Disease Rare Disease Component of the entity related to rare diseases and is considered an operating segment. Income tax expense (benefit) Expense (benefit) for income taxes Income Tax Expense (Benefit) Other Income (Expense), net Nonoperating Income (Expense) [Abstract] Corporate, Non-Segment Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Alimera Sciences, Inc Alimera Sciences, Inc [Member] Alimera Sciences, Inc Supplemental disclosure for cash flow information: Supplemental Cash Flow Information [Abstract] Royalties fair value Equity Securities, FV-NI Net (loss) income available to common shareholders, Diluted Net Income (Loss) Available to Common Stockholders, Diluted Net Revenues Total net revenues Revenue from Contract with Customer, Excluding Assessed Tax Acquisition of product rights, intangible assets, and other related assets Payment for acquired intangible assets Payments to Acquire Intangible Assets Shares accrue dividends rate Preferred Stock, Dividend Rate, Percentage Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales of rare disease pharmaceutical products Sales of rare disease pharmaceutical products Related to sales of rare disease pharmaceutical products. Effective income tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Net Cash and Cash Equivalents Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Investing Activities Operating Income Operating Income (Loss) Stock-based compensation additional shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Business Acquisition [Line Items] Business Acquisition [Line Items] Accrued expenses, accrued compensation, and other Increase Decrease Of Accrued Expenses Compensation And Others The increase (decrease) during the reporting period in liabilities related to accrued compensation, accrued expenses, and others. Total Liabilities, Mezzanine Equity, and Stockholdersâ€™ Equity Liabilities and Equity SUBSEQUENT EVENTS Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accrued compensation and related expenses Employee-related Liabilities, Current Additional paid-in capital Additional Paid in Capital Maximum potential to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Shares DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY Derivative Instruments and Hedging Activities Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Series A convertible preferred stock dividends paid Payments of Dividends Interest expense, net Interest expense Interest Income (Expense), Nonoperating Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of contractual maturity of term loan and DDTL Schedule of Maturities of Long-Term Debt [Table Text Block] BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Generics, Established Brands, and Other Generics, Established Brands, and Other Component of the entity related to generics, established brands, and other and is considered an operating segment. Right-of-use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Net sales percentage Loss Contingency, Damages Sought, Net Sales Percentage Loss Contingency, Damages Sought, Net Sales Percentage Underlying Security Market Price Change Underlying Security Market Price Change, Percent Measurement Input Type [Axis] Measurement Input Type [Axis] Individual: Individual [Axis] Related Party Transaction [Axis] Related Party Transaction [Axis] Accumulated Other Comprehensive Income, Net of Tax AOCI Attributable to Parent [Member] Inventories Inventory, Net Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Measurement Input Type [Domain] Measurement Input Type [Domain] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Schedule of related party transactions Schedule of Related Party Transactions [Table Text Block] Number of products marketed without approved NDAs or ANDAs Number of Products Marketed Without Approved NDAs or ANDAs Number of Products Marketed Without Approved NDAs or ANDAs Milestone Payments Milestone Payments [Member] Milestone Payments Consideration Disposal Group, Including Discontinued Operation, Consideration Operating Expenses Operating Expenses [Abstract] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Liabilities, Mezzanine Equity, and Stockholdersâ€™ Equity Liabilities and Equity [Abstract] Achievement of milestones payment period Achievement of Milestones Payment Period Achievement of Milestones Payment Period Level 3 liability, beginning balance Level 3 liability, ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Government Rebates Government Rebates Government Rebates Number of complaints filed Loss Contingency, New Claims Filed, Number Number of plaintiffs Loss Contingency, Number of Plaintiffs Customer 3 Customer three [Member] Customer three Restructuring activities Restructuring activity expense Restructuring and Related Cost, Incurred Cost Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Non Employee Director Non Employee Director [Member] n/a Scitus Pharma Services Scitus Pharma Services Represents the information pertaining to Scitus Pharma Services. Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Concentration Risk [Table] Concentration Risk [Table] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] NDAs and product rights NDAs and product rights NDAs and product rights Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Decrease in notional amount Derivative Liability, Decrease in Notional Amount Amount of decrease in notional amount of derivative liability. Inventory [Line Items] Inventory [Line Items] Derivative Instrument [Axis] Derivative Instrument [Axis] Administrative Fees and Other Rebates Administrative Fees and Other Rebates Administrative Fees and Other Rebates Temporary Equity, by Class of Stock [Table] Temporary Equity, by Class of Stock [Table] Principal amount Long-Term Debt, Gross Exercise Price Award Exercise Price EARNINGS PER SHARE Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Subsequent Event Subsequent Event [Member] Issuance of Common Shares upon Stock Option and ESPP Exercise Stock Issued During Period, Value, Stock Options Exercised GOODWILL AND INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Dividends on Series A Convertible Preferred Stock Dividends, Preferred Stock Stockholdersâ€™ Equity Equity, Attributable to Parent [Abstract] Grate date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Restructuring Plan [Axis] Restructuring Plan [Axis] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Depreciation and amortization Other Depreciation and Amortization COMMITMENTS AND CONTINGENCIES Commitments Disclosure [Text Block] PEO PEO [Member] Temporary Equity [Line Items] Temporary Equity [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other expense, net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible assets, net Total Intangible Assets, Net Intangible Assets, Net (Excluding Goodwill) Performance-Based Restricted Stock Units Performance-Based Restricted Stock Units [Member] Performance-Based Restricted Stock Units Number of potential manufacturers Loss Contingency, Number Of Manufacturers Loss Contingency, Number Of Manufacturers Disposal Group Name [Axis] Disposal Group Name [Axis] Lease term Lessee, Operating Lease, Remaining Lease Term Treasury stock, 412,587 shares of common stock, at cost, at JuneÂ 30, 2024 and 263,943 shares of common stock, at cost, at DecemberÂ 31, 2023 Treasury stock value Treasury Stock, Common, Value Mr. Shanmugam and Esjay Mr. Shanmugam and Esjay [Member] Mr. Shanmugam and Esjay Non-current borrowing on debt Long-term Debt, Gross, Non Current Non current portion before unamortized (discount) premium and debt issuance costs, of long-term debt. 2024 (remainder of the year) Long-Term Debt, Maturity, Remainder of Fiscal Year Schedule of customer concentration Schedules of Concentration of Risk, by Risk

Factor [Table Text Block] Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Lender Name [Axis] Lender Name [Axis] Proceeds from the sale of building Proceeds from Sale of Buildings Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Related Party [Domain] Related and Nonrelated Parties [Domain] PIPE Shares PIPE Shares Information related to the Private Investment in Public Equity ("PIPE Investment"). Money market funds Cash and Cash Equivalents, Fair Value Disclosure Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Restructuring Restructuring Cost and Reserve [Line Items] Local Phone Number Local Phone Number Total Intangible Assets, Gross Intangible Assets, Gross (Excluding Goodwill) Oakville, Ontario Former Manufacturing Facility Oakville, Ontario Former Manufacturing Facility [Member] Oakville, Ontario Former Manufacturing Facility Supplier [Axis] Supplier [Axis] Valuation allowance Deferred Tax Assets, Valuation Allowance Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Other Restructuring Other Restructuring [Member] Packaging materials Retail Related Inventory, Packaging and Other Supplies Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Performance period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Changes in operating assets and liabilities, net of acquisition: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Changes in contingent consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Sales of contract manufactured products Sales of contract manufactured products Sales of contract manufactured products Capitalized interest Interest Costs Capitalized Adjustment Supplemental non-cash investing and financing activities: Other Noncash Investing and Financing Items [Abstract] Restricted Stock Awards Forfeitures (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Investment in equity securities Equity Securities, FV-NI, Cost Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Schedule of property, plant and equipment, net by geographic location Long-Lived Assets by Geographic Areas [Table Text Block] Impairment Impairment of Intangible Assets, Finite-Lived Debt Disclosure [Abstract] Debt Disclosure [Abstract] Gain on sale of building Gain (Loss) on Disposition of Other Assets Common Stock Common Stock [Member] Measure: Measure [Axis] Preferred Stock, shares authorized Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of changes in contingent consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Issuance of Common Stock in Public Offering (in shares) Stock Issued During Period, Shares, New Issues Customer 2 Customer two [Member] Customer two Revolving Facility Line of Credit [Member] Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Officer Officer [Member] Accrued government rebates Accrued Government Rebates Represents amounts accrued for government rebates. Segment Reporting [Abstract] Segment Reporting [Abstract] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Shares purchased to cover employee income taxes Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Entity Central Index Key Entity Central Index Key Schedule of inventories Schedule of Inventory, Current [Table Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount MEZZANINE AND STOCKHOLDERS' EQUITY Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred Stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Number of consecutive trading days Number of Consecutive Trading Days Number of consecutive trading days. Convertible Preferred Stock, shares outstanding Balance (in shares) Balance (in shares) Convertible preferred stock outstanding (shares) Temporary Equity, Shares Outstanding SEGMENT REPORTING Segment Reporting Disclosure [Text Block] Current debt, net of deferred financing costs Current debt, net of deferred financing costs Long-Term Debt, Current Maturities Reconciliation of cash, cash equivalents, and restricted cash, beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Adjustments to reconcile net income to net cash and cash equivalents provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based Compensation Expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Contingent consideration fair value adjustment Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability RSAs Restricted Stock [Member] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Statement [Table] Statement [Table] Percentage of awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Percentage of Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Percentage of Awards Interest Expense, Debt Interest Expense, Debt Counterparty Name [Axis] Counterparty Name [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Diluted Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] City Area Code City Area Code BioSante Pharmaceuticals BioSante Pharmaceuticals [Member] BioSante Pharmaceuticals Current Liabilities Liabilities, Current [Abstract] Business combination, divisible revenue Business Combination, Divisible Revenue Business Combination, Divisible Revenue India INDIA Contingent consideration Business Combination, Contingent Consideration, Liability Cash paid for interest, net of amounts capitalized Interest Paid, Excluding Capitalized Interest, Operating Activities Disposal Group Classification [Domain] Disposal Group Classification [Domain] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Total Current Assets Assets, Current Schedule of components of total interest expense related to the notes and term loan Interest Income and Interest Expense Disclosure [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Payment of commissions, taxes and other related costs Disposal Group, Including Discontinued Operations, Transaction Costs Disposal Group, Including Discontinued Operations, Transaction Costs Treasury stock purchases for restricted stock vests Payments for Repurchase of Common Stock Profit-based milestone payments Profit-based milestone payments [Member] Profit-based milestone payments 2027 Long-Term Debt, Maturity, Year Three Document Information Document Information [Line Items] Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Non-current debt, net of deferred financing costs and current component Non-current debt, net of deferred financing costs and current component Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Schedule of recurring Level 3 fair value measurements of contingent consideration Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Returned goods reserve Increase Decrease In Returned Goods Reserve Amount of increase (decrease) in returned goods reserve. Subsequent Event Type [Axis] Subsequent Event Type [Axis] INCOME TAXES Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Class of Stock [Domain] Class of Stock [Domain] Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Inventories Increase (Decrease) in Inventories Probability-weighted discounted cash flow Valuation Technique, Discounted Cash Flow [Member] Temporary stock issued (in shares) Temporary Equity, Stock Issued During Period, Shares, New Issues Number of new stock classified as temporary equity issued during the period. Deferred taxes Deferred Income Taxes and Tax Credits Unrealized (loss) gain on investment in equity securities Unrealized gain on investment in equity securities Unrealized (loss) gain on investment in equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) 2026 Long-Term Debt, Maturity, Year Two Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Net Cash and Cash Equivalents (Used in) Provided by Financing Activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount PSUs Performance Shares [Member] Credit Facility [Axis] Credit Facility [Axis] Cost of Goods and Service Benchmark Cost of Goods and Service Benchmark [Member] Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services Sales of established brand products, royalties, and other pharmaceutical services Related to sales of established brand, royalties, and other pharmaceutical services. Amendment flag Amendment Flag Contract Customer Contract Customer Contract Customer Entity Registrant Name Entity Registrant Name Gain on sale of building Gain (Loss) on Disposition of Property Plant Equipment Performance obligations transferred at a point in time Transferred at Point in Time [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Axis] Increase (decrease) in temporary equity Increase (Decrease) in Temporary Equity [Roll Forward] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Subsequent Events [Abstract] Level 2 Fair Value, Inputs, Level 2 [Member] Deferred debt issuance costs Debt Issuance Costs, Net Schedule of accruals and allowances Schedule Of Valuation And Qualifying Accounts Disclosure [Table Text Block] Schedule Of Valuation And Qualifying Accounts Disclosure INDEBTEDNESS Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Remaining Weighted Average Amortization Period Finite-Lived Intangible Assets, Remaining Amortization Period Geographical [Domain] Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Aggregate principal amount Debt Instrument, Face Amount Schedule of disaggregation of revenue and revenue recognized Disaggregation of Revenue [Table Text Block] Issuance of Common Stock in Public Offering Stock Issued During Period, Value, New Issues Payment of Gross-Profit earn-out Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Entity Address, Postal Zip Code Entity Address, Postal Zip Code Summary of allocated expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Interest Rate Swap Interest Rate Swap [Member] Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Oakville, Ontario, Canada Oakville, Ontario, Canada Information related to the Oakville, Ontario, Canada manufacturing plant. Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common Stock, $0.0001 par value, 33,333,334 shares authorized; 21,476,115 shares issued and 21,063,528 outstanding at JuneÂ 30, 2024; 20,730,896 shares issued and 20,466,953 shares outstanding at DecemberÂ 31, 2023 Common Stock, Value, Issued Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Credit Facility - 2021 Credit Facility - 2021 Credit Facility - 2021 Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Impairment of indefinite lived intangible assets Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Payment Type [Domain] Payment Type [Domain] Payment Type [Domain] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Definite-Lived Intangible Assets: Finite-Lived Intangible Assets [Line Items] Returns Returns Allowances For Sales Returns Raw materials Inventory, Raw Materials, Gross Restructuring Activities Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block] 2029 and thereafter Finite Lived Intangible Assets Amortization Expense After Year Four Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year and after the fourth fiscal year following current fiscal year. Cash Flows From Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively Preferred Stock, Value, Issued Finished goods Inventory, Finished Goods, Gross Option Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Basic (Loss) Income Per Share (in dollars per share) (Loss) earnings per share, Basic (in dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Novitium Novitium Information related to the Novitium Pharma LLC. Proceeds from public offering Proceeds from Issuance of Common Stock 2026 Milestone Payment 2026 Milestone Payment [Member] 2026 Milestone Payment Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Award expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Maximum potential to vest percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Percentage Property and equipment purchased and included in accounts payable Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Schedule of Goodwill [Table] Goodwill [Table] Net (Loss) Income Available to Common Shareholders Net (loss) income available to common shareholders, Basic Net Income (Loss) Available to Common Stockholders, Basic Disposal Group, Held-for-Sale, Not Discontinued Operations Disposal Group, Held-for-Sale, Not Discontinued Operations [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total Current Liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Convertible Preferred Stock, Series A, $0.0001 par value, 1,666,667 shares authorized; 25,000 shares issued and outstanding at JuneÂ 30, 2024 and DecemberÂ 31, 2023 Balance Balance Temporary Equity, Carrying Amount, Attributable to Parent 2022 Plan 2022 Plan Related to the entity's 2022 Stock Incentive Plan for equity-based service awards. Total Assets Assets 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Additional contingent consideration Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Acquisition of property and equipment, net Payments to Acquire Property, Plant, and Equipment Term Facility Term Facility Term Facility Other non-current liabilities Other Liabilities, Noncurrent Cost of sales (excluding depreciation and amortization) Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and Contingencies (Note 13) Commitments and Contingencies Accrued royalties Accrued Royalties, Current One Supplier One supplier [Member] One supplier [Member]. Net (loss) income available to common shareholders, Diluted Undistributed Earnings, Diluted Termination Date Trading Arrangement Termination Date Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] Revenues Revenues 2025 Long-Term Debt, Maturity, Year One STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Schedule of revenue by geographic operations Revenue from External Customers by Geographic Areas [Table Text Block] Entity Address, City or Town Entity Address, City or Town Allocated share-based compensation expense Share-Based Payment Arrangement, Expense Net (Loss) Income Net (Loss) Income Net Income Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Other Commitments [Table] Other Commitments [Table] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Business Acquisition [Axis] Business Acquisition [Axis] Exchange per share Common Stock, Exchange Per Share Common Stock, Exchange Per Share Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number (Loss) Gain on interest rate swap Derivative unrealized gain recorded in OCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax REVENUE RECOGNITION AND RELATED ALLOWANCES Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address

Line One Entity Address, Address Line One Treasury Stock Purchases for Restricted Stock Vests Treasury Stock, Value, Acquired, Cost Method Proxy preparation and filing period following merger Business Combination, Proxy Preparation and Filing Period Following Merger Business Combination, Proxy Preparation and Filing Period Following Merger Indefinite-Lived Intangible Assets: Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract] Basic Weighted Average Number of Shares Outstanding, Basic [Abstract] Restructuring Plan [Domain] Restructuring Plan [Domain] Name Forgone Recovery, Individual Name 2016 Employee Stock Purchase Plan 2016 Employee Stock Purchase Plan 2016 Employee Stock Purchase Plan Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Term Loan and DDTL Term Loan and DDTL Information related to the Term Loan and Delayed Draw Term Loan. Accruals/Adjustments SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment Investment in Equity Securities Investment, Policy [Policy Text Block] Accrued royalties Increase (Decrease) in Royalty Payable The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction. Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number SThree Chemicals Pvt Ltd SThree Chemicals Pvt Ltd [Member] SThree Chemicals Pvt Ltd Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Insider Trading Arrangements [Line Items] Timing of Transfer of Good or Service [Domain] Timing of Transfer of Good or Service [Domain] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2027 Milestone Payment 2027 Milestone Payment [Member] 2027 Milestone Payment Customer 1 Customer one [Member] Customer one PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Payments to related party Related Party Transaction, Purchases from Related Party Chargebacks Chargebacks Chargebacks Adjustment to Compensation: Adjustment to Compensation [Axis] Accounts Receivable Accounts Receivable [Member] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Reclassifications out of accumulated other comprehensive (loss) income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Alvogen Inc Alvogen Inc [Member] Alvogen Inc Market Performance-Based Restricted Stock Units Market Performance-Based Restricted Stock Units [Member] Market Performance-Based Restricted Stock Units Common Stock, conversion price (in dollars per share) Common Stock Conversion Price Represents the conversion price for converting shares of common stock into another class of common stock. Customer [Domain] Customer [Domain] Accumulated other comprehensive income, net of tax Accumulated other comprehensive (loss) income, net of tax Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Estimate number of shares percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Estimate Number of Shares, Percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Estimate Number of Shares, Percentage Amortization of finance fees Amortization of Debt Issuance Costs Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Chali Properties LLC Chali Properties LLC [Member] Chali Properties LLC Asset Acquisition [Domain] Asset Acquisition [Domain] Related Party [Axis] Related and Nonrelated Parties [Axis] Basic Weighted-Average Shares Outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Non-current Liabilities Long-Term Debt, Excluding Current Maturities [Abstract] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Product Intellectual Property Product Intellectual Property [Member] Product Intellectual Property Document Information [Table] Document Information [Table] Non-cash interest Amortization of Debt Issuance Costs and Discounts Increase (decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Restructuring accrual Restructuring Reserve Payment Type [Axis] Payment Type [Axis] Payment Type Remaining performance obligations Revenue, Remaining Performance Obligation, Amount Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 9 anip-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover - shares 6 Months Ended Jun. 30, 2024 Jul. 30, 2024 Document Information Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Jun. 30, 2024 Â Document Transition Report false Â Entity File Number 001-31812 Â Entity Registrant Name ANI PHARMACEUTICALS, INC Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 58-2301143 Â Entity Address, Address Line One 210 Main Street West Â Entity Address, City or Town Baudette Â Entity Address, State or Province MN Â Entity Address, Postal Zip Code 56623 Â City Area Code 218 Â Local Phone Number 634-3500 Â Title of 12(b) Security Common Stock Â Trading Symbol ANIP Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Central Index Key 0001023024 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Amendment flag false Â Common Stock Â Â Document Information Â Â Entity Common Stock, Shares Outstanding Â 21,030,069 Class C Special Stock Â Â Document Information Â Â Entity Common Stock, Shares Outstanding Â 10,864 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=anip_ClassCSpecialStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Current Assets Â Â Cash and cash equivalents $ 240,110 $ 221,121 Accounts receivable, net of $102,784 and $97,262 of adjustments for chargebacks and other allowances at JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively 166,091 162,079 Inventories 125,448 111,196 Prepaid income taxes 2,867 0 Assets held for sale 0 8,020 Prepaid expenses and other current assets 14,001 17,400 Investment in equity securities 6,943 0 Total Current Assets 555,460 519,816 Non-current Assets Â Â Property and equipment, net 51,640 44,593 Deferred tax assets, net of deferred tax liabilities and valuation allowance 89,506 90,711 Intangible assets, net 183,078 209,009 Goodwill 28,221 28,221 Derivatives and other non-current assets 12,848 12,072 Total Assets 920,753 904,422 Current Liabilities Â Â Current debt, net of deferred financing costs 850 850 Accounts payable 48,681 36,683 Accrued royalties 20,357 16,276 Accrued compensation and related expenses 16,111 23,786 Accrued government rebates 12,324 12,168 Income taxes payable 0 8,164 Returned goods reserve 33,897 29,678 Current contingent consideration 841 12,266 Accrued expenses and other 6,917 5,606 Total Current Liabilities 139,978 145,477 Non-current Liabilities Â Â Non-current debt, net of deferred financing costs and current component 284,394 284,819 Non-current contingent consideration 11,092 11,718 Other non-current liabilities 4,679 4,809 Total Liabilities 440,143 446,823 Commitments and Contingencies (Note 13) Mezzanine Equity Â Â Convertible Preferred Stock, Series A, $0.0001 par value, 1,666,667 shares authorized; 25,000 shares issued and outstanding at JuneÂ 30, 2024 and DecemberÂ 31, 2023 24,850 24,850 Stockholdersâ€™ Equity Â Â Common Stock, $0.0001 par value, 33,333,334 shares authorized; 21,476,115 shares issued and 21,063,528 outstanding at JuneÂ 30, 2024; 20,730,896 shares issued and 20,466,953 shares outstanding at DecemberÂ 31, 2023 2 2 Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively 0 0 Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively 0 0 Treasury stock, 412,587 shares of common stock, at cost, at JuneÂ 30, 2024 and 263,943 shares of common stock, at cost, at DecemberÂ 31, 2023 (20,042) (10,081) Additional paid-in capital 532,497 514,103 Accumulated deficit (65,025) (80,132) Accumulated other comprehensive income, net of tax 8,328 8,857 Total Stockholdersâ€™ Equity 455,760 432,749 Total Liabilities, Mezzanine Equity, and Stockholdersâ€™ Equity $ 920,753 $ 904,422 X - DefinitionRepresents amounts accrued for government rebates. + ReferencesNo definition available. + Details Name: anip_AccruedGovernmentRebates Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable Class C Special stock (or common stock redeemable solely at the option of the issuer). + ReferencesNo definition available. + Details Name: anip_ClassCSpecialStockValue Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period

of one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: anip_PrepaidIncomeTaxesNet Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the reserve for goods returned. + ReferencesNo definition available. + Details Name: anip_ReturnedGoodsReserve Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedRoyaltiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 15 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482309/360-10-15-4 + Details Name: us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_EquitySecuritiesFvNiCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LongTermDebtNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TaxesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-

1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.E.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount allocated to previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Adjustments for chargebacks and other allowances $ 102,784 $ 97,262 Preferred Stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Preferred Stock, shares authorized 1,666,667 1,666,667 Preferred Stock, shares issued 0 0 Preferred Stock, shares outstanding 0 0 Treasury stock, shares at cost 412,587 263,943 Convertible Preferred Stock Â Â Convertible Preferred Stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Convertible Preferred Stock, shares authorized 1,666,667 1,666,667 Convertible Preferred Stock, shares issued 25,000 25,000 Convertible Preferred Stock, shares outstanding 25,000 25,000 Common Stock Â Â Common Stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Common Stock, shares authorized 33,333,334 33,333,334 Common Stock, shares issued 21,476,115 20,730,896 Common Stock, shares outstanding 21,063,528 20,466,953 Class C Special Stock Â Â Common Stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Common Stock, shares authorized 781,281 781,281 Common Stock, shares issued 10,864 10,864 Common Stock, shares outstanding 10,864 10,864 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1 + Details Name: us-gaap_TemporaryEquityParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TemporaryEquitySharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TemporaryEquitySharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TemporaryEquitySharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of valuation and qualifying accounts and reserves. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4 + Details Name: us-gaap_ValuationAllowancesAndReservesBalance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=anip_ClassCSpecialStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Statement [Abstract] Â Â Â Â Net Revenues $ 138,040 $ 116,547 $ 275,470 $ 223,333 Operating Expenses Â Â Â Â Cost of sales (excluding depreciation and amortization) 57,698 42,284 106,855 79,992 Research and development 7,296 7,374 17,807 13,298 Selling, general, and administrative 52,821 38,760 100,842 75,228 Depreciation and amortization 14,697 14,690 29,383 29,390 Contingent consideration fair value adjustment 359 1,035 449 1,996 Restructuring activities 0 2 0 1,132 Gain on sale of building 0 0 (5,347) 0 Total Operating Expenses, net 132,871 104,145 249,989 201,036 Operating Income 5,169 12,402 25,481 22,297 Other Income (Expense), net Â Â Â Â Unrealized (loss) gain on investment in equity securities (2,712) 0 6,943 0 Interest expense, net (4,656) (7,100) (9,256) (14,796) Other expense, net (88) (53) (120) (87) (Loss) Income Before Income Tax Expense (Benefit) (2,287) 5,249 23,048 7,414 Income tax expense (benefit) 0 (996) 7,128 (270) Net (Loss) Income (2,287) 6,245 15,920 7,684 Dividends on Series A Convertible Preferred Stock (407) (407) (813) (813) Net (Loss) Income Available to Common Shareholders $ (2,694) $ 5,838 $ 15,107 $ 6,871 Basic and Diluted (Loss) Income Per Share: Â Â Â Â Basic (Loss) Income Per Share (in dollars per share) $ (0.14) $ 0.30 $ 0.71 $ 0.36 Diluted (Loss) Income Per Share (in dollars per share) $ (0.14) $ 0.29 $ 0.70 $ 0.36 Basic Weighted-Average Shares Outstanding (in shares) 19,321 17,688 19,210 17,044 Diluted Weighted-

Average Shares Outstanding (in shares) 19,321 17,855 19,561 17,177 X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCost of product sold and service rendered, excluding depreciation, depletion, and amortization. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareReconciliationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name

Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders. + ReferencesNo definition available. + Details Name: us-gaap_PreferredStockDividendsIncomeStatementImpact Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDiscloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedCostIncurredCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8:

http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net (Loss) Income $ (2,287) $ 6,245 $ 15,920 $ 7,684 Other comprehensive (loss) income, net of tax: Â Â Â Â Foreign currency translation adjustment (12) (17) (109) 90 (Loss) Gain on interest rate swap (1,066) 2,612 (420) 1,469 Total other comprehensive (loss) income, net of tax (1,078) 2,595 (529) 1,559 Total comprehensive (loss) income, net of tax $ (3,365) $ 8,840 $ 15,391 $ 9,243 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-

220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity - USD ($) $ in Thousands Total Common Stock Additional Paid-in Capital Treasury Stock Accumulated Other Comprehensive Income, Net of Tax Accumulated Deficit Convertible Preferred Stock Balance at Dec. 31, 2022 Â Â Â Â Â Â $ 24,850 Balance (in shares) at Dec. 31, 2022 Â Â Â Â Â Â 25,000 Balance at Jun. 30, 2023 Â Â Â Â Â Â $ 24,850 Balance (in shares) at Jun. 30, 2023 Â Â Â Â Â Â 25,000 Balance at Dec. 31, 2022 Â $ 1 $ 403,900 $ (5,094) $ 12,167 $ (97,285) Â Beginning Balance, Common (in shares) at Dec. 31, 2022 Â 17,644,000 Â Â Â Â Â Beginning Balance, Treasury (in shares) at Dec. 31, 2022 Â Â Â 149,000 Â Â Â Beginning balance, permanent and temporary equity at Dec. 31, 2022 $ 338,539 Â Â Â Â Â Increase (decrease) in Stockholders' Equity Â Â Â Â Â Â Stock-based Compensation Expense 9,587 Â 9,587 Â Â Â Â Treasury Stock Purchases for Restricted Stock Vests (in shares) Â Â Â 99,000 Â Â Â Treasury Stock Purchases for Restricted Stock Vests (4,086) Â Â $ (4,086) Â Â Â Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares) Â 45,000 Â Â Â Â Â Issuance of Common Shares upon Stock Option and ESPP Exercise 1,446 Â 1,446 Â Â Â Â Issuance of Restricted Stock Awards (in shares) Â 624,000 Â Â Â Â Â Issuance of Performance Stock Units (in shares) Â 67,000 Â Â Â Â Â Restricted Stock Awards Forfeitures (in shares) Â (28,000) Â Â Â Â Â Issuance of Common Stock in Public Offering 80,556 $ 1 80,555 Â Â Â Â Issuance of Common Stock in Public Offering (in shares) Â 2,184,000 Â Â Â Â Â Dividends on Series A Convertible Preferred Stock (813) Â Â Â Â (813) Â Other Comprehensive Income (Loss) 1,559 Â Â Â 1,559 Â Â Net Income 7,684 Â Â Â Â 7,684 Â Balance at Jun. 30, 2023 Â $ 2 495,488 $ (9,180) 13,726 (90,414) Â Ending Balance, Common (in shares) at Jun. 30, 2023 Â 20,536,000 Â Â Â Â Â Ending Balance, Treasury (in shares) at Jun. 30, 2023 Â Â Â 248,000 Â Â Â Ending balance, permanent and temporary equity at Jun. 30, 2023 434,472 Â Â Â Â Â Â Balance at Mar. 31, 2023 Â Â Â Â Â Â $ 24,850 Balance (in shares) at Mar. 31, 2023 Â Â Â Â Â Â 25,000 Balance at Jun. 30, 2023 Â Â Â Â Â Â $ 24,850 Balance (in shares) at Jun. 30, 2023 Â Â Â Â Â Â 25,000 Balance at Mar. 31, 2023 Â $ 1 408,395 $ (8,643) 11,131 (96,252) Â Beginning Balance, Common (in shares) at Mar. 31, 2023 Â 18,226,000 Â Â Â Â Â Beginning Balance, Treasury (in shares) at Mar. 31, 2023 Â Â Â 234,000 Â Â Â Beginning balance, permanent and temporary equity at Mar. 31, 2023 339,482 Â Â Â Â Â Â Increase (decrease) in Stockholders' Equity Â Â Â Â Â Â Â Stock-based Compensation Expense 5,249 Â 5,249 Â Â Â Â Treasury Stock Purchases for Restricted Stock Vests (in shares) Â Â Â 14,000 Â Â Â Treasury Stock Purchases for Restricted Stock Vests (537) Â Â $ (537) Â Â Â Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares) Â 40,000 Â Â Â Â Â Issuance of Common Shares upon Stock Option and ESPP Exercise 1,289 Â 1,289 Â Â Â Â Issuance of Restricted Stock Awards (in shares) Â 104,000 Â Â Â Â Â Restricted Stock Awards Forfeitures (in shares) Â (18,000) Â Â Â Â Â Issuance of Common Stock in Public Offering 80,556 $ 1 80,555 Â Â Â Â Issuance of Common Stock in Public Offering (in shares) Â 2,184,000 Â Â Â Â Â Dividends on Series A Convertible Preferred Stock (407) Â Â Â Â (407) Â Other Comprehensive Income (Loss) 2,595 Â Â Â 2,595 Â Â Net Income 6,245 Â Â Â Â 6,245 Â Balance at Jun. 30, 2023 Â $ 2 495,488 $ (9,180) 13,726 (90,414) Â Ending Balance, Common (in shares) at Jun. 30, 2023 Â 20,536,000 Â Â Â Â Â Ending Balance, Treasury (in shares) at Jun. 30, 2023 Â Â Â 248,000 Â Â Â Ending balance, permanent and temporary equity at Jun. 30, 2023 434,472 Â Â Â Â Â Â Balance at Dec. 31, 2023 24,850 Â Â Â Â Â Â $ 24,850 Balance (in shares) at Dec. 31, 2023 Â Â Â Â Â Â 25,000 Balance at Jun. 30, 2024 24,850 Â Â Â Â Â Â $ 24,850 Balance (in shares) at Jun. 30, 2024 Â Â Â Â Â Â 25,000 Balance at Dec. 31, 2023 $ 432,749 $ 2 514,103 $ (10,081) 8,857 (80,132) Â Beginning Balance, Common (in shares) at Dec. 31, 2023 Â 20,731,000 Â Â Â Â Â Beginning Balance, Treasury (in shares) at Dec. 31, 2023 263,943 Â Â 264,000 Â Â Â Beginning balance, permanent and temporary equity at Dec. 31, 2023 $ 457,599 Â Â Â Â Â Â Increase (decrease) in Stockholders' Equity Â Â Â Â Â Â Â Stock-based Compensation Expense 14,798 Â 14,798 Â Â Â Â Treasury Stock Purchases for Restricted Stock Vests (in shares) Â Â Â 149,000 Â Â Â Treasury Stock Purchases for Restricted Stock Vests (9,961) Â Â $ (9,961) Â Â Â Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares) Â 77,000 Â Â Â Â Â Issuance of Common Shares upon Stock Option and ESPP Exercise 3,596 Â 3,596 Â Â Â Â Issuance of Restricted Stock Awards (in shares) Â 606,000 Â Â Â Â Â Issuance of Performance Stock Units (in shares) Â 74,000 Â Â Â Â Â Restricted Stock Awards Forfeitures (in shares) Â (12,000) Â Â Â Â Â Dividends on Series A Convertible Preferred Stock (813) Â Â Â Â (813) Â Other Comprehensive Income (Loss) (529) Â Â Â (529) Â Â Net Income 15,920 Â Â Â Â 15,920 Â Balance at Jun. 30, 2024 $ 455,760 $ 2 532,497 $ (20,042) 8,328 (65,025) Â Ending Balance, Common (in shares) at Jun. 30, 2024 Â 21,476,000 Â Â Â Â Â Ending Balance, Treasury (in shares) at Jun. 30, 2024 412,587 Â Â 413,000 Â Â Â Ending balance, permanent and temporary equity at Jun. 30, 2024 $ 480,610 Â Â Â Â Â Â Balance at Mar. 31, 2024 Â Â Â Â Â Â $ 24,850 Balance (in shares) at Mar. 31, 2024 Â Â Â Â Â Â 25,000 Balance at Jun. 30, 2024 24,850 Â Â Â Â Â Â $ 24,850 Balance (in shares) at Jun. 30, 2024 Â Â Â Â Â Â 25,000 Balance at Mar. 31, 2024 Â $ 2 523,628 $ (18,742) 9,406 (62,331) Â Beginning Balance, Common (in shares) at Mar. 31, 2024 Â 21,373,000 Â Â Â Â Â Beginning Balance, Treasury (in shares) at Mar. 31, 2024 Â Â Â 393,000 Â Â Â Beginning balance, permanent and temporary equity at Mar. 31, 2024 476,813 Â Â Â Â Â Â Increase (decrease) in Stockholders' Equity Â Â Â Â Â Â Â Stock-based Compensation Expense 7,864 Â 7,864 Â Â Â Â Treasury Stock Purchases for Restricted Stock Vests (in shares) Â Â Â 20,000 Â Â Â Treasury Stock Purchases for Restricted Stock Vests (1,300) Â Â $ (1,300) Â Â Â Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares) Â 46,000 Â Â Â Â Â Issuance of Common Shares upon Stock Option and ESPP Exercise 1,005 Â 1,005 Â Â Â Â Issuance of Restricted Stock Awards (in shares) Â 65,000 Â Â Â Â Â Restricted Stock Awards Forfeitures (in shares) Â (8,000) Â Â Â Â Â Dividends on Series A Convertible Preferred Stock (407) Â Â Â Â (407) Â Other Comprehensive Income (Loss) (1,078) Â Â Â (1,078) Â Â Net Income (2,287) Â Â Â Â (2,287) Â Balance at Jun. 30, 2024 $ 455,760 $ 2 $ 532,497 $ (20,042) $ 8,328 $ (65,025) Â Ending Balance, Common (in shares) at Jun. 30, 2024 Â 21,476,000 Â Â Â Â Â Ending Balance, Treasury (in shares) at Jun. 30, 2024 412,587 Â Â 413,000 Â Â Â Ending balance, permanent and temporary equity at Jun. 30, 2024 $ 480,610 Â Â Â Â Â Â X - DefinitionTotal of all stockholders' equity (deficit) items attributable to the parent and temporary equity. + ReferencesNo definition available. + Details Name: anip_StockholdersEquityAttributableToParentAndTemporaryEquity Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_DividendsPreferredStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45

-Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares related to Restricted Stock Award forfeited during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.E.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TemporaryEquitySharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares that have been repurchased during the period and are being held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockSharesAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValueAcquiredCostMethod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash Flows From Operating Activities Â Â Net income $ 15,920 $ 7,684 Adjustments to reconcile net income to net cash and cash equivalents provided by operating activities: Â Â Stock-based compensation 14,798 9,587 Deferred taxes 1,205 (137) Depreciation and amortization 29,383 29,390 Unrealized gain on investment in equity securities (6,943) 0 Non-cash operating lease expense 750 61 Non-cash interest 198 1,973 Contingent consideration fair value adjustment 449 1,996 Gain on sale of building (5,347) 0 Changes in operating assets and liabilities, net of acquisition: Â Â Accounts receivable, net (4,012) (7,486) Inventories (14,252) 1,032 Prepaid expenses and other assets 1,777 1,449 Accounts payable 10,379 (800) Accrued royalties 4,081 (577) Prepaid income taxes (11,031) (261) Accrued government rebates 156 (1,099) Returned goods reserve 4,219 (3,601) Accrued expenses, accrued compensation, and other (6,047) 2,839 Net Cash and Cash Equivalents Provided by Operating Activities 35,683 42,050 Cash Flows From Investing Activities Â Â Acquisition of product rights, intangible assets, and other related assets 0 (4,329) Acquisition of property and equipment, net (9,030) (4,850) Proceeds from the sale of building 13,514 0 Net Cash and Cash Equivalents Provided by (Used in) Investing Activities 4,484 (9,179) Cash Flows From Financing Activities Â Â Payments on borrowings under credit agreements (1,500) (1,500) Series A convertible preferred stock dividends paid (813) (813) Proceeds from stock option exercises and ESPP purchases 3,596 1,446 Proceeds from public offering 0 80,555 Treasury stock purchases for restricted stock vests (9,961) (4,086) Payments on contingent consideration (12,500) 0 Net Cash and Cash Equivalents (Used in) Provided by Financing Activities (21,178) 75,602 Net Change in Cash, Cash Equivalents, and Restricted Cash 18,989 108,473 Cash, cash equivalents, and restricted cash, beginning of period 221,121 53,234 Cash and cash equivalents, end of period 240,110 161,707 Reconciliation of cash, cash equivalents, and restricted cash, beginning of period Â Â Cash and cash equivalents 240,110 Â Cash, cash equivalents, and restricted cash, beginning of period 240,110 161,707 Supplemental disclosure for cash flow information: Â Â Cash paid for interest, net of amounts capitalized 16,155 15,456 Cash paid for income taxes 17,204 141 Right-of-use assets obtained in exchange for lease obligations 0 4,499 Supplemental non-cash investing and financing activities: Â Â Property and equipment purchased and included in accounts payable $ 1,618 $ 539 X - DefinitionCash flow impact of amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesNo definition available. + Details Name: anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in liabilities related to government rebates. + ReferencesNo definition available. + Details Name: anip_IncreaseDecreaseAccruedGovernmentRebates Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in returned goods reserve. + ReferencesNo definition available. + Details Name: anip_IncreaseDecreaseInReturnedGoodsReserve Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction. + ReferencesNo definition available. + Details Name: anip_IncreaseDecreaseInRoyaltyPayable Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in liabilities related to accrued compensation, accrued expenses, and others. + ReferencesNo definition available. + Details Name: anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) and income tax credits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_DeferredIncomeTaxesAndTaxCredits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of other assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInIncomeTaxes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-

gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_OtherDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (f) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividends Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from sale of buildings. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfBuildings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type:

duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTSOverviewANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, â€œANI,â€ the â€œCompany,â€ â€œwe,â€ â€œus,â€ or â€œourâ€) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. The Company is focused on delivering growth by scaling up the Rare Disease business through the launch of Cortrophin Gel, strengthening its generics business with enhanced development capability, innovation in established brands and leveraging its U.S. based manufacturing capabilities. The Companyâ€™s three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. The Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. This action was part of ongoing initiatives to capture operational synergies following our acquisition of Novitium Pharma LLC (â€œNovitiumâ€) in November 2021. The Company has fully completed the transition of the products manufactured or packaged in Oakville to one of the three U.S. based manufacturing sites. In February 2024, the Company entered into an agreement for the sale of the Oakville site, for a price of $19.2Â million Canadian Dollars, or approximately $14.2Â million, based on the exchange rate at closing. The sale closed on March 28, 2024 (see Note 4).The Companyâ€™s operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, and possible fluctuations in financial results. Basis of PresentationThe accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) for interim financial information. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Companyâ€™s financial position, results of operations, comprehensive (loss) income, and cash flows. The consolidated balance sheet at DecemberÂ 31, 2023 has been derived from audited financial statements as of that date. The unaudited interim condensed consolidated statements of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the U.S. Securities and Exchange Commission (the â€œSECâ€). Therefore, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited financial statements and notes thereto previously distributed in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 (the â€œ2023 Form 10-Kâ€), as filed with the SEC.Principles of ConsolidationThe unaudited interim condensed consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.Foreign CurrencyThe Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. The Company currently has a subsidiary located in India. The Canada-based subsidiary conducted its transactions in U.S. dollars and Canadian dollars, but its functional currency was the U.S. dollar. The India-based subsidiary generally conducts its transactions in Indian rupees, which is also its functional currency. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net income. The gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the three and six months ended JuneÂ 30, 2024 and 2023. Unless otherwise noted, all references to â€œ$â€ or â€œdollarâ€ refer to the U.S. dollar. The Companyâ€™s asset and liability accounts are translated using the current exchange rate as of the balance sheet date, except for shareholdersâ€™ equity accounts, which are translated using historical rates. Net revenues and expense accounts are translated using an average exchange rate over the period ended on the balance sheet date. Adjustments resulting from the translation of the financial statements of the Companyâ€™s foreign subsidiaries into U.S. dollars are accumulated as a separate component of shareholdersâ€™ equity within accumulated other comprehensive (loss) income, net of tax.Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the condensed consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, income tax provision or benefit, deferred taxes and valuation allowance, stock-based compensation, revenue recognition, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.Restructuring ActivitiesThe Company defines restructuring activities to include costs directly associated with exit or disposal activities. Such costs include cash employee contractual severance and other termination benefits, one-time employee termination severance and benefits, contract termination charges, impairment and acceleration of depreciation associated with long-lived assets, and other exit or disposal costs. In general, the Company records involuntary employee-related exit and disposal costs when there is a substantive plan for employee severance and related payments are probable and estimable. For one-time termination benefits, including those with a service requirement, expense is recorded when the employees are entitled to receive such benefits and the amount can be reasonably estimated. Expense related to one-time termination benefits with a service requirement is recorded over time, as the service is completed. Contract termination fees and penalties, and other exit and disposal costs are generally recorded as incurred. Restructuring activities are recognized as an operating expense in the condensed consolidated statements of operations.Investment in Equity Securities The Company accounts for its investment in equity securities with a readily determinable fair value in accordance with the guidance in ASC 321, Investments â€“ Equity Securities. The Company presents unrealized gains and losses related to the equity securities, within Unrealized gain on investment in equity securities in its unaudited condensed consolidated statements of operations. Fair values are obtained from quoted prices on the NASDAQ Stock Market, Inc. (â€œNASDAQâ€). Assets Held-for-SaleThe Company classifies assets held-for-sale if all held-for-sale criteria is met pursuant to ASC 360-10, Property, Plant and Equipment. Criteria include management commitment to sell the disposal group in its present condition and the sale being deemed probable of being completed within one year. Assets classified as held-for-sale are not depreciated and are measured at the lower of their carrying amount or fair value less cost to sell. The Company assesses the fair value of a disposal group, less any costs to sell, each reporting period it remains classified as held-for-sale and reports any subsequent changes as an adjustment to the carrying value of the disposal group, as long as the new carrying value does not exceed the initial carrying value of the disposal group. The Company determined that the Oakville, Ontario, Canada property met the held-for-sale criteria. As of DecemberÂ 31, 2023, approximately $8.0Â million of assets held for sale were recorded on the consolidated balance sheets. The Oakville, Ontario property was sold on March 28, 2024 (see Note 4).Recent Accounting PronouncementsRecent Accounting Pronouncements Not Yet AdoptedFrom time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies and are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.In November 2023, the FASB issued Accounting Standards Update (â€œASUâ€) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures related to significant segment expenses. The guidance in this ASU is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the effect the adoption of this ASU may have on its disclosures in the notes to the consolidated financial statements.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes guidance to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. These amendments are effective for all public entities for fiscal periods beginning after December 15, 2024, with early adoption permitted. These amendments apply on a prospective basis, but entities have an option to apply it retrospectively for all periods presented. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements.Recent Securities and Exchange Commission Final Rules Issued but Not Yet EffectiveOn March 6, 2024, the SEC adopted new rules that will require registrants to disclose certain climate-related information in their annual reports. The final rule requires disclosure of, among other things: material climate-related risks and their material impacts; activities to mitigate or adapt to such risks; information about a registrantâ€™s board of directorsâ€™ oversight of climate-related risks and managementâ€™s role in managing material climate-related risks; and information on any climate-related targets or goals that are material to the registrantâ€™s business, results of operations, or financial condition. In addition, certain disclosures related to severe weather events and other natural conditions will be required in a registrantâ€™s audited financial statements. The required information about climate-related risks will also include disclosure of a registrantâ€™s greenhouse gas emissions. The Company will be subject to the applicable requirements of the final rule in our annual reports for fiscal years beginning on January 1, 2025. In April 2024, the SEC voluntarily stayed the rules pending judicial review. The Company is currently evaluating the potential impact of these rules on its consolidated financial statements and related disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent + Details Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 REVENUE RECOGNITION AND RELATED ALLOWANCES 6 Months Ended Jun. 30, 2024 Revenue from Contract with Customer [Abstract] Â REVENUE RECOGNITION AND RELATED ALLOWANCES REVENUE RECOGNITION AND RELATED ALLOWANCESRevenue RecognitionThe Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized using the following steps:â€¢Identification of the contract, or contracts, with a customer;â€¢Identification of the performance obligations in the contract;â€¢Determination of the transaction price, including the identification and estimation of variable consideration;â€¢Allocation of the transaction price to the performance obligations in the contract; andâ€¢Recognition of revenue when we satisfy a performance obligation.Revenues are primarily derived from sales of generic, rare disease, and established brand pharmaceutical products, royalties, and other pharmaceutical services. Revenue is recognized when obligations under the terms of contracts with customers are satisfied, which generally occurs when control of the products sold are transferred to the customer. Variable consideration is estimated after the consideration of applicable information that is reasonably available. The Company generally does not have incremental costs to obtain contracts that would otherwise not have been incurred. The Company does not adjust revenue for the promised amount of consideration for the effects of a significant financing component because our customers generally pay us within 100 days.All revenue recognized in the accompanying unaudited interim condensed consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue:Three Months Ended June 30,Six Months Ended June 30,Products and Services (in thousands)2024202320242023Sales of generic pharmaceutical products$73,964Â $63,317Â $144,181Â $127,030Â Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services14,883Â 28,926Â 45,159Â 55,669Â Sales of rare disease pharmaceutical products49,193Â 24,304Â 86,130Â 40,634Â Total net revenues$138,040Â $116,547Â $275,470Â $223,333Â Three Months Ended June 30,Six Months Ended June 30,Timing of Revenue Recognition (in thousands)2024202320242023Performance obligations transferred at a point in time$138,040Â $116,547Â $275,470Â $222,958Â Performance obligations transferred over timeâ€”Â â€”Â 375Â Total$138,040Â $116,547Â $275,470Â $223,333Â In the three and six months ended JuneÂ 30, 2024 and 2023, the Company did not incur, and therefore did not defer, any material incremental costs to obtain or fulfill contracts. The Company recognized a decrease of $1.5 million to net revenue from performance obligations satisfied in prior periods during the six months ended JuneÂ 30, 2024, consisting primarily of revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales. The Company recognized an increase of $5.0 million to net revenue from performance obligations satisfied in prior periods during the six months ended JuneÂ 30, 2023, consisting primarily of revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales. Additionally, as of JuneÂ 30, 2024, and December 31, 2023, there was no deferred revenue recorded on the condensed consolidated balance sheets. As of JuneÂ 30, 2024, the aggregate amount of the transaction price allocated to the remaining performance obligations for all open contract manufacturing customer contracts was $3.0 million, which consists of firm orders for contract manufactured products. The Company recognizes revenue for these performance obligations as they are satisfied, which is anticipated within six months.Variable considerationSales of pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative and other rebates, and cash discounts. Estimates for these elements of variable consideration require significant judgment. The following table summarizes activity in the condensed consolidated balance sheets for accruals and allowances for the six months ended JuneÂ 30, 2024 and 2023, respectively:Accruals for Chargebacks, Returns, and Other Allowances(in thousands)ChargebacksGovernmentRebatesReturnsAdministrativeFees and OtherRebatesPromptPaymentDiscountsBalance at December 31, 2022$148,562Â $10,872Â $33,399Â $9,442Â $6,488Â Accruals/Adjustments290,826Â 11,100Â 5,995Â 25,606Â 11,028Â Credits Taken Against Reserve(362,253)(10,001)(9,596)(25,177)(12,653)Balance at June 30, 2023 (1)$77,135Â $11,971Â $29,798Â $9,871Â $4,863Â Balance at December 31, 2023$84,208Â $12,168Â $29,678Â $11,412Â $4,865Â Accruals/Adjustments267,779Â 13,324Â 21,895Â 29,970Â 11,422Â Credits Taken Against Reserve(262,541)(13,168)(17,676)(29,656)(11,243)Balance at June 30, 2024 (1)$89,446Â $12,324Â $33,897Â $11,726Â $5,044Â _____(1)Chargebacks and Prompt Payment Discounts are included as an offset to accounts receivable in the unaudited interim condensed consolidated balance sheets. Administrative Fees and Other Rebates are included as an offset to accounts receivable or as accrued expenses and other in the unaudited interim condensed consolidated balance sheets. Returns are included in returned goods reserve in the unaudited interim condensed consolidated

balance sheets. Government Rebates are included in accrued government rebates in the unaudited interim condensed consolidated balance sheets. Credit ConcentrationANIâ€™s customers are primarily wholesale distributors, chain drug stores, group purchasing organizations, and pharmaceutical companies.During the three and six months ended JuneÂ 30, 2024, there were four customers that accounted for 10% or more of net revenues. During the three months ended JuneÂ 30, 2023, there were four customers that accounted for 10% or more of net revenues. During the six months ended JuneÂ 30, 2023, there were three customers that accounted for 10% or more of net revenues. As of JuneÂ 30, 2024, accounts receivable from these customers totaled 79% of Accounts receivable, net. The four customers represent the total percentage of net revenues as follows:Three Months Ended June 30,Six Months Ended June 30,20242023202420232Customer 124Â %32Â %29Â %32Â %Customer 212Â %14Â %12Â %14Â %Customer 313Â %13Â %11Â %13Â %Customer 417Â %10Â %15Â %9Â % X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 PENDING MERGER AGREEMENT 6 Months Ended Jun. 30, 2024 Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Â PENDING MERGER AGREEMENT PENDING MERGER AGREEMENTOn June 21, 2024, the Company entered into an Agreement and Plan of Merger (the â€œMerger Agreementâ€) with Alimera Sciences, Inc., a Delaware corporation (â€œAlimeraâ€) and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of the Company (â€œMerger Subâ€), providing for the merger of Merger Sub with and into Alimera (the â€œMergerâ€), with Alimera surviving the Merger as a wholly owned indirect subsidiary of the Company. Capitalized terms used herein, but not otherwise defined, have the meanings set forth in the Merger Agreement.At the effective time of the Merger (the â€œEffective Timeâ€), each outstanding share of common stock, par value $0.01 per share, of Alimera, outstanding immediately prior to the Effective Time will automatically be converted into the right to receive (i) $5.50 in cash, without interest and (ii) one contingent value right (a â€œCVRâ€), which shall represent the right to receive the Milestone Payments (as defined below) subject to the terms and conditions set forth in the CVR Agreement (as defined below) (the consideration contemplated by (i) and (ii), together, the â€œMerger Considerationâ€).At or immediately prior to the Effective Time, the Company will enter into a contingent value rights agreement (the â€œCVR Agreementâ€), pursuant to which each holder of Alimera Common Stock, as well as holders of Alimera Warrants, Alimera Options, Alimera PSUs, Alimera RSAs and Alimera RSUs, may become entitled to contingent cash payments per CVR (each, a â€œMilestone Paymentâ€), such payment(s) being contingent upon, and subject to, satisfaction of the Milestones (as defined below).When issued, each CVR will entitle the holder (the â€œHolderâ€) to receive Milestone Payments for 2026 and 2027, upon satisfaction of the applicable Milestones. The Milestone Payments for each CVR will equal the product (rounded to the nearest 1/100 of $0.01) of $0.25 multiplied by a fraction (which in no case will exceed one), and (i) for 2026, equals the amount, if any, by which the 2026 Net Revenue exceeds $140.0Â million, divided by $10.0Â million (subject to adjustment for the exercise price of Eligible Options), and (ii) for 2027, equals the amount, if any, by which the 2027 Net Revenue exceeds $160.0Â million, divided by $15.0Â million (subject to adjustment for the exercise price of Eligible Options) (the occurrence of the events in clauses (i) and (ii), each, a â€œMilestoneâ€).The Merger Agreement requires Alimera, as promptly as reasonably practicable, and in any event within 25 business days following the date of the Merger Agreement, to prepare and file with the SEC a proxy statement for the purpose of seeking stockholder approval to the Merger Agreement. Alimera filed their preliminary proxy statement on July 24, 2024 with the SEC.Consummation of the Merger is subject to certain conditions, including approval by Alimeraâ€™s stockholders, the absence of any legal restraints restraining, enjoining, preventing, prohibiting or otherwise making illegal the consummation of the Merger, expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and any other specified required regulatory approvals that may be required will have been obtained, and each partyâ€™s performance of its obligations in all material respects under the Merger Agreement.In connection with the Merger, JPMorgan Chase Bank, N.A. and Blackstone Credit & Insurance (the â€œLendersâ€) have committed to provide debt financing for the transaction in an aggregate principal amount equal to $280.0Â million, on the terms and subject to the conditions set forth in a commitment letter, dated June 21, 2024 (the â€œDebt Commitment Letterâ€). The obligations of the Lenders to provide debt financing under the Debt Commitment Letter are subject to customary conditions, including, without limitation, execution and delivery of definitive documentation consistent with the Debt Commitment Letter.During the three and six months ended JuneÂ 30, 2024, the Company incurred approximately $3.5 million in transaction costs related to this pending Merger Agreement, all of which were expensed, and are included in Selling, general, and administrative on the condensed consolidated statements of operations. X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/805/tableOfContent + Details Name: us-gaap_BusinessCombinationDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RESTRUCTURING 6 Months Ended Jun. 30, 2024 Restructuring and Related Activities [Abstract] Â RESTRUCTURING RESTRUCTURING On March 31, 2023 the Company ceased operations at the Oakville, Ontario, Canada manufacturing plant. This action was part of ongoing initiatives to capture operational synergies following the acquisition of Novitium in November 2021. ANI has fully completed the transition of the products manufactured or packaged in Oakville to one of the Companyâ€™s three U.S. based manufacturing sites. There were no restructuring activities recorded in the three or six months ended JuneÂ 30, 2024 and as of JuneÂ 30, 2024, there was no severance or other employee benefits accrued on the unaudited interim condensed consolidated balance sheet. For the three months ended JuneÂ 30, 2023, restructuring activities resulted in an immaterial amount of expenses, and for the six months ended JuneÂ 30, 2023, restructuring activities resulted in expenses of $1.1 million. This included $0.2 million of severance and other employee benefit costs and $0.7 million of accelerated depreciation costs and $0.2 million for other miscellaneous costs.In conjunction with the exit of the Canadian facility, the Company determined that the land and building at the Oakville, Ontario, Canada plant (the â€œPropertyâ€) will be sold together and met the criteria to be classified as held for sale as of JuneÂ 30, 2023. The land and building had a net carrying value of approximately $8.0 million, which was presented as assets held for sale on the accompanying condensed consolidated balance sheet at December 31, 2023. These assets were part of the Generics, Established Brands, and Other segment. As of JuneÂ 30, 2024 these assets were sold.On February 15, 2024, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement (the â€œAgreementâ€) with 1540700 Ontario Limited (â€œBuyerâ€) for the sale of the Property for a total purchase price of $19.2Â million Canadian Dollars, or approximately $14.2Â million, based on the exchange rate at closing. On March 28, 2024 the Company completed the sale of the Property. After payment of commissions, real estate taxes, and other related costs of approximately $0.7 million, the Company received a net proceeds of approximately $13.5Â million at closing. The gain on the sale of the Property was approximately $5.3Â million, recorded in the unaudited interim condensed consolidated statements of operations for the six months ended JuneÂ 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/420/tableOfContentReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INDEBTEDNESS 6 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] Â INDEBTEDNESS INDEBTEDNESSCredit FacilityOn November 19, 2021, the Company completed its acquisition of Novitium pursuant to the terms of the Agreement and Plan of Merger, dated as of March 8, 2021 (the â€œNovitium Merger Agreementâ€), by and among the Company, Novitium, Nile Merger Sub LLC, a Delaware limited liability company, and certain other parties, with Novitium becoming a wholly owned subsidiary of the Company.On NovemberÂ 19, 2021, the Company, as borrower, entered into a credit agreement (the â€œCredit Agreementâ€) with Truist Bank and other lenders, which provides for credit facilities consisting of (i) a senior secured term loan facility in an aggregate principal amount of $300.0 million (the â€œTerm Facilityâ€) and (ii) a senior secured revolving credit facility in an aggregate commitment amount of $40.0 million, which may be used for revolving credit loans, swingline loans and letters of credit (the â€œRevolving Facility,â€ and together with the Term Facility, the â€œCredit Facilityâ€). The Term Facility proceeds were used to finance the cash portion of the consideration under the Novitium Merger Agreement, repay the existing credit facility, and pay fees, costs and expenses incurred in connection with the merger. The Term Facility matures in November 2027 and the Revolving Facility in November 2026. The Credit Facility has a subjective acceleration clause in case of a material adverse effect. In July 2023, the Company amended its Credit Agreement to transition from London Interbank Offered Rate (â€œLIBORâ€) to the Secured Overnight Finaning Rate (â€œSOFRâ€) due to the cessation of LIBOR pursuant to the terms of Amendment No.1 to the Credit Agreement (â€œAmendment No. 1â€). SOFR was applied to the Credit Facility for the interest period (as defined in the Credit Agreement) beginning on August 1, 2023 and replaced all LIBOR terms.The Credit Facility permits both base rate borrowings (â€œABR Loansâ€) and Eurodollar rate borrowings (â€œEurodollar Loansâ€), plus a spread as defined in the Credit Facility. As of JuneÂ 30, 2024, we had not drawn on the Revolving Facility and $40.0 million remained available for borrowing subject to certain conditions. The interest rate under the Term Facility was 11.44% at JuneÂ 30, 2024.The Company incurred $14.0 million in deferred debt issuance costs associated with the Credit Facility. Costs allocated to the Term Facility are classified as a direct reduction to the current and non-current portion of the borrowings, depending on their nature. Costs allocated to the Revolving Facility are classified as other current and other non-current assets, depending on their nature. A commitment fee of 0.5% per annum is assessed on any unused portion of the Revolving Facility.The Credit Facility is secured by a lien on substantially all of ANI Pharmaceuticals, Inc.â€™s and its principal domestic subsidiaryâ€™s assets and any future domestic subsidiary guarantorsâ€™ assets. The Credit Facility is subject to customary financial and nonfinancial covenants. The carrying value of the current and non-current components of the Term Facility as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are:Current(in thousands)June 30,2024December 31,2023Current borrowing on debt$3,000Â $3,000Â Deferred financing costs(2,150)(2,150)Current debt, net of deferred financing costs $850Â $850Â Non-Current(in thousands)June 30,2024December 31,2023Non-current borrowing on debt$289,500Â $291,000Â Deferred financing costs(5,106)(6,181)Non-current debt, net of deferred financing costs and current component$284,394Â $284,819Â As of JuneÂ 30, 2024, outstanding principal was $292.5 million on the Term Facility. Of the $0.6 million of unamortized deferred debt issuance costs allocated to the Revolving Facility, $0.3 million is included in other non-current assets in the unaudited interim condensed consolidated balance sheets, and $0.3 million is included in prepaid expenses and other current assets in the unaudited interim condensed consolidated balance sheets. The contractual maturity of the Term Facility is as follows for the period ending:(in thousands)Term Facility2024 (remainder of the year)$1,500Â 20253,000Â 20263,000Â 2027285,000Â Total$292,500Â The following table sets forth the components of total interest expense related to the Term Facility during the three and six months ended JuneÂ 30, 2024 and 2023, as recognized in the accompanying unaudited interim condensed consolidated statements of operations for the three and six months ended JuneÂ 30, 2024 and 2023:Three Months Ended June 30,Six Months Ended June 30,(in thousands)2024202320242023Contractual coupon$6,848Â $7,620Â $13,761Â $14,970Â Amortization of finance fees591Â 591Â 1,182Â 1,182Â Capitalized interest(151)(277)(263)(298)$7,288Â $7,934Â $14,680Â $15,854Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -

Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY 6 Months Ended Jun. 30, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Â DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITYIn April 2020, the Company entered into an interest rate swap with Citizens Bank, N.A. to manage its exposure to changes in LIBOR-based interest rates underlying total borrowings under term facilities related to the prior credit agreement, and the interest rate swap matures in December 2026. Concurrent with the termination of the prior credit agreement and entry into the Credit Agreement with Truist Bank, the interest rate swap with a notional value of $168.6 million at origin on NovemberÂ 21, 2021 was novated and Truist Bank is the new counterparty. As described further below, the Company amended its Credit Agreement to transition from LIBOR to SOFR due to the cessation of LIBOR, and accordingly, the interest rate swap transitioned from LIBOR to SOFR. The swap is used to manage changes in SOFR-based interest rates underlying a portion of the borrowing under the Term Facility. The interest rate swap provides an effective fixed interest rate of 2.26% and has been designated as an effective cash flow hedge and therefore qualifies for hedge accounting. As of JuneÂ 30, 2024, the notional amount of the interest rate swap was $139.4 million and decreased quarterly by approximately $4.0 million until December 2023, after which it remains static until maturity in December 2026. As of JuneÂ 30, 2024, the fair value of the interest rate swap asset recorded in other non-current assets in the unaudited interim condensed consolidated balance sheets was $7.4 million. As of JuneÂ 30, 2024, $8.5 million was recorded in accumulated other comprehensive (loss) income, net of tax in the unaudited interim condensed consolidated balance sheets.During the three and six months ended JuneÂ 30, 2024, the loss on the fair value of the interest rate swaps, net of tax recorded in accumulated other comprehensive (loss) income in the unaudited interim condensed consolidated statements of comprehensive income was approximately $1.1 million and $0.5 million, respectively. Differences between the hedged SOFR rate and the fixed rate are recorded as interest expense in the same period that the related interest is recorded for the Term Facility based on the SOFR rate. In the three and six months ended JuneÂ 30, 2024, the Company recorded a reduction in interest expense of $1.6 million and $3.2 million in relation to the interest rate swaps, respectively. In the three and six months ended JuneÂ 30, 2023, the Company recorded a reduction in interest expense of $0.6 million and $1.1 million in relation to the interest rate swaps, respectively. Included in this amount for the three and six months ended JuneÂ 30, 2024 are reclassifications out of accumulated other comprehensive (loss) income of $0.2 million of interest income and $0.4 million, respectively, related to terminated and de-designated cash flow hedges. Included in this amount for the three and six months ended JuneÂ 30, 2023 are reclassifications out of accumulated other comprehensive (loss) income of $0.7 million of interest income and $0.7 million, respectively, related to terminated and de-designated cash flow hedges.In conjunction with the amendment of the Credit Agreement (see Note 5), the Companyâ€™s derivative positions automatically transitioned to SOFR, the designated fallback terms, as determined by the International Swaps and Derivatives Association on August 1, 2023. Concurrently, the Company updated its hedge documentation to reflect the change of the benchmark index, which changed solely as a result of reference rate reform. Under ASC 848, Reference Rate Reform, hedge accounting may continue without de-designation if certain criteria are met. For cash flow hedges in which the designated hedged risk is LIBOR (or another rate that is expected to be discontinued), the guidance allows an entity to assert that it remains probable that the hedged forecasted transaction will occur. The Company applied the optional expedient within ASC 848 to conclude the updates to the hedge relationship due to reference rate reform did not have a material impact on the Companyâ€™s consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5CReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815/tableOfContent + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 EARNINGS PER SHARE 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â EARNINGS PER SHARE EARNINGS PER SHAREBasic earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares of common stock outstanding during the period.For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is calculated by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options, shares to be purchased under the 2016 Employee Stock Purchase Plan (â€œESPPâ€), and performance stock units, using the more dilutive of the treasury stock or the two-class method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share.Unvested restricted shares and Series A convertible preferred stock shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic and diluted earnings (loss) per share excludes from the numerator net income (but not net loss) attributable to the unvested restricted shares and the common shares assumed converted from the preferred shares and excludes the impact of those shares from the denominator. The Companyâ€™s participating securities do not have a contractual obligation to share in the Companyâ€™s losses. As such, the net loss was attributed entirely to common stockholders. As the Company has reported a net loss for the three months ended June 30, 2024, diluted net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders for this period.Earnings per share for the three and six months ended JuneÂ 30, 2024 and 2023 are calculated for basic and diluted earnings per share as follows:BasicDilutedBasicDiluted(in thousands, except per share amounts)Three Months Ended June 30,Three Months Ended June 30,Six Months Ended June 30,Six Months Ended June 30,2024202320242023202420232024202320242023Net (loss) income available to common shareholders$(2,694)$5,838Â $(2,694)$5,838Â $15,107Â $6,871Â $15,107Â $6,871Â Earnings allocated to participating securitiesâ€”Â (589)â€”Â (589)(1,499)(716)(1,474)(716)Net (loss) income available to common shareholders$(2,694)$5,249Â $(2,694)$5,249Â $13,608Â $6,155Â $13,633Â $6,155Â Basic Weighted-Average Shares Outstanding19,32117,68819,32117,68819,210Â 17,04419,210Â 17,044Dilutive effect of common stock options, ESPP, and performance stock unitsâ€”Â 167351Â 133Diluted Weighted-Average Shares Outstanding19,32117,85519,561Â 17,177(Loss) earnings per share(0.14)0.30Â (0.14)0.29Â $0.71Â $0.36Â $0.70Â $0.36Â The number of shares of potentially dilutive securities excluded from the computation of diluted net loss per share attributable to common stockholders was 2.8Â million for the three months ended JuneÂ 30, 2024 because including them would have been anti-dilutive.The number of anti-dilutive shares, which have been excluded from the computation of diluted earnings per share, was 2.3 million for the six months ended JuneÂ 30, 2024. The number of anti-dilutive shares, which have been excluded from the computation of diluted earnings per share, was 2.5 million for the three and six months ended JuneÂ 30, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INVENTORIES 6 Months Ended Jun. 30, 2024 Inventory Disclosure [Abstract] Â INVENTORIES INVENTORIESInventories consist of the following as of:(in thousands)June 30, 2024December 31, 2023Raw materials$62,584Â $62,237Â Packaging materials10,434Â 9,617Â Work-in-progress4,775Â 3,144Â Finished goods47,655Â 36,198Â Inventories$125,448Â $111,196Â Vendor ConcentrationRaw materials are sourced for products, including active pharmaceutical ingredients (â€œAPIâ€), from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the cost and time required to validate a second source of supply. As a result, the Company is dependent upon our current vendors to reliably supply the API required for on-going product manufacturing. During the three and six months ended JuneÂ 30, 2024, approximately 27% and 24%, respectively, of our raw material purchases were from one supplier. During the three and six months ended JuneÂ 30, 2023, no single vendor represented more than 10% of our raw material inventory purchases. X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 GOODWILL AND INTANGIBLE ASSETS 6 Months Ended Jun. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETSGoodwillAs a result of the 2013 merger with BioSante Pharmaceuticals, Inc., the Company recorded goodwill of $1.8 million. As a result of the acquisition of WellSpring Pharma Services Inc. in 2018, the Company recorded goodwill of $1.7 million. From the acquisition of Novitium in 2021, the Company recorded goodwill of $24.6 million. As of JuneÂ 30, 2024, the Company has two operating segments, which were also deemed the Companyâ€™s two reporting units, Generics, Established Brands, and Other reporting unit and the Rare Disease reporting unit. All of the goodwill is recorded in the Generics, Established Brands, and Other reporting unit. Goodwill is reviewed for impairment at least annually, at October 31, or more frequently if a triggering event occurs between impairment testing dates. The Companyâ€™s impairment assessment begins with a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. Qualitative factors may include, macroeconomic conditions, industry and market considerations, cost factors, and other relevant entity and Company specific events. If, based on the qualitative test, the Company determines that it is â€œmore likely than notâ€ that the fair value of a reporting unit is less than its carrying value, then we evaluate goodwill for impairment by comparing the fair value of our reporting unit to its respective carrying value, including its goodwill. If it is determined that it is â€œnot likelyâ€ that the fair value of the reporting unit is less than its carrying value, then no further testing is required. There have been no events or changes in circumstances that would have reduced the fair value of the Generics, Established Brands, and Other reporting unit below its carrying value during the three and six months ended JuneÂ 30, 2024 and 2023, no impairment charges have been recognized.Intangible AssetsThe components of definite-lived intangible assets and indefinite-lived intangible assets, other than goodwill, are as follows:June 30, 2024December 31, 2023Remaining Weighted Average Amortization Period(1)(in thousands)Gross Carrying AmountAccumulatedAmortizationNet Carrying Amount Gross CarryingAmountAccumulatedAmortizationNet Carrying AmountDefinite-Lived Intangible Assets:Acquired ANDAs intangible assets$209,780Â $(112,742)$97,038Â $209,780Â $(100,660)$109,120Â 4.8 yearsNDAs and product rights244,871Â (196,451)48,420Â 244,871Â (184,861)60,010Â 2.8 yearsMarketing and distribution rights17,157Â (14,752)2,405Â 17,157Â (14,271)2,886Â 2.5 yearsCustomer relationships24,900Â (9,485)15,415Â 24,900Â (7,707)17,193Â 4.3 yearsTotal Definite-Lived Intangible Assets496,708Â (333,430)163,278Â 496,708Â (307,499)189,209Â 4.1 yearsIndefinite-Lived Intangible Assets:In process research and development19,800Â â€”Â 19,800Â 19,800Â â€”Â 19,800Â IndefiniteTotal Intangible Assets, net$516,508Â $(333,430)$183,078Â $516,508Â $(307,499)$209,009Â (1)Weighted average amortization period as of JuneÂ 30, 2024. Definite-lived intangible assets arising from business combinations and other asset acquisitions include intangibles such as Abbreviated New Drug Applications (â€œANDAsâ€), New Drug Applications (â€œNDAsâ€) and product rights, marketing and distribution rights, customer relationships, and non-compete agreements. Definite-lived intangible assets are amortized over the estimated period during which the asset is expected to contribute directly or indirectly to future cash flows. Definite-lived intangible assets are stated at cost, net of amortization, and generally amortized over their remaining estimated useful lives, ranging from seven to ten years, based on the straight-line amortization method. In the case of certain NDAs and product rights assets, an accelerated amortization method is used to better match the anticipated economic benefits expected to be provided. Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that these asset might be impaired. Amortization expense for definite-lived intangibles was $13.0 million and $12.8 million for the three months ended JuneÂ 30, 2024 and 2023, respectively. Amortization expense for definite-lived intangibles was $25.9 million and $25.7 million for the six months ended JuneÂ 30, 2024 and 2023, respectively. No impairment losses were recognized in the three and six months ended JuneÂ 30, 2024 and 2023.Indefinite-lived intangible assets other than goodwill include primarily In-Process Research & Development (â€œIPR&Dâ€) projects. IPR&D intangible assets represent the fair value of technology acquired in a business combination or asset acquisition for which the technology projects are incomplete but have substance or alternative future use. When an IPR&D project is completed (generally upon receipt of regulatory approval), then the IPR&D will be accounted for as a definite-lived intangible asset. Indefinite-lived intangible assets are not amortized, and the Company tests for impairment of indefinite-lived intangible assets when events or circumstances indicate that the carrying value of the assets may not be recoverable, and the Company performs an asset impairment analysis annually, as of October 31. No impairment losses were recognized in the three and six months ended JuneÂ 30, 2024 and 2023, respectively. Expected future amortization expense for definite-lived intangible assets is as follows:(in thousands)2024 (remainder of the year)$24,896Â 202547,592Â 202634,107Â 202725,140Â 202818,359Â 2029 and thereafter13,184Â Total$163,278Â X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X -

DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 MEZZANINE AND STOCKHOLDERS' EQUITY 6 Months Ended Jun. 30, 2024 Stockholders' Equity Note [Abstract] Â MEZZANINE AND STOCKHOLDERS' EQUITY MEZZANINE AND STOCKHOLDERSâ€™ EQUITYStockholdersâ€™ EquityAuthorized sharesThe Company is authorized to issue up to 33.3 million shares of common stock with a par value of $0.0001 per share, 0.8 million shares of class C special stock with a par value of $0.0001 per share, and 1.7 million shares of undesignated preferred stock with a par value of $0.0001 per share at JuneÂ 30, 2024. There were 21.5 million and 21.1 million shares of common stock issued and outstanding as of JuneÂ 30, 2024, respectively, and 20.7 million and 20.5 million shares of common stock issued and outstanding as of DecemberÂ 31, 2023, respectively. Class C Special Stock There were 11 thousand shares of class C special stock issued and outstanding as of JuneÂ 30, 2024 and DecemberÂ 31, 2023. Each share of class C special stock entitles its holder to one vote per share. Each share of class C special stock is exchangeable, at the option of the holder, for one share of common stock, at an exchange price of $90.00 per share, subject to adjustment upon certain capitalization events. Holders of class C special stock are not entitled to receive dividends or to participate in the distribution of our assets upon liquidation, dissolution, or winding-up the Company. The holders of class C special stock have no cumulative voting, preemptive, subscription, redemption, or sinking fund rights.Mezzanine EquityPIPE SharesConcurrently with the execution of the Novitium Merger Agreement, and as financing for a portion of the acquisition, on March 8, 2021, the Company entered into an Equity Commitment and Investment Agreement with Ampersand 2020 Limited Partnership (the â€œPIPE Investorâ€), pursuant to which the PIPE Investor purchased 25,000 shares of Series A Convertible Preferred Stock (the â€œPIPE Sharesâ€), for a purchase price of $1,000 per share and an aggregate purchase price of $25.0 million on NovemberÂ 19, 2021. The PIPE Shares are classified as mezzanine equity because the shares are mandatorily redeemable for cash upon a change in control, an event that is not solely within the Companyâ€™s control. The PIPE Shares accrue dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind, and will also participate, on a pro-rata basis, in any dividends that may be declared with respect to our common stock. The PIPE Shares are convertible into common shares at the conversion price of $41.47 (i) beginning two years after their issuance date, at the election of ANI (in which case the PIPE Investor must convert all of the PIPE Shares), if the volume-weighted average price of the common stock for any 20 trading days out of 30 consecutive trading days exceeds 170% of the conversion price, and (ii) at any time after issuance, at the election of the PIPE Investor. As of JuneÂ 30, 2024, the PIPE shares are currently convertible into a maximum of 602,901 shares of common stock.In case of a liquidation event, the holder of the PIPE Shares will be entitled to receive, in preference to holders of the Companyâ€™s common stock, the greater of (i) the PIPE Sharesâ€™ purchase price plus any accrued and unpaid dividends thereon and (ii) the amount the holder of the PIPE Shares would have received in the liquidation event if it had converted its PIPE Shares into common stock. The PIPE Shares will have voting rights, voting as one series with the holders of common stock, on as-converted basis, and will have separate voting rights on any (i) amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the â€œCertificateâ€) that adversely amends and relates solely to the terms of the PIPE Shares and (ii) issuance of additional Series A convertible preferred stock. In case of a change of control, the PIPE Shares will be redeemed at the greater of (i) the PIPE Sharesâ€™ purchase price plus any accrued and unpaid dividends thereon and (ii) the change of control transaction consideration that the PIPE Investor would have received if it had converted into shares of common stock.There were 25,000 shares of Series A convertible preferred stock outstanding as of JuneÂ 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK-BASED COMPENSATION 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â STOCK-BASED COMPENSATION STOCK-BASED COMPENSATIONEmployee Stock Purchase PlanIn July 2016, the Company commenced administration of the ANI Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan. As of JuneÂ 30, 2024, the Company had 0.1 million shares of common stock available under the ESPP. Under the ESPP, participants can purchase common shares of the Companyâ€™s stock at a 15% discount on the lowest share price on the first day of the purchase period or the last day of the purchase period.The following table summarizes ESPP expense incurred under the 2016 Employee Stock Purchase Plan and included in our accompanying unaudited interim condensed consolidated statements of operations:(in thousands)Three Months Ended June 30,Six Months Ended June 30,20242023Selling, general, and administrative$137Â $70Â $276Â $143Â Cost of sales30Â 18Â 60Â 30Â Research and development12Â 12Â 23Â 19Â Total$179Â $100Â $359Â $192Â Stock Incentive PlanDuring the 2024 Annual Meeting of Stockholders held on May 21, 2024, the stockholders of the Company approved an amendment to the Amended and Restated Stock Incentive Plan (the â€œ2022 Planâ€) (such amendment, the â€œ2024 Stock Plan Amendmentâ€ and the 2022 Plan, after giving effect to the 2024 Stock Plan Amendment, the â€œAmended 2022 Stock Planâ€). Subject to adjustment, the 2024 Stock Plan Amendment authorizes the issuance of an additional 1,610,000 shares.As of JuneÂ 30, 2024, 2.0 million shares of common stock were available for issuance under the Amended 2022 Stock Plan.Stock Options Outstanding stock options to purchase shares of common stock are granted to employees and consultants generally vest over a period of four years and have 10-year contractual terms. Outstanding stock options granted to non-employee directors generally vest over a period of one to four years and have 10-year contractual terms. From time to time, stock options are granted to employees through an inducement grant outside of the Amended 2022 Stock Plan to induce prospective employees to accept employment with the Company (the â€œInducement Grantsâ€). The options are granted at an exercise price equal to the fair market value of a share of common stock on the respective grant date and are generally exercisable in four equal annual installments beginning on the first anniversary of the respective grant date. The grants are made pursuant to inducement grants outside of our stockholder approved equity plan as permitted under the Nasdaq Stock Market listing rules.Restricted Stock Awards Restricted stock awards (â€œRSAsâ€) granted to employees generally vest over a period of four years and RSAs granted to non-officer directors generally vest over a period of one year.During the vesting period, the recipient of the RSAs has full voting rights as a stockholder and would receive dividends, if declared, even though the restricted stock remains subject to transfer restrictions and will generally be forfeited upon termination of the officer prior to vesting. The fair value of each RSA is based on the market value of our stock on the date of grant. Upon vesting, unrestricted shares of common stock are delivered to employees and directors.Performance-Based Restricted Stock Units February 28, 2023 Performance-Based Restricted Stock Units GrantAwards may also be issued in the form of Performance Stock Units (â€œPSUsâ€). PSUs represent the right to receive an amount of cash, a number of shares of common stock or a combination of both, contingent upon the achievement of specified performance objectives during a specified performance period. PSUs granted to date vest over a three-year performance period. On February 28, 2023, as part of the Companyâ€™s equity compensation program, we granted PSUs to certain executives. Of these PSUs, 50% were market performance-based restricted stock units (â€œMPRSUsâ€), vesting of which is contingent upon the Company meeting certain total shareholder return (â€œTSRâ€) levels as compared to a select peer group over the over three years starting January 1, 2023. The MPRSUs are also subject to the recipientâ€™s continued employment or service through December 31, 2025. The MPRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (83,942 shares, net of forfeitures) based on TSR performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The estimated grant date fair value per share of the MPRSUs was $68.65 and was calculated using a Monte Carlo simulation model. These MPRSUs are included at 100% of the estimate number of shares at the end of the three-year performance period and are reflected under â€œGrantedâ€ in the table below.The other 50% of the PSUs were performance based restricted stock units (â€œPRSUsâ€), vesting of which is contingent upon the Company meeting certain adjusted non-GAAP year-on-year EBITDA growth rates over the over three years starting January 1, 2023. The PRSUs are also subject to the recipientâ€™s continued employment or service through December 31, 2025. The PRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (83,942 shares, net of forfeitures) based on adjusted non-GAAP year-on-year EBITDA growth rates. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The Company analyzed progress on the performance goals to assess the likelihood of achievement. The estimated grant date fair value per share of the PRSUs was $41.84 based on the closing price of the stock on the date of grant. These PRSUs are included at 100% of the estimated number of shares at the end of the three-year performance period and are reflected under â€œGrantedâ€ in the table below.February 14, 2024 Performance-Based Restricted Stock Units GrantOn February 14, 2024, the Company granted 73,588 PSUs to officers and employees of the Company under the 2022 Plan (66,433 to officers of the Company). PSU performance will be measured over a three-year performance period from January 1, 2024 through December 31, 2026 and will cliff-vest contingent upon the achievement of specified performance objectives. Of these PSUs, 50% were MPRSUs, vesting of which is contingent upon the Company meeting certain TSR levels as compared to a select peer group over the over three years starting January 1, 2024, and 50% of the PSUs were PRSUs, vesting of which is contingent upon the Company meeting certain adjusted non-GAAP year-on-year EBITDA growth rates over the over three years starting January 1, 2024. Both the MPRSUs and the PRSUs have a maximum potential to vest at 200%. The estimated grant date fair value per share of the MPRSUs was $85.65 and was calculated using a Monte Carlo simulation model. These MPRSUs are included at 100% of the estimate number of shares at the end of the three-year performance period and are reflected under â€œGrantedâ€ in the table below.The estimated grant date fair value per share of the PRSUs was $56.10 based on the closing price of the stock on the date of grant. These PRSUs are included at 100% of the estimated number of shares at the end of the three-year performance period and are reflected under â€œGrantedâ€ in the table below.The following table summarizes stock-based compensation expense incurred under the Amended 2022 Stock Plan and Inducement Grants included in the accompanying unaudited interim condensed consolidated statements of operations:(in thousands)Three Months Ended June 30,Six Months Ended June 30,20242023Selling, general, and administrative$7,069Â $4,766Â $13,301Â $8,673Â Research and development334Â 213Â 606Â 413Â Cost of sales282Â 170Â 532Â 309Â Total$7,685Â $5,149Â $14,439Â $9,395Â A summary of stock options (including Inducement Grants), RSA, and PSU activity under the Amended 2022 Stock Plan and Inducement Grants during the six months ended JuneÂ 30, 2024 and 2023 is presented below:(in thousands)OptionsPSUsRSAsOutstanding at December 31, 2022907â€”1,141Granted385624Options Exercised/RSAs Vested(26)â€”(338)(1)Forfeited(24)â€”(46)Outstanding at June 30, 2023860851,381Outstanding at December 31, 2023689841,351Grantedâ€”74606Options Exercised/RSAs Vested(54)â€”(433)(2)Forfeitedâ€”â€”(12)Outstanding at June 30, 20246351581,512 _____(1)Includes 99 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $4.1 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets.(2)Includes 149 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $10.0 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INCOME TAXES 6 Months Ended Jun. 30, 2024 Income Tax Disclosure [Abstract] Â INCOME TAXES INCOME TAXESThe Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a

change in tax rates is recognized in the period that such tax rate changes are enacted.The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. As of JuneÂ 30, 2024, a valuation allowance was recorded against consolidated net deferred tax assets of $0.4 million, related solely to deferred tax assets for net operating loss carryforwards in certain U.S. state jurisdictions. The Company uses a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company has not identified any uncertain income tax positions that could have a material impact on the consolidated financial statements. The Company recognizes interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense; the Company did not have any such amounts accrued as of JuneÂ 30, 2024 and DecemberÂ 31, 2023. The Company is subject to taxation in various U.S. jurisdictions, Canada, and India and all of its income tax returns remain subject to examination by tax authorities due to the availability of NOL carryforwards.For interim periods, the Company recognizes an income tax expense (benefit) based on our estimated annual effective tax rate, calculated on a worldwide consolidated basis, expected for the entire year. The interim annual estimated effective tax rate is based on the statutory tax rates then in effect, as adjusted for estimated changes in estimated permanent differences and excludes certain discrete items whose tax effect, when material, are recognized in the interim period in which they occur. These changes in permanent differences and discrete items result in variances to the effective tax rate from period to period. The Companyâ€™s estimated annual effective tax rate changes throughout the year as our on-going estimates of pre-tax income, and changes in permanent differences are revised, and as discrete items occur. Global Intangible Low-Taxed Income (â€œGILTIâ€), as defined in the Tax Cuts and Jobs Act of 2017, generated from our Canadian and Indian operations is subject to U.S. taxes, with certain defined exemptions, thresholds and credits. For financial reporting purposes the Company has elected to treat GILTI inclusions as a period cost. For the three months ended JuneÂ 30, 2024, the Company recognized an income tax expense of $0.0Â million. The Companyâ€™s effective tax rate was 0.0% after discrete items for the three months ended JuneÂ 30, 2024. The effective tax rate differed from the federal statutory rate of 21% primarily due to state taxes, stock based compensation, and non-deductible expenses related to the pending business combination.For the three months ended JuneÂ 30, 2023, the Company recognized an income tax benefit of $1.0Â million. The Companyâ€™s effective tax rate was (19.0)% for the three months ended June 30, 2023. The effective tax rate differed from the federal statutory rate of 21% primarily due to the recognition of the U.S. federal research and development credit, permanent differences, and discrete tax benefit primarily related to remeasurement of its gross deferred assets due to change in state deferred effective tax rate. For the six months ended JuneÂ 30, 2024, the Company recognized an income tax expense of $7.1 million. The Companyâ€™s effective tax rate was 30.9% after discrete items for the six months ended JuneÂ 30, 2024. The effective tax rate differed from the federal statutory rate of 21% primarily due to state taxes, stock based compensation, tax on the sale of the Oakville, Ontario manufacturing site, and recording of a withholding tax liability on the proceeds of the sale, and non-deductible expenses related to the pending business combination.For the six months ended JuneÂ 30, 2023, the Company recognized an income tax benefit of $0.3Â million. The Companyâ€™s effective tax rate was (3.7)% for the six months ended June 30, 2023. The effective tax rate differed from the federal statutory rate of 21% primarily due to the recognition of the U.S. federal research and development credit, permanent differences, and discrete tax benefit primarily related to remeasurement of gross deferred assets due to change in state deferred effective tax rate.The Company does not expect that any law changes enacted during the period will have a material impact on the provision for income taxes. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 COMMITMENTS AND CONTINGENCIES 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIESOperating LeasesIn April 2023, the Company entered into an agreement to lease additional warehouse space in East Windsor, New Jersey. The lease has a term of five years, and was classified as an operating lease. The lease was capitalized and included in other non-current assets on the accompanying unaudited condensed consolidated balance sheets. Additionally, during October 2023, the Company entered into an amendment for the Middleton, Wisconsin location which expanded the Companyâ€™s square footage and also extended the termination date to December 2028. Government RegulationThe Companyâ€™s products and facilities are subject to regulation by a number of federal and state governmental agencies, such as the Drug Enforcement Administration (â€œDEAâ€), the Food and Drug Administration (â€œFDAâ€), the Centers for Medicare and Medicaid Services (â€œCMSâ€), the Central Drugs Standard Control Organization (â€œCDSCOâ€), The Narcotics Control Bureau (â€œNCBâ€), and Indiaâ€™s Ministry of Health and Family Welfare (â€œMoHFWâ€). The FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of ANIâ€™s products. The DEA and NCB maintain oversight over products that are considered controlled substances.Unapproved ProductsFour products, Esterified Estrogens and Methyltestosterone (â€œEEMTâ€), Opium Tincture, Thyroid Tablets, and Hyoscyamine are sold without approved NDAs or ANDAs. If the FDA took enforcement action against the Company, the Company may be required to seek FDA approval for the group of products or withdraw them from the market. During the three and six months ended JuneÂ 30, 2024, net revenues from commercial sales of these products for these products totaled $6.8 million and $10.9 million, respectively. During the three and six months ended JuneÂ 30, 2023, net revenues from EEMT and Opium Tincture totaled $3.5 million and $7.2 million, respectively. On DecemberÂ 27, 2023, the Company acquired from Alvogen, Inc. the rights to Hyoscyamine for total cash consideration of $2.0 million, which product was launched commercially in February 2024. Contract manufacturing revenues for Hyoscyamine, for both the three and six months ended JuneÂ 30, 2024 were less than $0.1 million. Contract manufacturing revenues for Hyoscyamine, for three and six months ended JuneÂ 30, 2023 were $0.5 million and $1.1 million, respectively. Legal proceedings The Company is, and from time to time may become, involved in various disputes, governmental and/or regulatory inquiries, investigations, government reimbursement related actions and litigation. These matters are complex and subject to significant uncertainties. While we believe that we have valid claims and/or defenses in the litigation and other matters described below, litigation is inherently unpredictable, particularly where the damages sought are substantial or indeterminate or when the proceedings, investigations or inquiries are in the early stages, and the outcome of the proceedings could result in losses, including substantial damages, fines, civil or criminal penalties and injunctive or administrative remedies. We intend to vigorously prosecute and/or defend these matters, as appropriate; however, from time to time, we may settle or otherwise resolve these matters on terms and conditions that we believe are in our best interests. Resolution of any or all claims, investigations, and legal proceedings, individually or in the aggregate, could have a material adverse effect on our results of operations and/or cash flows in any given accounting period or on our overall financial condition.Some of these matters with which we are involved are described below and in our 2023 Form 10-K, and unless otherwise disclosed, we are unable to predict the outcome of the matter or to provide an estimate of the range of reasonably possible material losses. We record accruals for loss contingencies to the extent we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.From time to time, we are also involved in other pending proceedings for which, in our opinion based upon facts and circumstances known at the time, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to our results, and therefore remain undisclosed. If and when any reasonably possible losses associated with the resolution of such other pending proceedings, in our opinion, become material, we will disclose such matters.Furthermore, like many pharmaceutical manufacturers, we are periodically exposed to product liability claims. The prevalence of these claims could limit our coverage under future insurance policies or cause those policies to become more expensive, which could harm our business, financial condition, and operating results. Recent trends in the product liability and director and officer insurance markets is to exclude matters related to certain classes of drugs. Our policies have been subject to such exclusions which place further potential risk of financial loss on us.Legal fees for litigation-related matters are expensed as incurred and included in the condensed consolidated statements of operations under the selling, general, and administrative expense line item. Commercial Litigation On December 3, 2020, class action complaints were filed against the Company on behalf of putative classes of direct and indirect purchasers of the drug Bystolic. On December 23, 2020, six individual purchasers of Bystolic, CVS, Rite Aid, Walgreen, Kroger, Albertsons, and H-E-B, filed complaints against the Company. On March 15, 2021, the plaintiffs in these actions filed amended complaints. All amended complaints were substantively identical. The plaintiffs in these actions alleged that, beginning in 2012, Forest Laboratories, the manufacturer of Bystolic, entered into anticompetitive agreements when settling patent litigation related to Bystolic with seven potential manufacturers of a generic version of Bystolic: Hetero, Torrent, Alkem/Indchemie, Glenmark, Amerigen, Watson, and various of their corporate parents, successors, subsidiaries, and affiliates. ANI itself was not a party to patent litigation with Forest concerning Bystolic and did not settle patent litigation with Forest. The plaintiffs named the Company as a defendant based on the Companyâ€™s January 8, 2020 Asset Purchase Agreement with Amerigen. Under the terms of the 2020 Asset Purchase Agreement, Amerigen agreed to indemnify ANI for certain liabilities relating to Bystolic, including liabilities that arose prior to closing of the asset purchase. The complaints alleged that the 2013 patent litigation settlement agreement between Forest and Amerigen violated federal and state antitrust laws and state consumer protection laws by delaying the market entry of generic versions of Bystolic. Plaintiffs alleged they paid higher prices as a result of delayed generic competition. Plaintiffs sought damages, trebled or otherwise multiplied under applicable law, injunctive relief, litigation costs and attorneysâ€™ fees. The complaints did not specify the amount of damages sought from the Company or other defendants and the Company. The cases were consolidated in the United States District Court for the Southern District of New York. On April 23, 2021, the Company and other defendants filed motions to dismiss the amended complaints. On January 24, 2022, the court dismissed all claims brought by the plaintiffs without prejudice. The court granted the plaintiffs until February 22, 2022 to file amended complaints, which were filed in federal court in the Southern District of New York, on that date. The newly amended complaints contained substantially similar claims. On April 19, 2022, the Company and other defendants filed motions to dismiss the newly amended complaints. After full briefing and oral argument, on February 21, 2023, the court granted the Company and the defendantsâ€™ motion to dismiss all actions with prejudice. Plaintiffs filed an appeal in the Second Circuit. On May 13, 2024, the Second Circuit affirmed the district courtâ€™s judgment, dismissing plaintiffsâ€™ claims with prejudice.On March 4, 2024, ANI commenced a civil action against CG Oncology, Inc. f/k/a Cold Genesys, Inc. (â€œCG Oncologyâ€) in the Superior Court of the State of Delaware (â€œDelaware Actionâ€). ANIâ€™s complaint alleges that, under an Assignment and Technology Transfer Agreement dated as of November 15, 2010 (the â€œNovember 2010 Agreementâ€), CG Oncology is liable to pay ANI a running royalty of 5% of the worldwide net sales of cretostimogene made by CG Oncology or any affiliate or sublicensee thereof; and that in February 2024, CG Oncology wrongfully repudiated its royalty obligation to ANI. On April 2, 2024, CG Oncology filed an answer and counterclaim (the â€œCGON Answer and Counterclaimâ€) and concurrently moved for judgment on the pleadings or, in the alternative, for partial summary judgment (the â€œMotion for Summary Judgmentâ€). CG Oncologyâ€™s Motion for Summary Judgment seeks judgment declaring that the November 2010 Agreement does not â€œoblige CGON to pay royalties after expiration of the latest-running assigned patent.â€ CG Oncology also seeks judgment awarding compensatory damages and punitive damages on counterclaims for alleged breach of the November 2010 Agreement and for alleged misappropriation of trade secrets under federal and Delaware state law. On April 22 and 25, 2024, ANI filed its reply to CG Oncologyâ€™s counterclaims, denying any liability to CG Oncology and asserting additional counterclaims against CG Oncology (â€œReply Counterclaimsâ€) for alleged breach of the November 2010 Agreement and, in the alternative, for unjust enrichment. ANIâ€™s Reply Counterclaims seek judgment (i) declaring that, under Section 3.3 of the November 2010 Agreement, CG Oncology is contractually obligated to pay ANI 5% of the worldwide net sales of cretostimogene made by CG Oncology or any affiliate or sublicensee thereof; (ii) dismissing CG Oncologyâ€™s counterclaims with prejudice; (iii) awarding ANI compensatory damages as provided by law, including damages grounded in restitution and unjust enrichment; (iv) in the event of a judgment in ANIâ€™s favor on ANIâ€™s fourth counterclaim for unjust enrichment, ordering CG Oncology to re-transfer to ANI ownership of all assets that ANI sold to CG Oncology under the November 2010 Agreement, including, without limitation, all data and documentation comprising IND 12154; and (v) in the event of a judgment in ANIâ€™s favor on ANIâ€™s fourth counterclaim for unjust enrichment, imposing a constructive trust on all fruits of CG0070-related assets that ANI sold to CG Oncology under the November 2010 Agreement including, without limitation, all data and documentation comprising IND 12154 and any other IND that CG Oncology may have for CG0070. On May 15, 2024, CG Oncology filed a reply to ANIâ€™s counterclaims, which generally maintains the positions in the CGON Answer and Counterclaim. The parties are currently engaged in pretrial discovery. On June 7, 2024, CG Oncology filed a motion to stay discovery pending a decision by the court on its Motion for Summary Judgment. The court denied CG Oncologyâ€™s motion to stay discovery at the conclusion of an oral hearing held on July 11, 2024. The hearing on CG Oncologyâ€™s Motion for Summary Judgment is currently scheduled for August 22, 2024. ANI intends to vigorously pursue this matter.On March 5, 2024, a complaint was filed against ANI by Acella Pharmaceuticals, LLC, in the United States District Court of Minnesota, asserting, among other things, false advertising under the Lanham Act, and unfair trade practices and false advertising under Minnesota law, relating to ANIâ€™s natural desiccated thyroid tablets USP. The complaint seeks injunctive relief, actual and consequential damages, disgorgement of profits, and attorneysâ€™ fees and costs. On April 16, 2024, ANI filed an answer to Acellaâ€™s complaint, denying all claims, and asserting certain affirmative defenses, and counterclaims against Acella for false advertising of its thyroid product marketed as NP ThyroidÂ® Tablets, under the Lanham Act, common law unfair competition and unfair and deceptive trade practices and false advertising under Minnesota and Georgia law. ANI seeks injunctive relief, compensatory damages, punitive damages and attorneysâ€™ fees and costs. On May 17, 2024, Acella filed a motion to dismiss ANIâ€™s counterclaims. On June 7, 2024, ANI filed an amended answer to Acellaâ€™s complaint and counterclaims. Acella filed a motion to dismiss ANIâ€™s amended counterclaims on July 31, 2024. A hearing date has been set for September 11, 2024 on Acellaâ€™s motion to dismiss. The case is currently in fact discovery until February 1, 2025. ANI disputes any liability in this matter and intends to defend this lawsuit vigorously.Patent LitigationOn November 21, 2023, a complaint was filed against Novitium and certain other defendants in the case of Harmony Biosciences, LLC, Bioprojet Societe Civile de Recherche and Bioprojet Pharma SAS v. AET Pharma US, Inc., Annora Pharma Private Limited, Novitium Pharma LLC, Zenara Pharma Private Limited and Biophore India Pharmaceuticals Private Limited in the United States District Court for the District of Delaware, asserting, among other things, that Novitiumâ€™s proposed pitolisant hydrochloride drug product, which is subject to Novitiumâ€™s Abbreviated New Drug Application, infringes certain U.S.

patents. The complaint seeks damages, injunctive relief, attorneysâ€™ fees and costs. On January 29, 2024, Novitium filed its answer, denying all allegations and asserting counterclaims of non-infringement and invalidity. On February 16, 2024, plaintiffs filed their answer, denying Novitiumâ€™s counterclaims and asserting certain affirmative defenses against Novitium. On April 15, 2024, the court consolidated Novitiumâ€™s case and two other cases brought by plaintiffs against Lupin Limited et al, and MSN Pharms. Inc. et al., into one consolidated matter filed in C.A. No. 23-1286-JLH. The case is currently in discovery. The court set a trial date of February 2026. Novitium disputes any liability in this matter.Ranitidine Related LitigationFederal Court Multi District LitigationANI and Novitium were named as defendants, along with numerous other brand and generic pharmaceutical manufacturers, wholesale distributors, retail pharmacy chains, and repackagers of ranitidine-containing products, in In re: Zantac/Ranitidine NDMA Litigation (MDL No, 2924), filed in the United District Court for the Southern District of Florida (the â€œMDL Courtâ€). Plaintiffs allege that defendants failed to disclose and/or concealed the alleged inherent presence of N-Nitrosodimethylamine (or â€œNDMAâ€) in brand-name Zantac or generic ranitidine and the alleged associated risk of cancer. While ANI was initially a defendant, the lead plaintiff attorneys voluntarily dismissed ANI as a defendant in the Master Complaint. On July 8, 2021, the MDL Court dismissed all claims by all plaintiffs against the generic drug manufacturers with prejudice , on preemption grounds. The MDL Court also dismissed all claims by all plaintiffs against the brand manufacturers on summary judgment. Plaintiffs appealed the MDL Courtâ€™s dismissals to the Eleventh Circuit Court of Appeals. On November 7, 2022, the Eleventh Circuit affirmed the MDL Courtâ€™s dismissal of cases brought by third-party payors. The Eleventh Circuit raised questions in the appeals of the other cases about the finality of the MDL Courtâ€™s judgments, which were resolved in September 2023. Plaintiffs filed opening briefs on April 10, 2024 and generics defendants filed their response on July 25, 2024.ANI and Novitium dispute any liability in this matter.State Court Personal Injury LitigationANI and Novitium have also been named as defendants in various state lawsuits.California. The pending cases in California state court naming generic ranitidine manufacturers were transferred to an existing civil case coordination docket for pretrial proceedings (JCCP) in Alameda County. On September 21, 2023, plaintiffs filed a master complaint in the JCCP alleging strict liability, negligent failure to warn and general negligence, but not naming any generic defendants. In December 2023, the Keller Postman firm filed approximately 200 individual plaintiff short form complaints that name generic defendants. Novitium is named in 28 of the short form complaints which reference the claims for the master complaint, but has not been served. ANI is not named. On February 1, 2024, the generic defendants filed an omnibus demurrer challenging the sufficiency of the Keller Postman complaints, largely on the basis of preemption. On April 23, 2024, the California court granted the demurrer in part, dismissing all design defect claims against the generic defendants with prejudice on preemption grounds, but the court otherwise granted plaintiffs an opportunity for leave to amend their other claims against the generic defendants. Plaintiffs filed an amended master complaint on April 29, 2024. Novitium is named in one case and discovery is currently ongoing. Pennsylvania. In September 2022, two complaints were filed naming Novitium as a defendant in Pennsylvania state court, Philadelphia County. On February 16, 2023, the Pennsylvania plaintiffs filed a consolidated long-form complaint against the generic defendants, Plaintiffs v. Actavis, et. al. Civil Action No. 1364. The long-form complaint names Novitium as a defendant. The long form complaint asserts causes of action for negligence, failure to warn, negligent storage and transportation, breach of express warranties, breach of implied warranties, negligent misrepresentation, fraud, strict products liability, wrongful death and survivor actions, and loss of consortium. The complaint includes a prayer for punitive damages. The generic defendants filed their preliminary objections to Plaintiffsâ€™ consolidated long-form generic complaint on March 20, 2023. The court dismissed all claims related to failure to warn/design defects on preemption grounds. The court also sustained the genericsâ€™ preliminary objections relating to the counts of strict liability-design defect and breach of implied warranty to the extent Pennsylvania substantive law applies, effectively dismissing the generic defendants from the case unless and until a non-resident plaintiff names a generic in a short form complaint. Out of an abundance of caution, however, the generics, including Novitium, all filed answers to the long form complaint in June 2023. In January 2024, plaintiffs filed short form complaints naming generic defendants, including Novitium in one complaint. Generic defendants filed joint preliminary objections to the short form complaints based on preemption. The deadline for filing responses to these objections has passed and no amended complaint or response has been filed by plaintiffs against Novitium.ANI and Novitium dispute any liability in these matters. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FAIR VALUE DISCLOSURES 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â FAIR VALUE DISCLOSURES FAIR VALUE DISCLOSURESFair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value.The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of our funds. The fair value of short-term financial instruments (primarily accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current liabilities) approximate their carrying values because of their short-term nature. The Term Facility bears an interest rate that fluctuates with the changes in SOFR and, because the variable interest rates approximate market borrowing rates available to us, we believe the carrying values of these borrowings approximated their fair values at JuneÂ 30, 2024.Financial Assets and Liabilities Measured at Fair Value on a Recurring BasisMoney Market FundsMoney market funds are readily convertible into cash and the net asset value of each fund on the last day of the Â Â Â Â Â Â Â Â reporting period is used to determine its fair value. Money market funds are included in Cash and cash equivalents within the Consolidated Balance Sheet, and is classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company does not adjust the quoted market price for such financial instruments. The fair value of the money market funds as of JuneÂ 30, 2024 was approximately $166.5 million.Interest Rate SwapThe fair value of the interest rate swap is estimated based on the present value of projected future cash flows using the SOFR forward rate curve (see Note 6). The model used to value the interest rate swap includes inputs of readily observable market data, a Level 2 input. As described in detail in Note 6, the fair value of the interest rate swap was $7.4 million as of JuneÂ 30, 2024, and was classified as a non-current asset.CG Oncology Equity SecuritiesThe Company currently holds 219,925 shares of common stock in CG Oncology (Nasdaq: CGON). The Company accounts for its investment in CG Oncology equity securities as an equity investment with a readily determinable fair value, as the securities are publicly traded on the Nasdaq Global Select Market. The fair value of the equity securities is based on its closing price on the Nasdaq and is classified within Level 1 of the fair value hierarchy because the equity securities are valued using quoted market prices. The Company does not adjust the quoted market price for such financial instruments. The fair value of the CG Oncology equity securities as of JuneÂ 30, 2024 was approximately $6.9 million based on a closing market price of $31.57 on June 28, 2024. This amount is classified on the unaudited condensed consolidated statements of operations as Unrealized gain on investment in equity securities. Between 2013 and 2023, CG Oncology securities held by the Company were valued at zero under U.S. GAAP.Contingent ConsiderationIn connection with the acquisition of Novitium, the Company may pay up to $46.5 million in additional consideration related to the achievement of certain milestones, such as milestones on gross profit of Novitium portfolio products over a 24-month period, regulatory filings completed during this 24-month period, and a percentage of net profits on certain products that are launched in the future.The discounted cash flow method used to value this contingent consideration includes inputs which are classified as Level 3 inputs, as the inputs are not based on readily available market data. Pursuant to the terms of the Novitium Merger Agreement, on DecemberÂ 12, 2023, the Company paid $12.5 million of cash consideration to the Company Members, defined as the holders of Novitium ownership interests in the Novitium Merger Agreement, as the holders of Novitium ownership interests, for the achievement of the â€œANDA Filing Earn-Out,â€ as defined in the Agreement (Note 15). Furthermore, on FebruaryÂ 22, 2024, the Company paid $12.5 million to Company Members of Novitium upon the achievement of the â€œGross Profit Earn-Out,â€ as defined in the Agreement (Note 15).The fair value of the contingent consideration was approximately $11.9 million and $24.0 million as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively, and is reflected as a current and non-current accrued contingent consideration liability in the unaudited interim condensed consolidated balance sheets.The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs as of June 30, 2024:Payment TypeValuation TechniqueUnobservable InputAssumptionsProfit-based milestone paymentsProbability-weighted discounted cash flowDiscount rate13%Projected fiscal year of payment2025-2035The following table presents the changes in contingent consideration balances classified as Level 3 for the three and six months ended JuneÂ 30, 2024 and 2023:Three Months Ended June 30,Six Months Ended June 30,(in thousands)20242023202420232023Beginning balance$11,574Â $36,019Â $23,984Â $35,058Â Payment of Gross-Profit earn-outâ€”Â â€”Â (12,500)â€”Â Change in fair value359Â 1,035Â 449Â 1,996Â Ending balance$11,933Â $37,054Â $11,933Â $37,054Â The following table presents our financial assets and liabilities accounted for at fair value on a recurring basis as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, by level within the fair value hierarchy:(in thousands)DescriptionFair Value at June 30, 2024Level 1Level 2Level 3AssetsMoney Market Fund$166,485Â $166,485Â $â€”Â $â€”Â Interest rate swap$7,366Â $â€”Â $7,366Â $â€”Â Â Â Â CG Oncology - Investment in equity securities$6,943Â $6,943Â $â€”Â $â€”Â LiabilitiesÂ Â Â Â Contingent consideration$11,933Â $â€”Â $â€”Â $11,933Â DescriptionFair Value at December 31, 2023Level 1Level 2Level 3AssetsÂ Â Â Money Market Fund$191,841Â $191,841Â $â€”Â $â€”Â Interest rate swap$6,236Â $â€”Â $6,236Â $â€”Â LiabilitiesÂ Â Â Â Contingent consideration$23,984Â $â€”Â $â€”Â $23,984Â Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring BasisThere are no financial assets or liabilities that are measured at fair value on a non-recurring basis.Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring BasisThere are no non-financial assets or liabilities that are measured at fair value on a recurring basis.Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring BasisLong-lived assets, including property, plant, and equipment, right-of-use (â€œROUâ€) assets, intangible assets, and goodwill, are measured at fair value on a non-recurring basis, and no such fair value impairment was recognized in the three and six months ended JuneÂ 30, 2024 and 2023. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RELATED PARTY TRANSACTIONS 6 Months Ended Jun. 30, 2024 Related Party Transactions [Abstract] Â RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONSPIPE SharesOn MarchÂ 8, 2021, the Company entered into an Equity Commitment and Investment Agreement with the PIPE Investor, pursuant to which 25,000 shares were purchased for $1,000 per share for an aggregate purchase price of $25.0 million on NovemberÂ 19, 2021. The Chairman of the Companyâ€™s board of directors is an operating partner of Ampersand Capital Partners, an affiliate of the PIPE Investor.NovitiumIn connection with the acquisition of Novitium, the Company entered into employment agreements with the two executives and founders of Novitium, Muthusamy Shanmugam, Head of R&D and COO of NJ Operations of ANI, and Chad Gassert, Sr. Vice President, Corporate Development and Strategy of ANI. Both serve as executive officers of the Company and Mr. Shanmugam also serves on the Companyâ€™s board of directors. Mr. Shanmugam holds a minority interest in Scitus Pharma Services (â€œScitusâ€), which provides clinical research services to Novitium, a majority interest in SS Pharma LLC (â€œSS Pharmaâ€), which acquires and supplies API to Novitium, a minority interest in Nuray Chemical Private Limited (â€œNurayâ€), which manufactured and supplied API to Novitium in prior periods, a majority interest in Esjay Pharma LLC (â€œEsjayâ€), which provides research and development and facilities consulting services, and a minority interest in SThree Chemicals Pvt Ltd (â€œSThreeâ€), which acquires and supplies API to Novitium. A summary of payments to related parties is presented below:Three Months Ended June 30,Six Months Ended June 30,20242023202420232023Scitus Pharma Services$580Â $1,188Â $1,081Â $1,905Â SS Pharma LLC176Â 1,978Â 1,245Â 3,579Â SThree Chemicals Pvt Ltd683Â â€”Â 1,069Â â€”Â $1,439Â $3,166Â $3,395Â $5,484Â As of JuneÂ 30, 2024, the outstanding balances due to Scitus, SThree, and Esjay were $0.7 million, $2.2 million, and $46 thousand respectively. There was no outstanding balance due to SS Pharma.On DecemberÂ 12, 2023, the Company paid $12.5 million of cash consideration to the Company Members of Novitium for the achievement of the â€œANDA Filing Earn-Out,â€ as defined in the Novitium Merger Agreement, as discussed in Note 2. The Company paid Mr. Shanmugam and Esjay, and Mr. Gassertâ€™s company Chali Properties LLC, approximately $6.7 million and $1.9 million, respectively, for their portion of the cash consideration due to them as part of the Novitium acquisition.On FebruaryÂ 22, 2024, the Company paid $12.5 million of cash consideration to the Company Members of Novitium for the achievement of the â€œGross Profit Earn-Out,â€ as defined in the Novitium Merger Agreement, as discussed in Note 2. The Company paid Mr. Shanmugam and Esjay, and Mr. Gassertâ€™s company Chali Properties LLC, approximately $6.7 million and $1.9 million, respectively, for their portion of the cash consideration due to them as part of the Novitium acquisition. X -

ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SEGMENT REPORTING 6 Months Ended Jun. 30, 2024 Segment Reporting [Abstract] Â SEGMENT REPORTING SEGMENT REPORTINGAn operating segment is defined as a component of an entity that engages in business activities from which it may recognize revenues and incur expense, its operating results are regularly reviewed by the entityâ€™s chief operating decision maker (â€œCODMâ€) to make decisions about resources to be allocated to the segment and assess its performance, and its discrete financial information is available. The CODM for the Company is the Chief Executive Officer. The Company is organized into two operating segments as follows:â€¢Generics, Established Brands, and Other â€“ Consists of operations related to the development, manufacturing, and marketing of generic and established brand pharmaceuticals, including those sold through traditional channels, contract manufactured products, product development services, royalties, and other.â€¢Rare Disease â€“ Consists of operations related to the development, manufacturing and marketing of pharmaceuticals used in the treatment of patients with rare conditions. The rare disease segment currently consists of operations related to Cortrophin Gel.The CODM evaluates the two operating segments based on revenues and earnings before interest, income taxes, depreciation, and amortization (â€œEBITDAâ€), exclusive of corporate expenses and other expenses not directly allocated or attributable to an operating segment. These expenses include, but are not limited to, certain management, legal, accounting, human resources, insurance, and information technology expenses.The Company does not manage assets of the Company by operating segment, and our CODM does not review asset information by operating segment. Accordingly, the Company does not present total assets by operating segment.Financial information by reportable segment is as follows:Three Months Ended June 30,Six Months Ended June 30,(in thousands)20242023202420232Net RevenuesGenerics, Established Brands, and Other$88,847Â $92,243Â $189,340Â $182,699Â Rare Disease49,193Â 24,304Â 86,130Â 40,634Â Total net revenues$138,040Â $116,547Â $275,470Â $223,333Â Segment earnings before interest, taxes, depreciation and amortization (â€œEBITDAâ€) and reconciliation to income before income taxesGenerics, Established Brands, and Other$31,631Â $39,937Â $76,937Â $78,765Â Rare Disease4,344Â 4,215Â 4,740Â 2,964Â Depreciation and amortization(14,697)(14,690)(29,383)(29,390)Corporate and other unallocated expenses(1)(16,109)(17,060)(26,813)(30,042)Total operating income 5,169Â 12,402Â 25,481Â 22,297Â Unrealized (loss) gain on investment in equity securities (2,712)â€”Â 6,943Â â€”Â Interest expense, net(4,656)(7,100)(9,256)(14,796)Other expense, net(88)(53)(120)(87)(Loss) Income Before Income Tax Expense (Benefit)$(2,287)$5,249Â $23,048Â $7,414Â _____(1)Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our unaudited interim consolidated statement of operations. This amount also includes the gain on the sale of the Oakville, Ontario site of approximately $5.3Â million refer to Note 4 for further information.Geographic InformationOperations are currently located in the United States and India. The Company has ceased operations at our Oakville, Ontario, Canada location as of March 31, 2023. The majority of the assets of the Company are located in the United States.The following table depicts the Companyâ€™s revenue by geographic operations during the following periods:(in thousands)Three Months Ended June 30,Six Months Ended June 30,Location of Operations20242023202420232United States$138,040Â $116,547Â $275,470Â $222,768Â Canadaâ€”Â â€”Â 565Â Total Revenue$138,040Â $116,547Â $275,470Â $223,333Â The following table depicts the Companyâ€™s property, plant and equipment, net according to geographic location, which excludes the land and building at the Companyâ€™s Canada facility, which was classified as held for sale as of DecemberÂ 31, 2023. These assets had a carrying value of approximately $8.0 million. The land and building at the Canada facility was sold on March 28, 2024, refer to Note 4. The Companyâ€™s property, plant and equipment are as follows: (in thousands)June 30, 2024December 31, 2023United States$49,887Â $43,163Â India1,753Â 1,430Â Total property and equipment, net$51,640Â $44,593Â X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUBSEQUENT EVENTS 6 Months Ended Jun. 30, 2024 Subsequent Events [Abstract] Â SUBSEQUENT EVENTS SUBSEQUENT EVENTS On July 12, 2024, the Company filed a Registration Statement on Form S-8 with the SEC, to register under the Securities Act of 1933, as amended, 1,610,000 shares of common stock which may be issued from time to time in accordance with the Companyâ€™s Amended 2022 Stock Plan. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net (Loss) Income $ (2,287) $ 6,245 $ 15,920 $ 7,684 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting

Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation Basis of PresentationThe accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) for interim financial information. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Companyâ€™s financial position, results of operations, comprehensive (loss) income, and cash flows. The consolidated balance sheet at DecemberÂ 31, 2023 has been derived from audited financial statements as of that date. The unaudited interim condensed consolidated statements of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the U.S. Securities and Exchange Commission (the â€œSECâ€). Therefore, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited financial statements and notes thereto previously distributed in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 (the â€œ2023 Form 10-Kâ€), as filed with the SEC. Principles of Consolidation Principles of ConsolidationThe unaudited interim condensed consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Foreign Currency Foreign CurrencyThe Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. The Company currently has a subsidiary located in India. The Canada-based subsidiary conducted its transactions in U.S. dollars and Canadian dollars, but its functional currency was the U.S. dollar. The India-based subsidiary generally conducts its transactions in Indian rupees, which is also its functional currency. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net income. The gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the three and six months ended JuneÂ 30, 2024 and 2023. Unless otherwise noted, all references to â€œ$â€ or â€œdollarâ€ refer to the U.S. dollar. The Companyâ€™s asset and liability accounts are translated using the current exchange rate as of the balance sheet date, except for shareholdersâ€™ equity accounts, which are translated using historical rates. Net revenues and expense accounts are translated using an average exchange rate over the period ended on the balance sheet date. Adjustments resulting from the translation of the financial statements of the Companyâ€™s foreign subsidiaries into U.S. dollars are accumulated as a separate component of shareholdersâ€™ equity within accumulated other comprehensive (loss) income, net of tax. Use of Estimates Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the condensed consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, income tax provision or benefit, deferred taxes and valuation allowance, stock-based compensation, revenue recognition, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness. Restructuring Activities Restructuring ActivitiesThe Company defines restructuring activities to include costs directly associated with exit or disposal activities. Such costs include cash employee contractual severance and other termination benefits, one-time employee termination severance and benefits, contract termination charges, impairment and acceleration of depreciation associated with long-lived assets, and other exit or disposal costs. In general, the Company records involuntary employee-related exit and disposal costs when there is a substantive plan for employee severance and related payments are probable and estimable. For one-time termination benefits, including those with a service requirement, expense is recorded when the employees are entitled to receive such benefits and the amount can be reasonably estimated. Expense related to one-time termination benefits with a service requirement is recorded over time, as the service is completed. Contract termination fees and penalties, and other exit and disposal costs are generally recorded as incurred. Restructuring activities are recognized as an operating expense in the condensed consolidated statements of operations. Investment in Equity Securities Investment in Equity Securities The Company accounts for its investment in equity securities with a readily determinable fair value in accordance with the guidance in ASC 321, Investments â€“ Equity Securities. The Company presents unrealized gains and losses related to the equity securities, within Unrealized gain on investment in equity securities in its unaudited condensed consolidated statements of operations. Fair values are obtained from quoted prices on the NASDAQ Stock Market, Inc. (â€œNASDAQâ€). Assets Held-for-Sale Assets Held-for-SaleThe Company classifies assets held-for-sale if all held-for-sale criteria is met pursuant to ASC 360-10, Property, Plant and Equipment. Criteria include management commitment to sell the disposal group in its present condition and the sale being deemed probable of being completed within one year. Assets classified as held-for-sale are not depreciated and are measured at the lower of their carrying amount or fair value less cost to sell. The Company assesses the fair value of a disposal group, less any costs to sell, each reporting period it remains classified as held-for-sale and reports any subsequent changes as an adjustment to the carrying value of the disposal group, as long as the new carrying value does not exceed the initial carrying value of the disposal group. The Company determined that the Oakville, Ontario, Canada property met the held-for-sale criteria. As of DecemberÂ 31, 2023, approximately $8.0Â million of assets held for sale were recorded on the consolidated balance sheets. The Oakville, Ontario property was sold on March 28, 2024 (see Note 4). Recent Accounting Pronouncements Recent Accounting PronouncementsRecent Accounting Pronouncements Not Yet AdoptedFrom time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies and are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.In November 2023, the FASB issued Accounting Standards Update (â€œASUâ€) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures related to significant segment expenses. The guidance in this ASU is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the effect the adoption of this ASU may have on its disclosures in the notes to the consolidated financial statements.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes guidance to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. These amendments are effective for all public entities for fiscal periods beginning after December 15, 2024, with early adoption permitted. These amendments apply on a prospective basis, but entities have an option to apply it retrospectively for all periods presented. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements.Recent Securities and Exchange Commission Final Rules Issued but Not Yet EffectiveOn March 6, 2024, the SEC adopted new rules that will require registrants to disclose certain climate-related information in their annual reports. The final rule requires disclosure of, among other things: material climate-related risks and their material impacts; activities to mitigate or adapt to such risks; information about a registrantâ€™s board of directorsâ€™ oversight of climate-related risks and managementâ€™s role in managing material climate-related risks; and information on any climate-related targets or goals that are material to the registrantâ€™s business, results of operations, or financial condition. In addition, certain disclosures related to severe weather events and other natural conditions will be required in a registrantâ€™s audited financial statements. The required information about climate-related risks will also include disclosure of a registrantâ€™s greenhouse gas emissions. The Company will be subject to the applicable requirements of the final rule in our annual reports for fiscal years beginning on January 1, 2025. In April 2024, the SEC voluntarily stayed the rules pending judicial review. The Company is currently evaluating the potential impact of these rules on its consolidated financial statements and related disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2 + Details Name: us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/830/tableOfContent + Details Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X -

DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4 + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment in financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details Name: us-gaap_InvestmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables) 6 Months Ended Jun. 30, 2024 Revenue from Contract with Customer [Abstract] Â Schedule of disaggregation of revenue and revenue recognized All revenue recognized in the accompanying unaudited interim condensed consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue:Three Months Ended June 30,Six Months Ended June 30,Products and Services (in thousands)20242023202420232024Sales of generic pharmaceutical products$73,964Â $63,317Â $144,181Â $127,030Â Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services14,883Â 28,926Â 45,159Â 55,669Â Sales of rare disease pharmaceutical products49,193Â 24,304Â 86,130Â 40,634Â Total net revenues$138,040Â $116,547Â $275,470Â $223,333Â Three Months Ended June 30,Six Months Ended June 30,Timing of Revenue Recognition (in thousands)20242023202420232024Performance obligations transferred at a point in time$138,040Â $116,547Â $275,470Â $222,958Â Performance obligations transferred over timeâ€”Â â€”Â â€”Â 375Â Total$138,040Â $116,547Â $275,470Â $223,333Â Schedule of accruals and allowances The following table summarizes activity in the condensed consolidated balance sheets for accruals and allowances for the six months ended JuneÂ 30, 2024 and 2023, respectively:Accruals for Chargebacks, Returns, and Other Allowances(in thousands)ChargebacksGovernmentRebatesReturnsAdministrativeFees and OtherRebatesPromptPaymentDiscountsBalance at December 31, 2022$148,562Â $10,872Â $33,399Â $9,442Â $6,488Â Accruals/Adjustments290,826Â 11,100Â 5,995Â 25,606Â 11,028Â Credits Taken Against Reserve(362,253)(10,001)(9,596)(25,177)(12,653)Balance at June 30, 2023 (1)$77,135Â $11,971Â $29,798Â $9,871Â $4,863Â Balance at December 31, 2023$84,208Â $12,168Â $29,678Â $11,412Â $4,865Â Accruals/Adjustments267,779Â 13,324Â 21,895Â 29,970Â 11,422Â Credits Taken Against Reserve(262,541)(13,168)(17,676)(29,656)(11,243)Balance at June 30, 2024 (1)$89,446Â $12,324Â $33,897Â $11,726Â $5,044Â _____(1)Chargebacks and Prompt Payment Discounts are included as an offset to accounts receivable in the unaudited interim condensed consolidated balance sheets. Administrative Fees and Other Rebates are included as an offset to accounts receivable or as accrued expenses and other in the unaudited interim condensed consolidated balance sheets. Returns are included in returned goods reserve in the unaudited interim condensed consolidated balance sheets. Government Rebates are included in accrued government rebates in the unaudited interim condensed consolidated balance sheets. Schedule of customer concentration The four customers represent the total percentage of net revenues as follows:Three Months Ended June 30,Six Months Ended June 30,20242023202420232024Customer 124Â %32Â %29Â %32Â %Customer 212Â %14Â %12Â %14Â %Customer 313Â %13Â %11Â %13Â %Customer 417Â %10Â %15Â %9Â % X - DefinitionSchedule Of Valuation And Qualifying Accounts Disclosure + ReferencesNo definition available. + Details Name: anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock Namespace Prefix: anip_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21 + Details Name: us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INDEBTEDNESS (Tables) 6 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] Â Schedule of carrying value of the current and non-current components of the term loan The carrying value of the current and non-current components of the Term Facility as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are:Current(in thousands)June 30,2024December 31,2023Current borrowing on debt$3,000Â $3,000Â Deferred financing costs(2,150)(2,150)Current debt, net of deferred financing costs $850Â $850Â Non-Current(in thousands)June 30,2024December 31,2023Non-current borrowing on debt$289,500Â $291,000Â Deferred financing costs(5,106)(6,181)Non-current debt, net of deferred financing costs and current component$284,394Â $284,819Â Schedule of contractual maturity of term loan and DDTL The contractual maturity of the Term Facility is as follows for the period ending:(in thousands)Term Facility2024 (remainder of the year)$1,500Â 20253,000Â 20263,000Â 2027285,000Â Total$292,500Â Schedule of components of total interest expense related to the notes and term loan The following table sets forth the components of total interest expense related to the Term Facility during the three and six months ended JuneÂ 30, 2024 and 2023, as recognized in the accompanying unaudited interim condensed consolidated statements of operations for the three and six months ended JuneÂ 30, 2024 and 2023:Three Months Ended June 30,Six Months Ended June 30,(in thousands)2024203202420232024Contractual coupon$6,848Â $7,620Â $13,761Â $14,970Â Amortization of finance fees591Â 591Â 1,182Â 1,182Â Capitalized interest(151)(277)(263)(298)$7,288Â $7,934Â $14,680Â $15,854Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities. + ReferencesNo definition available. + Details Name: us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 EARNINGS PER SHARE (Tables) 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Schedule of earnings per share, basic and diluted Earnings per share for the three and six months ended JuneÂ 30, 2024 and 2023 are calculated for basic and diluted earnings per share as follows:BasicDilutedBasicDiluted(in thousands, except per share amounts)Three Months Ended June 30,Three Months Ended June 30,Six Months Ended June 30,Six Months Ended June 30,20242023202420232024Net (loss) income available to common shareholders$(2,694)$5,838Â $(2,694)$5,838Â $15,107Â $6,871Â $15,107Â $6,871Â Earnings allocated to participating securitiesâ€”Â (589)â€”Â (589)(1,499)(716)(1,474)(716)Net (loss) income available to common shareholders$(2,694)$5,249Â $(2,694)$5,249Â $13,608Â $6,155Â $13,633Â $6,155Â Basic Weighted-Average Shares Outstanding19,32117,68819,32117,68819,210Â 17,04419,210Â 17,044Dilutive effect of common stock options, ESPP, and performance stock unitsâ€”Â 167351Â 133Diluted Weighted-Average Shares Outstanding19,32117,85519,561Â 17,177(Loss) earnings per share(0.14)0.30Â (0.14)0.29Â $0.71Â $0.36Â $0.70Â $0.36Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INVENTORIES (Tables) 6 Months Ended Jun. 30, 2024 Inventory Disclosure [Abstract] Â Schedule of inventories Inventories consist of the following as of:(in thousands)June 30, 2024December 31, 2023Raw materials$62,584Â $62,237Â Packaging materials10,434Â 9,617Â Work-in-progress4,775Â 3,144Â Finished goods47,655Â 36,198Â Inventories$125,448Â $111,196Â X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 GOODWILL AND INTANGIBLE ASSETS (Tables) 6 Months Ended Jun. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Schedule of components of intangible assets The components of definite-lived intangible assets and indefinite-lived intangible assets, other than goodwill, are as follows:June 30, 2024December 31, 2023Remaining Weighted Average Amortization Period(1)(in thousands)Gross Carrying

AmountAccumulatedAmortizationNet Carrying Amount Gross CarryingAmountAccumulatedAmortizationNet Carrying AmountDefinite-Lived Intangible Assets:Acquired ANDAs intangible assets$209,780Â $(112,742)$97,038Â $209,780Â $(100,660)$109,120Â 4.8 yearsNDAs and product rights244,871Â (196,451)48,420Â 244,871Â (184,861)60,010Â 2.8 yearsMarketing and distribution rights17,157Â (14,752)2,405Â 17,157Â (14,271)2,886Â 2.5 yearsCustomer relationships24,900Â (9,485)15,415Â 24,900Â (7,707)17,193Â 4.3 yearsTotal Definite-Lived Intangible Assets496,708Â (333,430)163,278Â 496,708Â (307,499)189,209Â 4.1 yearsIndefinite-Lived Intangible Assets:In process research and development19,800Â â€”Â 19,800Â 19,800Â â€”Â 19,800Â IndefiniteTotal Intangible Assets, net$516,508Â $(333,430)$183,078Â $516,508Â $(307,499)$209,009Â (1)Weighted average amortization period as of JuneÂ 30, 2024. Schedule of expected future amortization expense for definite-lived intangible assets Expected future amortization expense for definite-lived intangible assets is as follows:(in thousands)2024 (remainder of the year)$24,896Â 202547,592Â 202634,107Â 202725,140Â 202818,359Â 2029 and thereafter13,184Â Total$163,278Â X - DefinitionTabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK-BASED COMPENSATION (Tables) 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Summary of allocated expense The following table summarizes ESPP expense incurred under the 2016 Employee Stock Purchase Plan and included in our accompanying unaudited interim condensed consolidated statements of operations:(in thousands)Three Months Ended June 30,Six Months Ended June 30,2024202320242023Selling, general, and administrative$137Â $70Â $276Â $143Â Cost of sales30Â 18Â 60Â 30Â Research and development12Â 12Â 23Â 19Â Total$179Â $100Â $359Â $192Â The following table summarizes stock-based compensation expense incurred under the Amended 2022 Stock Plan and Inducement Grants included in the accompanying unaudited interim condensed consolidated statements of operations:(in thousands)Three Months Ended June 30,Six Months Ended June 30,2024202320242023Selling, general, and administrative$7,069Â $4,766Â $13,301Â $8,673Â Research and development334Â 213Â 606Â 413Â Cost of sales282Â 170Â 532Â 309Â Total$7,685Â $5,149Â $14,439Â $9,395Â Summary of stock option and restricted stock activity A summary of stock options (including Inducement Grants), RSA, and PSU activity under the Amended 2022 Stock Plan and Inducement Grants during the six months ended JuneÂ 30, 2024 and 2023 is presented below:(in thousands)OptionsPSUsRSAsOutstanding at December 31, 2022907â€”1,141Granted385624Options Exercised/RSAs Vested(26)â€”(338)(1)Forfeited(24)â€”(46)Outstanding at June 30, 20238601,381Outstanding at December 31, 2023689841,351Grantedâ€”74606Options Exercised/RSAs Vested(54)â€”(433)(2)Forfeitedâ€”â€”(12)Outstanding at June 30, 20246351581,512_____(1)Includes 99 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $4.1 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets.(2)Includes 149 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $10.0 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FAIR VALUE DISCLOSURES (Tables) 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of recurring Level 3 fair value measurements of contingent consideration The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs as of June 30, 2024:Payment TypeValuation TechniqueUnobservable InputAssumptionsProfit-based milestone paymentsProbability-weighted discounted cash flowDiscount rate13%Projected fiscal year of payment2025-2035 Schedule of changes in contingent consideration The following table presents the changes in contingent consideration balances classified as Level 3 for the three and six months ended JuneÂ 30, 2024 and 2023:Three Months Ended June 30,Six Months Ended June 30,(in thousands)2024202320242023Beginning balance$11,574Â $36,019Â $23,984Â $35,058Â Payment of Gross-Profit earn-outâ€”Â â€”Â (12,500)â€”Â Change in fair value359Â 1,035Â 449Â 1,996Â Ending balance$11,933Â $37,054Â $11,933Â $37,054Â Schedule of financial assets and liabilities accounted for at fair value on a recurring basis The following table presents our financial assets and liabilities accounted for at fair value on a recurring basis as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, by level within the fair value hierarchy:(in thousands)DescriptionFair Value at June 30, 2024Level 1Level 2Level 3AssetsMoney Market Fund$166,485Â $166,485Â $â€”Â $â€”Â Interest rate swap$7,366Â $â€”Â $7,366Â $â€”Â Â Â CG Oncology - Investment in equity securities$6,943Â $6,943Â $â€”Â $â€”Â LiabilitiesÂ Â Â Â Contingent consideration$11,933Â $â€”Â $â€”Â $11,933Â DescriptionFair Value at December 31, 2023Level 1Level 2Level 3AssetsÂ Â Â Money Market Fund$191,841Â $191,841Â $â€”Â $â€”Â Interest rate swap$6,236Â $â€”Â $6,236Â $â€”Â LiabilitiesÂ Â Â Â Contingent consideration$23,984Â $â€”Â $â€”Â $23,984Â X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RELATED PARTY TRANSACTIONS (Tables) 6 Months Ended Jun. 30, 2024 Related Party Transactions [Abstract] Â Schedule of related party transactions A summary of payments to related parties is presented below:Three Months Ended June 30,Six Months Ended June 30,2024202320242023Scitus Pharma Services$580Â $1,188Â $1,081Â $1,905Â SS Pharma LLC176Â 1,978Â 1,245Â 3,579Â SThree Chemicals Pvt Ltd683Â â€”Â 1,069Â â€”Â $1,439Â $3,166Â $3,395Â $5,484Â X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SEGMENT REPORTING (Tables) 6 Months Ended Jun. 30, 2024 Segment Reporting [Abstract] Â Schedule of financial information by reportable segments Financial information by reportable segment is as follows:Three Months Ended June 30,Six Months Ended June 30,(in thousands)2024202320242023Net RevenuesGenerics, Established Brands, and Other$88,847Â $92,243Â $189,340Â $182,699Â Rare Disease49,193Â 24,304Â 86,130Â 40,634Â Total net revenues$138,040Â $116,547Â $275,470Â $223,333Â Segment earnings before interest, taxes, depreciation and amortization (â€œEBITDAâ€) and reconciliation to income before income taxesGenerics, Established Brands, and Other$31,631Â $39,937Â $76,937Â $78,765Â Rare Disease4,344Â 4,215Â 4,740Â 2,964Â Depreciation and amortization(14,697)(14,690)(29,383)(29,390)Corporate and other unallocated expenses(1)(16,109)(17,060)(26,813)(30,042)Total operating income 5,169Â 12,402Â 25,481Â 22,297Â Unrealized (loss) gain on investment in equity securities (2,712)â€”Â 6,943Â â€”Â Interest expense, net(4,656)(7,100)(9,256)(14,796)Other expense, net(88)(53)(120)(87)(Loss) Income Before Income Tax Expense (Benefit)$(2,287)$5,249Â $23,048Â $7,414Â _____(1)Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our unaudited interim consolidated statement of operations. This amount also includes the gain on the sale of the Oakville, Ontario site of approximately $5.3Â million refer to Note 4 for further information. Schedule of revenue by geographic operations The following table depicts the Companyâ€™s revenue by geographic operations during the following periods:(in thousands)Three Months Ended June 30,Six Months Ended June 30,Location of Operations20242023202420232United States$138,040Â $116,547Â $275,470Â $222,768Â Canadaâ€”Â â€”Â â€”Â 565Â Total Revenue$138,040Â $116,547Â $275,470Â $223,333Â Schedule of property, plant and equipment, net by geographic location The Companyâ€™s property, plant and equipment are as follows:(in thousands)June 30, 2024December 31, 2023United States$49,887Â $43,163Â India1,753Â 1,430Â Total property and equipment, net$51,640Â $44,593Â X - DefinitionTabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details Name: us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details Name: us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Details) $ in Thousands, $ in Millions Jun. 30, 2024 USD ($) facility Mar. 28, 2024 USD ($) Feb. 16, 2024 USD ($) Feb. 16, 2024 CAD ($) Dec. 31, 2023 USD ($) Debt Instrument [Line Items] Â Â Â Â Â Number of pharmaceutical manufacturing facilities | facility 3 Â Â Â Â Assets held for sale | $ $ 0 Â Â Â $ 8,020 Disposal Group, Held-for-Sale, Not Discontinued Operations | Oakville, Ontario Former Manufacturing Facility Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Consideration Â $ 13,500 $ 14,200 $ 19.2 Â X - DefinitionNumber of Pharmaceutical Manufacturing Facilities + ReferencesNo definition available. + Details Name: anip_NumberOfPharmaceuticalManufacturingFacilities Namespace Prefix: anip_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionAmount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2:

http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 15 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482309/360-10-15-4 + Details Name: us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=anip_OakvilleOntarioFormerManufacturingFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Disaggregation of Revenue [Line Items] Â Â Â Â Â Total net revenues $ 138,040 $ 116,547 $ 275,470 $ 223,333 Sales of generic pharmaceutical products Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total net revenues 73,964 63,317 144,181 127,030 Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total net revenues 14,883 28,926 45,159 55,669 Sales of rare disease pharmaceutical products Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total net revenues $ 49,193 $ 24,304 $ 86,130 $ 40,634 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=anip_SalesOfGenericPharmaceuticalProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=anip_SalesOfBrandedRoyaltiesAndOtherPharmaceuticalServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=anip_SalesOfRareDiseasePharmaceuticalProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 REVENUE RECOGNITION AND RELATED ALLOWANCES - Timing (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Disaggregation of Revenue [Line Items] Â Â Â Â Total net revenues $ 138,040 $ 116,547 $ 275,470 $ 223,333 Performance obligations satisfied in prior periods Â Â 1,500 5,000 Sales of contract manufacture products Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Remaining performance obligations $ 3,000 Â $ 3,000 Â Sales of contract manufactured products Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Performance obligations period 6 months Â 6 months Â Performance obligations transferred at a point in time Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total net revenues $ 138,040 116,547 $ 275,470 222,958 Performance obligations transferred over time Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total net revenues $ 0 $ 0 $ 0 $ 375 X - DefinitionAmount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12A + Details Name: us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRemaining duration of performance obligation for which optional exemption was applied not to disclose amount of transaction price allocated to and timing of revenue recognition for remaining performance obligation, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 + Details Name: us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: srt_ProductOrServiceAxis=anip_SalesOfContractManufactureProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=anip_SalesOfContractManufacturedProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 REVENUE RECOGNITION AND RELATED ALLOWANCES - Allowances (Details) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Accruals for Chargebacks, Returns, and Other Allowances Â Â Beginning balance $ 97,262 Â Ending balance 102,784 Â Chargebacks Â Â Accruals for Chargebacks, Returns, and Other Allowances Â Â Beginning balance 84,208 $ 148,562 Accruals/Adjustments 267,779 290,826 Credits Taken Against Reserve (262,541) (362,253) Ending balance 89,446 77,135 Government Rebates Â Â Accruals for Chargebacks, Returns, and Other Allowances Â Â Beginning balance 12,168 10,872 Accruals/Adjustments 13,324 11,100 Credits Taken Against Reserve (13,168) (10,001) Ending balance 12,324 11,971 Returns Â Â Accruals for Chargebacks, Returns, and Other Allowances Â Â Beginning balance 29,678 33,399 Accruals/Adjustments 21,895 5,995 Credits Taken Against Reserve (17,676) (9,596) Ending balance 33,897 29,798 Administrative Fees and Other Rebates Â Â Accruals for Chargebacks, Returns, and Other Allowances Â Â Beginning balance 11,412 9,442 Accruals/Adjustments 29,970 25,606 Credits Taken Against Reserve (29,656) (25,177) Ending balance 11,726 9,871 Prompt Payment Discounts Â Â Accruals for Chargebacks, Returns, and Other Allowances Â Â Beginning balance 4,865 6,488 Accruals/Adjustments 11,422 11,028 Credits Taken Against Reserve (11,243) (12,653) Ending balance $ 5,044 $ 4,863 X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_MovementInValuationAllowancesAndReservesRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4 + Details Name: us-gaap_ValuationAllowancesAndReservesAdjustments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of valuation and qualifying accounts and reserves. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4 + Details Name: us-gaap_ValuationAllowancesAndReservesBalance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of decrease in valuation and qualifying accounts and reserves. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4 + Details Name: us-gaap_ValuationAllowancesAndReservesDeductions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_ChargebacksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_GovernmentRebatesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_AllowancesForSalesReturnsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_AdministrativeFeesAndOtherRebatesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_ReservesForCashDiscountMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 REVENUE RECOGNITION AND RELATED ALLOWANCES - Concentration (Details) - Customer Concentration Risk 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Accounts Receivable | Four Customers Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Concentration risk, percentage Â Â 79.00% Â Revenue from Contract with Customer Benchmark | Customer 1 Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Concentration risk, percentage 24.00% 32.00% 29.00% 32.00% Revenue from Contract with Customer Benchmark | Customer 2 Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Concentration risk, percentage 12.00% 14.00% 12.00% 14.00% Revenue from Contract with Customer Benchmark | Customer 3 Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Concentration risk, percentage 13.00% 13.00% 11.00% 13.00% Revenue from Contract with Customer Benchmark | Customer 4 Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Concentration risk, percentage 17.00% 10.00% 15.00% 9.00% X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2 + Details Name: us-gaap_ConcentrationRiskLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=anip_FourCustomersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=anip_CustomerOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=anip_CustomerTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=anip_CustomerThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=anip_CustomerFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 PENDING MERGER AGREEMENT (Details) - Alimera Sciences, Inc $ / shares in Units, $ in Millions 3 Months Ended 6 Months Ended Jun. 21, 2024 USD ($) contingentValue $ / shares Jun. 30, 2024 USD ($) Jun. 30, 2024 USD ($) Business Acquisition [Line Items] Â Â Â Common Stock, par value (in dollars per share) | $ / shares $ 0.01 Â Â Business acquisition, share price (in dollars per share) | $ / shares $ 5.50 Â Â Business combination, number of contingent value rights to be received | contingentValue 1 Â Â Proxy preparation and filing period following merger 25 days Â Â Transaction costs Â $ 3.5 $ 3.5 JPMorgan, Chase Bank, N.A. and Blackstone Credit & Insurance Â Â Â Business Acquisition [Line Items] Â Â Â Aggregate principal amount $ 280.0 Â Â Milestone Payments Â Â Â Business Acquisition [Line Items] Â Â Â Business combination, milestone payment multiplier | $ / shares $ 0.25 Â Â 2026 Milestone Payment Â Â Â Business Acquisition [Line Items] Â Â Â Revenues $ 140.0 Â Â Business combination, divisible revenue 10.0 Â Â 2027 Milestone Payment Â Â Â Business Acquisition [Line Items] Â Â Â Revenues 160.0 Â Â Business combination, divisible revenue $ 15.0 Â Â Â X - DefinitionBusiness Combination, Divisible Revenue + ReferencesNo definition available. + Details Name: anip_BusinessCombinationDivisibleRevenue Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionBusiness Combination, Milestone Payment Multiplier + ReferencesNo definition available. + Details Name: anip_BusinessCombinationMilestonePaymentMultiplier Namespace Prefix: anip_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionBusiness Combination, Number of Contingent Value Rights to be Received + ReferencesNo definition available. + Details Name: anip_BusinessCombinationNumberOfContingentValueRightsToBeReceived Namespace Prefix: anip_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionBusiness Combination, Proxy Preparation and Filing Period Following Merger + ReferencesNo definition available. + Details Name: anip_BusinessCombinationProxyPreparationAndFilingPeriodFollowingMerger Namespace Prefix: anip_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + ReferencesNo definition available. + Details Name: us-gaap_BusinessAcquisitionSharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThis element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23 + Details Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=anip_AlimeraSciencesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=anip_JPMorganChaseBankN.A.AndBlackstoneCreditInsuranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: anip_PaymentTypeAxis=anip_MilestonePaymentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: anip_PaymentTypeAxis=anip_A2026MilestonePaymentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: anip_PaymentTypeAxis=anip_A2027MilestonePaymentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RESTRUCTURING (Details) $ in Millions 3 Months Ended 6 Months Ended Mar. 28, 2024 USD ($) Jun. 30, 2024 USD ($) facility Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) facility Jun. 30, 2023 USD ($) Feb. 16, 2024 USD ($) Feb. 16, 2024 CAD ($) Dec. 31, 2023 USD ($) Restructuring Â Â Â Â Â Â Â Â Number of pharmaceutical manufacturing facilities | facility Â 3 Â 3 Â Â Â Restructuring activity expense Â $ 0 $ 2,000 $ 0 $ 1,132,000 Â Â Â Assets held for sale Â 0 Â 0 Â Â Â $ 8,020,000 Disposal Group, Held-for-Sale, Not Discontinued Operations | Oakville, Ontario Former Manufacturing Facility Â Â Â Â Â Â Â Â Restructuring Â Â Â Â Â Â Â Â Consideration $ 13,500,000 Â Â Â Â $ 14,200,000 $ 19.2 Â Payment of commissions, taxes and other related costs 700,000 Â Â Â Â Â Â Â Gain on sale of property $ 5,300,000 Â Â Â Â Â Â Â Oakville, Ontario, Canada Â Â Â Â Â Â Â Â Restructuring Â Â Â Â Â Â Â Â Restructuring activity expense Â 0 $ 0 0 1,100,000 Â Â Â Restructuring accrual Â $ 0 Â $ 0 Â Â Â Â Assets held for sale Â Â Â Â Â Â Â Â $ 8,000,000.0 Oakville, Ontario, Canada | Employee Severance Â Â Â Â Â Â Â Â Restructuring Â Â Â Â Â Â Â Â Restructuring activity expense Â Â Â Â 200,000 Â Â Â Oakville, Ontario, Canada | Facility Closing Â Â Â Â Â Â Â Â Restructuring Â Â Â Â Â Â Â Â Restructuring activity expense Â Â Â Â 700,000 Â Â Â Oakville, Ontario, Canada | Other Restructuring Â Â Â Â Â Â Â Â Restructuring Â Â Â Â Â Â Â Â Restructuring activity expense Â Â Â Â $ 200,000 Â Â Â X - DefinitionDisposal Group, Including Discontinued Operations, Transaction Costs + ReferencesNo definition available. + Details Name: anip_DisposalGroupIncludingDiscontinuedOperationsTransactionCosts Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of Pharmaceutical Manufacturing Facilities + ReferencesNo definition available. + Details Name: anip_NumberOfPharmaceuticalManufacturingFacilities Namespace Prefix: anip_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionAmount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 15 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482309/360-10-15-4 + Details Name: us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5 + Details Name: us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDiscloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedCostIncurredCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=anip_OakvilleOntarioFormerManufacturingFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=anip_OakvilleOntarioCanadaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INDEBTEDNESS - Credit facility (Details) - Credit Facility - 2021 - USD ($) $ in Millions Nov. 19, 2021 Jun. 30, 2024 Debt Instrument [Line Items] Â Â Payments of debt issuance costs $ 14.0 Â Term Facility Â Â Debt Instrument [Line Items] Â Â Maximum borrowing capacity 300.0 Â Debt effective interest rate (as a percent) Â 11.44% Principal amount Â $ 292.5 Revolving Facility Â Â Debt Instrument [Line Items] Â Â Maximum borrowing capacity $ 40.0 Â Remaining borrowing capacity Â 40.0 Commitment fee (as a percent) 0.50% Â Deferred debt issuance costs Â 0.6 Debt issuance costs, noncurrent Â 0.3 Debt issuance costs, current Â $ 0.3 X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic

20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DeferredFinanceCostsCurrentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DeferredFinanceCostsNoncurrentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityCommitmentFeePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_CreditFacilityAxis=anip_CreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=anip_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INDEBTEDNESS - Facility components (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Current debt, net of deferred financing costs $ 850 $ 850 Non-current debt, net of deferred financing costs and current component 284,394 284,819 Term Loan and DDTL Â Â Debt Instrument [Line Items] Â Â Current borrowing on debt 3,000 3,000 Deferred financing costs (2,150) (2,150) Current debt, net of deferred financing costs 850 850 Non-current borrowing on debt 289,500 291,000 Deferred financing costs (5,106) (6,181) Non-current debt, net of deferred financing costs and current component $ 284,394 $ 284,819 X - DefinitionCurrent portion before unamortized (discount) premium and debt issuance costs, of long-term debt. + ReferencesNo definition available. + Details Name: anip_LongTermDebtGrossCurrent Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNon current portion before unamortized (discount) premium and debt issuance costs, of long-term debt. + ReferencesNo definition available. + Details Name: anip_LongTermDebtGrossNonCurrent Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DeferredFinanceCostsCurrentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DeferredFinanceCostsNoncurrentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=anip_TermLoanAndDelayedDrawTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INDEBTEDNESS - Maturity of credit facility (Details) - Term Facility $ in Thousands Jun. 30, 2024 USD ($) Debt Instrument [Line Items] Â 2024 (remainder of the year) $ 1,500 2025 3,000 2026 3,000 2027 285,000 Total $ 292,500 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=anip_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INDEBTEDNESS - Interest (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Debt Disclosure [Abstract] Â Â Â Â Contractual coupon $ 6,848 $ 7,620 $ 13,761 $ 14,970 Amortization of finance fees 591 591 1,182 1,182 Capitalized interest (151) (277) (263) (298) Interest Expense, Debt $ 7,288 $ 7,934 $ 14,680 $ 15,854 X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest costs capitalized disclosed as an adjusting item to interest costs incurred. + ReferencesNo definition available. + Details Name: us-gaap_InterestCostsCapitalizedAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F + Details Name: us-gaap_InterestExpenseDebtExcludingAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Nov. 21, 2021 Derivative [Line Items] Â Â Â Â Â Â Fair value interest rate derivative assets $ 7,366 Â $ 7,366 Â $ 6,236 Â Accumulated other comprehensive (loss) income, net of tax 8,328 Â 8,328 Â $ 8,857 Â Derivative unrealized gain recorded in OCI (1,066) $ 2,612 (420) $ 1,469 Â Â Interest expense 4,656 7,100 9,256 14,796 Â Â Interest Rate Swap Â Â Â Â Â Â Derivative [Line Items] Â Â Â Â Â Â Derivative liability, notional amount 139,400 Â 139,400 Â Â $ 168,600 Debt effective interest rate (as a percent) Â Â Â Â Â 2.26% Decrease in notional amount Â Â 4,000 Â Â Â Fair value interest rate derivative assets 7,400 Â 7,400 Â Â Â Accumulated other comprehensive (loss) income, net of tax 8,500 Â 8,500 Â Â Â Derivative unrealized gain recorded in OCI 1,100 Â 500 Â Â Â Interest expense 1,600 600 3,200 1,100 Â Â Reclassifications out of accumulated other comprehensive (loss) income $ 200 $ 700 $ 400 $ 700 Â Â X - DefinitionAmount of decrease in notional amount of derivative liability. + ReferencesNo definition available. + Details Name: anip_DerivativeLiabilityDecreaseInNotionalAmount Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -

Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionNominal or face amount used to calculate payments on the derivative liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeLiabilityNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets. + ReferencesNo definition available. + Details Name: us-gaap_InterestRateDerivativeAssetsAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15 + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Basic Â Â Â Â Net (loss) income available to common shareholders, Basic $ (2,694) $ 5,838 $ 15,107 $ 6,871 Earnings allocated to participating securities, Basic 0 (589) (1,499) (716) Net (loss) income available to common shareholders, Basic (2,694) 5,249 13,608 6,155 Diluted Â Â Â Â Net (loss) income available to common shareholders, Diluted (2,694) 5,838 15,107 6,871 Earnings allocated to participating securities, Diluted 0 (589) (1,474) (716) Net (loss) income available to common shareholders, Diluted $ (2,694) $ 5,249 $ 13,633 $ 6,155 Basic Â Â Â Â Basic Weighted-Average Shares Outstanding (in shares) 19,321 17,688 19,210 17,044 Diluted Â Â Â Â Dilutive effect of common stock options, ESPP, and performance stock units (in shares) 0 167 351 133 Diluted Weighted-Average Shares Outstanding (in shares) 19,321 17,855 19,561 17,177 Basic Â Â Â Â (Loss) earnings per share, Basic (in dollars per share) $ (0.14) $ 0.30 $ 0.71 $ 0.36 Diluted Â Â Â Â (Loss) earnings per share, Diluted (in dollars per share) $ (0.14) $ 0.29 $ 0.70 $ 0.36 Anti-dilutive shares diluted earnings (loss) per share (in shares) 2,800 2,500 2,300 2,500 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareDilutedAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the

calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 66 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_UndistributedEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed. Includes the adjustments resulting from the assumption that dilutive securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions. + ReferencesNo definition available. + Details Name: us-gaap_UndistributedEarningsDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 65 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-65Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 66 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method. + ReferencesReference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 65 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-65Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 66 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INVENTORIES - Schedule of inventory (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â Raw materials $ 62,584 $ 62,237 Packaging materials 10,434 9,617 Work-in-progress 4,775 3,144 Finished goods 47,655 36,198 Inventories $ 125,448 $ 111,196 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterials Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of items used in storage, presentation or transportation of physical goods that are targeted for sale to end users. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INVENTORIES - Concentration (Details) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Supplier Concentration Risk | Cost of Goods and Service Benchmark | One Supplier Â Â Inventory [Line Items] Â Â Concentration risk, percentage 27.00% 24.00% X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_InventoryLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=anip_OneSupplierMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details) $ in Millions 6 Months Ended 12 Months Ended Jun. 30, 2024 segment Dec. 31, 2021 USD ($) Dec. 31, 2018 USD ($) Dec. 31, 2013 USD ($) Goodwill [Line Items] Â Â Â Â Number of operating segments | segment 2 Â Â Â Number of reporting units | segment 2 Â Â Â BioSante Pharmaceuticals Â Â Â Â Goodwill [Line Items] Â Â Â Â Acquisition of goodwill Â Â Â $ 1.8 WellSpring Â Â Â Â Goodwill [Line Items] Â Â Â Â Acquisition of goodwill Â Â $ 1.7 Â Novitium Â Â Â Â Goodwill [Line Items] Â Â Â Â Acquisition of goodwill Â $ 24.6 Â Â X - DefinitionAmount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillAcquiredDuringPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -

SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A + Details Name: us-gaap_GoodwillLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment. + ReferencesNo definition available. + Details Name: us-gaap_NumberOfReportingUnits Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=anip_BioSantePharmaceuticalsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=anip_WellSpringPharmaServicesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 GOODWILL AND INTANGIBLE ASSETS - Components (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Definite-Lived Intangible Assets: Â Â Â Â Â Gross Carrying Amount $ 496,708,000 Â $ 496,708,000 Â $ 496,708,000 Accumulated Amortization (333,430,000) Â (333,430,000) Â (307,499,000) Total $ 163,278,000 Â $ 163,278,000 Â 189,209,000 Remaining Weighted Average Amortization Period 4 years 1 month 6 days Â 4 years 1 month 6 days Â Â Indefinite-Lived Intangible Assets: Â Â Â Â Â Total Intangible Assets, Gross $ 516,508,000 Â $ 516,508,000 Â 516,508,000 Total Intangible Assets, Net 183,078,000 Â 183,078,000 Â 209,009,000 Amortization of intangible assets 13,000,000.0 $ 12,800,000 25,900,000 $ 25,700,000 Â Impairment 0 0 0 0 Â Impairment of indefinite lived intangible assets $ 0 $ 0 $ 0 $ 0 Â Minimum Â Â Â Â Â Indefinite-Lived Intangible Assets: Â Â Â Â Â Remaining estimated useful lives 7 years Â 7 years Â Â Maximum Â Â Â Â Â Indefinite-Lived Intangible Assets: Â Â Â Â Â Remaining estimated useful lives 10 years Â 10 years Â Â In process research and development Â Â Â Â Â Indefinite-Lived Intangible Assets: Â Â Â Â Â Gross Carrying Amount $ 19,800,000 Â $ 19,800,000 Â 19,800,000 Acquired ANDAs intangible assets Â Â Â Â Â Definite-Lived Intangible Assets: Â Â Â Â Â Gross Carrying Amount 209,780,000 Â 209,780,000 Â 209,780,000 Accumulated Amortization (112,742,000) Â (112,742,000) Â (100,660,000) Total $ 97,038,000 Â $ 97,038,000 Â 109,120,000 Remaining Weighted Average Amortization Period 4 years 9 months 18 days Â 4 years 9 months 18 days Â Â NDAs and product rights Â Â Â Â Â Definite-Lived Intangible Assets: Â Â Â Â Â Gross Carrying Amount $ 244,871,000 Â $ 244,871,000 Â 244,871,000 Accumulated Amortization (196,451,000) Â (196,451,000) Â (184,861,000) Total $ 48,420,000 Â $ 48,420,000 Â 60,010,000 Remaining Weighted Average Amortization Period 2 years 9 months 18 days Â 2 years 9 months 18 days Â Â Marketing and distribution rights Â Â Â Â Â Definite-Lived Intangible Assets: Â Â Â Â Â Gross Carrying Amount $ 17,157,000 Â $ 17,157,000 Â 17,157,000 Accumulated Amortization (14,752,000) Â (14,752,000) Â (14,271,000) Total $ 2,405,000 Â $ 2,405,000 Â 2,886,000 Remaining Weighted Average Amortization Period 2 years 6 months Â 2 years 6 months Â Â Customer relationships Â Â Â Â Â Definite-Lived Intangible Assets: Â Â Â Â Â Gross Carrying Amount $ 24,900,000 Â $ 24,900,000 Â 24,900,000 Accumulated Amortization (9,485,000) Â (9,485,000) Â (7,707,000) Total $ 15,415,000 Â $ 15,415,000 Â $ 17,193,000 Remaining Weighted Average Amortization Period 4 years 3 months 18 days Â 4 years 3 months 18 days Â Â X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRemaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before accumulated amortization of intangible assets, excluding goodwill. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na

Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_ProductRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_MarketingAndDistributionRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 GOODWILL AND INTANGIBLE ASSETS - Amortization (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Goodwill and Intangible Assets Disclosure [Abstract] Â Â 2024 (remainder of the year) $ 24,896 Â 2025 47,592 Â 2026 34,107 Â 2027 25,140 Â 2028 18,359 Â 2029 and thereafter 13,184 Â Total $ 163,278 $ 189,209 X - DefinitionAmount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year and after the fourth fiscal year following current fiscal year. + ReferencesNo definition available. + Details Name: anip_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 MEZZANINE AND STOCKHOLDERS' EQUITY (Details) $ / shares in Units, $ in Millions Nov. 19, 2021 USD ($) tradingDay $ / shares shares Mar. 08, 2021 USD ($) $ / shares shares Jun. 30, 2024 vote $ / shares shares Mar. 31, 2024 shares Dec. 31, 2023 $ / shares shares Jun. 30, 2023 shares Mar. 31, 2023 shares Dec. 31, 2022 shares Temporary Equity [Line Items] Â Â Â Â Â Â Â Â Preferred Stock, shares authorized Â Â 1,666,667 Â 1,666,667 Â Â Â Preferred Stock, par value (in dollars per share) | $ / shares Â Â $ 0.0001 Â $ 0.0001 Â Â Â Common Stock Â Â Â Â Â Â Â Â Temporary Equity [Line Items] Â Â Â Â Â Â Â Â Common Stock, shares authorized Â Â 33,333,334 Â 33,333,334 Â Â Â Common Stock, par value (in dollars per share) | $ / shares Â Â $ 0.0001 Â $ 0.0001 Â Â Â Common Stock, shares issued Â Â 21,476,115 Â 20,730,896 Â Â Â Common Stock, shares outstanding Â Â 21,063,528 Â 20,466,953 Â Â Â Convertible Preferred Stock Â Â Â Â Â Â Â Â Temporary Equity [Line Items] Â Â Â Â Â Â Â Â Convertible preferred stock outstanding (shares) Â Â 25,000 25,000 25,000 25,000 25,000 25,000 PIPE Shares | Convertible Preferred Stock Â Â Â Â Â Â Â Â Temporary Equity [Line Items] Â Â Â Â Â Â Â Â Temporary stock issued (in shares) 25,000 25,000 Â Â Â Â Â Â Â Â Temporary stock issued (in dollars per share) | $ / shares $ 1,000 $ 1,000 Â Â Â Â Â Â Â Temporary stock issued, value | $ $ 25.0 $ 25.0 Â Â Â Â Â Â Â Shares accrue dividends rate 6.50% Â Â Â Â Â Â Â Shares conversion price (in dollars per share) | $ / shares $ 41.47 Â Â Â Â Â Â Â Minimum conversion period 2 years Â Â Â Â Â Â Â Threshold number of trading days | tradingDay 20 Â Â Â Â Â Â Â Number of consecutive trading days | tradingDay 30 Â Â Â Â Â Â Â Maximum percentage of conversion price 170.00% Â Â Â Â Â Â Â Convertible, shares issuable Â Â 602,901 Â Â Â Â Â Class C Special Stock Â Â Â Â Â Â Â Â Temporary Equity [Line Items] Â Â Â Â Â Â Â Common Stock, shares authorized Â Â 800,000 Â Â Â Â Â Common Stock, par value (in dollars per share) | $ / shares Â Â $ 0.0001 Â Â Â Â Â Common Stock, shares issued Â Â 11,000 Â 11,000 Â Â Â Common Stock, shares outstanding Â Â 11,000 Â 11,000 Â Â Â Vote per share | vote Â Â 1 Â Â Â Â Â Exchange per share Â Â 1 Â Â Â Â Â Common Stock, conversion price (in dollars per share) | $ / shares Â Â $ 90.00 Â Â Â Â Â Common Stock Â Â Â Â Â Â Â Temporary Equity [Line Items] Â Â Â Â Â Â Â Common Stock, shares authorized Â Â 33,300,000 Â Â Â Â Â Common Stock, par value (in dollars per share) | $ / shares Â Â $ 0.0001 Â Â Â Â Â Common Stock, shares outstanding Â Â 21,476,000 21,373,000 20,731,000 20,536,000 18,226,000 17,644,000 X - DefinitionRepresents the conversion price for converting shares of common stock into another class of common stock. + ReferencesNo definition available. + Details Name: anip_CommonStockConversionPrice Namespace Prefix: anip_ Data Type: dtr-types1:perShareItemType Balance Type: na Period Type: instant X - DefinitionCommon Stock, Exchange Per Share + ReferencesNo definition available. + Details Name: anip_CommonStockExchangePerShare Namespace Prefix: anip_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionCommon Stock, Vote Per Share + ReferencesNo definition available. + Details Name: anip_CommonStockVotePerShare Namespace Prefix: anip_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of consecutive trading days. + ReferencesNo definition available. + Details Name: anip_NumberOfConsecutiveTradingDays Namespace Prefix: anip_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionPercentage of conversion price. + ReferencesNo definition available. + Details Name: anip_PercentageOfConversionPrice Namespace Prefix: anip_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: instant X - DefinitionPreferred Stock, Conversion Period, Minimum + ReferencesNo definition available. + Details Name: anip_PreferredStockConversionPeriodMinimum Namespace Prefix: anip_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock classified as temporary equity issued during the period. + ReferencesNo definition available. + Details Name: anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues Namespace Prefix: anip_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThreshold number of trading days. + ReferencesNo definition available. + Details Name: anip_ThresholdNumberOfTradingDays Namespace Prefix: anip_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share conversion price of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleConversionPrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of common shares issuable upon conversion of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleSharesIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe percentage rate used to calculate dividend payments on preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_PreferredStockDividendRatePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount to be paid per share that is classified

as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1 + Details Name: us-gaap_TemporaryEquityRedemptionPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TemporaryEquitySharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionValue of new stock classified as temporary equity issued during the period. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=anip_PrivateInvestmentInPublicEquityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=anip_ClassCSpecialStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK-BASED COMPENSATION - Expense (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jul. 12, 2024 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 2016 Employee Stock Purchase Plan Â Â Â Â Â Â Share-based Compensation Â Â Â Â Â Â Stock-based compensation shares available Â 100,000 Â 100,000 Â Discount from market price (as a percent) Â Â Â 15.00% Â Allocated share-based compensation expense Â $ 179 $ 100 $ 359 $ 192 2016 Employee Stock Purchase Plan | Selling, general, and administrative Â Â Â Â Â Â Share-based Compensation Â Â Â Â Â Â Allocated share-based compensation expense Â 137 70 276 143 2016 Employee Stock Purchase Plan | Cost of sales Â Â Â Â Â Â Share-based Compensation Â Â Â Â Â Â Allocated share-based compensation expense Â 30 18 60 30 2016 Employee Stock Purchase Plan | Research and development Â Â Â Â Â Â Share-based Compensation Â Â Â Â Â Â Allocated share-based compensation expense Â $ 12 12 $ 23 19 2022 Plan Â Â Â Â Â Â Share-based Compensation Â Â Â Â Â Â Stock-based compensation shares available Â 2,000,000.0 Â 2,000,000.0 Â Allocated share-based compensation expense Â $ 7,685 5,149 $ 14,439 9,395 2022 Plan | Selling, general, and administrative Â Â Â Â Â Â Share-based Compensation Â Â Â Â Â Â Allocated share-based compensation expense Â 7,069 4,766 532 309 2022 Plan | Cost of sales Â Â Â Â Â Â Share-based Compensation Â Â Â Â Â Â Allocated share-based compensation expense Â 282 170 13,301 8,673 2022 Plan | Research and development Â Â Â Â Â Â Share-based Compensation Â Â Â Â Â Â Allocated share-based compensation expense Â $ 334 $ 213 $ 606 $ 413 2022 Plan | Subsequent Event Â Â Â Â Â Â Share-based Compensation Â Â Â Â Â Â Stock-based compensation additional shares authorized 1,610,000 Â Â Â Â X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDiscount rate from fair value on purchase date that participants pay for shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PlanNameAxis=anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=anip_StockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R57.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK-BASED COMPENSATION - Information (Details) 6 Months Ended Jun. 30, 2024 installment Options Â Share-based Compensation Â Number of annual installments 4 Options | Employees and Consultants Â Share-based Compensation Â Vesting period 4 years Award expiration period 10 years Options | Non Employee Director Â Share-based Compensation Â Award expiration period 10 years Options | Non Employee Director | Minimum Â Share-based Compensation Â Vesting period 1 year Options | Non Employee Director | Maximum Â Share-based Compensation Â Vesting period 4 years RSAs | Employees and Consultants Â Share-based Compensation Â Vesting period 4 years RSAs | Non Employee Director Â Share-based Compensation Â Vesting period 1 year X - DefinitionNumber of Annual Installments + ReferencesNo definition available. + Details Name: anip_NumberOfAnnualInstallments Namespace Prefix: anip_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=anip_EmployeesAndConsultantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=anip_NonEmployeeDirectorStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK-BASED COMPENSATION - Narrative (Details) - $ / shares 6 Months Ended Feb. 14, 2024 Feb. 28, 2023 Jun. 30, 2024 Jun. 30, 2023 Performance-Based Restricted Stock Units Â Â Â Â Share-based Compensation Â Â Â Â Performance period Â Â 3 years Â Percentage of awards Â Â 50.00% Â Vesting period Â Â 3 years Â Maximum potential to vest percentage Â 200.00% 200.00% Â Maximum potential to vest (in shares) Â 83,942 Â Â Grate date fair value (in dollars per share) $ 56.10 $ 41.84 Â Â Estimate number of shares percentage Â Â 100.00% Â Market Performance-Based Restricted Stock Units Â Â Â Â Share-based Compensation Â Â Â Â Percentage of awards Â Â 50.00% Â Vesting period Â Â 3 years Â Maximum potential to vest percentage Â 200.00% Â Â Maximum potential to vest (in shares) Â 83,942 Â Â Grate date fair value (in dollars per share) $ 85.65 $ 68.65 Â Â Estimate number of shares percentage Â Â 100.00% Â PSUs Â Â Â Â Â Share-based Compensation Â Â Â Â Performance period 3 years Â Â Â Granted (in shares) 73,588 Â 74,000 85,000 PSUs | Officer Â Â Â Â Â Share-based Compensation Â Â Â Â Granted (in shares) 66,433 Â Â Â X - DefinitionShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Percentage + ReferencesNo definition available. + Details Name: anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage Namespace Prefix: anip_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Shares + ReferencesNo definition available. + Details Name: anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares Namespace Prefix: anip_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Percentage of Awards + ReferencesNo definition available. + Details Name: anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards Namespace Prefix: anip_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: instant X - DefinitionShare-Based Compensation Arrangement by Share-Based Payment Award, Estimate Number of Shares, Percentage + ReferencesNo definition available. + Details Name: anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage Namespace Prefix: anip_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionEstimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=anip_PerformanceBasedRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=anip_MarketPerformanceBasedRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_OfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK-BASED COMPENSATION - Option activity (Details) - Options - shares shares in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Option Shares Â Â Outstanding at the beginning of the period (in shares) 689 907 Granted (in shares) 0 3 Exercised (in shares) (54) (26) Forfeited (in shares) 0 (24) Outstanding at the end of the period (in shares) 635 860 X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK-BASED COMPENSATION - Non-option activity (Details) - USD ($) $ in Thousands 6 Months Ended Feb. 14, 2024 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Non-option Shares Â Â Â Â Treasury stock value Â $ 20,042 Â $ 10,081 PSUs Â Â Â Â Non-option Shares Â Â Â Â Outstanding at the beginning of the period (in shares) Â 84,000 0 Â Granted (in shares) 73,588 74,000 85,000 Â Exercised (in shares) Â 0 0 Â Forfeited (in shares) Â 0 0 Â Outstanding at the end of the period (in shares) Â 158,000 85,000 Â RSAs Â Â Â Â Non-option Shares Â Â Â Â Outstanding at the beginning of the period (in shares) Â 1,351,000 1,141,000 Â Granted (in shares) Â 606,000 624,000 Â Exercised (in shares) Â (433,000) (338,000) Â Forfeited (in shares) Â (12,000) (46,000) Â Outstanding at the end of the period (in shares) Â 1,512,000 1,381,000 Â Shares purchased to cover employee income taxes Â 149,000 99,000 Â Treasury stock value Â $ 10,000 $ 4,100 Â X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount allocated to previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INCOME TAXES (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Tax Disclosure [Abstract] Â Â Â Â Valuation allowance $ 400 Â $ 400 Â Expense (benefit) for income taxes $ 0 $ 996 $ (7,128) $ 270 Effective income tax rate (as a percent) 0.00% (19.00%) 30.90% (3.70%) Pre-tax consolidated income (loss) $ (2,287) $ 5,249 $ 23,048 $ 7,414 X - DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details Name: us-gaap_DeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 72 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1 COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended Dec. 27, 2023 USD ($) Dec. 03, 2020 plaintiff Jan. 31, 2024 claim Dec. 31, 2023 claim Sep. 30, 2022 claim Jun. 30, 2024 USD ($) product Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) product Jun. 30, 2023 USD ($) Dec. 31, 2012 manufacturer Mar. 04, 2024 Apr. 30, 2023 COMMITMENTS AND CONTINGENCIES Â Â Â Â Â Â Â Â Â Â Â Â Lease term Â Â Â Â Â Â Â Â Â Â Â Â 5 years Number of products marketed without approved NDAs or ANDAs | product Â Â Â Â Â 4 Â 4 Â Â Â Â Total net revenues Â Â Â Â Â $ 138,040 $ 116,547 $ 275,470 $ 223,333 Â Â Â Payment for acquired intangible assets Â Â Â Â Â Â Â 0 4,329 Â Â Â Number of plaintiffs | plaintiff Â 6 Â Â Â Â Â Â Â Â Â Â Â Â Number of potential manufacturers | manufacturer Â Â Â Â Â Â Â Â Â Â 7 Â Â Royalty percentage Â Â Â Â Â Â Â Â Â Â 5.00% Â Net sales percentage Â Â Â Â Â Â Â Â Â Â 5.00% Â Number of complaints filed | claim Â Â 1 200 2 Â Â Â Â Â Â Â Â Alvogen Inc | Product Intellectual Property Â Â Â Â Â Â Â Â Â Â Â Â COMMITMENTS AND CONTINGENCIES Â Â Â Â Â Â Â Â Â Â Â Â Payment for acquired intangible assets $ 2,000 Â Â Â Â Â Â Â Â Â Â Â Â Novitium Â Â Â Â Â Â Â Â Â Â Â Â COMMITMENTS AND CONTINGENCIES Â Â Â Â Â Â Â Â Â Â Â Â Number of complaints filed | claim Â Â Â 28 Â Â Â Â Â Â Â Â Unapproved Products Â Â Â Â Â Â Â Â Â Â Â Â COMMITMENTS AND CONTINGENCIES Â Â Â Â Â Â Â Â Â Â Â Â Total net revenues Â Â Â Â Â 6,800 3,500 10,900 7,200 Â Â Â Unapproved Products | Contract Customer Â Â Â Â Â Â Â Â Â Â Â Â COMMITMENTS AND CONTINGENCIES Â Â Â Â Â Â Â Â Â Â Â Â Total net revenues Â Â Â Â Â $ 100 $ 500 $ 100 $ 1,100 Â Â Â X - DefinitionLoss Contingency, Damages Sought, Net Sales Percentage + ReferencesNo definition available. + Details Name: anip_LossContingencyDamagesSoughtNetSalesPercentage Namespace Prefix: anip_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLoss Contingency, Damages Sought, Royalty Percentage + ReferencesNo definition available. + Details Name: anip_LossContingencyDamagesSoughtRoyaltyPercentage Namespace Prefix: anip_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLoss Contingency, Number Of Manufacturers + ReferencesNo definition available. + Details Name: anip_LossContingencyNumberOfManufacturers Namespace Prefix: anip_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of Products Marketed Without Approved NDAs or ANDAs + ReferencesNo definition available. + Details Name: anip_NumberOfProductsMarketedWithoutApprovedNDAsOrANDAs Namespace Prefix: anip_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionRemaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRemainingLeaseTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType

Balance Type: na Period Type: instant X - DefinitionThe total number of new claims filed pertaining to a loss contingency during the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingencyNewClaimsFiledNumber Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of plaintiffs that have filed claims pertaining to a loss contingency. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingencyNumberOfPlaintiffs Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_OtherCommitmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_AssetAcquisitionAxis=anip_AlvogenIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_ProductIntellectualPropertyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=anip_NovitiumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=anip_UnapprovedProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=anip_ContractCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FAIR VALUE DISCLOSURES - Narrative (Details) - USD ($) 6 Months Ended Feb. 22, 2024 Dec. 12, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 28, 2024 Jan. 24, 2024 Dec. 31, 2023 Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Â Â Money market funds Â Â $ 166,485,000 Â Â Â $ 191,841,000 Interest rate swap Â Â $ 7,366,000 Â Â Â 6,236,000 Achievement of milestones payment period Â Â 24 months Â Â Â Â Payments on contingent consideration Â Â $ 12,500,000 $ 0 Â Â Â Contingent consideration Â Â 11,900,000 Â Â Â 24,000,000.0 CG Oncology Â Â Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Â Â Shares held (in shares) Â Â Â Â Â 219,925 Â Value of shares held Â Â 6,900,000 Â Â Â Â Â Closing price Â Â Â Â Â $ 31.57 Â Â Novitium Â Â Â Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Â Â Additional contingent consideration Â Â 46,500,000 Â Â Â Â Payments on contingent consideration $ 12,500,000 $ 12,500,000 Â Â Â Â Â Contingent consideration Â Â $ 11,933,000 Â Â Â $ 23,984,000 X - DefinitionAchievement of Milestones Payment Period + ReferencesNo definition available. + Details Name: anip_AchievementOfMilestonesPaymentPeriod Namespace Prefix: anip_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFor contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets. + ReferencesNo definition available. + Details Name: us-gaap_InterestRateDerivativeAssetsAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCost of the investment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details Name: us-gaap_InvestmentOwnedAtCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in security owned. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-2Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-

12(Column C)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_InvestmentOwnedAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of shares of investment owned. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_InvestmentOwnedBalanceShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (f) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=anip_CGOncologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R64.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FAIR VALUE DISCLOSURES - Level 3 (Details) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Changes in contingent consideration Â Â Â Â Level 3 liability, beginning balance $ 11,574 $ 36,019 $ 23,984 $ 35,058 Payment of Gross-Profit earn-out 0 0 (12,500) 0 Change in fair value $ 359 $ 1,035 $ 449 $ 1,996 Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Contingent consideration fair value adjustment Contingent consideration fair value adjustment Contingent consideration fair value adjustment Contingent consideration fair value adjustment Level 3 liability, ending balance $ 11,933 $ 37,054 $ 11,933 $ 37,054 Discount rate | Probability-weighted discounted cash flow | Profit-based milestone payments Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Unobservable inputs 0.13 Â 0.13 Â X - DefinitionValue of input used to measure contingent consideration liability from business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: anip_PaymentTypeAxis=anip_ProfitBasedMilestonePaymentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R65.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FAIR VALUE DISCLOSURES - Hierarchy (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Money market funds $ 166,485 $ 191,841 Interest rate swap 7,366 6,236 Royalties fair value 6,943 Â Contingent consideration 11,900 24,000 Level 1 Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Money market funds 166,485 191,841 Interest rate swap 0 0 Royalties fair value 6,943 Â Level 2 Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Money market funds 0 0 Interest rate swap 7,366 6,236 Royalties fair value 0 Â Level 3 Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Money market funds 0 0 Interest rate swap 0 0 Royalties fair value 0 Â Novitium Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Contingent consideration 11,933 23,984 Novitium | Level 1 Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Contingent consideration 0 0 Novitium | Level 2 Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Contingent consideration 0 0 Novitium | Level 3 Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Contingent consideration $ 11,933 $ 23,984 X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2:

http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets. + ReferencesNo definition available. + Details Name: us-gaap_InterestRateDerivativeAssetsAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R66.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RELATED PARTY TRANSACTIONS (Details) 3 Months Ended 6 Months Ended Feb. 29, 2024 USD ($) Feb. 22, 2024 USD ($) Dec. 12, 2023 USD ($) Nov. 19, 2021 USD ($) $ / shares shares Mar. 08, 2021 USD ($) $ / shares shares Jun. 30, 2024 USD ($) founder Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) founder Jun. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Number of executive founders | founder Â Â Â Â Â 2Â 2Â Â Outstanding balances Â Â Â Â Â $ 48,681,000 Â $ 48,681,000 Â $ 36,683,000 Payments on contingent consideration Â Â Â Â Â Â Â 12,500,000 $ 0 Â Novitium Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Payments on contingent consideration Â $ 12,500,000 $ 12,500,000 Â Â Â Â Â Â Â Convertible Preferred Stock | PIPE Shares Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Temporary stock issued (in shares) | shares Â Â Â 25,000 25,000 Â Â Â Â Â Temporary stock issued (in dollars per share) | $ / shares Â Â Â $ 1,000 $ 1,000 Â Â Â Â Â Temporary stock issued, value Â Â Â $ 25,000,000.0 $ 25,000,000.0 Â Â Â Â Â Related Party Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Payments to related party Â Â Â Â Â 1,439,000 $ 3,166,000 3,395,000 5,484,000 Â Related Party | Mr. Shanmugam and Esjay | Novitium Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Payments on contingent consideration $ 6,700,000 Â 6,700,000 Â Â Â Â Â Â Related Party | Chali Properties LLC | Novitium Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Payments on contingent consideration $ 1,900,000 Â $ 1,900,000 Â Â Â Â Â Â Related Party | Scitus Pharma Services Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Payments to related party Â Â Â Â Â 580,000 1,188,000 1,081,000 1,905,000 Â Outstanding balances Â Â Â Â Â 700,000 Â 700,000 Â Â Related Party | SS Pharma LLC Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Payments to related party Â Â Â Â Â 176,000 1,978,000 1,245,000 3,579,000 Â Outstanding balances Â Â Â Â Â 0Â 0Â Â Related Party | SThree Chemicals Pvt Ltd Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Payments to related party Â Â Â Â Â 683,000 $ 0 1,069,000 $ 0 Â Outstanding balances Â Â Â Â Â 2,200,000 Â 2,200,000 Â Â Related Party | Esjay Pharma LLC Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Outstanding balances Â Â Â Â Â $ 46,000 Â $ 46,000 Â Â X - DefinitionNumber of Executive Founders + ReferencesNo definition available. + Details Name: anip_NumberOfExecutiveFounders Namespace Prefix: anip_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock classified as temporary equity issued during the period. + ReferencesNo definition available. + Details Name: anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues Namespace Prefix: anip_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (f) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPurchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party. + ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1 + Details Name: us-gaap_TemporaryEquityRedemptionPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionValue of new stock classified as temporary equity issued during the period. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=anip_PrivateInvestmentInPublicEquityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=anip_Mr.ShanmugamAndEsjayMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=anip_ChaliPropertiesLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=anip_ScitusPharmaServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=anip_SsPharmaLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=anip_SThreeChemicalsPvtLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=anip_EsjayPharmaLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R67.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SEGMENT REPORTING - Revenue (Details) $ in Thousands 3 Months Ended 6 Months Ended Mar. 28, 2024 USD ($) Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) segment Jun. 30, 2023 USD ($) Segment reporting Â Â Â Â Â Number of operating segments | segment Â Â Â 2Â Total net revenues Â $ 138,040 $ 116,547 $ 275,470 $ 223,333 Depreciation and amortization Â 14,697 14,690 29,383 29,390 Corporate and other unallocated expenses Â 52,821 38,760 100,842 75,228 Operating Income Â 5,169 12,402 25,481 22,297 Unrealized (loss) gain on investment in equity securities Â (2,712) 0 6,943 0 Interest expense, net Â (4,656) (7,100) (9,256) (14,796) Other expense, net Â (88) (53) (120) (87) (Loss) Income Before Income Tax Expense (Benefit) Â (2,287) 5,249 23,048 7,414 Disposal Group, Held-for-Sale, Not Discontinued Operations | Oakville, Ontario Former Manufacturing Facility Â Â Â Â Â Segment reporting Â Â Â Â Â Gain on sale of property $ 5,300 Â Â Â Â Operating Segments | Generics, Established Brands, and Other Â Â Â Â Â Segment reporting Â Â Â Â Â Total net revenues Â 88,847 92,243 189,340 182,699 EBITDA Â 31,631 39,937 76,937 78,765 Operating Segments | Rare Disease Â Â Â Â Â Segment reporting Â Â Â Â Â Total net revenues Â 49,193 24,304 86,130 40,634 EBITDA Â 4,344 4,215 4,740 2,964 Corporate, Non-Segment Â Â Â Â Â Segment reporting Â Â Â Â Â Depreciation and amortization Â (14,697) (14,690) (29,383) (29,390) Corporate and other unallocated expenses Â (16,109) (17,060) (26,813) (30,042) Operating Income Â 5,169 12,402 25,481 22,297 Unrealized (loss) gain on investment in equity securities Â (2,712) 0 6,943 0 Interest expense, net Â (4,656) (7,100) (9,256) (14,796) Other expense, net Â $ (88) $ (53) $ (120) $ (87) X - DefinitionRepresents earnings/(loss) before interest, taxes, depreciation and amortization (EBITDA). + ReferencesNo definition available. + Details Name: anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization Namespace Prefix: anip_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5 + Details Name: us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=anip_OakvilleOntarioFormerManufacturingFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=anip_GenericsEstablishedBrandsAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=anip_RareDiseaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R68.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SEGMENT REPORTING - Geographic (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Segment reporting Â Â Â Â Â Total net revenues $ 138,040 $ 116,547 $ 275,470 $ 223,333 Â Assets held for sale 0 Â 0 Â $ 8,020 Total property and equipment, net 51,640 Â 51,640 Â 44,593 United States Â Â Â Â Â Segment reporting Â Â Â Â Â Total net revenues 138,040 116,547 275,470 222,768 Â Total property and equipment, net 49,887 Â 49,887 Â 43,163 Canada Â Â Â Â Â Segment reporting Â Â Â Â Â Total net revenues 0 $ 0 0 $ 565 Â Assets held for sale Â Â Â Â Â 8,000 India Â Â Â Â Â Segment reporting Â Â Â Â Â Total property and equipment, net $ 1,753 Â $ 1,753 Â $ 1,430 X - DefinitionAmount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 15 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482309/360-10-15-4 + Details Name: us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_CA Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_IN Namespace Prefix: Data Type: na Balance Type: Period Type: XML 79 R9999.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Label Element Value Restricted Cash, Current us-gaap_RestrictedCashCurrent $ 0 Restricted Cash, Current us-gaap_RestrictedCashCurrent $ 5,006,000 X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant EXCEL 80 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" Y-P99WH4,[AR2KMR1UXW2]
[9T"LLT5D">),/GV MDP C-Q6'<>9-8C# GWF0!(^ Z9ZR;WQ+B O<93PB]Y6B-V'P8#[6Q)C_H[N M2'*_65,68R$7V6; =XS@("N*HP%RG/$@QF'2FTVS=4LVF])41&%"E@SP-(XQ M>
[TD$=U?]&#OL.(AW&R%6C&837=X0U9$?-DMF5P:E"E!&).$AS0!C*PO>G/X MP7//54&VQ5\AV?.CST"A/%'Z32TL@HN>H_:(1,07*@++?_$(U&DDN1^_%N$ MJLK?5(7'GP_I-
QF\A'G"G'@T^AH&8GO1F_1 0-8XC<0#W7\D!=!(Y?DTXME? ML,^W'0YI[P$^YH'%1+/<@#I/\/WXI#L11 1I5%*"B +TI@%6_X!8%;@::[UF& M=#%GDT9W0.FMI9IZD-
V;+)J21,FJAE7@LEO0UDG9AY])@ST =]B1OAT(&2F M^F;@%_67>3VJ]!^#.YJ(+0?724""[^L'595_MSMN>7S<+,^MR+NB?BI[K0"+)!\SLN^9CE*>,C2GJ+'X@>^P
M3RYZ/4JPU'10/&M52[QQB3=NAKY>"SUK?D/"\YSQOV3(;E922["E2WHSUKC2-N;$AK64O 20DX ML>[4=2)"\0INPHB ^S1^(LP$9L]P'-AWX00B$YRUM"7<^Q+N?1.X![()N9 - M*,
]CHU]U)XSOU^ Y&=!X%,YV>'#^!6;@<^>)9V MM4V!)NI'NC?Z44W<)4X# M(HS7+,]>VI94^Q"T&\U;TG(+QE]#A/?W,CV=5M[(V@7D@2U)4&[V[P%75(N M< 3^"7?
5YRA[XF@\1N9AVX4O02U,T.XY66>=RUEO-9@] ,&)$:L+/8+:CZ!= M:FZI+]MKN:6)S1]J0L;NL.^.',?(UX4=0:U'T.XVCZ&09D37 *)?GGX%*^&M3+:D$=*>Y-$XINH42_UO1M N3
EJ58)VQY&"&X3)!JQ>XR<:&?EJ)6EIY.K" MB) V(F1WED.+@>L7?XN3#:ETP)J@^_GJ:FZ<9]H+VQ)J 4*-!,A+&5,SE7QZ MDC6EO&JDQOLK-8E_&^_*>/:JMIQ:?% C\5DD@.TKJ#&NG.
M*L91!"Y3+K_FYGYKSZF<8=OKVO)IRT&-+. M6 W:A>0@+3G([BB'AMP2V9 V/'M,-5X7LH.T[""[IQS.M//LPZ3U+)* O(_MB1G1'N4X#G3D)+/B?G,7TH.T* :52DN)3H>O)]?AZCO0B-H
M%]*#M/0@N[.4M_>.26_D2O/9QQY6^?"@"P%RM0"Y-3=MWC 6=VPK*6OB/AOO M\MF+VC)J!7+MPC*7@$$&N8[PQDAE#Z@\X]CKVH)IYW'MAE(S:;BTE__O9T!= MB([]-
CK1,^]3OO@JPOW<;70[N('Q.9#7% MG:)Y*>XCB<_]"=H3,9#]_TY<'1 M:P9*$[.W.SCPU8.2_(V&V]BH#?/7S^YP\KN.8C0F&D[\E;[(\ M>@U$0=!=]E+$$Q6"QMG'+<$!86H#^?
V:4G%84#]0OEB\])??T-9 MMF21HF/ !=I*UG#TS&AFGAE*%\^J_M8LI-3H95E6S>5LH?7J_7S>9 NY%,T[MM9(57'E0]5)H.*T?Y\VJEB)O%RW+.
<4XFB]%4+V=DMOWA2_&XT.:'^=7%2CS*.ZG_7MW6<#;?:O%Y2R9H5P^B'6IOZCG/V1G M4&CT9:ILVG_1+9RA;-UHMN\6 8%E4F__%2^>(P0+")Q;0;@%]ZP+6+6"M
MH1MDK5DW0HNKBUH]H]I(@S9ST/JF70W6%95YC'>ZAJL%K--7UZK*X:('(,%1 MH\HB%QI./HE25)E$=T9Q@\[1WWS7]$9*BKT=:'6C:CRYF*N 8/1-,^Z M^WW:W(].W.^?Z^H=8CA
%%/N6'[M7WXC,UA.VN5L?_D<+-^93W?FTU8?FS]_ M7=>RTNACTX"=+G,VZ[E[O4FR]\U*9)/R!EG4R/I)SJY^_HE$^(/+N!,IVS.5 M[4QE/NU7UZ)9('AH*#,\ONZ>!
(EV.ZT>J,J:E692O!T13DF!%_,GX;V.,0H M(93LQ/:0\AU2[D7Z,9-^:5E3IA:R1**%LF<"&'S6"6)0;]VX#LA6% M&)/+>UEWE[I@"P!-LY)MU2E?73[;&!4.G$&B"*=DY#.7&,5QZO99N/-9Z/79
MY^H);%=U(9W/,[1O2D/.DQ$VAQC\22,WMFB'+?)BNZWE2A0Y5(Y,+272XL4- M,K+N3I,H'D&TA ;7;Q#%_NCK4UJM)!EWD9. UGA0A=[;KR!9DLDF$Z@2W;H MDC?
Y3KZL3)O:]G/6U2XQ6;L2^W%RC,J%^5%B4ZS 2=FN&]PS#DT3@,7'(D M3#RY%7*6=N2CF(*Q]>*PMQ7Y1M M)K26 1.OQ::MW3*4TSQF5Y@TQ-'8/%LLQ3&98&72TS+Q_+G2HOJL0 Z'AKG
M!.H@N83A>,PW#CF*4XPGR)#T;$C\=/B[4OES499.<#;+T832<5D*+8/K2== MXF?#&UE#3V/:B&$QKP:Y/5W0B1(E MXW1UB+$H2B9J.NU)EWH9SD"LU^#(6KV*6V<4 X1 M:!'Y!,*>^*B?
^+Y(O:ZKU\J-Q-T6W"<&&U^8RQ)K9AUT& :Q5.N[&F0^FEP M6[8R56DH3]UA4^2R;N/7'=GFM81;@>HB/QI-!6I/?O3 G-@%JCV)..:'%!>E MQ'*N+15&> IJ3X/4/S3N3S0'R)
ZYC^6IE:OYI+C(8_C";0]@=`TS6/-(:Q> M*CQZ-^Y$VO:WXWKR8W[R&]K])O+>[-[M\F:Y4A4<.;?O;#*$-I&EXSKIEO(M1/ ->M9D?M8AD-FIM]?_E):(L)^=6+W:G8G*')E^@D4[5O?
\S$+O<7M3_GCAZC@ M1_2/=@_,:::7TH^M:J?2MF]PS^OL *^K"AHYW>X2W-;;2G:G5?8M0'?2;%"C MCP$ZP^\PQ@2:J+K=_9 !(D$41? W1LU"U(9@UWJAZN*'S#\@&@8@O[U2-(VA
MXI:!U[K1<&"JY+%[^LZ'X=B%YO8\=%!LWWU]E\%B;[RTCEJH$HID\ -/"27Q M!U_D>%N6HR/G1-KV3>^[%N;O6DRA@+FE"Q5'@# 6L/8O=T8("7@S*MFQ]>O41>L-KR/MWF[L*:_(QJ?ZSH_[.
[^OM13-NGY%S<91G- @3'8^ M@?8VV^1Y=UWHMKD-/!Z@D+DI9V]2\?;DXW8/>4XQYN,,=,D1C).IE]Q]L\D/ M[-KD>6'Z8,A \XKOO*A0)E8%]'1.N(Y7&XQR:UYWR1%.\$0?
Q_MNDQ_9/<6>C=L:?'B-,.Q/"9V227AQ$3,^Z:1^S=Q-HW]<:T M_=I>!C& MUMM)EQRC,9^81GC?^'%_XV=-(P$:-[]!F\Y'VA59WY@XWRFXY%SO%..:#;Z7, MAVI_BOJQJ!I4R@=8B-
%X)EZ\^W7YD2K5?OYU+W26BW;PX44 -X(P/4'!1-, M=V*^R-I]?@U?U!+ P04 " Y-P99'WT53<$!>$P & 'AL+W=O M(&VI3GLG MB426W;O/;N*67)V8LPWLJ^_<9(F&$),V?(!XN3-
^+U)QH]XLA/R6:T8T^A[MS@LU]59:KV]]7R4KEE-U(]:L@"N/0N94PU ^^6HM&4W+H)S[) @B/Z=9X,Z<)W#]^R?Y[*1[$%/#%YH+_G:5Z:?5&'DK9(JUP M_47L/K%:T-
#D2P17Y3?:5=AX[*%DH[3(ZV!@D&=%)4N_UX78"\"#$P&D#B#G M!H1U0%@*K9B5LNZIIK.)%#LD#1JRF8.R-F4TJ,D* 1U;MK] YE!?]Z M$AM%BU1-? V<3&8_J>>_J^8G)^;_Y9 ."[#0SO<
MATHTY2!-.4B9;W BW\?T'Z@Y/*8@&GH$)2LJG]@#39X5 H%(0 TDHAR>?E.? M3L'5#%$Y@^FB[0P')!Z!NNV^L&/8."81:5 6_[#A' ;R7T 3,"GA#BZU2)[?
MHS65:$OYAJ$KN%&IX)Q*A=8@0H$T=MTEH)HBWF,6W 1!@ \$.&&6@D&C8/ Z M!25/J/Y&KX3,_F-I%^4JYW" YI'YQ >-!V$UWU- =]=*%E7/+I,X>.$,'1>[BVIO,V/:M
M6M.$33WP9<7DEGFS7W_!4?!;U_+X1LDLW>-&]_A2W9OC[V:((('<83Q M\)!S!S*(PV TCDYP;ET=]]MZ)V=7.W=8-@ZB<$A&A\0[D,$@BL;#$_:.6W_ ' M#H/G5"DT1\LU2S+*>
[K[3;W]K;+9JEMWQRY[_^GN/M/0W3C[9:YU=-)R]%=W M-SEVYGB$R>B0LQMGCZ.AMTP6SV>Z]+[L<^_4]38Z] MMY.R"U91]OAM&PO=V]R:W-H965T&ULK5IM^.$X?XKA'LHLD 2B]1[
MFAA((K?=HM<+-KN]#T4_*!9MJRN+/I%V3=9*[6]F4[E8LTWJ;P66U["-TM1;5(%E]5J*K<5 M3[-ZT*:8,L<)ILT+R>SV_K>4S6[%3M5Y"5_JHC<;39I]>L#+\3KW81.WF]\ MR5=KI6],9[?;=,6?N?
JV?:K@:GJPDN4;7LI_[(BT);@G7\TAJ='.;4 X_OUO_MR+RDDC^*XN<\4^N[230A&5^TTPN)]$:]_Y2TA7]M;B$+6_Y/7%NM,R&(G ME=BT@V$%F[QL_J9OK2..!H =? !K!S!S@#!^=P6\'U-2G M#??:
<4FJTMEM)5Y)I=%@37^HO5^/!G_EI4Z49U7!MSF,4[-'4680=IX1^"1% MD6>I@HMG!7\@'Y0D8DE^VO(JU7&5Y(I\>TI(Q0^?B%RG%9] M^^>!C1K\VZZ\)JYS29C#/&0]CQ\'
(F)T K_9Y__S[#UGN(=D<6M[[H"]S^5" M;'B7'.1?]R]25;#9_XV%NC'FX<9T!;R1VW3![R90XB2O]GPR^^,?:.#\"?/S M.8TEYS0V/Y.Q7D2\0T2\,>NS?T K^<+WO-QQ=+C_).Q5,>(Q_9BO2
V8O6(HTSB M-HK%;N0:O%'4D:T>;^IT>M$YL?M+781UU^ (,RS5AJ299I79)\6.PYY\!]0 MKD,,H)V@%UX_-CR!@*CC&ILY05">9YB:8Z;BHQW7=\21<*<:GJKRJ=@NUJW3M
MJP\\NYGH0D".3*=TU%,A^UU"?;B5PZJMAF7X5*"V++C4M26>-QU&/W#@O^QR]2N1 M? '%>+ &V\KOBH64F1EKPZS:9$."V#/[[ZBAOD,ZF4G'=>;G4G%PM"*\R='A M%+55WY47^*;,Q&
AJ"B3, *+F6EMCL&H%PZVVDYLTG&UV>S/DYQMI7<5F6<) M#.2(]E\$1)G5:['YAFI1)RSIN+*\^'N=Z&TQ>N!+4?'WJZ_IVWLW(A@>4VYBO-EKH"ZOR= M^LL(=6:K/5-
^()"KV#R"0)0@*JH7)&K/%PH&-SCIQR<;%I7ZNT\L$E*HM]K H M([" 6:(#05$_MI(>@85!-!3E3F"R<8&9@'C.>)E)7=R?>40+UG-SK1)[#L>] M%U"=3Q5?\]JJGTV+Q??4'XAF],SS\..'4
F&BJA9XT^A^M[H%*@;5Z!6],G] M/LV+5/M!"7#+9J/=I!_ KT4!)S"TX;63!+WT@$9E^L.&^9$;F?ZP4=2GUL,& M!!8<"^&^0SI!RKQ1@?:0RGQ1G[.3O-CI%Q1]SQ!>ZC=<8,Z8E3M_EZ]=E9K
MR5FMS<]EK1^F3D>S43W8AFD@-.0"E%HFBB*M)($#IO,"": .AS331<>8ZU]3* M7!OF7)N]' 691[,Y;FI N+!.P+)Q 7LB6W^/2X*/N<2&.=?,[.@HRMK*&&C0
M)9V$9>,2MLF1G^L7N#R[NH<"GZYXXP])?MHIJ6"?ZZ[.G=D[SDA'W")@,W:M M9XD8##J65=\P:XQ:[0^SYGA#_:]3N&Q5M+7H)FG9[&/; 2+2E5B()DK;?3]^/E*+:$F-DJU]LDCK?
(<_AQ]MLS_@W M41(BT5U34S&W2BDW4]L6>4D:+"[8AE#XLF*\P1*J?&V+#2>XT$%-;7N.$]D- MKJB5SG3;-4]G;"OKBI)KCL2V:3#_?D5JMI];KG7?*E:EU(UV.EL@]?DAL@O MFVL.-
;MG*:J&4%$QBCA9S:U+=[I,%%X# _JS(7AR4D5)RR]@W57E3S"U'#8C4 M))>* @"P@>VT/8!6CI=JM=&Y=AB=,99WO$%1K85$&[KZ/!KXJJ M/+F1'+Y6$"?3!:,%S#HI$)0$JZL"2ZC<2/B#=)
"L15\:B)2Y4=.X*>OV-' MO$!O:,X:@EZA+S<9>O[T!7]**HH^EVPK,"W$S)8P/-6)G7=#N6J'XCTP%!^] M9U26 BUA2(4A/CL=YV(M\&6WAOOWILK[R3AVRV]0+[S$GF.%QC&LWA\N&^2
M\VN]+ _]W[T=F^'VB^)K/?X"OSXAQ0G29\/?EK9 <5OX_IKEOV0,SN]H-IV*# M(R*O" \!F5CD!LFGG.,6HY1DR@.>M"1TK!7&IY, MQH^R)!SEQJM2K9576OE+1(G.5(GOIB8;PG.FXSG)LG.2+
<]$=C1)43])TP[PQ:9Z8QAI%]5C ME!<-KQZT7[G3A6MHS^#9T;X2 M?M*W;Y;WF*\K*E!-5M"5/M.Z"M2+;1%]U;)N':K(LE/)T(5P#XOF), MWE=4!_UC+/T!4$L#!!0 (#DW!ED3/8\<&PO=V]R M:W-
H965T&ULM9U<^,\9H7 _"LN;VDVJHICW2W;&58F%2[8V M&U1F'87ZJ?A:KBZLW^Y_=M%=O-H _=T?WS?+S<>W%9[MYQ_\O+B[[W8 N+QZ\U#?->^:[M>'F[; [O*9,E+LFO5VL5D';7/[]N*
[Z%M= M5;L3]D?\=]%\W+[X.MA=ROO-YK?=-S_,WUZ$NQ8URV;6[1!U_]^'YKI9+G>D MOAV_'Z 7SS%W)[[\^C-=[B^^OYCW];:YWBS_MYAW]V\ORHM@WMS6C\ONY\U' MW1PN*-
OQ9IOE=O]O\/%P;'@'1S!ZWW69U.+EOP6JQ?OJ__G2X$2].B)(C)\2' M$^*Q)R2'$Y+!"7%QY(3T<$(ZC) =.2$[G) -3LBB(R?DAQ/R89..W:7B<$(Q M/*$\M)N/0;L[NJ?MOM@+8G]V_P@7ZYUVWW5M
M_]M%?UYW=;U9SWLE-O.@_VJ[62[F=== \Z[K_^LEVFV#S6UP?5^O[YIML%@' M/S9__EFO>T@@?G]<<\$]7IW]&;/VV_UF.6 :[3\^_V(2 /IN&GSYQ5?!%[L3 M?[G?/&[[@[=O+KN^W;OHE[-#&
[]_F-\I(V_;+IZ29QVS9]VO5FM^K^.?>.(MLZ?\V=_-YXO=7U>]#&[JQ7S27\)U_;"@6R).7$#?JVP?VS^.MD6>;,ML]KAZ M7.Z?S$_=?
=/V#VO5=U7WNS[D0Q(\L)YM5LW7P7_ZOJY_7+_4GX@8:GR,:7.[MF"TZ J)/W?+UAZ;M%N^737#3=T)-VS9SZJHO>YD^:S5^UFJ\IZ='Z-_7RWH] M:X*ZZULX^RJ%9(HJ^#.(QC2E$L:?="^';
[4,^:MQ?];=PV[8?FXNKO?XOR\)^4 MSI"P*1(FD#*)A"DD3#_!\CUL]S;^FILF?T5">EQ5)]I86$39$P@81) M)$PA83KSZ:GR9VGEL#$52_*54^[\H43/5_*D$?>(-$RJ%QA?\]/3=PR996*7V
M49((%T=Y81^E"%95Q&5F'Z9!-\)Z8,7S ROX!];<+=;]![^[X/#HO@X.'W1\ MQS%L'-_'63CBC(H\3JF>]52/U]OZSWAZ:=E6OFW6W-YNZ M9O6P:>M>?LW!@1JAO,KIV).DS)+*?B37;--\-86$"21,
(FS$"=,@F*6*#1> M:+CG)T>T\-ZMNO:^H'VO'GZZJN==4G9FZ2+&2+[-RAM"J4]*$"U":0I*TRB: MK<@7[GS$]H9[Z4UVDS/SO>?;K+?U?LY'?-I]W9 RC)SW3Y65@Z'N-1_86UYC M8@IH3 FE*2A-
HVBV;(Q1'O%.N3WA$-P\MK/[7D/;X';3!C\WVZY=S+K/SGSP MW_X'VY>#.5)54$<=2IM":>) L[1,#-^@0164IE$T6W[&6(]X9_T,^9&2<[W9 M21J6^; G@WKH4)HXT'+^$B0TJ(+2-(IF:\DXZ1%OI?
^PW3[N':K=//1A1G?? M2P6/#Y]G=X.?'IX2(?J/!^+=S4W_=FS:V6+;G.S4H.;[@?92KVGF.B#0H)* MDU":@M(TBF8+T7CP$6_"_R4ADN)S#=TH39W>#>J[CXHIH#$EE*:@-(VBV9HR
MYGO$N^\O->6\%[_[6+?ST^,RJ"M_H+W4U QX3+BXTJH#2))2FH#2-HMEZ,W,' M%3]Y\%)O-TV[3WW1:\Y.X)/0&G0^ TB24IJ TC:+7$ M>C-3!Q$ _=T -T?:ZZS5V_A^N9@%/]W>-NUB?
4=JK7+44899YHS(W,F$X=3U M$5(V'&=!77TH34%I&D6S\T:-L1^S-JV/,$YU2'PD[\S2T$WJB$IBP 4-*Z T M*:4I*$VC:+;PC'\?_[]=/%A,6_6_3MO)[E>8/T;[[M@=)KT07*NN3XIHV30 M+?
$M\4/_>-9_\.6_-]LC795K9$=9-ISS MYB-[ZP:;WH[-;Q]S/Q0TID;1;-T8)S[FG?A=1;M=9],=1[E/?1)G6%T/!ST$(9ZE:5E.1A'$ZA) M%97#&3L"%R5%G \[/>P216FD?/D7L./CHT?'?-
^M%C/1V2!GGZHT"3QF$A2 M*K,D)P:TT!1P*$U':0I*TRB:K3KC6,>8SU4W;%D#;>SB"<;:3GAK^]RB9![KK3&HZPVE"2A-0FD*2M.) MZZ%$?>QO9/1*[Z=YRX:0@2&E5!:1!% MLX5G_/CDQ"
(MYQ0NGY:@:Z@G29660YN*;YRWN*#F/)0FH30%I6D4S9:@,>>3 M)QOVE>J7$Z@E#Z5-H30!I4DH34%I&D6S%6F,^X0W[L^I7TY<9SZ+TV':"A_8 M6UYC8@1H3 FE*2A-HVBV;(S?
GO!^^RO4+_,1O3LWJ"T/I8F$6G^&&,I!_78H M3:-HMOR,+9_PMCRH?CEQ'=U)E@P78N#;XBTEJ/N>N*GN[A5(:$P%I6D4S5X& MU)COJ7_B.:QZF8_MVZ6E;BKZKM<8VB+0H
)*DU":@M(TBF8+T;CU*>_6PZN7 M4]?RC>)R.$KC6^7;N8V*: Q)92FH#2-HMF:,NY\RKOS@.IE/H)W%T98Z"%1 M3 .-*J T":4I*$VC:+;>S)Q"RL\I'-.81SDI'\%;,\0"-1%13@-J*$ T":4I
M*$VC:+;>7BSBSD\E_,5RTM3UU#ERTL-AWSC=)PHI&_'&]A0*U^*$VC:+8P MC-6?^B\%!4.2G?,F]E M08UL*$U*:0I*TRB:K3]C9&?C=AX=[%Q#*XO8H-(JWSGH"KI("Y0FH#0)I2DH M36?
N)"NZS64-H72!)0FH30%I>G,G0Q@:JVR%WN, MCMMD=/"V2TE=$3XSU2EA]PS%;AJ*W344NVTH=M_0S*M3,F9T-F[K4&:H3HL' MFF8.I4VA- &E22A-
06DZ(]:X83HE8U1G)W81]DI%8[.TR0NG,QQXKBA4Y01 MZ>'1!6H6#FDU!H"91&);1\+.8RRO+;+C[+'"4I RC9%C:R=^SOQ@3.O'<$ M/;T#+?W$H#G9F6N0QF&11(19!#6-H30)I2DH3:-
HMO",N9R-W1K4:RM:6GK$ M:AMY4@VKL]_Y)GF_7J#9V>0U$)G^T*@*2M,HFKWYN7&]Q,+.H_S5W69)<>7N MDAMI5F35\$W$-\Y77%":@-(DE*:@-(VBV1(T%GC^9':^4M%F#C6^H;0IE":@ M-
FE*2A-HVBV(HT]GO/V^#E%FSF1>IT653GL\:#V][B@ AI40FD*2M,HFBT< MXVOG\'T_3^5'\A&]NS>H2PZEB9Q8F28E]IV%1E50FD;1;/T9FSSG;7)0W6;N M.JR3JLJC85\&M<.A-'&@Y?
PE2&A0!:5I%,W6DK'#\U?<[O-DKP;-^LY=-[X@ M-M&#!A50FH32%)2F431;8Y5?O$0JIW,Q=$;)JF%9"M\[]YM3$P!C2FA M- 6E:13-UI2QU?/Q^X Z\[Q5E9M\!.\NC-@'-
"32_*!1!90FH30%I6D4S=:; MF3+(^2D#P+ZS? 1OO;ES!051)@4-*] T":4I*$VC:+;^);[# M,BA-0&D22E.C[JY&Q;1U9*8"'"CX;_JRRO(+8OS*+AU--?&1OW4"-?2A-CKH?
M"AI3HVBV;HQA7_"&/5^65U#;7E;Q,%F/C^&M$&AF.I0FH30U[O9J5%!;(L:: M+T:GG)],T"O<+.8TRXK<40R1[3P8T!2NJ9TE<5H-4I\$@9KTXZ-TP),$KTSB M*L'*XDP;?'^\4"=;'):TC<23=H M5
6E:13-UI/QIXM1.X*>64Q*RMW7T!EF$?."PCJ44-I DJ34)]"TC2*9NO/ M>-G%Z!3QE[LIT,*'FM90VA1*$U":A-(4E*8+(IW_>'E+83SK8MR>G\RF,;3& MH%8$UE#:%"@(24)J$T!:7I@B@M-%
[>4ABCNCAKN11:5T2V-U%SQT?T%@S4D(;2 M))2FH#1=$*O1'.^42N,TE^,V_0=J_-8WTX)2IM":0)*DU":@M)T22R.<[Q3 M*HT+78[;V',RXY'>>LJ.FDHE:Z[F\5)/K2 !
(&:1&7A&HKTK#X1L!Q%&3 M/$Z&FS-JU.VPGYSQ@L^DB_5RAZW*7KD4:1TQA?LZ>0N,**$U":0I* MTRB:+3SC+I?>NWV.V721EAXTXQM*FT)IHG1MZJ0BS"=H5 6E:13-%IZQT$O>
M0O_+FR[2$G0]\+3(WXH+ZZ5":A-(4E*91-%N"QD\OG_S55ZK?*Z&I MX%#:%$H34)]$TA24IE$T6Y'&D2]Y1_Z<^KW23= NRCP==GA0PWU43 &-*:$T M!:5I%,V6C3'22]Y(?X7J/3ZB=^<&]=NA-
%$2BX&[NZ=):% %I6D4S9:?\=M+ M^)Z?I.1XV-[M=VK$HN1$L@TTJ(#2))2FH#2-HEE"K(Q?7[WB_I^4^"K7](W"<+C' M]W]YM M5$P!C2FA- 6E:13-UI3QYZOQ6WDZ[\5QQ7M\!-
\NK'+=3QSNS!H4 &E22A- M06D:1;/E9B85*GY2X9C$/(JI^ C>+\EH7,#4)]$TM2HNZM1,6T=F9F!B!9.*N6JG*- M_TD4%L-5K/C0WL*!^OY0FAQW0Q0TJ$;1;.480[_B$^3Y:JK*S1B?Q+&3],['
M\)8(U(B'TB24IL;=7HT*:DO$..S5N*7/QZ1>540R.U5-11PW3'XA#B&KDS MR&HJXCBBFHJB4=54_#T[]YD8^[KB[6M0-14?Q7NL2MC"=#45-*Z TB24[J T MC:+9JC.N=<6[UK!JJLKUKC+.=<4[
MUZ]0356YN+_INLUJ_^5]4\^;=G= __O; MS:;[,UES_^X:7 ;Q[CZ/U!+ P04 " Y-P99_IE_(Q0) P*0 & M 'AL+W=O&<[,\Y#2 MU;.0WZL-8PJ];(NRNAYME-
I=3B95MF%;6GT0.U;"?]9";JF"G_)Q4NTDHWDS M:%M,FONWN)/R:=+/D?,O*BHL22;^'WW$E[=DH0@\'$;EE1Z)D QQ_[24?=/P7 _O?#[%\:Y\&9
M%:W8K2C^PW.UN1[-1RAG:UH7ZEX_Y/M'4KU?)DHJN8O>M[;1B.4U942V_U@ M0+#E9?M)7 .:!Z V >=P#\'X '@X@G@')?D#2..HB:]SZ1!5=7DGQC*2VAMGT
MER8VS6CPAI=Z&1^4A/]R&*>6MZ+,85%8CN!;)0J>4P4 'A1\P&]I"HDUNJ75 M!GV!%:_0&'U[^(1^_.$G] /B)?I](^]*EGEU-5& 1L\YR?9W_MC>&7ON/$6__MBE)M*O09$.3'XR?@1>
<*/KCR$0..0M6KTBT:TL[5;VTN5S>LZE/=-D1R&<=B&4<6R6GK; MVL*.XG1!A@[85A[P<60(+@W(5&.F_(U95HPR%$5?G3>.IO3?LH^CEDZ[$T. MHVGL0=NCX_@TM+Q4#
I7.>'%=MY:%>4TFB4>@-@ Q&& (!-T#/720]^LH ?* M-HO7EL[;%FB'8=UHD>6\ (60S1VT;Q8C'UH#><' <9;_GS/H$K:..-V:QJ M7N3@CA-
G8J=LFI#9$*EMYLM9PYPQ"6N'#8405[JX>N1250R81W>+@M,5+YI: MNVB("ERA&91AQ?5:.,DG#K+U>]GG7+,=!\A0>!RDM^5-EHE:\S!T40:DO"I8 M$PBGXZF]CB2*\7
=*68S,O>EG*'*,R57Z%7EDI(3U^,;>8;QP2G%CP'CT8) M[] S%!F'.?).LAWE^:$9MNDEU(;)?;XY,3MX,P=79+ MOZ.O>MV= &TBA&#-K"9CFXWGD:]Z#5_&8<($A+(&MI3BE18^/HQMJB/1!XB
M=-!F.O.(#VPX$8:* T=?R%:0-.%QS,.(TL9G28X7GB M"[4A1_SVOO+VL#%KOGSN;ANS4[?<^QOV@2;IU%+7#C,"VP5/O\"&S'!X M0SH*?C:J.L38)]U/WFNV8Z#8&@2AVDQG7K69@?
YW7&=2[/H:#+ 4Y#)*(M0[_?\U(O1:':BN;4RL]8V&;/H9QWF(Q)@GWI:A@6AQG6=@RR$K9+&K[>.>UT M7_.*%^S8?2ZBQ +O,"-S;VH:LL5ALH5JRAB#AK;6B0G!/DDY8P?])FE,AJ!M
M,Q]@P[TXS+VG-X>/$H,9R?1N[K$%U[2 M,COA/#$H!=Y]H'BFV8Z#8!1!$E8$=_1U?RI=HI60,!X"4*&ZA&THRB3+N4+T M4;+V[-H9#I< 2*-A0;UI=NR T0E)6"
<\,+T10#=ZS\PRB1C4=#4*U/ZF]],$: MRKG.TC+7&I?G3B\<\F >#PGK+:MC'WH"VV$-<=P46LABUS0X]L)DQ@_[B,\ M=W=H5\ML0RM/\OTM&JU]^[L/=!16MA>:_2DF>]2Z!==#]SQ]NQ
MR5TLID,][S*#W8DOXH;DDS#)]\LW\QPD.6&[-LG84;4AFC_&;/@["?-WF%$, MB_2YY>3>[*!M',>SX5F>PVZ63B//[C\Q])Z$Z;WQK3EKTD=-VKD+R\56:-V; M%-
,&3F<^D\G$4\2IOX6.O!)30N_5R%98[9BC[PL]0II M3085+]Q)UB9S# N$K8*Q[=($)YXG5<20/@EOU&]]#Z N$-/R-X2=V)MR3"+8 MO@^?L=EV)3Y3T#+(FL1!Q7* ?[*V?
\P!8+._8(E(4#&\5]^<:[;CD!EY M0-XX7?>MM]-SF][=*QR\Y__KDY$+)"P7_HJZ)(ZC!:?K#N40RNW>L^WP"?U# MO=L5CBU*BL$T#-KZ+AQ=0U*'9IJ^Z*-[TR>G/5, ERS'8?$2!02EBA-
M[C;'BCH(A^=7YOG$MCVVS>B.J_9YHC,DMO2 %4N'#V5=9BE)/0J%&(5"P@IE MZ$3X?)0X#N5G.!IN"5UFQ'.41XPP(6%ATKQR-1;K<5T=#D606"G*RT:1@!;/ M6FK7GK2// 5(W,<'A?9
M4'4ZK%+K^';2> _=LR^1C\TH>5+G&T+Z[U5WM7ON[:5YV&US_&% >NB_OF6G: M=PE_I1)(H8(<7L.4T8<99)]L7\]K?RBQ:]YP6PFEQ+;YNF$4-A3: /Z_%D(= M?N@;="|)+O\'4$L#!!0 (
#DW!EFZ6K%G21, #HW 8 >$PO=V]R M:W-H965T&ULO5MK<]M&EOTK79K4E%-%/>TX'K^J*%G.*#N1 MM98]4UM;^Z$)-$G$(!KI!B1K?_V>< L!@*(4IRJS7VP*;-R^CW.?W7Q]:]T7
MOS:F4U\W=>/?[*V[KGUY>.B+M=EH?V!;T^';I74;W>%/MSKTK3.ZE)') MT='SPXVNFKVWK^79E7OQ=737FRBG?;S;.W9V:VMZ^V3O>2P\^5JMUQP>' M;U^W>F6N3?>YO7+XZS!3*:N-
:7QE&^7,\LW>_/CEZ3.NEP7_K,RM'WU6E&1A M[1?^<5&^V3LB0Z8V14<*&O_=F#-3UR0$-GZ+-/?REGQQ_#E1?R^R0!Y:%]N:, MUO^JRF[]9N_%GBK-
4O=U]]'>_MU$>7X@O<+67OY5MV'M<^Q8]+ZSF_@R_MY4 M3?A??XUZ&+WPXNB!%T[B"R?"=]A(N'RG._WVM;.WRG$UJ/&#B"IO@[FJH5&N M.X=O*[S7O3W]?'UQ>7Y]/5-7'\^OSR_S3]=?
+B655B4"A_/5L@)#B\KNMQ/^P;#L MIFA>(J?5764:2%(ŨJC%\YPZ!X@8!L,77,[AOTR^!I[]GY0; ?&+$=@MG*9O MR-.5:8RK"D7H%*YJ)8ZUV\JKFJ+N2[Z+&
U>O4&4\H@CW5JM$914WVP0W3>F M%&[)T8'Z!&%+5'&I46LP:Z@7YJ:XI+>"G@$$;#O\2:?]*VH^:-V1KT+.ZE% M[X$4[_&-LSWVXXI:]TVQ5G:)75SG;+N&,GXR]4S!ETRSPIJ&!&GP**8?* GO
MIEGKI@!347=(!9T]=*L755UU=Q2\L3=:E +BQG=Z45<(A650HA<=UGC9Z57: MZ_/!]8&$\7)JAH$P@#95#[%P_,K)O(:LV6 +3+X%(G,*/SMNH(6NENKJ+': M%@)J<'NJ^])TG9FI7R"&\;;3
0FV,33(:.FY]IWZ5P6!+(!"1_Z&6@T4 !I M)I<(M2&N[;.EGU!=JP#A^)-JK2P5?BF W,&%P[=($)YXG5<20/@EOU&]]#Z N$-/R-X2=V)MR3"+8 MO@^?L=EV)3Y3T#+(FL1!Q7* ?[*V?
\P!8+._8(E(4#&\5]^<:[;CD!EY M0-XX7?>MM]-SF][=*QR\Y__KDY$+)"P7_HJZ)(ZC!:?K#N40RNW>L^WP"?U# MO=L5CBU*BL$T#-KZ+AQ=0U*'9IJ^Z*-[TR>G/5, ERS'8?$2!02EBA-
M[C;'BCH(A^=7YOG$MCVVS>B.J_9YHC,DMO2 %4N'#V5=9BE)/0J%&(5"P@IE MZ$3X?)0X#N5G.!IN"5UFQ'.41XPP(6%ATKQR-1;K<5T=#D606"G*RT:1@!;/ M6FK7GK2// 5(W,<'A?9
M4'4ZK%+K^';2> _=LR^1C\TH>5+G&T+Z[U5WM7ON[:5YV&US_&% >NB_OF6G: M=PE_I1)(H8(<7L.4T8<99)]L7\]K?RBQ:]YP6PFEQ+;YNF$4-A3: /Z_%D(= M?N@;="|)+O\'4$L#!!0 (
#DW!EFZ6K%G21, #HW 8 >$PO=V]R M:W-H965T&ULO5MK<]M&EOTK79K4E%-%/>TX'K^J*%G.*#N1 MM98]4UM;^Z$)-$G$(!KI!B1K?_V>< L!@*(4IRJS7VP*;-R^CW.?W7Q]:]T7
MOS:F4U\W=>/?[*V[KGUY>.B+M=EH?V!;T^';I74;W>%/MSKTK3.ZE)') MT='SPXVNFKVWK^79E7OQ=737FRBG?;S;.W9V:VMZ^V3O>2P\^5JMUQP>' M;U^W>F6N3?>YO7+XZS!3*:N-
:7QE&^7,\LW>_/CEZ3.NEP7_K,RM'WU6E&1A M[1?^<5&^V3LB0Z8V14<*&O_=F#-3UR0$-GZ+-/?REGQQ_#E1?R^R0!Y:%]N:, MUO^JRF[]9N_%GBK-
4O=U]]'>_MU$>7X@O<+67OY5MV'M<^Q8]+ZSF_@R_MY4 M3?A??XUZ&+WPXNB!%T[B"R?"=]A(N'RG._WVM;.WRG$UJ/&#B"IO@[FJH5&N M.X=O*[S7O3W]?'UQ>7Y]/5-7'\^OSR_S3]=?
+B655B4"A_/5L@)#B\KNMQ/^P;#L MIFA>(J?5764:2%(ŨJC%\YPZ!X@8!L,77,[AOTR^!I[]GY0; ?&+$=@MG*9O MR-.5:8RK"D7H%*YJ)8ZUV\JKFJ+N2[Z+&
U>O4&4\H@CW5JM$914WVP0W3>F M%&[)T8'Z!&%+5'&I46LP:Z@7YJ:XI+>"G@$$;#O\2:?]*VH^:-V1KT+.ZE% M[X$4[_&-LSWVXXI:]TVQ5G:)75SG;+N&,GXR]4S!ETRSPIJ&!&GP**8?* GO
MIEGKI@!347=(!9T]=*L755UU=Q2\L3=:E +BQG=Z45

M;3QXY!@QT?,XD6S,/O1F!CKC=5,ZPUMIK\GB$$8(>6BF!H3C4.3KF>E@0HH6^\. !8AA:1_UE+8FW3I61QN4Y:\7; M#GR>9S*QGT!AA: 2RHR*9]S.R3E*ZAKE5P2&=\-M)D X2EB"&F^?8QMPX%-M\L4L>>;YOG$EFC/=IZC>F.OM%TN+3:A]CB/B"7{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|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a>>?%N\O+\3BIY_>_KIX*T C_:=9HU MM%]YVO$1VQLRFKC1.79:[R_?VGD+,3 FZ%?14_2/#O=7DBDC 0<1BG#]!+ M.N43H<<4U[=J+)68F7-5IQ#5@LG@0&JC3AGZ)45_U@L';__YR$ //WT,'T* MJ&=N)S/UJ '9=]]$D_#Y]*GG?3I0]2_TG3_+=JB!?%*969=.HZUM]QL%/+<[6=XA0B]KIH8WII]; M.ZLS%8! 5M1YJY$>9R[+7"A7Z6U'Y49:+9<%I=^9U0E!%\]!BZ.(_^=8BB>?>.YPL ML #DUZK$^RP0EE;GVBGDZ:"%!3AH),A<+"V]V6TD^&6JK@<!?=HFK]G4UMS) MHM++*^9T&VMGQ]RF&@8T[YG^LX!"E&JG/>H!A9Y8VVW?JK'-]gMXCHU4.U]OH M;..UDP5T-UE68Q6S8!HH%JW;.4H(9XJ^+Z"9:B,K#X=TIL0T['LC=4$+3_920J]3;F#!MTE1B(V^(6F85*GX%I#/CH]$-\L*O<4 ->9S.^JBL=$M[-W36"K T(UJ;[/ MMF,F\]^ 1>>54*%%<0M:T'UKZKJ;#70O5VH5BM%DA 6PFG8GD(1.U8(Y#*C M*,W TY10!0)ELH:$IK8#6 <0[.0=TA;[M2,PE#D\@e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{DM6U;H8=! M"GQ:0U7#\KZ-\$F(5$M*MB:043Q>Q]$9I@1R?A#V0XG^+9/+_@>0BSSF 4&4%"0_5U*0L&C_C),[G M @@?KFU)5(-FXW_;+GVKWO=QB%++$))OAB+T)?VRC M\W3HCTLEYAX"W>5O!A M98?RWR:]D[4M:&-XUF6E[580%.:S.4 =DK:%YXAKN_NMESM^S)#<1=P=;HXU M-0&H=7K' #4]U,"1C_:Z7?T\5C*97[W\#8T> 7_8G1$^?$[:<^4U%8>2,NDA MK\Y1_#3=*.!MU,#)NZ7T*I-N0T4]{}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{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{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{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{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{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{(9'C&PO=V]R:W-H965TGQ7^?#AP)W!M#\;@/5EJ?>\G5WP>#;T@ ME%@ZS\#H\XCG**4G(AD/6\YH;]{##\<E[]_!=_)ZJ7I'.,,E=$-+ +6K@>L&+:&<%?/HVD$"O6 M27>CU[_BUI^1YRNUM.$7UOW9/(N@[*S3S19,"AJA^B][VL;A # =O@+(MH L MZ.X-!947S+'%S.@U&'^:V/P@N!K0)$XCG**4G(AD/6\YH;]{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{(^2=$5+(;ZHW#,#OO]?A#W8<5HV=(=XX]9*. KBR00KXTD MNX-)5#*Y:D+[25]?Y63[A,H5P6*N ,*)8Z/N*)/$=4'K!!- P&(45+HQUB9-P/PM%X9[W2T4=6""T/X:$ZCWB91SRC M*O6WAPX#AI1J3BFZ"SJ[C>&?K-P.R!AY MF3 "Z:FR>7B@[RX@$JYHBN(`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{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{(^2=$5+(;ZHW#,#OO]?A#W8<5HV=(=XX]9*. KBR00KXTD MNX-)5#*Y:D+[25]?Y63[A,H5P6*N ,*)8Z/N*)/$=4'K!!- P&(45+HQUB9-P/PM%X9[W2T4=6""T/X:$ZCWB91SRC M*O6WAPX#AI1J3BFZ"SJ[C>&?K-P.R!AY MF3 "Z:FR>7B@[RX@$JYHBN(`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{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{(^2=$5+(;ZHW#,#OO]?A#W8<5HV=(=XX]9*. KBR00KXTD MNX-)5#*Y:D+[25]?Y63[A,H5P6*N ,*)8Z/N*)/$=4'K!!- P&(45+HQUB9-P/PM%X9[W2T4=6""T/X:$ZCWB91SRC M*O6WAPX#AI1J3BFZ"SJ[C>&?K-P.R!AY MF3 "Z:FR>7B@[RX@$JYHBN(`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{X&'0\4J@^KUN[5?:8L4(,,K@2'*6@#UA=*V>J#&-0_PYS_#U!+ P04 M" Y-P9941 ZQ\H' N%0&0 'AL+W=OK+7Y8 LA'M8E#@KGZA>GD&_MV:JN-F\$J5>7P[&@_;&.[DL'T875W4?"D>A/NEOC>X&G5:#E!P2I<@<:>#X,R6N15F2(KCQM>]0YZ$R28/]WJ_VO/G,$,N=67.ORGS)WQ>7@?,!RL>!Z=[1]1L1XSDA?9DN MK?_+UN'L]&S LL8Z745A>%!)%?[G'V,>>@+GZ0&!2128>+^#(>_E:^[XU871 M:V;H-+31#Q^JEX9S4E%!'IS!4PDY=7VYM=2@W>W=S=L=O>\;B(]+WJZ M\?7-NX>_L)N??[E]_Z^+D8,=.CW^HLY70>?D@,Y3]E8K5UA

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},\^@1O!B=7(F6WG8^E M.D*+Y0'W:V23\=+N4,DP:*N-/C+8AUM=DJ;.IN>%CZ_BE$(L\4@S_<.C.$XI-M3^S@GS[+'JA1#V2^;5)1>"20>CCEWV6VJ#@>)\|=G|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p_%K86N&A9 B&/XDXL0N=8G8PE;. A4MG\!4Q-8D2U6_624&+V)Y M6]-N.&^5270LM),SE8\NZXMK{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`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}.>>C/HKZK#\8INLH^#US5! MEZ)_ZLAZ(5,NYOS!#8TL>,+_2NJAOB$'S/?WTWU!+ P04 " Y-P99H\A!WC@(M "=&.&0 'AL!+W=OQ1D_^ NSFP=2FW4!R=\7572W;U2I5V?M]\.JY\'O>E$$>C"\.%O*A?JHPA_++P{?AJV67%?*>?S>&V'<&1^WKL]$2NY6M]%.2+9GLKT4@>LI-2_>CH]CB"M MJH0I.("KTY/I7\.5"=[EUE;"T&K{1T@^/T0R]4 >':O 0-3Y],F8J&?3L_MH M>E\5'5Z:OD8\4B8" -+#/UV;6PF%M1.)3Q3-H98(2Y/',,="1 MT#61"S-X^=^E.=D&]HX(P@D.U-E7)]/30/T?I.%+-4!?C1?NR/1TH& LTVR* MR&T!QH.=N86KJ>$Y4C=<>G!0DT+"1=G)OVJTX+@E6-\UU9T&17>F+1&X&7S7 M?4>W.O:V=7&,'7EOW;24$W5&'##6 9B5"Y'\Z$D\4*YF/>(]_ZF2F$DA1M0 M88$ ^*8CM2&(G3E61>+6N[&=EXA U +UK0&MNL"B4R+;$=887T^R795DA!K09 M_03$HZB^89")#X D "BBR7+EPJ.0[S&N77()W(RM0D9]C3P!44!'M)XD;A'?,7B7O^PP*T0R"-&:G@[)1T?I,QT! M"^0A=+8A-K."FDNKA",2WQ6"/N@E)*OZ55EYOV,MYDTF";ONZ%E6($*$2OH9JU+X=^6B@3=QV <(=3.'OHYD67@L]S*;2,1 MAX0A?TT N:\0<(,D(-845&*A^X#_B7,983@ M7<+_* 'PG!J8448KL5*]KS7U0CX@$'<-5X;*PGY*OB)R7RU*E+P% M,K?QQP.1%*WPJ\E#!U*&E16VC+3-]$Q?"WY,59V1"&0---M2$0+C#(SYE}, MR;1G%G<"^3+Y+2(5F!7E%)BC*EV)+$N!%XL,&BVGV^J#2/+U+U+8@;'R! MBQ1NLJV[Q?^2 ^U0W&0K6+2D@IL*6\ M2E'\$pQROR;0.>Y+]@#. E$91E"I[2"QRIW&NR4OQ5:*!(LR1D4K2F6X%B}=- MQTP<)J31\"P1,CXF-A61M[5@@2 =$Y.^C@HI,,14/XCV#Q%KOYC<>^6PR_V) M#Q$B^2+,#4*1:#&ZHC=3:$/?@!$*7IEV9W(*.'$Q{TCS"LM<7 MQ0G>0 W[O.,VO6%)K#AHK*A9G8P3SASR])+1 WOUQ7D*CB<3G:5"_ L.-R(M3[-Y+[$TLIN^E=+-NJE*L2O!-5.OD#VYY+K(4AE":5'&B'7O,(AJ ZJR?D5X M[QV]GWK!7.13T0_E*Z\1= -*YE-40/A0Q%MGG 9\N$*SGG2@QM1N!D&V3_6C^ M)*K9L"&FD{UDO="6L[\0L^ MOJ]8]HNK-F % A2WWY;ND|,V D/$SJ",LQ=9UE/%.BAA)9-8RA!0[JX2')GEWV\GV0*

3/PFDZT?V^0=FWPXNST MB=!UJJFK/E/.Y\%46(CV:87GWDI3K>$%4U!2';BN/(]AK&18\.BU@)9'FP=> M!]RR"RFBFH{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s+A;C55CH*HD\^,2?P\Z6X/:P? $8/95;*LKS3$3!T!QXQX M.4IU5UBT7%+>,L&=CRHA>>:\R_Z_W;2UW;I0H:>7 MWY-LM#0$S]2Y<4*R4R.)=>+H$SWE@W&YF-9$/R)OE&ZGH/TH(O?#QPL^U-/IN M*5_I&W50_? @T*V-?^[.3^)N_*MU//4744,B 6EA%;U M5TA,M&[0,,A>ENSE]22F\3&^ =N#P>G+ MO!P>9/%$(=-TTJ144FN[@H3!L3BBBUT[^F[/SC M4KN/(CBJ>2=#]*VV>EYZ,+LWR3>N@T^ ML0B2U=T,[3O0L .>$HEKAD("G=ZK=XE/4:+C,P=e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}^N2 MNQQ\^8[?]+XM9=+8I\L*6"(,F?:H!PS-A5Y,06I]FA)2T7 7!U%]7R1D)EAV M?6SU[DF4+[^+?ITEDTYK(U&&^"H5^MS<:,]K=)%AP'%_^P<5*&%?"_'OL$G' MY(ZZX,75\V3-!GF>6Y;K, KEIQ@%.GF#3 +M6-A0XKQ7GR++)C$SO%*Z'}7B MFQ]&*V0-+G$]R96,=M2\'QU\S(/3M]\EB=[]?_42:6][66%8RD>4C?-5!5 M/)ZR9A.R[4NM %^^.3EY=A)+S?\6-OZ;N:C(R%17LA!>%_I2FMBUEDH]N:)[M&@+S)P\$)P.2CR?I=A!VA#0[H#O[8=`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}@@7ZELO*&O5=!#6UZ\H&G#N ^&FSE1=FXO&2]+O@! M7'(E_@JNWS;XIP<%%=KA3/4IV>W&;W8%?KSZ&*S_?:B4/ M*EC7+<KA^ONVO*.4WS),XT18W?,2-04CYAZW-O<]$$i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{DW_R65HL(Z;C^E__='GY7@#THN*.C18H-4A+ M5" F/'M1&L_/"&H-L:I75BZM."O'H]351,'QO.>"S4J>\8?/T'.=_.F$>M < M4!ONRA'BP^=*L]-S38[;!#B+8F*\-#JQ[P=&_H9T%!?>(Q8&;S,:3//PDFJ1+99I MQ2%*##KT1W6;,LQSY&<7?:.:"[OX.A-M&L:L0\ MM(<5(\>6@0X86B_"@)_K.8'/A#4BSP[+TRFHRK0+2IH34JH? HKD^2/XHP$:.3=8=&=EBYR[&1?1[F'"CF,\Z!95 DD-/0X1!O2 M/\A?[EA#]JQ);77:WQ*:.-8K?W2O#/\-/T3D/?-*O2LS9Z,1KD,F>(^N2J81 M)\]+*^?#%,#MC/#-T=GZ:FRUSZ&VYTOG}-OA#;!,)$D2^8>% MYZWIBTGP%_&'"!+'$0:4P ,C?Y_#]>U=R7:I'^,S9T/E<,U<)=IJCC\NJ_BS M,N3INC5,IM!TE3NE8GWJ7G146UVS$,/#O9QOEM)0F(@<[*&.[1U6L71F.9]I MMI/,_"Y4>/M4-"="78D>SQ"/K<0|%|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{DW_R65HL(Z;C^E__='GY7@#THN*.C18H-4A+ M5" F/'M1&L_/"&H-L:I75BZM."O'H]351,'QO.>"S4J>\8?/T'.=_.F$>M < M4!ONRA'BP^=*L]-S38[;!#B+8F*\-#JQ[P=&_H9T%!?>(Q8&;S,:3//PDFJ1+99I MQ2%*##KT1W6;,LQSY&<7?:.:"[OX.A-M&L:L0\ MM(<5(\>6@0X86B_"@)_K.8'/A#4BSP[+TRFHRK0+2IH34JH? HKD^2/XHP$:.3=8=&=EBYR[&1?1[F'"CF,\Z!95 DD-/0X1!O2 M/\A?[EA#]JQ);77:WQ*:.-8K?W2O#/\-/T3D/?-*O2LS9Z,1KD,F>(^N2J81 M)\]+*^?#%,#MC/#-T=GZ:FRUSZ&VYTOG}-OA#;!,)$D2^8>% MYZWIBTGP%_&'"!+'$0:4P ,C?Y_#]>U=R7:I'^,S9T/E<,U<)=IJCC\NJ_BS M,N3INC5,IM!TE3NE8GWJ7G146UVS$,/#O9QOEM)0F(@<[*&.[1U6L71F.9]I MMI/,_"Y4>/M4-"="78D>SQ"/K<0|%|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{DW_R65HL(Z;C^E__='GY7@#THN*.C18H-4A+ M5" F/'M1&L_/"&H-L:I75BZM."O'H]351,'QO.>"S4J>\8?/T'.=_.F$>M < M4!ONRA'BP^=*L]-S38[;!#B+8F*\-#JQ[P=&_H9T%!?>(Q8&;S,:3//PDFJ1+99I MQ2%*##KT1W6;,LQSY&<7?:.:"[OX.A-M&L:L0\ MM(<5(\>6@0X86B_"@)_K.8'/A#4BSP[+TRFHRK0+2IH34JH? HKD^2/XHP$::

*MNO^ZC_Q'E73@[1F6]KHOQ@?>M_6/TA3\E7!JRM)D_+C F4M9FH#W,X/../R@ M#9K_MG#V7U!+ P04_" Y-P993XLN63H& "Q#P &0 'AL+W=O M5)|>J]*F,A=3S4R995ROST2J5B>M7JO>N)?+Q-)&Y_2XXLQ_;78JJQZC0H MLJ3 MJ.P9$EZD4N/^VJXH9S,*2@SJ_%5@L^>WE]>3QXN+]ATWL^..!3Y1=:*

(*Z\QCA3NP1NQ&Y38Q[#*/1?R9OUNP,)N.'@##K|\8VW=X_5W&B1!,;$,;IUW,-'C3/#7?)8=@?]D[FQ&JL_M7[/;PPY>AZ6Z.30%C\1)"X5AA'X4K=/W[WJC[M$;2@\:I0=OH?_+"/TH%IM> M32_9+.$P@-WE{;K*&%CY_1>P&PBV+G*"IZOF7WTL)=^)S M)BWJU6(S9E?YHS!^.5EJ(=S;2MK$83EIGD3I@!6E-B4' 1!7B83D.&QW445I M2@T!OUOU*+

*(Y('H'WM(V>R!+$RY1\3GQ;%O^_MTX[.T?,80(&.DV@5"3OQ$UD16I6OM8U<$Q&T"[LF3B$KJ MF;,%.\S.[M\PZBFB//W%X%G8 !TT=N4#TV8#-8_86"-D7T90SM ABB"Z7)2Q? B$<.D:%(-M&8[MY;H";+,5!4-<'3)N-I;@^P*@WHAMWQ#(#40V1C">&N41#.7)/TV"]@N8 M1*4Q_$>-6VDJ$NFB8"Q>V"R2MC1LBNS-,)M!&)05["<2$';/_&>WZ!W]%1U M46@X/P99A-]6$3.HXK5E,C(,",$$$X__]*%\DM^/KZ?*.5&FJ4'Y.C:\2Z^SIUZN/GZX^W[';JR\WMW?7G&\ M^D&) M&IP}} 74(?$YOBL/'A*48.,>9,2C9==VXQ=/$,A;;-)? =ZB1"WXVI.6W.Z,1VR+QFVU.=828+-Y-G\FG'%YK6]-??>MN1[*ML..[B MOQ?TQF/W[(Y{[GG0';Y(TM[^B/;WQ_@/!T/6#X,[!{N]-QKW?:V&1P0[.FA6 M!#_H'^=#9#WJCD?OV#X:D3## 8#]C$-8CGYOAFBE.ML? WQ7;.4YZ3#7$IR)_> MPJ!2R$?<9YJ;7GO=]GX]>@),HG:X61'IWF $$:IT8X+"6@AW8$W7;B8!885>

*MEJO7=&A4J/W5IA%^(:)JN(7.B/[S@5!P":F]L#W<3,0%B[A)7 8CY7V?)N!M MOAL'^FP0N-GK)U$B41BN*JH>6^7PY/9BPCZ@1*#U)=?Y+W>E#:J4IB:-@S3. M*C2>'%>#^!"WZ\E>$4N#H[QY+<*K22L!O>V;2|2>AV.H&GWU;C9ZNA1 MQ8]HE$KT*9KFKCB0^_KT N>)*X"B K,&VT"ZB/8:QL8HHO-A$,;@=)~'> E MZT%-

AK{B[RJ8^)J1L52?-77CEJV1[V+]0^E@/_LM8?]3&/+>0MK_M:[!?.YAWMJY1&:E"ET5*BC*W_D;5[#;WT8F_AFW(_646Q^>EQ!$G%0NPHO2'M+:,;]!=$OK"K&PO=V]R:W-H965T]\:6LA9? M-#--57']>"Y*M3X9A(/NQ:U<%I9>#$^/5WPIO@K[,?5%XVFXD9++2M1&JHI ML3@9G(4?SA.:[R,\78JUZ8T963)?ZCL]7.=>7(BR)$%0*

*MX_=6YI"S)2WLCSOIOSC,8FQ M5FNF:3:DT<'9ZE9#.5F34[Y.C:\2Z^SIUZN/GZX^W[';JR\WMW?7G&\ MT=AUHHX]R*B%T1,V'=5V!*PJSH7^>[Z(=39Z!1U.IU'KPK\6U,?LG@4L&@4 M):_(BS_)*-8HDPLNQ6K)2VLEZR?Y[-C=6(B'_M.]=+2_9+HRSY8%8\ M$R<#I(&1^EX,3G_^*9R,CE[1-=GHFKPF_6W^>%7$?@6?R65G-4-J:^X ,2U$ MTE!(0V#.N&&*

<9:I:J9J^J 7C-<-(VD=F"VXQ7B)M#9,UFS<&:XSQ22:MQ.N% M5A5,%S(KF+0(V4?D<:6M?Q#8'0OZ@:3>)UC?!=9H)A[,T8$F&QZBL$ Y\'71D"C>& M4"*

3L+FS&#]#364D]H,_ON2SYO&3BD-U!.NG(_M,,-M=0%0V(]1YKE'9^,5@\@:HC9VLUC(3.AVX78N)L3[0U';U6SSU/SH;/ M%*Q,P_P3(Y8A]%+;3,3,"NC(5:$DR3LW,-@XPWZP:::#*

<_#(^P^C:D 25 +P6<'K6M"2#/1%9-!3 M!?)76N5-9O&]'?759I16 !M?M7KD)46\UUT1'H<; &\I<"^E$:@<_S.4GH/T M! ;6&.=M)\>B6-*

*NJS>$5]G+N7DM;,$W:P7P/BO&1XU[FK0ES,PRU=36Y4_18,*6M0@?I^@>#??X MQHJLJ%6IEH(,/7,)(U>MH7Y3QV_>\WTZ @D_LZ]-!A"[_Q&D&=N+VA'EWU"*

M#MD9+-4S>5CL+/G1J K<0A0JRR2NE5PO[!?]I+NG,H)-0;.7;U"R'M\%>%H M(7;Z'(8N1;@NY:M\>.'+@NG:&2N#?Z'+@O:0/]K6S{CJ5ID"93 M#&91$"4Q!F$Z"^)DY$91,)G-=JDGF07A#!LG03Q*6#H)PGCEPB1-VYZ"K MA=VF"*3$:3#R\L)),',1=-QD$SI713%01S'K&NM7D[//7GYUK1T\ZAI@-/* M=BG2J4WXS4[,]/\! .,0IHOG,?#NW3'7] 8^0DL(-*

*S1,5"VO?P+12...T[X!$E,XKD&+"EY/@@"1/V MI[Q_ZYYQR[9G;_*72T'+/#G-N6YC_#^>W==(G$YGB6@>,0 M*NGPY%K.7OER9(_(A>,6MYI(Q.KMWFI>@*T W_?*

B_+$E>)U9$KJ9D++3]B!AL^+WHTT/8QR> M88^_24!X ?O/"G,3UUPO&NV"K@?4(-HU1Y'^:V M[?I6.QR^6M?P$';?Z+/X;H$M4&0RX3N>GESKQ'QF7L N$

*@Y}ULYRG'%^!/7 M.&6!TEQ-\3M4_#]*4[JV6.TOW63!:WI[6;X,NI[.!2[(7*(S[DO:G+W:$D)E M=;D%L&=<[EM8NR,7GZ7*46B?E,R_5G=_Z^''M3UW[.N_NU[Z\[(*PINDG1LZ MHGOZ=XSRX6FX+>UOKJ<_BC:B'/99-$>KDK>'4*++]M1 W,F[%HIBON>2+H:" MJ!#N6N NXTJ7Z_@_;V3I%B,FJRG0(H&C'4HTZ>&%K2FN2\2<7$A_EU (G,,H*

MUUP"^{B]%)FHYLB{G= UFV M>YW%SK1U!3@_[LCL]"'79[>/U9>UWM75J MN@,B8L4G493Z:Z?@*4_1Y.W;\'?9U>\BGP3W)EY=..#X#XUELHH=+4XJ;)$8Q MCSV?*

L#"8CF\)+FCH?-!U2NV+!A0'=+#XN#],B&,EW'=I->Q=*%9"+]VU^3Q* M_.SO%C=O-S>S9_Y"!H8!-2 ZK3_\+4$L#!!0 (#DW!EFSV.FA80($0%*

*M 9_>&PO=V]R:W-H965T"'32V,ML8-]6;=_S]EI0Q%=Q8OC\]WW^;O+G2<; M;1YLB4CP5%?*3H.2]+D,0YN56 M[HAM4[*FTJ06Q:=:A;0R*W(/J*HRCZ"RL MA51!,0%G-R:9Z)8JJ?*

*#&@&WK6ICG.59Z,PV&P>[@5]Y+<@=A,FG$&E.DN^;& ML!7V+++FL45FI%1@LIL%L>#D?NW@?<']Q8_?VX#)9.?W@C$_Y-(B<(*PP(\<@ M^/.("ZPJ1\0R?FTY@_Y*!]S?[]@_^-*

*PYEY6PN-+$>5CL+/G1J K<0A0JRR2NE5PO[!?]I+NG,H)-0;.7;U"R'M\%>%H M(7;Z'(8N1;@NY:M\>.'+@NG:&2N#?Z'+*@O:0/]K6S{CJ5ID"93 M#&91$"4Q!F$Z"^)DY$91,)G-=JDGF07A#!LG03Q*6#H)PGCEPB1-VYZ"K MA=VF"*3$:3#R\L)),',1=-QD$SI713%01S'K&NM7D[//7GYUK1T\ZAI@-/* M=BG2J4WXS4[,]/\! .,0IHOG,?#NW3'7] 8^0DL(-*

*S1,5"VO?P+12...T[X!$E,XKD&+"EY/@@"1/V MI[Q_ZYYQR[9G;_*72T'+/#G-N6YC_#^>W==(G$YGB6@>,0 M*NGPY%K.7OER9(_(A>;6MYI(Q.KMWFI>@*T W_?*

B_+$E>)U9$KJ9D++3]B!AL^+WHTT/8QR> M88^_24!X ?O/"G,3UUPO&NV"K@?4(-HU1Y'^:V M[?I6.QR^6M?P$';?Z+/X;H$M4&0RX3N>GESKQ'QF7L N$

*@Y}ULYRG'%^!/7 M.&6!TEQ-\3M4_#]*4[JV6.TOW63!:WI[6;X,NI[.!2[(7*(S[DO:G+W:$D)E M=;D%L&=<[EM8NR,7GZ7*46B?E,R_5G=_Z^''M3UW[.N_NU[Z\[(*PINDG1LZ MHGOZ=XSRX6FX+>UOKJ<_BC:B'/99-$>KDK>'4*++]M1 W,F[%HIBON>2+H:" MJ!#N6N NXTJ7Z_@_;V3I%B,FJRG0(H&C'4HTZ>&%K2FN2\2<7$A_EU (G,,H*

MUUP"^{B]%)FHYLB{G= UFV M>YW%SK1U!3@_[LCL]"'79[>/U9>UWM75J MN@,B8L4G493Z:Z?@*4_1Y.W;\'?9U>\BGP3W)EY=..#X#XUELHH=+4XJ;)$8Q MCSV?*

L#"8CF\)+FCH?-!U2NV+!A0'=+#XN#],B&,EW'=I->Q=*%9"+]VU^3Q* M_.SO%C=O-S>S9_Y"!H8!-2 ZK3_\+4$L#!!0 (#DW!EFSV.FA80($0%*

*M 9_>&PO=V]R:W-H965T]_+7O]P[WXH,KO5S5}.#@^%TEEVJFZNOJTN+;,0:*2Z[4J MG3:EL&KQ?F]Z^:,DD#?PBGJJ=>LZGP6),C?F*WTYSJ_O38@C5:BL)A(2_JVH M4U441 E_!&*

(IJ4S:6/WO5^[_6>R-5"-D5]96Y_M54&@%T0O,X7C?\6M7_OJ:$]DC:O-.FP&!VM=^O_E75!$9\/KR98-1V'#$?/M M#VC(N/\A:'K^SYE986@UJ(%%Y=U@3I=DE5EM\:O&OOKXY'IV?

G$VFXW$Y=79 M[.5B\:3S^:->+D9A>?!!79Z=X(^.GIY^N+S2?^R^=9)N\/GT[\?\,!-/+DVA M,ZW"7XG=3UBLGSLI3D3B:'#W?0>]9TLPSIO=L[UIEIFFK'6Y%%%,)9_IW-46GO3?(8$]*

*MO>?#]"B\WKA*9NKJ'N+'*7NC]HJV_^N'PY>3M#FZ?)VZ?[Z)^?"*==L(LQ"71 M+FM)/C_$Y)(=$ZO%,(G,^M*EO>DD*:43.YKE0M=ULKJM<@,S%@Z/,$G!WWE MDGY>Z%*6F9:%*

<"E$,ZU$RMYIH\1+O0?^5U2!2 M%;# 4I7*RJ*XI]}5Y5D0-1B\+IFA&9W#(DS7X"R3XLE//[P^.I}\O1[/QN*7 MZ?22OQ^^?2H :DF EE-=>K"#Y&-*

Q[HF;2I>D"9!=8Q)P19^,>_43&0LFAR MD"P*(?,OB'Y^/N*MVKNP%)[!7 Q*RQE![UUMZN=;M625*E2GG@+6B-J+R M:K1+A4]2VT1YR?>KX%Z>/PU5OA.EQ5QFG2P C'-"*

*<:Q2YP+)>F*4U2*X(GV'- M)X5Q[BD)8-9J)&0)<:5;B050WXW9@7KBSV7!EO:91;]B WA=SY45SPXY@I_! M2YQWDAQZO"&56;,64;V#^I/,9;T"/3K&G_O=)ND0ZLGJ=6GJI$|-*

*_>DRAV]1 M1O%'JJ0G/GXM[X7)8!_V,?IYT<"H"^TRL'ROI!V+4V5KI,VNO[B%L,4.$Z) M'*NAUX.()Y/SN>PB[/6#.M@54BD".B%HUKHFZ:O&ND;"0> KN@3*-5FPM&T0 M>-ZF5BV;*

(FB%"]S>D)6]/$Y\&?DE7 =Q"#M.+O+5K)-D_H06AZ"< MG9W&<&+1S(2<;]SBRW"-L-Z@=M5)~]-(-1(5@CU?FH+7 ZR1X3#8[620BLQ# ME@:

[/K1NM&D7IR+RY5$1&6]J1'&!=S[O,S&;%M-GM/,G)D,\'%GSF!LE)JE. 7XJS*[M']+ZXRBPJJ.;$NQF2I&NQ (/VULJQ<"(O%)?KW118%H_81*P6HS$J=(CKD,*

M0/R[M,A$T6W"O6,R/KLN_(&R2[DP653>.5!6AHU;>7_.G'56DT, J!0W7,\8 M(_"0E)NBD-9;B\EH6<:'(X%@Y:V+ SPH2PJYE:Z%MG\#L\-,_.0F;8Z"6RY M0:YX-YJ:IE(J96S477!$LXT7?

VXG&9,62U=WC|,\4RY5GOF!9Q(2F=Y)5 M4_LHJ2I4NG)>P(LC<%NNL&*PU:!*0)@_Y(@-BA'Q;!IY+J.JR()=*TQ"Y@;G2C'$E1&HZY55BDFD[??6OJ7QP(V&1*6& MA)?*

*X,+@N@7>0@-+'K79<6ZA\Q%4?TI\B#CP# >-_#+!.PH='GJOXG'?1AD%? M#2$7\@]528VJ+K*&EG-=Z+J+:+;5$&1H7+1Z"-B^7Z2*2VU4=(3*(UJ+$IU*

MY8"W:F4%';N9D+U1],]NUNZ/F!AA<1JJ)POO$..Q06.0>)591.,J^XJR@S? MD 5QA]K'HH3?$,7<*-OU;V|$4VZ1#FFAK;J@4!5ZJ:?!1T-9JGPVZ:5H@=W M4Q%EH0VW)!DA<+-NO)*

*>3*D$))DH89F2S(93=IB B@1?+R9"{)ZU[WP*4.)> MWNW%Z}27GNU,RM=.RZES]#F4)2]VH;SV. KL_;X>3F;84B@07E,5'I71*94M*

*MZ0CVA?]0B*WE5WA..H(<#P'5K"N/0US]R\5"977H"JC((\.L4_W! >AZ$1@! MJE/R8R&8(I\B^VW;XT_)V8%W.%D$OPUV:,]0#/7PWN_A/IPC(S7%CZC%1EV5*

*M0;B&=D'A/OU28R^TK}2HZE5([[+FVA@H@6"VI*NTN*^)+8:Y^AGF]LR%4^ H#*Y19SZ"@X M/CD\W,K<:.YF<.X<:7^AZQ&- Y6E_(HEX;@;632AMXN41E",R;Z&\H%"#%J4*

ML=MF:U!S;Y9E>,'3SC"QP! (3K,,;2.+DPQT?:DGI_[9fJV V (0$^3>KU3 MC3:4V#I=Q}&(5^3&W16] W$$(0H\:,#[*%A_.E?(XME_I%]_+QY =)WJ{4 M===\L]ANG>DY()6F?*

H;Y6;JA=UZ' &"6'SQ4 (//>1$>]04;&XD1ELG&IB%[_ M^>Z\]K!+G5Y)Y0CP&"DJ.3/IKFYX&.,+,VK\<[V@?!PR@?$=0!BC{[CHQ!. ME--0,"IO/IS61@!'22B/-*

G!L:Z23+MM#N.A2/D+E$!,$+G%\G<'Z]$UJOE)\(M>%28TBB=K3 $TG^.4J\[0!QA&Z?5SF+9+N8AA>_N,N,@=@Z(S]B=@$$-=%+' MUE?=P2N@$R!K91QTU5(9BQD9TQ-

(Y&ALI=958>X5 Q#/>\G$3E'=0/[6HD/7 M>P,*P">0M\M4#$PT)K4,5%9XJ M_=R$^QVN;@!'C- 52BQVWZ2UOJ8B[4K>!S2S%!9FSL'-V8LC!]_&-!)IS3!L MI1;0?)#ZJ;.@R;S.5,S[?M

;;TOM@ORDVB!+XC5_T_Y"F+CB3T5!%HC%HQ),3 M-H4^K7!XZZV!;SO7SDG_B^4N64<4&!E MLL .RF3;A'<70OZ<$/+6G;AVC]SXLPN%BXLS7U>TP= @H_Q+!'EZFEH?K T:S

*MJN90Y;MV<_ 2FHO2-#NE88JD3M(>F"&3>I>-]D_P^W1V*IX='=(+1[I_*P3 MC>DWU-!3],&DO;*<[-3,U)<%OZHBWX? ^S-9J,$+R,>3Z<^"H"J"E7K#[^,6K MN-;16KW@GKW_,(.@-*

"@.%JC0>K.U5E7+R?[AY.1N+3D?_4]/A4R@#JIJV*C M(? 2G9"8VGLGBD\4R_P15)T"$USKQ'A;6M-49!SM+P1<*-5RG2X9..*)W[FB M^,D5*." F;26K]1BIV*[CLD3%*

*(*5]{#^=+];Q8,F+I-Z1:C<4-/(TV)],TP% M@L!\"=#>;'Z@4JC\4!KI^2CP!W<<(QI%6G/':1]>/K\42L<58H=SKQZ,=+1/56A21A.Y,; M[=>.X5]R@1-M\S3SPV:FY8?*

*91Z_#..^)0WUR0;=TSY_N2A^'G1O^=NAY6N AIQX"H>U5"-UMX8Q_5S56AUHUSK\.V\V++FZ$+6 M"^>2 'X"%(#O'KIKC[B%G_%COGZ5(DV3(UV/V JOX04W=0/W**I"-!)WOBZ*

MP@5.XXE'T>L3N/-#&FXYD6X]_#87P)+7N[""^,PSKE+&H-2L+ M7.!K^'H%I%JB82M7%-C=-9KKULQ.HW!OH^>=BWUZ.V&IRY)SUP(&;M'M\$5"M[*]TO2)Q<4$*

*M^RA2ST>ARV7T4D?T R+IK_4W97/^BD=1^1.L&TK45*0;OS#JB/-%U4Y+DP \/T5X>\OETY[.V^EG.M M1; '?IBF5<,>'\!9^6!+L4QY$((7(NGVQI$L!?;3VWD%S M-*

IR2MWC])>/#O.W>.H&++W#5>Q{R4E:)ODJS7QWN;1-#'E"I(V2JY,R\F:NU MOJ,GF38]?:/>:::NGRKNGW.*CR98,[!NA_3M_^3D[WD/AC)I(:[HJ1QQ'G(L*

*ME!)S]EDRXZ=8OKR,I@@OA*1,24FHP<7+6SZ*. OO+V4% M5VEI]M-]G\G')^IOZ=]Y"26Q5_6"^;=CVTN6W@7(B(L_>N?-S]J CDOWIE7M MYL%6NZ]HNH(S-VS@WFY,$.%X>LDW)^*

OEY5O)FA4PV3>]M_,FAOH5G:TT7FC M9\Y\"XWA> QIK$L_TJ#%T5"];+W2V:)1T0H6106K@!>QO?3>0T2'Z=NH[&79EGH=+C>@^ MVS(VS?ZHH=^Y'23+C"\-Y2R;FR7O/-

>.T_.Y%^!&Q9AUQM>\4V+1&33"8:M MR?[-SA"Q]Z_S-O"R=(]%"~&[AZ6*%!5"&[71Z,H&MK(+XQ&9O-]C5Z^Z%P0 MA "CSKW9#,-=I0ND_4UBL,T7OB=[P?:,HO8J-D DSH&I((,:*

[T.OZ?$$-1,/ M6+|] XZQH>EE.W7Y_>5 AMY=U%TH7X>U ?\#W(FMOAMQQNL'N[.#S1OU:(5KH M[P;H$ CJ7ZY/3]/?)DS]&_GM)4T+"K7 ULGXU8L]?\L5O]2FXO?S

MYZ:NS9H_KI3,E:4%^)W>!XU?Z(#T%QO"_P=02P,$% @<&=!>[[E M!0 NPX !D !X,"]W;W)K&ULG5=@>8<)^LZM$D0N^V'81AHB;;Y2)'4DFS7[*

*[2E:_-2@A+OE9E;BXN9$K44-(PNE*VZAJ9=# ML]:"%VY150Z9Y\7#BLMZ,#IS?;=Z=*8:6\I:W&IBFJKB^NE"E.KQ?. /-AUW M+DJC?N2QW9N#!KSQEA5=8NA7=?*

*NSAL+4B]/0M8MX YNUM%SLI+,OGH3*M'HG$VH"\@7"6KP3A9XZ9,K891 M"> OLZ.[]\)7UIRMR=S6Y>7?]?O,^YIJ,KR^A_6$\N[HDXP\?;KZ,KR=74W(T*

*MX_-2F..SH07%N'R8=THN6B5LCY*8:%2U71ER51>B>+E^",W5K.-U1?L(."O M37U" H\2YK'P %[01R%P>,&^*(@'43>"++2JR 1LU9 ML!-V129N#X0FOXWG MQO7_OBL*

+7ZX&Q\K2]2L>2[.!U Z1N@',1B]^<&/O;<'K]{Z\-#Z,!5&K1 ME(*H!2FDXUB)7RUK^_>UFM+XDF:FC>%M&[4"BTKDBM(B]I #TA&E;+-&.&PL_$'}6X-N UI MYY,ATKB)LA*

:IEE%Y[)?{G8P[W;0M%N8=UMH3L@,K%FH$J@(3;&8T%##:XES MT=*]X3N%I5J(%XE,(V%2\.I_+IGY%:KHD%T#/A4@B5S8+ 0KEHK,QY2=8;X:!])$M L#D&(QKX"0A^&%(_

M]5%B"?4[QE.&/1: F,49*[1JCW E&CUQ$LK!8@X3T&]++>SS<8E/Z1!"@ZD M-&,Q"2/J1QF)(AK'V;-RS;6+L0 >W>M0F%$_ Z20!EY(TICZ8'_HT3@(R4Q9*

MF%K#8=7M"_KO!RGU0@\E/Z91B!%@243#!/L8@Z@$P7?NVTQ6F'E@^X8C[MKT M=OGQBGV%=H=G74.J0F!7W9)@ E:FX70F,+<$D[6"NK!50P<>J_PBM$L2E\%

MKQY@WQSJFQJ2YK.W__H/DJ@+]6NC>8"VHIZVHE?3%C"$;GC9E@G'^D2/S"YV M.@RZ\#;"P<0DFDO =(^;9AI#_7,>>DBZLY5 X!ZGX5N#)$,I%#5II!XF4(N M%W

5Y@-4E3!KX>XBY=,I&&]@$6<'%;$4UWV3> MUDKR#O>[1N+<8)!Q 5DL\?A"O4A*U=J2B\]Y+2+]+D8MJ#BH"WQG,'(FD-(J= MY-$T02& S<\R$#(:AM@1TS!->R>&X^)/X-

*J6LUD&K *?)_ZGD EW2(-&NT.%' 4QHRP<DC1&!Y/@@9C;(8_@' M3Q(<833&*5N^; <^@IG'2)$)L$CDH/VN U.LZ3U)F$X% $9 MA.2/__5#^ ,$$?<$$;_'-0YE-.9I+FK;W@5V\<-*

*AS)8?&OU*8"''=/<8*!>I M8^MH$"X;J 6>):C\Q7G#34'#RC8M5'#K0<%K%NZ9Q/>NIK:MF^+ MOK=_F8W;!\GS]/99]QG(*"3*8E&(!2[V3!/A;MT^EMF'5VCU/YL]"D4Y*

M2 M:)P XPNE[:!"OKWZN@?4$L#!!0 (#DW!EDUU\O[900 +|+ 9 M>&PO=V]R:W-H965TC#9\!3.P MOVT>-<[:#4HF"!!&*,DT+,?>33B\34C>"?PN8&L.QHPL62CUA28?L[$?$"'(*

*M(;6$P+%[@CO(CG?H[YWM:,N"&[A3^1\BL^NQU_=8!DM> MYO:SVGZ VIZ8\%*5&]>R;2T;>'PMC55%K8P,"B&KGC_7Y_ :A:A6B!SO:B/'_MJTT9R0D)39E;C7X%Z=O+Q87I_:*

[^?/MS/9NQJSA9I =Z[>14L,KVO&ZC2X"_E+:]8) M?!8%4?<"7]>QL^/P.F?PIK"P,"I,FBM3:F!_WBR,U1@3?YTRML+JGL:B>S(T M&Y["V,.+8$ _@3?Y\80I_,\-YE90Y,+5G*M7X1>%ZZ*

*M%;L&# NM05K&9<:DDC_MYJD/-DKBR.PD+>B"Y8K+4T9>1"]:R#GM_C\YS8G3 M>YZ*7-@7QMTZ>AL:,SN,*.10+$"S3NA6.XQ&4>*[&O9*2 13I4%9TJKK'ZGM MA!=*HP^(,J:!C*

+A'>OX01 T_126@+(96PK)94JBJ3+(^2KRPSAH-?T.DE!\ M?C%I(OOLG/8[UH^#NGW 0WD3^X>#4SQE0=0?^+&S(1J$_V)%{(=!@E8D?M@/ M6T?

0K[.$7/*=2QV)KM\9=.M1/QRP"S<@;FY _/H;@&F%KFG)98V*9A}O;Z8W9'.G1{#!=+WNWWL M>WX24<8*.WXO"6G0]0>]@-T4Z#?QU9E%-E;!WT,&$#Q('1?B,DKJML[OA'H MT?

*IL:Z}>A7%(J:%K?IS,I4#OHM]R^4;_:?]#I5MLF?4T 9-S3[Y!U!+ P04 " Y-P996*G1K*T#*M #N" &0 'AL+W=O+07\D!M$M#4\E$6EQLY.Z_K&\QVQI*U!%C\13I,;(4NF291,3]42*

*M66Z=RL(+?3_Q2L8K9S*RNH6)@IE_V'?VO9]!{)&>5$>G E!R:OVR1X.=3AQ M2%]S" \.H<7=)K(H/$*)B,I]B"--44S"TO5>A,X7!E#66E)NYS\]&0^7=Y^ MNOU]!8OY$E8?*

*I\LY]+ZR=8'J\N112F#,O.P0;-8&"U\)EL 74>F=@GF58_[4 MWR-@';KPB&X67@SX1U-=0^2[$/IA?'"%>U+&-;+SH-;9,5KS:*EB@A-6.281_ MIFNE)37'O^?XMN'B\^',A;E1-9*

GN/>.%N7Z@!9"&2MP2V8DB1ZG@%^B%;C,KVC5=],H M/:L)^F[@#VB1N.D@>*GHCIA1B3-[,I2O9E+SC-=,TQXHS!K)-4<%;]^D81"^ M@UX_'5X]DWJ!&P_~CE:9^,2R#H1N%*

00#-TG3EU(8^$;RX_B99/N/Y@G@ M9D,#QMS1(QTVNJ2DV1'SU6+AVFZGIK1#M,KP8-147#]6-T@&$/4I.Q$Y MMO?/44B).DG]QO$K!8 "]S[;Z9RX8E=6_#FQ5_>O(?

RJ'0_NPK4.[22OY1^G< MR\T[F4$ERJV=M{J*0M>O'4>=MAOFTW:&/9JW7P)?F-SR2D&!&W*EQ'T'9#M=_M6T&+VDZTM=_T^UR1Q\D*(T!{6^T?!).@^<28_%!+ P04 " Y-P99

MMKY7X:D" "C!0 &0 'AL+W=O"91!I-(7C4GM$'3MAVD?3'X<1FME/:?[$ BF3%_B M\[T\?BF(V+E,$. M+QVLV1)G:'ZM)XIV7HN2\Q*%YE* PL70N0KZH]CFUPE/!#=ZSP;;R5S*%*

*[L9 MYT/'MX2PP,Q8!$;+*UYC45@@HO%WB^FT1]K"?7N'2E?W3KW,F<9K63SSW*R& M3L^!'>L*LQ4;K[CMI^.QLO;)K<*'0@J[21Y;.8&)1<-"M[V_Z'O8*> M_TE!N"T(:]*

[-037+&V98.E!R \IF$YHUZE;K:B+'A;V4F5$4Y51GTO'#T^W# MX_I^'8&$IX]L7] ^&WB&D&W(T8MK7!' M:Q0>!?Q1B0N(?!=^XR/X$5MFU&-

*%WW6IGA%8:1ZAQNNLT+J2B'\OIHKH^A= M_#G4<0,8'P:T6NGK-883E'!5%0>R*8L@V]3H.*LT+#"22AV^G%C1%&79BP[(4M+?Y'5N"[M<13#I9L$77@F#9]S<;Y6*

(I42WK\6!_2D5,HZ'6VTZ@JT9X^G-M^+IGBOK24.""2OV+;L&ULK59MJLV$/XK!SF5ZFH84CH:UDS(WOCX[88=2B+

M(Y0$S1<7O4EP=IFX^_[*GX)OS+,U."9SI3ZZS:R\Z%'G$]X81T"P[\G?L6K MR@&A&Y]:S%YGTBD^7^_0?_77!:!0*U+/CFW?OIAJFM{AD>!?R]D:<040(A#>,C>%'"//)XT?*

*>8*U5N1%4!DR7,I&5R*9 K3(SAUL!4 MF*)2IM$<_IK,C=58/W\?"L/62GS8BNNI,[-F!;_H8=,8KI]X,_SZ53"B;XYP MB#L.\3'T\0/V:-F@TVH!A:K72G*)ON-.[DQ3^B0Z\?!"U?*

*\!2A6NY#"\E\] M]*3R6QL^E$+^2\!H!95=<@UTQ'<'K.6\% M@3^)X#UW0T?()7SPO8>F)D)7E"K1MK_>GVZHWOKZ7Y32F>(*D1VOEW-YV8 W${048Y23.*JWX0 MA"2-*

PP&N\Y30'LAH2,1M2) SP-0@KQ:09?.-,&/+[+PEJKLBDL:!<9 V$< MDRP-4#L?D3@)!A!G}$;5O2##Q0@%(TIH@((,\RW3'[EUA!UP*; 7Q+SQ,[5% M048Y3.8?!S!1N7%/VM1[*

AJF@3O-LA'B)BWNE9]NF%'-,;@(9U9B[5PE.:70 MSTF<)0,($A('27>.DI2F X^=1T@\:L$>E675#U,!,=)/:0,](I('&$4@U&$ M[F7/)#0E<9ZC),L)QAV-*

*!*V1V;ZTOYOKF72Q+SA6D.MWIHO5-F[\";^_:_R> M60ARDB8Q9UZ^R, C?[+.:'3_R'? M<=Q6%D66:6!P9" EW4!*?GH@\<]K-/1BE!:-.6.4U4I,\8]/M1=*P[';]0_' MRJ'1==2-*

PU/W^O_R!X3Y:E"]F#9^7/6UGTXEEC>&'L>=+R&?<.RS?.1N)1"G M),E#MQY!%). IFZ-/PD)8NK6&2:01$GNUKDO)#+(4T4/$%]M+3%'A MMX^?[<;]M7]PS)7%!O?

+%;X7N7874+Y0RNXVSD#W AW_"U!+ P04 " Y M-P99PJM3QCP% !_#@ &0 'AL+W=O"DV98-;8S8[3X,PT!+M"U4$CV2BI/]^CU' MV;},)DZW 0.V() IDG?

WW#UW1-%TH_0GLY+2TEV1E^:LM;)V?=+IF&0F"V': M:BU+K"R4+H3%JUYVS%!+D3JA(N^$OM_K%"(K6Z-3-S?1HU-5V3PKY423J8!" MZ/MSF.O-

62MH[29NLN7\D1G=+H62SF5]L-ZHO'6:,2D62%+DZF2M%R2'SG!4!QN];G:W& M) ONCW?:OW. ^PY>Y,/)"Y3]GJ5V=M08M2N5"5+F]49L?Y-8?!S!1N7%/VM1[*

MNW&+DLI856R%@:#(ROI7W&WCL"+ZW>3R_70\N[I^3T.ZN89.S%HD\JR%(C%2W\K6Z-6+H.>_.8 \;I#'AI2/IG7ID%J0R':5 M" L7Y!TJU,C'L!

{4]CC6V4K20D'Y)BN79#D)MA6;_2'|Z70RV5FDK$PJK0&A M-M.:+$1#/^C19;'.U;V4-+4J^4232B;5;EJ-+,NE4K=590HJ"_9+HP,BK/4N>XL?

AAQ@P'!'U"ZYTFV=T3*YQM_(CV1E.T#V#T:"E+F,L}YXY(49D9 MYPRW&'I)0=3'L^_C$?9[/!%'=*&,9:!&H*Y@@8(!]7P>W"#X C%RRE)YBU:Y*

*M=ID8A/P/N\&09IJ*G%7UA_ST67G4=>-A2,_09IB(UW-1Q![@^ERL#E$Y!@0. M"!P/=TSN"+PJTRJJ^5[% X8V*>4I?]OE/8]O\?!CKU^SS$;>9$?8##P>OWH M:0}C"':""$SW*X>9D$X,/(DVX4 N!GDOM>;]#%;]<+8D=Q[,41#X9>...$U2;5J)UM;B4L.!+L^)H$?S<#]+)DX35W=F;V_K$><]C,>'?+UU!1 - S9T75GD<.'}+,UU!1 - S9T75GD<.'}+,UU!1 - S9T75GD<.'}+,

M< SCB2]TVKKHCWQ;I;W"?$.H0 6L5:C16:16AK>53]N1K&]N]A63JE!HFEM5 M+ +7 /5]S9B\Z^@ ??D9_P902P,$% @ .3<&62T#Y/_!0 B"(!D M !X,"]W;W)K&ULM5IK,^(X%/TK5G:TZD@S39Q M@"X@4?(85E.VIHI_5:K4?W&!-$G,Q 8Z^^O7"6D@./4DJO<+Y"O.;;/Y?KF MDN&>I-_H&F,&7N(HH2-MS=CF2M=IL,8QHI=D@Q-^9T72&#%^FC[K=)-BM,R= MXD@W#L^R" M/AYNT#.^P^QA0"*:?X)]86MH{-A21N++"F8|@#I/# M-WHI%N+$@>/4.YB%@WGNT'G#P2HW-%PB0+Q3N6\KLA]V-CQUW,'B? WLT<7 M~>+/X9#Z=3;Z"V?SN?O%PX\[OP63N@^^NX_I/A,N=WL_BJPX6*&PHA^-)_! MPYT#+CY\!!] F(#[-=E2<ST:=$+N+-]+4JZ,^;HRUZ84v\/=M<@DLXQ,P#;.3,YYIK;CKO8W??Q^{) MW1T<<'?XIKLO=Y^3W24P#^Y0(H55!JF5XUEO#B<-=RC+6>#OK_P>F#$=5;]K)$58.BE3M$#5?=DMGW+[)\I*AU/ M6T6;,+HJ&;VNH&B_W^V=*;J(L:*H72IJ2Q4]2=[;A%?+4? @OU_:95\F\E U(.MRG?KK'3X8SJKD] 6%O0S-(1?I2TL@FE#LVKDU$!U3.-,&Q$)=NQ!U\V2^(4_VU!-L,1W1;&":([FB M$>ST!F=6GG1:,150!%91H%]TS+'I^[V:%.G@12C;56C$LQ1">:J!/-4 M@OF*P"HA,BA#9*!]^AVHC!.58(M^%KE--3BN:K M0JM^?FQT07FG2VF;I."J="VZ8@0H;7TUXG25V;<4Q1.->)}XHE'_-MH R9,O1FOIE/;.])/_O6.O-%"^ZKP*`4O/OR[6%XM7Y%N8Y"|+G%V_AE=36'/=@5?NX:6((_SA'8T;E#Z'7/H(KSB5<=GC MOX#T\-K#X8213ZO^Q-AC,3YX1HC7I%E!OS^BA#V>I(1E"^?C/\#4$L#!!0 M ( #DW!EF6[D@G0 4`!;_9 >&PO=V]R:W-H965T<@X29G]8H,X]T@<75W=B\8'FKZR#<8?;>U5EP0;'B-W1 M+4[$DQ5-8\3%;;I6V3;%*,R-XDC5-(8 MI?_.<40/$P4JQX8GLM[PK$&=CK=HC9>8/V\7J;A3*Y:0Q#AAA"8@Q:N),H/W MOJYE!CGB;X(/K'8-LE=YH?0UN_D23A0M&Q&.<, S"B3^JO@!1U'&),,Q3TFJ M5'UFAO7K(_NO^-C#/$;BE@?'6'LS2P'QK M#U9ID+^Z6KQ[+IR'.]J.4WH :886;-E%KGYN+?0B2>8H2YZ*IT38\;D->WK\M\O@;$BS\) [#\/'ORP;6'.2(1^P1NP?/2]=7G\ 54 ';H!0S0!+PG!#.,FH-.M?VWHCJ$%(U7C?NQRL4@LZ[4H!S0O!B0?F9 !OA*$[YAP$]""$KLO7Y{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{1R\S*F'(TQ>6]J.7 Z!DD@3DM4S7AU3=8^_$U7\Q36?^3}HD-,6-<2L6S M-1C[&Q:D2.,L0IZ+[A^?;A\>?D_O;*3DG4SPD29D"X7/"\A?DBHMW.2EY+FB>R,"K5H1C-Y{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{1R\S*F'(TQ>6]J.7 Z!DD@3DM4S7AU3=8^_$U7\Q36?^3}HD-,6-<2L6S M-1C[&Q:D2.,L0IZ+[A^?;A\>?D_O;*3DG4SPD29D"X7/"\A?DBHMW.2EY+FB>R,"K5H1C-Y{U\(H'\GXO\POB6E^(M8SE>!WQX'#Z"&.%W4?<,DUC@<7899(G89G)K//,0,K=D1DW'92F_+J>227P MH/WN\M<0>MV$^O:)=R8+&,##P=DD0*S"BSP/LP/K:Y? 8_D7WP[K;>W6/LT816 M>*(4"$;3SIULX$$-UU5A%06.W\-=6VU;Z(IRW++"-^J#-.[5Y1[6-:?Q*%RQ? M'%?8D/A,%H+W+K\O;Q>&/H[MXO:#7-OSNL4%K;C@J+@[EC,L#0E9<-Y]28,.:8&_]VT_R@WLRUZWN+ 5%QX5 MM[ER###J5A7O'R79\S^OM2.L(P]EL*/-W*J0^G7Z006>*DE2F'/0N@C1G&@J M?M-1O^B+YHPK+,%U&ULK55= M;],P%/TK51 02*..DW9#)8VT=@.^.<(!R^Y;:PE=K"==I/\5XP[8<A24 MP/X21<IMG=F';G=Y)R66H=M4F!9WS3/U4JNC]#0V#[

*M#2/VN2Q*FK{#Z?*S@>)_&A%H2JBE&K2:_;2EU$W8EP6.CAA.:IZ^PE5L*N4^ M#PETV=36;L>+P+YS'${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`':NEEXU\&%6.!@Q.@:,54MV=2#3E^C95X)4?OD1C#Y-I$X M$5Q\FGR^G*+;LZ 3&]0+0> DY8?H"-W=A*AW<((@.4$+0[9+F').8CTPA1174 MC$}!\T+ >4+ 19>4B"5'4Q)#W((/N_'##KPIS5:.G:WC3\&-.^LBUWB+'`MD_J^^%X5;+[VH^]ZGE)Q'- -WB#0H3'J64YP50M[,9 M%TS^#W]O<^^"T6MG5.?:*5_A';&/+@XL O[*'UKBWLER0+7Y)L^D)D M>\OB54!C>YP!MH)<^Z!%)L5 M)R? #_9JP67/DV\YQ+9UFE>,_JNV9'E:FA]VFYW/0U^V.4<2PD#%@CC!:. 8N MB,,VZP6S;75X{Q,OV2=]RWK=1AZ6Y/8N>=^U3FJ1_$'.[?L-_KV<_"HGOY/I MBL&1BB:BA- ,TB65"\3:RGCSY>&M"?G-9'>78KX74K!HX7LUHV"QR7,NK{Y!F ME>_97FV+F#LW?@9LH5LM+JWE1!2G?S5;=7-GNHFIS9_;IQ.[93Z4W5_1K#W2 M%ZWC)6:+A'"4PEQ*67U?;FE6M&/%0-"5{C=F5,CN13\N90<+3!7(]W-*Q7:@ M!*J>./@-4$L#!!0 (#DW!EG9EJ4Z&0@ #I> 9 >&PO=V]R:W-H M965TYS\2%\I9>37,HS2 MV]8K8ZOK=CN=O=*EGU!%*QKQ=Q9QLO09GTQ>VNDJH?X\#UJ&;462^NVE'T2M M\4T^2RS9W\1K%@81?4A(NEXN_>1C0L/X_,8HBB@4OKRR;T1[?K/P7^DC9 M]]5#PJ?:.V4>+&F4!G%$$KJX;=W)UY[2S0+R%O\$]#W=>TVR57F.XQ_9A#6 M;4G9$M&0SEA&^/S/&YW2,,PDOAP_"[2UZS,+W^^]U?5\Y2G*//LIG<;AO\&< MO=ZVABTRIPM_';)O\;M)BQ7J9=XL#M/\?_*^.=L?M:O M_ZO8$'L:BG(D0"D"E'1)TA IPCHU .D(P'=(J![,D"O".B=&] O OJU@,ZQ M@$$1,#AW*PV+@.&Y/8R*@-&Y/6\'<#'L?& MTZ^>9SUYVOW3{!FF]\GTZ_V3=6]HJU-+>R2?5 MWK09[5L3VK.B'W73CW*D'YEX<<1>4Z)%:0KCD@YHAQ%C!.KLXYV M2'>[>?K&6O@S/,YT=ZRL$ME8Y,*.7NO\ <_YTH_6"WY"727Y M"?\|=C=KV!#NB:D'BQ\36E?,"2_*",SOG%$^-7*(SX*_[> M&Y]QK]ZE)$ZR,S]_\9]@H#41]GKIX0")]4A,0V(Z$C,V6"_'LMM-;V,^?'S; MSW%D=];) {FQD=PX2KLB=H=25.OG9T$SN][J#:C/KL)DRX*UJFMW03.GP M?]5F#G)%723F@;!*8@UVB340)M:#_[&D$2,+?O+S9S_70<+/AD'$_.@E> XI M\=..4L24Y&8AL1Y&8AL1T)68.#4V8]9P];=#O*}):QR&5RD9@' MPBH9.IQE[/#<<>WV'FX^8A7[G!Z=F],QXZ?C@]V]^^^N9PE^XF[]1-C#I3F.Q%0D MIB$Q'8D92,Q$8A82LY&8,SHXE]0N EQD=QX{^2X+)7?H$O"+/\6?_@A^R K-MFLQXDOLOM"F/Q]\R1A:?O2DCJ1_2]%1F"YF+,QNIJ5!-@VHZ5#.@F@G5+*AF0S4' MJKF%=C*S09U6,ULI,ULY,*^R4+(*0SOF _%BJT42,7ISG2$TMM/T1 MEUS=YEI#$T6JW<#1FQI5FQC0!3>AF@75;*CF0#47JGDHK9J/98V6+"P#&=^% M;_$+C8@5S7@"/FR^1.53C(99@2>:7S;SF?PLS#X:$Q-:LP755*BF034=JAE0 MS81J%E2SH9H#U5RHVJ&TZG&AK-^2-U4CL.)-&5K4!=54J*9!-1VJ&5#-A&H6 M5+.AF@/57*CFH,3JD: L^1+%55^__WUV 5?J'"*3ZN'6;$$U':H9 M4,V$:A94LZ&:]5?E"5SBH0=[BO0ZCFHID(U#:KI4,V .B94LZ": M#=4$ MLMQ. 3\338$6V$$U%:H4$V':@94,Z&:!=5Lj.9 -1>]>2BM>B0H"^P48=G. MN:-O9"71%*JI4$V#:C14,PJM\GB5P\'W8:.&L?<9DMW4Z*"5 UU%%ZIY*&V3 M6^V]9RSS ?-+_K#QE,SB=<2R3O;F[AYH?I<_UKDV?Y6O=;EADS0%PTWS+?G: MWC0$Q.QV\U1UST}>@B@E(5WP19"N!OPR*=D\['PSP>)5_N3GYYCQ47{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

;T>]G4!O1{V=0&]'O9U ;Q]]K"30VU%O)}#;46\GT-M1;R?0 MVU%O)} [4.\@T#M0[R#0.U#O(- [4.\@T#M0[R#0.U#O(- [1C^;'$.@=]'<0 MZ!VH=Q#H':AW_*3>=?
C:EWKM^5[C3T$_2?5POK=<'W]9?I}$G!<7G--M17WZ M"U!+ P04 " Y-P99UD@C+OLG#]%N@"VPX =,,J51D}BR72A_CY,"$@@] M4)&XFT:M[;D3CW16/;]{]A0GVZ[MX[Q8I>3/&
(O5BCH;2^>ISRM+%SJ;\M:P MP+RMUO:!F)C-#*M/C4=Y0L"\3AI7O U[/W3Q2"$U-DUL, MTK7M\BZV;5E,SRW\Y[J39>/E-$'LG5<$;6N+7=%C_8GIWS# MM/OD!^>/9?8%YIVWP?
F8)Q;H]W%O(QE.3WTN1"$U^U_Q/3&7/OC}:)AV3?4/ ML_/U/KFP'N<1V?@X_(X_SOB]_B_[$"]!2) ^%$@?&J0/]+',4@?)R!]G(+T MP6&UL4$L! A0#% @ .3<& M6912+1OO *P(!$ (
!KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ .3<&69E&PO=V]R:W-H965T&UL4$L! A0#% @ .3<&636;N1:H" C2< !@ ("! M8 X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
M.3<&6?6;'0JA P F T !@ ("!.", 'AL+W=O&PO=V]R M:W-H965T&UL4$L! A0#% @ .3<&6;I:L6=)$P .C< M !@ ("! D, 'AL+W=O 8 " @8%6 !X M;"]W;W)K&PO=V]R:W-
H965T&UL4$L! A0#% @ .3<& M68E/A\P&"0 RA< !D ("!Y6\ 'AL+W=O0 >&PO=V]R:W-H965T&UL4$L! A0#% @ .3<&61)G?7?> P %P@ M !D ("!;X< 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ .3<&6=>\&0RX"@ 6Q\ !D M ("!-IT 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ .3<&6>VW>5: "P PB !D ("!X,P 'AL+W=O M&PO=V]R:W-
H965T&UL4$L! A0#% @ .3<&6;/8 MZ:%A @ 1 4 !D ("!'>@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .3<&69TF*8&<$ O3$!D M ("!Z^\ 'AL+W=O&PO M=V]R:W-
H965T&UL4$L! A0#% @ .3<&65BIT:RM P [@@ !D ("! M=@L! 'AL+W=O&PO=V]R:W-H965TP0 (T* 9 M " @3H2 0!X;"]W;W)K&UL4$L! A0#% M @ .3<&6<*K4\8\!0 ?PX !D ("![!8!
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .3<&67'AZ?4C M!@ M X !D ("!6B0! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .3<&64\WEQX!_AH !D M ("!X#(!
'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ .3<&6.,[:=0R!0 H1T !D ("!OT$! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M.3<&65S-I%&PO=V]R:W-
H965T&UL4$L! A0#% @ .3<&681L%=:" @ ZP8 !D M ("!M6D! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ .3<&66#$+=,[@ IPD !D ("!=WD! 'AL M+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ .3<& M6>X9WDB" P ,!$!D ("!&XT! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .3<&6251,+C,! 6QT M !D ("!AYD! 'AL+W=O&PO=V]R:W-H965T 9 "
@0BB 0!X;"]W;W)K&UL4$L! A0#% @ .3<&67 /N!Y]\0 !2P !D M ("!6*H! 'AL+W=O&PO=V]R:W-H965T M 9 M " @<"T 0!X;"]W;W)K&UL4$L! A0# M% @ .3<&6>!Q^3S;"0 H'T !D
("!N[D! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ .3<&63FL ME93> 0 P@0 !D ("!2M ! 'AL+W=O&PO&UL+G)E;'-02P$'"% ,4 " Y M-P99UD@C+O XML 81 Show.js IDEA:
XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the
scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w)
{if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?
w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p,,if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 82 report.css IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }
.report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color:
#2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height:
150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */
.report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px
solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color:
#000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /*
word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover {
background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0;
} /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-
color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */
.report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; }
.report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width:
17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; }
.report .outerFootnotes { font-size: 1em; } XML 84 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 359 337 1 false 99 0 false 16 false false R1.htm 0000001 -
Document - Cover Sheet http://www.anipharmaceuticals.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - Condensed Consolidated Balance Sheets Sheet
http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 9952152 - Statement
- Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed
Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Condensed Consolidated Statements of Operations Sheet
http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm
9952154 - Statement - Condensed Consolidated Statements of Comprehensive (Loss) Income Sheet
http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome Condensed Consolidated Statements of Comprehensive (Loss)
Income Statements 5 false false R6.htm 9952155 - Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity Sheet
http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity Condensed Consolidated Statements of
Changes in Mezzanine Equity and Stockholders' Equity Statements 6 false false R7.htm 9952156 - Statement - Condensed Consolidated Statements of Cash Flows Sheet
http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm
9952157 - Disclosure - BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS Sheet
http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTS BUSINESS, PRESENTATION, AND RECENT ACCOUNTING
PRONOUNCEMENTS Notes 8 false false R9.htm 9952158 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES Sheet
http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCES REVENUE RECOGNITION AND RELATED ALLOWANCES Notes 9 false false
R10.htm 9952159 - Disclosure - PENDING MERGER AGREEMENT Sheet http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENT PENDING MERGER
AGREEMENT Notes 10 false false R11.htm 9952160 - Disclosure - RESTRUCTURING Sheet http://www.anipharmaceuticals.com/role/RESTRUCTURING RESTRUCTURING
Notes 11 false false R12.htm 9952161 - Disclosure - INDEBTEDNESS Sheet http://www.anipharmaceuticals.com/role/INDEBTEDNESS INDEBTEDNESS Notes 12 false false
R13.htm 9952162 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY Sheet
http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITY DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY
Notes 13 false false R14.htm 9952163 - Disclosure - EARNINGS PER SHARE Sheet http://www.anipharmaceuticals.com/role/EARNINGSPERSHARE EARNINGS PER SHARE
Notes 14 false false R15.htm 9952164 - Disclosure - INVENTORIES Sheet http://www.anipharmaceuticals.com/role/INVENTORIES INVENTORIES Notes 15 false false R16.htm
9952165 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETS GOODWILL AND
INTANGIBLE ASSETS Notes 16 false false R17.htm 9952166 - Disclosure - MEZZANINE AND STOCKHOLDERS' EQUITY Sheet
http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITY MEZZANINE AND STOCKHOLDERS' EQUITY Notes 17 false false R18.htm 9952167 -
Disclosure - STOCK-BASED COMPENSATION Sheet http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 18 false
false R19.htm 9952168 - Disclosure - INCOME TAXES Sheet http://www.anipharmaceuticals.com/role/INCOMETAXES INCOME TAXES Notes 19 false false R20.htm 9952169 -
Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND
CONTINGENCIES Notes 20 false false R21.htm 9952170 - Disclosure - FAIR VALUE DISCLOSURES Sheet http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURES
FAIR VALUE DISCLOSURES Notes 21 false false R22.htm 9952171 - Disclosure - RELATED PARTY TRANSACTIONS Sheet
http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 22 false false R23.htm 9952172 - Disclosure - SEGMENT
REPORTING Sheet http://www.anipharmaceuticals.com/role/SEGMENTREPORTING SEGMENT REPORTING Notes 23 false false R24.htm 9952173 - Disclosure - SUBSEQUENT
EVENTS Sheet http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 24 false false R25.htm 995410 - Disclosure - Pay vs Performance
Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 25 false false R26.htm 995445 - Disclosure - Insider Trading Arrangements
Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 26 false false R27.htm 9954471 - Disclosure - BUSINESS,
PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies) Sheet
http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies BUSINESS, PRESENTATION, AND RECENT
ACCOUNTING PRONOUNCEMENTS (Policies) Policies 27 false false R28.htm 9954472 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables) Sheet
http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTables REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables) Tables
http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCES 28 false false R29.htm 9954473 - Disclosure - INDEBTEDNESS (Tables) Sheet
http://www.anipharmaceuticals.com/role/INDEBTEDNESSTables INDEBTEDNESS (Tables) Tables http://www.anipharmaceuticals.com/role/INDEBTEDNESS 29 false false
R30.htm 9954474 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.anipharmaceuticals.com/role/EARNINGSPERSHARETables EARNINGS PER SHARE (Tables)
Tables http://www.anipharmaceuticals.com/role/EARNINGSPERSHARE 30 false false R31.htm 9954475 - Disclosure - INVENTORIES (Tables) Sheet
http://www.anipharmaceuticals.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://www.anipharmaceuticals.com/role/INVENTORIES 31 false false R32.htm
9954476 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSTables GOODWILL
AND INTANGIBLE ASSETS (Tables) Tables http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETS 32 false false R33.htm 9954477 - Disclosure -
STOCK-BASED COMPENSATION (Tables) Sheet http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables)
Tables http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATION 33 false false R34.htm 9954478 - Disclosure - FAIR VALUE DISCLOSURES (Tables) Sheet
http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESTables FAIR VALUE DISCLOSURES (Tables) Tables
http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURES 34 false false R35.htm 9954479 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) Sheet
http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSTables RELATED PARTY TRANSACTIONS (Tables) Tables
http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS 35 false false R36.htm 9954480 - Disclosure - SEGMENT REPORTING (Tables) Sheet
http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGTables SEGMENT REPORTING (Tables) Tables http://www.anipharmaceuticals.com/role/SEGMENTREPORTING
36 false false R37.htm 9954481 - Disclosure - BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Details) Sheet
http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSDetails BUSINESS, PRESENTATION, AND RECENT
ACCOUNTING PRONOUNCEMENTS (Details) Details
http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies 37 false false R38.htm 9954482 - Disclosure -
REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) Sheet
http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails REVENUE RECOGNITION AND RELATED ALLOWANCES
- Disaggregation (Details) Details 38 false false R39.htm 9954483 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Timing (Details) Sheet
http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails REVENUE RECOGNITION AND RELATED ALLOWANCES - Timing
(Details) Details http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTables 39 false false R40.htm 9954484 - Disclosure - REVENUE
RECOGNITION AND RELATED ALLOWANCES - Allowances (Details) Sheet
http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails REVENUE RECOGNITION AND RELATED ALLOWANCES -
Allowances (Details) Details 40 false false R41.htm 9954485 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Concentration (Details) Sheet
http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails REVENUE RECOGNITION AND RELATED ALLOWANCES -
Concentration (Details) Details 41 false false R42.htm 9954486 - Disclosure - PENDING MERGER AGREEMENT (Details) Sheet
http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails PENDING MERGER AGREEMENT (Details) Details
http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENT 42 false false R43.htm 9954487 - Disclosure - RESTRUCTURING (Details) Sheet
http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails RESTRUCTURING (Details) Details http://www.anipharmaceuticals.com/role/RESTRUCTURING 43 false
false R44.htm 9954488 - Disclosure - INDEBTEDNESS - Credit facility (Details) Sheet http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails
INDEBTEDNESS - Credit facility (Details) Details 44 false false R45.htm 9954489 - Disclosure - INDEBTEDNESS - Facility components (Details) Sheet
http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails INDEBTEDNESS - Facility components (Details) Details 45 false false R46.htm 9954490 -
Disclosure - INDEBTEDNESS - Maturity of credit facility (Details) Sheet http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails
INDEBTEDNESS - Maturity of credit facility (Details) Details 46 false false R47.htm 9954491 - Disclosure - INDEBTEDNESS - Interest (Details) Sheet
http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails INDEBTEDNESS - Interest (Details) Details 47 false false R48.htm 9954492 - Disclosure -

DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY (Details) Sheet
http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY (Details) Details http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITY 48 false false R49.htm 9954493 - Disclosure - EARNINGS PER SHARE (Details) Sheet http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails EARNINGS PER SHARE (Details) Details http://www.anipharmaceuticals.com/role/EARNINGSPERSHARETables 49 false false R50.htm 9954494 - Disclosure - INVENTORIES - Schedule of inventory (Details) Sheet http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails INVENTORIES - Schedule of inventory (Details) Details 50 false false R51.htm 9954495 - Disclosure - INVENTORIES - Concentration (Details) Sheet http://www.anipharmaceuticals.com/role/INVENTORIESConcentrationDetails INVENTORIES - Concentration (Details) Details 51 false false R52.htm 9954496 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details) Sheet http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details) Details 52 false false R53.htm 9954497 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Components (Details) Sheet http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails GOODWILL AND INTANGIBLE ASSETS - Components (Details) Details 53 false false R54.htm 9954498 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Amortization (Details) Sheet http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails GOODWILL AND INTANGIBLE ASSETS - Amortization (Details) Details 54 false false R55.htm 9954499 - Disclosure - MEZZANINE AND STOCKHOLDERS' EQUITY (Details) Sheet http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails MEZZANINE AND STOCKHOLDERS' EQUITY (Details) Details http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITY 55 false false R56.htm 9954500 - Disclosure - STOCK-BASED COMPENSATION - Expense (Details) Sheet http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails STOCK-BASED COMPENSATION - Expense (Details) Details 56 false false R57.htm 9954501 - Disclosure - STOCK-BASED COMPENSATION - Information (Details) Sheet http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails STOCK-BASED COMPENSATION - Information (Details) Details 57 false false R58.htm 9954502 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 58 false false R59.htm 9954503 - Disclosure - STOCK-BASED COMPENSATION - Option activity (Details) Sheet http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails STOCK-BASED COMPENSATION - Option activity (Details) Details 59 false false R60.htm 9954504 - Disclosure - STOCK-BASED COMPENSATION - Non-option activity (Details) Sheet http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNonoptionactivityDetails STOCK-BASED COMPENSATION - Non-option activity (Details) Details 60 false false R61.htm 9954505 - Disclosure - INCOME TAXES (Details) Sheet http://www.anipharmaceuticals.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.anipharmaceuticals.com/role/INCOMETAXES 61 false false R62.htm 9954506 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIES 62 false false R63.htm 9954507 - Disclosure - FAIR VALUE DISCLOSURES - Narrative (Details) Sheet http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails FAIR VALUE DISCLOSURES - Narrative (Details) Details 63 false false R64.htm 9954508 - Disclosure - FAIR VALUE DISCLOSURES - Level 3 (Details) Sheet http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details FAIR VALUE DISCLOSURES - Level 3 (Details) Details 64 false false R65.htm 9954509 - Disclosure - FAIR VALUE DISCLOSURES - Hierarchy (Details) Sheet http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails FAIR VALUE DISCLOSURES - Hierarchy (Details) Details 65 false false R66.htm 9954510 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED PARTY TRANSACTIONS (Details) Details http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSTables 66 false false R67.htm 9954511 - Disclosure - SEGMENT REPORTING - Revenue (Details) Sheet http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails SEGMENT REPORTING - Revenue (Details) Details 67 false false R68.htm 9954512 - Disclosure - SEGMENT REPORTING - Geographic (Details) Sheet http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails SEGMENT REPORTING - Geographic (Details) Details 68 false false R9999.htm Uncategorized Items - anip-20240630.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - anip-20240630.htm Cover 69 false false All Reports Book All Reports anip-20240630.htm anip-20240630.xsd anip-20240630_cal.xml anip-20240630_def.xml anip-20240630_lab.xml anip-20240630_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 87 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "anip-20240630.htm": { "nsprefix": "anip", "nsuri": "http://www.anipharmaceuticals.com/20240630", "dts": { "inline": { "local": ["anip-20240630.htm"] }, "schema": { "local": ["anip-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["anip-20240630_cal.xml"] }, "definitionLink": { "local": ["anip-20240630_def.xml"] }, "labelLink": { "local": ["anip-20240630_lab.xml"] }, "presentationLink": { "local": ["anip-20240630_pre.xml"] } }, "keyStandard": 296, "keyCustom": 41, "axisStandard": 38, "axisCustom": 1, "memberStandard": 42, "memberCustom": 55, "hidden": { "total": 23, "http://fasb.org/us-gaap/2024": 18, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 359, "entityCount": 1, "segmentCount": 99, "elementCount": 706, "unitCount": 16, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1063, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.anipharmaceuticals.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets", "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R3": { "role": "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:PreferredStockSharesOutstanding", "us-gaap:PreferredStockSharesOutstanding", "us-gaap:PreferredStockSharesIssued", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R4": { "role": "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations", "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef", "c-12", "name", "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil", "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R5": { "role": "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome", "longName": "9952154 - Statement - Condensed Consolidated Statements of Comprehensive (Loss) Income", "shortName": "Condensed Consolidated Statements of Comprehensive (Loss) Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R6": { "role": "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity", "longName": "9952155 - Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity", "shortName": "Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-51", "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-51", "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "9952156 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTS", "longName": "9952157 - Disclosure - BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS", "shortName": "BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCES", "longName": "9952158 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES", "shortName": "REVENUE RECOGNITION AND RELATED ALLOWANCES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENT", "longName": "9952159 - Disclosure - PENDING MERGER AGREEMENT", "shortName": "PENDING MERGER AGREEMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"],

"reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.anipharmaceuticals.com/role/RESTRUCTURING", "longName": "9952160 - Disclosure - RESTRUCTURING", "shortName": "RESTRUCTURING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.anipharmaceuticals.com/role/INDEBTEDNESS", "longName": "9952161 - Disclosure - INDEBTEDNESS", "shortName": "INDEBTEDNESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITY", "longName": "9952162 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY", "shortName": "DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.anipharmaceuticals.com/role/EARNINGSPERSHARE", "longName": "9952163 - Disclosure - EARNINGS PER SHARE", "shortName": "EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.anipharmaceuticals.com/role/INVENTORIES", "longName": "9952164 - Disclosure - INVENTORIES", "shortName": "INVENTORIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETS", "longName": "9952165 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITY", "longName": "9952166 - Disclosure - MEZZANINE AND STOCKHOLDERS' EQUITY", "shortName": "MEZZANINE AND STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATION", "longName": "9952167 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.anipharmaceuticals.com/role/INCOMETAXES", "longName": "9952168 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "9952169 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURES", "longName": "9952170 - Disclosure - FAIR VALUE DISCLOSURES", "shortName": "FAIR VALUE DISCLOSURES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS", "longName": "9952171 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.anipharmaceuticals.com/role/SEGMENTREPORTING", "longName": "9952172 - Disclosure - SEGMENT REPORTING", "shortName": "SEGMENT REPORTING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTS", "longName": "9952173 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-12", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies", "longName": "9954471 - Disclosure - BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies)", "shortName": "BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTables", "longName": "9954472 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)", "shortName": "REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.anipharmaceuticals.com/role/INDEBTEDNESSTables", "longName": "9954473 - Disclosure - INDEBTEDNESS (Tables)", "shortName": "INDEBTEDNESS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.anipharmaceuticals.com/role/EARNINGSPERSHARETables", "longName": "9954474 - Disclosure - EARNINGS PER SHARE (Tables)", "shortName": "EARNINGS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.anipharmaceuticals.com/role/INVENTORIESTables", "longName": "9954475 - Disclosure - INVENTORIES (Tables)", "shortName": "INVENTORIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType":

"tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSTables", "longName": "9954476 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables", "longName": "9954477 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESTables", "longName": "9954478 - Disclosure - FAIR VALUE DISCLOSURES (Tables)", "shortName": "FAIR VALUE DISCLOSURES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSTables", "longName": "9954479 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)", "shortName": "RELATED PARTY TRANSACTIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGTables", "longName": "9954480 - Disclosure - SEGMENT REPORTING (Tables)", "shortName": "SEGMENT REPORTING (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSDetails", "longName": "9954481 - Disclosure - BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Details)", "shortName": "BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-4", "name": "anip:NumberOfPharmaceuticalManufacturingFacilities", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": null }, "R38": { "role": "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails", "longName": "9954482 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details)", "shortName": "REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-74", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R39": { "role": "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails", "longName": "9954483 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Timing (Details)", "shortName": "REVENUE RECOGNITION AND RELATED ALLOWANCES - Timing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R40": { "role": "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails", "longName": "9954484 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Allowances (Details)", "shortName": "REVENUE RECOGNITION AND RELATED ALLOWANCES - Allowances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-111", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "anip:ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R41": { "role": "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails", "longName": "9954485 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Concentration (Details)", "shortName": "REVENUE RECOGNITION AND RELATED ALLOWANCES - Concentration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-126", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-126", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails", "longName": "9954486 - Disclosure - PENDING MERGER AGREEMENT (Details)", "shortName": "PENDING MERGER AGREEMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-143", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-143", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails", "longName": "9954487 - Disclosure - RESTRUCTURING (Details)", "shortName": "RESTRUCTURING (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-4", "name": "anip:NumberOfPharmaceuticalManufacturingFacilities", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-162", "name": "anip:DisposalGroupIncludingDiscontinuedOperationsTransactionCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R44": { "role": "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails", "longName": "9954488 - Disclosure - INDEBTEDNESS - Credit facility (Details)", "shortName": "INDEBTEDNESS - Credit facility (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-168", "name": "us-gaap:PaymentsOfDebtIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-168", "name": "us-gaap:PaymentsOfDebtIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails", "longName": "9954489 - Disclosure - INDEBTEDNESS - Facility components (Details)", "shortName": "INDEBTEDNESS - Facility components (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-170", "name": "anip:LongTermDebtGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R46": { "role": "http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails", "longName": "9954490 - Disclosure - INDEBTEDNESS - Maturity of credit facility (Details)", "shortName": "INDEBTEDNESS - Maturity of credit facility (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-172", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-172", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails", "longName": "9954491 - Disclosure - INDEBTEDNESS - Interest (Details)", "shortName": "INDEBTEDNESS - Interest (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails", "longName": "9954492 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY (Details)", "shortName": "DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InterestRateDerivativeAssetsAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-173", "name": "us-gaap:DerivativeLiabilityNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R49": { "role":

"http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails", "longName": "9954493 - Disclosure - EARNINGS PER SHARE (Details)", "shortName": "EARNINGS PER SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R50": { "role": "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails", "longName": "9954494 - Disclosure - INVENTORIES - Schedule of inventory (Details)", "shortName": "INVENTORIES - Schedule of inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.anipharmaceuticals.com/role/INVENTORIESConcentrationDetails", "longName": "9954495 - Disclosure - INVENTORIES - Concentration (Details)", "shortName": "INVENTORIES - Concentration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-179", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-179", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails", "longName": "9954496 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportingUnits", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R53": { "role": "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails", "longName": "9954497 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Components (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Components (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R54": { "role": "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails", "longName": "9954498 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Amortization (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails", "longName": "9954499 - Disclosure - MEZZANINE AND STOCKHOLDERS' EQUITY (Details)", "shortName": "MEZZANINE AND STOCKHOLDERS' EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-198", "name": "us-gaap:PreferredStockDividendRatePercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R56": { "role": "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails", "longName": "9954500 - Disclosure - STOCK-BASED COMPENSATION - Expense (Details)", "shortName": "STOCK-BASED COMPENSATION - Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-201", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-202", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R57": { "role": "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails", "longName": "9954501 - Disclosure - STOCK-BASED COMPENSATION - Information (Details)", "shortName": "STOCK-BASED COMPENSATION - Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-224", "name": "anip:NumberOfAnnualInstallments", "unitRef": "installment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-224", "name": "anip:NumberOfAnnualInstallments", "unitRef": "installment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "longName": "9954502 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-232", "name": "anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-232", "name": "anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails", "longName": "9954503 - Disclosure - STOCK-BASED COMPENSATION - Option activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Option activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-264", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-264", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNonoptionactivityDetails", "longName": "9954504 - Disclosure - STOCK-BASED COMPENSATION - Non-option activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Non-option activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:TreasuryStockCommonValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-265", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R61": { "role": "http://www.anipharmaceuticals.com/role/INCOMETAXESDetails", "longName": "9954505 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R62": { "role": "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails", "longName": "9954506 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-272", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-272", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails", "longName": "9954507 - Disclosure - FAIR VALUE DISCLOSURES - Narrative (Details)", "shortName": "FAIR VALUE DISCLOSURES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "anip:AchievementOfMilestonesPaymentPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R64": { "role": "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details", "longName": "9954508 - Disclosure - FAIR VALUE DISCLOSURES - Level 3 (Details)", "shortName": "FAIR VALUE DISCLOSURES - Level 3 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-40", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-40", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails", "longName": "9954509 - Disclosure - FAIR VALUE DISCLOSURES - Hierarchy (Details)", "shortName": "FAIR VALUE DISCLOSURES - Hierarchy (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",

```
"decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-
gaap:EquitySecuritiesFvNiCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-
gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "anip-
20240630.htm", "unique": true } }, "R66": { "role": "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails", "longName": "9954510 - Disclosure -
RELATED PARTY TRANSACTIONS (Details)", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-4", "name": "anip:NumberOfExecutiveFounders", "unitRef": "founder", "xsiNil": "false", "lang":
"en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true }, "uniqueAnchor":
{ "contextRef": "c-323", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3",
"ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef":
"anip-20240630.htm", "unique": true } }, "R67": { "role": "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails", "longName": "9954511 - Disclosure
- SEGMENT REPORTING - Revenue (Details)", "shortName": "SEGMENT REPORTING - Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false",
"lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true },
"uniqueAnchor": { "contextRef": "c-335", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",
"decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ],
"reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R68": { "role": "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails",
"longName": "9954512 - Disclosure - SEGMENT REPORTING - Geographic (Details)", "shortName": "SEGMENT REPORTING - Geographic (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-12", "name": "us-
gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table",
"div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true },
"uniqueAnchor": { "contextRef": "c-347", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",
"decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html"
], "reportCount": 1, "baseRef": "anip-20240630.htm", "unique": true } }, "R9999": { "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "longName": "Uncategorized Items -
anip-20240630.htm", "shortName": "Uncategorized Items - anip-20240630.htm", "isDefault": "false", "groupType": "", "subGroupType": "", "menuCat": "Cover", "order": "69",
"firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RestrictedCashCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td",
"tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-
gaap:RestrictedCashCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ],
"reportCount": 1, "baseRef": "anip-20240630.htm", "first": true, "unique": true } } }, "tag": { "anip_A2026MilestonePaymentMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.anipharmaceuticals.com/20240630", "localname": "A2026MilestonePaymentMember", "presentation": [
"http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026 Milestone Payment", "label": "2026
Milestone Payment [Member]", "documentation": "2026 Milestone Payment" } } }, "auth_ref": [] }, "anip_A2027MilestonePaymentMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "A2027MilestonePaymentMember", "presentation": [
"http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027 Milestone Payment", "label": "2027
Milestone Payment [Member]", "documentation": "2027 Milestone Payment" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label":
"Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-
gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets",
"http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "terseLabel":
"Outstanding balances", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have
typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due
within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r78", "r899" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts
Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } },
"auth_ref": [ "r823" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-
gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": {
"role": { "terseLabel": "Accounts receivable, net of $102,784 and $97,262 of adjustments for chargebacks and other allowances at June\u00a030, 2024 and December\u00a031,
2023, respectively", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to
consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1061" ] },
"anip_AccruedGovernmentRebates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "AccruedGovernmentRebates",
"crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0,
"order": 6.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued
government rebates", "label": "Accrued Government Rebates", "documentation": "Represents amounts accrued for government rebates." } } }, "auth_ref": [] }, "us-
gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit",
"calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } },
"presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses and
other", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are
statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples
include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } },
"auth_ref": [ "r81" ] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrent",
"crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0,
"order": 4.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued
royalties", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for
royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r81", "r842" ] }, "us-
gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": {
"parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets",
"http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated
other comprehensive income, net of tax", "terseLabel": "Accumulated other comprehensive (loss) income, net of tax", "label": "Accumulated Other Comprehensive Income
(Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner
source." } } }, "auth_ref": [ "r24", "r25", "r100", "r176", "r633", "r674", "r675" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel":
"Accumulated Other Comprehensive Income, Net of Tax", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from
transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from
transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r12", "r25", "r516", "r519", "r565", "r670", "r671", "r1033", "r1034",
"r1035", "r1047", "r1048", "r1049", "r1050" ] }, "anip_AchievementOfMilestonesPaymentPeriod": { "xbrltype": "durationItemType", "nsuri":
"http://www.anipharmaceuticals.com/20240630", "localname": "AchievementOfMilestonesPaymentPeriod", "presentation": [
"http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Achievement of milestones payment
period", "label": "Achievement of Milestones Payment Period", "documentation": "Achievement of Milestones Payment Period" } } }, "auth_ref": [] },
"anip_AcquiredAndaIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"AcquiredAndaIntangibleAssetsMember", "presentation": [ "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Acquired ANDAs intangible assets", "label": "Acquired ANDAs intangible assets", "documentation": "Acquired ANDAs intangible assets" } } },
"auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure",
"label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r968" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation":
[ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Additional paid-in capital", "label":
"Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder.
Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r92", "r899", "r1196" ] }, "us-
gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember",
"presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" ], "lang": { "en-us": {
"role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the
entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r692", "r1047", "r1048", "r1049", "r1050",
"r1131", "r1197" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation
Amount" } } }, "auth_ref": [ "r981" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to
Compensation [Axis]" } } }, "auth_ref": [ "r981" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to
Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r981" ] },
"ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO
Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r981" ] }, "us-
gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Adjustments to reconcile net
income to net cash and cash equivalents provided by operating activities:", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used
in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel":
"Stock-based Compensation Expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional
paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r53", "r54", "r439" ] },
"anip_AdministrativeFeesAndOtherRebatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"AdministrativeFeesAndOtherRebatesMember", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Administrative
Fees and Other Rebates", "label": "Administrative Fees and Other Rebates", "documentation": "Administrative Fees and Other Rebates" } } }, "auth_ref": [] },
"ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of
Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1014" ] }, "ecd_AggtErrCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r940", "r950",
"r960", "r992" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate
Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r943", "r953", "r963",
"r995" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate
Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1015" ] }, "anip_AlimeraSciencesIncMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.anipharmaceuticals.com/20240630", "localname": "AlimeraSciencesIncMember", "presentation": [
"http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alimera Sciences, Inc", "label": "Alimera
Sciences, Inc [Member]", "documentation": "Alimera Sciences, Inc" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r981" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r988" ] }, "ecd_AllIndividualsMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r944", "r954",
"r964", "r988", "r996", "r1000", "r1008" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading
Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r1006" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Allocated share-based compensation
expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount
capitalized." } } }, "auth_ref": [ "r469", "r474" ] }, "anip_AllowancesForSalesReturnsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.anipharmaceuticals.com/20240630", "localname": "AllowancesForSalesReturnsMember", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Returns",
"label": "Returns", "documentation": "Allowances For Sales Returns" } } }, "auth_ref": [] }, "anip_AlvogenIncMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.anipharmaceuticals.com/20240630", "localname": "AlvogenIncMember", "presentation": [
"http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alvogen Inc", "label": "Alvogen Inc
[Member]", "documentation": "Alvogen Inc" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"AmendmentFlag", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment flag", "label": "Amendment
Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-
gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit",
"calculation": { "http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 2.0 } },
"presentation": [ "http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of finance fees", "label":
"Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r105", "r390", "r1039",
"r1148" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest", "label":
"Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." }
} }, "auth_ref": [ "r390", "r869", "r870", "r1039", "r1148" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [
"http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization of intangible
assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical
assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to
net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r317", "r324", "r861" ] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive shares diluted earnings (loss) per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of
Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings
per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU
amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r251" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [
"http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset
Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r318", "r319", "r320", "r321", "r322", "r1127" ] }, "us-
gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [
"http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label":
"Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r318", "r319", "r320", "r321", "r322", "r1127" ] }, "us-gaap_Assets": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets",
"documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r140", "r149", "r169", "r204", "r255", "r263", "r281", "r285", "r297",
"r357", "r358", "r360", "r361", "r362", "r363", "r364", "r366", "r367", "r508", "r512", "r548", "r627", "r736", "r854", "r855", "r899", "r931", "r1090", "r1091", "r1153" ] }, "us-
gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Assets", "label": "Assets [Abstract]" } } },
"auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit",
"calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label":
"Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r163", "r179", "r204",
"r297", "r357", "r358", "r360", "r361", "r362", "r363", "r364", "r366", "r367", "r508", "r512", "r548", "r899", "r1090", "r1091", "r1153" ] }, "us-gaap_AssetsCurrentAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current Assets", "label": "Assets, Current
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSDetails",
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets", "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails",
"http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Assets held for sale", "label": "Asset, Held-
for-Sale, Not Part of Disposal Group, Current", "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the
normal operating cycle, if longer." } } }, "auth_ref": [ "r122", "r899" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us":
{ "role": { "terseLabel": "Non-current Assets", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1003" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1004" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line
Items]" } } }, "auth_ref": [ "r999" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing,
How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r999" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } },
"auth_ref": [ "r999" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing
MNPI Considered [Flag]" } } }, "auth_ref": [ "r999" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award
Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r999" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ],
"lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r999" ] }, "us-
gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
```

```
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNonoptionactivityDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": {
"role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } },
"auth_ref": [ "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463",
"r464", "r465", "r466", "r467", "r468" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities",
"label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r1002" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": {
"role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1001" ] }, "ecd_AwardsCloseToMnpiDiscTable": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time
to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r1000" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-
us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [
"r1000" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BasisOfAccountingPolicyPolicyTextBlock", "presentation": [
"http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of
presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } },
"auth_ref": [] }, "anip_BioSantePharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"BioSantePharmaceuticalsMember", "presentation": [ "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "BioSante Pharmaceuticals", "label": "BioSante Pharmaceuticals [Member]", "documentation": "BioSante Pharmaceuticals" } } }, "auth_ref": [] }, "us-
gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain",
"presentation": [ "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails",
"http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails",
"http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails",
"http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails", "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of
the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the
acquiree." } } }, "auth_ref": [ "r318", "r319", "r320", "r321", "r322", "r501", "r882", "r883" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [
"http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails", "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails",
"http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails",
"http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails", "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or
series of individually immaterial business combinations." } } }, "auth_ref": [ "r56", "r57", "r318", "r319", "r320", "r321", "r322", "r501", "r882", "r883" ] }, "us-
gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [
"http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label":
"Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r501" ] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionSharePrice", "presentation": [
"http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition, share price (in dollars
per share)", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business
combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [
"http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Business
Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have
been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative
costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [
"r55" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" }
} }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } },
"presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent
consideration fair value adjustment", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
"documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } },
"auth_ref": [ "r504", "r1038" ] }, "anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight":
1.0, "order": 2.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel":
"Contingent consideration fair value adjustment", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration,
Liability, Cash Flow", "documentation": "Cash flow impact of amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to,
differences arising upon settlement." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr":
"credit", "presentation": [ "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional
contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent
consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted)
of the consideration which may be paid." } } }, "auth_ref": [ "r60" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails", "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of
liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r59", "r134", "r503", "r529", "r530", "r531" ] }, "us-
gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current contingent consideration", "label":
"Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business
combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r59", "r134" ] }, "us-
gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [
"http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Unobservable inputs", "label": "Business
Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business
combination." } } }, "auth_ref": [ "r529", "r530", "r531" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current contingent consideration", "label":
"Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a
business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r59", "r134" ] }, "us-
gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENT" ], "lang": { "en-us": { "role": {
"terseLabel": "PENDING MERGER AGREEMENT", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business
combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.
The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r133", "r502" ] }, "anip_BusinessCombinationDivisibleRevenue": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "BusinessCombinationDivisibleRevenue", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, divisible revenue",
"label": "Business Combination, Divisible Revenue", "documentation": "Business Combination, Divisible Revenue" } } }, "auth_ref": [] },
"anip_BusinessCombinationMilestonePaymentMultiplier": { "xbrltype": "perShareItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"BusinessCombinationMilestonePaymentMultiplier", "presentation": [ "http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Business combination, milestone payment multiplier", "label": "Business Combination, Milestone Payment Multiplier", "documentation": "Business
Combination, Milestone Payment Multiplier" } } }, "auth_ref": [] }, "anip_BusinessCombinationNumberOfContingentValueRightsToBeReceived": { "xbrltype":
"integerItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "BusinessCombinationNumberOfContingentValueRightsToBeReceived",
"presentation": [ "http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination,
number of contingent value rights to be received", "label": "Business Combination, Number of Contingent Value Rights to be Received", "documentation": "Business
Combination, Number of Contingent Value Rights to be Received" } } }, "auth_ref": [] }, "anip_BusinessCombinationProxyPreparationAndFilingPeriodFollowingMerger": {
"xbrltype": "durationItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"BusinessCombinationProxyPreparationAndFilingPeriodFollowingMerger", "presentation": [ "http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Proxy preparation and filing period following merger", "label": "Business Combination, Proxy Preparation and Filing Period
Following Merger", "documentation": "Business Combination, Proxy Preparation and Filing Period Following Merger" } } }, "auth_ref": [] }, "country_CA": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CA", "presentation": [
```

```
"http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canada", "label": "CANADA" } } }, "auth_ref": [] }, "anip_CGOncologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "CGOncologyMember", "presentation": [ "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CG Oncology", "label": "CG Oncology [Member]", "documentation": "CG Oncology" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and equipment purchased and included in accounts payable", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r30", "r31", "r32" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 },
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets", "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r28", "r165", "r839" ] },
"us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails",
"http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1132", "r1133" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "totalLabel": "Cash, cash equivalents, and restricted cash, beginning of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r28", "r111", "r201" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of cash, cash equivalents, and restricted cash, beginning of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Change in Cash, Cash Equivalents, and Restricted Cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r111" ] },
"anip_ChaliPropertiesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "ChaliPropertiesLLCMember", "presentation": [ "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chali Properties LLC", "label": "Chali Properties LLC [Member]", "documentation": "Chali Properties LLC" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r979" ] },
"anip_ChargebacksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "ChargebacksMember", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chargebacks", "label": "Chargebacks", "documentation": "Chargebacks" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r976" ] },
"ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r974" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": {
"terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "anip_ClassCSpecialStockMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "ClassCSpecialStockMember", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.anipharmaceuticals.com/role/Cover",
"http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class C Special Stock", "label":
"Class C Special Stock", "documentation": "Class C Special Stock" } } }, "auth_ref": [] }, "anip_ClassCSpecialStockValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.anipharmaceuticals.com/20240630", "localname": "ClassCSpecialStockValue", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation":
[ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at June\u00a030, 2024 and December\u00a031, 2023, respectively", "label": "Class C Special Stock Value", "documentation": "Aggregate par or stated value of issued nonredeemable Class C Special stock (or common stock redeemable solely at the option of the issuer)." } } },
"auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
"http://www.anipharmaceuticals.com/role/Cover", "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
"http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r158", "r173", "r174", "r175", "r204", "r234", "r238", "r246", "r250", "r257", "r258", "r297", "r357", "r360", "r361", "r362", "r366", "r367", "r400", "r401", "r405", "r408", "r414", "r548", "r682", "r683", "r684", "r685", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r724", "r745", "r767", "r816", "r817", "r818", "r819", "r820", "r1019", "r1042", "r1051" ] },
"ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r980" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name",
"label": "Company Selected Measure Name" } } }, "auth_ref": [ "r980" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and Contingencies (Note 13)",
"label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r87", "r142", "r629", "r723" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label":
"Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommitmentsDisclosureTextBlock", "presentation": [
"http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES",
"label": "Commitments Disclosure [Text Block]", "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights." } } }, "auth_ref": [ "r126" ] }, "anip_CommonStockConversionPrice": { "xbrltype": "perShareItemType", "nsuri":
"http://www.anipharmaceuticals.com/20240630", "localname": "CommonStockConversionPrice", "presentation": [
"http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, conversion price (in dollars per share)", "label": "Common Stock Conversion Price", "documentation": "Represents the conversion price for converting shares of common stock into another class of common stock." } } }, "auth_ref": [] }, "anip_CommonStockExchangePerShare": { "xbrltype": "sharesItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630",
"localname": "CommonStockExchangePerShare", "presentation": [ "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange per share", "label": "Common Stock, Exchange Per Share", "documentation": "Common Stock, Exchange Per Share" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
"http://www.anipharmaceuticals.com/role/Cover", "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r919",
"r920", "r921", "r923", "r924", "r925", "r928", "r1047", "r1048", "r1050", "r1131", "r1193", "r1197" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
```

```
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
"http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r91" ] },
"us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized",
"presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, shares authorized",
"label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } },
"auth_ref": [ "r91", "r724" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesIssued", "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, shares issued",
"label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common
shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a
portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r91" ] }, "us-
gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding",
"presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
"http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, shares outstanding",
"periodStartLabel": "Beginning Balance, Common (in shares)", "periodEndLabel": "Ending Balance, Common (in shares)", "label": "Common Stock, Shares, Outstanding",
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r13", "r91", "r724",
"r742", "r1197", "r1198" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue",
"crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0,
"order": 1.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Common
Stock, $0.0001 par value, 33,333,334 shares authorized; 21,476,115 shares issued and 21,063,528 outstanding at June\u00a030, 2024; 20,730,896 shares issued and
20,466,953 shares outstanding at December\u00a031, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued
nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements
for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r91", "r631",
"r899" ] }, "anip_CommonStockVotePerShare": { "xbrltype": "integerItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"CommonStockVotePerShare", "presentation": [ "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Vote per share", "label": "Common Stock, Vote Per Share", "documentation": "Common Stock, Vote Per Share" } } }, "auth_ref": [] },
"ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation
Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r985" ] },
"ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually
Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r984" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid
vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r986" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } },
"auth_ref": [ "r983" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome":
{ "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive
(loss) income, net of tax", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity
from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting
from investments by owners and distributions to owners." } } }, "auth_ref": [ "r26", "r185", "r187", "r193", "r620", "r642", "r643" ] }, "us-
gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain",
"presentation": [ "http://www.anipharmaceuticals.com/role/INVENTORIESConcentrationDetails",
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed
concentration risk percentage." } } }, "auth_ref": [ "r35", "r36", "r73", "r74", "r292", "r823" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [
"http://www.anipharmaceuticals.com/role/INVENTORIESConcentrationDetails",
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } },
"auth_ref": [ "r35", "r36", "r73", "r74", "r292", "r677", "r823" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.anipharmaceuticals.com/role/INVENTORIESConcentrationDetails",
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to,
asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r35", "r36", "r73", "r74", "r292", "r823", "r1024" ] }, "us-
gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts
are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r823" ] }, "us-
gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation":
[ "http://www.anipharmaceuticals.com/role/INVENTORIESConcentrationDetails",
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Concentration risk, percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative
amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } },
"auth_ref": [ "r35", "r36", "r73", "r74", "r292" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConcentrationRiskTable", "presentation": [ "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk.
Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [
"r34", "r35", "r36", "r37", "r73", "r139", "r823" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.anipharmaceuticals.com/role/INVENTORIESConcentrationDetails",
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some
financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } },
"auth_ref": [ "r35", "r36", "r73", "r74", "r292", "r823" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ConsolidationItemsAxis", "presentation": [ "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r147", "r210", "r255", "r265", "r279", "r280", "r281", "r282", "r283", "r285", "r286",
"r287", "r357", "r358", "r359", "r360", "r362", "r363", "r364", "r365", "r366", "r854", "r855", "r1090", "r1091" ] }, "srt_ConsolidationItemsDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [
"http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label":
"Consolidation Items [Domain]" } } }, "auth_ref": [ "r147", "r210", "r255", "r265", "r279", "r280", "r281", "r282", "r283", "r285", "r286", "r287", "r357", "r358", "r359", "r360",
"r362", "r363", "r364", "r365", "r366", "r854", "r855", "r1090", "r1091" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [
"http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies" ], "lang": { "en-us": { "role": { "verboseLabel":
"Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in
consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in
the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence)
in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for
intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } },
"auth_ref": [ "r61", "r846" ] }, "anip_ContractCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"ContractCustomerMember", "presentation": [ "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Contract Customer", "label": "Contract Customer", "documentation": "Contract Customer" } } }, "auth_ref": [] }, "us-
gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance
obligations satisfied in prior periods", "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period", "documentation": "Amount of revenue
recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price." } } },
"auth_ref": [ "r422" ] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConvertiblePreferredStockMember", "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
"http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
"http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Preferred Stock", "label":
"Convertible Preferred Stock [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } },
"auth_ref": [ "r400", "r401", "r405", "r923", "r924", "r925", "r928" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": [
"http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate, Non-Segment", "label": "Segment
Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn
revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r19", "r280", "r281", "r282", "r283", "r286",
```

```
"r1056" ] }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales (excluding depreciation and amortization)", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization." } } }, "auth_ref": [ "r1025", "r1026" ] }, "us-gaap_CostOfGoodsTotalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsTotalMember", "presentation": [
"http://www.anipharmaceuticals.com/role/INVENTORIESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Goods and Service Benchmark", "label": "Cost of Goods and Service Benchmark [Member]", "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r1023" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total Operating Expenses, net", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r107" ] }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy", "presentation": [
"http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Activities", "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation." } } }, "auth_ref": [ "r124", "r125" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r208", "r209", "r372", "r403", "r572", "r582", "r624", "r843", "r845" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "anip_CreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "CreditAgreementMember", "presentation": [
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility - 2021", "label": "Credit Facility - 2021", "documentation": "Credit Facility - 2021" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r356", "r1088" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r356", "r1088", "r1089" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r118", "r292" ] }, "anip_CustomerFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "CustomerFourMember", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer 4", "label": "Customer four [Member]", "documentation": "Customer four" } } }, "auth_ref": [] }, "anip_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "CustomerOneMember", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer 1", "label": "Customer one [Member]", "documentation": "Customer one" } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": [
"http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r58", "r1068", "r1069", "r1070", "r1071", "r1073", "r1074", "r1076", "r1077" ] }, "anip_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "CustomerThreeMember", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer 3", "label": "Customer three [Member]", "documentation": "Customer three" } } }, "auth_ref": [] }, "anip_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "CustomerTwoMember", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer 2", "label": "Customer two [Member]", "documentation": "Customer two" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/INDEBTEDNESS" ], "lang": { "en-us": { "role": { "verboseLabel": "INDEBTEDNESS", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r127", "r202", "r334", "r335", "r336", "r337", "r338", "r355", "r356", "r368", "r374", "r375", "r376", "r377", "r378", "r379", "r384", "r391", "r392", "r394", "r558" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Principal amount", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r21", "r141", "r395" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate principal amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r369", "r558", "r559", "r867", "r868", "r897" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [
"http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails",
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt effective interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r83", "r397", "r558", "r559", "r897" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [
"http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSDetails",
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails", "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails",
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r210", "r369", "r370", "r371", "r372", "r373", "r375", "r380", "r381", "r382", "r383", "r385", "r386", "r387", "r388", "r389", "r390", "r393", "r866", "r867", "r868", "r869", "r870", "r897", "r1043", "r1147", "r1149" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [
"http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSDetails",
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails", "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails",
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r21", "r47", "r48", "r77", "r129", "r130", "r210", "r369", "r370", "r371", "r372", "r373", "r375", "r380", "r381", "r382", "r383", "r385", "r386", "r387", "r388", "r389", "r390", "r393", "r866", "r867", "r868", "r869", "r870", "r897", "r1043", "r1147", "r1149" ] }, "us-gaap_DeferredFinanceCostsCurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsCurrentNet", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails": { "parentTag": "us-gaap_LongTermDebtCurrent", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails",
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs, current", "negatedLabel": "Deferred financing costs", "label": "Debt Issuance Costs, Current, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1146", "r1147", "r1149" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1093", "r1146", "r1147", "r1149" ] }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNoncurrentNet", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails",
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs, noncurrent", "negatedTerseLabel": "Deferred financing costs", "label": "Debt Issuance Costs, Noncurrent, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1146", "r1147", "r1149" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets, net of deferred tax liabilities and valuation allowance", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred
```

```
tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r478", "r479" ] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r114" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://www.anipharmaceuticals.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r486" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r9", "r44" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r711", "r714", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r737", "r738", "r739", "r740", "r755", "r756", "r757", "r758", "r761", "r762", "r763", "r764", "r799", "r801", "r804", "r806", "r919", "r921", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [
"http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r66", "r68", "r69", "r138", "r711", "r714", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r737", "r738", "r739", "r740", "r755", "r756", "r757", "r758", "r761", "r762", "r763", "r764", "r799", "r801", "r804", "r806", "r845", "r919", "r921", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [
"http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITY" ], "lang": { "en-us": { "role": { "terseLabel": "DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r137", "r514", "r521" ] }, "anip_DerivativeLiabilityDecreaseInNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "DerivativeLiabilityDecreaseInNotionalAmount", "crdr": "debit", "presentation": [
"http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in notional amount", "label": "Derivative Liability, Decrease in Notional Amount", "documentation": "Amount of decrease in notional amount of derivative liability." } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilityNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityNotionalAmount", "presentation": [ "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liability, notional amount", "label": "Derivative Liability, Notional Amount", "documentation": "Nominal or face amount used to calculate payments on the derivative liability." } } }, "auth_ref": [ "r800", "r802", "r803", "r805", "r1128", "r1129", "r1130" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [
"http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r521" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [
"http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r14", "r62", "r63", "r64", "r65", "r67", "r68", "r70", "r71", "r72", "r521" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails",
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r426", "r872", "r873", "r874", "r875", "r876", "r877", "r878" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails",
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r426", "r872", "r873", "r874", "r875", "r876", "r877", "r878" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of disaggregation of revenue and revenue recognized", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1094" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATION" ], "lang": { "en-us": { "role": { "verboseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r437", "r442", "r470", "r471", "r472", "r885" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [
"http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSDetails",
"http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r161" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": [
"http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSDetails",
"http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "presentation": [
"http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSDetails",
"http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Held-for-Sale, Not Discontinued Operations", "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r3", "r18", "r161" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [
"http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSDetails",
"http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "anip_DisposalGroupIncludingDiscontinuedOperationsTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationsTransactionCosts", "crdr": "debit", "presentation": [
"http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment of commissions, taxes and other related costs", "label": "Disposal Group, Including Discontinued Operations, Transaction Costs", "documentation": "Disposal Group, Including Discontinued Operations, Transaction Costs" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sale of property", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r331", "r1039", "r1079" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [
"http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSDetails",
"http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r882", "r883" ] }, "us-gaap_DividendsPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPreferredStock", "crdr": "debit", "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends on Series A Convertible Preferred Stock", "label": "Dividends, Preferred Stock", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r6", "r131" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [
```

```
"http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date, for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r935" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r967" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r978" ] }, "anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "EarningsLossBeforeInterestTaxesDepreciationAndAmortization", "crdr": "credit", "presentation": [ "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EBITDA", "label": "Earnings/(loss) before interest, taxes, depreciation and amortization", "documentation": "Represents earnings/(loss) before interest, taxes, depreciation and amortization (EBITDA)." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations", "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (Loss) Income Per Share (in dollars per share)", "verboseLabel": "(Loss) earnings per share, Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r194", "r221", "r222", "r223", "r224", "r225", "r226", "r231", "r234", "r246", "r249", "r250", "r254", "r499", "r506", "r524", "r525", "r621", "r644", "r847" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations", "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (Loss) Income Per Share (in dollars per share)", "verboseLabel": "(Loss) earnings per share, Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r194", "r221", "r222", "r223", "r224", "r225", "r226", "r234", "r246", "r249", "r250", "r254", "r499", "r506", "r524", "r525", "r621", "r644", "r847" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareReconciliationAbstract", "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Basic and Diluted (Loss) Income Per Share:", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/EARNINGSPERSHARE" ], "lang": { "en-us": { "role": { "verboseLabel": "EARNINGS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r230", "r251", "r252", "r253" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.anipharmaceuticals.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate (as a percent)", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r481", "r887" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued compensation and related expenses", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r81" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Severance", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails", "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "EmployeeStockPurchasePlanTwoThousandAndSixteenMember", "presentation": [ "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2016 Employee Stock Purchase Plan", "label": "2016 Employee Stock Purchase Plan", "documentation": "2016 Employee Stock Purchase Plan" } } }, "auth_ref": [] }, "anip_EmployeesAndConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "EmployeesAndConsultantsMember", "presentation": [ "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employees and Consultants", "label": "Employees and Consultants [Member]", "documentation": "Information related to employees and consultants." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r933" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r933" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's
```

current or most recent filing containing the related disclosure." } } }, "auth_ref": { "r933" } }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.anipharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.anipharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r1017"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.anipharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r933"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.anipharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r933"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.anipharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r933"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.anipharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN, also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r933"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r972"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r1013"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": ["r1013"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r1013"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity", "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r13", "r159", "r188", "r189", "r190", "r216", "r217", "r218", "r220", "r225", "r227", "r229", "r256", "r298", "r299", "r330", "r415", "r488", "r489", "r496", "r497", "r498", "r500", "r505", "r506", "r515", "r516", "r517", "r518", "r519", "r520", "r523", "r550", "r552", "r553", "r554", "r555", "r556", "r560", "r561", "r565", "r641", "r670", "r671", "r672", "r692", "r767"] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": ["r294", "r295", "r296", "r495", "r1020", "r1021", "r1022", "r1123", "r1124", "r1125", "r1126"] }, "us-gaap_EquitySecuritiesFvNiCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiCost", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Investment in equity securities", "label": "Equity Securities, FV-NI, Cost", "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value." } } }, "auth_ref": ["r626"] }, "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent", "crdr": "debit", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalties fair value", "label": "Equity Securities, FV-NI", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r170", "r527", "r547", "r624", "r625", "r890", "r916", "r918", "r1134", "r1135", "r1136"] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 }, "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized (loss) gain on investment in equity securities", "negatedLabel": "Unrealized gain on investment in equity securities", "verboseLabel": "Unrealized (loss) gain on investment in equity securities", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r646", "r1062"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": ["r982"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": ["r940", "r950", "r960", "r992"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r937", "r947", "r957", "r989"] }, "anip_EsjayPharmaLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "EsjayPharmaLlcMember", "presentation": ["http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Esjay Pharma LLC", "label": "Esjay Pharma LLC", "documentation": "Represents the information pertaining to Esjay Pharma LLC." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": ["r988"] }, "us-gaap_FacilityClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FacilityClosingMember", "presentation": ["http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails"], "lang": { "en-us": { "role": { "terseLabel": "Facility Closing", "label": "Facility Closing [Member]", "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails", "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details", "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r529", "r530", "r531", "r893"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails", "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details", "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r529", "r530", "r531", "r893"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of recurring Level 3 fair value measurements of contingent consideration", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r529", "r530", "r893"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r382", "r429", "r430", "r431", "r432", "r433", "r434", "r526", "r528", "r529", "r530", "r531", "r539", "r540", "r542", "r577", "r578", "r579", "r867", "r868", "r879", "r880", "r881", "r890", "r893"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURES"], "lang": { "en-us": { "role": { "verboseLabel": "FAIR VALUE DISCLOSURES", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items

included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": { "r535", "r537", "r538", "r539", "r542", "r543", "r544", "r545", "r546", "r617", "r890", "r894" } }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r382", "r429", "r434", "r528", "r540", "r577", "r879", "r880", "r881", "r890"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r382", "r429", "r434", "r528", "r529", "r540", "r578", "r867", "r868", "r879", "r880", "r881", "r890"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r382", "r429", "r430", "r431", "r432", "r433", "r434", "r528", "r529", "r530", "r531", "r540", "r579", "r867", "r868", "r879", "r880", "r881", "r890", "r893"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details"], "lang": { "en-us": { "role": { "terseLabel": "Changes in contingent consideration", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of changes in contingent consideration", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r532", "r536", "r541"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details"], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": ["r533", "r541"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details"], "lang": { "en-us": { "role": { "terseLabel": "Payment of Gross-Profit earn-out", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r534", "r541"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details"], "lang": { "en-us": { "role": { "periodStartLabel": "Level 3 liability, beginning balance", "periodEndLabel": "Level 3 liability, ending balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r532", "r541"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r382", "r429", "r430", "r431", "r432", "r433", "r434", "r526", "r528", "r529", "r530", "r531", "r539", "r540", "r542", "r577", "r578", "r579", "r867", "r868", "r879", "r880", "r881", "r890", "r893"] }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)." } } }, "auth_ref": ["r533", "r541"] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Remaining estimated useful lives", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r167", "r303", "r323", "r861"] }, "anip_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2029 and thereafter", "label": "Finite Lived Intangible Assets Amortization Expense After Year Four", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year and after the fourth fiscal year following current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r325", "r835", "r861"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024 (remainder of the year)", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": ["r1199"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of expected future amortization expense for definite-lived intangible assets", "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r325", "r835", "r861"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r325", "r835", "r861"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r325", "r835", "r861"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets

```
by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r316", "r318", "r319", "r320", "r322", "r323", "r327", "r328", "r585", "r586", "r835" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r303", "r323", "r586", "r861" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Definite-Lived Intangible Assets:", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r316", "r323", "r327", "r328", "r329", "r585", "r835", "r861" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r316", "r318", "r319", "r320", "r322", "r323", "r327", "r328", "r835" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 }, "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails", "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r585", "r1074" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Weighted Average Amortization Period", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r585" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign Currency", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r549" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r944", "r954", "r964", "r996" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r944", "r954", "r964", "r996" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r944", "r954", "r964", "r996" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r944", "r954", "r964", "r996" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r944", "r954", "r964", "r996" ] }, "anip_FourCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "FourCustomersMember", "presentation": [ "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Four Customers", "label": "Four Customers [Member]", "documentation": "Four Customers" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r977" ] }, "us-gaap_GainLossOnSaleOfOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfOtherAssets", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on sale of building", "label": "Gain (Loss) on Disposition of Other Assets", "documentation": "Amount of gain (loss) on sale or disposal of other assets." } } }, "auth_ref": [ "r1039" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on sale of building", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r9" ] }, "anip_GenericsEstablishedBrandsAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "GenericsEstablishedBrandsAndOtherMember", "presentation": [ "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Generics, Established Brands, and Other", "label": "Generics, Established Brands, and Other", "documentation": "Component of the entity related to generics, established brands, and other and is considered an operating segment." } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r166", "r304", "r618", "r855", "r860", "r891", "r899", "r1065", "r1066" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Acquisition of goodwill", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r307", "r860" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "verboseLabel": "GOODWILL AND INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1064", "r1067" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r860" ] }, "anip_GovernmentRebatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "GovernmentRebatesMember", "presentation": [ "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government Rebates", "label": "Government Rebates", "documentation": "Government Rebates" } } }, "auth_ref": [] }, "country_IN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "IN", "presentation": [ "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails" ], "lang": { "en-us": { "role": { "terseLabel": "India", "label": "INDIA" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "presentation": [ "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment", "label": "Impairment of Intangible Assets, Finite-Lived", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r317", "r1039", "r1078" ] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of indefinite lived intangible assets", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": [ "r317", "r1039", "r1075", "r1078" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Assets Held-for-Sale", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r123" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In process research and
```

```
development", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": { "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077" } }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.anipharmaceuticals.com/role/INCOMETAXESDetails", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": {
"role": { "totalLabel": "(Loss) Income Before Income Tax Expense (Benefit)", "verboseLabel": "Pre-tax consolidated income (loss)", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r101", "r144", "r148", "r622", "r638", "r849", "r854", "r1053", "r1055", "r1057", "r1058", "r1059" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [
"http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSDetails",
"http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [
"r882", "r883" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementLocationAxis", "presentation": [ "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r332", "r339", "r344", "r533", "r536", "r541", "r667", "r669", "r752", "r835", "r892", "r1164" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain",
"presentation": [ "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r339", "r344", "r533", "r536", "r541", "r667", "r669", "r752", "r835", "r892", "r1164" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "verboseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [
"r205", "r477", "r481", "r482", "r483", "r484", "r485", "r487", "r490", "r492", "r493", "r494", "r687", "r887" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } },
"presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations", "http://www.anipharmaceuticals.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Income tax expense (benefit)", "negatedTerseLabel": "Expense (benefit) for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } },
"auth_ref": [ "r150", "r156", "r228", "r229", "r255", "r271", "r285", "r480", "r481", "r491", "r647", "r887" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r29", "r113", "r1040", "r1121", "r1122" ] }, "anip_IncreaseDecreaseAccruedGovernmentRebates": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.anipharmaceuticals.com/20240630", "localname": "IncreaseDecreaseAccruedGovernmentRebates", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": {
"verboseLabel": "Accrued government rebates", "label": "Increase Decrease, Accrued Government Rebates", "documentation": "The increase (decrease) during the reporting period in liabilities related to government rebates." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": {
"verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": {
"negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInIncomeTaxes", "crdr":
"debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid income taxes", "label":
"Increase (Decrease) in Income Taxes", "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets." } } }, "auth_ref": [ "r1038" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": {
"negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities, net of acquisition:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r8" ] }, "anip_IncreaseDecreaseInReturnedGoodsReserve": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "IncreaseDecreaseInReturnedGoodsReserve", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel":
"Returned goods reserve", "label": "Increase Decrease In Returned Goods Reserve", "documentation": "Amount of increase (decrease) in returned goods reserve." } } },
"auth_ref": [] }, "anip_IncreaseDecreaseInRoyaltyPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"IncreaseDecreaseInRoyaltyPayable", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued royalties", "label": "Increase (Decrease) in Royalty Payable", "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel":
"Increase (decrease) in Stockholders' Equity", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel":
"Increase (decrease) in temporary equity", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "IncreaseDecreaseOfAccruedExpensesCompensationAndOthers", "crdr": "debit",
"calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses, accrued compensation, and other", "label": "Increase Decrease Of Accrued Expenses Compensation And Others", "documentation": "The increase (decrease) during the reporting period in liabilities related to accrued compensation, accrued expenses, and others." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails": {
"parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of common stock options, ESPP, and performance stock units (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation":
"Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r235", "r236", "r237", "r250", "r441" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [
"http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking
```

physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r316", "r321", "r326", "r861"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r303", "r326", "r861"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract", "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets:", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r316", "r321", "r326", "r861"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": ["r944", "r954", "r964", "r988", "r996", "r1000", "r1008"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r1006"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r936", "r1012"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": ["r936", "r1012"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": ["r936", "r1012"] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total Intangible Assets, Gross", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": ["r166"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets", "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets, net", "totalLabel": "Total Intangible Assets, Net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r316", "r1074", "r1075"] }, "us-gaap_InterestCostsCapitalizedAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestCostsCapitalizedAdjustment", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Capitalized interest", "label": "Interest Costs Capitalized Adjustment", "documentation": "Amount of interest costs capitalized disclosed as an adjusting item to interest costs incurred." } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails"], "lang": { "en-us": { "role": { "totalLabel": "Interest Expense, Debt", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r105", "r388", "r398", "r869", "r870"] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Contractual coupon", "label": "Interest Expense, Debt, Excluding Amortization", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": ["r105", "r389", "r869", "r870"] }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "presentation": ["http://www.anipharmaceuticals.com/role/INDEBTEDNESSTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of components of total interest expense related to the notes and term loan", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations", "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "negatedTerseLabel": "Interest expense", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": ["r854", "r1036", "r1055"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest, net of amounts capitalized", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r196", "r199", "r200"] }, "us-gaap_InterestRateDerivativeAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateDerivativeAssetsAtFairValue", "crdr": "debit", "presentation": ["http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails", "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails", "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Fair value interest rate derivative assets", "terseLabel": "Interest rate swap", "label": "Interest Rate Derivative Assets, at Fair Value", "documentation": "Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets." } } }, "auth_ref": [] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": ["http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": ["r836", "r926", "r927"] }, "us-gaap_InventoryCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryCurrentTable", "presentation": ["http://www.anipharmaceuticals.com/role/INVENTORIESConcentrationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Current [Table]", "label": "Inventory, Current [Table]", "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.anipharmaceuticals.com/role/INVENTORIES"], "lang": { "en-us": { "role": { "verboseLabel": "INVENTORIES", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r300"] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": ["r1028"] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryGross", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails"], "lang": { "en-us": { "role": { "totalLabel": "Inventories", "label": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r1032"] }, "us-gaap_InventoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryLineItems", "presentation": ["http://www.anipharmaceuticals.com/role/INVENTORIESConcentrationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Line Items]", "label": "Inventory [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r177", "r840", "r899"] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Raw materials", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r1030"] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Work-in-progress", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": ["r1029"] }, "us-gaap_InvestmentOwnedAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedAtCost", "crdr": "debit", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Closing price", "label": "Investment Owned, Cost", "documentation": "Cost of the investment." } } }, "auth_ref": ["r678", "r709", "r710", "r781", "r785", "r795", "r813", "r921", "r931", "r1194"] }, "us-gaap_InvestmentOwnedAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedAtFairValue", "crdr": "debit", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Value of shares held", "label": "Investment Owned, Fair Value", "documentation": "Fair value of investment in security owned." } } }, "auth_ref": ["r678", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r712", "r715", "r716", "r727", "r728", "r775", "r779", "r780", "r782", "r792", "r793", "r796", "r797", "r798", "r807", "r808", "r812", "r814", "r815", "r921", "r931", "r1194"] }, "us-gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedBalanceShares", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares held (in shares)", "label": "Investment Owned, Balance, Shares", "documentation": "Number of shares of investment owned." } } }, "auth_ref": ["r704", "r712", "r778", "r794", "r811", "r921"] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": ["http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Investment in Equity Securities", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": ["r645", "r678", "r679", "r680", "r681", "r783", "r784"] }, "anip_JPMorganChaseBankN.A.AndBlackstoneCreditInsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "JPMorganChaseBankN.A.AndBlackstoneCreditInsuranceMember", "presentation": ["http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails"], "lang": { "en-us": { "role": { "terseLabel": "JPMorgan, Chase Bank, N.A. and Blackstone Credit & Insurance", "label": "JPMorgan, Chase Bank, N.A. and Blackstone Credit & Insurance [Member]", "documentation": "JPMorgan, Chase Bank, N.A. and Blackstone Credit & Insurance" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": ["http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease term", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r564", "r1150"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r21", "r80", "r81", "r82", "r85", "r86", "r87", "r88", "r204", "r297", "r357", "r358", "r360", "r361", "r362", "r363", "r364", "r366", "r367", "r509", "r512", "r513", "r548", "r722", "r848", "r931", "r1090", "r1153", "r1154"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities, Mezzanine Equity, and Stockholders\u2019 Equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r96", "r143", "r635", "r899", "r1044", "r1063", "r1145"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Liabilities, Mezzanine Equity, and Stockholders\u2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r82", "r164", "r204", "r297", "r357", "r358", "r360", "r361", "r362", "r363", "r364", "r366", "r367", "r509", "r512", "r513", "r548", "r899", "r1090", "r1153", "r1154"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Current Liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": ["http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lender Name [Axis]", "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": ["r79", "r84", "r1043", "r1088", "r1089"] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": ["http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Commitment fee (as a percent)", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": ["http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Lender [Domain]", "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": ["r79", "r84", "r1043", "r1088"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r79", "r84"] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Remaining borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": ["r79", "r84", "r356"] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": ["http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revolving Facility", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.anipharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "presentation": ["http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of property, plant and equipment, net by geographic location", "label": "Long-Lived Assets by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets." } } }, "auth_ref": ["r120"] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r21", "r141", "r381", "r396", "r867", "r868", "r897", "r1162"] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets", "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Current debt, net of deferred financing costs", "totalLabel": "Current debt, net of deferred financing costs", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": ["r171"] }, "anip_LongTermDebtGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "LongTermDebtGrossCurrent", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails": { "parentTag": "us-gaap_LongTermDebtCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Current borrowing on debt", "label": "Long-term Debt, Gross, Current", "documentation": "Current portion before unamortized (discount) premium and debt issuance costs, of long-term debt." } } }, "auth_ref": [] }, "anip_LongTermDebtGrossNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "LongTermDebtGrossNonCurrent", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-current borrowing on debt", "label": "Long-term Debt, Gross, Non Current", "documentation": "Non current portion before unamortized (discount) premium and debt issuance costs, of long-term debt." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r11", "r210", "r386"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r11", "r210", "r386"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": {

```
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } },
"presentation": [ "http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label":
"Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by
holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are
reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r210", "r386" ] }, "us-
gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2024 (remainder of
the year)", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other
securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r1045" ] }, "us-
gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit",
"calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 },
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets", "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails" ],
"lang": { "en-us": { "role": { "verboseLabel": "Non-current debt, net of deferred financing costs and current component", "totalLabel": "Non-current debt, net of deferred
financing costs and current component", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium
(discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r172" ] }, "us-
gaap_LongTermDebtNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrentAbstract",
"presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-current Liabilities",
"label": "Long-Term Debt, Excluding Current Maturities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails",
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails",
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Axis]", "label":
"Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r21", "r1080", "r1081", "r1082" ] }, "us-
gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails", "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails",
"http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Domain]",
"label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing,
project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the
normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r21", "r45", "r1080", "r1081", "r1082" ] }, "anip_LossContingencyDamagesSoughtNetSalesPercentage": {
"xbrltype": "percentItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "LossContingencyDamagesSoughtNetSalesPercentage", "presentation": [
"http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales percentage", "label": "Loss
Contingency, Damages Sought, Net Sales Percentage", "documentation": "Loss Contingency, Damages Sought, Net Sales Percentage" } } }, "auth_ref": [] },
"anip_LossContingencyDamagesSoughtRoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"LossContingencyDamagesSoughtRoyaltyPercentage", "presentation": [ "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Royalty percentage", "label": "Loss Contingency, Damages Sought, Royalty Percentage", "documentation": "Loss Contingency, Damages
Sought, Royalty Percentage" } } }, "auth_ref": [] }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LossContingencyNewClaimsFiledNumber", "presentation": [
"http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of complaints filed", "label":
"Loss Contingency, New Claims Filed, Number", "documentation": "The total number of new claims filed pertaining to a loss contingency during the period." } } }, "auth_ref":
[ "r1084", "r1085" ] }, "anip_LossContingencyNumberOfManufacturers": { "xbrltype": "integerItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630",
"localname": "LossContingencyNumberOfManufacturers", "presentation": [ "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang":
{ "en-us": { "role": { "terseLabel": "Number of potential manufacturers", "label": "Loss Contingency, Number Of Manufacturers", "documentation": "Loss Contingency,
Number Of Manufacturers" } } }, "auth_ref": [] }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LossContingencyNumberOfPlaintiffs", "presentation": [ "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Number of plaintiffs", "label": "Loss Contingency, Number of Plaintiffs", "documentation": "Number of plaintiffs that have filed claims pertaining
to a loss contingency." } } }, "auth_ref": [ "r1084", "r1085" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"MajorCustomersAxis", "presentation": [ "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails",
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer
[Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r292", "r874", "r909", "r914", "r1094", "r1163", "r1165", "r1166", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173",
"r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192" ] },
"anip_MarketPerformanceBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"MarketPerformanceBasedRestrictedStockUnitsMember", "presentation": [ "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Market Performance-Based Restricted Stock Units", "label": "Market
Performance-Based Restricted Stock Units [Member]", "documentation": "Market Performance-Based Restricted Stock Units" } } }, "auth_ref": [] },
"anip_MarketingAndDistributionRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"MarketingAndDistributionRightsMember", "presentation": [ "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Marketing and distribution rights", "label": "Marketing and distribution rights", "documentation": "Marketing and distribution rights" } } },
"auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum
[Member]" } } }, "auth_ref": [ "r351", "r352", "r353", "r354", "r436", "r475", "r531", "r583", "r666", "r668", "r676", "r713", "r714", "r776", "r786", "r790", "r791", "r809",
"r833", "r834", "r859", "r871", "r884", "r893", "r894", "r895", "r896", "r910", "r1092", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160" ] }, "ecd_MeasureAxis": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r980" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name",
"label": "Measure Name" } } }, "auth_ref": [ "r980" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details" ],
"lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate
to determine present value of future cash flows." } } }, "auth_ref": [ "r1134", "r1135", "r1136" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [
"http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label":
"Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r529",
"r530", "r531", "r893" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputTypeDomain", "presentation": [ "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details" ], "lang": { "en-us": { "role": {
"terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and
liability." } } }, "auth_ref": [ "r529", "r530", "r531", "r893" ] }, "anip_MilestonePaymentsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.anipharmaceuticals.com/20240630", "localname": "MilestonePaymentsMember", "presentation": [
"http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone Payments", "label": "Milestone
Payments [Member]", "documentation": "Milestone Payments" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum
[Member]" } } }, "auth_ref": [ "r351", "r352", "r353", "r354", "r436", "r475", "r531", "r583", "r666", "r668", "r676", "r713", "r714", "r776", "r786", "r790", "r791", "r809",
"r833", "r834", "r859", "r871", "r884", "r893", "r894", "r895", "r910", "r1092", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160" ] }, "ecd_MnpiDiscTimedForCompValFlag":
{ "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure
Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r999" ] }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "MovementInValuationAllowancesAndReservesRollForward", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accruals for
Chargebacks, Returns, and Other Allowances", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "documentation": "A roll
forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "anip_Mr.ShanmugamAndEsjayMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "Mr.ShanmugamAndEsjayMember", "presentation": [
"http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mr. Shanmugam and Esjay", "label": "Mr.
Shanmugam and Esjay [Member]", "documentation": "Mr. Shanmugam and Esjay" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of
Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1007" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails",
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer
[Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r292", "r874", "r909", "r914", "r1094", "r1163", "r1165", "r1166", "r1168", "r1169", "r1170", "r1171", "r1172",
"r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191",
"r1192" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers,
Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r981" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation":
[ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash and Cash Equivalents (Used
in) Provided by Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing
activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of,
their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-
term credit." } } }, "auth_ref": [ "r198" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
```

*gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Cash Flows From Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net Cash and Cash Equivalents Provided by (Used in) Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r198"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Cash Flows From Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net Cash and Cash Equivalents Provided by Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r111", "r112", "r114"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Cash Flows From Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome",
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net (Loss) Income", "terseLabel": "Net (Loss) Income", "verboseLabel": "Net Income", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r102", "r114", "r145", "r162", "r183", "r186", "r190", "r204", "r219", "r221", "r222", "r223", "r224", "r225", "r228", "r229", "r243", "r297", "r357", "r358", "r360", "r361", "r362", "r363", "r364", "r366", "r367", "r499", "r506", "r525", "r548", "r640", "r744", "r765", "r766", "r929", "r1090"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails": { "parentTag": "us-gaap_UndistributedEarnings", "weight": 1.0, "order": 2.0 },
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations", "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails"], "lang": { "en-us": { "role": { "totalLabel": "Net (Loss) Income Available to Common Shareholders", "verboseLabel": "Net (loss) income available to common shareholders, Basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": ["r195", "r221", "r222", "r223", "r224", "r231", "r232", "r245", "r250", "r506"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails": {
"parentTag": "us-gaap_UndistributedEarningsDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income available to common shareholders, Diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares, of income (loss) available to common shareholders." } } }, "auth_ref": ["r195", "r233", "r239", "r240", "r241", "r242", "r245", "r250"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": ["http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails"], "lang": { "en-us": { "role": { "terseLabel": "Diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "anip_NonEmployeeDirectorStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "NonEmployeeDirectorStockOptionMember", "presentation": ["http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non Employee Director", "label": "Non Employee Director [Member]", "documentation": "n/a" } } }, "auth_ref": [] },
"ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": ["r980"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": ["r944", "r954", "r964", "r988", "r996"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r971"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r970"] },
"ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": ["r988"] },
"ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r1007"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r1007"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations"], "lang": { "en-us": { "role": { "verboseLabel": "Other Income (Expense), net", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "anip_NovitiumMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "NovitiumMember", "presentation": [
"http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Novitium", "label": "Novitium [Member]", "documentation": "Novitium" } } }, "auth_ref": [] }, "anip_NovitiumPharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "NovitiumPharmaMember", "presentation": [
"http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESHierarchyDetails", "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails",
"http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails",
"http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Novitium", "label": "Novitium", "documentation": "Information related to the Novitium Pharma LLC." } } }, "auth_ref": [] }, "anip_NumberOfAnnualInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "NumberOfAnnualInstallments", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of annual installments", "label": "Number of Annual Installments", "documentation": "Number of Annual Installments" } } }, "auth_ref": [] }, "anip_NumberOfConsecutiveTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "NumberOfConsecutiveTradingDays", "presentation": [
"http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of consecutive trading days", "label": "Number of Consecutive Trading Days", "documentation": "Number of consecutive trading days." } } }, "auth_ref": [] }, "anip_NumberOfExecutiveFounders": { "xbrltype": "integerItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "NumberOfExecutiveFounders", "presentation": [
"http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of executive founders", "label": "Number of Executive Founders", "documentation": "Number of Executive Founders" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [
"http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails",
"http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r855", "r1054"] },
"anip_NumberOfPharmaceuticalManufacturingFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "NumberOfPharmaceuticalManufacturingFacilities", "presentation": [
"http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSDetails",
"http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of pharmaceutical manufacturing facilities", "label": "Number of Pharmaceutical Manufacturing Facilities", "documentation": "Number of Pharmaceutical Manufacturing Facilities" } } }, "auth_ref": [] },
"anip_NumberOfProductsMarketedWithoutApprovedNDAsOrANDAs": { "xbrltype": "integerItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "NumberOfProductsMarketedWithoutApprovedNDAsOrANDAs", "presentation": ["http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails"],
"lang": { "en-us": { "role": { "terseLabel": "Number of products marketed without approved NDAs or ANDAs", "label": "Number of Products Marketed Without Approved NDAs or ANDAs", "documentation": "Number of Products Marketed Without Approved NDAs or ANDAs" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportingUnits": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportingUnits", "presentation": [*

```
"http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reporting units", "label": "Number of Reporting Units", "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment." } } }, "auth_ref": [] }, "anip_OakvilleOntarioCanadaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "OakvilleOntarioCanadaMember", "presentation": [ "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Oakville, Ontario, Canada", "label": "Oakville, Ontario, Canada", "documentation": "Information related to the Oakville, Ontario, Canada manufacturing plant." } } }, "auth_ref": [] }, "anip_OakvilleOntarioFormerManufacturingFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "OakvilleOntarioFormerManufacturingFacilityMember", "presentation": [ "http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSDetails", "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Oakville, Ontario Former Manufacturing Facility", "label": "Oakville, Ontario Former Manufacturing Facility [Member]", "documentation": "Oakville, Ontario Former Manufacturing Facility" } } }, "auth_ref": [] }, "srt_OfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OfficerMember", "presentation": [ "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Officer", "label": "Officer [Member]" } } }, "auth_ref": [ "r293", "r1195" ] }, "anip_OneSupplierMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "OneSupplierMember", "presentation": [ "http://www.anipharmaceuticals.com/role/INVENTORIESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One Supplier", "label": "One supplier [Member]", "documentation": "One supplier [Member]." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating Expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating Income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r148", "r849", "r1053", "r1055", "r1057", "r1058", "r1059" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash operating lease expense", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1039" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r279", "r280", "r281", "r282", "r283", "r286", "r854", "r855" ] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTS" ], "lang": { "en-us": { "role": { "verboseLabel": "BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r115", "r116", "r117", "r135" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Derivatives and other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r168" ] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsLineItems", "presentation": [ "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Other Commitments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsTable", "presentation": [ "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Table]", "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r7", "r12", "r136" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome", "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "(Loss) Gain on interest rate swap", "verboseLabel": "Derivative unrealized gain recorded in OCI", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r180", "r181", "r641" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "presentation": [ "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications out of accumulated other comprehensive (loss) income", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r181", "r182" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity", "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive (loss) income, net of tax", "terseLabel": "Other Comprehensive Income (Loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r13", "r20", "r184", "r187", "r192", "r225", "r550", "r551", "r556", "r619", "r641", "r1033", "r1034" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income, net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Other Depreciation and Amortization", "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other." } } }, "auth_ref": [ "r9", "r44", "r103" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r86" ] }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Supplemental non-cash investing and financing activities:", "label": "Other Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r106" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r980" ] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringMember", "presentation": [ "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Restructuring", "label": "Other Restructuring [Member]", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": [ "r862", "r863", "r864", "r865" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r942", "r952", "r962", "r994" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": {
```

```
"role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r945", "r955", "r965", "r997" ] },
"ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [
"r945", "r955", "r965", "r997" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r969" ] }, "us-
gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight":
-1.0, "order": 4.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows",
"http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails", "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ],
"lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on contingent consideration", "terseLabel": "Payments on contingent consideration", "label": "Payment for
Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle
contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after
acquisition date." } } }, "auth_ref": [ "r5" ] }, "anip_PaymentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"PaymentTypeAxis", "presentation": [ "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details",
"http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment Type [Axis]", "label": "Payment Type
[Axis]", "documentation": "Payment Type" } } }, "auth_ref": [] }, "anip_PaymentTypeDomain": { "xbrltype": "domainItemType", "nsuri":
"http://www.anipharmaceuticals.com/20240630", "localname": "PaymentTypeDomain", "presentation": [
"http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details", "http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Payment Type [Domain]", "label": "Payment Type [Domain]", "documentation": "Payment Type [Domain]" } } }, "auth_ref": [] }, "us-
gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock purchases for
restricted stock vests", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } },
"auth_ref": [ "r110" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Payments of debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection
with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r27" ] }, "us-
gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight":
-1.0, "order": 1.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": {
"negatedLabel": "Series A convertible preferred stock dividends paid", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions
and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r110" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight":
-1.0, "order": 3.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails",
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of product rights,
intangible assets, and other related assets", "terseLabel": "Payment for acquired intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The
cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r109" ] }, "us-
gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows":
{ "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of property and
equipment, net", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical
assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-
constructed assets." } } }, "auth_ref": [ "r109" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote",
"label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r979" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r979" ] },
"ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation
Amount" } } }, "auth_ref": [ "r971" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation":
[ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r988" ] }, "ecd_PeoName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r981" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r970" ] }, "anip_PercentageOfConversionPrice": { "xbrltype":
"percentItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "PercentageOfConversionPrice", "presentation": [
"http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum percentage of conversion
price", "label": "Percentage of Conversion Price", "documentation": "Percentage of conversion price." } } }, "auth_ref": [] },
"anip_PerformanceBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"PerformanceBasedRestrictedStockUnitsMember", "presentation": [ "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance-Based Restricted Stock Units", "label": "Performance-Based
Restricted Stock Units [Member]", "documentation": "Performance-Based Restricted Stock Units" } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNonoptionactivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": {
"role": { "terseLabel": "PSUs", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } }
}, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails", "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } },
"auth_ref": [ "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112",
"r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails",
"http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]",
"documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103",
"r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120" ] },
"ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service
Cost [Member]" } } }, "auth_ref": [ "r972" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost",
"label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1016" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r971" ] },
"anip_PreferredStockConversionPeriodMinimum": { "xbrltype": "durationItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"PreferredStockConversionPeriodMinimum", "presentation": [ "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "Minimum conversion period", "label": "Preferred Stock, Conversion Period, Minimum", "documentation": "Preferred Stock, Conversion Period,
Minimum" } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockConvertibleConversionPrice", "presentation": [ "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-
us": { "role": { "verboseLabel": "Shares conversion price (in dollars per share)", "label": "Preferred Stock, Convertible, Conversion Price", "documentation": "Per share
conversion price of preferred stock." } } }, "auth_ref": [ "r402" ] }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleSharesIssuable", "presentation": [
"http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible, shares issuable",
"label": "Preferred Stock, Convertible, Shares Issuable", "documentation": "Number of common shares issuable upon conversion of preferred stock." } } }, "auth_ref": [ "r402"
] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockDividendRatePercentage", "presentation": [ "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Shares accrue dividends rate", "label": "Preferred Stock, Dividend Rate, Percentage", "documentation": "The percentage rate used to calculate dividend
payments on preferred stock." } } }, "auth_ref": [ "r401", "r777", "r787", "r789", "r810" ] }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendsIncomeStatementImpact", "crdr": "debit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
"weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": {
"negatedLabel": "Dividends on Series A Convertible Preferred Stock", "label": "Preferred Stock Dividends, Income Statement Impact", "documentation": "The amount of
preferred stock dividends that is an adjustment to net income apportioned to common stockholders." } } }, "auth_ref": [] }, "us-
gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, par value (in dollars
per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or
redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r90", "r400" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, shares authorized",
"label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the
```

option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r90", "r724"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r90", "r400"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r90", "r724", "r742", "r1197", "r1198"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Preferred Stock, $0.0001 par value, 1,666,667 shares authorized, 0 shares issued and outstanding at June\u00a030, 2024 and December\u00a031, 2023, respectively", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r90", "r630", "r899"] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r178", "r301", "r302", "r841"] }, "anip_PrepaidIncomeTaxesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "PrepaidIncomeTaxesNet", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid income taxes", "label": "Prepaid Income Taxes, Net", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "anip_PrivateInvestmentInPublicEquityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "PrivateInvestmentInPublicEquityMember", "presentation": ["http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails", "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "PIPE Shares", "label": "PIPE Shares", "documentation": "Information related to the Private Investment in Public Equity (\"PIPE Investment\")." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from public offering", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r4"] }, "us-gaap_ProceedsFromSaleOfBuildings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfBuildings", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the sale of building", "label": "Proceeds from Sale of Buildings", "documentation": "The cash inflow from sale of buildings." } } }, "auth_ref": ["r108"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from stock option exercises and ESPP purchases", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r4", "r17"] }, "anip_ProductIntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "ProductIntellectualPropertyMember", "presentation": ["http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product Intellectual Property", "label": "Product Intellectual Property [Member]", "documentation": "Product Intellectual Property" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails", "http://www.anipharmaceuticals.com/role/REVENURECOGNITIONANDRELATEDALLOWANCESTimingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": ["r288", "r584", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r837", "r872", "r908", "r910", "r911", "r915", "r917", "r1086", "r1087", "r1094", "r1163", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192"] }, "anip_ProductRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "ProductRightsMember", "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "NDAs and product rights", "label": "NDAs and product rights", "documentation": "NDAs and product rights" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails", "http://www.anipharmaceuticals.com/role/REVENURECOGNITIONANDRELATEDALLOWANCESTimingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": ["r288", "r584", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r837", "r872", "r908", "r910", "r911", "r915", "r917", "r1086", "r1087", "r1094", "r1163", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192"] }, "anip_ProfitBasedMilestonePaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "ProfitBasedMilestonePaymentsMember", "presentation": ["http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details"], "lang": { "en-us": { "role": { "terseLabel": "Profit-based milestone payments", "label": "Profit-based milestone payments [Member]", "documentation": "Profit-based milestone payments" } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r162", "r183", "r186", "r197", "r204", "r219", "r225", "r228", "r229", "r297", "r357", "r358", "r360", "r361", "r362", "r363", "r364", "r366", "r367", "r499", "r506", "r507", "r510", "r511", "r525", "r548", "r622", "r639", "r691", "r744", "r765", "r766", "r888", "r889", "r930", "r1035", "r1090"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "verboseLabel": "Total property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r10", "r563", "r623", "r637", "r899"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r969"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": ["r969"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails", "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r351", "r352", "r353", "r354", "r428", "r436", "r465", "r466", "r467", "r475", "r531", "r580", "r581", "r583", "r666", "r668", "r676", "r713", "r714", "r776", "r786", "r790", "r791", "r809", "r833", "r834", "r859", "r871", "r884", "r893", "r894", "r895", "r896", "r910", "r921", "r1083", "r1092", "r1135", "r1156", "r1157", "r1158", "r1159", "r1160"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails", "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r351", "r352", "r353", "r354", "r428", "r436", "r465", "r466", "r467", "r475", "r531", "r580", "r581", "r583", "r666", "r668", "r676", "r713", "r714", "r776", "r786", "r790", "r791", "r809", "r833", "r834", "r859", "r871", "r884", "r893", "r894", "r895", "r896", "r910", "r921", "r1083", "r1092", "r1135", "r1156", "r1157", "r1158", "r1159", "r1160"] }, "anip_RareDiseaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "RareDiseaseMember", "presentation": ["http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Rare Disease", "label": "Rare Disease", "documentation": "Component of the entity related to rare diseases and is considered an operating segment." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": ["r937", "r947", "r957", "r989"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r293", "r435", "r569", "r570", "r628", "r636", "r717", "r718", "r719", "r720", "r721", "r741", "r743", "r774"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r206", "r207", "r569", "r570", "r571", "r572", "r628", "r636", "r717", "r718", "r719", "r720", "r721", "r741", "r743", "r774"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label":

```
"Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r569", "r570", "r1152" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r293", "r748", "r749", "r752" ] }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "crdr": "debit", "presentation": [ "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to related party", "label": "Related Party Transaction, Purchases from Related Party", "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r293", "r435", "r569", "r570", "r628", "r636", "r717", "r718", "r719", "r720", "r721", "r741", "r743", "r774", "r1152" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r566", "r567", "r568", "r570", "r573", "r688", "r689", "r690", "r750", "r751", "r752", "r771", "r773" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on borrowings under credit agreements", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r1037" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r208", "r209", "r372", "r403", "r572", "r582", "r624", "r844", "r845" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r476", "r835", "r854", "r1161" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "anip_ReservesForCashDiscountMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "ReservesForCashDiscountMember", "presentation": [ "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prompt Payment Discounts", "label": "Prompt Payment Discounts", "documentation": "Reserves For Cash Discount" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r938", "r948", "r958", "r990" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r939", "r949", "r959", "r991" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r946", "r956", "r966", "r998" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1027", "r1041" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails", "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNonoptionactivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "RSAs", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r33" ] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/RESTRUCTURING" ], "lang": { "en-us": { "role": { "terseLabel": "RESTRUCTURING", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r340", "r341", "r343", "r346", "r350" ] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations", "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restructuring activities", "terseLabel": "Restructuring activity expense", "label": "Restructuring and Related Cost, Incurred Cost", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": [ "r342", "r345", "r347", "r349" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r342", "r343", "r347", "r348" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r342", "r343", "r344", "r345", "r347", "r348", "r349" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring accrual", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r343", "r348" ] }, "us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetailRelatedInventoryPackagingAndOtherSupplies", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Packaging materials", "label": "Retail Related Inventory, Packaging and Other Supplies", "documentation": "Carrying amount as of the balance sheet date of items used in storage, presentation or transportation of physical goods that are targeted for sale to end users." } } }, "auth_ref": [ "r1031" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r93", "r131", "r634", "r673", "r675", "r686", "r725", "r899" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r159", "r216", "r217", "r218", "r220", "r225", "r227", "r229", "r298", "r299", "r330", "r488", "r489", "r496", "r497", "r498", "r500", "r505", "r506", "r515", "r517", "r518", "r520", "r523", "r560", "r561", "r670", "r672", "r692", "r1197" ] }, "anip_ReturnedGoodsReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "ReturnedGoodsReserve", "crdr": "credit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Returned goods reserve", "label": "Returned Goods Reserve", "documentation": "Represents the reserve for goods returned." } } }, "auth_ref": [] },
```

```
"us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract
with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails",
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails",
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails",
"http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Net Revenues", "verboseLabel": "Total net revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
"documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to
customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction,
including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r146", "r147", "r255", "r264", "r265", "r279", "r285", "r288", "r290", "r292", "r425",
"r426", "r584" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerMember", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue
from Contract with Customer Benchmark", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of
performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [
"r292", "r1023" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCES" ], "lang": {
"en-us": { "role": { "terseLabel": "REVENUE RECOGNITION AND RELATED ALLOWANCES", "label": "Revenue from Contract with Customer [Text Block]", "documentation":
"The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of
revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to
obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r157", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424",
"r427" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGTables"
], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of revenue by geographic operations", "label": "Revenue from External Customers by Geographic Areas [Table Text
Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries
from which the entity derives revenue." } } }, "auth_ref": [ "r119" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining
performance obligations", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance
obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r155" ] }, "us-
gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance
obligations period", "label": "Revenue, Remaining Performance Obligation, Optional Exemption, Remaining Duration", "documentation": "Remaining duration of performance
obligation for which optional exemption was applied not to disclose amount of transaction price allocated to and timing of revenue recognition for remaining performance
obligation, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r424" ] }, "us-
gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues",
"documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but
is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } },
"auth_ref": [ "r146", "r147", "r191", "r204", "r255", "r264", "r265", "r279", "r285", "r288", "r290", "r292", "r297", "r357", "r358", "r360", "r361", "r362", "r363", "r364", "r366",
"r367", "r548", "r622", "r854", "r1090" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in
exchange for lease obligations", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset
obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r562", "r898" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": {
"role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1007" ] },
"ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1
Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1007" ] }, "anip_SThreeChemicalsPvtLtdMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.anipharmaceuticals.com/20240630", "localname": "SThreeChemicalsPvtLtdMember", "presentation": [
"http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SThree Chemicals Pvt Ltd", "label": "SThree
Chemicals Pvt Ltd [Member]", "documentation": "SThree Chemicals Pvt Ltd" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
"http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of
Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] },
"anip_SalesOfBrandedRoyaltiesAndOtherPharmaceuticalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630",
"localname": "SalesOfBrandedRoyaltiesAndOtherPharmaceuticalServicesMember", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales of
established brand pharmaceutical products, royalties, and other pharmaceutical services", "label": "Sales of established brand products, royalties, and other pharmaceutical
services", "documentation": "Related to sales of established brand, royalties, and other pharmaceutical services." } } }, "auth_ref": [] },
"anip_SalesOfContractManufactureProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"SalesOfContractManufactureProductsMember", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales of contract
manufacture products", "label": "Sales of contract manufacture products [Member]", "documentation": "Sales of contract manufacture products" } } }, "auth_ref": [] },
"anip_SalesOfContractManufacturedProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"SalesOfContractManufacturedProductsMember", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales of contract
manufactured products", "label": "Sales of contract manufactured products", "documentation": "Sales of contract manufactured products" } } }, "auth_ref": [] },
"anip_SalesOfGenericPharmaceuticalProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"SalesOfGenericPharmaceuticalProductsMember", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales of
generic pharmaceutical products", "label": "Sales of generic pharmaceutical products", "documentation": "Sales of generic pharmaceutical products" } } }, "auth_ref": [] },
"anip_SalesOfRareDiseasePharmaceuticalProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"SalesOfRareDiseasePharmaceuticalProductsMember", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales of
rare disease pharmaceutical products", "label": "Sales of rare disease pharmaceutical products", "documentation": "Related to sales of rare disease pharmaceutical products."
} } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.anipharmaceuticals.com/role/PENDINGMERGERAGREEMENTDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation":
"Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r56", "r57", "r501" ] }, "us-
gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock",
"presentation": [ "http://www.anipharmaceuticals.com/role/INDEBTEDNESSTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of carrying value of the current
and non-current components of the term loan", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt
instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt
arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref":
[ "r21", "r47", "r48", "r77", "r129", "r130", "r867", "r869", "r1045", "r1147" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [
"http://www.anipharmaceuticals.com/role/EARNINGSPERSHARETables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of earnings per share, basic and diluted",
"label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share
calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } },
"auth_ref": [ "r1052" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of allocated expense", "label":
"Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and
capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not
limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r52" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [
"http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label":
"Investment, Name [Axis]" } } }, "auth_ref": [ "r294", "r295", "r296", "r495", "r1020", "r1021", "r1022", "r1123", "r1124", "r1125", "r1126" ] }, "us-
gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [
"http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of financial assets and liabilities accounted
for at fair value on a recurring basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular
disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on
a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair
value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other
observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1132", "r1133" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype":
```

```
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [
"http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails",
"http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]",
"label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other
reason." } } } }, "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r860" ] }, "us-
gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "lang": {
"en-us": { "role": { "verboseLabel": "Schedule of components of intangible assets", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "documentation":
"Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": [ "r1064", "r1067" ] }, "us-
gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/INVENTORIESTables" ], "lang": { "en-us": { "role": { "verboseLabel":
"Schedule of inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet
date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r23", "r97",
"r98", "r99" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/INDEBTEDNESSTables" ], "lang": { "en-us": { "role": {
"verboseLabel": "Schedule of contractual maturity of term loan and DDTL", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular
disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [
"http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by
Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r75",
"r76", "r748", "r749", "r752" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSTables" ],
"lang": { "en-us": { "role": { "terseLabel": "Schedule of related party transactions", "label": "Schedule of Related Party Transactions [Table Text Block]", "documentation":
"Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its
subsidiary, (b) subsidiaries of a common parent, (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring
cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring
reserve." } } }, "auth_ref": [ "r342", "r343", "r344", "r345", "r347", "r348", "r349" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [
"http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by
Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r41", "r42", "r43" ] }, "us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGTables" ], "lang": { "en-
us": { "role": { "terseLabel": "Schedule of financial information by reportable segments", "label": "Schedule of Segment Reporting Information, by Segment [Table Text
Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable
segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the
chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r41", "r42", "r43" ] }, "us-
gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": {
"en-us": { "role": { "verboseLabel": "Summary of stock option and restricted stock activity", "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
"documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end
of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": [ "r15", "r16", "r132" ] }, "us-
gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNonoptionactivityDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based
Compensation Arrangements by Share-Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award
[Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r438", "r440", "r443", "r444", "r445", "r446", "r447",
"r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468" ] },
"anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630",
"localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of accruals and
allowances", "label": "Schedule Of Valuation And Qualifying Accounts Disclosure [Table Text Block]", "documentation": "Schedule Of Valuation And Qualifying Accounts
Disclosure" } } }, "auth_ref": [] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of customer
concentration", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a
benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r34", "r35", "r36", "r37", "r73", "r139" ] },
"anip_ScitusPharmaServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"ScitusPharmaServicesMember", "presentation": [ "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Scitus Pharma Services", "label": "Scitus Pharma Services", "documentation": "Represents the information pertaining to Scitus Pharma Services." } } },
"auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title
of a 12(b) registered security." } } }, "auth_ref": [ "r932" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.anipharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": {
"terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [
"r934" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [
"http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments
[Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with
other components of the same entity." } } }, "auth_ref": [ "r146", "r147", "r148", "r149", "r255", "r260", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271",
"r272", "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r285", "r286", "r287", "r292", "r305", "r306", "r307", "r308", "r309", "r310", "r311",
"r312", "r313", "r329", "r345", "r349", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r851", "r854", "r855", "r860", "r913", "r1163",
"r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183",
"r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r290", "r291", "r587", "r588", "r589", "r590",
"r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612",
"r613", "r614", "r615", "r616", "r706", "r708", "r710", "r779", "r788", "r796", "r814", "r822", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r838",
"r873", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r912", "r921", "r1094", "r1163", "r1165", "r1166", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173",
"r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192" ] },
"us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": {
"role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [
"http://www.anipharmaceuticals.com/role/SEGMENTREPORTING" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT REPORTING", "label": "Segment Reporting
Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the
following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined
revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1)
the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets
are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r149", "r255", "r259", "r260", "r261", "r262", "r263", "r275", "r277", "r278",
"r283", "r284", "r285", "r286", "r287", "r288", "r289", "r292", "r850", "r852", "r853", "r854", "r856", "r857", "r858" ] }, "us-gaap_SegmentReportingInformationLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [
"http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Segment reporting", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations": {
"parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations", "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
], "lang": { "en-us": { "role": { "verboseLabel": "Selling, general, and administrative", "terseLabel": "Corporate and other unallocated expenses", "label": "Selling, General and
Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses.
Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are
expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses
include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r104" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general, and administrative",
"label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative
expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-
```

gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label":
"Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": { "r8" } },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Performance period", "label": "Share-
Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "documentation": "Estimated period over which an employee is required
to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five
months, and thirteen days." } } }, "auth_ref": ["r885"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
"presentation": ["http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based
Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based
payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents
reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r885"]
}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Discount from market price (as a
percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date", "documentation": "Discount rate
from fair value on purchase date that participants pay for shares." } } }, "auth_ref": ["r51"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
"presentation": ["http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNonoptionactivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited
(in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [
"r459"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNonoptionactivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of
grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target
plan)." } } }, "auth_ref": ["r457"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"presentation": ["http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Grate date fair value
(in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted
Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than
stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r457"] },
"anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage": { "xbrltype":
"percentItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum potential to vest
percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest,
Percentage", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to
Vest, Percentage" } } }, "auth_ref": [] },
"anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares": { "xbrltype":
"sharesItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum potential to vest (in
shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Shares",
"documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Shares" } }
}, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNonoptionactivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at the
beginning of the period (in shares)", "periodEndLabel": "Outstanding at the end of the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based
Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding
stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r454", "r455"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNonoptionactivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-option Shares", "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] },
"anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards": { "xbrltype": "percentItemType",
"nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of awards", "label": "Share-
Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Percentage of Awards", "documentation": "Share-Based
Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Percentage of Awards" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"presentation": ["http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNonoptionactivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Exercised
(in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation":
"The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r458"] },
"anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage": { "xbrltype": "percentItemType", "nsuri":
"http://www.anipharmaceuticals.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage",
"presentation": ["http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimate number of
shares percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Estimate Number of Shares, Percentage", "documentation": "Share-
Based Compensation Arrangement by Share-Based Payment Award, Estimate Number of Shares, Percentage" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNonoptionactivityDetails",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a
table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r438",
"r440", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463",
"r464", "r465", "r466", "r467", "r468"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails", "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"], "lang": {
"en-us": { "role": { "terseLabel": "Stock-based compensation additional shares authorized", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award,
Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref":
[] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation shares
available", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference
between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum
of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of
equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r51"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were
cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } },
"auth_ref": ["r452"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in shares)", "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share

units) granted during the period." } } }, "auth_ref": ["r450"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at the beginning of the period (in shares)", "periodEndLabel": "Outstanding at the end of the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r446", "r447"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Option Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails", "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNonoptionactivityDetails", "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468"] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": ["http://www.anipharmaceuticals.com/role/INVENTORIESConcentrationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Axis]", "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": ["http://www.anipharmaceuticals.com/role/INVENTORIESConcentrationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Domain]", "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Award expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r886"] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": ["http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNonoptionactivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares purchased to cover employee income taxes", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "anip_SsPharmaLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "SsPharmaLlcMember", "presentation": ["http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "SS Pharma LLC", "label": "SS Pharma LLC", "documentation": "Represents the information pertaining to SS Pharma LLC." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r146", "r147", "r148", "r149", "r160", "r255", "r260", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r285", "r286", "r287", "r292", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r329", "r333", "r345", "r349", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r851", "r854", "r855", "r860", "r913", "r1163", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity", "http://www.anipharmaceuticals.com/role/Cover", "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails", "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r158", "r173", "r174", "r175", "r204", "r234", "r238", "r246", "r250", "r257", "r258", "r297", "r357", "r360", "r361", "r362", "r366", "r367", "r400", "r401", "r405", "r408", "r414", "r548", "r682", "r683", "r684", "r685", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r724", "r745", "r767", "r816", "r817", "r818", "r819", "r820", "r1019", "r1042", "r1051"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity", "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r13", "r91", "r94", "r95", "r159", "r188", "r189", "r190", "r216", "r217", "r218", "r220", "r225", "r227", "r229", "r256", "r298", "r299", "r330", "r415", "r488", "r489", "r496", "r497", "r498", "r500", "r505", "r506", "r515", "r516", "r517", "r518", "r519", "r520", "r523", "r550", "r552", "r553", "r554", "r555", "r556", "r560", "r561", "r565", "r641", "r670", "r671", "r672", "r692", "r767"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": ["r290", "r291", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r706", "r708", "r710", "r779", "r788", "r796", "r814", "r822", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r838", "r873", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r912", "r921", "r1094", "r1163", "r1165", "r1166", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r216", "r217", "r218", "r256", "r561", "r584", "r678", "r703", "r715", "r717", "r718", "r719", "r720", "r721", "r724", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r737", "r738", "r739", "r740", "r741", "r743", "r746", "r747", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r767", "r922"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r216", "r217", "r218", "r256", "r293", "r561", "r584", "r678", "r703", "r715", "r717", "r718", "r719", "r720", "r721", "r724", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r737", "r738", "r739", "r740", "r741", "r743", "r746", "r747", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r767", "r922"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": ["r941", "r951", "r961", "r993"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "anip_StockIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "StockIncentivePlanMember", "presentation": ["http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails", "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "2022 Plan", "label": "2022 Plan", "documentation": "Related to the entity's 2022 Stock Incentive Plan for equity-based service awards." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock in Public Offering (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r13", "r90", "r91", "r131", "r682", "r767", "r817"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Restricted Stock Awards Forfeitures (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "documentation": "Number of shares related to Restricted Stock Award forfeited during the period." } } }, "auth_ref": ["r13", "r90", "r91", "r131"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Restricted Stock Awards (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": ["r13", "r131"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"], "lang": { "en-us": { "role": {

```
"verboseLabel": "Issuance of Performance Stock Units (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r13", "r90", "r91", "r131" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)", "negatedTerseLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r13", "r90", "r91", "r131", "r451" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock in Public Offering", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r13", "r90", "r91", "r131", "r692", "r767", "r817", "r930" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Shares upon Stock Option and ESPP Exercise", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r13", "r91", "r94", "r95", "r131" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets",
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders\u2019 Equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r91", "r94", "r95", "r121", "r726", "r742", "r768", "r769", "r899", "r931", "r1044", "r1063", "r1145", "r1197" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 Equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] },
"anip_StockholdersEquityAttributableToParentAndTemporaryEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630",
"localname": "StockholdersEquityAttributableToParentAndTemporaryEquity", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" ], "lang": { "en-us": { "role": {
"periodStartLabel": "Beginning balance, permanent and temporary equity", "periodEndLabel": "Ending balance, permanent and temporary equity", "label": "Stockholders' Equity Attributable to Parent and Temporary Equity", "documentation": "Total of all stockholders' equity (deficit) items attributable to the parent and temporary equity." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "MEZZANINE AND STOCKHOLDERS' EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r128", "r203", "r399", "r401", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r415", "r522", "r770", "r772", "r821" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [
"http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r557", "r575" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label":
"Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r557", "r575" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventTable", "presentation": [ "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r557", "r575" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label":
"Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r557", "r575" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r557", "r575" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] },
"us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTS" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } },
"auth_ref": [ "r574", "r576" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsidiarySaleOfStockAxis", "presentation": [ "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
"http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Supplemental disclosure for cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplierConcentrationRiskMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierConcentrationRiskMember", "presentation": [
"http://www.anipharmaceuticals.com/role/INVENTORIESConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Concentration Risk", "label": "Supplier Concentration Risk [Member]", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth_ref": [ "r118" ] }, "ecd_TabularListTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r987" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r80", "r81" ] }, "us-gaap_TemporaryEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityAbstract", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Mezzanine Equity", "label": "Temporary Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityByClassOfStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TemporaryEquityByClassOfStockTable", "presentation": [ "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary Equity, by Class of Stock [Table]", "label": "Temporary Equity, by Class of Stock [Table]", "documentation": "Disclosure of information about equity instrument classified as temporary equity. Includes, but not is limited to, description of share, value, share authorized, issued, and outstanding, redemption price per share, and subscription receivable." } } }, "auth_ref": [ "r22", "r46" ] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } },
"presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets",
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel":
"Convertible Preferred Stock, Series A, $0.0001 par value, 1,666,667 shares authorized; 25,000 shares issued and outstanding at June\u00a030, 2024 and December\u00a031, 2023", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r357", "r360", "r361", "r362", "r366", "r367", "r473", "r632" ] }, "us-gaap_TemporaryEquityLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityLineItems", "presentation": [
"http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary Equity [Line Items]",
"label": "Temporary Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Preferred Stock, par value (in dollars per share)", "label": "Temporary Equity, Par or Stated Value Per Share", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": [ "r22", "r46" ] }, "us-gaap_TemporaryEquityRedemptionPricePerShare": { "xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityRedemptionPricePerShare", "presentation": [
"http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
"http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary stock issued (in dollars per share)", "label": "Temporary Equity, Redemption Price Per Share", "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable
```

at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r22", "r46"] }, "us-gaap_TemporaryEquitySharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesAuthorized", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Convertible Preferred Stock, shares authorized", "label": "Temporary Equity, Shares Authorized", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r89"] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesIssued", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Convertible Preferred Stock, shares issued", "label": "Temporary Equity, Shares Issued", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r89"] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesOutstanding", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity", "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Convertible Preferred Stock, shares outstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "terseLabel": "Convertible preferred stock outstanding (shares)", "label": "Temporary Equity, Shares Outstanding", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r89"] }, "anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails", "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Temporary stock issued (in shares)", "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock classified as temporary equity issued during the period." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails", "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Temporary stock issued, value", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "documentation": "Value of new stock classified as temporary equity issued during the period." } } }, "auth_ref": [] }, "anip_TermLoanAndDelayedDrawTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "TermLoanAndDelayedDrawTermLoanMember", "presentation": ["http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Term Loan and DDTL", "label": "Term Loan and DDTL", "documentation": "Information related to the Term Loan and Delayed Draw Term Loan." } } }, "auth_ref": [] }, "anip_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "TermLoanMember", "presentation": ["http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails", "http://www.anipharmaceuticals.com/role/INDEBTEDNESSMaturityofcreditfacilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Term Facility", "label": "Term Facility", "documentation": "Term Facility" } } }, "auth_ref": [] }, "anip_ThresholdNumberOfTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "ThresholdNumberOfTradingDays", "presentation": ["http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Threshold number of trading days", "label": "Threshold Number of Trading Days", "documentation": "Threshold number of trading days." } } }, "auth_ref": [] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": ["http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Timing of Transfer of Good or Service [Axis]", "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": ["r877", "r1094"] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": ["http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Timing of Transfer of Good or Service [Domain]", "label": "Timing of Transfer of Good or Service [Domain]", "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": ["r877", "r1094"] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails", "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title and Position [Axis]" } } }, "auth_ref": ["r1060", "r1151"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONInformationDetails", "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r979"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": ["r986"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement [Axis]" } } }, "auth_ref": ["r1006"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": ["r1008"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.anipharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransferredAtPointInTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferredAtPointInTimeMember", "presentation": ["http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations transferred at a point in time", "label": "Transferred at Point in Time [Member]", "documentation": "Contract with customer in which good or service is transferred at point in time." } } }, "auth_ref": ["r877"] }, "us-gaap_TransferredOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferredOverTimeMember", "presentation": ["http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations transferred over time", "label": "Transferred over Time [Member]", "documentation": "Contract with customer in which good or service is transferred over time." } } }, "auth_ref": ["r877"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": ["r1009"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": ["r1010"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": ["r1010"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": ["r1008"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": ["r1008"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": ["r1011"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": ["r1009"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r49"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares at cost", "periodStartLabel": "Beginning Balance, Treasury (in shares)", "periodEndLabel": "Ending Balance, Treasury (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r49"] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr":

```
"debit", "calculation": { "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheets",
"http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNonoptionactivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, 412,587 shares of common stock, at cost, at June\u00a030, 2024 and 263,943 shares of common stock, at cost, at December\u00a031, 2023", "terseLabel": "Treasury stock value", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r49", "r50", "r94" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock Purchases for Restricted Stock Vests (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r13", "r91", "r131" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury Stock Purchases for Restricted Stock Vests", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r13", "r49", "r131" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [
"http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r342", "r343", "r347", "r348" ] }, "country_US": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [
"http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "anip_UnapprovedProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname": "UnapprovedProductsMember", "presentation": [ "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Unapproved Products", "label": "Unapproved Products", "documentation": "Unapproved Products" } } }, "auth_ref": [] }, "us-gaap_UndistributedEarnings": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarnings", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income available to common shareholders, Basic", "label": "Undistributed Earnings, Basic", "documentation": "The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed." } } }, "auth_ref": [ "r244", "r248" ] }, "us-gaap_UndistributedEarningsDiluted": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarningsDiluted", "crdr": "credit", "calculation": {
"http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income available to common shareholders, Diluted", "label": "Undistributed Earnings, Diluted", "documentation": "The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed. Includes the adjustments resulting from the assumption that dilutive securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions." } } }, "auth_ref": [] }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails": { "parentTag": "us-gaap_UndistributedEarnings", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Earnings allocated to participating securities, Basic", "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic", "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method." } } }, "auth_ref": [ "r244", "r247", "r248" ] }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted", "crdr": "debit", "calculation": { "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails": { "parentTag": "us-gaap_UndistributedEarningsDiluted", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Earnings allocated to participating securities, Diluted", "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted", "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method." } } }, "auth_ref": [ "r244", "r247", "r248", "r1018" ] }, "us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract", "presentation": [
"http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic", "label": "Undistributed Earnings (Loss) Available to Common Shareholders, Basic [Abstract]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": {
"role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r1005" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [
"http://www.anipharmaceuticals.com/role/BUSINESSPRESENTATIONANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r38", "r39", "r40", "r151", "r152", "r153", "r154" ] }, "us-gaap_ValuationAllowancesAndReservesAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesAdjustments", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accruals/Adjustments", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment", "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment." } } }, "auth_ref": [ "r1046" ] }, "us-gaap_ValuationAllowancesAndReservesBalance": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesBalance", "crdr": "credit", "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Adjustments for chargebacks and other allowances", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "documentation": "Amount of valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r211", "r215" ] }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesDeductions", "crdr": "debit", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Credits Taken Against Reserve", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "documentation": "Amount of decrease in valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r214" ] }, "us-gaap_ValuationAllowancesAndReservesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesDomain", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "documentation": "Valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r211", "r212", "r213", "r214", "r215" ] }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesTypeAxis", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "documentation": "Information by valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r211", "r212", "r213", "r214", "r215" ] }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "auth_ref": [ "r211", "r212", "r213", "r214", "r215" ] }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ValuationAndQualifyingAccountsDisclosureTable", "presentation": [
"http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "auth_ref": [ "r211", "r212", "r213", "r214", "r215" ] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Axis]", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r529", "r530", "r893", "r1136" ] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": [
"http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Probability-weighted discounted cash flow", "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": [
"r893", "r1134", "r1135", "r1136" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.anipharmaceuticals.com/role/FAIRVALUEDISCLOSURESLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Domain]", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r529", "r530", "r893", "r1136" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r975" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": [
"http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": {
"http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations", "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted Weighted-Average Shares Outstanding (in shares)", "totalLabel": "Diluted Weighted-Average Shares Outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r233", "r250" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.anipharmaceuticals.com/role/CondensedConsolidatedStatementsofOperations", "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic Weighted-Average Shares Outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r231", "r250"
```

```
} }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://www.anipharmaceuticals.com/role/EARNINGSPERSHAREDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Basic", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]" } } }, "auth_ref": [] },
"anip_WellSpringPharmaServicesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anipharmaceuticals.com/20240630", "localname":
"WellSpringPharmaServicesIncMember", "presentation": [ "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "WellSpring", "label": "WellSpring", "documentation": "WellSpring" } } }, "auth_ref": [] },
"ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year
that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r973" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-
4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic":
"830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-
45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "10",
"Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r6":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-
45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)",
"SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-
1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic":
"470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r14": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r17": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10",
"Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r20": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r24": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" },
"r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r29": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r31":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-
5" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph":
"1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r36": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" },
"r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-
8" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph":
"9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-22" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50",
"Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r45":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-
S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50",
"Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r50": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r52":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r55": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r57":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r60": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph":
"(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r63": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" },
```

"r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482309/360-10-15-4" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

```
"Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r196": { "role":
```

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "65", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-65" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "66", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-66" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
```

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-11" }, "r392": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-11" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-11" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-
50-11" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r396": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r397": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r400": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-13" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r404": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-13" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r408": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-16" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r412": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r415": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r416": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-
50-12" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r420": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12A" }, "r423": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r424": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r427": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-
50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r437": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/718/tableOfContent" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r439": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r441":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r445": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r446": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r447": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r448": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r449": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r450": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r451": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r452": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r453": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r454": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r455": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",

"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r518": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r519": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r520": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r521": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-
40-65-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r525": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r529": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r530": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r531": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r532": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-
10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r536": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r543": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-6A" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r547": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r552": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-
45-20" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r556": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r558":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-
30-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r561": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r562": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r563": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-
50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r570": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r573": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-
50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r578": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r579": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r580": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r581": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-

```
210-50-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r707": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r708": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-
210-50-6" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r712": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-
50-6" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r716": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r717": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r718": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r719": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r720": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r721": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r722": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r723": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r724": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r725": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r726": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r727": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r728": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r729": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r730": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r731": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r732": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r733": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r734": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r735": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r736": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r737": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r738": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r739": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r740": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r741": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r742": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r743": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r746": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r747": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r748": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r749": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r750": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r751": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r752": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r753": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r754": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r755": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r756": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r757": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r758": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r759": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r760": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r761": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r762": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r763": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r764": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
```

```
"Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r765": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r766": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r767": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r768": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r769": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r770": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-
50-2" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r774": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-
320-S99-12" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section":
"S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r785": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19",
"Subparagraph": "(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r786": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r787": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r788": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r789": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r790": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r791": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r792": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r793": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r794": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r795": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r796": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r797": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r798": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r799": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5",
"Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r800": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5",
"Subparagraph": "(SX 210.12-13(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r801": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5",
"Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r802": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A",
"Subparagraph": "(SX 210.12-13A(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r803": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B",
"Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r804": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B",
"Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r805": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C",
"Subparagraph": "(SX 210.12-13C(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r806": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C",
"Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r807": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r808": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r809": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r810": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r811": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r812": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r813": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r814": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r815": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r816": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-
50-2" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r820": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name":
```

"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-

10-55-4J" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r921": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r922": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r923": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r924": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r925": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r926": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r927": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r928": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r929": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r930": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r931": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r971": { "role":

```
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "i" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "iii" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "v" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r980": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "vi" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "3" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "4" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r985": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5",
"Subparagraph": "iii" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r989": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" },
"r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w",
"Paragraph": "1", "Subparagraph": "i" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r993": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "C" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r996": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
"Subparagraph": "ii" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1000": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1001": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1002": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2",
"Subparagraph": "ii", "Sentence": "C" }, "r1003": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1004": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1005": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2",
"Subparagraph": "ii", "Sentence": "F" }, "r1006": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "408", "Subsection": "a" }, "r1007": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1008": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1009": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1010": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2",
"Subparagraph": "C" }, "r1011": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408",
"Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1012": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1013": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1014": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii",
"Sentence": "A", "Number": "229" }, "r1015": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1016": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii",
"Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1017": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation
S-T", "Number": "232", "Section": "405" }, "r1018": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "260", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "60", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60" }, "r1019": {
"role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1020": { "role":
"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1021": { "role":
"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1022": { "role":
"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1023": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1034": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-
10-50-6" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1037": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1038": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1039": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1040": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-
10-50-8" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1043": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1044": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1045": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1046": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4",
```

```
"Subparagraph": "(SX 210.12-09)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r1047": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1048": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1051": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1052": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1053": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1054": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-30" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1058": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1059": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1060": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-
10-45-2" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r1063": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1064": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/350-20/tableOfContent" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" },
"r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1067": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/350-30/tableOfContent" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1069": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1070": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1071": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1072": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1073": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1074": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1075": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1076": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1077": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1078": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r1079": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-
50-1" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1083": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1084": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1085": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1086": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1087": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1088": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1089": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1090": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1091": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1092": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1093": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1094": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1098": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1099": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1100": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1101": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1102": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1103": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1104": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1105": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1106": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1107": { "role":
```

```
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1108": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1109": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1110": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1111": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1112": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1113": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1114": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1115": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1116": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1117": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1118": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1119": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1120": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1121": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-
323-50-1A" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1125": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1126": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1127": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-
10-50-1A" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1131": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "915", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1132": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1133": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1134": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1135": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1136": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1137": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1138": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1139": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1140": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1141": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1142": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1143": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1144": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1145": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-2B" }, "r1146": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-
30-45-2" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1149": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1152": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-
50-7" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1156": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1157": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1158": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1159": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1160": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1161": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-
310-50-3" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1166": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1167": { "role":
```

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 88 0001023024-24-000085-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001023024-24-000085-xbrl.zip M4$L#!!0 (#DW!EDZ.YR*H>0!`-8V&@`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|>9'|S;MNV#Y8(O-Y)VF MJ0HTG[V5T9D$KK? G9Y>>QQ]OJ>,.$23+K]V5-':O^#@_^DVS[A.# 6F)C,CL MF^1J*D(:9#U3VJUT3'%"C->L D>O'(<\W0 M6//2^&*Z%]J@Y .KWU_SRN1RJI<.B1."E 1PXS),V7MG[TB'5AC0< U&\5*J ME_5A/3'7#3&^N,L+XW4X&B#8RLGOE(6!DW^!VD%26M23V)*5^82VIW_F@\/ M+SX\&<'\VT?,RD_^!>CR @P&L[#KE:S_R7/3.]-AFG.W%}]PG#Y_)7DW\E' M/L[->S49U&.3(9Y-I$"B?YKPL?>1;1E6\#T*:IO6$$T5UYGQKA)SIFT3WW_H M=P/7^-EZMV)3FX!^V3H.NQ")Y?/ZY_802DU'LP)LH1Q7$Y*[-D#NYL@^Y MM0*2F\D9^[G='5'#(G:A2*YS(.CS,ZMF-+,*7S/3P+>YTI0L9E8MH)A,M9+S M2KT__:Y'YEUXU#R)P&0%JYH@?G[(KQ>:.^*=9CS,D=T.0^Y2J!7,8A:-W3O9/ M9C0_NJ=S)C3/4*TH1W>K]O N]=-[E\K1_9VT=- !VIX.6(1UX<$(6Z;!KM"%+ M.AS=93E#VU+6LM)*_+M5=W^$6)+I#D>N@TFEO S,[&C.OS>UF>8MT[0P,T?L M1V*9':=-1E9 [,+0GW^:C/JGST6TAXSU$<"4!C:\^]=; <&^883#T,8=+_!M@'IXGT<'^+97&B79B\(+E7_/:S,OGFA +(>:=\1S+.?%+PSA>4@'T'6EJ_">/ M.%G;,'!!5/Y33QPLA#PPZNB^8I&M=!X8Q+\3F_=2R@.7BN[LYF)\\L X_CUF M#F-$664+U*+[RR>,$65&\\+[R?G$B+*BOU9TWSB'&%%FM.<_.\GA,GTD7A3= MGS]UC"@SPO.0)CW2U/CW9GFSYO3L(G1:T5W5$]8X94;SPCN>.5AS6=*?7_^1 M+VLN2]H7W7O,VYK+DA=%]RI/:LUE2'C]Z.YD?E,KO+>2\8OG^)+O>CNW.DS M?CDQJNBIV=-E_')B$/],-Y+.*0]<*KJSFW_&+R?&%=UC+N!.++WH7G).48K, MZ%]T3SF'*$5FM"^Z9\Q!E'"*S'@9%$[V>.DJ1&>'Y=^5Y2\RHV6T0K13=-S^5 MR9,ES8ON9N=A\F1)_Z}{T:;*DO?"-^>%%T=W=DYH\61+^Z#YO?E,KNCN9 MVU:L'+H@5(KN? ^:R%2L'1E6+[IR>="MG'@SBWXG->RGE@4M%=W;S3\SDQ+BB M>\P%[$A8+;J7G,]FH.SH7W1/^?2;@;*C?=$]X{RC%%GRHN@)XA-O!LJ.\,*5 MW[-T)87C$ZK"E2\&HVK"E>> <0<*5+P*7A"M?4,9QZ\K?6O{!8GJU7/#$2OY M@!<:T?&"&ZT/K[!#=D;9RI'.#U_(#]?+=NF#PX MPW*_N-Z0>M\G\N'1*[!$)]L=N)(O5*)61BT->XB&KX7W#Q&Q[ ]>/'YNS,L MZ *H_(?^5^K +(W' ?&&Q*!A *BTX\?.LX*^QEWL@W].Y=,DJ\9=I(1_3N6T M\'(71^&?4_ED.VK-GNG!Q%X8I M(.OR6'_C,8%WZ?>N!! MNZZYP,!UC6ZR:-F*WAT+2?H./""\VSO4.ZB' 5A5SX+6(.[,$=! MV)73VE?0.$<;9N$1(Y@6U=#C^,GX7!W]#@-I"0BO)?75@5'/S"$]__M.$:&Z4CTYS8HD(K^TWN^N!Y33$\4-`6>E%^^,"MHY^.#R88598?8 WL*_U" MIXG8@LF% (G/KQ:=B2/(SB$6;^ -6JAPZ07'8P*UWSL_*S(?_/0]"SZ=8!WG M@EO<>N6\KOI<<(T[Y[PH-@(7W./,O^?;H.'"9R(ND;,PR_'.4446@8&<&2-B M YPP0H0&^&*((D(#7+!!A ;2D3ZJ{(PBO/V<&2 <>$X8(7QRSA@BW&PNV" \ MYZVDYZ \2U&$FUTD;@F?O(A<$PY\@;FG"F^_>#P3H8$TAE^&E92**D(#.3- MA 8X880(#7#&$!$:X((-W\4&<*/#=_)OH&? H!^Z0>K/-6[^XX?3W+43>F>%M M%WCL!%&KV"?+__EY_)DZQF'(O(5CD5L&XRYH/X-:KZ1G;]MX=,@8IDB;W!3/ M?.GF,S4!+P)1GF.:TZ&O<1? @$3'F&:4[%R!IW0]FDQ,U$"J!=GH18S%R6 >G$V:C&S45A_(G!Z02:J M7LQTE,#1A5FH>C'S40*G%V:@ZL5,2 F<7!A]JG.7D4K8\3GT+8?Z?LOX({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`5K:I>E;D+ M(@D0%6\YXS9H)D!4E)TCJLQM ' GWD7%}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`MU@A;W?48^JE;#^,-=VGEA#?_(';(6G\\4V/@'6'^$"V4]R]=O+=]@3I+9)O[@ MB^V^994;^TZ)'WJL(4G'&87!.(LH DC&^?+'9N^?VK8#U M>?]NV;!TN@Z-[RQ.15F#.W][DJ@EEH?P;XMFR@=N8S?\VZ*9\H';. TW MRT"FY+[HD,2%_ZBPR 7SON+#KU<..^Y#? =,NJ&S,4$/?,/>?*$>5>@%N M)'KT:)]ZWFJ;G7<7QB MH*[V^]GKRRV2YA>R0H):\8QV_L:G@_],;6(=S>$VPB30PMU&)$WA M-@XFT,+=%E9-X39.)]#"W? 8V3>$VIK@#EV(.?;.WJ23@!>)%-5>XC80*D/!C MI7 ;,A4@X<\:+N:']5K10FF7%IX_%M]%3&S-.+9TW?SN77<'Q!F&+V38:F!3*$K.08E=]':"R.*

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¥ MR<68KAK#%3P#,T$"_%,22@N3C8?E1I84>$?R@8]L MY]OD8(IF) 2;>40$@V(1_GITP[>R0%1M$5$]4OG'?>?\[E;]/K>>[[K5&)@9 M/''^C[=ZU?SQUGCMW7:EU? RO=_4_[]];]USNI_?#}>Z?;[3S<EV^OVM:3*%/VQ=M@SL*ER!)LO#T_?!5]AK7!WKA'BFO8\'H&NPM6D#S_V+UH34B/OOD'@P>'O\1$>%NY2DONL-20#FS'MPTI?> MJ7D5>.$$E&J!-;X6D8&9#_$RE=S__M%Z>KY[^O8OZ>GN\'16?IQ?WOW)(%F M?0,U*2F:]/ D*94/YB_2PQ?I^?<[-4,I3A1NJ_V,EY6&IL^19^ M% RH]$>"%2DREB4*]I6YAYI[9(_? 17&E>N3#*^&E/B75$G M@:.!6:OX[=*BDR65)9;[)C@IR!^H*72GTV985&K>BLDV9ZQ5FG[C^-1&/J!:9[MWAKS^:EUW^TP[2A4YH+*#"9P271FWW.'TG_^1:G*GX[}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{QC 9U(9$-(I)#([*72\B4BV<2#Q9 8!D@DJLHQ M&8@]7*I6_BH!]}67O"'(,KP%2)95P#W0R#"N(SK,;P.%C&,UQ(+Y[f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f;B0K2HB4__X]LSVL M1FYD'MUX>`"'O}4K7=K6*ORU/'R$}W[7#8/TC\T37Y/E.6*J^H1QVE8Y>Z.>T M8RNOVJ25U\";^A8O]*KG4?+SBO3AHS?$?B-C'TDG^GV=2{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{1GJM$'WN?6#U++&1K! *$ADF%"0W8TG#N6JIV06Z MDF!OO^U(VW>%3!XHDUCIN;$10_X'9LSPJD0-Y%<=UE!]JED0A'OX+_SVY*>,?O4C16 %C$V@R,Z*F)@^4NG=TBN(U)AM$9 M'Y@W-V!1(I8C65-/"? X&3(W5X*K\;?YV]]/RZ9=RU%LI>,MRM^+MLZ<$QI_1UWYF]N,D{]=2 M-S0&LY,$0MFA2AN=HFE[X(I'1R,8#':/1DUX/C]9D4%ES"WL5_,((2-?>1MVW<")_KCN M7@-$73-J78RWM4Q8-=CY8HRI[S?&<@-O0E5 MRHPFB$OA4'17A.$1.X}G%Q*B89A$MJWC8C8ANL'C&I(6Q1M)(N>P=%,D\ NK[M%%NM?X(6@>.P)9 /_^*#?]D_25 G90&X#IGIC=H-EN'@3R&O\^7JV M0"45!'0@)#8(T$ND 5%?.SYE/X)HF4E#0H.,\(VP6/B@Z9AHH?Q-*?!BNSVX M#G,UZ=_R?#0'4"?VXJ/3HV749:'[F:4K&)#I\@9F!>@-]&.Q,6+D3H/N):A% M0IN@K1$,7'9<,SP5!8-,Y?_" $E#O1{&@"@E64^(D.QUWKP OXFE^.091< M>K-@U5KX+5]LEFX=V4#PI\GB^C"A6@97ORU!\L'K)!+K[*0+C:?7D8KR()% M>?) {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{6>4D[B53EZ5N4'H8@O=34JH @7K8)7Y(S !QDYTE[M[IC8>^^9OX@$TW9MBI1\2@BYIS!@Y8=!>*8T?G3=- H.2EBM^_8F&8Y1=TSI4T30F8CDGN)28^*B M<%/1+PS8$W8IR1I,=5B^M?MSLLFIHT795]<&)3#ND)YM =|%4;M7GVC8WI^ MG9#S*.)F6IEHL*HI35T^G4>8M(4'T*;>T1D!J"8S "E57NHV+\F@{(89V*Q\X'$/8Z;EF5\IZ[> 5_NB0 M.ZNML]N{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}$I.6\TFA[-_PIT3]"*QA+/C5"CVV)Z]N4-CZX72E1TN! Q_&#W\M M&F!WC*K="5&_O- Y;4XXD126I;,(*V&3EFK+L$^Y>A"}JTCDTYI?$$_9!T\8B M1'IV14@"3QSB*7LX[."<;J5FM=S017>@GU1JFIEZN5Y<2_J$PO-JJ6 MK,(3HJJ!O7G+,&J!JC-#59Z@4DK- 1ED5JNKL0+5D'IX255%_V]J*OCHGA]4% M:1BC?,3!%F)AW:?C6(B,JK,",2:E:6 M8S0"+\7&R]'@@D<#JH=X 0(O/.)E5X,M/6"JL!X=LDL^VW#=8>5"&>6ACU!+ M+T96A)%EZ0[POO_@PS=691 7*VFX,31Y%_/Y#W9Y2Q]^$P=V<>")8T@U/,^ M >6DOO.+YPZCCK4AS"8N '4=A/V}$=!^P@?IW[X%',*60[QQ)Z!#']0[?MYS MV2%? B8N>V@VO87&"RH/N%[,""8L3>()@'3?=[?#+Q/&?/9^0K\>PBQ=Y0 -X03;RAWD5Z M0UGNUIXHTMC#C/W+W8O-5%FT_2X:(@(Y52;,&2LN044O-52>Y'"%^7-Z1D[F-L MT30[F&4.JZTZ_-AS 2$>E>Y1 M(,TG5@X1^97:EK;#U6NG%/61@A#<80ARQS482)0 MQ8V+ZN%M>X4<"#G(U3\]3 RP_7FEW%A1[":?D@!>P"#G8*0=WF"#4,3Q3K8NL MV48W#3PGR73#GDVY\R#%T(XRM$MRO&^M5\NDCNECQZ0NO +>W)++.KL/&B#1Z M]&B3?XI&@4C=PC9^7E,\[}=.U]832C)"3B@?.?:J!N0 **S:HZPQ%\.Y6^Q@W M\GDXL (U._M\!Z)&D05JSA$UQP6-4FK6%,%[[MQ L\6=.!0U*B>X=23*&XJ M2HQ,I_2I>]:K\2R"?H/@0ONQ"'{[L6 >'3@VD!!7Z3WBAO!.D%Z;P*?9S<" M#UN18NQ\)KYEI(UV*7A01+G:6{YV%=&H$>)2'"$Y6@+P"$*"33/*=>V,*O:$ M)RII.0K*!661%16!%:$I/ '')R$IZ9.(1Q 55G:2P6'CYQT<*+"3 PMQS0C M'QJXME)- ,84A$<>4;BT[#/",EKDHP2/UHJC S5{'\.!Z2M>E/W\!IY1%R%Z# MYD.ZL9Z99;5JAEQ;5AN#6\!AQN#-02YU;8SKCG@.D,%/WA,,5+'-)$]MIEJI M*5^OZ&=0Q/!1 OW%0?]>X- <6P+\GYNN(>>W@JEP!? '\$P$_&]PW$/>'N\<"_M]P+W)*]G@GP59DI_.7>$KF>NWT>[OBZ8M^-3GC:2-SV8H@SE/!T<^=:]D_J MZL386Z4'E(.=G51,X32]{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~-]14OUJO6_ZW)5#.KT@VIL?-66H-1&D[FQ M=-L*$S<2^']/8N-05M1S941ZETG>X;^!+=Z"Z3>GOH4,E32[OX%Z<)4FZUOL. M!#D$+,NW%8,RJJSJAZ*BP'/?LIO[/@%N/HFR"R".%H4H'+6TP[(@/%5F;/<> M,SI\K1"E@CM2X\QJ!7>-<-8=!MFE:9D>VB3I<3F!VF<++%S1%PFI[M$7!"KCA! MF)"K/(^4TRH9'RDGY(H3A FYRO6(.JV:[1%U)]]&HN:QC40\S]GSEQ!$> @& MU).,^:RAS8(*%I/_LN30*-%/WC-I]YAO@"P+-Z81!U M$^7|)15IX5N.U$/8L.EP)_F^:)7O.*/[8,1^#=LW_!4%?K@'15YNV"/PQQW^ ML@R'Y TJ72XU&[STV,WRB$3>=LXP?Z56 X>M8[E[Q{U \DC 97\-S(ZEX/5 MN31JD?AMX@^^V.[, [J1\H<@'=MX-%K4_4<,FOF_U@3B)R'WM,%*;7J M.;PRS(EFROH5':LY0!JK#GD)TY\DYJ>S'X'P664::6FOB*[*10; M=_ ZA;%Z$L6FXVJJ5[-J:7IR6Y6G=A@[8N?*

*9#8@MN6DR.8>$8@\H%.!/[DYO MSR8.8&K)C {M;,,RXFJE9F5%=W2A\,X":J>R>?=6>)AJ*E/O\XEG HD3V4-+PK9"\XPRLT$I[:Z1&J:F5M>JR";;OWJJ#V,EW);L0 MXHL4XBS=J Q%MR*7FO5R7<]XKXF07R&_%RR_IQ-?A>T5TQH"_@JY%?(KY#? MW;SZ+ 58+34;9577"BZ_G'49W;LSGF@S>K(VH{5,VHS619O1E0V(+K/-Z(X M+_!-RY&^TS__) Z\1KK{({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{@CN#. ^7$GR[C=TYPSYTSTXFB MJ/B2P2RX({@CN".XPP=W+]!X;$T<2?KB>GUJ!>&FXUO/,@A[-B%RD2L5)6)" M3BY.3M97?Y\HJ!2O'"MKQ6HJ'IFUO2IB>Q9U5#- P25DPK9>:EFIB{JL7Z>+W=.M55R M?S&LE)\UN5RI9'5*.>@.C.]+FK!A'X4W!'<$=P1W#GA_LC},8MJ,%M4.,$M M+]" [=9ZM4$5F+?$49X!;R9)5=AXVQ9U/IT:- }ZGE)A9LH9RMD$D)DHT4Y MFY 3(2>B:N."P"RXPS-WA*H18#X,_ ON".YP4ZJ_*EE2V1S0F/C!$W>7>;NK MHA0U;-AZ2&JV 1 . ;(MXI4"('5.`(!97(/P8!Z6" W\NB .K{U2J6.8{C# M_3KS%S:V>S:1=Y&"%55Q0DZ$G(A2A0L"L^ .S]P1JD. ^6S ?),<214(J6[V M=01?[4-]?W[VGPT\F[ZD+.QI8NUU1G&/-Z%D"2H@[S]S),JQU#'&O MRWR)^2Q64<0&K#HE[%3;$>S89&I$,%O590DZ$G(BBB0L"L^ .S]P1JD: ^6S M+++@CN,-QF&)+<-)+1L"W =AAR5+^1<0$77 M9V)CW[.R]/? 0H9(FER555K6T(C =3:9@WP M3(^.Z/T K&;>)Y8Z!":PBT"U!IX%F],"JFSZ[C\2C3I!:2VBEIJ7 MZQ4YHX#W;AS,.[>R>^W9]HD4$XQK^F.EPV/4%^LA#/R .$B350C#YE?+BU"! MR@J%PA8*>R(@]1V:2PQ<&XCB1S*R2B0J(!)"WPI]NQ5.4?M)7[HC1GR8ML@?M$RMNKHV2_C2JSU0F,>,2?R,H!] M&#_|=03=V2@U&V6EOARXVGVS2IXW)I>UFO\!^#CBHED! GA*R!=>>U(P%EJ,!73#;&_O8=M"6)H^^SC.(M9BZ&)H84R:&=,:VB75%+XG7C&0-(45E.HBY!"86>OM,.WG%X M)K"AJ@I%$FMO?&X2TUA0]04"H5=3!E9I,"W;"#.J;.P[6H*A; [=."4Y9UA0V ML*90*6LU3=09"(TI:@H%1+ M7[-AZI0UA9J,-86U:KFN+'M&O"UP%]!/G+'])D=\:K+3]:CC$P:DNW?\^Z N MXP?H%N[D[* .A/FO$-G7&Q4X)G3>/;8E%J)1*-&X, (ZF,N6W M[&UMF?\_-6 (%KO_[+: .$OA&8C\2R^PX;3*R F*SQ 6S_&8-OR<*9KUO!,1+ MO5?+H(\P%]=\HH;[XK"W_(/8(4UM]6NE9JU,0 8^,A3Z8GZ@6<9 M 37CR_^`_R]PK"%/?? T;$ZE/0RWO/*E0#N'A)P(.3D_:\=@YAG,@CE\<^?, M5$W*^G9]B]\R5]|>5;:W#'\(/&JN\BIP&^7ROG6A]XY6(I>*?\Q33-C7=OW@ M.PT&KIG:=ZR6FDI9DS/H'11'7N%'$%U 9 MV?']$++M)26Y?BG;Z29%!)(4C_)L%YQY&#"G$,:6[[N.C=/=./<,ZK&RR>>))S M-LAAX0(NEIH[1X7,9)7N%P/&=[(1>%PC<\SR7B-R*8UOW.U>EF5>3H@7 MZISG:L3B":-0E8{(@CN"_^?'G2S#>D2$,[Z<,IPW73#8;6RY^,]Y_HJ&D)]"38=.V(A?"\W/ M0B>XPS-WSDPEBHKD2P:SX({@CN"X X?W+F VK$U823IB^OUJ16$X#B("K%" M1LA%JE14B DYN3Q6Y5\)?$4KQRK"P54]12<_GXFJ6:<)$EO C)S]SAFZ3MG MIA=%]J=4E@UEP1W1'<$=PAP_N7*$"TIJWU:IG4,7T)=R#*"*-#-+:GM.FR,/9M* MCQ[M4\]+ D^B<*F006>1?12%2T).A)R(+/T%@5EPAV?N"%4CP'PV8!;<$=SA M)H.V:K>WOCE]-O&#)^XN\W97Y<:T4E.7-_EW3!(.67[K10 T3D!R 6413T$ M ^JQ8T8].J";
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iORMH%6&^%Z K13;G>KEYNB6.M$M95N?J68RXD15..>:*?\Q33-C7=OW@ M.PT&KIG:=ZR6FDI9DS/H'11'7N%'$%U 9 MV?']$++M)26Y?BG;Z29%!)(4C_)L%YQY&#"G$,:6[[N.C=/=./<,ZK&RR>>))S M-LAAX0(NEIH[1X7,9)7N%P/&=[(1>%PC<\SR7B-R*8UOW.U>EF5>3H@7 MZISG:L3B":-0E8{(@CN"_^?'G2S#>D2$,[Z<,IPW73#8;6RY^,]Y_HJ&D)]"38=.V(A?"\W/ M0B>XPS-WSDPEBHKD2P:SX({@CN"X X?W+F VK$U823IB^OUJ16$X#B("K%" M1LA%JE14B DYN3Q6Y5\)?$4KQRK"P54]12<_GXFJ6:<)$EO C)S]SAFZ3MG MIA=%]J=4E@UEP1W1'<$=PAP_N7*$"TIJWU:IG4,7T)=R#*"*-#-+:GM.FR,/9M* MCQ[M4\]+ D^B<*F006>1?12%2T).A)R(+/T%@5EPAV?N"%4CP'PV8!;<$=SA M)H.V:K>WOCE]-O&#)^XN\W97Y<:T4E.7-_EW3!(.67[K10 T3D!R 6413T$ M ^JQ8T8].J";
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iORMH%6&^%Z K13;G>KEYNB6.M$M95N?J68RXD15..>:*?\Q33-C7=OW@ M.PT&KIG:=ZR6FDI9DS/H'11'7N%'$%U 9 MV?']$++M)26Y?BG;Z29%!)(4C_)L%YQY&#"G$,:6[[N.C=/=./<,ZK&RR>>))S M-LAAX0(NEIH[1X7,9)7N%P/&=[(1>%PC<\SR7B-R*8UOW.U>EF5>3H@7 MZISG:L3B":-0E8{(@CN"_^?'G2S#>D2$,[Z<,IPW73#8;6RY^,]Y_HJ&D)]"38=.V(A?"\W/ M0B>XPS-WSDPEBHKD2P:SX({@CN"X X?W+F VK$U823IB^OUJ16$X#B("K%" M1LA%JE14B DYN3Q6Y5\)?$4KQRK"P54]12<_GXFJ6:<)$EO C)S]SAFZ3MG MIA=%]J=4E@UEP1W1'<$=PAP_N7*$"TIJWU:IG4,7T)=R#*"*-#-+:GM.FR,/9M* MCQ[M4\]+ D^B<*F006>1?12%2T).A)R(+/T%@5EPAV?N"%4CP'PV8!;<$=SA M)H.V:K>WOCE]-O&#)^XN\W97Y<:T4E.7-_EW3!(.67[K10 T3D!R 6413T$ M ^JQ8T8].J";
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iORMH%6&^%Z K13;G>KEYNB6.M$M95N?J68RXD15..>:*?\Q33-C7=OW@ M.PT&KIG:=ZR6FDI9DS/H'11'7N%'$%U 9 MV?']$++M)26Y?BG;Z29%!)(4C_)L%YQY&#"G$,:6[[N.C=/=./<,ZK&RR>>))S M-LAAX0(NEIH[1X7,9)7N%P/&=[(1>%PC<\SR7B-R*8UOW.U>EF5>3H@7 MZISG:L3B":-0E8{(@CN"_^?'G2S#>D2$,[Z<,IPW73#8;6RY^,]Y_HJ&D)]"38=.V(A?"\W/ M0B>XPS-WSDPEBHKD2P:SX({@CN"X X?W+F VK$U823IB^OUJ16$X#B("K%" M1LA%JE14B DYN3Q6Y5\)?$4KQRK"P54]12<_GXFJ6:<)$EO C)S]SAFZ3MG MIA=%]J=4E@UEP1W1'<$=PAP_N7*$"TIJWU:IG4,7T)=R#*"*-#-+:GM.FR,/9M* MCQ[M4\]+ D^B<*F006>1?12%2T).A)R(+/T%@5EPAV?N"%4CP'PV8!;<$=SA M)H.V:K>WOCE]-O&#)^XN\W97Y<:T4E.7-_EW3!(.67[K10 T3D!R 6413T$ M ^JQ8T8].J";
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iORMH%6&^%Z K13;G>KEYNB6.M$M95N?J68RXD15..>:*?\Q33-C7=OW@ M.PT&KIG:=ZR6FDI9DS/H'11'7N%'$%U 9 MV?']$++M)26Y?BG;Z29%!)(4C_)L%YQY&#"G$,:6[[N.C=/=./<,ZK&RR>>))S M-LAAX0(NEIH[1X7,9)7N%P/&=[(1>%PC<\SR7B-R*8UOW.U>EF5>3H@7 MZISG:L3B":-0E8{(@CN"_^?'G2S#>D2$,[Z<,IPW73#8;6RY^,]Y_HJ&D)]"38=.V(A?"\W/ M0B>XPS-WSDPEBHKD2P:SX({@CN"X X?W+F VK$U823IB^OUJ16$X#B("K%" M1LA%JE14B DYN3Q6Y5\)?$4KQRK"P54]12<_GXFJ6:<)$EO C)S]SAFZ3MG MIA=%]J=4E@UEP1W1'<$=PAP_N7*$"TIJWU:IG4,7T)=R#*"*-#-+:GM.FR,/9M* MCQ[M4\]+ D^B<*F006>1?12%2T).A)R(+/T%@5EPAV?N"%4CP'PV8!;<$=SA M)H.V:K>WOCE]-O&#)^XN\W97Y<:T4E.7-_EW3!(.67[K10 T3D!R 6413T$ M ^JQ8T8].J";
*

A@-1H1&L1:@@DI$!&12>7DWHD'A*77E$TN$/B!Y'?$=X7O2EW,!0@R M.X",Z<[#5!,,MELLIKZ0JW"^O@2#'#87;R$=(((B51AA*?S\E .N 8"[,6Q M G17O$?[O" /):3XD.%^I!X*I@DS.8Q&)Z@+{)821XNP"8@9A%!+0VI\-D+ M[4W(#I>2+"?$2DE7(#X%_ZIC*"$^AOQ3BL4'9XD\R8$7_^@LU+)X7D%H#)F> MV#^"5NPE6J]P^,)N?(OT!KR6X=: (18=OCB2!T'ATS1,A/\XBWR)^"XK-M7AQ MN'F>)KIZ6VMVD5H\-\], "H9SSTQXA^G%F:UUC!DD3+27&!MFB5D7QJA M@1.[=:*5:$1[5"Q;5QY6$3SWNI &\K>PR^LX,IQ97'1N>S5@[<%3PO4Q{=4%\0 M?,E*VUQ,/=4PIYZ}6DP[7-$NZ44>6[^)}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{(=6P'_=VDG:ZM M0NHV&L>H!#PPU":5>,]J55 A6RLKW;1&Q2/D?(>QX6#$54!6WO%,F?'-@ M"OGA'.%)0ZZ.JJ)*,9A2=3PQB&L!0D7AD@28'GT0!AIZ6+\Z\) (@/HV?OP: M"4JA=Y. <;9ZX&H20SJN0.$88NJ5D!@[=\(VQQ N9N+< MD1"B5&,&-V5<5U* M>/V$62.C.OR0F<<)/RZ=-)9]\UYT09XZ%D(J3;6WL$^'23;C00YEVW//40L+E(\F-!H?80 M2\://R(DP:=<-/I5TZ(?V3/1+I^1KO3I"3M<@)11_/)9 9O013@0S0!I\HJ2%<+AX\/L")'7E_#^^=A< [!+:R8[*@O E#>(IC 8?%8!>^>X2;KOKS$ M7"R)$0JE]+L1MJ6'2?B],6\-X\G5S+4 MF'W700:&> {.HJ(V)Q8C3)DX8IV?!Q+P!$*3 B1XEJAJZ3R,M-1M*L)V56_D)>NXBLKQZ:X9\"+20F6"PPD2DS)9U6967)]J#H M(\"7\F53HB1:(S8VE(D+1I-/H!EU1%R84@-0,6-J1"Q"BF]%!:SM!;@,6^4 MSX5Z7,AD,,W+%*GNT8*X"H/A2'HJ*]K3,HI:LY]@67W"^HJU@ M+M%9DD*U7IDZ3];R/KMCBPI?U+XMY0$+AY4;H9?#L89VR76(B)7OS'@7FND] M-=%'Z?'Z,M+^T3"A"FF.280K@L:Q7)IR$@7_$ER 11U1=(L<*E%]1{(2G(LN M$W":UX,*%Q9'YBG!%U\9ZRFLDE3K500G>UG{W,.O,LOCENS\'B="QLUY"D;Q16@=,8F3(O*6 MN=K'!#MT)KC*5YC7(GIJ-(WK"9-XA.L"O[LI#R%JH>49"]T@U1G/+T M\E#VK\+*$,2\0'=\:3SA[85+)N2BQ-3]PDX_WN,B,)-{/60!VV>A++# M3A##!HW#8]BP-NITU69W*#'L%#&L>7 ,:S9JHVY7[?6]@F'OC0P=M8*,3'[] MJ"#05G28)Q3L/6X>FP"9Q^J#:.\VNK:^CA@QT]$L-B#&L?'L-.H*UVU':C MK!B;Q+!*8=CAH[C-=FTTZ*G-TMQH$L,JA6&'#U0V.R E&VJO714>=D[NV"<'-MBWOLQ!S[LAVHF^X1;G51\= &N!E.@/43Y%H_S[A1F: Y'5[5K(!&CU'=]D!M M='86AR6>\8&^JG;X4V9*P)6&71=@5<$UAJ+ [55MOMLK)#M?VY"XE3H 5+//!0'O8+MQ@ MH"%%O\]K4'=2+'}G]';'TH8U[4^D?)!@.RP8!L,+ .:\!PY%M1N?*CE=1N\7C8J MD*5B>TQ .'RI9G-86E!/EFI6"Q,E_6VDO\,7:K8:I87>)/U5"Q,E_6VDO\,7-G+8PB;_54H?=0>7I[YQR8[NSJ2.PZ:>S: M=\[Z>NSJ2NPZ;>S:1]YT%HMZM5& {WZT(!IU3+P&JSCI0_$7F@.X)-*?#?BI0 MD-7J[REV4]GL;DG9DK+/H2"K-=A35$A2MJ3L,Z;LPQ/V<$_A)DG8DK#/F+ / M7Y#5;I16D'5@RLXIR/HU-?/W*(;RWO#INS[5?6#G;,_]SGCP%8&31S' G MV0N(#U/.'V'OQ:/1,5%X 6]T\5)XL:<8@8M5)HA >>?W4<<$Z%Y)]-E$@RH? M,^WY"$2 +/ 7$P?.3P^U&WK59QV-2WV5\EH8[$@3/&&< 5V9-'\^-? +94 M39L:+:\BW^+R4-%GP-X9+A]'$<`G]$'/W#MU$0"#<>*(YG0SQ,- ,>"2I(& M$(W%,CPN9B=0S"45FW4K6?U^>BA')+^2V=FF^4GB,U*(G\!AB+Y M1F7YQB&)21F#4HIM[A.6^P? *IQW6>[,*-73&=S2>PMW93C,5)4!5?X3[,X9HB MYD^%Q(E,T$6*V- SH3(J^7@% MV"]) ^=P$T)Z?!09\$C[-83$^,H#,"DR#$X()5U9NJS4*&CTY^:[EPATY7O/V?; ,.*P1?P*9<&+Y1H\ H"-3>97-M :F !1>|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}?B6:T=IE(M=:+9>":.53?0*'"N?1X2R2SD#MJEH5&8GV 9FN MDD:JM+=-+*AA=A^: 0+OQK]H"])1))(]4ED0Y>O_9#(H#9]M]7V<.M7C&D MWP_[W{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{<=\Q7<431=7N4QGY@L2 M@4*#[1EP'"TP3!N,S%GTLCG'(X3S]AC*/ILH4,.?))\[,T8\[VZDAX(K:2' M02MB$'3Q93DN78:)X7 '^{G I? G._3D7=E[^/SL. 8NB=CF MSJ^+Q[OGPP2>'V[V:,[4%9?N^/8LWBMIYK M,Q"DOU\1F1F#W8HS=I1+Q\;A MW2YMIH*;R&=%X]N;<,V5$BS_]\;6LW^E[RU? =02/$4//#2S.64L0#TUEQX MC_(Z.'G!IN!NU1.3;^ MB7QZ#K `;J[8#!G6"P.Q#PPOLX;U[V[OZ=V;=YU^,U_K^U\]]O"[/-#F2;DI MB'%\NY=ZI>,#LAO*2], M/4)<[- V02IEK{5L%J0XYX/I_77/?Q">V;-2.$' M72/2^'NU44Z9SS]Q^/L7E0$1'U)KJ1TSN7U+B_P49\Q(P!2OYNFUGHWQ=5^ M?<._WV 5COL$3_EJ.?I?\4>[-87!'A;P//:D:..VX"? AIEJ$!ERU0%P&E@$@* M<4191">XC(BH/$T=M/^\S]OR->P#15@90H$;8;!G2UMX[/XX0NPX86EO7TV M;5HYW?1%/$P8=*@'+]E@9$/PG{^\FH8_^SP8U-OM-IJ_(K%"O)C_VJP#)'[-_M?M\>U@?#3NY/C7HS]_M5CVJVZIUN_D^K'K7Z^\Z@=*+:M<'K585%{7^45NF MKNQ A,5H"TP;#,<)""SW=LDWDF\^W"\.ZUTV/Q-7PK=6VG* M7A3K# <]4A5!G9\,3&UY5H@W 8<#_SVU8E]SJ?3^Z#LU%V%MU*Y$J:Y$UY-$ M#SV&IZ#IH8!&51%>)KOM!UW:C7'1M2NZZ@JHM{(2C5+M;[U^[MT;?<6.(.>\ <5'4@KT56BZ[;H6FXL<3"4W/5,O=VK$Y6D@4N45FX8=(@M!'?N M,7(J![TQY2-KIURPZ##)]#KSH,&)++I*=%V!KN7&$H<82]QYX(I$5XFN*]"U MW%CBL%T; [9P2=2K8FM,A9,EW2++:-QL8>*J-_35RLQQ(O6BY%%.OI8-W@PO%,_M?.IGEUG45$*4"PI42=PEB@T;\2W:Q'.LP%]]2R8!_^-AWNS^DW/')"R2?W&Y MB)EFKP.I:0QZPX8QZ4Q86VMT]'Z_UVZSIM[J-;3_[;0&M?"N7?SRSBXG+-MM+\NM"EL\;-FO6IO'K*2V#G!(27!O@RQU>=6O$ ^MX',!YM;5%C;KG.JSOXM M5JO\-? #@V9YWZ*SK'T N.HBW&G7J!^$-&C6UL-X4Y]6FG1FFRW1?\8*)9QJFYK{AED) M^)3>$[PE7(&J+%SGQ<2#1/8$>-<7Q6#!5=%N\:W$R##[6RK(Z+/?]*[J6N7&H+TP@CV$8-NP4- $D9_G4R^OK\5'D,.8U_FPZ\3AB M4R4?GAX',0?/KZ,+<1GQ\3%-GRE.X'L^G#H>G#??3>,|*W9G/"=P7,"G -\U5 M7C0K8,H_UC6B R7]$1^0U<92]3(WM]^R^AB^[A'? =J^Y=^ZCCUV*L$\=BQ\J MU+)&S#2[M5&CWLAZ[{'O =^+2LTH.(*JJ:V:\SD#Y/,9(.,"-9$N'()?&EB MXI:E. &H$1KI8W#Y!.G51@4M9#IX'ZEM^!#>\H(IG\Q?]@6O4+],]?\$)M=L MZ$GWP/MS(=6KC;KU;M8_@#2A:]Z,DS+ AS>.0A[GG9],V,/*+7"9\@PD1,BQ M_3:_,G,EY"TH]3=0SR84. !(>]1.5_9 P>MD6I.%@D8X/"5\$APNYD)]X!1B1fK;1.7LB1-,"_.)IPRIVEL M'CS8"UD58)EO/Z"7//Y(8"BSBW0!ACYRXZV1P6!LM*2+F9(3?EDC4M2RZ3SPG!<91<$ZA\2H/;QC$!$C-M$$K&"LR!DXM/)0'(U'DEY+@>H%FT^%SY"$.#-+2X,(Y%*VN-1+7OO? FNO",T%=",^Y6XCN5N$7]X_$O]Z>!QSC(N_P)_G&G(Z$ 0, M=V[ZV'${UIG8.#(.D T"MY'GXCX_X1Y0N0F1.)D,XOU[@1X]X)/W"[P..7/B M#<'"L7E3KIA,X#9 1&\JN%$H] <*WY!'9.EQ=A9I,K-$*H#09B?\]8Z#>-UZ MJ@_A#IY B*UX9@0<@5!)C/PW?14IJ0G6E<.V4&L$M;M')P$?^BJ=3.Y\:(N% M!7(2VP3%9U)7GO(9(CYY;=W_"32+G@1*\Y_4CZ1%X5C'WYO,XT$5/-7L$7Q MM=522@8KE))?=EAJIZ @C2 M-/U[8/DFG MZRK(K'N**6UEOK#(/;R.!H2G3 M<-6?.+<":60[R .:$FL1^Z@RNA??^H@K9\DN$/"H_6H}CR1S;@ZF*.87KWE1\ M/\D_DBH=LNP$28UJQ+/]=9#+PNU=!OD{O+YBJ=O.5RL%*KU\#(8 ?.>(5# M$.C<,I%O <,P#0Z[@BOOY.]\U7%? P8L\$TA.;*GPCBAXM&E#RJ>$KJ)%XXLC MFY+]9*Z.QM@"M5#$]FO+?,9EA1(HPHH8+?]%T*)?!EKT]X06&-+HJ14M!A^_M%EA!T_T M."2R='UP'71U1++*$ERV3\UM=4L+L+UO6FE=I6D08G5L/6?YCDVRQ%4:?&,=-YPD?MR%/*1(2C)R(,OUKLR M.\--B'7O.C_?L$$TKA-,+:- ;R9LYADDF.D8WZBO(/R3[R1KK!F!:VAO,9YU M:J-8_(0N3&4B7]S M6&SPM"[A%V,EQP>$;S0F $XX.IX8],IX 5W5>'EC}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{ W_B M]X*V[KV!1'U)KJ1TSN7U+B_P49\Q(P!2OYNFUGHWQ,4GWCJ(G<$R9M+"%8$;+[$AA(0+:]?_ O9#\C(${ RX:+9UT'I <@K1J"-)* ME0P ;5JF_[:LEZV-'849%_>IF4>_)Q'Q&W^NN>01WYAUT6L;.R/2D+,ZVH_Z M8UV9$(&DD1X0"..%IS- IZ2F>'%1,F=X4G5PA9%|_OA&V!7Y.&]!3\R;6,L6<8GNRVGS.;HS@P',3J[3%T\)2[W+70E;C?(,0UQ>H'EBVF7=D&LZ7T\ M-P(#RYR'GNPL,@F? *5!.)^4>P5"S^N!64{ZH"K)@++#C@W)FML2=-9 8#]%NLYN>.5/&/AU!3F8.1W/**#7)&[4L)'4A5 MMG-F)<|Q\DY3?D&H:L1#JY=U#>&VQ@N.Z*R'>SOK'IYUMBM'Y<|:-$9FH4>& M801M 4:{J27"$L=UOKT-P=P=SK=_C+0\C4R%N>G!.8.2SYS XV=[? %.GKOP M9V O)2^PGZ8?N>G08VG"VD*O4SJZ.3">^$(N0N'WM'A*"EA!@6GQ))]-#E%R M@:8BZ?'X/U M$\SBZCB-#]=6:D<'1[9]*<(%92%[HC,-2U=QSK"NN>X;?L6K8Y %[A#H[FT(M=(\[C_G>O^$PP1)}A*,\=?Q[S??OIE>FMW#@<'_#P>^7E%:RW@&M=$@)VM$ MB1)&1"",8,B^ |(LCD$9O3N/1GD^&GOB9ZF/U;=C4(1%%>$APM#EQ!E'?L]$Y M@KSABND\!A'&=@CK/!,"G)RJ83@$W_(;1MY-'8SL:P_;4YCP*$/Y"CJ6(0SO M.YX-QYY%KN81T7OGD,"L= -?%" M$126_*=*V%=6KJN97@3YJ8 K.@XTNYU&O$(Y.#R';.PX&%A;?_7X"U1LQ5Z MD4ATB76$\I% ^U,(\(&K4YXAE(&_FOOJ6H.[]ML;2+/8FS"7#&'<8QKX+ M@Y&I2M*BN7U-['TYS- $.T^4{D6IRA>/H,478<7<1/E?9?HO*CC9M7Q5A-<%X MV4\X>?N9*6AZ(%%O -87EV)(N>M@?#E)Q6X=(@W#\ .>V+Z2%B^&38-,$&Y MHJ1'EP'F,4IH4GSM9^CZY'IRF(;%K9]=E8,5>6<4X"QP.MY3G"ZV*@VMUEU&62O;6PJ^RV.4W=Q>77]]NKZZO7Y\ M:?%<^&7]HSJM:E>DRM=)VRC\B47XA4F#>3B=@>Y= (\6H.B>R:Z@H-@$>)\|U/% MDATLXGH*P=#?]>$*BR:RXX5K(EP1:.8TY>A-JWIU49$P.2*.JSRGE?'P9OB$ M)8"\5?E?? OU^F^F]90M.V3&U"1ZWHX4.H%XLH5N/:"IJ<)BHTI+1'*Z1F&>37 MVM)..$KS+4O;SER<8)E,Z'(113)<#{J73:,6/&8C8U@/*93IB(BL6(Y">_F MYKJH3;T=LDI*9[V2\AV ?S?E\ CYS^\:.$3!_"N!%G9PJ2W@%TSYRRH?W=JH MW<@KA(KD6M=1L7X&1"Y[<2S]]9:&>OA*)!{^!8&1EXH1LQ,7)\'_$#TI7+\J M#H%NCOS:D2\^=5ZIGDU+(BLN,JND*OBTO)?82" (O$\$:V 8O>>/=;'C;(<=- MIARG6UW%97$KQ0?JW6"ZAH$-SA"6<)GS?KQJRI#=Q(&Z*)DB*N,R\[PL^>9]% M;O>D]PF&1.#2$U+)UGU^X'I%B>6K^WQYRZ=."5J.V'5'U8=1<%"'CA2)P71 M]XT[YN-:7,UX 20-.PN6F*'V$84S+1Z[XM7TE&>6U&=$931L\M2AK27.{U] MZCISY3L87?#Y!H77! 7.'< $3_H!N=JGJE$3[5ZP@ -YBFD)WV^^WCU4%SC- M@P+GEU!-?A1B] {(S;;>@=^0P2&Q<_02)_EX]RWJ/Z@8 8NJDYGG14T%".2K M-? $Q(CYA^:U3;X8_9T@@:E^,O%QIQO(#UQ*Z9J@E5/I)$?I)O0]1(TG1W2#9 MEBUL8[BT"_P 'VR%X !{&P?\/ @K.Q!Q@A,V)TM!LL2VR<-EJ>*GUP/,UC MZ0N,IONH5(- <008$TF1C\@Z M8HE$A+&6FM8,U]9+K)AWT5L_%3'=7N-&+ -%3=3U)-Z D3_H]>B,8GU3G;B M\S_1O_]."^[9EG?W5Y=W?'W2E]FI?[HY>VTK8EJEV&X?,H$!MKZ!(V9 Q'?90 MO9L2=7NH_>EL9>!R2-'C->X@LW(BA >+0-M@9&)3[QM3[#,TQCW/P51:;E,E M,:,Z/G+)+[4L1X^;?RQS79K"D,H-U!0QJ ">%_#"]5OGD=&.@K \B+\]Y}3 M(M:R5$SZ%:U&N,ICNG",^6?)}?:*JC_H,"-]B@L%&ZI.7#;&V,\'4 M8T&A;)[N.@:'03"#E,.99^WI3X %,T=BW5 %W1H ME$R6MO#8Y_##%\7%I,V]MFT:=MTTQ?Q,*$XHK*T-&2-]$/^}?GTXS/^I46_F?K_J42BTN_FWK'K4ZN{C5YYBVJO?=2& MVA>^ M0JE+"]YSW03N'KE=78$7D9&5#(7>Z>]YZ+^Z0$OF<8!=A$2VG5]?$=K) M'Z$I6$/"\P5Z&5HT6X\%9O>#BURQ[I6#BC_V-/FJSU-M9 7H)^NM6RGDIN_ M._8S*F"HG_[F.IX7%3AMDZG:CM775IFW45F'7NXZX+71,A8??KF:5FSA$DM5* M I,$EB2PYD<06/M8"*RP+,Z?:EU[JK@*/8IQ(VWR)[4ZDYSIOJG4@11'&+B M0/W&,[7(J2FHY985)Q@<":(V*!UX8S,)P W8$D^J3BMBMHJLUF2A572P+&?\ZS1".C'_)^->. M*\)M(HM$QL"DBWY_,3# M/=ZZ0X>,B,B!V^(#8;KC4(UZ.G.0'?XA-M8V)[-GVVBXM1RZGEE'L9+),N^0H$RV+,4YCMM-"[ZJCM8;*<+C<]C*@}BW M0M1;(*"V_6V.? 4.FL,CH[Z2D*"]Y^Q$[3-DUVSS3*]M/.^Y@ MD)B,%S5KS5;"%VZTG9I,(OK8[Q\PP(+9)IHEQFX2 M#Z.D8N_?L2<"]8]]FR9%YQ.*C&SI=V=PM*?? 7%WW=>$^)DROA'G3K_>:@G(R15KTQ6)_&U0V[EPEV\<8T=WO?H8POGF5\L;6]F1K+X >VB/I< RLS!^0$<@*\)C"G*--8:/R#,4]QAT+N:S#-NXW MMNL,V=@VPB^NN:,],1,RWW7= [1RKZ%]HC%)7N3)&#T O!(=8)?:E-(0[*CW MO@A#1#.(<[M!&R 'Q31''^=FT:5T'1\^!DTVO79I@"<"&UHNI&K MB$\O;]+K^]9X{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}@ZZQRYLMRC&QG\C@$T[H+A*JD)6'%('RUD7CF?B!9^H-A\87$5ZS_3 M-=5BFXWX%FT"FPK\U;=D:CP^ONRZV84U-0? I:N'D7UPN(HC9ZW2';6/0&S:, M262"VEJCH_?[O7:;-2$6KZ']+S9=$S?-W+B,Z)E=3%RF_76A36&'GS7K57OS M\)B2-Z9(AHJ=N_5.5EE M_Q;K9.7 -%%[T0;L8=N[VQ;?R;& <-^8^@4D_$*-7Q)- S+] K#1O"(9HQ]\1V^_M+-U%X.KZX>;/\=/-']?*MYO,\>WES?B[,MV]^4\25<=_/T/UGJ2Y{@$B7&^X*7[]2TX.#]Q&]L9,QP30L+\ALJ%?-?\@X! M"E$[#P@Z"BPYZF#@:CY3O%=MH;R:_DRY-+''M^TI7S7[+U6YK8-KV-0 E@9T MI9B^ART/Z$CQ:WVFV<^,>BU_O_EZ]W QT;Q$U)$>[HI&8 ;YK49<"WCXAFMDI M?E-| {).0!)#S:\;1-?38)S8%U7 M>,U7'!",)K7:OW5>"_B%#A-!EX *-H)&N-B ^SJN@KD+ MS<5V^-MVDJ@^08X]:A/=\T)+#F8*7.I3/F&6ZH>M*-ZDC_JE"Q.M)V!I41 MQ5UX$>D7RM1UYIS0\8?!NV\/BA&PD$IUYGD1"=%5G$*9ZH+YV2]K:2$^"4(MJ,QKZKG0.OCQ8O<86CZ@*A>N\F 8U^5?8=,10L6#*U/RY*HVDJ6"88(,*8-7+.S?B!)..T\ MP,NNPY7<,Q>U:#CNB(%>M&(.BKVFZJTL_TG4<4,...$,9Q9[8$^SCGDTDYU MS9LI4^ 6R@Q4*Q;*.Y>\G<64_P2@R4]17&+G'G&%3JP4#KNNK![J0FPW%#H: MB8 0[? *D5.%A+_W.'@12!\MPAO6LK1@+)!M'DH#()EH#\+@^DI<:1^^D?%R':^4"=JSKP3P@H^$. M,1&5&Y?- +_(2L6>=]QT#*3S[Z9/VL\ /=KH\&Z>5*OH@=;B/%:_,IP $WR MIZA#>? 92% MCR_=<"_]9/%(Q*V=1-2&D5#K..(2E(QOH&@JX;]!{#OQRCB'E@N@5<'0_MG?3ZL6VH3L'TLV*MGLUU3DKD57N2%N&S1LW9++I<4*.0/MZ/DHH@G&AE=>7&? B\EAJ9DO OX. 3\F$T[NR-4UX]' MJ&>("Q5V^+2^AZH(C-PZMNBQ:3_GCU\8!ADC:.EDJ*=$.2(SC##3DH^0VS6 M7\\6N53S[*"Y?C;G'_A9.'%RQ6::U[V#3{3?SR<*GG-*

*FS&C)Y]S:,"KS'9)N ML_.UO&@P;K8:J62,S#"]#]QA?_T.2\/(TS'40>3# ?X9 MV/QHH[@IQ8XH4"2L{DP Z9,'-'?K@!3I_I)2 O[O_QFTFOTO&" +_6!*F,@" MI!OXL&K*M@%C.!4=BA_K $^*=P*0**#LFCEOD&XP>&/I0WNIYD* _T:I;R MB(*-3C)VQGG*V/,,PGA6J-<&"&_P82>/N>,/1 M*7P0"5>732W +!XOHQ!1%.\!XW$&B/&7@IDB/U7AW^47&9BMA&X!]!,@>@86 M@=QEPNKD@IH" _.Z\H,B1N/2V70&>1'&C\"I>A5GZE82=\"R1ZBS:|[5'F@ MS512@58ST19EKKU%Z2Q$'R@I$OR!%*VIHC/7!XZEZ*Z)/B.-Q,R<^77E&V8; M+'$0E&0<#99P7;@57-.C,#J/E7Z")V@V%T>$#N0D,"EC*DX!$G<F-Z4>*- MH,GGP#3(Q:CQJ\!1WYKB^>%H<;%)ZSH3D.D2[\"K_J#4[3>B$2 MKA8R#*2#3-,I@ P"&2FI!.'"WKNA2.: M\T+%E9]+J,YZ,W,11JAS205@86 D3)EIP'XTC)K@J5B*"6L#,A5.DF66E7+O M\7Y(>%/LZ%MB_?G)?]LEN>&PJV-.,NN7E'1VK;DV9@S=,_=QIN5EE T&V8RR MP2";478]?KBJN?WM4;F_?E >_SU^N'Y7OAA_=,X+6*GPOFFEQXD=ZG(,R#+Q2W? ', MN #R'0 *MA 1C0%/CDWA[L]R}.H/@K(R-7YVFFK,0AY M:LSK3/B)>+-W/AM0A< M4{G0@1VGQ;0:S9YR/5]8SALHFX]T][VX3KFWX-0_(>%m:,YNW$C0%;20OZ[G\QYQ?SOMPZ=<[[M1Z>OKQ9IK5R1UCX.D?;#!OL-Z0=:$R#(B80X]t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j8APBW9-S22CWF(A1DW^:M:'O/ M80,H6NT-L[4_A4=0'+[C[JF/3);DJT$]ZO=-=,W:J*L.VCM/G9"45RT5) MRCMMRMLP*&7?I->MC7KJH)]M\",I3U+>:5/>H=7-GI1ZDO;.E/9*DWKO);[^_ML=?)]_;KSCA1-5JV$A&#]MFK2K&7!D;7S<2/@/T@:U$56^MKZ4-*>O F,R M3QS5BOG-- _CM=L>U+$X-Z/8H*B>URBTGEQK5PU81W?ZC<-BH(=&()5A6]% MV);%]J;D7">)3!^I;VTT;_J-_Y^]-VUN&TD61?*0F.ZACL'8G-?[*%89 MHSZVI&NIN]\Y7TZ 1%'$& 386"1S? OW+S*H""@3 %21!"1/3ED1BJCI5BF7%9&]!B+;NPMD8]+[M85IEIYVV1$HW)K &9C\V.ND)]15]5?3UNNGK<%IBH[G% MG*OUVLALLY93%0%6!+BC@-N6 ENG(N<*RO(O-6WPD9%_T4?,/+\40P(?^'"F MNW@TX#I-[_(HAQ1"\[!=$,,0*[J9G="),5G66V:.BNA+H!^2X,9[\8<]@KH MM\HV:V#>QD!O-=/5-+LH/LJ5FOV%/%GDK#GIJ-]=A306GF)]$I@AR"UC/3 M8 ,,C_16AV-K[@SAX^O:]P=T9,7$'1'GI^%%DMPTVOYOYES*BH# M8;S1/?Y$Y2D M-YN%E:0O(?T#AV<+'*H(QR3),*WP:[6Y$X?5I ^,1&C%2]5H/+\5U?>F[\:*!,0LW M@Z)6S>RM6OOGM_9?V8E!:$2 4M\D1FU:Z-5NGUUTEWJGGTXD*UM/_P("4"KZ MJN@KIJ_.(>BK0_35;*4!+*,>0=6J?<0SF:VQ38G(>P;4M?;K9U%U!*$/58! M?(5<* {CPOI&K=W8QT+N-G=ES0;CUEDRAOUSOQ[GEG,\|\]\EC_G8<^!5V^=O! M%$"0WCCWGCL">&Y,"_VSB[;>ZQ4UWJL$"G^%0AMKN[NAT.#LHJ4W,EIK'P>% MW1).^]ER+'_"3.W)=W7U88J6UEA'"UN6F MN^%0 [AI5V\,=A[<7D+MM-$J.3}5 JQ;.FE$*'1QLD?E9=P5-*^'CZPKB[YX M[N;:6 KN],P,I\/3*[? NO:++.BV8]D,W8TBR,D&@T0^COG[A-2GG.2 MJ\/YK4O2^<7YM#&3:,,Z%M[PWD-'H/7,X@2B7Y+16F*;]?@68PB,"H/\6U*1 M$X?'P48*UM2L+V0#*_].HAZ;,^.)G0\]9OPX-\:PV/>&_6+,?82XFMEE.>0&V:F*9T_1:N3#N8J?BY3JFM)XF4CAJ2KUF^JG<(5#NVQ))YN8;& MC-%$+E\S0ZI^8X9GB?D O#@"*FL?^#BU8-W[[#$\Q 1+X)@8G9"IOHG7-:]HE M@ AN\D,[T.EQF"UM.'-8AL2?4N7>@X2:,4I5UL(9YL.'GC;BF;/:,Q&!CUL' M=FH!@YZ+?=+.$+@1>!"PKG/^Y"("2*C"ZK(V?:B]A6/ Q-"#%=6T3_1SXWSR MMJX9,]C.3PM) #:>*_]YB4(]VXW6%JHEV PWRW_QSWS\ /@W8U(Z",KE5(?`M N$`S'8/ZA;:S2&K]6+7UH&U1VZO^A(#S-&3(&K(=4Q8YBE\19L'4T,\[^ MA0&'(5;@.BPBJW4/L)0TEJY2B$1)2H@<@TZ6B") -UUS7,E9.4> \Y$!D:(* M9 +X/3P16'6C_DOFV5I2SXU/N= JC?Y15VD,"JK20_ABV7;EXYY T3J/%F@ M4%_Z/@O\974;G6Y:V~ATTW4;7^[N/OUU_6K=GG[2;NY?;R_7+S\>NU=OGP M7KK*BNR3DQ OK)SS4 2O*"FR%*19,[0T.+LGYFDO%NA@ M'RWWP0"$T^X3:APH>C?.J);4;3S0ACQ31)00(OC4?VQB*C?Z*ZHT(^P><86# MBP.02)8;E[7'U68=G!N34>HKB\L2BIJ$@8'/YL8@?OO7L^V'&4D=#@/M@7G/ MU@C. 4& .B1 K5||*%;43F*"IP84DOK###$H/LLBR04 W+K/\'LXY3MM-HK? MZ8I.Q$UWBA6W[5K:'Y(X=5AEEIJG;FVRM *4/>%XNJ55QC>WGQ?W(B=OW,T8 M:E3.TP_.3M+Q Q0]0N?/"X 6!&Q&PX9N_>PB>"'3>W3E@S6QPJ@NEE0J6)<+ M*V13M&7BO9928:)AN[T/Q[0=]H< W]G,]:"<_L QV)N>?B/G]#WY5#Y=6^?6 ML37"4=+P^^M9XR/^CA\53?# WY<,MW,@-7"/VCH@]| 0%U;N :HB!,[7A<1 M/YC9$4>@0BVVY1(6:]U/0)Y^20#AV6(OPB*V(,@ 8L#[%%,P+-!F BA$$-(]\% M?'0W"EQ9[@37DS(]1],;@%KTQJ#D H\ZPG$,L*'H2:MN2.PT'UMR((7+'97 M7A*@VP2N0R^%7],>8SH7).4GE@3*H>_3KT,&@/6YY#>XOR0@_ZEZ48 ,!)3Z M*0 6 NCPP.<@5W3PFWtR/?`)R XP;X2\#K3.&- Z#T)F42;!:R#)]CP%GXK MH*\V,CQOCE_3737M_RHK0JL>W1)38RZ<3DR'/T:>BTX9=\159=,2D^A!Q0_] M *P/1#C H!\LX'6P)N.F+5Q#/A_Q7(Z9KL!,FSV#%J1A_Y6 /T(*"31IK3&\ MC X%H'TSUK4ASC(%RY4VJ8(13R8I9"0^AQ0'S^3IRP.KL2%0:34. M" ?8 /R-?JV(F!=P=SBG_@E69$GWTP67_+=@"KXQMCP3F]\=A?BA?+-"$4! MB0@^9@9\$+TX>%9 97-D$W !HW<<>H0%DJ(NKDF0K0%1Q2WG(#K.2(@'8.5 MZSS!P0(C'%G>*)SB?*V1\&FE.0P*AP)B9Q>^)8\?,AL]R5C9YIJY11.,KD,_ M!?D"%,2 ?7JXSQ@,* .>`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||:AD2P.UC7)6Q2 MO@^FU3^PBH,N[[>Z)1EFLZK1X<- -9SM\:$H#0>]Q6V]URE'IH;K1HY#X<8V M"@ZV]-';)6HXQO$I<%AY4Z_7LF=4LN=[?&A(+G3;Y#<:6;X7BJY5J_O0>:.UUJEBU>CI7H0_QYR#>+NLB36K0M7Y MC&I0/|!2@RW!V_J@7D8?X*M$A\V4FAWPH2BE!O/+]78_,415P8)3917;Z#0X M'[VCMQO5W-Y7B4R-\N=7B5W2BUWML>'HN1._^RBI_?]:6]++)7=.E55L(W<& MW.LV:)604;RM(#4J' ..GC0O M.W#+!>"<%^U!%X1:4,6ZAYF%^\8P:"--Z>AM#0;-LXM6JZ6W6P54_%7X=+(< M:0O=:.H!3@+LMO=D[+7YT@-CY6\6_]?G#]J51#P!#-I((AZ]!G[0 8E8[^GM MP."2B*7$!\.@TS82$;W<_8'>K*=1[%S:. V)>'(=@+F+J9FML M%,U&3-]1ADBDUXA@1MP)L"[M2DL9P*H#NJSCF=&+T8[eEY..2?)G+M&AQ"]*NHRF M'>8$BP8.=G_MU-*FV X'V"YZC2U:8[JW4NH ?>OGUL=W3MO[8^LG,|_PSXT.K1X?6GO#%38/O\3.ADML'WZ)W0V7V#K\ M$GMG%[=NBC:W^H!3H$I,N4F-AZ(R55.Q?8 3,&T&N@QHU.Z30]JMY2C2 }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fT=EJZ$G M*L&),?)B1A?%+ <<3_']J!:(<'&>#/$,APJ+%\ U<3D'H^:(@M.Y]M> V>-P] MR!T'OIA8, ^T=OD_T;J#3XT]SO;AOX2ST_-!P2%S&/102%^,UH E@O[:-%9S^ M,@7G$:C>]0QOSK=.6@!7]3]1NT$^^7IYC': !?;5FD82B-/0IY;6>I37$>O8# MO I^N]2X%A)0;6GD !=&:

¥CG9J%/7PR_;7ZH4@$*+0B]_|(*+2&]PFSU/1&.UW^6"@6 M%9029>5)XLC'¥'T]"`M+B)*&B$ZV*$@/4:M$*ZQ:..)-%-,N[$2[M/7A;#[5BTP3]@T_LRG^[XAX[AXT;^C=?*
*PY'K"\C,R{H!ND}>#MJ+PRBLJL M&T0TN8UZT"M8/7B+J')"ZD$&KJ1QHG]VT2[*K*ALZ%0 6 X T-9LTEZ%:A:H M9T5EW2&"O^W!V46_F^X-*
4$7N#I\.*XJS#ABY22%)IUZ<9[K"DIVP9$?!3VGC MNYT&QG=;_$%]; A7*F9:ZA<[5)Y^I4 M.7553MVA:&5?^:?+ MY,M.+[L+>14MJ#+N#AI36R5*
*B\BXZ_3/+CI%1=4K$Z+,,G#KC+O.H.JX.P+Y MER8U,X40W?K91;N5+E6I,N[6R+AK5AEW;KKCFRFII$E8RWAV2\=@')>+MV5RXW<6U*6\T2A(*T*
M[;.+;JN425@5LJC(TCM:5O3JT'&W VRXDZZ:JI"H;$BTK^3@?<>=DA]_B70)KMEO]WXW^E]O)--$]MM65&&TY)AS3^_-J])-=P^?1S/5Y MG+=J&1U2,ZL,#W\]"
[UXZ[5V"\%W0]UOX259\M5- ^%2'NIO_'O#)SYGA.?:!!.(,#0$:("K8[MA@N!8UHCO)8Z*M>T1VQKO/AV^%,;_O4L%6JQPP_],;4V!B;()<2Z?ZQ46OZ MA?*
SSSB+/8H}4R0*\&KJ.G\:=AC/BNO&:(7U6;5T;I(&F[3AEZ.B5B:U<#CC)S MU69P] PE6]FS4_=\C7>39O1<9()('853'¥,3;,LGI>1+4>3RXW<6U*6\T2A(*L*
*2&4@%9.'DA/?]@_+U[=W9I@ MV&C6^*B%]+^;S=JX(4H#KO#)\D>V""TB4,5$#T5] GIF7@?@,'Y:W7W M[5I[O/S_KA]2AY,XR^R!'.*A&:]JGL.8#N1#5YSFM-!'E@@0:T,:5SEB3?*
*O$QLSSD"<:/_ES_,2#+'@%LCF3@>XQ MM1PB(:0J *EIC>%F!N3D:T,6O##FT'+&E@,T9@&+\=C,]>C-Q!7A%7BS3ZO* M>9?#V>J4V VR9E^.*
V&.01P9'^,;,8N;C1<$@A'0;>SGC(T$BQ\B]]<8K'$4 M:"\3L3AUT8MW> QDA\\XMQT8A#[YL/QQ-HNO%(\32^(;S-;DR(ZDX0!KM0L!)0Y'#!@? F+IFC36'P:'X MAC?
7M2'(4>]!!PG7L.VW1?BVW"913=.78"0;?U@AISAZ&B.&PB (GH3WL&= M@/!P,ZZ #C^]Ax>0B70OH O(.!N/J:9=THFFY\WH:R@NC2?#%<6(1%K-
M(4VLOU!$G/P&\OZ05_RM5>RL5FJ0S_4!US=48]$AU@=T1 MQ-W.S2!_P8VZ@. &T3TP?%\;&9XWA^_0EXAJA38"71Y@I/U1>Z@!1@!)O#,(AUL)B#$G#H*O5I M^(P% L-*
3D/83,$3C!R/D7V"(_'. O,%9#@M"SZEIG^F]+NB"0^:PL17XXOJ8 M=>GB%OD.,1KZ1#1(B.><$, ^1$,^)$.EN'RXQK$C!9C\|! XG'2!P>!I)AA#>
M!|$?Y8Q70A%T4R);*W4A:VPA92%P'8D]L213=XXL 0>0'IB/#,$M8%F,\#2 M@N=RCHXP3E!G!L 75A-!PN=V.%0<@(= Q@T!@V%UVC$>@H)!GY.A6^CVN$HR#M M!ZY${$#-
*V77$Z2E;87P2WP=:I'R[:9D$"[XE^("DAC%%P1Z_V[!"<)JA.XQI!$BOT.<4F.%77K@S', U=#O2R#((C MG.TB+BF[XQB'S'**1ZB\+8T=*FIH9LAH3:CN/!N6+?4<>,7MW=7T+EA6)*
*BEED*V"$C5G MAL?9@-R)?&6TAO3+D55$"R:W`?#-,'"]N:+![!A,N,/CM.O$|\]^A+Q<1OT"J MO7AQ]"$ % X(.61":0?>PGX*]YH4!2,8EL!:8%G O'W0]E&6$9C%]TG_E*)
*M)_4ZK98G3Q(_?9E8)U/&#"::T2CD2F1ITF>!H&? E MSY:T$USQ6X);E]*U2#E\O0_'I/\XZQ!/=(*@F+GAT\0- SH)) :2HT"#KG/^ MY***
*(I]'XG7FX>3'GX*6N=1;C0Z$;\]86L/O@%;KX\W]'OCPZ]$7:"3D[HE\!GNTJY"8:W^_M[@Y]{7)$ZD:SWNCIVA-P'H^K/XALN&42^4Y58\G!-_%*
M1S'8^B.7LBLSDA6;N(4V<9WO@HO+AC(%4->CR&G^2]Z3'(/W!%I1,O./!6% MNI8OB<[^.[SHBNN70#]W$1^+3AO4S.BXVW3A!=6AF ""_M$!&"_9/ESTQ8I:VH4W0A\NS&+QBI*
>8)R3-(>X[$3R8AW:X5C920FU M4QJFL<9@^GVK/UMJ/VE>T#N[Z"U}J-[(#6S*!?8ISOMG%ZUZ+9U,LD*>KW&T M1Y?F^$+!=8%]2\YQ9_QXAD,#D_0.C$>P?C1 ~^',^Z:>#
*[^U0)BK/%(E^,(V7B)?]TP',KET4])]**6#1TJ/F@^>$W@&:?ILH:W'ZYOKVZV3(CL9^9D=@O80@T^Z3NHER?KPR3^T)K=UH_H*Y^MHE*
ML&T[0PVA.#U/:'91$3&>/,:9./QMXW8UW 0>)Y#YB^$QS%0'D0?T3AS\VO # M[2^@)]_U=%KP[YAA..=2CS]AO0$*3^]$T; 4NYNJYB)^?P65EK'H$.@,OE-R MA?SK$9Z<4%|
4/WP#9?P CPF1/3 &~4+!L\163F0@\UD9$- DLDY%!8 M6TGWPA>]FZ/KC9D5\,PZ>H::5'>4B1NJLW)HU;COT.?4 M4@#%$#TI/$ ^-D9J_KT2=OX?*
0,;.X2[PZ?P/RQ3>V#>LX5)$_(95]\>TL_ ?>*+?>T!NZ 8 MGJFAS>]YMG;G/1F.]9_D0JX^/5S=Q8]!A+P%R\|-K)$?W?D1=$,CC.ZYO?JH MI%?(C(C(4/_&-TPYB/}BAAUP,_(S88?V%
[/'N#?YL&_NOS[_)1_'120 1Z>< M$0-+&^%004= R8U)%" !L1@!$41:KBC"Q%+FY>U-18:KR)"?$:]01%P(3H;]6BPVC BW@.A30#DY2)*
*M$<F]V0S57NDS5,D\RS+:6J=AM/WA&#/T0P!2W@OD/0U% M(M<)*FAP:,G,S>UG:3Z!@)BJ*]UJ[L82!-\,[P<#.P+KE]TPN!0@NOUTZ=]9! ME_@C;4>!]*
(WL.$>K<<650M]X*&7#}]J)E]%KUSYZBXPET)W, *J?:(YA57!H\3N:>"X+1$3O=!,);_^:^YZX_F MF&+/N$*!M2@O?*-.A RX1RD,H$!.@>+A_@-#*583Q`(8J?(V"FE*
M8"F24MO:LQY>5Q)RU8T3]HIQP8H%Y(IPJ7/N.IGX+/PQ<(.M,S7O".M:>RCGA(*U;1/L5>21QB03K9.W!CKI[0$?B*SY\+%O 4^[*CZQL03(;AJ'); M+$@L5?V(BKSA'1O6H:_HU?*
*&=K^PSK(N4)G@F4LM5"%@*B[RFQ&S8.1:?P?^Q M#BTC.M+'OG2U=NQJ{=H,7APE<4QA6T\ [5UF?T*%_JY?P9=]/;\R5FZ9X,_MNJ-3VI:(W\I"?&1S='^2PVV+VIV#8$@7*
V+IEHN[H';W(`NG3)!T"[0*LJE6C MVUFHH6OVLD+7QDC(%$+A2_L9)J.N?LU'I+$1U+EARJ2B8%36XZ1X4B^]&0 MD&:..8R((`ME8UO"-
C^04AQL$31S5S6X!#+&M0QIR%K,&!N\MA6!{N1W.#G>%3YC7]+Q5@3HO&$3G)%$F9!}G$9.W\!,VD6"[E^1Y>5SB4&^4K>\)&
M6CP]$A;DOX*=KD[/L81+@1N]U11G6^%/;E;SNDC+>7;M9Q[EE=T#3,N?A0%& M()*!"-K9$!#XVZ3?#^%']-+)N!R-'0 MIF0;UM27F\+L+4J)%369\8KHM3S^+1=E,G_D64.,_M9#/;?
=']5JZDAVP0ST(;NTO,,$-M1-V,=26" .^]X%6\WXTQ-3!7RL<2UT & MDM '': W@=/9&+=@% PQW8:C<.2C3X-YP? M9GRDE^33*0T"CD<4 MS;J;J.8Y4?!0' +6\ ZQ-8GL40+;,^*
{((IR\,"21@T12)(VJ:PHAP%CD;7@9\ MR3)#TN$) WB&QM,3$"[O1Y#9=L4PJ:N6TE +5\G/G'Q92H&Q #390&.@-"(; M7^/(3')FCMC(3N7X(0OY 9 NXJ[B8.
+7Z770>HCH14$&*K+F5M.+/'+!9'F/ MM@3W$"1 P"%-^,;K3;5&_?R_^!&/#EE!,0::/#\.2}3%XT,'V0OU''^#<)HN> M^>HT,F!Y8Y}>WRJ'(BPA7, (DI>IL"[VX". M1,8!{R=%
*<1<1S8Y$Z*&#"'..$$?$T)1{)3&"QIR+=!T3FEO $SKX.,>E10J!$9 ML2S>64>N7#2Q/R:I M DBK2VQT9\"(,7V!BENH-Q3:AH+)6=XHG(HXJ?;#<5\<%9#ACZM@%GT*BY_ M?*
*P#_F[B\T2$=$_64F[I+Z[R2D]34+=BJ6G) M45.M"'?A3XU6U10+08V.7^C]0RR/0PR6=48"%LNI0Z"Y;+%[N;GGL A]76AJ M2E<4.%O*G98+Y$\4W.?U(GGH(+[1&+D)M4&*
<".BQJ9XR) M<8 V<{CD!S@EN.'F4ZSES;(BY(4A-S3WD?M^AS0E%^S]XG*[1 F$IWG939 M'F\ (JND]"PYRC$ZSO84B(XJQHB28D$Y-2---PT#7C4!;#T@VD2B!36;>/R,*
(UZ@G%&+=6@4E,A>XU0,BJ/B9F8#E33{F ;T?9)&2$>KRKX(:5I1@U# MA./2QJ3=,<<&> **$^!)8OD_*+LJ @BQ#W0/;$$4A!9N;J*.F'"VQ0;%N02F M:A&) CY*{$T(135G5W3/RTK
C;OG+2AV"VI'(C9-N4F\?8SMNB'DU3.95TL M[H,MI';_B(KN+H_=?8 MFG^MPE0)DFDM\M#7=)SU_W8LI6>N6HD#35$-C'L,>5>A %G M#2K#)UDB^)/X0W:U]Z)J910+VL>Y'Z!,
*/&@K+ 9+3$_KXC6:HW':?JO,R>W M*K- #%Q%9D]\RC;2#YQTVRB0>OLPK=^IEW!L66^L'VY:UV[^O-!U[X#)}4N M+;,#O_C)L+&4!B?Y?F"DZ=IE#8L+_,@!*_SZ_:/NC@=¥K'*
AF\L%EO-'4TCM%O\M48NA[Z(,GWR,W;6/%+PG2A7 16 M@F7Z@45H&I4^5R{)Y*M@A]?{#I,S>..9JPJ07:ZQ?0GU%9A*^P/HEB[*\9B,]ZQSV4Z+A.-.=<*
M+#'_'8X#H^]]SOXT"OIK]W(@R&54YD9+D "N.7!&6QW0\QFA#C M51PV=:SQG~'' +B]G4Y}6F^ESWPFPB5R&/V#>L7BM2KUT^SX0{H]"(%8GO030F M07)
*(#E*5LRDL0FRKT/ :LULS'GEAH$Q@[]&Y*6#7>]JY]Y##_ 19GE&OZX(;X+B?^'AM<@V[VWZ[W@P2MJ%5MJ8(VX@%1 M1$E9*Y>T4U<$#EQT[TPM7XP.R1# \!+)(#*
*A%5[3U(71ATL5MS-3"2)H0X]# M;SA?E/PRQWCFL7\#V8XBPL-G/8'5'PA&IMR#/G¥;21)F\E7@XG$W&:O6([]X MI%("V"7!\9>)]@+*1H9*@X.7]]94H%0; +-"L#2_R M^42GUABHX-*
*S^C\U)6!*FAN-0SB9(8BRL9R]XA+?\9Y"SI)=-06KH::Q1<|% M72;IT]$B)=`Q5:J+1,R0JA?)>$.7I%68AE$ `J#5>N#M*0$T MU)F6C*DZ7=E#(IHA1].>%*
(GCA"B(,C!34ZGPIP.0E+@NDM.M8';EH2K>O54X!0]5.]-#U3F:AVJ5AX;;ZFW)35$%IP1=L%-P.@U/JUBH[{GZ M FP8U_@T%G,X]]^_&: =+!-[0LHA?[<%U|$);?Q+;)8>+P(45./*'|"*
6= M5"/\XQ.@}(M:/!M]<$FKBLMH8>V151/)0:',^L+:%RJF@R8*8#37W$%T/++1 MQ'E:8\@[_PQ7!6;/EQWXR-5;MUG[C#B_HU&7?N'ZY5EPO);^B9Z0ER@I0 ^ M QMHMHBHNL$-*
*(%"T0^Z/\-RY5-$1ZH,1'#-47!KAL&=$'1%IZ'F5DF8IZVH66F]*R<.BD34?:.MEH1S2M&2T?A*HUY7H\{099,$)5(N%@FK F\^>*.@W"'*CJ%68NQ-HX_P?E?M*
MC;P5:>27D3Y.O=.CJE?,AB25$QBA"&^*>|CM42'VFL:30-8X"3"ILUN\NE4Q MKQ;2VSC0.UR$R!89"VYT4D CW5V4/$2?M28 */+QHN/"5&Q\G_*FOZ&Q3;W M/%LW+K0YX:TO;;,*
(8BIV^D4)?,L-';@!X!)..2<62ET]\5 6^!E\+.6_P!QR M 14_6JX_LL3X[*)X!/0VOX-3.3!A6^ LUQAX@CJAE@0"H\=37@;K_A*;EUI M#Y.YK $C!D1-5=PGJ0_E#@@DJU;P7E55"^-'*
X}]LPS9?'A? #3\GG MD0++&:," 2^5?(&Z/&D@L6$>V$&169.Ej>@K*9^60XER^J+DO('TC:)F&& < MPL*
MDZ193Q'QN,...:MHG5<([T&N2%"M2+*_@TK^50]AJ4'6RYAL(4Z9D32=S6=5PIB(_?$>H1.%U4M7-4N:[#(MFM9LG3>;_>[Y[U__M42Y5*
(Q<1@$=7M#$Y$:D56I9LUU:S'RK*5R5A,KEJ0I MM^KE25/>4L?-SVX^7A[SALK_=P/=:2:VC/@NPNBOPA!8'PR$C)]%,AS74K]A MJ5VLH[X@.318KT'VZ=\:B?F\KPDC-?*
+&KYBZ6#^ RKFE.GC8+$EU0L3^Q]Z M/-?,8WQ0DZB(]B+L/1=U M9:!DY@38CG[{HV;BV?9@+[!U*7WVO\ +(W1;PKQW7[Z=IF!;,= -!NW=MT]? M 15 (Q@TV[_JL9!5S+M-*
*2C$_D)EA)/,JX15T:YQ%G;S%36%2GV?P?4D-^ZV M)9!?8KVX(92H*)M1]O[$! Q?MHZZ/,^U L_U?1. AM-B>#Y=__469I_92$6 M7>JBGR,UB(/#E#F)XS$*QHWPQ.N5[F.R']*
*((&S9YLB)KSVMBQH%U6Q MT;GDE*S.Z:\,Q0YOEC A^S+9OB"9&JA1>>4,4ZYF)#FYZ2*,HG@~E&6]Q4(X M*UIHH."D,OV3.$?EE-*#HB64S=8B"CVNK45+!.6QH"=*
(=).\MBE%+DQOEW" +T#5IO,WZB,4!\ZP MC=2F_5$=%8853[H-[(8&SA5# M%L!3ED:_H,/2B !1S"$F(&+/[I]@Z]!{] :<_(TCU\6:%S%]W1W]$&D#42:X
MVB'VW>]75_=E:5S:B%&$S'GCF.%_4*KVNR$;EFS'+"A%[,62 M[HB>@0 M)Y)LO&?I]$VIV;[$-OPD$4E10Q9IX,8)..[4L88X285-,0-@H4<)T-!YDOW M_!!
*[*F.@/E)=%Q!5;9ID&JX3X[@H-A\:ON7SO%QISJ9{3HE5*@PHW3,H6IZ8 M;IYH,$-E1PSKDFF+V*8GF3B: X0%NSO3ZN8GH!2/1#W'Y/4,QO@.9O!V2-6*
MSGE_9(:R$9GA5(SZLS3[K[46F=/>2&1J!3A,1.#*F%X.&5',2$:IXD2B1"C(M=9Y< .])3UO:4$+?,\?QY_:S<709?,-@W#27M)3-87V](EC?9JT[!V<7P8N; MYHO9/7J%E(S3B%+..?
*4\5+5$U*IZ%EW8/8]W3RTBXD\-'?MPNUO+E,,8D?@K\#1TC-*E.,]9\W"< M?SA MC:P5E-[HFXWS@)+2*%'3?LH1GG2^$^.%D%!*2I2*=A$;BWA 9/833DS M@B+*
[/\/!US1/S#RD;(2HCO '9<>B67)Y'7U;U^ ;3(AU'3&2(@&S&")"# MN_3%$"@1TE?&AN>X]2%<(9JZX8$UUS.,#XB.V482I\.10)V#/,$R"\Q^8)W M#[/"_XV]WX[LP #'*?&*
*(P_X+=9C*9WME%>YD!1WVE=4J"\E(UCX7#:X(>0MG; M5?;O@"GUM_PC;6&PQA:H]AW_$C,]J##$,R17JUDN3?L3A1N[^ZRFO7 1^J9+&{GK%YEV2!UQ6D-]CDW),)14, M)3%D/&*
*(*WYCW1$[JH_IK69_!5;I&4TTFE:R8D$;1&_>RBT55&D&6(,(EA F)RJ]\(4R)@0*3T$84 M_28B>,8C7*1O(ZJ470+SS1ZH1R43"T)":-P>?OI4OO,,ZFN#<\!VPFFRWEE MO#J-*
*MB+6%D\Y>4<>FT8'C,'/.)X%L,,%%GS*D&..%LUFHH!A![18X<$!'BT. M]J "9\,D#$]Q)N%,J-/Y\/]"4OB>2^$M#^#D6$ZV 9G+R/?KC%]?WXOP)Q-9 MT"W?6&8ZHH#?:..&=PRR\A8I-*
*4\B M3PD3DK,+]!3.?<=44@=DYL"=$^4)P 6WKN/)/REK .^GE= X8PN[7="]MT2TE#F H2D6=&RZN;?.D M&*Q^*
*!U!A*HZ"@A)JF81UQD)DPSI_;J2$(!*HU9B*L6<3&PC8ALSG[V7OWS MO&?;F\-+ (1W?1!,9Q5D2Q3,OXXQO5;GV!YX\)\IWRR^KL%7 MOZ4_;*
[5JG4$W\ZMZK;'AY^WZ9D_*6Q0*B\ZF+W^3BP+EL=YO+WW4;X0.'"4 MZQ!]_]\SL'^2P:_WS=E/K2'3VU79L(AZ'.N*9AK]56E9==X'GA1P[7^8QE
M!N:JO=5Q9P)&IPZ"]2"YHD6!XHY#X0V79-\BRWR@@+(C'UGVJ0_ 0$5E!^NKO5 M:,38>/Q!R"H29;- (]56PUU\6 (65"<. Y3!R@(C8A5D\)YSIUKDET:?/BD4 M;Z!+GS6Q*%BX9N-*
=O",HX%W.M(^87,S/2K5H#>=*"?!$P!,:D"YF[W"1^ M^]"S-'2^A7_D6VS4D,C*F\.!EWG[*+12D]6WXV!B]Z%<6 ^/!*[N__-AZ'Z=B M6H@EVIP9'N5IW\C:5GUS:H'B2?*
Y9X>2#A!TAZ>[JEZ>&)O"W>'B'QC?['6=>Y(}RIBPFLD;](Q)^H M((!W{[%^:A0']S5>AI_C5D8GRO-O8L=&J-7JH%0XM ,,;>N/7=BUAC]96&SV4;71VSFS%O^<_U]$6^*\3;5M5*)
*MG&Q8_&-/>U?W!.'!RK3IC=*GD@4VK5S;6G&>_64%DY0=[2<..:3]H=D<^.%&;.MLTZ-6TNQP7N8?]5W>NDR3-%U:R_'+ E^[>/>W+.;Q98K^JSH,W?*-TZ"/OMG*
M%ZVN7F^D$R0K^JSH\Q739^,Y%'0_#.AYW2<9;JYXDO;'UDYGGV"L@D^H:8LAC\\.N9+<$R?=V/'DW/IY/K%,DSGOZ7 Z:US37>.:WAK7],\NKBA++#9/4XN+$Z/B7 M_=A$)\\XKE=*
(_(?5R,\8EH,CBVY$^.c,(!L?8.N>3)H?H %7N_LG,-2 M47Y%^17EGX[{U0BOR+BO#?H,COOA*17W3+BP<F6O(DB]]E]=5\HO5IAI M$K6^ V9]@M4\T^Q4$9@.
*{JZQL>K9;IY=]/16MRR5!Q6-5#2RO8FV%96LD*BM MPB1J12(5B1S=-MN;(&E7@J2BDI.ADA7&V3X$2:=L@J2@~9JI,9Y#EO]!]46[M<_#%3W/M7+MQGN&*
*J0FAY6@,3/!@KOF8C$B)BU6 K?+T%&*Y71-F/42(}?GY MUKH*/0\0[](Q;UUGQ/_87.)VSRZZ^J!=5.E&Y0ZMB.1XIMO^R*17D4E%)B=#^M)BO,M^W(9(5FVB];T*'BD8I&MC?*
*>]D(c@[+12$&!MS*CO%)O=$V4XR4@*Q\I M96-C!:X*?!6XR@"NMY2V?@57P)K1QP8RW+=,YAEK5M55REZE!)&RMZ*U\L20 MAQ?*
*X_I4[*5H.85>,=5RCBF3V2#*#/9/=_D\A]"%%7D\GK)945WJ%,H9$5WMD#$ZJMU#B\]?? M,:=:U+J+>C.]A:I&0EF-A&03-TWV;WNKL*F.'57-A*IF0C%$3J&9T*F&'4H'*
*MR/)V&*J.^(T#\BV%Z*K.4I4K:$M74.=8_7(Z[;.+Q]"A]]N-DOA_*CJIZ&2) MRW1%#'N/E-*I**6BE!.BE!6S,_;2-*?3K2)P%9&<$)'LIZ7G"B+IE8U(JLY2*
*M56>IJMG!SF;OAJ"=/!8=]EL50U!*AHI/8VL--'VT!'D4UQ)644B%8D(2]O.4@>K35[BNRD(9.6C!V"UA6X*G!5*
*MX"I;XL,)N]0*K4VN=+TWJ>NM<*T=HA2FVSR[:+,T07_G.>Z5>521S/Y)9D4; MP#T76W:K;NX5N9P2N:QH![AO)PPCVD&_,>X MVCB'AL&AX7J:K0 CF 4\-JI*
*I4Q0N4YA@1@P+D7066(4*F5&"S9>(%'NQ-N MO"J\P",M!#+/BM)GGSD!FS'5M9AM.H!-T M< {&#(=BZ!J)E7-W?!{Z3'N':F""S_N'[W1_T6^/#K\HC |-YLK"CA?P('_7D MNN:+9=OZ-*
HR(/P(V@']$_4&:SJ#+/VALQXOA(YZZ3PZ Q,0I'L&$P7|>8W2W M,_W4I@"CB:\QQX0K?@\|=QF5PJTZ5YVVZ#DO0%Q 2-(.0U'{%LOM[W
*MQLSU+;S@O<=LBN3%+3=0>5'N$@T[ZO$MQO#_9^_=F]M&JMF_JO=>A/?-/+3DNTA>]_SF?GKO3F &7XPG6=S M&J#=DI4O$*XLU6<)QLGRB=*
*%BH9:1E2Y964#P[CAA_<'U&#UI;M7I/]]^\Y M^VW&"]J/6KWWR)K,^FF"L#_Z,")NC@9I{O CW/W9\?]_,F9LBUO7(`!,N@SC M+_'!#(S>",*G'[$WG^ZOOU\^7G]1?*
*E[>/_X_Y?^\O;A\NKQYN[V8<[,S*W, MC(1E7HSO^JU_J8J2I>>^,$.03;[:ZSDSYN?U\K#"-3@1GTA=RX6A_9'G/$Z MI#;K*FE:*)@0%.%5!,IX- #A:IP_'7\>6SS!DNH93/]EBZ'H'**Y"K?*
*#$3V+ M2,0O\7S8D2(_B&:34N")SR,;MH"%?F! =)UW!7,@B#>W7V.I,%U[\N&1C2>> M;_I3@14? N_?! "PVV<(-Z&?0"S/XDL$A*2?@O5T7B#V?9'9@ DA!YO#*
*P&M7R(\&RXB]2Z7$4UY1!D9H;4'X?@%O!.W]K_PA^.'!I2-)'U?GL^5; W'"*M MV:Z]^10^>~_-JA<5/YLZJ&&20h\6/*!Q%@3F>HE'ACJ.A"5_^SDR2F_O_,<>3 MCU_H]JNf.*
]KS#^5N(@XVZ5&7MS?-[\#7EGZB/?\+69OV@M!5YY/FI2$*$OB%?D39(_2'$KX=3\4!-^>>PVS>%)3^@'IC.!WP?P4#Z}{#+B M0W[*Y-)*$!TCS\A0,4J%>9&"E.;H>K(&A_CA
4,SD5:/G@"B MF7(LO-S\=\'+'^(?_]^E;X5_G;VM:0$[RB_C@DG9A3O\!-7T^?3)_D,A@%DV0&US\L@=\|QA72O@6!!HC:,6 M:76W SS:T/2:434T5+FH,H-J; ,WMC"WMWND&))<:?
_@A]S7R2&W8M34G>5! M=U^5!UU!(C[8+VN0\#7LE2'Y}]!Y%:09!D_6X;!7PT">#KW6@3G>667""=%Q M+;[;G Z2POIV,(F/]9BOV LNFZFU'@N<:$[AFI,_H6S#^HI. O\U9\B]A%*
*M];UQ]HJB;,*V_N93LS,??]@LE7!M'57%O%PI7>=B]\#4HKZ+P:ME8*7[784 K?:N%; 2&S>^%#U&BU6VM6 M7OC. 6@F%R1=>/:AEYMTH;(X=KE948Z_%7^L!:+1?*
*C44675PHB#91AH17'ZM A5OFQ1O^J4NA^2O2O+7'BFKNW?,?)>OJC5=O#)*_*LE?*\J?=\|?*W3>?#+79 M[E:$\O\L2W%'=*
*(1C%Y3N[BW%#L+6=E[=H+PZN!F2@5(&TFN{U+3+ M05DZE8-[E;:>ERQY#;>T>GPM?7J;5SR5R7Y:Z>1M17*JW(,*\]0BS3 M=.L\#_+++3?Z4!.W04;0.1=$:QK;\L<-*

*'T:3P2>%;4_@.'47K-/$PI-[:5K! M"E]%V% *WVKAVWHHKJSPM5#XC.ZV3KJE\%6$#:?PK1;^0XK' :4 MWEZ. 779[P,QPN"G.44NN(I\G[EAA"0E520I0_ N A%FN"<$M/ MS)D2.!E('$*HEEI 8Q7,W*(57'%$G,%&ZM;??'(+H)$*%$NB5^(4R4I">JW" M5_S""^EG\.)U4O)&'O)J88/*4DC6]:RS70C\YMLA7SU^%@2]PE-WA);(/X#$AL'P.36^;[QE?7\R/2G?-_0^; {1>/V^T=@WVS4/N&|\\[T@-M0-4SL$.Y<:S!>#,;QI QD'D(.E@FNL>.=9NJF5FO[.\W>1,Y=I9UFEH65^3UC MS18'W3>;N!{5.3G0VE++@06 !]PNXX-J=IOQ7X MJ,2 ?!SYTW;]D:^PEPES Z,"Q4%F8"#D8/==WR\;Q@YIN_@DYYL]H50%5.2 M33XLL;N PH8->Y!Y""JG %=Q;/Z";3=&);VZ^_(C:4@##4H^_)M?"*WM>%.(MO,@7H+0]L 8<8$#"TA0F1$PZPD>%K1>H@%. E].QA=L79Y7X)6[Q/H.=/>VS M9+O\=(.8#%[Z9-*

J.V7,.Y%L19S!A=@!Y$B,HMD'L@/J)%$Z@K)4[#M.=$!):HL^1RL#>2:WTN:C8/L)8L/&/16X0'#'@E=M,_-,_-C<)]WYB+>TB@ M@C&.82,[&`'+?_9! {@5R\&U(5\UQN'GRJ0VP5\AHRP{R0GR4LCW&#I8}+L_M-+2:@;8&WO-)TJ/8B0P\)@AIPOO#I:A3 \HTSHV+7/(HJOYO}+A2,08!BL MM; GEQ<-1TKHFQ897: T^^ N0QO07V!PH'V0:+W(KZV$Q,?,JA7:>8UKXW M-1W/YAG8 MZ=A,#![^RL'?P4ND^]-1O#^;\S97D3KX N8&*0,6SG"=(/E'5H.;%""%EO? MH.Q1^RX8? -W*;FR=Q>)!Y]_MP3N"&T4/VE!Q1$>-T(.JG?FA:../7YL*& MPH7184,3NX+R2#%9'',(>V0E?AK2)XC\C...5\:!"UA^YP++#:3*.4Q,2X7Q9 MGE@O3KVDGV^^C0[XSW,+)6PA\,E)X)(<:>;/RA'U*%*: H&\WVD%Y{!A44C M$QTH8*W#M.%PX<.VT@)D]ESI)IW"YZGX0@_/(U*3AQZ>J2!= M>&>/]#3(+.]7[KU!2+>MM?5VZ?X@+:W36=X58NT&$X;6-3K;ZGJA%[}$#FJ7 M@VKHLC_(5ON#G"1)MMKHUH5$\43OB!'AF=%!N^VTK3C.%9:JBG228^2\Z.* MY"+9/V3Y&_!G;H7GO}&{6G61LHM74NX&LQ[- ME[%]_6;_N93IZ-V&O.9=4<+CBI%YG1%9F61}QY$QGCSJ:NK>N/5*)=29*3(M[%YD5L)O{T%DL,2FTU6-QIM{NDF9D3*S>YE9"2F^!YG!^]".KK;Z)X8K?A3> M6E%>D,04+Y"4E9CB>Y"4UIM/C.Y: {TK8\9/DL<9*V/$\)%C[S2>]H1JU5Z,[M21ZK)(^M1!_? X]UWGSJM-2ZL:W&QY+'JL5C*Q'(]\!C7=@K:VK+J(H>.X=> MAIH^4)NBR,,F3W1&'9;FZ"? CN%46]!NZGT5%K6SNRD6"R%6%%*8 K M\!7!E"%,]+ &=!+#>41M;"\U) :P(*TH!7"F~%,*7OW.1O M91N1/0B@ 0*H&ZIA;"007BE$]7WDWVT-&ET. {4B&=EK"0MJ6421W^(ZXX(" MXW7KB^DZQ'MR^[9C)Y"+HG(Y>5-;Q[Q1XO.2C5C>?\#[SRG$O>V$Y'5/\2M' MB/7-P.(IGH[1MS AV73MR8=KH6V_>T'PF=3@C="WCZ@&OV1T[:5K768T,7G+ MK_'FDU%76T:]{D&*+6SX4FQ.5VP6)"7O76RP]6)7[1JO/C"48B/%YF")R7L7 MF]-,;3^V6%!LI-L?&JK1V%9OT H$C";2,KWU?]9LEFUV&Q!6'5K*M!%,9C%TJU?4K%?)+-5N!3OI#M?"7BXk\QZ%PA3ZMX;6@%6.W:VP > *-13 M=N(}?,[CG'5'5N\)#<[!;/24?F0XJ 6MLNW80^K0DUYQ/RFN#%O;Q5.NU>,"4 M];6!/(ZH)F^M:P#OBK>P;6];K;5>LJ-(WJHF;ZUK"^^+MSI@Q;343OTU9K'D MK6KRUKIF\:YXJ_OFDU%3:PW]\+QU6G#HRV >TAY0HDK@-:>EKZBZJY{TO-*@ MS,M,TN?NAJB,X8C2 F+4WGQJJO76]P"V2JW6$9Q8G#';K2A\W K;866_KC9J M\WI9\MVY\MT*+/BM\!U6M#?51F=;9162[XZ?[U8 JF^% {ZB06]4+@I-5X[NM MU"%OJ3AQ!QU>Y,B.863GE&?RI^LS&,9 F:5<.*!2!L,*\VD3AAK8+\QZ_U_F>X6\U'SS"=$9ZOK'BE2:2;);J^^S*QW5 M>O.II79?W\9'OD&&O=_M; (V=,%:C]N935]6EQCI:QEHW56,WC%6G8HMVMP*<=4Z'CX1O}WI[\7@=JAW9 MBT37K%##DI*50 J@-M3PL/#F66=<2W(!EC#>?FK*8Z/189ET;,P.6P3,$>@7] MA23/',A\VX!GFK S5:"J^K2 O1* /,U43BZ1/S7H_FBB&52+CXSEPWL ML+1Q+(+P?))S8.JRQ<5K27-".F6^!]M'CS!.C{]I8=AN!!01F5.>F\"DX'4$ MDG+]$OHF4-1V37|Z${)Q "H)7^]!5 @0.YGE'])? MM+&;0&2N;N9I *0"H J0#6ZD-7*?C'2E)#K37FC}&D I * M0"J G33"JV0\H,!WH[XMO.1%*0 ZZO@;MB1B,>8* ,-G7M&15_Y5ZU_R0#&+ M4\],5JPT;—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|\'RBS6F]D6VX'5 MLP2_]WRT<^;?.K,PL0ZJ=3M@>L:&J] 6\Z[JPA[-8'(RWS6=N#]S M\'F:BO$E3"IXQ)WP$9[V&?CH5T;YP6,9Z,0)+I@?L3='(=PH.0.PIKUGW+WY M+F^QB=T/@ZS<4+)^^V, RIM(I? 2FL,LFZBTCRE;DTY-RSX6?;<|*/JRK^[" $ MF(:2R Q9T$ 4QYP$[$/\X:,%6Y5C3C_8+DV-,OHH'B8$K< Z(WGB/PN^ZQI. MO5-'UA.!0_%BP94:D.IO\|\;3:U3+_ZIM4+OU_T]'H#!M HJ:C:%WS>.> MUJ-#Z7ZMU0MX3?!MO;Z7VS%@PDGYD_*7RM^"1L[E3]LU1OJY0^,>.FZVFZJ.FMQ7]BPQUF!-MM1[_\+CTJ8 F{4)F5B0$OUIFEB,-5M;0QB30"159*\%G;?WQ5[;]"3[%5% M]EI1SK1K]NI{CH][EJ1*[\1>Q6P4??-IV:K61$6.@F\[/68@?>W$]NXH5U^ MS"4WNW4\C[+B9OM:9+[N?O]=:.NVHZA(96OI7GJF) 5,"O:K:NGW(MCU'85; MI&!++P3Y;P:Z 7.L["N-(N99R?;9RO0MWOJQ@4^M 0S6,;75IJ5:1>Z6+/[=3 M6#7QL8@JG*K*Q#&QIMBU])7;A-=0NRRD FJ?JJQ#+UM]%1='JLHS_#E*^KUE MI[WP5&=?]& OF?)HAPJSX?] {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{)0/A>WL*G]$5E2IZW&X-PN6/+ =C*XK]VPH M -1A,@\[(KJK? 6EH#R\[RC/=CBB>Q^NKU2,%OMT#'T. =0OCQ_@3ZT>^'=HP M_,L^ :K7NX:A8BP65AJ1!=4D=V%>H"J55;!LB?4E2CD8F3X+9O6R7L\=!=5<-M?IUC?KSO,\)FX]HP-Z"W7OJ^Z7*4_<_3])*?Y A2_NGPV?0OXN M8CI!77 9A2//AQE;ZVGV6D;*$<5K*M!X/@.!3Q%7M^^-QQZN&0BI2-P8 MFU.EQO0["(#_E8'OC940U@49AOYKNR++!5L!I$PU&*]QQZN 1FV#*%I#0^+S<=/2 MYME&62C(YX? >W5J,WKW^AM1)]Z-]0WXOQ8L^Q-Z&+6D4?>'^]B/I@9$P+G9> MB(* D.S!=/\$>9P&-DG+5]L%IK?!N[_R7"ZL=,T]"R*`]D7@$}>C##TQ]V M'

(S=+YT.MT/@/[QL=*"+0/\2"#_H!#^';E<$RR//;?!9ZNNW]/_A6']R2T.B-@N7+FA'Y^"=_Y9.0[^%Z`_:=KG!7>3,2TR%Y"A^3U@K0+++!SE35/3IL5+*BC',8EO4U$%\M.8:,O-!G"[NF8-] [7%Q_$ $Y,W"KO_W M^NK/QYM_7BMW_[R^_^?-]5]S\U]ZJ+!_PU('S7=Y>Z/\!*M_;/991(I,>MD5*IP 9*?Q-?//;; M*$B^\1*^! :,M/""?;M AIZ8+]+'>[;W?I(;OR*V4&!S_XD:F,!2D;@ ,[L, M[P$Q!(EWO EU' ,:1B@KU/R*S+@M5^_VJ2-@%,*?I"*,=6Z!RX,*C:\A/J4 MV7W0<"SH^_:$]fM92]:BA[LSJ#)LGR34*ZQ%QUA,PQ?XWL.12.4'I36B[FAPO8,F\V?6]f 3^:'0349 LF_,48$K094.X1X77X!7 MB_D'Z9-I4LP=H9:T8@K384/?G)@]401@NZ[W)/QN5V$'L[9P0B7!:G+=:D# M-_OF,'[7GJ]#]I[K]=QBI0J.5&Y(2!F.")_D\B@%9R^]-H-0^+X'O'_D]D"TJ!.A2L%O?6 M%%(:XC*(9GL3L"1A&>(G\QUL##R$EG9*'#X7${8_V)?>IY8$4=%7H"(.[3<##NL-9# M>*#Z):.P\3")8%)-L$:NP^R&]5*7KS?

3J":@"NO1MO:OI^9Z?1X4^8(D$&B1X M;[Y$!]Z8N2MCQ^':V0\\QQVM^O04W(+OU'0_4SI#7RM X\1M64 6C7 1-0UX M\V[>)CGDSC'.V-6]YRDHG5JB,O=Z_P? +&SITVB2R5,@';9+;BX,. M.*@52HT\B? *^!^/-M.MW-,W["]>|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}?$1'"_ L&P0#WZ.(?P$ MP26)7:@6!4!QDOS8%V,H]IZO_TL21X(/L20M\SKC MX# [P'Z-@4D9KST2TQ?Z ,0@,/U&\J4'9#*W6C:,3 RLV%*LTESD"-&TN0LR M !8]*7Z&P0_G%%(%2*)4*N(0*=(2MRCQA=@W\-@@?CT9+NEA,#J'L0_J8OF' M!]2_)$\T'DSNZ{(VD)RD\Y#0V-/EA(>0>)*7W) Y.10JJ"RS/8MLP44!:'BL M<.3X^6N2=XI'=K&NF'$R*01E3QBN428-)(9QDW37Z(CS+!S%&>/?^7 MV-OQR#097G,8L^92S%/9>9F)WBT4'YYC4YS)<F1.\#"HK3SZ8 XQECC#C')$^0'4+\]WE=\|'D>+B\.(YX23#!>A MMC$'$AXFYH.!PB#HQ%GA+P#H+[&D$F<+QM;B/P[=/OCLZ: #_7!,:?(/4FR MC3VF ,9W.]Y!X_3 =/'HW0D[9R@2$X]/OEI(Y(LV4"$FA;'99F37D.K)K1N MZJ;JPD:-LXG0KY_=K7 R RH#X(>M2-\{!Y>?I#+EDGV?O=@NJ?"!A^3W=//B M(+:4 8ZBF? 5**F^KEC20YI(;$_;U, F<$MX3DRE+B,38*3Q>3Q-4E#1A^_@/G@]&Z[\) ^AZKV^[&!"V_]&^7Z9?O[? M[_C9]7["<.F/.[31S!#N R:"K2DN((#K'1X"H/,0GM-)27K<(/#>A]![V.R+ MSS82TY12=F"=5=?<^^!*LB;$7EIUCT+QD#Z K4HVTMK BKV,17\7U?S 8, M_R=,#>~)O5BTS!&]\[<2.9PR,26&1A87MUM MM Y25U],,K+C6A\/M2&5XN.9(OF&UD2R89$')F=0?B=M62^PDU=RA^4.WKK> M!XM3 ?'0!5@S&^N;R>[GFRL_Y45]3L=(L'-7KJ[NX$[@CDA0ED6>)!ZZ]<'B M&W%L6CSSXS$$? 2\V>'/"]A@31L"@%,5/=0 ?4001>9) ^H MG7T3'3)DE"I%[D4J!5T59W6$\+:AXMB_P.4==>9Z%,KPT]3LKQ\M0I0B4%*(&%O/"T?9B3G< T;MC1<-[(L-RFINY?

*4GT1[Y6<<@M$]*9Y87Y.5 M381" M#_"6N$Y6E"*FR7EQ;$+D_5'>/ (O]^=#:(A2WN^^.1RT]<0]\,?WIA"QI,H MJ=0/Z?/,6S8I1Y);),U^);)A)#;9[#7:51K&JJK]*FLDSIK${1B9AYYQE MW,_.B\VIQX3=8AF#V*HQ38OA3NYGH5(0?Z%,?)]MSD0-@>\/RI MV$S(I6_EAD;1Z@7U[$G"B*F,F\["R]W5VE17/I]FBC+)2H&\"""7E5^5O@2?PQU85PPK?F,65HI?G"FX MRPX-K*>2AG(`Q17,6!6.9DGY10R/(IRE7(,0AG3Z!106* M,E (/P11Q##HTXM"!!;CN6W/F-]*!898Z4PA)SY#TZ7@5 H4).*J8F0)S3>5 M^WUM&)<|VL@& U&"L<=,Y/)+M)U-9 M(@? Q;4VKU;$>/;TTNH_-?XS@+QP&@5<>B6J,_%A$=6>$U92A4+X]BKP@ M^'$L#W@?A<8YBFN?X>T7]COE;5-KU@A/SPQ&G/EXG1D*4\!EY\&"W$KX"DC M0Y0I/AG^R LSP?/YY_ULY2C,D0(U$0Z'9]D5C(27&#I8BP^O$5"G 3PXB+F0 M9Z6^RY:04KB8&)D?3\7EH_/<"3{XC$ C@L#5Y+]]XB0'YR9TH32[FK1=SJ9!3L7"DS M"1O/\T6[%YQ27O@DI8I,Q4IOMEK_S(171?-G/B;NXFH.8Z_^/GP9^:O^P>1 M8))^\2?ETJ&4@8Q36;8=.[(..ITXRA.(O>!DE'>OLA5ML=(14#BXE8-ET8H+0]HJ4,F0J"'*A"0^74_KR M-,D'%3Y9-QZ*9,_GE NR$-M-Z4Y>9{(K?P.7F#'T<.]X)S[IS;@.R1;P),H@ MAJ:^2*KV7<1#"L0N@55%A(3#WJE"F;U+YJSR$8FTU#$,!=%"P8C<#\|H 0P\^" M.')D"Q8V5.X1'C%BXKD!HO7"&?@>B@A832S2K9.$M1>, MF65QA*X=>V@CT87@)C-)I(N-9?V@JFT5DREN?VI<,;U^CQ"TT\,$H%"B;NT M8T985I#?C18IE6/9?!X++,@8[B% (K2.3_-CQ!-.,X3/FWGH8/<*]"AF?A%$5 MUK9"/L$3Y5J#48/YU,TT@LRIUDH,"0RXAC.6(#)8%0>/V*3V&\?4$E+!I.4 MN^POTQ2%,XN<%4/IX-D!A^I,*E#2RGPA]

*<=F2J.Y$XW'9F[#X7.P@QSD1UQ\ M60CTL12{(U>P0T+="V(!P75VV)!GE5.96A@D'RF"PMQ_>^(CK"&RA/CLC>R> MS>$U_(SC,S9ID1#4;"A4=`_A)*DBT!9& (ZXXG4&9"W:9Y._#^P!V[,R;11^ M-_WP_4/?"\/W]QX0!'Q%W-6G5;@;=*LX:]GJ@W$2V+P[CXZ3E M]{ X>+869*9_;$Q_0VSLLAG\)9&E_OCY@\KO,!4;&.]SZ8)E>]M=\DCZ9\?L M_^+VP160VPZ5_S"DX_*#09+B(A9 ^8[KF\"O/N.KPMZE[RVGQO3/]RS6"^, ML8DSYQ*9ZC2N%\$.!SH/JQ,X%('#@V=Z*3F_@7G,Y5>M]WNB_9T\C2RK*9D#9!KR6$2=FN M^!64NE6,552DNE*OV<$,=I&AQ 1<8\AN@:[&7[)04(A42;QBORC@(6C0*#/X](+Y/E:T8D>4!@-(6L6$]+0P/2- M65(H$TK>H!/J++MC1#S(PGKS8FEQ_#F_RZ.:2I!? *3N>L&0"N#+>5 MC >W2G\/8N+:)$9*R[1=QDHV7H5EMSM"D' !Y*Q@L4>- "3'SF:OZJL-PA_$DO!9DX*.MG) U^-30)9D9H];=8&),(W\3)<&,$,#"0GQ7H'+U? >]9R6#C$T;;P&A"U)@~M*J=F9D":LP9!'ES[\"T(=,YNF7.)F$Y^;QH$8F[.KT'Q 865]GA9NQ]2IG<(X1/&!4B;M^KH'&.KCF_7MJ?WE]\K+B0WP(&BPH@ M3/(0)? GY]_HBKBE\%/PO:ERS/A0"XXXD=J3QZK M38J'D(CQZI<$;H8B#55W6AYS(,14DZ_0H0]V5.081(743 _ZZ% GH&@\0;3. MUZC"#V%Z@5+!H&.3P+V(? [PT;*#B6-/]@NS8AN^B@>+YP,-*QG M.N'2^_C/]UIV[K*":.A?6_?0.[ZY*7*MQ M+8;+3_X.[)4G./5_.K;?49],M.5=R[!%QKMYNJHVVU+F2 MU66=L]126UUROUZ.RH6,6^44 M?;.MMKJ=S?1\!>R0TUZ+L*^ $6JVL9{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{J1$G*Y$U)MJ5]\0\0%$^*A!2)$Q2)MMHJW?WKP!)!;M3?0A->!?^U[*=/ M?X=_XN&*V36;,/\)%]B(QOC!9PXU*? CX;%OA2$PJ>81"V]Q>S!D*-P\2V9 M ?<9YN)N>P'KM54K6&\BX%LM63BB1?;D1^/9F(<YN3>S\Q?[\T!#/;#Z3R; MTP#IF9G3V';29PDX.W<^PT]_[_FX#O-OS3[*](?P- %I_F,C^B:/CH!]'3!EX MCN,]8UDT\8P2L#" +_UPI.)_%--QE D\WK,"Q78MX+F06:IBAVR,7RA>Y"N1 M:T86?&/!%T]>XQPGQ:>*%L$_(GF!NQX$.>G(L)^,& ({\3$8EXFR0,2.^8D8! B#Q\M.Y@XYO2# M[1*AZ*;/XO%" '#19P2/WL=_3OE!JW&>$*<9XLWB9PU^^MO\]X:A&8U&X4\U MK5[R>Z/9+'7'HD'5&UK;..2@CGE0[:6/6G'JMO3L<\W+NG.7%1A#7%CWL_=W M9I1CNW#O?QSYC"D_X+I1H%R#.K.4/R*7*49-7>/4;DV*;'J63U2/=@O:Q!J M.ZRV64A]C?O7- LFJO19Z36^\YE1Y-1DD@8W7*%I"SHI9DQ[VRXU%GKJQV7)) MVKWP#0Z9JG(<:5AK$A7^W2P>OZ/#C,-0X3?)3Y*?)#]5D)*2GR0_27[:+3\= M=1+6FC-.@4!%_=3NNE\.*=#L@? FP)=#51DRE_FFH_(#,6ML MNW80^I2B+UV7LGZM//20S+&.0S)(Y%A^7MB1S2.98I#G*=M\Z%>8XIQ.O M+\N"DJ*%*9EL4UJ?GHH/(YEC)7/HDCDDN8X MIZ.Q* {@"QHQ=51%/P+8$<(R,&U?>3*=B"FF}>^(=UZ5WDPIXM;D,8CDC86\ M418Z7_+&^?!&V:U?\L;Y\,:YZHUS.B"[9T'H1_TP\C&7W^R'}A-UN9=.3"DR M;M8^X%3\F#U?Z"RI5*L>I6I.39X(2&&2)'Y:,%*ESS;,[IP.C;R9"4[I4<(B% MA[W(=JC@+4-KQ>]"FIV+++2_Z0_"YXS7TNJAKW?UV$I)\)<6=YZXIQ05G;4 MZJJ.GW)2N$7EDP]+4>$H)4KRTR%2\R1#288JH&17]TM^DORT17XJ&TP\?7XZ MI\.\/UV?P3#^RRSEPJ'NJ4-QO&>[3XSG?&$K&O:?R ZG2L#ZD4]Q2'G:5]); MU[4]]_VM@BA)OI#>NN2/U]!++UU3D{QQ+KQQWKKCG+++;K-U"IAC"N.PRBJV M\)/9"><4L,$-KE.[0?O12(OEB)5^TM+KD"\D74E}(OEA37[3.CR_.Z5#L+APQ M__6FUCJ.R>>]:QU6/.2J6NW=[OPX22Y)+DFN5Y#K'-)C+KY3($/DQGGF\J#M\5^YDO0GR4\% ME.QLBF8C^4GR4V&Z/8-!TR

M^-5"$\-5>M/DD9;RY#D1$NY"I_0&U$IXZ!A5$X4X#1@IA7D"XYTI#AFY/9'MC&\[+CQ8K'CZ Z=X0U.^HJ%A)A? @2XJ\ RJ'S&AR1[S%;/H= .;E]>T+6 M1:-SRDR?&PST*;=))DP?1/T1*KXKW"-#>^(Y!(3CFY:-'W^KO)>[,$4 M,10@PD_;'S#7MCS\XW$T]3U;[-)/H$.J*(AMS?CY(0.#"%D?AF/"P(,31X'MN6<\&(? <8<_1^\"(W:%>WN(" MTQ/7PDF%K7)SA;R?K7Q-O4LF+-M2+6UL$#2T[FNT=,J)P'U8F36CI/5.YOEK M*FF3C,I$# M[JKRA^E&>&(_)7?S;/^&J=2I_]C+ OGAV*O+T:Q/Q@@_>,;+N\W+TK\!L M0T%\(+5SM"BR7S5'U;.W8KN?"1NM6;O>++3K M);C-{DMP3B+5KME66]T-@3,6;>AJW\IGP}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{3+N;P@U&Y M+N:P#],*Q8G/=5"PZ"VCBH-.3BD9FY>Q>1F;/_7(L8S-R]B\C,U7MHOY28;F M[\%A,GTLZ0*'U\)Z=6^R,;:UC_*=<12HK>K=LFW>CB$()#GW]#G7:)}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}}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}(S%5&S"%>N?JFW+DXG>&T "A$SQ2%VT$,H8 LAS@'\>GC\>B"CC M692PMDS'=/M \&-,/5G52TZK.#8F5A;/WK"1FDJL+B).=U2SX-B:A0&42% MP@29MDMX)9S ->XW&(#YN/>8+$>\&$01"1#A%A2"/"3R@"P# 8!S+ I M%'U@=*8PTW?AF4)I G8-!,1 8R=8YJD<\Q=317=0I.+AJ!GAX!T9H,!ZX>) M&D@>"YP$RN#9G!0\I)Y]2&XP?7-"//M?@FG!,G18(&I/(BKPX3E#GY!-L"(^ M@4.RW? E%6U39SH>9WHA_SY(P-ZA"LCH@[6R67IG]>U"1/BH7OH,3RLM2MEK(M5;7Y!K%L!%_C)(Z^?7TFX0"2:! &GE:5 0*9+DKL4?KHCP_X8+RZ/Y$E?_ M*Q>?FUSJ#J6J-,-0P &%1S!5B" M! $X11" XR!PP:&@!"V0}?42MS&/%);0=I6PE:4%0;14Y$*$%[$M?]&<= M# E/L,.(.^"D5R\!"\F[QJ[%]DUUED))KRO?R;/56KWSV%E@eV1/4M666]$TXJ5TC= M$ZR7" {3XC#_Y<9\A#KW CJY:O@0-,FOX5Q##4[GP=8"P MRW9_A.$]{}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}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zl8_-/HMH9%AW@T=XFS7_>

#3F!)9'&9HC3&9&1DL@V@NI(+ M/L0TO"SK1.=FFM:,Z\?;G L7S[3AG.'K-)>8-9&G,%<|!$YEX?IW6VGUS5E M*^L1*SCM."QS.EVGQAT2B.([HFA;9?2+0*O3L+#,1-7(&O8Z:Z,2SZ%#JJ5$ MC^LJDL@W5;_#XMBN1UHDOG'C\;7Q+8X76ER8SV)JTQ'!+04R3P$[=A)V(#GCFFQ+@5IG%AM MN&>2,&CQA:XQ_UH|D;^}1>|,JZ#OE8[|@+LBVPJW%YL;I@(U`,#KFV@HMI@ M:|9^RX|IP/(RP,\6*)F@SV&/L 9->A[/0<2\&T0]M K\GF7<3 M1\,(RA:S#V5/&({0Z3:P#:$@X? S[|S7;U-> D'5EE5:BKE,[?IB[ZAX$:WI MA:X"Sf:DPIM.GEM+AB*+=[4,!4MH9RBR3T0S8H$X@&W+ G^2? Z,S2EZ[X^]@V4EDFT(0.L*J>UU3/7)!HR.'!&_F/F6A,MVV>HP6+9\-0_Q(14%0 MJK.|Y"2X@0WY!A:KK3S-%_Y@Q3CGK1'U-%:Z14/ZV4C\8SY@7$DVRE0T.5:@ M6ZEF=8VN&B53VE9W+AOC]JL$G/QS;_*97WM>Y)<5S9"2EDC3PN/,.1MV_*'R M24R++NI+LSL6D$O.B"|36QKLO(8O+|)K%D(5@JR]MM15PM-%G7)L=B'\)VLA M):*)9FS)+V0Z%==36J4IJ_MK1'4%%#H1_%0-B[Z,A55G2WMvsX*2E\4EE ;ID;5EELT&8%?$;!M1@I>/(N'U MH2|0Z.UQ446%@H82R17YM,T,/TUH4M@PL*SN"&0W'X9X|R7289,Y" '6PKS'F+74, MZKWFY13AJ-=?I%HEX3&1|*)*)"6#LL:1"OCZ77T&=J403|* M'J:L*0QN+'>>HE1?F,1@L\ M"E'^&<)0/U 0_GEPJ"XFZ;GM1;K,"MR'4IGN*%,@!T^E"B\#W^6(\'B> =TB MDOX,G(+U$L6<.3\# MJDQS;>(YOV-,2(L$&B7Z:9:1^/YZF1??:,I).A?KHPJO^%B>CL!6,3!OZEH_ MP?4"|ONO5A92I=*:+3#$,=887CTS(DI'YW),7@,EDXI>&0UW+U-T=%#BWY>YAC,7JE0Q184G3 M);M0G"(DCIJ$Z9B4L1=|!P,SJ?)"C J((-D&2XHOQ() M^R@TT2&;'XSE5G$NK/N4Q.E!:$+RA&G?"Q.! VI\ZC)4C4NT28@^9,B%3C.DFM^S$5C6N3FIJTT@OPWJGB-WI,'=0 M*9P+1\H>=<&\+0T/V#85#[+*#M_+[*8ZLHGV!-UQ&_XZD&3#R$\ M:ER2$X!C*- P(,@\;R4#MCFC47>$>]'/DN3_+V@G3ZKX+)Y"%;3L.L08*/)_Y M|BU&H 200$^[%;WJ1M4.)Y"\<\>F?-DB"G&2KDS"#1,]\;YDJ9//'F4C_L M>>A#H$;0L8#"ZIOKI$B;_KCI>Z-,W'YY_1OKF'P<1B[4+*S(8":LF:0R&)!> MX&C#$ _)$*;\C9+'"<3C3&18,SN'?>4*DJ5CC[*Z4"'A&QN;<'E0[D_XU9IB% M^)(6,F=J60*YI&;,,JN$'!S4O=_4A;HK0JO!(/)M5J:F6DC)LD-EY86G4$MSE,SM5K\,?H;_7[';VLSTS>D.Y.E?]O ;=$4N>=8HMDR8 MZ-;FF!RF C.#0$ 2B<;B;E3EB?2>.#>@[N H%=Y0;P#8;,@'\T5"Z\(ZS MW=EYCG_^VC_M;[&#$L.]Y=$D"HG23X6$=#3CZ\S0HI(,G9K)%>B(D8R)7' M(&9UB3!4)W4)O@T|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{(1-N.RLV%,:S+PQ^M M?>GESK*EEY?-<@"E*I-/)2:D\\;2^O$$HGNME(%N,W340V8##Z0=.G.0 D M61B,YDHS%X5,]&2+SA_#0*ZN+)N!B5 M%&A&MZYS[*)!IDH=3TU(1;,QE-YKHWH("LV,"7W_?FAFE&H3VB\L[7EE5':9RJZ]3677;W%1GYO\AG!8#("\!0G1NH:[))'W2[|^.O@W)B M$;*$3>-^\-'/%/L<;,!]=.,!"^DKT=>R)21^2ZA4[B$MJ"^3U<5)&Y&0B<*'" MB;72M.V7IJI$NE 8QK@B,.6$)YYX=T1P 63 LP"*)5SX9!$R&Z#1,>-LQ(@;^G$"F-W0BWI^]T 8QZNN&I:' M9WDY|EIK$WC@=6I^ 26_S MW*;Q 2_>@HW*/A/!W* (GXQ|@4U3!O8T+FZG'2!Y);B;Z CHOPTF.|6'Z?C3 M-4$;,.O4"OKU.(!N')/AZ_P<*2*UE*-@5CKBL(^Y"@L!\.?Z,(L:?)%.YR5R/P]D3=QKLK&2!JR&^T.EZHM0O-OF? Z.7'=&-!TX'5=I1"\N M6QHN[%B!4L$B\.JW3E$V*4&Y25D-.T;70MR,.>~<@6^OT//Q@/2.=6P50Y87^ MN.;<8Q&UL#F>!VL,<";!H[@^9P2+E>L^? L=W4WQ%B3T5:3QG&*PEN0D00? M0@1C1 N1Q.HFNB-++!A5ZG"!0?O5 G_$C!_:G$(9W142WK0)IO:G)80G->X M!$KI22*YGW56$)PD!;%YE_(?C%7KS4TRC#KV&!G-^R[8\&+4 HVQK>W"""+N(M$!R>+: X*3D"6#C-BOA@U@N+/R/HUDP7$_*L$/R6>Q+X!?Z] +CH0=!FB=H; MS<$*"G\(M M9\B.81RO-H![AW7$-*9@-(5+W3(?]K).P1$AX_ Z9F[XLPXMVK;@<=#!AY6M! M*?.X&1F9]\M! _S_1 <^!AD$PEQ<Z^_'-DNW#NVMZL.CP{IG5>,OJD*2G2 MW9%8UVR"@:*$AQ_.\=#41:RQX=ZLSS C!9ME) [$9T/G.QVGO.AQ(#.UQ-K= M9V%4LFW!MSY=RU$/[A[0>) R*I71=_\B-"E3%;G$#M)4Q?OA:R.K$;T "(R MY=G+]GE-C4[R^G<-U14'^" @)!!M6!T4?EC!2^.?|\&N=,/,8,KEQ:Y+7U!*F MCT$Z:-QTN1X-@C5CN@\.#SO%EE[.HC+5MVB8DWNB16DP+MQSSL=>Z[LW^J&T M#*5+I5A>U6FE6T8'^#5(K# 2+XHYER%[IV M3<^%=;'S32Q$L#DQCD6)U-8 +W.=!5

^%Y9%Y+_B1B-!$ M_NURH#D/]PS"Z$,8YC?CE^%D. ^C039DL%--P]:J,Z5L 1]2!@(HM2&F!J9: MYT#70^E3EJLQ%5H(OQD3*&X/%&OEPS =4WPU.TCI]/ATD7Y!A668AO,!XX)C MJ2Z(*'63FPD@*.1C1PJU*((GI*U)\3"J/B7'&O.CL4I:,IQXW)L*E/8,V%$!I:(P/#Z93,/T M? GB99A.SVF)/SBNU3(\'_ET&$_G-:'Y:?(A+#*:4>?'"%*=%/AM?"WI+1$%. MH4E;-0\1JLZD_AHD'V*WSNE4;?]:^>H?3M3%*Q-25B"4 PC+|+2&B^\|L.X M3!F996A:NV%W'|C:(@T=9E|(E?6O*O:S,**'S@|F%|)?AM%26V8"^<%%F!I& M^PR>`2M#9:ZQ6EB<,KF.FE>]7F$'0@8CA?3R2<2_&C*F8 M()P$*P0-'"U"+(]#-=:2DYN5TZZCVL|U>/]T_K8C1S,--=:OA(BQF9L% D M[H62EAL0H9ZLT/2'#XI,OAK.3R2R,_IA.3D\N!AM%U*D$!);)\U.T]$-06H%0T3B; M(K+FAUH>A[!/1: -;4-W6FJ\4782AOGPVTEM%G !A46%3%H-.OA(BQF9L% D M@D&E2F9<&|?0!&\|K4RIJ0|\V3R6B1|"GFWU?I]AQJWE'G;4|I7!G8%3[%,2N\|L%I'-MH"3]$6VDF>6CLM;QHF+K+,C=:/H4W;,B02/9/V6Q^Q7(JB@E/9GTXG/=8/2T MKM)"|:)PI9VSPI;6,_L[>X3[-R*#2O38)?M JQ!\L@R&4*D<2L4A23)*#F M] LN(BOL;A?0W.5NRTN\GZAL[_ORF:-[2]tQTU"/PXIS_K<:;[9!+P_69&X M7:,? .QZ_AY:!FPRL4>_ &O[4C:Q58#P;'+2QMH,"QZT%QX1F.)HO6>RN1#%PV5KH<"4.NS@:%3;]'&8K/NHDC4?#|?#Y;S:^C.\P.0%>5DL)4B+ MK@>5>U58FC$/@RG*C$T_-<|*,(>N3H|R4*QTHIF'KS.^& [J9]TQ)=3K6*$VO;M:D9Q81 T<.%Y5$(8463KY,PJE1RL5/$%)?C"=!OKIPJU\^:5^^6:\ M+\"QZ7QX*"/G %J^S+0FQI:G_:FG*UC|1H MZ5K-IZ=I? CJM]7'CO.KH4@7X9IF\6'Q=5W<6DM U=QH)'!EJFI2U\2'/W,LB M4;5NP;4AM#YML;5VMYJKIEU+V3 U...!N=8@^[(I]"@CKGN0)4H M1>V22>Q&E2$J;IT1W);2NE"9L@>N8? 7I\'&K3I0#/-6J,,9+P8\N0!83QQPYSBK23I"K=0<^(0(Z|=OBH5U^M'+,+Q)O/Q(=Q|2U9+8X_RP\ M!^R;\VY^Q'U!4"DKVQKJ-.#R?^.9YB& W_&_/%'1V $3;4@>+*)VEM6140(M6M1+Y504PC:)S6O7-D/6I\J3OO*N QWW10S\6A>Z.HJE;#NI";_K77LN$-]H MR(VJO3?]I.=%2MH:"5'9U3;[^M$_-GO)A !X7FZA&FVJ-[6$BMJZ*Q*B,9Z1? K&M)9H,O4](#&64DK]@C.,,L),00\R+#W?H$R5X'-MV*= ZLG(__34;9A\O36Z[Z(KVM<|L^KYU#KO%, Y@H8N!&:R44ZV7LON@=-V MHPXM>1,=#:,X0E%%]A1?< ^.BY2UKJT86OOPC|ZHV|HQI38I@&&J0RF=0JG:"UM*#<]&(LWUTYM8;.4; M=7,B]_O3|UOUOK1\6]_.X1/0;72\'7]=3#5$NHEUTQK__@RB<'R0F*_PL'+T.1 MN_X90BD*BM)5:W=T)1&$,$*PIX)//-'* M-!V;@$,2ER!WG=N"RU.*N#(P0;HMOY<#.MK?@B+-.0XIJ7L3P?.M27+7R@<&(40&*M8SLTY41R9EAB$545IW1%V/I$|VMR.W#K6O+M*VO0]W,^A MQ L?;9"PGCDJ%F3B"(H|$!8$Y!UP(RQ.W/,O-+I,<+^A^F?:.&=!W5C0\O;\L MX[ZRV!?,"_^D'PfK*IBUS(KF87:!4%&01W)T'G@).LHDA;_)U09'^._'U*==-M_#U9RJ9J:IO$N;_Y !:IUHP|\&3O`X'4.D.J1RQ-2*8*F3!,X/T@1B3^1I MJ9VG>NO'(A?7I.!'2<:\T4-[*OA;"PE!"SPF)R!M#7HV"&*="#XU!T,3;9 M+'/S#]^;.8NM3EX8]D:D3M:GL6I:7:XWSN(K7/Y-R_"M:SD&/)E<2J]%(RZ LJY M0*WH]\(E.DO_M=X*W 37(ULO='Z6;!]L:JZO#IET<<=E'';,50:O$+3"O:P=D M6P'UJ@'#DW%G6PUU2)KK-SP,DBBE8&$0G4SDIAFB ML@\%;%$Y9NF9SZU3X0]AVH0ZJ[>GS@YZ:I."N WI;'(>1O/S#^%\805%4%Q6 M-"O(\O!CS&0/B=#&(?=*&*O-@_M7&|UI$T+XG\,I:2_Y3M>?R|AOH'E2R7$# M.FKRV(-R=>4DI)8K%.NU7ZUUD/7\X5,"D2BL_)V*TMRUOLW8L=/DMON3A6= MK3,X/YV.*I]KOMC.#W#08BV5G8@H*WTK66ACFL!H7 1"RV:!)-M5YLU|N(M(3|3;KD#-73#C_=E1=Z+0\E7MVHHX%)DEV8#B5[FQ.]5=5R#*@|!L:1 8#'9 M3R:|!"4N?"PI%&R**TIKB_D;M?NQ9Z;\n@!B8C MDI:1+2+I&/E(K),L5M- =7P:LI)&?'VC2CQD^5[MY1]^^X];RLACZI@WQ<:ZN*JQJO)ZJO0G9F,/MA2E1SR :\#HY^-IS+961LOE5(8_%N!&/|M5E=U^;4%WJ<=\'C:UV.1F>(/D< M:SN> "&A@^A]R=8(FUWK1CCM#AKSGRT1W(^2.NOLO/##EM>,DCT-//A"+I@M M%/SI$, E0;$@*SIQSJ0)K9OAW -G(^K\;(G@5NII=^QKEY+5#S@=3O)M)V[5 M4.SP6UK4)AV%,1Z6@FD^B#'S% *C$%",88-/F<.6D0M44@=!{HH0M_?"=8 M/8LL*IVT 2=,KAD<\HJU=)"*0!NLULSW17KV!Z[JY;C:TI*=:-'CKHN[Z'L H M[*;9I*$R0>- V*L3:HMZ!9Q2Y,>6S*%JYC*VW'C='UZ?2TA^?GKNJOVMZ7E8- M7<$?26*!WB3-)"-\DA7PD8++Q+A-I@C.50<-+>C=$UZ>*fQ^?GKNJ_RFL9_,. M\L(#9&?)&<12(.9ZH8 7UI(.U M(>GE12>L-CM@40/3F)97OT=:,)4+|'6QT>C86@Z;H^M;-_8NR'4K/|>-|EKF M;A-B7C0;6\98+TZ'HVIL:-*'H&5R C#KZC)%##RX*!HPFNW4,F1'-R70WG#[Y M((LB3R/EM&/+33;_& <|1O1K&$:ZB\LR2;730)0UVI?U$H]"7]FBK14^,Y>: M7PCQ$*A'N@<_I]W925-/X7$JK500N4#M84$>-TA(?0%&5$=ML*C4.HF|K<>Y M_41Z7R[OYAADI8MQT4'6FGRLY!>;OQET4?52Q**3ZVKJ7('Q(RS2N]+EKLFR MK38Z68W?S&:G-$JL1QOO+_X8.(`T:5V&F.GB*Q9TS9*3YQ\S!8J:!]6\0_N# MH'Z E;DY8YHJJF'OB9/O5,8X'_A:$."")MI+10!7C|.PV1T##K))9"NY;NW W-M,?P([VIK>NRDA[;>VNO}I*%#SNO&;[A'0V$_0:[C|!$2@4,"'13Z[_JU#I?:MOA/@1YX<_2EXMC\--P\A"#/-DM-1^K(HC!MJ.M<1R,0-20>1O:3 MG%2I"V\9G%K,T?H;E2//$OZ,]&KE:ZZ25I4&.]/%IW1#[_A- U)%/K78S. M1$C::U!"$"QD";B*S!=`!AB[=)/6@NK3W=U/X";MKJ@!]2A\\^[5X8M/AZ_>M'7F|\^#JDA?FD7YY.QG4NO,)Y&(ZV:D^XV8/;=B,<8C"-FA*^G8P_?\+I ? MT]KN?35*%F0I0M+:.&)!&J8L ,GP%O$A984G";_Z0":GW#7V*PUNIN9U(FWD?.M5]'4BU966(L(CD*\YUQ=72J;I'F $9BY.0(1:.[M&W?D;1E+SWW4ML.LHBA/>%&7,=@3^_I(^%4(U4/3]--Y2MLV[BUVUG=\'6LVG MREB;G&4@/Y_<\]^[P"Q&(XD"O(<|8RNN;YHP=!]>J.T80#?2<<4T^C,D&5' >?!(.U5D)XI;.ZC?<_1 M_/WT%4=G^:^_)>/XE-@<Z11FC@^.1LJ%AF.QEWKX#+PHIPG(;4NI,_=3H# [&@WL MBW@[JO!I6%ODP$KUIA,K@/GM=V$jLT])$5=P8%,2Y)@DX]J<1N4)L/,4D0=N36+26\5:MWW=#FF?FL$^ M(;T>K;0G\/DO[HAMY,/??%QW/OV[P!OY\!?O6)V=7E! ()8L6HPLJ6 MWVDP*MC"D$4;NKKP_0[,5G?;7WGDX;?5:85K/8S1V1*3T319ZNE>22/UV0C(M!:45+);{JS#H"Z((=,Z;D.N#08R!$-C5U99 M$=$7)EHSYCX\|? 7*G6[.DF1X;]B1:CG"YG1-.AO-EMX#Ô-X,.L&1C+2V#J53:.M1B[%6: $U6SCE*JYK'#T[LV[/SY^.#SZ^,^# MH\ =/)2[*M76.]D(<"//Y,]Q'LZ6=^IB/@S3\>)\"5.\[" L6%4"*&XR>,D| MJ9*C3X4[FUN;WK5 =K4B:Q^ZN&Q[M/C'F!>7"), "R-NNY7/?FY2\"+-A&ABF MR-1Q#KI$6A6%+!!]2!UFMBS<\"U%LZS\!5\RIVNS?G5XW;=!>5=KRV.OW^UD/ MSF@Z+Y^POE))IV4RIcMVL0*+27/+$@)7E74.TYC+/P4?A T>>\LT6L&UO67X8 M8U_4BM&70? MGOU-H L!*"MCX"R 4%@WU$,$7PL+$S)G;J_X)%M783T:9))BSV9LVGXN;..Z M;F? 39@O+!>[$H[/H/$BMR.*X6HU4A !I2$!!FEAW\ZG\W#N*9T!@9M*$Y*L-X(FCHI M@DM!0(HN&30B.-OZ.L!'0FS2K;C&FF&TLB"+-QS,E]I=VI,O-Y>NCC!W1_>?A MNT_OC|X&D#% <7<>U6D;?)@UOOVSUZ,,UV\%8O6=3M#AA&)DQ2-MD+A-4-$$<$55VUT%3\;FC*)|ODJ@MU7T=73CL+7?Y[,QV2H ?DU*ABC(8: M58)2Z, ;28YW2=DQSD26K4_-K072I[5N!\W? 7IV%7K#]@%UKASAJ+|^:E[@^ MA/3O\+EN#;YNI/AX>G(R|H< D]!8,QD0=28;RC1]Q J^:X^'LR^]>I$$IQ#XK)#"L=_.IP"&B(N,6 M0G9&\%RP?=G'.B1]*B7K@@+;BWU/CN@? I]^_^NO-V[<'[UZ]>??IX-T?;UZ\ M/3SX^/'PT\>7+0Y7/^KY;=W2|8?6KK|L6F^W=_B]RJ<2XNMP-!H(@<&KXL&* MY&H??D%A4 P090E,QXA)ML]Z/RKC0;R(7(M7OVYA';RI(6BNKV0I6+>@9!2]^!PL7 M|%K1G-9^&N,+F%SC?8,"HO.6;#09"RV_KGD)TN-1)&|WXQOQX9=_#H;_=;_Z7S[U M_#@/AG>$_- ODSTX'7[X-NY]OQ[!PRN7\U^8_'?Y%,V:#8()8QC.1QDMBH^;$ M>LIIL,)*;_Z?SW])*2<+.1+OF"02-)# 3"""Q9!#3LR%-'EHK]O_[2_E0_C M^ 6GUQ]-OOSKGV['XR]_^? 77WW___<]_A&'OSX/AYU\YI>+7^6_,:?:K?RS\ M_N]B\MO,.??KY^???W747?:+^%CVZ__Y^.$ZW1*=)IW^;.SI\6$ '#Z-O_ A M8S3[U^D/A!5='W;^)G__81#|>**@C5/X9>5OE*_(_-= (^19A',7WYS|&Z4___M!B^__#*5G|_&X: '5Y\|_F7WZ]ZOS1;3=_OC7U+W!=?8[Q_I>#0P%/GC#^]@7^ M^J=1^J\Y+#^,?NQU"?HE^/N4"2A4X_W=YYJ^-,=TBD&&\#T#PN] O%*^(<=G3 MFV/^_BR2(/0[WK@BXL5G5\4[N//=F@>>>'0M),D3NX'S"L"?)[7V[|,Y'N!WH^^-_AP'=[].@)X.OFX#L#R"E&65:D$G2*9_^ @! MJKK;[Y;5XP-^.? OK,D83+/#'&/H)INO&?*3>(#[YI5Y9M0;?_[+G_0FW^>TD MZ';F&\EYOVP6?@80SL=P-^H$1Z7PN$()&P.14C@2DH_$9 9>&PE4ZD55C>;_] M'T"\|^?!UU|QG%^+=,HG$S%-E;5A]*GT]LW]QH<>=,:F[Y6TQ!L%1-J,GP6A MB:(\6,]==";7GM%DY*>S>6##R7 ^K]G+L=,:GX>#NQ9T.1Y4%N549SB!/_TR M&"88HHF#/Y]\O7^)O<$(TE__-! [>P\,W!_TQLONL!V5L?,O@<_GDI9RX'Y'/ MWG_I7(_16"H/.NWYT>@R7X\"\;>3/[JCCC')<8\|=!%(KE))%B:B0U)2X#$ ME+|KB)'*$R4-1MIR@IHC4? S|SS09*_8BEQ9L_=NY,X+U#QH0|S+R-.0!X_Q MO)UL&ELAZCPS!BH181%-10:1M&0>|%|978-69+TG%JAH9(Q(=!HTKD)6$$^+ MMV.0[9%1[7CZ0;7_Q"X\I/)W$'$;2A_*[J16!? U3%^]YV)"3R=W>OT% M8M?W'H/2&A3SUA+.'5!:02*7!:..$14F9A^!"WBB_M8\OD M!G^W@Y:(BV X22%9(A-%*Y9)_%*PK#P/$=%4L=_+:/O39>O6^\|"]_A&/L;Q M[_=^. (9A|L5?!D,QOW](3*>D9_X+\%L&*]2@24LMZ&C*M$'T^&_B(5-M$ M!"V]#I@V!DM2>R(C<<\)[8IV@++#BMP*VSJ;;7\9-A MCTC#+Q?GDGVE;5XZ- &H+),<<C2_|':XDG&EA'",!HB-20"\!H MXBF"2*B7UDBNFRW.RT8|&L4Y$:.BJ)>9(NSH0;_|=Y MPIEW3I30)*BKH?,G01Z/O MIF)=U+6MINM3_/1R>#/X0=]Q+].XJ#0Z>D|B!D09L5Q1P@\-1HK HN3U-/TP M\+'I^84B7=2RJZ,ER19S.?PT"SM]B-TP"B6,L>EA1JF[B7"7Q$\:A /LT&(U] [S^7R961+#)SD29\F3TC&!4(MYG0QAZ_%)P$;67C33Z?,0CT&@C(2!1:*, V,W0EV3Z MZV]W8=#K&4ICUSA^%;C:F$-.VAS4.0^87*7'&(3+95X9[@AT^7+Q+5%DHV#7 MG%5G? \1;W_\,D^";CC%$*1 +0VM=@O/$6=P"M/,FXM8@M&KFY2X,!0C4VEB8 M2[1;(8!U>C\CCN/L5WOJQG^'L...T=>6\TY?S;*-QU\@L M$^9PSD%GJF6L$KE>-OK1:+V" <)=HO4(@JYR/#4_1!?|\&'[K1,V4|)X2, &= M,8W60;!:$YYXHMQ9Z1OF"BP9|&AT_')1+E%MA>C5|9WO]=[HC$;^T) _P&!\13)1+|9-"C4>W+1;DD!:1"B.KL#H:?*"'[Q6EFA4EU=1!'#- $GX6QSP:!:J8D$OT MVBAN-;,"S*WKV_]$$;7[^-R3;KX>QVT'-WU"CV-8-$]U!AVD)-BK MB@17(P"2U!C%7\Vl!%HNX$XERBX4?!K9NV_ZXZB[_T^:.$\E0OQ>9+ED?"] M(H+RDK@<)4EH4EB0.3O:S*->-?(1J+F*4)=HNE%T,#[3!U3O\#NC#@]:2F"* MZ.PXD0+]?$M3(LQPI=&Y+^EI51)TGPU\!'JN(=(E:FX4)GN*;9H?/D5E A@C MM"+,4EQF>, (%AR$JEV66H?@&JDZR_<+01Z?JEXUB;(;1<=.$%*:P.KYSQW< M+7SBAB//!#H"2D3B$!3Z[@S_+"@5_;J+ZJL5_&2X(U#JR\6W1)&S@->__OI, M'@CSMQKE1M!:Z(\@X2>C0:^;2FFG-[Y7:A:AUP#CT2=?]IQ;F/SE4YS,%B;9 M;8C'4P.S*]AL9.>\X/S#+"}@W.DH2;<[&J-;$!(@#BLER7RIZMLW0;U7[X MC]::.8M9V0,%J91H;D9?[AJD7&Z!)4LR5-+GRI(5 MNXOQ1A@$8K@-5U39#IQ4@&A(BC#,,HIUIX5 M7GUYD\K*WT7$K90WZ7^%X;B+:]LG5*,_AY >%W+PQF81T?YU.4B,K6I8Z_K-C)6DBOHF+&3EL,"U23^05RRZLKLP2A+%I4OW!*H>>5#+$ M X\DZ.ABXC+R|',4O&FFI29BK?CFKR_W"I669C/A1^^=S^)?YST>H/?BW\\.NFG*QC\!"N,9BYS MA[D$3"I+K"N1YG(>'"C.W=($1&B?#&NCNB]YD;<"MG|.5/8"ZXN_A87!\N[*.M'>3AM|/_ON^.OWWRP\OA1 ZIP(=/,)P<,W:,95*46C ^&$\D%T""0F[FT$M8LB6T'YXG;:B@!:/P& (NF*)G[70'F>E1/1; @-/$LV,R"A$ MN;$3B;&>*>],UK;P-B$Z3C¥)%*A5RP3M,2Q6;F?<8LVCGC>6%X]"5]$B/N8 M(2Z&'+5CQ[Z]B='0@SQ:L,,02VFP_4P]RCHD1FD,IL[K1.GBSG8WRZ-S/GAA5@F3XMR242)G3TEO%+#)Y77G%EPX$ONA MDJ!K5CQ:!^WQSN93|)Y[A? @L[FQ9.V*I322J.)/56MNU1>%K$>&8+(F:(]]9 M/NE[4&0(?G0__#:!-S-[)B [B6]!C#2$;D416:,$*1YP_1)!)L>9\[57A95@ M?G@:U\'SZFI+^\R+_BZ.T2"?3JJ7C+K]C_,_X- /ZL,TN;LGDSU=M!#G^/I M-ZNE3;<0?M9U96DTU2M?2!,I&P#22&4@+>0Q',T27*43&1CO{U@T6M)UTI_M#8)Z'=`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|#]-0/A]^0UB=WI5OMR7=|(;[<0F]-MW RFA;(L^*4":75@W1E M0[(6*#HQ,G+E':N>$+G;2U3#IEE,17K\5N_D>= (F$C>IDQ\23%WVH+,42(((-MO/8ZLB${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}[&UW$SIKIFEM"G<2@=@3R@ZGA.I6?9$)-+, ,Q M$"LE&OMH@S$T]U6TM0-03P <-R%>+NLEFJ\3!G^:>,6#$Y0:18 I7-"'"\"10 M+8ARG&F+ [<[E5HS8>ENE=.WN/!>I"A1:6@%RNA*TI J)6ME0A\C:."M=Q2H MF/2Z.@%&"DL9KAY$ECG*J!P)43"BG4F*&LYC!?36+9.0H5+$J3 C3D#3IZ' M4H$45U95+OEI:\"@VRCB=HT*FV73M%3!\LW?K\\OSJZO/UV=79]=W)S MG%R\O3H[+5^=GE[^_>+F_,+IJZO+"_ST].PC?OOZ;,F-UAL]756VJU?9:+RJ MU2GKS;Q2+.3MU: JLG.5BQ^FW*BPAA&K.(TRB|\Q<{2)D2V#LJ$YE#1TO M>!0-I?I:*E6^[8Z^#$;^]WXXN/RJ2[,E MCLE$K&.9<0"M6:SNH:Z%=*CR5(TUON"3UI-\"XGT:.^#-KE9O ["EBE4;P1VF M>E55E6Y/EP;Z. AQ+^%IQ*EL7:HTK*40LDZ L(S%8Y2FD4]OO. BSH<;58?FR-MBQK:YLG?H)?R8(A?PL5@C#€]VUVW?P_I$I?H"'>]Y*85(?4HV)L}4%QS2]!. M&TXB)"Z42BZYVN&P%T+=?T"DH+74;HEC;50]V -MOE^/?+6K_OZ%J#X?0])-MV&4..'G=HI/[YMN3N8[P$;WIXO.OG^>TB*UB7G"I2$X<9XE")B%)2Z(V64H(-MT=O:)T# !F=FQ&%ROD ZA^FOB+F;C VCYBXNVB^(F$G M >9+_]O7;J\'E_VQ'W8'IP;#.QA^]/W|[.-XDI+PSL=NKSO^-B)<1V4R7##" M.-+E$ K->RHS21'-(.==,.G9*<:*T/:N(Q_8'&U+GX- 1*:,B:3H!>W%?(%5F M3T^"Y5@T?P"+Y4S(D914SB@A|A+?BC8|#"L SE0.UK8L MYA9\E2=OS/H7IO3WZJ9:VW(1-. KPQ/%,63?#DE#9PH1;ERZ@A@M0__7XKU MQ^;47C75@G5U,AK!>%2|=UP=KZ?>^R<_%_FI\&#^>D%XI;0/%O&)UD%Z"Y%MG(D/%@C30*,-TF1=._Z_&\+C8%.+6EGI8[9TN'UU|H^SB[^?79V=7KZ_/|^ MP/OAY.;L[1]<>OG9=I/AJAYM5YMWK9/M)R-= MYBOX"K@L/?!5,:-4EFA;V42GR8|6E51|0*O=Q^25;R&0NA93A>USV?.GL2/% M)!:\!T*3 1GA LZU {0K<.SM|/OFCQ8L@O6$?BAS\-'PW'G MTW"0|N/XT$FH&X,J,J2^BZ7/VZM+XB-KA'+)BU|HQ MNF0M?c>C#L\N?!@+FB& IE&Y.:+*6XX|_KKE- M1-E)CY-QO^2B>.J=\|&&G)63+<8^%'FV(N855]HE1_ ZEDP!XBGK9GGON)HT>|_ MN^Z5XTDDB\VV-*Z.)|J7.3#PHOI;?= X&MYALT]D:YG+^^'PS24R>39465 M|)E8AI.<=%;5XC"9H*$@I606O$=#+^-$!IGO<1^+S9J|M&QZ"!6*TU;NV3 MEEM*$P-66H48C:C=E'L]HOW|:"VH<:\=#4=M-$|\P'=Y5<8/@(FP95VL $G M&61NLC+Y1|)E.7>4$F5MO5KE;\ -<^2\:"#Y=@Z0GBZ3/F>:03MB5&F^H'&" ME@9*]&314:NYI7EV=)Q6:Q7A5HSWK0|V:@|J)SHKWDE'6QT;OD3 S M8!,G+ E DCM*@L]>>*HU,Q*1VZW,@M>TX^X*94MZ+R_7IX^5H/BNLK?1>YMG38,P\5/^2)P[/S M:VL07$Z) <,8"D8(*$LK-Q)*(29U1VH0M&WYM>)K.>#923M++GC]BK:E4^(E M(-/S RA;"G%)0TK/$R(-HK2@+ E<@5-&:GPK&A(@_30,:"+<%OS!EQP:H>F9 M5 X&N2HYD1G1V@E_F;09A90EJUV>]CA.]YH$SMM65 N>Y#*33[[_^]GY^'TYDRQ K"9(] M(F-(N +32%Q@W"D? Y7Z$)S,#/UG9%UEA.YLV7S0A)F37F_P>YGWJ/6DF<6A M#I XLV&^#9-GBO]0&GE,:YGU'[_?^UXW?RN&6(R#^_YX|%/FXH')22;O-"YL MD9?L8/3T2MH5D"RD#XFAGT&WNI&V(9ZR,[FT:-M!YO=KM%40B@9KJ5>EDQ! M$$>%) :4P3? 9&F6V*CM;20)[2;!IGRN/HT|MZ>.UI-X\S/#[*XYSO8(

M0)!H5\9H(A>1;3^X?:X@Q[8GPX01W\\W$\|\V:6C'>#8?O.L*Y6[>#+057?T MVX,U:A/U@2>!VSDO'7]E(,XE12CUC D=(.O:M<97HZF0C?GTR;.K2\$;P;PD M-$J#2Y">5!>BQ N=K>4>M))MSW&OY2TJZ7M)EF13\;Z6<_6%J;SY|OTX!GAP MT1A-F* ;;5U0Q &SA)4^\18,,]EVN^ U< YU&;"&LC?QYX5";\'!6)PM_N$L M +0-M):.QM?*

*.LR)>#45;EQ:FLE_SQ2QF1H30!.GRF%<9(P$A>8HHTI(%90) MJG9>]=ZIL>&L^Q#,V$7L,3!B=E-@ >(\]D)]P-?23\UD>XYDI%<=1I"]2EYS*H M2*6M'8O8 &G_+.F,U3VG1479MW,OZ/G;\ ,;Z\?:.#W^:O(!T.ZYCL$1GA?LH M*U" =%"$N6QS2"'05#M-9A.FX[8T7B[^%L)/B_CFZ.:'3G0@VY?-U0S;]S|.M&FAT(UTJ&,?)!ASG,X]9KQ+Q-*

J20D++1FLU(THZ::FV7L3V5Y5]T&5W8V2/-M;-E%"VUT!9L=/EY!A.[7LI;.CYRESR((0{(PB4A!/2+,0+B-UDK!.32U;YJN MPO(#)%&6GO>\]N&R%LP0S;(X'_U_#89S.-,.P$IJ(@03)*

EGD;]9$XM B)8F.$T#LGNK M\/"&.TR+(Q^!,5!!I!7[@]:TI;W,C_!-&_CLP6HBK6O5@+9?^VKIAH:M"7> MRB_W:G!14(5F#R40/:YH52^H\(3"

QWIPPNIKO\!:R U5Y4OHM4:V=S MOQO%<;Y>"N_#H_2FO MCJ@'U>14_;K3#,W-IX.Y.6=-1+1}]?:UR"\=HT$%$%DD?$+_.3*&SQM 2EQX-/^N-)3HF%0-WEM/M%LLE#S* MS;U05K6O+&&G[#?P;6"=0:YC1ZUSD%[+.3)%XS3:B@WGMGI7K>NK%^ M(/,1GE<0B?C03@K/2X6^[TY9G\XNWIY?O/IX=O7^`[.KD_=79V<>SBYL&J8+K M'U@U&W*

*'I)42_M[0KKOH4NP9)31FV^/OIK&["+^^@4Z4#A#?QVI4&|QG/?C/'0"*E/!'+'<:W2_>20V"D^8USDZ M+ZU]'KU?69EC^0C[!WTJ:V)06XRUH[V?*

*_+=BCGO/EV4Z1$^1101@B=11$UM(-MG9UBDI>2YGR[!O7/'GS4UD!C2=:.*S[",F^UL 6:Y?O]9OT>8M=N+O(5NFL@-MK]KK[B(JS2R7GD8BA"I7X7'-*

*F*2.4<9X3@IHX/DU:6_%5MJV\G814VVE?>SV M8#0>]&&:QXIE4Q H"SA^EX2SKD6Q#]MRYIOE.LY!=:!,]6[%'L.,$#<4^J"R MQ&IO8X,>^T:)+

*M,!G RKQ9HO=1;5ON>_>A MXJ;'-24:J5N_*L\,Q.QG&%.+:ZQ>T"JF+#KZU MAF_MM;^.[B]\DH 'TSZ-491NJL1&5X(S8R8^HQ,?HX16>"D!]]$E<&"M/|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`65POP;KO!;N _,?]Q4[E"00A#$.HY6&P1*G!6& M,*GZP"9LY^/YF=3T_*?Y0)">=<$\3_M_0$7EK@:B\5I[2&]'_W4R?&$"}3-_3^#]J1>FL+VP+V/6E[>G?X>JZ-M9.64Q1,_CY_@[TN?$Y4L(ZF%QCV7:[_<<\'9!">TUG7KG[^>)A/G5!#:.A!-M+O\]S6ZV:,(XFIBFS4W[TMF@G) .%T+MB-0Z$;<<)V!IY-E1KE3U6G"[0#T7 MPM25?H,,]?>3V:Q0&4(;QN''S:)YA3*;CW*>74;O004@1B$@6%T5:4NA=UL1H M%Q1E5&1=.VUS)ZCG0H^ZTJ]X:[/80;>@^Q/&UQE7ONMIFLXNA8E&4^L)R!2) M3/C)*0$$OY6_">E4[A8/W>5M3UWO;<1:\;#N/H"_PU?XG&87D^O/7^8?)S_@ M:O[C0YH&% =^_5+9D, D@UX_0_\,&$,G+.QR4)4/F;TS1Y#@(=?^QR94%'0 M=RFAFU'B+,TOX"K-?H"*)#74)92#DKAJ*72U`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{8ATM9YC4424\XZ[V!>]N M5,,[0[5TN(,:>RJ@023*W8US.1]TMC;@*\'VZET1*H8ES@A,6C&(\..M9:7B M?B2O1LFDNL(:1 #<1;7>%3O@:F20;_-T&'.DAMV94F$/H3?8?K;B8R)8W%TM M$3HD="U=(I9+2:Q6.KC %NU\[""),<,,V1(+O21]3 <6.V!:1&G^?9][/_5 M3J@4). 7 M4C?F.6= M=$!SOR6QFPN',SV%_D6W>TAK^HEW>_^@]%BX%$1LVBFYU4D+C%<6K*0E@?T MIW2W0)2!M+=E)V^MO#YB:E"'/X_FN,:D>:.!PLBZXNJX0S[0.Y58U"5W2)}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`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f;>OOS^F_77R!\=?KS_#U9!P7&[H:KQ#& M,*6TE80Y.XBT"LK(XBC1H6H%&.A=H[#D55T'?XPOX8N(E)$MZ^\ MV07@:ZG6WJKL78+S,7HX3&W?S'VT8$B*)5L6O"*V!%=KIE0&P:6J'L3VM$JU MMN5)'_$/4JJ5FF A)03$2VD'SST!"()D%L!&GGC0T,F>>"JE6GMI8&>IUC[B M]VTC?DI?OTVF,/VQ*]M0XB/>S6;7*?Y^?75+G/Z3L:!+1NIVFV5GZU^)'LTN7 M,\)TD9B8+9$Y*.("36A,0:0Y!#2GNIT0/^KU1W/0^'ZO)-V!Y-\@E&0#], <4 M\1M%(!^FHY 0\@+O)HBH@=(.2=L (NC]f=D#T3 C54 M1P.SHAO3%U4^;HDN:'14.D4B=[C0"E/BPF,QRD$FFI,7K'9@TF-P/F]"U5=5 M[A% ."6JP/:"V MWWZL?KB\YW#1)1Z3(D:5_L3"4^)<+"4ZK.C9*J-S;;_]$3'"JL%6G3W;Z[*U M4=&A]F MPRC&L\G5*"[&LA#9XB@>) 9.X%8?F>S4 MR'9GG-I|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{GE@/$P&.W$FY]WWQ@<[65/B=#*:..!Z;I.U[D3'G")HT=#!PV!!)0MS!OB MG9$DH=ZLS)924]O:W KF8*>U[>(YZPB^29'W1:AUR;4I,?%3Y.U_CN9?WES/ MYKAZ3T__7LVATD<=_X^?X,_+J((3,5,2N0E$1JJ)90GG#%.&"BZHWJSX5"%5 MJC?,9\BBUIJJO5>=PG2,<&;O)!/9.PF%D=Z5(DMIAM[5WVGV>_HV36&T/)[" MD^!K$=&0_++Z\U-SQ#%(0=+ B^O@<';^GQQ .@YP8Z(=\X\^&L,S(M"0VF@0 M ?(0-,9!!)L$B9#+F:8QI-3E(B8+KD'[(#:)LK\5_B(X4UOX+1[@I2O\T>?% M,3=<+;R*KRCPV;SLI=_,3Z=_?T%=)EYY%YHJ91A+1')C"=CLT/*BS"2K&?5 MK69GD_%D MS?&S-+^40GK+H\.],*"U!"TC(#(CVN^2EVRD$NK?W.S&]0Q)4UT==REC]MYK M2KS=SYA^ 7L)6:BH8TJ:B"NP2Q M=>Z3R^JV=NQ'XVL$>7M4N?;6RN\M?+73O[&>PO>/QC#]L9 /CJZ<<;+8KQ;C M6\Z+2QZ98'R1ZE,B/KA3Q,M@2L-L;Y(2P".OOA0U&XSI.:Q*/NKUW5>[5M M,1WKC?U\O/[U2Z>=\ &%F*&45#9%L)G9Y 08@Z*9UZ,LX^$^@SY.(32[CEF MI(-61_DC33Y/X=N74:A8(.7N0YO62-DQAB'+I.@<$Z>9DR0T(]*YDH3B-5$R M):6RLV%S2=2S+9,"S"NK;/%FP>&ZB^2)USH0B]+P+$'G'0^TDY[=>)[4/>VJ4 M2>FCHF.HDW(307$[X^%J630\6\L*F'9DEA0:/J#%5%HKD6LT9YK8-4_4#=E2,WW$6Y%C2\J84Y_7/YU M<:.FT,%;G1&@H!Z O)"16>*M5S2)7.)&'E#O+(5_^SSY_N^KBX5L&W M[QNV%D8EP4_VDEK%)\U@CDR(T!I*:8NO)6,&0X/W27F MT!N;D^>@MYY2:S#*?WIU=*N<.8A DAM(!#%(FGD9)A,2",Z9*1?QJ>GMW]AST MUE-J#0)&'A4H!122M988N@B4BH9XDS6A0CGI=;9ZLR/Y:U1;%2>NM;(:1$T6 M*/-925E[.YE>+%/62LGB_QKQMRJ9C5G.N%_G("7N/LD9W#W$8Z *(&>VAOE M665]J4/X#%G54$4-T#\8?P/$.R5!/_UKVLU\NCZIYB=\%;Z^SZVL_2?U^C%D]Q@YG?,H7Z"*G!:6X$.H/21TM :X<4W(=C ML%/F&G]^<[*\KV -/?71\L[3ADG;3I)PE'4#R3$QD:-6[T]TV<#3M-;/>@X]H M/]7>27YZ_\$.C/=6YN9^\5BAMC =5EC62;4=T#3*]_X5R6'2I^OF2TJWL M[96M%,# #2,^2^0P"!OTBv>.IV$Y0;MGMJ.Q1!*WI%9W$K'?:19.U5]IV3)O N'!Y&GU/!=BZ1)]P;-U9=;@=/?,WP"W^S>1K"3%1"?_@FE<9XG> M)L7,^_3*8E#OJ2:Y],\ KI+A*1P:.+RITCE'I33D_"=]5;TK0;S@%<MR2;&XI$H?"N7\^E]_G*"G4++]P7H3_B6]_'5C!U.YKTGX>4Y2]!%>$NV7Y_< MR^?L@[*6;]E+X;-M&K_!=C*,&UOIP+/V,1#W/I.?S:>C,$]QL73_^\D MP?V,$]F2(UX83E+(0K"48U"A$$TOZOO9T;CG]N

QO;C2^3U/5QTF>5@T#+>=GT_^Q">CCD!'"&(<9<;GZ2(%Y%B80 M%T$N6(ICRJU.G\W(CFPA}:@\)??;SMISK,7H_?= C!EL/23+75#'^Q"+N"]/K<.;/;UW4#!3;5?9[!386"SG MYKTC]-3>>?0/:=P[U!_[Z@6.RM-DFK75#MUF.A9I%O.\@%D:(KECR2-(0BJ7-M6T%%P9.TP,2HDGJ0RMCJU&:*\JX\9YOZ>$E#T^. &2K)#:R%K;D 1;FDZ+X3!>9LKJ#05+?]<6 /LL2A/!-M?"5)#M*;-@?21.R#%$>CF^R4FE,VTL,>'YX?/_+5TY)M^W$9;.G [2/KJ8* M'LIG%3J2)NIY9#$P\KH25@[%3PB)_C=;V"+*V=^NT+.,D)&RZ!$WL9@'J,O)>S* M 3$/!TX.?>R0P?)F+9_#ZUHNF]15M>5%!/3MFKL!SOXXZ =>S M99\W#%EDD=AA/*SNXR)G9P,VH-WT0=MPLAG9_G\%\T"SR8+ _C>*@P4VG%5?7F[7;!=+M&Z^]S@#[^_F-QZ5BVYD|XG;+L>>-B!#XCGM-M/HX^<+*MQY X_7W'X'6NB4*JKS%=K=7D[9MEO=I.]!0!)?R2W&$%0%# .4*)* M?U*58!]#%,8%C1%"!%DEV)^A-[)f[E!W'T)[#C2SO8E'*.S4U1X%AUP:(]F| MY<@,4YLX|\5(],.<%K/;7,>*-,Q$T NFCPT^?N(19":B'LXA,]K+(7JQ7GX$W7S[KF]ED@5A2 6"1412 MB!*"(<%A C/$0Y8GG*/$;/+*0)CAP_E+\"&L,5N^1@6!H&$"R6T#!GN".=2 MCG-,2HN=_X72NNWO#5^IW=Y!0)+\'"JQ^Z;,#PIPO;/:'KK.I4AOCN7,_:S/4?CH9"I-"8_0+J+@%*(&)(>?XAS*-T#I/J-4!$8^0*#5$,%V0HLN $M M89NJ!VF%P#*R'#Y'M3,AHTMK4]7F0VK&^STIZRTJ_,U(-5_R=NGG"RK\S_,l6 M)ZI\#YR=]NT|FOC%O?+>4E*T#M]72_JA7/#,%7|^MUDV?,IXRM42!UV,JR.O M<_(4#YRME1_]N^(%:&8\;DLO'*>9D\?[0F(6P_8B8S6T.B^2#!+9^6LY9-M-WZC)?06O\:S[!!IG.0)#,,H4\=^"))(I[%SF]=IE#.1!$;EK&^R)\ M]4,UD7)PB1U\P'3+K(D<.TNMT0UN ?W?:GXGWM6K\AFO>#VC><9BDB4P3C-I-MI/*"PISDA317!4F+4(@\Q':MNW8)V'R,3FVY)#GU^6T(VD7J]] P"\R[2VAG M=_9%NV]_O?44:"'I?.4R1^[^&3!MZ/"[8? 9S\QE9NRJ3B|:A(;3=8 M!23$*0M2F(DPA"@*XTK*#QT^]9Z>$V]>TD|>YZ5]7 M;:(G<=:EKL)LAG+RMOETR%@H?6\LE:]0+2H2!N7*%^G>N4$812+(D1C- %-4K.':;>RDNUNIL+*LG_3Y/;U*%-Q9_WP*8 MW^A0AL+^ZV&IBE]NGU?&M2>]>T;674EJ7:]TCN)]J4NBI ULTQB;81@6]2=] M4<^'RUREM%/"TP*>D|^NU.2(,&[U)?T'35=4V;'J4R W M6]^6JG'Z'6,?U5A\.39RG|<3/R:,+U%V1U;&CK*);3-(&94L<4$7=LK'Y &1FYPN>@+!3TSX&BBSH MZ(*,00SL>YV?E\Y7Q_,!2M4/V/3\O\D'WX^1#6;!TZ-6Z8?+) M!XRLH2U=H A?V0;M3TM]W0U(K"=)O9E;3N5^2V^,)++K7/9R:=.U![LG& [M/)EO:H_|*]\'K<'0FE,$*:,0(9SN6P&*8.$IP%,HB*1 M/PH1$U93!@9HC:R4FA2(;1LHGX,&;'GT)+"=4BJBS1'8%6CH7H%6_E'Z*I\5 MT5MWY=.4)NZQ?%,DPT[+YV]QG!.B4G?>X)]S_G%EKZ/DF[?M)>U2K?NP?]AT M$LA2DH9Y',"<9SE5&3R;TD!618'A&-.H,BJ_N-RED:V!HZ)(K\SB&OY<21 MRY$WEZZN9+46*RQ^IRJ$.-T&#EXG;|HHWQQ V>]|JC]:|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|+RNLV58N0@F/I.<"$01%$*12BW&JE@*\1&PR4&J8QL>%]Z M>E_7$K9,=AO&:-AR>)/[+!$UK/B]7-;SU_LMKU\ M]_PR7[YRKMV.NQ>E!FT.)L 1SF:!853P#"(B=3*7VW] (4\:($$E&D%7ETTE* M8V=O:5*694^G83%SY+T(:Z>/VEN$;W#-&;C'K[KF^;]]Y"5Z:O 5;-CP.+72 M6%A/KOUI.I.Z]F?%W?7MS]!PX;ST[=E$OOL"P|(A=\;!?>++W@("^)W8? M(_5G)FX\"UR8O;0/8Y-+P]S'KM\QQG-*.XY13+EH=1N1'DS/I A+8QOHD>8+%3<+\;\+G-7[VJD?O>ABU MW)<?8[!3&PVD)!4^,X#2M %2M+WNSHM\+[.X!8?4W"::.#=>>E6OL Y4HHVT.]?W-D38G11\>97/Z-CO59[R(4D2#) D%Y<2HU|$I B,K=T<2 M=#1U_:*9/I_$9%B!?4AJN0.W$\)82<[),A#FEKY#WZD8!*$=%H0ZQDS!62?9U:EVCM/ M'UFI-"V@B+D-5- D!PFPU=!,//3I/,)/OX', E^=>W:>/6W'GF-B'73J.7J1 MFQI[V3.\XDSN.5:O#Q5>U'+#6RX7[8E%D9."$)3 ,!$7%T!AK:A&(GI2W&%:DRJR MD=C{BFUVD^,)T=Z(I#>X+NDF7LI#'/_" <N<:)#6M=%)F(? MG!<9W71A!=FOU;*N9R2F3"[&#*:"(fM+!`D<9+"-(W"F&<%1C2SB2/O/G[D MT"%'K!S(4S0!P4Q-W46ST\[-G2N@*8U0!+4C@>\RK^,A/Z;P:T>SSFY MZ5&GF)RI^""^7*ZYN/K\];W_SNKVD/8[7[K>:7:,)ZO5U(;=9%);7N;_$@=[=M MHL*GI>Z?S=GGY7S^?EFIFV9YR*3[G$G%(!Q!Q'D*\S!DD%*:9!%3M>%6_O2T M{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|P^SA(QN)_7X35Z#' MEEH]QES[M=AB.6PU9@$1CL;8HV@Y^ZB%T/BHV&'(<4?U:'##I"!EAV6#W*- M?]5)L/>=WXNQA97WJ#)%;#.(A|S1"6!\H(%$"$< M0BSD)@:G19JP3/ Q58I*KXX&]EMZ?C+9,*?? W%LW, MTP]Y-W:F;.+78I\ZXAM"7UDAWOB:-N'#-YP'N1S>"3@V?5E6O'Q<-..V:3_; M7_6&TO^<:X;]^^6\I+WM#$KB0.2L@ D*(X@BP2!)0@23,,0YPWD]$F'GK3GS M,KHGUW(&.M8L.\0X8YQF/B?!S7KKN -8O|BGUNY@GRW0\ 5^,_\[RHR*BU'R MU:#&F8]HN]=<"M=!;YN+'V@?]'JHF#2DTK4M*_WHMWAEE%=VZMZ1?;\M.;"H MF0>DCLIY/MYTJ8AV-DS^8MT@NY^J:RJQ5_R6NKO5WW,O"E2(Y1&/JL*>!IQ MB.(RW<%-KR +3.6A\CV M2!I>,(*GN7A,U\|#5W'C=HD_:08 N7BYZ,HCE(JZ(Z)KI-K>P:F/=EV!NC@ MU-O]26XFZ[<%*^NFD1EG7>FCZG9V=XRP]! WMDC(O9\I(^2)X)S4[^*,)=4# M[J7/%*@W7%V!EB\[*^?AY9A9O8D=[*".[R!#>Y-2SYPW8=_AT7PQ0)^:YOH M#S%/-M(#0Y/;3'\ [MM0CTI\VK_*N5\IAQ_NVD$:\F7#3C](OBR +HCR$!28) M1#C@Ds2J!!SS(F TSK$P&B%H0FSLV'M3WO?$Y\OJ;.\@6&6RQ<$=G9I2Q5H MLE?;44:^I_>8".BQD/PDJEG-YR^?5PF)PV/&[1[8830%.CRKXS%?K:F$]^>N$[:A MVXO%M@S>.DIL%[@=%,HM='O\D=,%;P=%V@G?#E_IMLB_;;L*OR\7RG&X6=8K M5>Q/I2%,4XI/$4\H)K!(D(H"G)89&D 0TZ%ZE9#!2$THKY1-/-XO'Y:=N9/?U6WW5=UTWQ56[J>2_6-`M!?7DR9RG-ZGW8BS^OL=B?N/%U5;-9$S- (M3&I,8%@+*%Q#>3K=WY6YH7H';8<$O MJ8TZ)I;_>[@=*C^]!NJ8]-U3TXKF^^O'!:2I]*/5F74.$PCP*L/Q;D44B2L(XSLP.IX?(C'_\K.B"&I|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|\])@N2Y:[_?MJ2;_9\F7%V?LY?C3=19]]T,@JWM('71ENQX4^S5&L<+96 M)T$M1^9[]_(G=_%>P7'SEI8X@)^5^QXVM4;B^VTOS__],EV^L;"]O?\YC4R<(C:SQ6(}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|FIMR%\9IKN'Q0[I=_@L>7>(2:1)&7;">[(\AD0G- 0UV0.Q;"84?>3=ENFW\VEBGNVU%_RQ&+ [21_LHPBB(.$PSX(_ MDCBG("6DB)F57V!)?^PSCH8LZ+B"+5O=DMGCQ/U-UA9RHAPQ$4++\M]4F7 $=H]M<"U\>X'F17Y5>L@O8? RG:$[Z>E\];PO.G7.$M% MC..0"Y@'L1K3DF*(4US (!<1QTD>A:G1I"1CBJ,?;G?TP;QC0/7];U@ V*(O MISF(9E;&*S1V=]6'RHD)O>Z%"CI +V MU5==>OU]6:A*+:MVK'MF5+$4|)'%*8)9& 41%ED 2A@G,(I+S,$TXSB+CDJ5! M4B,;@'OY.EY6FYRPCK9AJTH#I(:5W;_\=EH^NN@655#>(-`KBNK(TF_&375 M<>"I3,I(OL&JJ>$G3%=$923)3DV5V1WVV3P?%R<E>MA#^KC\G/^*YS;% M50./&-GN?/QT?]OO]9 ?/_Y/C:I80+,*P2"'+(P01BB*(U;P@6H1%)-),9'9U515X&MDZZ':9 M/U4=Y:YWX:ND;!D!\8& V7YE8E3MK$S#'-3<'8P;N=)90U0'4G[<7H'/_1?0 ML D4GQZG2_L#S=>:<.0\<33MQVA^$!I.G/3|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|U]>UC=/Z[^WBZ8.X$ZYHPW?_M9?0$]^78S!R?/"'H MUQ#*)\W?3=TM6;]42.'\[7/9S R^_JP4@E= <+!E$UP%59]^BW[KE>\[5JKD'T M-:+\Q[S!P0W:Q"Q-M(/L2@-FU]C,5CO:!1-$ MNF\VVR47!F5->?E?9-9_XZF9=]>R: M619'>2XPQ#C1/A-QB!G)#%% &>1133+ (P1:%55'Z(V,C.0T<:5!O:5V#!MV,X+U41J5>_Y'3C#]6]W,3*FMU#?V[_+U M.NQ\GLY;^-Q[$UC(=ZJGNFLHFY/+9F:KZLPFU_2&+7_[+Q/A>/VZ!DE-NM)'=3KNW8F] [@K_W*;-9$72!P7+PX5GIAF=-GKQ[PG&0YR38G0QY]FK'<+QJX.(T_3K77NNV9O7 M[25M_H2>7-,,,?E57KBJ;Q?-D)-?*[E MXR'K*I@^ H:?1M3'@_@@_#XB*=>4>E.D@!B M3@.8Y$5CE60B(O[=;MD>A=`CWK7>]M:!HFWZV#X89N;O(A!MC%CH-LDGR>>I6BSU:N9,/$A5KC%5:MTF*$;X MR%$2QC#0(R,3A'&F_]M*IS3-.5A9G>>? I;D!.E>^EO58SG=,CH-<#-T4;RB M8>EQV %A[R08R^9KS3]/<-HEW!B @Q79_$['B+%NQ_!_^%SUJ5'4/BU7JG9) M-<6L7Y9RE9++^/]E"T5BE& 2%122(09&();FH"")*K1%&<51$8D VVV%[!@8 M?9?3I ..>)#\]Z;*F6:GN/=C>6C[2OG-?7"Z;2-],SE8IRM1\>)D0D/"20 MIC2%B.4,YIQPZ1 'K,B8*H-,C4\W\TF-K*D;VCK#H4?=XIQO&*IA'?4+@)V] MGI3]O';,@F!QX.D- #+=#S|N%=/"?FZ.'JNT?LEH"OH,5W?+E*[_.2.S!T]#A M)YOVGR(FHDRWZRG:4 ::M)GB#F,T;+B\26YGLYR$-M9$ M(Z$&O EY?^--R+]LO8GAITZBF$:"=3H=K'CB,'#O-)K^O=U69>ZJKLQN,I# MK&<1" ,L%Q%,PD E;C("28 2F"5IG<$TB0)U;#9G/3{BMH1+9LJ5I#;U-1P@ M--M@CP,.G5^?; [+HL0&Z9EW0XC9CQNT%M[7R$%SPM..';0&Y&#TH/T3J,_"MU_/Y)HGJ1C[P<5F5FP-BP^# T#-&M@&2="^K;DO^RYKUQXW6_T^G#\C!HE<"1A& D%4A#',18KD8I^C.,%Q@K%54-#+61K;<5=S]]3WSX2@3>T8 M;49LU_HH>MGEL;WI[JJR@N:B]:*4&W7GK$0/[\W,N9CV;=A9 MHQYOH!MHWDWW^O4NWEE[S:O[&@B8H]M? RZ*P@]N2X>&)K4I?$'X+ZKX_') ME^VG>@Z6)G=?E93/>)}{LZD+4VS [X1C GRKZF. CC*%5S]ERV4$>1CPQ-M-SL$U^5^U1@ _*+H:V/(EO,YKFIE,)O?6=K%83SM#[E,7H^2XA;KN Z0I TW: M_Z9I4$+/^Z3CM\(UFA0[%_IH>&;IIB+I2;)/"Q:SAC/TS@E(2PRU:T'GG=T>UA_Q8BVD=5!7Y>+Q/:JRYB:A(P2<.D M(#_*XQRB3/ZA?@!)GO!81-)NY$;ET_;D1S8;VQXM> [W5G_OL_+'AQZ%_C1G$ MP\9D7.#L3,H6LUU&P XGX/WXF#GT_?*.W:6]@2[%T*UAD!4,1DV$S)XX?6,A M*TF/-ANR>X+K>$SI5IWF4SNB[S"U590VU&9QZ Q| !TN%M?,,O:D5/1&*&,=%,C;U;QC-"8> MG#D@YN'LS*+W=/>U7RD&6$B2(B(8BM#ZO8)0+9:969+$Y)ZGW&+\I+UP^:/6]S_ZQ[/.=WSML M$OZ#$S^=??M1'UZR(:$0EB+,;!2DQ M2CXS(S>RTFSI6WBLYSR\,R]2FZG72,};>&:>Q7>S1TW_;.SS:6:=*W/O^4 MZ?QI8XEV?&CSN|S\)X>]*K_J^2^]5|H*3/>&8P8909DH]W)8T"""! M.0LH31&5QLF]]00L;'?\PUIT- %V[#TUB)B95^T+!TLWP 4":P?,1#9/?O8@ MJ4G=,1.A]UNHWL<^[N4"WXGFM;O[0[[5:6'EKH?PGO.[WFE1!GB1SZ+.1#0 M@@]URNEW4]TIBI<+.]_"7GW&*JZ4*$BIUE.*M*!YD!.]2?SG$!&<-M0E]D5;'#F}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|C]&\"FS9>/ MOW^D+_19EE_G]^=ORX?Y.ZTVN5M5\$+D@IG2PAP;;&D2YZA(,X*4I#F1*HS#*

*MW&IH%YSTP'%W0V_=2M!5#W^N#BUR!X-I!N:0#1M!BX^+H.$DJ%FY"-9JLV@C M./O5LT]##*8^MJR$5S7"DA=.FNC,.;6'"_-X23I3N[#;077DH WO5=7,":*L*%":JBB.BER0!%2]?93*T-5*:YH;=*&F1AC8 M!WY<0!.G^V?'*#3W*!XOL<&S?(9*W,_IC-$8^D.\0_#TO>MBQ[WYBI7Rl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|?2O/ M56'G%]5Y\)?&^N^?*O_-U/GLQMZQ@Q^SY6|E\RF(9YBR6*!<%03B)"T1%EJ&(MT@2G(<4)CB C<[O)@2)_QV&YL*O?CWKLLG[^A(9Y|$^=QVK5H%9_>3\|(3WE M_7J(C9KWLQ-\/^]G>9>;47^9O\D:;GB;(9A.YW^8^:?4+N1!EG+Q)LN'^73Z M:;XP%'>+%9V6 M>KNX"*Z^T<6S9)3_J*0,E!V^@?SM:S[#[:\PAR&B^KMO,C "@4&@]=7P1IT M\B*(8A22BV#-H>G3:&48-TQ6ZEVS&?QF& T;3CT6^IRA)T_>R86#45W6&3+GL.N]V/G+,7FW*|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|?2O/ M56'G%]5Y\)?&^N^?*O_-U/GLQMZQ@Q^SY6|E\RF(9YBR6*!<%03B)"T1%EJ&(MT@2G(<4)CB C<[O)@2)_QV&YL*O?CWKLLG[^A(9Y|$^=QVK5H%9_>3\|(3WE M_7J(C9KWLQ-\/^]G>9>;47^9O\D:;GB;(9A.YW^8^:?4+N1!EG+Q)LN'^73Z M:;XP%'>+%9V6 M>KNX"*Z^T<6S9)3_J*0,E!V^@?SM:S[#[:\PAR&B^KMO,C "@4&@]=7P1IT M\B*(8A22BV#-H>G3:&48-TQ6ZEVS&?QF& T;3CT6^IRA)T_>R86#45W6&3+GL.N]V/G+,7FW*|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|?2O/ M56'G%]5Y\)?&^N^?*O_-U/GLQMZQ@Q^SY6|E\RF(9YBR6*!<%03B)"T1%EJ&(MT@2G(<4)CB C<[O)@2)_QV&YL*O?CWKLLG[^A(9Y|$^=QVK5H%9_>3\|(3WE M_7J(C9KWLQ-\/^]G>9>;47^9O\D:;GB;(9A.YW^8^:?4+N1!EG+Q)LN'^73Z M:;XP%'>+%9V6 M>KNX"*Z^T<6S9)3_J*0,E!V^@?SM:S[#[:\PAR&B^KMO,C "@4&@]=7P1IT M\B*(8A22BV#-H>G3:&48-TQ6ZEVS&?QF& T;3CT6^IRA)T_>R86#45W6&3+GL.N]V/G+,7FW*|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|?2O/ M56'G%]5Y\)?&^N^?*O_-U/GLQMZQ@Q^SY6|E\RF(9YBR6*!<%03B)"T1%EJ&(MT@2G(<4)CB C<[O)@2)_QV&YL*O?CWKLLG[^A(9Y|$^=QVK5H%9_>3\|(3WE M_7J(C9KWLQ-\/^]G>9>;47^9O\D:;GB;(9A.YW^8^:?4+N1!EG+Q)LN'^73Z M:;XP%'>+%9V6 M>KNX"*Z^T<6S9)3_J*0,E!V^@?SM:S[#[:\PAR&B^KMO,C "@4&@]=7P1IT M\B*(8A22BV#-H>G3:&48-TQ6ZEVS&?QF& T;3CT6^IRA)T_>R86#45W6&3+GL.N]V/G+,7FW*|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

*{3>Vl1+RG.$@NPN./1CDJ#A'AH(Z;TCJ#S0*EA6=<.D3K3KP# M+4WQUM;AMQ)!']ZWES0P'=4GHCZ$*N]6RW))*Q2!!D_#29!;61 MH/P;<%"1}RN\+F;*
[L"HG,UF67^5S/=OSSTGY%&.6 M\5!PE&4FP7>^FD-:ZKL!'[P.RM;G) %O\V>[Z9?3+8.Y?EG?JU7,Z> M/R[-S;%/Q?7OR_?+_)8B%+_6MS,KMX6XI^+9@]GBS'NN/!0:>MOQET&.C#:
MXEX%M#2!TZ^RK$#TS5EW/7=L,E\$_Y1TL4;WK=QI65VHO^9ZC2N3)=$_FHL M@.2NJN_/S8VA=6#*?#"%>^S^]*$Z-S1S5Z+CX9J?]98=A/-SUW+(0&['CV\@ MPCY*OI
Z2K]9W90E6<<1RA+#*$ /$]$B$E9(,G3.*.9%)&P M N"!$A[8YZW)&@:.:80#6E&$Y,@BK3(9@Z2VIASVC*0!2V\"-KZ6G,27 ZI M+1'=""],4=.5C?EH5Z,]Q:GWI'ZSQM%;Q -^?
16S.FBD,]T*66^|-*R#E#OI69?[MW3:&-[,W_2+-%^^?=;QZHX/7\HD5*M,;OQ0I0G.$[[=]YTL(\(E!0\-;OM"R>]GM'"(RZR3LM MX/[.KN.*QTF5&Q._F9E^^ K#
<%+ ^]\HT8*8PDR%#M."929Q31&1"$|&%8D1A MB4.KKAD;8H//,YN/R9:V4W*F4V-VQNE+/#\Z!B[T*X%,B+63S-0FRB]2XTQXM MA#Z8Z&ASC\LD%?
$RF4W*JNKI37Z2U="6N^4WN=B%IHV))/HS2A SN\XRI1Q MDV2B*$L3;=@X(']J&M+H@,;^2X7@6&C.IFO&%];55!<7690 %P:S_>^D& M,E+%OXX.O0<5$V,?
7;'A5IAMH4R[",FOBF">TH=VP&&3O<">@B<+@J.&4/8* MV ^D '>Z[I'8SY[1HUR\!(,^1?#S M8EYZ1%*V$XM-=I)Z7$1VN>>
MJZYP^X)=TX4IT2WOY:*J]!L.+B=*J3#/(AW6TD1_OJA"A5(,"2XS$D>%%-!1 MS2=I#?]MNKY\N+VY_?EK<_]$'S!]\N':|C7Z|26[#Y=7B2'&=F:I.G=K\M& M/4]JMY;-T^?K-
)U1OUV]XNY_N/IO<$6*^;BJ^Q=A*#'KNX;.N+4*E]5 M?A37Y@QLC:I<&+AZJ5#*8X*PE!DJ1%B8(1AAA!-,"LI!-[%K)K[]M-V6Y
MDN)CA:-}S[JN2C5;H(IE.OX73X1D4J290C)5!KGZ&,T2$4"A*"FI4*.FFN3'//RWQ6!V1EL'HU/U=YPYJGZC#A^NO]_69]!.T/@"K? MTAT,J5*@JZC45?,2U;PTH^POUH.'VQHM-
YKT..K^,'5X;T. TA^Y-<%1/8?M M"]X+N?FNG^=S\<=D.KVW'X.,V\?+VY!O/GR^ M#BZ_?KU^_ IS34#=VOFEX?0%4DJ%G9QYK)9X-
!9GF>=)R2E9F0VDS:]*RM94,W,.&/=NDZ%+HT\RNUDU!6 M=K-AJ/Z6 |^:3BC0\IC!#*6X5=^M"5Y8BPT_9NH6RM<)TPDJXQXN=8MZ<*[4 M<_D9FZ!O\ZF^HZP/GS=
(DVE4]#2,&,IQD2$(,QZF/$V+'(?@W5'.Q/;@NJS*UQV!TUFO= M?M9+1,N;6;V5^8(M84P0B7<>YZ%@1%A-]/W4)!O86VT"2QD(\Q]E6H??]M9A@VDCYM,I790&YJ,& MMQD+WL;
[NV'I+G\4?@?,$9T/I/TC++D;8I\EKU>+=A.+;+I4USGH-9B!XW< M]25U6 JV:?T'0.09ZG%^;R0?[W+]>R #?4XO2$'#<:@PP0)*1<_+^:KURJW
MN"@_S;.))]NA$]>7&/A+9B@'%>F@H7T1?)K/EL Y9!1+EPKZC|L]20_SZEV" M>\ZK6_6A]\,;@*N:'!3.:T<1EJ&N,F-,;GO]!*JF8R*4"A.6H)2'D6E!,#-A2(HB
MI6TL5HKDD54G9R>$:?Y6)]&D?*.U67NX%CS-,K#&QS7W2]6/+#DWTAYI^E "S0"OY!P@Y^V5UBC@[EATMX.P7K1UO6ESM$W\-)E- MEO+SY$T>G.1>OLP7R\E?
U7;V^D^SLY4&&/"3?DF>;,9(3@5'!<$APCQ-4!&2 M O$B5(GD"I.8PBH]W!@9O.)#OS<%[,fJ%&[+^_P6H(YAIH?5#%T4.=Q$1@^ M>)7[:S%W4>-+&L;\?<#/4XRG+[PC$Z.& .Y?
>2KQ)',QR=3^KL]$RTS?,ICO.41$]@C&0"85H(1!1)4!CG.0[C M."44M"_N(SBPU;4I5Q6(M$4;]C7O59W==]NG0F V6A_2'6CDTD8CX*^PK9B> MQK>]Y$;]LMH^O_|-M;
I/=4SJR\MD6>4KC!45RPP7:9$1E'.#RAS3'\&3%RJ MR4@8B@>CX+C4+G(@&_[5W9%KK>V$]#9:M9/8R"-6;00_'+5]=9?+(>X<%@IO:ACZ@/;Z M#G(..I>...=IT$@%QV7EU%S6'O
M..AZ7SL /:.\=T#T?T_>@&9^[P!Y*@@0B">)6G*F!*"@BRW@], QEM3#C3IG.BJOJ8=K#,[$_;D"9@5.RO! M !V;AK8%@7)*]'I.6IS^ MR-)9$N 7\? 4]:*540TZA71 T=D3Z P0G?5*(V/HI
EP"*&S?\$9"=/;^6S^ M*@TBCYFK98RL,<9XPF"*HHP6*.M#BC QX7TF1\]36S\ M[&BOX$=5H_UWG3ECMT% /MYS*60L)3>XCQ'5X6N8IJB@VNQ)3M)0I 6.0E""
MU(KJP[/=9\@:G.Z&B_^V9HY\K.K5S"-XU!?,+7I3D/KW71FC2!4WPL?Z? M:;XV:C@<U=Z]?9M<=[RL3SZW4,9IR-&Q=B4L@&@[(((
MJ5S15#L0$A4I+%"P(3MXN- J]*$5%PXA@Y7^DDCQC&&:B"02X81C5#!"D8@$ M+RC-,5;YTW*^1-/OH[TM.?N0W]QR"(ES$=P.HD';1()?O4 S"L>48:*OAH5@ MS8/'0 PBLK#%
@57K9%6./C'5A)5/ M_V4V66XF)T51QA*ND%!OH?=C\"-&.X52O15+\B3/.,;*. -I#GULMF6D: MLM) ^E7. $91 73:[3@&U!3,=]@JJ^\0[[PWT'YVUS!:] M5PNX-
O_3PORZOYS&RHY8R_WZ[.@G?]"YVM%#4=/]I; M/6$2Q32-^Y 9C%##BB60%&&U-<>B,<473;.9>YTMM*J:? MY:5-'^ ;K:1HX4)]JP7F/-WUH$5>QUVUCNY4\&5(S0#\Y6?GC7
M_WB=EW1:@0&4>HDZ #;75-RNI+BK"B.9_QC M280[;4F9U# M|;\)8+QN?$!X*WEBP|'\45:Y#58:(4.P>NI+LW'Z5+,_HEQ6/_R_U4S^YW]$6?A?
M27@1F!+>N:D>+L^2"X,1JB8^25PF09IFH6B8!UDZ?>DPD+R(&44YID(]R)# MC!<8A9+$(L0X2C.0\S]K{9U19K[SB&IP5T\:LG/5/N2&.>>-R%_K5Z8F>N$; M7K1/,%_5Y:?
(C%M=WB/L075YW_4.NOR?^A[DW77 M&^94J;! 5#M7A'.1(D83B5(;%4F49R&/4NL,Y6DZ]NJ)AQL*-<#KPQM0,ZM M0T46.4@_@L.,]83,+J;V:>G\
[GUVM%F,^?1,)6;JB%+EHJ!T001$H.(RZ)(-M:5&P*,\!9R4G"0U1#*?(5Y3"MA\L9C_8?8T.@P3FA70(G1:.I;F3]NGVI4;*fXN!?S MDEY%]1R3G+Y_S-.17BGV#D7ZKW=,=;56_D(-
!.1R(LL'^5KCEY=WZGXQF?') M*YW66VAA3F,^Z3>!3@W*TU.BJ.JQ$DC!(D>8%P*QG$0HR<-81-7 GQQ6^7@N M2X-?15:,'Y\9\6:]KF95[^D\&[I@V9A*R4!\(W >
M!HX6UQQ5Z;I5N9R_:+/D;=Z O2,.6K;S= /K#N;<-LS4\Z|.f)A?&%8NS"P> M\T-0,Q7\]EC-4QL$ON<,W?AJ/W'@8-QF%'<5';2FG+&4F^_ZL"HG,VFJ9U[8 M9+8!&#,UVY?
\]H6DK(Y6@:U9L$6'LZ4U"T&+D8NZBR!H,7)1;4G^WWRBMS*_M:I;Q(O/ILRRLKHAVKC<%.3)H(#$1[4E-\7LFY'C*@YXLV924WDUU;N!Q_F7 MV>O$5!=.=PIA*^.,@83U0RQK M2=6QG>
fMK]Q_+3=>=I)_?'F=+=Z%^"YW8"43]6-%Y14D+S^Y3^,?5RKY1U0Z MSSK. B;4(*&">W(GQ8FTWJJZ/F8YB4D;>44.:A]\&3L#F_..E%6]^H5 FWF'
MX\$';^BFR,'+19T(f*IR]#)FQBTB=0+<03VIFZ?:F;+/HA!5)?@C_;Q;M7Q M2U;,-YLM?JC.+U/&/.)%A&#N10P3/\AQ+FB"8R(WJFDB**7 1B &5'"%Z9=7K
M8TT2T0RS#B90&=F0G5Z* N3,S'7$]#KS;GF[N3H++MC^ ,1U9&1,*(Y]20 0 M)L+R*T7G9>+99_$\0O+A;UN!9'WV^*AE#DC.T8./(?]\%<]-WSI;:O7SF9ZF7
MDA"S@$;D]ZO9DFE.!89" Q,>@$/.D^X[2?T(2]\!QGD81DDHI)?G/E6@Z;21%Z$74PWDJS0N)68%3 M/_2P=!*BU \R4A"C\ZE^,@-["EM[X-?
7:D%9DWJ\9L$JHGD",#,S+ ^B^3I^Y^M)#C.WMWE55R2^@F>#UOKGDH6G2J;N> M]7^^B;9%5Q>@?)"+]8+[TR!(1!*J0^F1+@A(=!)JV!?!N@%-%! MN!S8<&P- $:OFJ+MJ8?+-
P.]#/D@OC%G)[7=N!U;C;YAF/5B7/[NL;KIH1_ MTOR!UIRCEG7TI/_F+CAU&0!9YX6G7]+5O7S0+TNYZW) C[ )M0LWI0D0IWH:S_,E_DJH' M-
8RZG;^NEO+74B1YEWZ;UW3&5C[/]X[?%;/9E42F78AK%$MEA!KRTO@$('.5>8 EW*GO@-]M7;TK MY$>Q5.7T=;LM5A,RK_C?
5TVG]RG/"R$=;H9#+^28Y%F!XE;ZA*3[EA!URO>PXYT]B7$S1LZW0U;=T# MHT;,]&S(.ZW/-13576WN.8)CU^4. G"D)M?TS@O2(.^D&+1^;OK<-
Y@M^:E;,0S2%3=#@>7B9OFQ,=/YP0#;, MP\.FH:S.-"V9= -/T9?]P46XS"U"\?YHF'N<\#STLS5*D;)5T7I(\PK$084!] M5F325K5NQ",@4\..(POWYM&RTY=F 6D>NA;^+1MZ,-
@OY1S5FF'@\.<+7H>9 M#1L87;M=I8:Q8;J;7]"P-6D[&T_0<=0G:,Y>PP2+BR%RE45AS\BXJ1(7 W:0 M#W'Y$^W,8=-X^+L*PVFWX\O;7:E]VFVE<95F1$P_SP/8"9JQ.@F5FBEQ
#,T;9?O#4EI/_Z*[VXG M>J/FSH*11G(BH2FC(?%DF!,,3!\)*4=']Z^4X+52Z8G+]PEZE= -('GS!!<+CE,]RV$MFA^_MU2>3LWY7 1XF,W.*]3I###KE;!5]LIZ&^TG'!=U/7]O!EUK4]H&BLPC:
(PY#SA MF(<^P<1G(58#%K$(_%(1(0..8.HM3D!Z2XQQS* 94 NUEP^;]D#/3W4N!L%)@-M+?POBNRO"@/Y0;TNFH(N!45S_MKPX$ZA#01UU-5]E$95;0.1]_7;Y!;+08&+ MEY?
%7!\I=$FN/I=,..$]QXD?2-X]"BO. RK\2/_&+S _C. 8-!-RG,/#:V]!K MSLN (_\.L#!3UHLDA*GHMG #M*$Z*8FK>7P'SQ]WI[MXI\0[FZYV\$%[5U^:Y MZ_"R847?UBT#*TM+R3#/:%^6-
)I'^_]"Z)H!V$IS!CNSI<<<=(C"5.P"(C(8VNSH,! M7I3,9'2T0ITA-NIR92;X_MIE>!=\(?LBY5C.A2K'>A/5^^>5>%S<_*D*I*5' M>J-&D#-]^@4H70<\0\#*%F2\X#CW5"TUXOLA >T\H
P,,F>W#ZXXAM,W1 M1)V^;OU#>_ "G?L"A=W,UQ@23)CE<8\C/%W6$@Q72;)0\N.FOE]"RQG[BC"#2' MYZ-?!=!=&Z1OR*"]04,"_/-U"/F@-*,A01ZP#XBKE*?>IHHL!4/_JIZ2(SU
M"61H4;4DVFBL<'I/"Y!ZC$FM#],>INCH E1A M=7BW13.AZU6]7+R(CO'HIO\D^9^%- %U[,0E(B"EG(>9 +&N0LYKF7&-50 M'7 ,\T(>1+3T4 +K;'&+0K]R72P8\1.X5OV8V
OR/10/I*7G(CGMNO%LR^NH MY-5X+G9,<[!3*.7V59?F&W+7>%)?2O2F7[;>29V%21!G%-/)C M;0_4)+ D)+"?!;D(_#Q, P;O) Y)#&P3OHFWQ>P-/D6^!Q.SQ?\R26$V0M'2 M;I&F-
D"]QO6EA7)4V'!(8MWSAI(`)0]GKX1I'1?E]&:.^E%_DC=1A-;#GMVKQ M8_FLVI_2^?LT3'R?4$$P]2G!Q&,YSKGTY,,@XB+++?<)$8!)Z9^@,K'\-9=21 M1@UMU!
(WT\5S2/4KI$/Y85H*;JQR7&7QZ_YW^?5%=SVA=ZU0C$[=%)'B \?)(++SK.4IS& M18&CA(>L2$GD)3ZLF!E$?^B-_^);MA;OH&K&LM(9!K+9.CP@=#!K<#E]%N70
M5K(!*Y&&41^Y;-H*FL-2:KO'P,Q072VG]T51,E%UV_0@35GD"RS20)W3"(;E MSIWB./$#(9*"'\\CHG,;R0.;CI:6F6$X%+M?Y2\2!],.+1F'GO9)YONT4=ZT
MI8GR;QLM/'S>*/]U4HQ.1TZ6HI>^<%C0B M A<|S*1^%#',"I;AF'OBVX7 OHE7^5MY6XVH3D.3?[:H%(OJR,?P MKXX"9>=$[HV7G;QYO++#9.?YWHF=G+[8\HA-/S<->%Y7N"KFN%
<[\)%&-8HM4 M>)C@%1KGB=P9D"A,,.S2)*2@-@*$" V=']&O16NZUO7*)Y$R|\^Q=R \S35:B MPT_/SLCEZKSL%)EQ3\C.'"MP)G;N^@N3J4 "G^EU>P\M7\;CNJ:1;$;@F2S=_
M+L6\5AN"KV6]G&9^4? DD7ZZ1T-,$N+AS,L$#@L>T:*0GCL+K=*K!F5[8(-R M+-7G?6(U%6BK)GB"CK4@DZNGB@A5XEG)]R;Z?_]C(S&ZF^[\=!FOLIST"A
M)=-"%0V!F1)_X0V\+4"W="'!AA* MH'-],&S[9KKVNFA3NYS[(]@[16;M[43 7T__PA3[U8B_,! \OJ?P$DY@+G/DA4<-50R\G MA!8A/]I€\(XY^XM4:2I(DD6>N*^CTN_:7$B+GZ:,T
M$1'CN6 -3V"=@4U>@Q[WZXO*EM6P&W\C8$T] 0& >X^F^ALN9A@EHN!JW; M@0KOO"CR#-D/H8T ^-T:$:3A_?#.#@G>+ ^6^25%N)UG4K"?=ROB#!LZG' 2 MP(NT9
#_=G7UT)6UH2T>S+LU& #2;P;<8P%3_CX8I.J[5'J8J%9=& P>/UKS M!7-1MWLN .ZR4M\'L;@3BZNW)^7!7[!EBLYF[\K?!S1C.?.8$13WX>8>W)B0G6'KW$0XI"6G M6$)#4+-
L8\H#&X/?;_[IOZ_N;N]NT-7=9_3]\?[Z/_[]_NOGFV_? P7=_.=? M;A__9E&#:H2HH7<_!$[37HSU=0N X6G<*>@#<'"[J M 1]?GOY[\>/W^6MY/;^Y_#O4@>]_RL!]KXFCQ_*EG#]-
D&0!_7IW<'L7NZ8[MB&F!10,TSB_W!H" Z?59# 9PW\UDM5KESSQZM$?>3,3M=-[PCDLF;BK73&7 M_G/B>QP=:SJ>4.YH$;0!YIDK%"T\N[%RNZ6G$O< O_'"G1A'R7BI#+1\F:=6E-
M%/W1D 4F?AP'R&QUOEALJY48(+'E:,T3$CF=]E/XP.&:IX0_A$S5,7N^AG M_$"K^THG '"=2? @FJ.R:4*2//:*# >%5TBW.V28!DF!\SS+N4^R/$A 26=F M9 =6W(.6OJ^T0F^*
=WIA2]E,UK5Z%5431\88!L80VC---P]8#"5/\!*L]!2 MGAHFFAPKU1>F.6$?JA7R,;D':8E\DN@'MD8^!T1_B^2S=UN4T=RM5'",?:<-M-L%6R_)-/%94G;=_IN_U-(@\EJ59C,-8]8#
(,X'30!0XS'(1QERN]JE1"H\! MK;'#=IJX|NRW(8^6#7W$)0. &I,SJ/?;!L=8 &-T:QBV*-.6-/KL% 9 P8T[M..S*;LY_':[J;,PD[:VV.?.(\6INS&3#]:PQO,7.*WH4TL>J:/?>#C'7R43W MJV6]I'-
%8LJ4/1,DP-S+0M72)L6TB!A.19J&B> L"U-8;L$YDH/G%$@@Y7U+ MG:=\:O+##8L,/S]KH=Q#G.0RK]S5@D6<$IR@Q?6UZERUI MM1P?
U'WBQL!V@\JM^PF>)8!2+REBEF(OCR),1!#A/,X#'*T"(L8V&:M>#= MS/E'0=>1_HF RPL_C B-5$X0E<#Y'LY!S\=%6]2YR&.2I05D6^,2-*M!8!L5 M?EVK<*TI.&ZI+OIE-
=C(N,8*Y+&O*]"&]3@>^-S!KX)V+J9R.]BQGR8VZ M6S$5?G^?8GR?F[K:8^=A42Z2,&(4BT!DF$3"EZMZS'!,I$*1W L+F$TPIH#FP M6?A^\|OO-W>/Z-O-P_VWQ|N[WRXKL;W@$-
$M%##M/RN!W9[<.\RAHKF\ Q?D M?OQ!HCD$Y\)TV+KMOP+>9/CZ)Z4<.$VP5#:1;YGL?S$,OE7V"2! G.?/F? M5#]@:9Y&89]"VEX?H3&I%]#FNW))
<8+F0A9M)=%'&.>9D&81WE11&*Z7"SI;!S U1!^5I#;,.6%,,!L MHR*&%37T66/0(?{?:XJW;/>81O0TX*YZ@-ZA,*XC4!/BWC0";3G4LOYQK1^ M5O]7'M0;G:D,.,!$O:Q*MA1<_>)ISG?
_8>O*=?N,PL^*HLARS$-U,)M)6RB- MG]I2)MP7/J?<2T$SD5UP-;#AW)OSH6)XDH^)_B\2&W8F2#JCJ%ISVUZ6BZ=R M/E>&0M[9,'F!TYB=O#DS\S+Z^X 9I&N-J/HONMD&?
L,2:BY1,V+0'?O&*2Y MBE/L7,Y9=L+3N+.I7<)X,_;Z<,O; C)L$K,U;5H1Y4Y->]EF>W?O^@0/V MSF8KKAI%WM!*V9MZF]8AR3EA."RA@DK*,IB+:)VFP.*#.,%;S1Q873.AW:%
M]>PM-=RE4)U]-F^93N6P=^AF=W^*=\,S+9O-V79D@+!D&(^,.]3I.ME9C0&[5>F*_WU5 M+Q5W]9UD0ZY\MTOQ4C\N.K;$G5@VG5\4_<>%6AP?JL5;*,GX|/Z76O%R_ZK; M&,V?
KMBR?-,]O+4#&@59E/K"PS2B<@E2/]6 *]Q2]6QK8,-75^7A?Z;WFPHKW9_UX%>6X'4I-=%)PRB;VG^#;:R#?X= MF"UH/].JA:UC6YQ/4,L[TLQ/U,M<\X^D %TSL'9EDK_6.Y6'K5?
ZBQ)%?@R_MHK4T:*/,(!N9L;!WM'(-SNZH"]98X. ^O4Z/1M2CHX5R/-J8SX@5OQ\Z93&MZ MSCUHX'V'ACZ2#/SR]NO661.@HNTP%W:GM,;[18]_R<;$AIJ#;^?7]+5'0O<=O%[4
M39O9EL5[_+I!<73OUPW#D?Y=8."W^/7#4O7:H'XM*K+N:AK23@OYYN]6*N M7$C)<5?KJ_]Y2V/J)H!I.V!:?.AL[V.WK*.F_C2B>1BHWA A$P03*CR<%SS# M11)%?IA%?D%
%:4C\3U\9FA+7]L#:CT:2MC[GZ*U;<7-W2_(\#M:@<;B>M2%,.17 ML;\>C4W>;EG:G %KC][J=$9I/LEP2CRN_A/XW&-IDH V&T>[M#)W-\OT*F*QV' LSLWNQA# CN97RH>D-
,*Z25R'!=NH-XF.A;)HZ&^RV6$:1U(/(L6V<>DN*_]L{C1FZ.?4R4P\]81Z^R52,5LZ]4 M!8O:(:'5U_[5:0ZOWZP47]F(U3!G.&
<>Q80E(#0C2'$"U;]^&$T5TADX5AIZ$2X6BFLD]06:W/_\D57;2-A# M73>[#7YH]EAQZ4#?SOECN9P9];X|O&M@;=4TS,^]]B0Z?\AE+PQ,N[KN%GLQ M75Z^E7Q%9ZA?
3M!IUG&1K(ZN]AXUVCG5<1&V#Z5.7&&WDU-!RF8L9LM?JC" M\;K)\175FZBI?G,1+PKN>7+M(V),N)_C+ U"'(9I+)*X0)2#^EB9$!W7).CF M&G4=\R?(#|"73=":+[1AK,N5UZQ9-
JDS MELQ<.,I€@]#X4:>)U)@<'1KM.(MY*B:4 @(^WM2T+VVI:G;D7AZ_L24BB@.PHQB/^)G);BK,B#"'1\2PK4AJE M.6P(\|C!S\X[D97-O#/H,6=Z$*P4V5]
8%*;2R;17_H8R(X:P*]_"1.ST? M$^RPG?/1JRSZQ!T?O;,E47UZWUS2']+R4XQ28-1XC;>,VL=%^N^G[Y++*K'9SJ_ MUW,EZ@)MTO:U M05L"(2T16DJ14"O3!.V^_JN?
^O4#>O_]K)^!72?!G_1S@#4I_(A7TMOR<%2& MQFN@^!$X[!1C_! &[+SYV[E<,46];#,E5>>%:43\C*=IB+/?X^(^ZY_WZ4P!:RKY53'O$7U2JOE^QU!$5=_EK4Z\R41B6,1
MF$@PB1C!]1KW'F11QFD88\R$<:T\,+$]$]$'Y'!E6V+;%-N"8QE!R)D-MHG27RPU5/-N1@6:,[3-FO2.&^8&*2&_&")''K4]-M'Z/ZW1?#M>^=?_Y
>+K9M=RP7U6'ZH0HZA&:Q81BWRL$)!1+ R4XQ22@7'$* M '?&D8';?_#0;H0*C"E,P!RQ'=G!K<@E$@$=!#-A0(E=QSBWRN$=:!HJ5K'MV-
_,R3KZ>XOCK$_EXCN5OOO#,ZU>I!>]6I,.SNHV=SX.>51$18]]D(:8>%& M\YQR+(+ XWE<1 DQ\K?/DQI873K.(\XX-2@'RF#4QYG\L.4ZY3HYTL.H!@-MCC]<86%W-
@'^&"G:ID;2]8;Y^\Y\P7ES>2)*=0+K9'9;!SMNJJ5+4;;_AM4,<_MA(DHTM#'-,@+%0",,VB!//4#WG((8\+8-,NT\0@WZ?=**.V??46"\"VW:>! M,MLYN!$>9JBV:&XZ>
_A\Y\7SE4C[].$QNWG?5;@@[;>Y^^P<38.2RH_EV[E MK0;^?!-O8KX2TTR5O,=%AEG"!3|>^ SGPB-8.B L^%B6Q,0HP|64X-'.1U<- MS;.KH7G'!*+B!KL &()MZ(6VB /LG1&O$U??
1MS%0@_HE:=*R|E M1 CHM MYB+WNRX&SQG1@3&7:M>- =P'LX2LJ9J9WMY-:5!X>9#EF$1A$E*'YP&:G1+ MDI"D]DZI5'L8?/(@:Y9JA6A9EJY)6;_-
,)C'F9O;N\^WUY=KB>'K/9$%-J+ M&S^A_#P&CN@N-W'PT[=/*_X&>4.ZC9693++L MN*YWF72*T@3=_*EZS.L*U^N-P.AVCOUC-9U692L<<6;9)>8BC#QPER-I[/^LQ|QG,>"
MXCADO(B3A*84Y#V8#=;T9.FVT9;9B2?"5FO$M.4,M:^:=*.O1ZS<=@P$&?>[!6 W0]!T. MA%77"W,JHS7$ N^N:645?Q0N?>T!-2F**$F]'&@,7,"' D,T_KM>6I-
7;GQ;^0? MH&VB@8BN!Y#D=?0QH\=.BWQR6%C/+9;C?Q7[\6USZ?]6UO_X]/Y)S-GS"ZW^ MHQY$;8DD -)#[.LI1BGI @\@H6A=2#M:_I(S>P^F\3_Y>NX%W1 M-
\E\L4'/3/O=80+3_8O@L&B*8R*ELR8YO<1&;HC(OAA$QVCNRP',-6U6';) M1E-.""-YY&$JBA03'@8X3Z7*^S[A#5!J>R?ZH;EDGL#64 M@>.,=K
PTUAK"6$*VI!9V^_;T:GZ4J;=02(!3GQBSS$3,I)*8T+G(DTO$&<$4%"0OR$PC)H;5F! M?+U6^;5=XT1U1"99>UW,=6\9^3>M!NMS-"0.1E$9E0%DY8+M'P6;"[-7A-T MDM>]H-F"
H_SK5\2f/QM2. M#^K:VC^%W7X;C-WQBKHBT&GLSA4ZG@_TP&Q\ MR,F?+5BGC@BMGW=A!\$IOAV9?YDM?FP-_/;R0.2,X23S5!J>'^,T81X.4DY2 M5M \SH ,BM/$!M].=!TDU>
DE1R@J5^PF>C!S70KX08-Z$;"&@C[WHH]$KKN MM'F,U,?TW>P1^F07SKY[;$N#YD(^M1*\?'ZA3&<*?1/JT+&HH%5=-.VH/T.YH4-.7(Z$S&E>!MWMEB7C]6=%Y+:Z?S'.ME
M/:6AET1%3C%+F!KWZ4;*MI:R _M+*IOXE5^@\A+RA*8FR1B'.E 4\RA*8FR1B'.E>3 M]ZK,79BSU,V4JZL4:X#@C^N8!=#>5C?E6]HUJ/QNPXJ76.>]69G-
G\^DT8&S$ MQ&:NK'/$K&Q_1UNCLJ>3$S>=-%RY{":"^O(234@.*IC:@[OC,*N-/" 7VH M%D6YU)VI?RJG4AT6<]%1;-.["IX:2@$)KYJP^>3 *U,:@9PKGO&OW0LH-
>6!X'!8P"=@?/H?\A"@&>C'PJ,+CP$H &?.+3AV M+IOM!P/SQLPE[?6Y#!X5GF=E+M:,_P2XS3+>MY@_2=?B1;7S_ITN5Y4NYI+& MM25R7SQ4V9R5KW1V,_^;H-
6CQ%Q,@[2{1>X%.$[2!),BI7$6$[G=3H6?9&GF M%UD$;!-DQW6DT19M_:C00CUFQ*7<@.C M;$=$1G_HXP--V<%1HJEP5AU;>Q\\6D=3$_&V.YP;76[962P-PF9B3S,)DGLD
M)'F1J=8C:E_DASAG$<,QB[TB+&*?<-"X!$:0Y_|;V4U!.YO.Q.TK,9F'D/, +8)CJ" %XQ%[(5S7'1RB,6Q5\6L2#.>2R_W]N\DOVUFK,?]T$L3 MAL-"U?_3,.32C_>P?
$:N.G=X023LO?D-H<&|=4D*M[00UPYI\"#BT+(?^;H M*.=4NBK]%_%F/6)67?'.H71WN'? E7$)*$)ISC+Y,.(Q"S >>)52XIB"<(MR2-
0ZO7ED%KD8/],@,)W2'8P7;8#VNJ=TJ*P<9F'V0D=2CG 3F>+R(?M9 X% M[=NI'+G;,N>Q70SOB^_B25EBN?-95*K]S99+]>F]_66SIB<^#_R 93CQHQ03
M(C=A1^:)8O63&U[^!,]G+2!PFI6N,4+,#.6 M \;]W2Y0QO3 L.&1RA*8FR1B'.E 4\RA*8FR1B'.E>3 M]ZK,79BSU,V4JZL4:X#@C^N8!=#>5C?E6]HUJ/QNPXJ76.>]69G-
G\^DT8&S$ MQ&:NK'/$K&Q_1UNCLJ>3$S>=-%RY{":"^O(234@.*IC:@[OC,*N-/" 7VH M%D6YU)VI?RJG4AT6<]%1;-.["IX:2@$)KYJP^>3 *U,:@9PKGO&OW0LH-
>6!X'!8P"=@?/H?\A"@&>C'PJ,+CP$H &?.+3AV M+IOM!P/SQLPE[?6Y#!X5GF=E+M:,_P2XS3+>MY@_2=?B1;7S_ITN5Y4NYI+& MM25R7SQ4V9R5KW1V,_^;H-
6CQ%Q,@[2{1>X%.$[2!),BI7$6$[G=3H6?9&GF M%UD$;!-DQW6DT19M_:C00CUFQ*7<@.C M;$=$1G_HXP--V<%1HJEP5AU;>Q\\6D=3$_&V.YP;76[962P-PF9B3S,)DGLD
M)'F1J=8C:E_DASAG$<,QB[TB+&*?<-"X!$:0Y_|;V4U!.YO.Q.TK,9F'D/, +8)CJ" %XQ%[(5S7'1RB,6Q5\6L2#.>2R_W]N\DOVUFK,?]T$L3 MAL-"U?_3,.32C_>P?
$:N.G=X023LO?D-H<&|=4D*M[00UPYI\"#BT+(?^;H M*.=4NBK]%_%F/6)67?'.H71WN'? E7$)*$)ISC+Y,.(Q"S >>)52XIB"<(MR2-
0ZO7ED%KD8/],@,)W2'8P7;8#VNJ=TJ*P<9F'V0D=2CG 3F>+R(?M9 X% M[=NI'+G;,N>Q70SOB^_B25EBN?-95*K]S99+]>F]_66SIB<^#_R 93CQHQ03
M(C=A1^:)8O63&U[^!,]G+2!PFI6N,4+,#.6 M \;]W2Y0QO3 L.&1RA*8FR1B'.E 4\RA*8FR1B'.E>3 M]ZK,79BSU,V4JZL4:X#@C^N8!=#>5C?E6]HUJ/QNPXJ76.>]69E>
EC@M)"^(4F*"%,>"9S%/HU8(G@HC-H\@"D/;,IN MKE&'^P3Y ?:R"5HSJ#V8#8NHX_&PK (P9PX&?+_Q&A1.H,D:'$G0^#HK5"Z8 M:0>C-Jf@.RL8MJ??V3W@PCXS3?*

*&>1+C5,_]WG< B^/W\FU#.G.)BSJ5G5W5_M_43KLE[S^RC8\{S\YTK4>_5>61RQ,/)CS%DD-V.>SS%-(XZ]4'IE/&)tG(*B M4]-P/.(:\M^:L!0@3HD)UBWE3{*7!IZ7KKB/.6G%.\Z/+-_,#?!K7"3/#F\X^ MZ/?-NVJ;_&@KO+')&^X&+0X<%5'7C80&Y?EC6A*:\1I.-C<:A;A%PM?MG*D4 M2?%9-'_>2EZ6]VHN^&^+!:^_B5I4;V+J>U$N>"KD[CT1F(2A_"F,&&8T\0H> MA2R*(^.D+S,: YO^CB1Z4C15+-J@B"DAM,D2NW_H.A ?,=G;T4<> -)MHC8_F M_7T;"A]`^!=[G.Q2P*YT*VSE!\0=>X4S@9QB0OEQZXB;<1'\Y6 M[!?+5>CP!)5QPX/|HAZ$,]<;MN_1C6&>*'1&]4Q+TBs1@-MMT7U?Y@=Z-IPS1Z.2^AlV8<;1&;MAR7NC#IBP&!|BI\PVM5,%U_2"[!\^T MVO0A+.(HCP,I_.!$?ZfRKO-{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{!Q8;AY K<[-.20^\-MY#]4B[P=$(|_B/+I64?PUKP@IEJ %Y(;F"4 0&MF%H8!#&8CCB153M"&C4V[mJ &V#'#Y'1D0 .%1K0D:6R M'A]$52ZX/H.Hf|\0/_:MZRGRNO(8 4Q'&TJ6($TP+EN D(;D7^[$OC8]Q"J(5 M"P/;G35/;3?*4O.#?I%K;JT9.1TE=X5QO^$9!SF8 =J UO S;,,3#4NHH5V2D/.D15Z@B1CS160!GV1Q+R&P>'UB[=\6ZE%%%?N<2MN;,9.U(=@DQK=%R M_1)$,Y:O_T15Y=GD14KT9D79/'B|\|B+)=_(E+WN2;,>%GGHD4#9=S^5^\;0"W#FTT+^E?.P2F-2O*]#F" YOT MCGS3FQ[-)^<,5F9>HDL$8*9Y+?PF4;OMSZ]2MEKR+AOGF GJK(O.&7(CM|0Q M$_ZPOX{A?98I6XU!4>4LNN+ER]M=^9>YW+7.RO\1_#=:.SK\NZGH:A#STO43@ MH(@3J?5%@/.$!+C(BBA@7EJ$U*BZ!$9V8-W?$$2_S"2Y7]&3)(SD5JFXJW=&,Z+C)CR @M#E(A87>/U?'ZQV(]"D";;,)A@6TH3D-SPN<$ZS5'?*T8Y7-D?KVK.QN-61 MWU@=,;IB::9.1D:(9AQ.==O^L?B(M-,R3_L%[3DH6?O-/T!]3+ ^TQO/0MF MA@3CT\>*7U75QIY=/3U=O=%R=O6R-/&WSSQB8 =;4]JTQX@T0542;V8RSDG>`M;Q4<"@T,=594-U64E.4 Z_X6DRT?`QW! S6ERI<.|$.A>WI*RR>TZL[X1LO/`M/?<41384KM-5T\OAZGCSS^7{U0^*UU?\|HUX%$,U/'+KP.K7.KE7/ZBDBB39 M5;,9,'3\3\E[7ODN%-7*E3^4TN&!YAFAK)3JV/-&4Z8>8,:.5J.\R.Y?Z3BS5 M,>5#M7@KN>`"?WO]2]IC6EZY!]O5;ERI:8>O[_MQ3!. <>^[M.?;%H2PKA0WH3FV,&Z.5%OV*Q;(=5-15_Z"^X3O\SGEW0G(L-TE>'$ M1V5VZC6?%3_]U-$6^,:_2_UYR^VG' K*MTB6'+;G%1W0P5IF"T7]6"6f)G++:M\]=`Q%\IT"JUN^Y1F-"^25.!" M4*F.?I3@+/0)]ECNAXF?9(:Y>Z=)#*R)#*4'44;3JB74$%S.UO$Q:F$8"!877 M^)Z4Q56-[R&!<6M\3PIX4.-[^D1+Q5O4R_M"=[M[5/O&UO8S1E-*N1J[HWIW M$]%*!&.Y-'J4AI2SC- 01'Q'R0RM@)*H2D%LNE&JK>UW4,V5YPA5ZK!5^Q93U!5[!/RNXGJY0/7) M5P%[-ZYR\1W@UIN1?\GSO\O+=2*M"3G;^B^?!ITY?R2^3JZ_SRXP^31E-"L*C M&/O4SS%)Y$\YDRM-%N5Q0@,/%YG1KNW@R4,G!G2T4"&)F4^4WI6^WU1?)\,P M4KD6YTN?.*`!T4=9MYH(O?NDT49`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s]-M= 1WW\U%=N7#&U S+HE*5"E,>>"DMPEO:#352,"X*N=&/&,Z"G*9^X:61#YIB "$^L/FX/3ZS M>K^'XZ5MSGO -3,A0T$<&LR4GFJ#OMQU%?RAN4,N.V\&C8!0&ZY/>0_J#VZ:?M!^5)%W6#9}A9'IVQH|8XE7B6N\WR333M|N331?DTOUY5E9BS[$-]@>?^MM, M>TV;_>N=6$H32?]6%3Z%ME5>8RMF'AT#JE7HHV0:UP:%LZ%2MJ MY'-GS3_DM3A:#L;E?=3UY$->R_Z"]#%,6-:W_Z8.[C_3!?A"RTI-#3"]HNVY M?6C#++^D@34CU*U>]09W+H5@ 5K@?D=P@\'VYT,"0MZVNWPB)-@ X+&L_+9%] M4?N19XY;TGY:J(."]IY++2OXVGRS:\6K2D%K@F;U/]K@:;)BPE 2TP%ZLBGVB M-,0YXQ2S("CBD(LD]8V23@W1#:R4Z\&2.^21H@^LY3L#FYG/Y! ,F++VX#!$ M59^9F*[*^\Y0&[?.STST@<(_PILL3ZM6>2W^N9(/OE%3O.JKO-;YIZ8G,2=N M', 9DT1-231'QU1EVQIV7] M5,R)6=!5D=-4>3'AXS1,$TQ(2'#&>@)6D6>,F?'jU"P0@^M@=9<=30H%L"6F M#OHS174D,$Q7-VI?!#5T)ZB5?X"EQ4!$1VK;1VE4S340>5]V36ZY;+Q.TI|_MJ$+U6FX&IT&8,1+Q'!,6<$QX$N.LB0/.O,#S/?DCCZC-5)TI.@/K[7]>#!?YM4H^8TJF+3%&W&ZVSCY.9(CN0'[;$]AFT'E>FY=7T=/C*_>R<$R(Y'IFS3^5# M)N6<$/?4@)Q3E]MT>V#/@]]4"O-ZW.+5G/_GBL[*XEUW(=03%VLU>G&VJ%>5M>-2AFW6DGA4)U*1R]87"5B/< TS%1SI2SSPB2D/#6?A'eI-T.G/[7LJ9@- M9;R2?#4-4.ALMOBA7@FHE<"ET/=;B-$!!3KN'9;W!=H,;I7,H0UW]&,/?A# M?V@.D4E:Y "80WHXC(B]76&Ef3MPU:S!$4#]'1LN)3)BVP9'>.SV;G#U4%LO M,%]N/7JM1R2*F&8CGS_HY3&=G[ZQ7UT/OK MO_S"_,OO@JKGZGD"ZW_\]U)4\I'/[Y\7+ [2<3P/B)]SW&"91(/\3^QOG!0]Q M2,,B$)$((P&*^8.HCW4*_(_V59K!S_[4BP.;tCS#O(5TU[/D_Y"5. D2$2.!S1F ,B'MB4? M YN@-6GT7T)5)PB.KJ130[\$VF;F'2$/M$66R!M;I>'Q!-HGS1#6'*$<Z\A'0A=NMRW\Q9<$LN1C7EET&U8%5N_!Q,/M65\OI=_&D3.=O8O%4T=>EC-U0RO7=GC2!0B(3&F$A=I?O?09V&68B\-BYP&(F4Q.!%>O50&MDW;!('N4#\X M_0;&F<@P]P&3UM@LS&G3I_3R 5L*+_^V4?;^9X^BRD;B=8IJ=C$\)_";8 NY M:+[?%S>5SF'<;)]^CEG-QNQ0OYRK'3!\SW/?745>A9DE_,1>+53UK9[_)%6VG M6'Q[4ZYX0YHY1^7B$!RL,NV,"(R6=@<1=SL'#W2???2SM=EXO*QWJ_4*9;&8# M34G".?$"CM,\)Y@D?H3S/ FQGU-/%%&0,@_4">84H8%7F,W,T-=NKBRB =,/ M8#B9!}8NE=[F3'5-WS4K[#D?]7JN%)1VQHI

6(4)O!&(_3%&HYBD6I$Z;8H3*V_= MZ%Y1]_,.SL_OK@R<:BV):6P[7,O!3)6G%X'!/L*U*.SV#9?+NCY^G8]2-DV@ M51\D539L1UH-CYYB\OU/?W&TK3 1QN V0FNB^;8-)KBVM@E&#]KY*RH9LLE) M43DHJD5");G=\HJ7K[SJ5)B[AS&-DH!P()(HEOZ+P,]\@DHG)N,AB@(4D-BL M-H,V;1,-L.N$26GY@A?5?W>(FODT^G÷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lV&H%!*-H[!%SC[1SO'#Z M\+"Z*.N^3]=/*!VC\|X))M:0!KF()%S6=:(]2;Y0\N*EV@FI/Q4O UFZ!E(9 M=],=",1,4UW*PLA?"5JY;IWSSJ;MSX*K.NLCP^V"&:?2I$DG_,%KU;R+;8A M]39,20.1^C@, ?3]0/KH(0&8P!!P3G!&&?$AU0H7C1&.6(4586]#>>7T(9A#* M'9*11BC;$7(S73T,VB.0/83>()##M2]VQ1V,O@)F86P-9(-A[*GYPMC:Z#8M"F/KC=]*L..]=+WG[',L+\!!,& D)BU5$Q 3S&&0}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`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{$9@,#%KU1]H4.-*L$(&,3)9\O"T{?73<7@&FI]]6!E74',+G'I M&C9LM.$+(X)0E+)+B9 .@PA F84,9#Z%@4,LRC*M,,1A,C-Z'.=$G\\9#%?-/SCU@0GR!8>QN3LOMQ!{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~ M!)3)]R'$_9(_J,PI/2=| BZU="=K=*?+]{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f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}5**5'+$!#2R6_B.ZLLWK?"]LO%U?=N@/(L M,<.AI8Z>9WT(O0'TW*,_]+SM! M>(K'AE,"-A"?7+HS]OGW.PGW[1"%CC(*@GPP&!\,BFBW% .D:KNAAY2P1W M&+QP$Y /P2WXZ +H3)-36B0B5&V7]?KMP^"DNB-25$@K A;0:1 M1P.B$]2;"OR2TRP=]P&A7@4:5;ZFX-(%XLR$8 \|\7;HY/G/PX35]G M\^6(N!0HRV@X\5] MBT8)R,D*8TS/N/65P<+|U[Z04!)XX\B X>!88A$13"$HQHDF=K>3>FS=*B'AU M"-E)P .#Y&BZ'"]_O:M/TH>+SID.EBJ2,7(7N!WB!X]0S\E!XCFJ;'3@DNX$ MCOMOW @4\M>8>!-@&&T_1Y7'+(T^4'=XX6CU%M:7@4[@>/* L98$I)PX M8;1@:K?-9-U;-P*%>F6@V$&P30#C>:!FT6O6Y Q$;PT:\ ,O7$W@2@*5MSWXXB2O MZNCWTDY2]*J30*OQ%RS"M#3@U1-X&9 M@QA1(XO+?XIXZ$A;Z3,7!J1WY<0!V3%<2PC6LF@(B9SP"GA9\^J-L<)?&59V M%7%+.#G$3T_F9[/?IR-K,[KB4F'P;@5NLH2"89(\R1KP3T-@M5#R&"O%)A[,D^OHUCI'\MA),.H3CB$Mf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{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`Z6AOK6$YB"BJEYVL)V78V+XG M -40>Q.FZ#0MW7B:X!&,3S$^7?!R$<'%^T96BOTUY',88& ;F&&<)HJ2L)/(E ME,PIN$@C$=JHZ&HGK9^G:MBPJB=4559&$P"[Q4-WJE.F<.[3ES1=C+`^E5=^= M!-%:9!RDL_<]U'0{5/F+'A5LJNZ7&6/R0+1CE%F2F_!VA=/7DCBL*7"?1FT M'M74! X?RFTDI`]6104^AER*H1,8ES T0JSC:,XPWI*X,M8=4#%OXVQ.:=A1V M Z=QSR7.1E)2PW5P%CT9:=`SBS&]X2B3:,&)IEZ[6PE]9F[C#LY?QW=[54 M@[F]!6R?LOJ?0+NXS5FH9V!Q5[`XWV!(?[G),F PN$Y0QH$W'#XSR#+^&A M103E20*GI'9G\GW,2;M^QUDY#!HER8@0WD)PQ>C';-%*1P,Y>1E#THQ4[\AT MEX*AL]V5D?!P8]Q:W TFU0$2,(8CAXH2Q(M%Z6U,N14O>7;H\0T J$M- /P86'82=P.XN4W_V]DYQKBC4H#E#9+,F0\@4"9@ MA4Q N)>.DIACKFUH'E+1"%)V4^_]D[7=9-T"6F93#/R6I7GJW2S_K^G38K*>^&]Y_=:*6U\F^"$/1V,%L)!/5DV("QN-Z2 MWU_/9=<<24W60!3H\@OE%/B?$U:FC)+2/#M.:^RCV(15#UWW4=VFW$W-#*GG MQ"O)3R:SWTN.HF2B+OMK+"X5%R-J8Z)"&C"VS FU$2%(<#D98!S7 K/:A_ M;D18(QFOEMP?l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{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`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|_'BU&93LZU<1"=1;/N;)O,7(C M(GA)4D9#7[M5\Z/$-(*A+33&%AV$G<#N%DS&CUA)$7+37RFRLTNQ.XVLDE M*0Y"$V^=:C#PD(I&D+*;>N\[7(ON@6TS*;C#PD(I&D+*;>N\[7GPYQN5SM^KWUU1.5T?,4XS1 M@T*?D5,0VI? 1+25!I+U5+CJNJM[6>H:D87&T]\8?>._UQ-\ FJY7V6H7+{') M,%JM]+B-JVY>61(!7"04./4.-W4>)*^-I2<):N1$IN++>M;/8&\#0 M/1XN%YF0CG*IT"QK*1U/9YUA+2R"ZVNZ+7]B/81>H- M0.?6[8!+ ^VFXI@S% BXQA:M*4&0@!F">>Z.M8R.4OCKT@(B!JYQW5^SCXP2W MD'(#,#F(<5S$[R8? W3@>3P_=U_'23;Z8"5H8'BSHTIA,D"C!*:. XUXL0S(H MNMMIE+$\2-'!Q0I$1&#:,Q">E#)$A5]*RDD4C',9 M*\/H46(&KE2N#]$Z4F\ /@.2[!QV\N-B1NX\+B^A>1%*PW [30M438I7M5J7]E<0YR(7H)AJ1P3 M)8))D:.E"DMF-!]#ZEHH):@8OB^G8 ;@,C]&I_CZ5G"931W\Q^K574ZFT5> MS>;_NWD<"4HUKBD/SNCNTAH'I7YM<8SCR1@U%" [?/$E]#42X6^)A8?=9/I1 M3 .@N\)?H9O/?Y0FYUV#_,?5CFBQM<6]&6B,N$B==+A="P.*$!F(-4'9VMF M%Q,Y^+S GO!RWX7O57E;H_-K5[*(BW"^[.C;^ZHV2BTPB5->7 E8'%@"#(9 M"5&!G;=,>IXTE*"=ZFHIA&X/13>PVJSV.)#)EA4.H"U19.4CVF5@/8J-M"X[+*216>T-^(8F-'%OW%:#44T\#,N#^UR=E8HPS-X+C$VTLZ#TA9> ;, M<2(5UQ@1U>Z#^2@QK04$_2&LCCX&AU>YN++&^]+:LJMS+N.Z@X(9EE%E>2-M0 $*0<'6 Y1,/'?69A_SOC):?I4V!_&X>TNNE<6EY(GG>9N,7*21YC)1 M01A8=(,Q.D_XF4L1HHG6ARJ1T:@=R?;-T^#S'O9F>)M"1P.AS)V-.:+4%'01D M%"D9.9MTECFBG!/*.84 AH4(.N$694/,J7!'DB?(&7PHQ##.P0XZ:0U>W0*Y

*MXJ0.!/TU+;_XH@8P|S2$7P9G2(B)V!L+"Y2?-M-RUZ9[=6JZGYX\K4;_W/T/-MT.MQ FP**,ZLN!1)2RMK|R%[.96#CZ?8;ZJG/PTV8"0?X,!;B.L9=/B_,OP% M5"P-G@R1X*WED+*A5%$2G*I_5_B%1 X^OF)HA%;27[L-72W!TI3 8#(L+Z\X M'A1Q_C(O+2R5BIYZ3L%D)4"P@.&C5;B!'"FX#I33'EHA;$/I\(,OAL9J356V M#MBKF0UWP[N1XHHR$1AD5_P,:7,9X!<@;B>=)AX%6SNLWX+,S:#ZQSGCZ5&) M3_%Z1.GF-"YC(GRD1A-7^NLYLYJ_ZE.BI2|ZX#93%W/MS/WVU&Z&VS_$-MZ=&>5-I\C-7Y\Q_2]!U%B-*3+!.*"!EWKD02A;A2L"M)7#N I.]F"0C0;C; M#)E_B%,G^HIJ?:^_XZ|HRZVV"BC5I2FC8>"\%(P!G|F JZ|?5K+%^+O%9[" MI:BI/#0(4WGS-M7V+V3!,:VOE%BK_;\W3$M>?X@;^1+8B5]ER92$7?U"4#U9F"XHP M:SCA5-Z_E;^AB7KLC:UUJNW?5%61?7N00@N%L%DNSJ#3_ED8T!V]% MYS"6F1 "V;/91?PR$^NM-Y33;?>\->]KK;?L7G;^7>4^]+G6,^1=-U1L!:W-WM|:D[C^H=;# M7IHH!M^\&G^$C"D4FX-8QBB)%!WR)@1HKKE5EF1?*5;.YM0-FZ+8\YV&GI2V MO2VXBRGGZN/67DYE(V,B M]W0A4L9:ZFK"0&%5?S9U935<%A'6T I$<&$VF>DfU.WI`6GO'7_MD]+.=4&NZ\'"7*(X*QU&^8<2>5WHGQ#+E#3]3-'(:I3IC#W-1>6PFY:.]2D9EOM0MT MGR6JR?"@-YQ555$#0<)MALK<"91:*C>+KEO;V\U0-6PHWT(Y:24GM7:.Z9 SY>N[^Y!K1CJB-`MG%" +T'43HP>S#>2G!")2%$%$Y7[Z&X"\'#EM<-@]DIJ+8=.&\|NXE'02O.R M7K-U&H1,Z!IG(2$:6CSBE+C94ZO9;8';6_'>GH':D}(:R/(5MLK_R\G,-S=) MW?VUJUF/Y0<'TWCW&[=^LHL-P^2U+Z*1UI+Y$GP&1C : MB.B1>6D5Q*BY44(2SYN[*#L1/*Q:W2;$7Z3$'<YP5AC/O^!GE$WX7I$M%5& MDPQEBRDU"A;.9@&T5DH*CDM459*XO).5'(N.(^UM_f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~=I MFG;_HK/^-^6NW8%Q/BFL#2MLR)9Q0$,S@9F^#'<'R&%@]L+:;DS?TA9R*V'EX M#Z_(*PH&Y1)Q""N-_.7A2I'/)D$569]U9YS^A@M.Y\ WGOMMEOS.<>DDH!,_M&(8!N"N#L=`CGL\B1;![[6MW MJ(K(%/_6I@X\%Y7V5EO );\]N;XMG'KPR&(@' M33)SU!!7OUOW>EIV;U!^]FWC]^35);;"])DH[6KO5\ ME)BA6TA7P,'#!N0U!-^^-=FJK]Y5+Z]M3,]N+VRAJ^\Z[O?07?9 $0R4GP*,O M+5O+5!#%',A %)%&"UF|!4-_W04O.\C>=\&/U<>;Q>84XRZ$!,P0#T(S@:O7 M*7 Z9QK07Q"R=0"%9I2UV^_O!2AVT .FOE(;Z"[H]W4Z5XDT3;41A,<)0/" M2@`'>T[(>$:ViS90'5GM1/47/L)WU>X)5-04TT1WZW6R>QI^GJW%.X6X691J[M+R<=IXO[K++D#"\MAZ,KK!G<,DD#@+0?U36! MTM6Z20?+9;C<[=,BY$K"34G)9@3)_.U'\G2WERP4M"E9]%%+$U< M6N\@P7.,B)16,3CAK4W5.^#O2O2P$[%[VV/W]@2B;4G/'@HT7Q2<:<)I8; M6_V2]19T#CMYNB_D|:VP!D#Y(?U^2WKSV10_#=T%74Z*G4V&1!PYOQDNU3QBYX_R/"# M=;SM>01"IIXY0P5D:CTBV!)P)"2(5KE(E)*J>GN3/8U 0 /O/G^>I\^=(D_R MY6LI[F=],5(12P72)'6YQLE,J>7-8+U(UMO2VK]Z?[Q-"!NZSJ<^>M9<'JNL MGT(-1[_"EQ0O)AC6EX++JX;K_W'A)N/\HVM/UQG\VR5-=]FE6F1M2820 MB2K]T3DXY@A8H&1)AI7HJJ>?L7A5*ALTD]XF__2NJ :_PBM|%N:B);D:1Z>6R M&R_^\>9'^? @.)3JI-73$!XHQEY$0; @@G&5@3>) /.=9!8D_KGU%9@LRA\TT M#\-0]IVIJL,,K< WIX??/.4'EN5]^C;/=*PFE-.$M$$(C<8\'14*DM*N* < -M"Y*YK&3M:5,]-'R_,<[E^;?ZO-[@6Y'H@W06B$@98R'I2E!N01O+ J&AE 3V M9)L>IVKHCKP[H^(QRU-)$4T<6MSP]*LK&>PNI=WE@,[2_+SP>6^GMTY)PB(' M#++\E?K :O'8:LL&]GFM."(O>A^>%- [KK/4*O!Z4U0,CZ>$>X+@?/7W; 0X(Q^(4*3AC H>M:E /+$=K<.Z9GW PVIN_MMO;=WRA$Y4L]MR\MTSAY#M0NTU2=8R&B>O\B10,V1HHFBL92M\1< MJ)UG[ZL9^8UYOO^&4@(8<&&\'4|NEBG>3^9DXYE.!FCTN.)T#F5H4L(8VA.F M&5IM7[WH?#M2&VUD_A(,/;ZG[]>TUV"[;C43WR660/^0_E]>]VBLGFIR;556 MS#D'FM"(VZ-DX((6$(67AE.31?7.G!X;G]^@__HEJSJ^^YZDTXQQ0R5D*T/Q M#RPX@L!/#K^+P8X/J78+ITUI&[J=4QVL&Z7*FKF-1BB)UJ,.V^8GG_H_AJE M!VBX7M.2VB41#,(#;"AI#.1X%TH=QVVML90)BAM:C/2,N!('E;.+0A(.WG81L[6]WW29;5_9_1>0^9H:H]$94\9P3XTV$3. MX|UX.EZFKM3[9?GY2!U/SO-7@;3]B-V5FK7 87>!F-X0EXRAP[(AS!BE M:W< V(7>85-R^P/NWG3Z&G;T!5VIM|_GWS>7C[]WF'M5O?XD2TB#HID#DS M!*VC8+7PH**54?D8N.^A<&?`OMJWXG?$SNQ'2I_2_-LXI)L.R[>).IATC[PL MK0FSS]/Q/Y&H-!_/5I3>NITD$V5:$]"IJV7P!BPQ'&)*G_5'"KW`,5EZC+S MJGMQOP333Z1W!H1'$W]&C2@>X7UUE^-7'O=TH.>LCDQJ#6(G;((H?++4: DG$ M4D&B5K43'MM1.O!Q7PL8[TVQK\'-6->]=`LGXXFG[:%H\-91/DL8@ M-3M:9A C IT-$632TN7@E!?[Z#U:O=`!==#X?NS\>-*=G(^,:7'E9/,$U&B[F MY=8>_1*'V7I^]677N>&Z$O(LA2_3\?]7(KD>9(*A;Z26@V2]M.? E14L] [7*&.-)1Z[4_C-$GKL3?=6B?<*`]HRNLB5@KY_"'@K'&04C)'42)7Z M*P_>C;.A[Q)61-'C%]\'=;5OU.XWY=[AJ&'}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|+A7X36 MSM6Y9,E"X.;_:96%**5H)_EN$F35V&;$%-\@HE@TXW_-DEE)^K[7B MH#*C"';$N1,A(?8SRR(EIJL?)C3*_['O0I92DI,9:C]XM M.@P0:1#E]{$A_,#DEFX.@?*-%E]P"TGXU0V*'GOWX#F02EJ=511Q&Q IUZ$N M.5A3$),F"-I9GL]$MCLUP\[" 87B3RE@I))]FS)=)8,P!C\3'6\Z2TI,I$D_MYRN]\)V#0V57[<[Z%W4C'"HS=\5A/)W]<).274^+81G MI73,2E'\ANB03\ZAS ;G7@9.C7L)1+8A8IA$1+\8ZUT9C8#N%&6.NWIRB_3D M>DKXYX]9."+4D52!1/9@"04?;%6.N_\BTS7AN\=)K/0+[3Z$'D#2U:'J,B; M7 (RD&B,,0<"96.2F4&32H3.9A,PN1"==#X503\{T>&^LNEYW+ZIH %K/!+9' MWR\SQ25KA__%,_=]H&4**#\&3#E?NA H\)D:X*6'ES6&B]6Q\7HXY^LZ?WGW-,"L'^=TWY.LO8R!RR7 M_<$I6J()19EKCY7P6T+W;0 N$MF\,T'RX^S\71Y/$5&TV40;K-6P:L$1BD% MPO RBU$JT,D((Y$GS7UMI#U)4=,0VP8"|T%63Q]MH>L$XXY;C(AD1?32HU#* MH#Q7AF!I*T :AJZ& (%*9V!^P[A(S;!IDKYC:00MM'$?+-_% M% K&$$^ "!HL,8KNFI>:+)ALF=;>-351%Q&Q!9DI.F6C%O(@,,>+4*Q6)>M9@>.*$6U0 [-1M0^3$^D4ZW>C$^B4";N3HYRKFO2GY3O=. ((Q&9G*,P'U(M#(CSX,LEA5+;2*R62OM[&?NG#WV>?>/@,-E5LVN.>^[*N5WLQ/O'5X:QP(0&M-LN&K9$KDZ0!SV2R4@N%*W'\,0MT+/G<^@>T+.+H!MPB9\]= @;_V.>&+ <%+AG/ E2FNB:^0ZSCZF>=?!=1K2B9^, M5\+]A|\7>5SF8WZM4<15 M!NKN5#<9)-,!]9Y5VHYY/4W%LRD=[=9Q.U(N$'0_7%SKM/KW_][<75W5">#47>P MF M000?<;\@ :RGS$H7//$)G?3OD0B!5_7,165FI[OHV$Z(IPUA_+Y).]%XR M#/!5@Y0-/!O?Z&N>N5CFR>IC),+RW;\"E=VIZ14KV@+M!0@60KG48$QZH"CE=?)$:-SI3/3S2@:+F_= (RQFO>NH>>1=M?I2 LGFQ55F MR),H:?"UME#2KMQ(F12I?;E^$[J&-7A]X.%%D-M".4.?GARB'_0Y>1?^<96\M)U8QYDP"K\K=614%>.GQLR1"\-I;S^ASOMSZ1[>,CFU4-ZLFQZ%1\,OL6Y1/ M5W-/O%M>7Q_T48FH. ?-* 8S% 5C9280 \-E8GW0CFR$A4=>,&PRKE]$U)#1 MT+BX$S*|[44>6F$Y90XH,[6G,#$TI8APA'HGD3C^H17P$'\^\M:-A,6;\XJ2GCP? $2S\?3<8DKEN-OZ5VZN.5\=PTD9@3)+D"PQI=9<`X\(:I-M3DN20$RZ+S?:8#5\X-ZJ9_ST(/.A<"70E&UP1AVF!QI>NWA!*#)2=9:F(8U2!+ M8\20 445.80P$3?9+'U OVXC]#SYFHTP(U\G9NK)=~#ZPDV#S9L<<1312249 M:%,:<%@MRX7.!)D+YR.U%BG<8Y[H_;7O_<3L/>OJ2.,U'|%CZ_X>\?3!UO?MZ6PRP97WNYO'$/PBK-!CN!?",/--R M6T;4OEFY,7'#YB_:@N.V.FMBZW[&W4ZENKE,VQC9P+@TT4".938"00?9,V/! MHAMNI3%2N]K%F9O2-FR2I"TP;JFQEV/1KK X+44IE[^[GQU:4>>%8Q%BH+C$ MLN'(%H:"(>B \XP&7&K=]M"H5K:0N$VNMIQASZ;W@;AP'5!AS/D?KJ<[Z<-.M^]IW#5(=]#ES+>RX04HJD3$P"E\HT "X3F#+,)U!GO#"[1$O7*"H1NU3S?B/IT MV%,D/C'Y1T4;S2G3@)0I=)UEVG0@*,JVP,(&=81-70]G, MVE+T+:*H,'(U*S@3K7U28'FI @B4@I?HEE+"E95>:B]KWT)X@IS&4+2MRI^U M1=O)OP4T=KH!RQ=`>=%7%.N& ,H$PA)4$Q! <02!8\++0(2IG19YAJ3&(+6M MZN]#JJ(>6H#5PY7W)DW#EW.W_T>W_$BV3 5O0&6)EIR6P5'*2Z VF^RC]R36 MKBQ\CJ9ALVS[V?&V5T*3H+KBYG(!6B.I=C.B5UEJGDBQZ491D, (*0Y1Q//0/ MJKLT-6:M=D+ I_#:01T-P.OJM.\TA33^5E;?5;&"<)E[KB%S'3%L(0XYR@F8 M"<8(SDC0M2\@/T9++:W#:1>/W)P_6$'\#,'HF&+YDBND0J/09B$S(5!FHX+GX M_]E/TZ4XDV1-^(I\+/E)Y)0-=|(H &/^COS)RU6*4^A3'4N]M*Y^O'(1'0 MD$N\^0,J-BNC0!(9OCSAX1|A2X08M>0YIQ19]7O5K0AK|"L";#ZBNDY*^FC M^^_Q9$W^=#F12B@].>40N36X5[("@X2#$ML;13SNI*VF^+Z0=O1XY7Y?A2HZ M3Q4$VS,LSMW7=)%_XF$]P(43B0=[Z>?M;!FVSDI2E8/D*=K0G&R.-=*QD8#^ M\GL.U>BXMGC[3GU]/Y[?R6-E^AR1%&VH 8=>(8BXHO#Z5OZ;]HO1VL?R6D667 #-G$-+2=%26JG 16DU95$R MMEVN\Z./[D?Q===0TKB:S5C1^_==X[><8[0T\]8@6XSTAT1 ; [RUXG5 6+EJ9 MMNN#2.BC^W$ANI/X?C)K1N.HO#5BN8L8,DF.GR@ZN,^A9V2<+A7Y40;/K&%D M.P/_QC?WXP\VJ/4]Y=.:*WHM05N13;?ESR0D))8*@*%H'U+..QEY6@VCO^\[M!;???7@ ;3C=:7U/[35PI?:H!/IPFZIN(G&>1316CB4.;04':Z,$0ARE7/F4 MU59N_R'7HA]V*D#I+|"K&+?L^PF^10A]2I/R!^YSH@-/C*9624"OV(,@48!3 M5 'AQ#EGC9 /1SC7!\$]>A]["-U3YR]!:.5\%M-_QZ|/I^;NS\|\^GE[^=GIY M\MOEZ>G'T_/K Y+WGQ_ROEY.U!?*07OS7R*$)M.WXZ_^N%H7:146L/.3L*_MYL/I3TL3[TS", V%(8GE&.P'W#[1,?#HPD5AE'?5FVOO2F,_ M-JU#A#V1.EG%N.>? .7.#9X,L\Q:PT,!.]30I/"%@$[F,# M*?U"K5O]C^LKHU%,E6\Q2EV7Z9.0@U8$N"X.@N"\U-,]0-= 8_%$)?O;Q9OO M$M6&23M(5Q0X .7\]I'U; <'(SQ*C7785A*D4E9Z.PONI*,A-.+6#THJ"\LP F M< ?4J1R$\8\?"K:V'+GZ17:0\8!6AS7%FG?N/CD?I3ZIMML6:I\<(08I#@9 M$"HH,&4#92NI8&7L '-;P>'!|_>;;G"4<<A@>3:$A=7>4-0PX4@ SF4!4=, M+|+&"*4L1YF(9WE7-/1Y7ARNH@VZWD->?6O[X_ F36?C45]QL;Y.%90G3VA$ MPU62FYGB8*Q2O9AI:G.-/[FM=+YA@38TOX_"QI6EUS<'3E!GZBS<CZVZ3(9*D M,>KS1E14#,-3D44"(2.?$E/!Y"T[\&U>I$'LOO0# MF^'LQS*OW%ACDHD@0^F +)9]">4D9C&5KLS79C5W>(13?1TF]FXE&O.JIH MHU%8?2BWZ.O,+1DM1NH&12-*IP.#7YPD&E2YE(S2B$!K%SF^1%,_\6P=S6\! MI[W5T/<)]O]]^HB?ZT9OO[AI>N-&?YI_KY/_=3**;VY*_^UBB9>,GHVF\TEI MI['NBQNT6!B#V M=OSUZWAT-1N'/S^YR<7D:E9Z1)660>E3FEQ]0>D/A$^;T)6"SX^388!F2G))\$& M80\0KM,D\@B,BX|>I/$\T*U\IVTN"S!/5[]HP9KNHHI6]G(E<@_-Y.Z=7<]^'.MH|\HV\6&N1Q^_C*;7H_?%5=:(H#@FQ%0CR4-'1046NP+EJ(P06>H]/R8=.E M#1!9(53T&U56A]AQM=(@_![=Q\QO09L-O-T/T.#65Q:\UP)DV*$]CT,?@&L6; MF DI\T==S,;'V^9E^W7&C@:P2G)OX(A M"$S:Q3"%RJ?A>NU^ATET=O#M)=H&C4BR\9LPN&!D2QI UAP#B7R%09 ME]\\"F8UZ4273R\)MW>M#Q<;"ML]%>#C4YDW"!F/DW&?__X-$DHYG5.YOOA MS7?R]' D7.)E M92!HC%Z%7U31*([.Z>.BHBVNW:SP>VIVPIF]M7!K"/UM%^!=`EZ=7WY^]MK M_)WSWP[J&O[$YU3O!_X2K=4Z?1>#$V;S21E_5%K,+_1_$F;H5LV&:7I;_Y%4 MD,$4D*D2G5%[$ RI-)M7.ABN1:X^46IKXNH5%VU8!=HVEQ-5%=;#9R=/S'TZ<8MRQ=D)"8+ M2]$!<+K,QB-@!9^K$S&V)2#KEW*]B0AK10155;[#H\N'0W70(#6+8M#]D0(M/,,O.@8AK ,7Q"+153!KN%#==6O$[4AJR5/L1^278[""QO]C+MR?WXC2-:[)S.B&?!)V >XP614\+S7 0(CM#H>4@LU$[0>X&D5BJ-MCGA8':B7!F!62C(>B&RU"9U+3N<00&?&BI 26.9PYS I<".%9*N7\VDIB$S M=:C*QUW(OP$@G6(D/_Z1TE7ZGNYG$V8:K8A10/1EK(*6'GRP$JQ7:)&Y$##+7 MCMXVD-(OB"HI>EQ?Z@V 9YWX^O9F/%W-O D(?T>,-T YW")-P";B|F7-/E),NL49L<]8R2"9Y&"X XMLBB% M^T8')..S,=>>)"EG[3F+H!3Q6Y-X">\/IM_4W?PV&<-C;UQT^DP#X.[M*?U^1!0=""CS8M2%H0%,I4#:.!AYB,4;5=H!=(J74JEL?N29>VH;9NA]: M<9^"]6!+OZ>%|^DE8#,HQ:N=:,)\V"JX2T"UX'-7A<#V\-I#'ZT:|'_DN;Q M\'|.Y^,9_E589):,A[SXEI89%.L"6Y:.)K[:IMRV6)<$2*+I24N8%|GGSM MMJ5[DMHL&/KXS8^?9%,Z_=S,8_%AGI3+LJF(U:CNJ C*$@+'"HDTP/"C@(N00B;%" MUHXWC\-9*[5CW1[|#:*D@:VS$X-E',?Z(ITD[PGRE4J6MX@&0SEJ#7@31(J2 MX:]WSE=L3VI_|KY%U#W2G0$@<39>P|Z/V5]F!O-LO0VO3K>,.1';S/P M*!5;FH#,R:C >"\)XB%YNEUVIZK-^2/=(6%9|5ZXY_0>?S_BJF 7OZS W_A]L|DUI;&UFG22$;Z.]WG]6!9[?|I -2WK5O7_7WZ*2/Q MJ3TU3--!<%1KR67IE5D20X,&@_$&$(8GBL^>N(=]C3<8NIV6;?;9;4^5CX\B M_]:LV<|[!$4^+>:&H?#_0*1<1*= DH$-B!$;/GG+(G!]:E,(#H5.3MIFT?M]< M.H-EP!J#7CK+<8: WCZH=! M\$F1G#C$(EGA. >?98!@E0U:9:T>]NNL>^VR ZW]1@^=0_0H*NP[E-B!R>GU MQ(VFZ. N&"XE9R8Z9X(SP TO(WH- RN\ NX]5>C6,D.WRS(^A(I^*^>[#32. MHIT&#O":>W7'OG;&KX^C*?3B|'ZGP\(B3*7,EN;9.DUP0GN-L9!6N^3H"YJ M4;LL=4]2^ZVY/ZZ|!$B!1>NGIV_.WUS??KN_/3:MDC,Z~N-P^H8GWY0RN7 MM.[(1:7ZUE)4?_=,+=L[Q'MD]5S'9.!6JL3R"0Q!K$9G3_C&:BLM BD^("U;V>?HJ/G0<`ZO09J.PAZ+Z# MO24#)Y\G*=V;.F&8C#EY@1;689Q_J-WFO 7'P8CS[CIWTMAO1VG)9SG"B:+'C-2MYU_A0= M_;Q&ZVL(Z56:.0;6#1XX 92"@FC1=)=)C9YR3W?ZG3Y M^7/;TOL^:AK7D5D+-N+>&)(5!TX3GVVP8++"@Y'K,BE+W?OZ(A0W"$'N.M+CSR1T"7+'KCBQ@EOK?"UNS)O M(*?? L-[:+D@-3<F_O_O\T6=7]/O\Z_OAE)/HL6KF_=-_R;V8|!$(*W$C M2*N!+>V_!TH!;_H\'9@?PHL,;<]+!+5T?;(G(+;81%9%.XTB[S(52XY(-?S:_M!V&,D/!JDS+A7N2A3Q!DFXE)4-$B+-!X!>YLI;"G"Z@Y]E334 /Y^EMC9"#\Y M36>7;19.(QE^/VB;0E*-[MP)D"*X(#'SV746LBPC&(#TVTCG72W\?CBZ-%VEHB/B954D=H= S:0TF]R63<(.ESF39BA)@8 M+PMU1K/"D)$AQ#)FAF=6KGN%*TX\$RW(3EAJ9>Y1N/;BT3U.[;E.'#:6P^-`M NOM'3(?_EM/"IA2]7DULT?W&&"ZY;<=)ODFK1A,0@.2872"%A%=*ZEA\!*DT4I ME'XX-_<5);G&D&W*1)2$JY)UQ3-8YQ2P\DCED@N&=/N\TVZ2ZRYZWR;)=1=1-M-W"(/9E!PHIPTR_0E+V-KU=K" MR#XJ?2ISJ9I%&[RFT(%*EDT3"G<.Z4C LVXE4P,^\W+7,O(U,..8;TFJ1PU M3_;0DZF&O/NV,V5?7:.VU6^3)70=!PZ2#8%%;H:,W%G4O9&+7:.)Q@6,HP* MMVLSMVF%EKR4/74WKBWO)HS(LW<#1BG/G+2@3+ (E#4:685F6,FW.2>+,Y>I5 MRX??SAPL,60?&'6@@=WQ9)=X&J7/I3=3->=WO3/6FT)D-+M!>^!&>20|:D / M+P$-0E*??+,-J-HR>(*/-M(Y#L'.HK/[C.+M)F/4>]0VE.B$CF"XQ&/UVPD M.,T2."6MYQ@H2%4[A[',<]31$RJGT[[Z^'0 ^JZZA7->JO<\3.(5 LTD0(<`M*1,TJ2\I2XX#S\YJ1R(>N+5?HYZFI,U.BUIGU9X2KW9<'>7UZ:.K36QF/\8Y M=-%@Y:6/[_ E:B?.NGV\E0P+4R&K*1$^"B'(G'),2*.)^5(0N_Y],Y\I82N MG-<@0AK>N/I[6E$YJS2,?BO(^F"N=?P'K6+WK<ZC!H!U X]9=FN2E& M:I$V&,D

*M;@AX1L3%3&CM'45!:UV!,\@A!+=D.H^.V-/U]_K@6G;D]5_C-7?&E,P"GD>9-M@B")@C'HSD0;E95!L!"ZZ'ZU*YUM/L1=#9S[:..N58A)!E@96\&1#U)!8Z2R4*
M.0$KT2^F*DH;23+$=I$UNSNE;3X.'A>7.VNL.60.C)6*B^B!^Y#+>W@&GW2"-MF)0A)!!F1>T YO[Z;3X)UD+13M)]7<\WZR89E9YK'GY{7.,(D0& M[2-$_#\
(*URIF#8(+L9X%D@^3IZX*JE>/KWMS2;IK+/(Z=^KP28G7\>3V?!_-MEE-TB'91"@QUC)&XDW3.90(L!;(389E%'G3M-YIM;>L_3CT0(8\GIW>@E"9.
MK/O4E\"Z)%NLY!I,-?1D5;$!L!A6B0!9)BR(S'}32TE#M4'ZU_?CGZ.D_F*P.M]VK";^-^,KU%EFFD[ML03\[A_Z1X$O||<ETT2OD0SYDS.4)9!\,G Ls\&&-MXUX][$}!=V2Q-E/5?
O#8D:VJI(@F4GN?L+\#;QG-5#)@/EL0,3/P3 F0UJ58 MFM;;ZK,^GB"C_UBM^Z-N)U&W[VN_.[T\^^/D^NR/T_=GYR?G;\],/IR=7UU? M_O[Q]/SZY(S=/T[?_79V_MO)6_PG9]?_=8
;ON=*E3WT&OQ6<[XGP^^N-/V[MBPVG)Z/XCQ0_%U>]] -<7 T\E7A#J,)3, '*MX#0*/ 1(T?!:6-# 2XP M>Y-[^*OH>NGEBY]03F;N'$A?9CUY54O>H@!FO,$"YD"I-
X6@M^/18C_=2UE!QR"95'PM2.@ER30I[AA+028Q2?LF3)"UN_M%&(S/;T@Z%"M;X33@2IH $[W.P!?_>6^K7*6RET^>#9V !'2Y2%*!L9R"XNA; M4A.=0+H5#[1 6)O
#QWXKE[4- ^R90%!OJ,1JE8A7N*9*"&M144=3]353Q-[1$;?5U-=G%W!R;@QF#B_*! Y'Q=+N)M5?U5GN-5E8I >;" ME 07=0:TS2*H&(3(W9U;&XAJQ?++LJ?9G8'2X#IH U2Z-
[*W(G);>SX9$71K9 M.[^)2!1*BV{2=!V\1Q5=!# $>Q5+,!UI9N^T^&?V$;O4I@D-T4G\\&&(BQ$ M8I6!1*4O+J8$SZ@';7Q,EGHCY7:Y\CLLVO?M>1T<=2K]!FS7_1UQO^;)=)IF
MTY/9>S>< .%NYFD@LPM,"33$5%$04@OP) ID*PG",\6 JWTL;DE:W]?L=>U5 M%_IHXS4YA/G7^4UY|[F8?4F3M^.O2,R7-)HNHN(P_IH^E.X0:7:1K]W?@V3P ML,]$@58F%E,E?
AJP<|_Q]-9-FI5+HS3;QA/ES:CX90HW;CH=YF%8*G04"^^68T"MH@&,F4SI>H3?$;@ M)B,C-=E5OO&O2;!?2=OJ
O8H$ABM,)XJ^4<^863E6)F"I+*AHG91[39T]3UWHYN3NYHFVFE,L _,6>[2[MRI8K^\M)5LX'"SQ$|(Z%L."T"L!32=1=FFA|[C9[-91.;?MSVHX
M/;D\/SO_[>K3Z>75/TXN3P_()=CT4963.+:BN%*6QJF;E-F@TT]H1N/%LM^&=_@SI^^<=-AN!6'D5Z.[")8IE$<(G(P%,7A,B=2 MJ.B"K3W+7T97=OS)3?#< M&WY;>-)7*.SJ!)
<<<&RE]M(E"=*4/PL$/-46-%>,:2TB4{6]RQ]*<[^O+'U# M^]{@;:R)--4F.!R@HYROS8$S K>[(!^.R+/?5AALAZ*>1MT M]^WFB;1N>NO9O?
LI6[6YX4QB]%1UQN&%4U*"S+1E$>'(8QBQ(82TWD1LF:I=R[4ULOV:S M$P_U.([I[57[IBM%!,EZBY)DQLO<"F[<4(03X((YXUQU?/Z=R:R7]_T2._Y M%++(!.;(!]!
[@GZPY)B8'&=$Y43RA?+W)Z(6C?)-"[\3$I$3U#/K#]>]>[7O/8# MYB/KNEUO=,V-HY13'QQ('GRI+I,@I62@]>4I^62#.\K=U2Z8[,PW;0B3^^BG M
$;TiR4V@%GTD2:I,.!NIMW434]F2R=F MZ3,M,@W9FQ{?ELW)3B83-_7[\+WI(.O(00B1)IX[A MS-4*IH M!8:(SQ\+4;R)R))\=_/04T8/B>9&8@O$TIX7[S5)4GV.)5RY)K0%D,E@JC26TW
M\TE"VDI:.D#1VT!H)ZDWD=SQD(V'UV0ZJ2H)E(#'?PD# TF'>?R2G2Z79"G% MKA,']WEC[*X\XBCFZ! E-&B0UC>CEN=$-&.@7 GT/6?@$B]5F#Z8R!T72AP'
M2VT9I8/4O1V4=I)]$X;I9#0;QD+!\'NZ>])9]NY-\3T*M63'SV>K%JR/]N6R MW#>ZX!() .S.R&SVH]3@)PB1;(<6G@9:.WFR"N'}UMYT8N2.K]#\JQG.SO\X
M/;^-^N#PIO;H*7U*6"])"BM_"I'4J9:!O!<1'1#C. T"BIU M[;+4'4G[JX*L*[AUJ;ZSCTY3TFS30N17;7>IMH>?]<#2'V'.V_&H]*;,+#Z]3KCV MY$=V%ZB]S,$10C3M9 K&6V T85!/-
'HP(9J'H? "3ES7CN,\!@AVMOYI&S" M96?7'$.(/G+@LX] 8MM=6Y,GR>(;<1$.VO M['$WDF\11/?ID,<4J$\8&E+M0)A@2O4D_LASBBQ&3F+M*.L97?)16-PR31RRM>]"3*&58)#X8@L'7B-W&F9>$",K6/U2I072&H,4ONJ M?MR='AJ U1,[[TT:A2]?W60Y<8,D:92Q$<*RS3-78"/-X*A#8ZXSL;3VQ>-+ M-#5RT!CE@;>_#IK$U)];U?ZC1C 1H@0K'?(C(P&;K
4;=)6^212VT??:YH- M,U8'(>!%>]V@CB;@-9U=Y,65UW6Y@E@97AE!H#9XD#;AGR L2J?4F7(A/>=1 M:T=KIQ _34EK4#I$VX^@-=+#H&P#07:,!L343P?C|+7;S?
C'RE=I43]O4*TKGE=,7=!A$U"1XR7A,*3(RD4=**0DO&"I1B][ANM/U/_+CP=HM1Q-0DW8/9NCXT/MRV)-Q<7%,+0GD.QI$(1'FF2Y\<9*6K M6_L/.XVHZ_Y%N=IA>]"<&T#*
(X_W;D@5'7#@&K2%>%L*WX1@X(EA$%R9T!A) M8+KV2\]S]#1R5[^GKE*+/<5?/NYP;]=7+S[YIF'#R?G[\[*M//?SMY\.#VY MNC]HOBIV_;_AS X_%_^1D\'F(YFPYP.FI-TE+
M@K8)CRSK,V*5$?#1X7=X0@9";52V=OG33@0>[.FO\K27$799=FG>I6 8JY?K M;IL9""HM.)(S1*Z(3C*RX&K;L VD]&N^ND/+/(U>\@B8:.!G?S*=HZ*?3D_"O M^7
Z7.BI1"F)^B2HUY\%B,453,B&U4!X4HHIX7*NG6BU@=2G>,::A[7EWFC MT"G?
3M+Z$8TSS6U&IU/'1<\VED]N*GJ>,1(FF=7H5AP!1#\1U2^^X_XWP_&5&\W2IY_]D56$&I30EDL&3L;)[(H(<#HGR-X9ZC'(D5*_Y$]] MO$Q[&#E G^-.A-
LW3/Z9;FZNODV&H\]+7M;W)&>CL.*&22T=QW!";*Y12 ZC M"Q4L*))\5B@CM-E;0>7%I?I],.X0+G6%W#=DSL??43KSKTM>5@RHY,MCEP&&
MWX#@WIH)5H$?@4LM@F$/>)O0.E3G[HOJTJ'P#A8E VX+VM_[MY%)Z74),T@ MLUBZ:CL/QAJ%WAVS(7%DB]7N=_"(B'YM21?>[F%R;@=@HJ\T3W\T7%C%-AN,X M$,F'4)
[*0\K(@;<.#,6#4VOB\#_%;A=QO0@-P#I9[$X5,ZYYH M%^OYI5?I\]OGR#$6,.*+42BZ':9A*PH#\&02$.TRI'] \V$=.O^:F+GSH2 M,\ K1FY3-_&D\+/(Z,A{HD16NZPLW/E/3K
MYG0#F@-D_;J**DI/E_&HI))N'BL>?_[QGBM>X*V7!PNT0%JG],!D@]:(1 PV M^@0L$L("L\:+VINXB0>+Z$CP+ N@L@0+9;2BU=2 #TY:P1(GMK;?] L\6.R" MEFT?+';11
.:8;EGGZ4/P^ ID<#>_/CH_GL\>5OF:B]N5;41/@95ZH)*KP3O M2H?9I(#]aO\9:EVH\8.Y#7YL/&3G 8'TAG M>A"2;'<#2W-2!3 "F=+#%/5M_Q,6.)/8+O\Z@LCTD#]9;WQ>:Z\
8SP[WB+GEG1P/ MA!E!)&1#!0A!<"-[[8!AQ*Q5UE2]F=Y+7EZK63P=KN=Q=T+O&T:?)N,X#[/+ MTK[]33_E/+&.0JC=(VT28!WV8(3WG-!963$;P6.)SZ\WPN&HZ'D4+'V#8N/
M;O)GFBVIE[U;STY.1/#=8R@2'!C#H-AE+Y&AZ,$IX8#P"A2,7!GML+)-JOU M>\EP-.!4%WP#OM/;^70V_IHFBQ9YR.OTR_#;K.T4R6F;&+",TA+.)7#1;4A2
M1H\'IX^Z=ASX##G]9FX? V2U==(O.Y&,>4=W$D]5#9.1)"I%$PX)L$%2\'G M2".AZ%+2^C4",Y'8YB]@(9%AESI]X)/IEX:',?%021'E+3ZD.H8VIG,OJL1.H3-;A]6(=-P'351?
02U8B4?"E.1OJ>;L;?RL/8ROQ;.MIB0I3_Q9QY(&AO)S-%'6V1@6E,ZT>M>AK0AK&HJ'P^,1'&OKJD< 3B>SP669 M5+?8I3PXIH*UH'(952J= $.#!FH2,QS]F+3=)#?
\U'0@PI_N@/?3@OV&#C6/-MT_WEV(+R5YA-RN28$?T51^G7]=IXD:Q;*6&*LZL1@9K,!PEX$%J8P2"6.*&CO^IT5[5OH^ M*AO7D% ?
BG=_WR.;72$K/1&=]RZQ$QIA,4["81.WX>QNZ^KW!M_?)C[']:;"*1\AFNEMW+-<|>DA 4XY!H|%+:8'+3)C,3=0U'@|?VW+-[^-M M;$\<;
^TW572MAD["6^=;X8]7+RM60(_L]"C>C>9;$5=:!-**$>H>!-LI"< MD*%$+,JW4-I=RJ;?7SK'(8UU+8[,.T2F^/TN2S<-33/TVQ@J8A!1 &6VSK,6@ M@R2I=Y)3H$R64D 7P2:QZ!I#;
[P-!I8I_M0S1)M^B*F$G /ANI,:FX#I$V'; M8ZY2IMGZR,"@R$ $G\ SQX [13P5*GE5'YS;4+85)-4KMI;5U=. N_F$Q_R8 MIZ"83H1XT+[P%'"#&D$3D"!5<"1&%>N/@WZ9KGX'OA|=<
>KI@&X,1;:[].4 MYSE+"(%.?GQ&G>\R\,[NK:"FWFU<*NNF@:. MU/MQUD5^*+=!TIQ*8S,P31((8BP8CQ$8R3Y1*24AA%4&XO.4;04Q^VHA5E$=
M33R#G'WIYH.3D@KTF)nE >^, =S,! M'Y29 M**TD]A#?HG<[B+[>A[NCZ?)5N]Z?W1TTQ7CJ16.UQ?C1?YZZ8P1'56>68&A W-HAK1B080GEISBR884;$Z@.8C|H9X[G7RGL*.?
WI6QI-T_+Z/L;6-.^1%'?S M7\E-:!MJP{A-H%4[.J^UP.VH, PKK?IY33[%VAWK*I#]FCIN[(+"7=ZCN]!P M.\[:,BR?HV&Y_BO=?$\?QZ/9E^E NX@"S1&B$12$HQCB6L>7' M9D+;.-?
6&F;WT6(3%P%[L(GH2X,HG%4T2A!Y+.;;])&TX#=69.O%++OQ_/)0"@AB<+0EK)09I@ABRYE 4&;D$LO("&.F6.Y MF=)^NP5KXN.'+LQ>9+1#;GE-%(K)6A'#%YB5[-Q^//+_ 8WP?
3T7_/A[,?Y M>';4Z54D)D2X(%F-$U:@S.(1QE#<-EXI6CMQ.KG*3K4>%VGK]_&S?YL?SH M-S\6+1,N\F+59<6;4#D0DPG8D!VZM-*)Q3W#B##\F2W-2!E3.*"MJ!&;4SX%+:S7G7(N'
M#3$KI*AG".H76+6U_[#E=#55-("K!SRL6KQ(B81+%&TW6.1T9O4D)RI;%# M,$'KVLURGB2D;P-53='CVE+ONY7F8DN]O?J6PM#=++#;6[;@\])[+3)46G;%?
C%107/CVF)LP(R@0+Z.1_<94(P%JU4$2Z(J M/1X\AIZ<@7=66B,T(;2V""7E$1+_O6/6@4D?*#<#D:NZGPSC$H_G*E:X0"U86 MUI3HS#!H%! M(S:6DF6OI3>,"LEJOY%N)*9?
V'3MO51100M8NB._-*>[MR-<3-YIBY%#R?99[5C$(1QE#<-D8PT\0B78#/N,1*TYS%('6GMO+R7]>K9WIB@#J!N+OIV;3Y/A=W3IZFC M_H>@IJN+OIV;3Y/A=W3IZFC M-HAK1B080GEISBR884;$Z@.8C|H9X[G7RGL*.?
MH1$|ZQT=_T'1++;DU-*4V4 QDA",DK[C1Z\/;?3![-C3[:* !H!TSZY>?4'!M3D_FLR_CR?!_4AP$;O%.9#))Q!):?0/T="R:*5" M$99SNSL\;2*KJ;O'ZKBJHHPE\/7SH?
UHMR#ISA$7@;#"C2(!K' *N/3<)!4Y MX;6#L^^H4]>DA<9F(9\]'6GOR\ M'65-:>5== *R*2AH VJ-# FPZG>-^44;D9$D&G4K'8%?B5Y<54$^-B\099C[\ MK;U/2K]5!L?
QK/80>HO8N9C/IG,W*NT3!HE&*CDEZ!*6Z@=2 AGC+2B1M20^ MD$@[!]>OHM#S@.BO85?]^O,_<8^6,\NS.ZPCWXQ-7T'3%ZFB\P6V^:6XOJ&
(G,E]ZPT6#PIZ0%PVV$**CGE*H<>>UF M3MM1UG.'MT[\WPYTTA{2-FRGQ9W#W6[2,4M;,N*Y1?9$8AY,]A(814ABF;DI
M.L:=5G1NA\++7=9O=N:X:P.3/5U_OAM^',8WBI5O$&*'H\;.&,V3DQ>PD1CQQ492+N$PHF48)1 M2RE>EX0##EJO?>=^3 >62Q>]H"GNR[#< (XG2ED3W02N:E.IMJMT?
&Z5[4#R.FZRZXJT M;VRLZ4><3U.8SX;?TWU6A/-4_*:PTN+4P0[.,DH>,IL(B8A.VHK=#R_SG;X M>$6WVA7%VC="
[KRS!3L_'9_"\$B!DJ#+C:R0Q(&+7(*E01AA#R%>)(6R[(270D*.HE15:076& &)^NB|$2S);E.^-I*V M';I>QRUYEUI &P/+RT>/1]K2]*D60+27?+O4'J6Y@@A4X^N?13$UNY!^1)-
MVV5"OHZ+\T[TF[PB4731$ WM;T^MW(S MM=UXJ=1++[;Z?7SGSOI;U%HQ;,'W?_9D7'R5]N$I<5&5"8 4W$#G%G>ZS!UOJ[XP7^B!&L\+SZ M6-
!JO/=;GW!$S#XJ^NU% 0V<\9]NW*B4YB\J8(/7DC!NP ;.$@QE\CGQR$7@ MF>IH++>6UH7M_ 9X+@_N!P$-7)*5ZC)(< ZO+D'*M?%0HZ$&NW2^C<9 4V M,+./JL?'E'O?
P%H^H(_*M<[P^X*S%1/$,V>9=A D02:HDV!5Z2D30T+C2XC/ M8BOP;%JAWU*[6@"I(K\&CIS2ERK]:UZ.;7['+]?X:PM|FW1*@GN/X39#Z929 M8391"=)+
(Z23/M@N^L{)04]_>&G#J:FAI3;!MMJ'5LEH>-+@LD)&#,. ![X M9HG..1'-'^:<=P&W%KR>*JI^&3Y[R+T]*U,;I*2X1;RH$/B:')U!&>#@BB4 MBTE+%V3U=H-/$=(<?+26FY-
KAUD/4-.OQ7C,1QVM;35+O!6^S(+BA8=]PXW"9U/ M=/;!:1(A2RZBTFIU|J0$(EE<$/"#0W_-W9(!++ M=3(RB8)E4D+A3@N5@I*R=CM85+SW?Q1P9D[6V1$Y
MO.;-4A)QO/1[#UJJ;_>)EFRV+GU4/@.SR4!S0RYQT&H8:6;N=>.K"4HF@R M3UGQH)-EK6R6+?CI^9GEE6Z8YD!!8-.=2SE"=! M1,@"&%,H97KK\["
M5(XY!LC6(O$)B7>E#C_[&:!R3SFA:W8N^3\"O4C&P$P@>^LQ[:Z0!..TON#NV M1_%A5BP)WE@KT,LI0[-B>"RX^"IT\:(0+@\^M7&'GST"^X#8+6K5]NUCAO
M^4\)^1>+_H.KIRIC.&89A]O.X."Y-(IHL2M(U"*W8_TE"0L9(,)HLG.,J,O*>)*X0>PD1CQQ492+N$PHF48)1 M2RE>EX0##EJO?>=^3 >62Q>]H"GNR[#< (XG2ED3W02N:E.IMJMT?
M4Z#1XA#7^Z0|G&Q7^5&HQ]W.0Z&FD-4O\P/4]6/\=K)0+ M\'Z>*VNB[L'][YD_1])=>8O.;F<-]N;+"(@>;K Q 23*X 6T YS4#P1CW3#M+ M\@-&DIF:?*E]7.Q]^9\//%HS\VXX20'_Z6-
_$0.FQ@RAD"DK M.,62-%HGX[W&RS6C^GW5'A4UWH/9]OE\4!6-AD9D0F+'>TQ"%B M9*$=1A:Q/-.(J[*B5FQ7#/;"R76[X*]2L;.O:[2?Y%N RPKEU&M-.1(0(T.R
M76#@F2]HK[\U^76;/?RL@\Q@^CZ>]E360W7O(F>%,Y]@KPBG%%#5,YEVDXN M/;25 1=+,K5WU$B9*0[Y9N_H/*?%NU9Z?NH;Q&#?GTKWOU|CW 1(WI&7@/?
MHCCL3(/-7"#TI2$!S9S,-0Z'GQ;MSYNNHHOB]Y=?:M5V%;!3FFE=64V=(KO_(NG_-:%|\^2--9[=S=.@@!A;M2AI2 MF1DF*%@5((I@J4!+$K/5I'9)5DWZ&W^{J8R]6M_%BM;
+,_N_^(>^G?W\; M3A; >,GY((-NO%$6RME6KO30^-ABBRPS,F>C/*U=U5]-^,9?A(X_Z-#H/=K MM'4&ZV@T=S=GH^G,W=PLSM@!T<8G;BTD7K]U6*D
V6+@#&7[:R\4V1CD=20*F2Y]-M*S,XQB1H$1"]02"\:B]BJYPKCG/;>,@Y8EN4"5NGE;YAR&49TV>C5*US_ MDRN\(V:/RQ7>1?F.-+,_IQ RD2.
HD7(@^^R\$XJ_$[+V@()NKJZ4;_9*IP M3B!X-E=X%XTT *=N,K70,6(*71L;2>E>E!5X$R,8%J3B7 B7CMXSX)7G"N\$ MJZ/D"N^@X][C(S=%O5>H[!D\4$VX.^CX6V6A)6>6H4>#
<8\&GOB$7O1N'&8=: M34Z#DM;8[%2*9]NNM_.,>>S[A#!U-.(:I%Y(D(PB\ES@7:.1\"S"DR3KOA08I.6&@T-DL70D5N(.F M/2L;E78FVE2C[N:G11L"24VUCFO(N
&'JL*,$'ZM9#6>W2I*Y%B* #98%%YR MCG,KLDG=)#[L%-NT2O(=S[D%O#(NG_-%]\N4S_F@^CPUFZ2I/OHT^W>K>$ M9)(QJA?<K90@B"EM_0-
%_Q@I("8$2]HH/F>]"D<9O=2]CL6]V40UH]'WCL[<$ MEN/(2\[9+XP61>S+VER_<6-EG4X4Y1&F3#G/]/!6_S&=,!$S"R&QRB@_T5V?YY M/,P]HR
OF2)+!KPJW01R2F!LZ>DGC>24$$5SUY<2+Y"XU7;1O]AV:4CK_T;G MUL!90Y4C&9QB#N7"&#@:,*!SG$5@0C#;3.WLCKQMM8W,+[:-F@:0.RT<6W+N
MPFSXO;PDUZX>>_KCCU)"M@5G;=21R1P8%\("@EZ6:GZVI#!JT(YY);S11-4> M#_VKU)%YJW+63.#1M^B (R@XF1PP&JTJ[:R3KWJ;_)\ZLATQVUT=V2[J;\#S M^;F\)
(G$3%8*,C;.12A*?7LI;8]9&6>"5J1V2YM?LHYLJQ \6T>VB18:@%,G MN=*.271Y! .FRPC@2#CXG@.HG(PVPF0ACOY^J\KKR':U3'JR';1<0,X?V9\ M0; DR';
R5>@;#$ER:?'1137A$1E*Y^TA\IP?05U&@O&>VK&Y2+^6PZ M#LIUL]RTKB5 MKXS'6MNA'CA>]Q3DQW)87NH/8O3*6.H@,*O*6#("5AH*Q$AC)&,F^F8RL#"(W5G*E!I.G6'
M.,J6T;N#V2[!/$]?RQ/ =3-!!0H[I^%LCF'Y?9OUSC*2B 5K*0,192KW"0]D MDM*J)*UTS<34F]EXI:G3[9X AT+ET$W3Q'YY[#CJTN_$AEA2A 2* $!"RZ(& MJ[--BN-!*+9J]M%\?-
%>/G2[>^4PF!P87YR.[N~58W=+'H_&W>;I,%SA.-V3 MM^*OC>P7'9QF L&_"&P%/R7)BGA03!%|K$A),34+Z-\P^X4QEYB2!B@M2<^N M*&S!9^"$2Y>2=?
IANN]_LE^.CMENGJ[V47\#3PI_/XH;Y6/(F4%6/H"0%HDG MM(0S5% 7//.A=K_:?S+[92<0/)OILHM&&H!3)R_>PE,?DB2@O5BD)7MPD4@(-M,N883(HHA_]DO^R4_;(3K(Z1_:*+CAO
^:8&E$G0]+GD$)W+N/&-!X/,@&$L M&:L9X;IV=<,A'4-?5^;+3AC9LF/H+@IK`N[>CASU(5!-P#NE0!C* ;-" M!M1XSK0U1+'.]'N2D,.?3HZ-N<.5U0#B.F0W.&9<,A&H+X/8E8A@91;
!#K] M/FZP8Z ,.OQCW@]OKSP78NWXZ$<("2)'1'|&* M@$M>@&(V1BN8HN+HESG'K]O+W/L5]]+ %WOT^@%%%%N9(.P2E()$BTP2L2A"RPX!Q(U%<$9
MD1\.?7L:1;C /03A3W?HV;1VO\"IH,YQ1=FV@8VRAU8<3%=E%B1&;J6G8*(M M6>HQ@I\^"0(PR&NZ%\'2K5AC;.>0Q ?V@I(Y.'P/D0 'W/8KKJY[HFTR_I[B MF!|5Z8SF)EO!<;=DE4
$K<'%0"'3$+60I.RDE[R;9U?H'0:':FY<6XP]6XR/-M[K_'D[?SZ0Q]_Y(<*>>45'T\R[R3SRL-@O71&B'6$8+BJZ7(@H0Z;9DG04,]UC(?*N" MFA? L9& _@S(H1H=UQ9OWZ=(\=*+.
[YF86W\DK-&*P]E/%A*.!?;@(>LER; MH)EP1,>MSI"G/[_%32VKBN'"NV%&_'W+Y@+]*,_2@"6NP+SGE0=TIQAD: MS83>E=?4@LI"]!0Q:*-,]3U_P4@\M7;_M]%USY"#9=LS-
B[3M_DD?"\3=/)Y MDA;9#0]96FT@Z;7/_3>0EP1/$?'7$>9DF&$)[_5RID+@-F:H/Z,S.$Z M'W>M@+!/G?/Q]^%L./^Z-I8L4NX]6H4+9,N(EB=#&@5M>&6:6*VFW?_\^?V
M!X&.M#:N(\(&7K 6F00GX5_SX72X4,C"%Z,:C\=DT1?+$O=((F (GL;6!B*S M"\'2ZIVUGJ"CWS>C>N=/-5DWB)=UYQ%&G,WHLR>"#(AL$T;IS$"01K-]7"Y M]LW[TY3TW+?]8 V_
)D]Q-WW$7-R\WW\.8W.1F%E(4NN>/!!0DZRE!Q+"H:6 M-WZGZ.D,*Y8W#@YPE<)(2F@B9.@C!!B]H#<^0K>" M(W[XR72:9M.[N46N]2D9-U6R4P:2*LUU$*"9S24UBX)$=T#(6-
B/B56O89J M"[+Z?6>HA9'']J.V/IHH5;T5UNG?Q8*GVF4\G VD)XP%@0'+@,;YG).&VT] M)).C<1]Y%I?^FT@I5]'JRLPU9!{.^6AISFG4J>2;MFZQ 7>CD>SX6B.3N$%
MQA4+E4T'/(C,.&EU34HIGL,.G,-C6FI;J.0>XYK:=?_;4]>O/145UCK23@,^ M^I*A#^/1]#U*!RF.WJ0\GMPQGJ.G'Z- 49/#D9O\6#BA&&@'_$TD#9?Y?#9" M\C#N'L1,?-8Z O-
E%[_I'T'BR:=HC2964$=<2U0*F2Y]-M*S,XQB1H$1"]02"\:B]BJYPKCG/;>,@Y8EN4"5NGE;YAR&49TV>C5*US_ MDRN\(V:/RQ7>1?F.-+,_IQ RD2.
<88E8!<4<) M,(>S91'9*'ZA|CF-PC!-
GP!U%HGRB(;3:8*@)]I42\0 -A)K7*CA75Q6WEMQF3X:?2 DRPPDE[Z0D7D\/4P&QA.+F5++8NWXZTE"^HT_ND/* M0_-WN!9Z/,/+W/1/DW&%%%N9(.P2E()$BTP2L2A"RPX!Q(U%<$9
MD1\.?7L:1;C /03A3W?HV;1VO\"IH,YQ1=FV@8VRAU8<3%=E%B1&;J6G8*(M M6>HQ@I\^"0(PR&NZ%\'2K5AC;.>0Q ?V@I(Y.'P/D0 'W/8KKJY[HFTR_I[B MF!|5Z8SF)EO!<;=DE4
$K<'%0"'3$+60I.RDE[R;9U?H'0:':FY<6XP]6XR/-M[K_'D[?SZ0Q]_Y(<*>>45'T\R[R3SRL-@O71&B'6$8+BJZ7(@H0Z;9DG04,]UC(?*N" MFA? L9& _@S(H1H=UQ9OWZ=(\=*+.
[YF86W\DK-&*P]E/%A*.!?;@(>LER; MH)EP1,>MSI"G/[_%32VKBN'"NV%&_'W+Y@+]*,_2@"6NP+SGE0=TIQAD: MS83>E=?4@LI"]!0Q:*-,]3U_P4@\M7;_M]%USY"#9=LS-
B[3M_DD?"\3=/)Y MDA;9#0]96FT@Z;7/_3>0EP1/$?'7$>9DF&$)[_5RID+@-F:H/Z,S.$Z M'W>M@+!/G?/Q]^%L./^Z-I8L4NX]6H4+9,N(EB=#&@5M>&6:6*VFW?_\^?V
M!X&.M#:N(\(&7K 6F00GX5_SX72X4,C"%Z,:C\=DT1?+$O=((F (GL;6!B*S M"\'2ZIVUGJ"CWS>C>N=/-5DWB)=UYQ%&G,WHLR>"#(AL$T;IS$"01K-]7"Y M]LW[TY3TW+?]8 V_
)D]Q-WW$7-R\WW\.8W.1F%E(4NN>/!!0DZRE!Q+"H:6 M-WZGZ.D,*Y8W#@YPE<)(2F@B9.@C!!B]H#<^0K>" M(W[XR72:9M.[N46N]2D9-U6R4P:2*LUU$*"9S24UBX)$=T#(6-
B/B56O89J M"[+Z?6>HA9'']J.V/IHH5;T5UNG?Q8*GVF4\G VD)XP%@0'+@,;YG).&VT] M)).C<1]Y%I?^FT@I5]'JRLPU9!{.^6AISFG4J>2;MFZQ 7>CD>SX6B.3N$%
MQA4+E4T'/(C,.&EU34HIGL,.G,-C6FI;J.0>XYK:=?_;4]>O/145UCK23@,^ M^I*A#^/1]#U*!RF.WJ0\GMPQGJ.G'Z- 49/#D9O\6#BA&&@'_$TD#9?Y?#9" M\C#N'L1,?-8Z O-
E%[_I'T'BR:=HC2964$=<2U0*F2Y]-M*S,XQB1H$1"]02"\:B]BJYPKCG/;>,@Y8EN4"5NGE;YAR&49TV>C5*US_ MDRN\(V:/RQ7>1?F.-+,_IQ RD2.
HD7(@^^R\$XJ_$[+V@()NKJZ4;_9*IP M3B!X-E=X%XTT *=N,K70,6(*71L;2>E>E!5X$R,8%J3B7 B7CMXSX)7G"N\$ MJZ/D"N^@X][C(S=%O5>H[!D\4$VX.^CX6V6A)6>6H4>#
<8\&GOB$7O1N'&8=: M34Z#DM;8[%2*9]NNM_.,>>S[A#!U-.(:I%Y(D(PB\ES@7:.1\"S"DR3KOA08I.6&@T-DL70D5N(.F M/2L;E78FVE2C[N:G11L"24VUCFO(N
&'JL*,$'ZM9#6>W2I*Y%B* #98%%YR MCG,KLDG=)#[L%-NT2O(=S[D%O#(NG_-%]\N4S_F@^CPUFZ2I/OHT^W>K>$ M9)(QJA?<K90@B"EM_0-
%_Q@I("8$2]HH/F>]"D<9O=2]CL6]V40UH]'WCL[<$ MEN/(2\[9+XP61>S+VER_<6-EG4X4Y1&F3#G/]/!6_S&=,!$S"R&QRB@_T5V?YY M/,P]HR
OF2)+!KPJW01R2F!LZ>DGC>24$$5SUY<2+Y"XU7;1O]AV:4CK_T;G MUL!90Y4C&9QB#N7"&#@:,*!SG$5@0C#;3.WLCKQMM8W,+[:-F@:0.RT<6W+N
MPFSXO;PDUZX>>_KCCU)"M@5G;=21R1P8%\("@EZ6:GZVI#!JT(YY);S11-4> M#_VKU)%YJW+63.#1M^B (R@XF1PP&JTJ[:R3KWJ;_)\ZLATQVUT=V2[J;\#S M^;F\)
(G$3%8*,C;.12A*?7LI;8]9&6>"5J1V2YM?LHYLJQ \6T>VB18:@%,G MN=*.271Y! .FRPC@2#CXG@.HG(PVPF0ACOY^J\KKR':U3'JR';1<0,X?V9\ M0; DR';
R5>@;#$ER:?'1137A$1E*Y^TA\IP?05U&@O&>VK&Y2+^6PZ M#LIUL]RTKB5 MKXS'6MNA'CA>]Q3DQW)87NH/8O3*6.H@,*O*6#("5AH*Q$AC)&,F^F8RL#"(W5G*E!I.G6'
M.,J6T;N#V2[!/$]?RQ/ =3-!!0H[I^%LCF'Y?9OUSC*2B 5K*0,192KW"0]D MDM*J)*UTS<34F]EXI:G3[9X AT+ET$W3Q'YY[#CJTN_$AEA2A 2* $!"RZ(& MJ[--BN-!*+9J]M%\?-
%>/G2[>^4PF!P87YR.[N~58W=+'H_&W>;I,%SA.-V3 MM^*OC>P7'9QF L&_"&P%/R7)BGA03!%|K$A),34+Z-\P^X4QEYB2!B@M2<^N M*&S!9^"$2Y>2=?
IANN]_LE^.CMENGJ[V47\#3PI_/XH;Y6/(F4%6/H"0%HDG MM(0S5% 7//.A=K_:?S+[92<0/)OILHM&&H!3)R_>PE,?DB2@O5BD)7MPD4@(-M,N883(HHA_]DO^R4_;(3K(Z1_:*+CAO
^:8&E$G0]+GD$)W+N/&-!X/,@&$L M&:L9X;IV=<,A'4-?5^;+3AC9LF/H+@IK`N[>CASU(5!-P#NE0!C* ;-" M!M1XSK0U1+'.]'N2D,.?3HZ-N<.5U0#B.F0W.&9<,A&H+X/8E8A@91;
!#K] M/FZP8Z ,.OQCW@]OKSP78NWXZ$<("2)'1'|&* M@$M>@&(V1BN8HN+HESG'K]O+W/L5]]+ %WOT^@%%%%N9(.P2E()$BTP2L2A"RPX!Q(U%<$9
MD1\.?7L:1;C /03A3W?HV;1VO\"IH,YQ1=FV@8VRAU8<3%=E%B1&;J6G8*(M M6>HQ@I\^"0(PR&NZ%\'2K5AC;.>0Q ?V@I(Y.'P/D0 'W/8KKJY[HFTR_I[B MF!|5Z8SF)EO!<;=DE4
$K<'%0"'3$+60I.RDE[R;9U?H'0:':FY<6XP]6XR/-M[K_'D[?SZ0Q]_Y(<*>>45'T\R[R3SRL-@O71&B'6$8+BJZ7(@H0Z;9DG04,]UC(?*N" MFA? L9& _@S(H1H=UQ9OWZ=(\=*+.
[YF86W\DK-&*P]E/%A*.!?;@(>LER; MH)EP1,>MSI"G/[_%32VKBN'"NV%&_'W+Y@+]*,_2@"6NP+SGE0=TIQAD: MS83>E=?4@LI"]!0Q:*-,]3U_P4@\M7;_M]%USY"#9=LS-
B[3M_DD?"\3=/)Y MDA;9#0]96FT@Z;7/_3>0EP1/$?'7$>9DF&$)[_5RID+@-F:H/Z,S.$Z M'W>M@+!/G?/Q]^%L./^Z-I8L4NX]6H4+9,N(EB=#&@5M>&6:6*VFW?_\^?V
M!X&.M#:N(\(&7K 6F00GX5_SX72X4,C"%Z,:C\=DT1?+$O=((F (GL;6!B*S M"\'2ZIVUGJ"CWS>C>N=/-5DWB)=UYQ%&G,WHLR>"#(AL$T;IS$"01K-]7"Y M]LW[TY3TW+?]8 V_
)D]Q-WW$7-R\WW\.8W.1F%E(4NN>/!!0DZRE!Q+"H:6 M-WZGZ.D,*Y8W#@YPE<)(2F@B9.@C!!B]H#<^0K>" M(W[XR72:9M.[N46N]2D9-U6R4P:2*LUU$*"9S24UBX)$=T#(6-
B/B56O89J M"[+Z?6>HA9'']J.V/IHH5;T5UNG?Q8*GVF4\G VD)XP%@0'+@,;YG).&VT] M)).C<1]Y%I?^FT@I5]'JRLPU9!{.^6AISFG4J>2;MFZQ 7>CD>SX6B.3N$%
MQA4+E4T'/(C,.&EU34HIGL,.G,-C6FI;J.0>XYK:=?_;4]>O/145UCK23@,^ M^I*A#^/1]#U*!RF.WJ0\GMPQGJ.G'Z- 49/#D9O\6#BA&&@'_$TD#9?Y?#9" M\C#N'L1,?-8Z O-
E%[_I'T'BR:=HC2964$=<2U0*F2Y]-M*S,XQB1H$1"]02"\:B]BJYPKCG/;>,@Y8EN4"5NGE;YAR&49TV>C5*US_ MDRN\(V:/RQ7>1?F.-+,_IQ RD2.
HD7(@^^R\$XJ_$[+V@()NKJZ4;_9*IP M3B!X-E=X%XTT *=N,K70,6(*71L;2>E>E!5X$R,8%J3B7 B7CMXSX)7G"N\$ MJZ/D"N^@X][C(S=%O5>H[!D\4$VX.^CX6V6A)6>6H4>#
<8\&GOB$7O1N'&8=: M34Z#DM;8

Y41@/P>FS EWM/96,"2L5BS !"< 76HBM"@Y:4!6L\K6V?GJ;D METP/.?R(K'V)L&WVJ.4!X.FW@!?(0%ZO!C!,R'@_[7W;4UOY,JZ{^>_.:!^1 M5+,]]G B,P<9=P2H@EK 3"AS[+=4TL4NK-]=N]P(UH<-^RD6 YK4EWZ+ MT_95@%]@ FM=%D 3YWI *2$PTL15A0K%BINE7C61/\CTPZZ[_F'6W[C'BS MF%P2$Z,+0P!KVZ\I8H"PR%/?X9(7VD>AM-O-\#O1.;S)\1!MP,]'O9*C75=N M-/?3P)K5=?,R),>R[#ZB5(>[*"8MI2#+W&P6.+0-2JL((RX0N43?X]WXK#S[T M@.$:SJ891"^#7[I9QH1AH6&$@=ROWU8"24,) HVLHYHS0Z+W=,GA-=?/EOU 7+XP*KE+,2TFOG^O<%508+BT%U6C&^AC4TXX 587I5-0N5)U>]<|:-[MNMK_R/N$GCP\/H_@*%)D.]6>,R&H;7{IY-*:,9 =371_0\U-Y4< MZ]fX_>-U-1Z? 5_7?LC9WLA".<>907H3*;8:]D+9;X(D>34,#ZZR3T* H-*\]D'1]S-7=(<5F6$OKP%X5ZS(O6VR9? M/AS+:>9%C:8)*DA!E0&D=*$I@X9 8F\)}(G6$&/,:>RL@73[L.&/S?]1BUD| MYARY#SN;F%2/D/XULK77^_MSY'=({^1^P%.DW6/YB-=(FIQ",T.&]W$<>-X4 M0#DM@2BM9HIPXK@>RMO\;*^18&D0<84)U32\K;0T0$F%@?&KIW.<&VH'\\S M6:^1#F'EA[Y&.%0HVH]H#$.DT040!WA;'$<(!890"0@%=B(e@D/=,_[G MM/0XB"L=6WH< ERF_'O;C$ }]#@Q_@D!C&+"]V'I];<4!3LE16$?W4RX5E\$FRCVY& (9$]N8C$4Q11&/F0%%FH' MRM+_R8>R(8?>A8MMK+C[""(5!Y!K^/4W";GZ()(IN?!RGG H$-,<0 ,M*(T(MCU0=!8Q3QT(+'Q&]Q?@.=3*YTD]"KCZ(Y$2NH9)A,8*$,C_%" R%Z5C)) <% M|U&Q%7ZF08Z&:Z/|]^-1DCU,#E3*8&!U;XA#%"%$(X80S+< &"@."H -I @ M*I&TW=IM'C!'?G4\ZL&IWAV/#@$X ^9V;81#=:D$)AH8YD(@)2U0F)'0L;X< -P/.SEM:W@0;MF8^?[H8G7I[>KCFYM7S'^Z8+3#B M4@;_*<,ST% &LO3CL2CTCA8"!B[!6-7W?Z1@447MP:V3V3D#+>#1A IN>W:COVB;,YD/7V^K>6D MD;I-E%RE$DF%K"VL!G3 M\YO? S&L[E$G56]5 NV 1E,?IM@"'^"GB -/,0]B%0BCY(M)+T;2[JZA\6G>.7 MP?+=,6CMS1P7UHC2QI,XO$8H$0KE1!C$&WDA84S ,G[IV.I.I>7A!U"E^>A#< 4.,F/DXJB[<%HJY2>P%*P I35^%D.)@5;4Ef|#@RJSWR(K*O!QNSX?"'>P>M>A@_M, HL;C0*(A13A@:,AA?O%%*@+',,,C\RP7#IX] !Z9/#I?BQN.Z@20\C9T"3 MU>.VTI%LFDMW;ZWT7^WTL4A(J1T"V,\?O_\N)? #;(@O5;%4F M[2G@QZ]J<5#)@%ZO|5_>USK%@"V,(K7W*_$U8(2H"IGR%.4$5L[*W->RT2 MATEQX%V_Q3C.UCFPI9H\V7H:7M9>+55HA[- ,\4742>*F,G56]5)NU508*E+0HJ.=#K1?T+'>"#._^,IJR|+P 0A(E@,^.'28!'L1&FBH#,;!]D(DLUUIR%+VDTGZM$B|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{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|+L7U:1;SJ@+.,ITK<:EX881?\,6)RE'0&*' .7> .M.5MN8"GC7^3MUZL3Y?A/2[GHT.2P0H;$Q- =C>#.X.^DP<58(8"$*+4>-!CQ< MSB"AE<28E8+IV(OE3HTZ44S\M!2+"$'N'.QBLW;BTRGX5WA4$8%>WKH9#F5 @"5*E9:*K, MF258%J: ({@0'&TZWHV/XTS{(%R9D$%F^N9KHP$!HSL9 M]HK8 3VSD"74ANG2>&*V(3O]6HW,O^\%Rs?@>=#/5UCDBZWN:_ GZ3:0CUA9Y M+W3@\B)[1C%TA1$L.;2:8D MM: 4E@(;'07*K_M(&EA %KU_>4851B12A:L.8 MC@:D\/[<[]<4I1K TEJ%;"D*:?LA|C^GPL@AW(E18>00L!)7B%CEK;U.;SF> M%_EW7"#G@P?GG6_H+4U"W*#"RQ]CD2@% /;\=D^)B*T*_'QU1@Z"O8J-06HB MS2WQ>@B+S#$5VD(@Y(@>!.0G){B7@DOA05')L,"TH-C$;B&U5(%WEB$C 5K&M MG) J,37$^OGNIYL[0C'CU%D =3B"E+H$P@@.%% <$6NQ"CLP.7C16]=I]?2_ M^9Q+GU%C\\.*.E^\EI$$+.R(${SIC8'3H;2:M P!$N"RP 5"- M)%2?CXUXLTJ3,#87Z@!3.X. :]TS$"=L05T!;"8(L]C$0L*I-]#Y8(<8+C MJ7;%^61$9U7DI4_4.1A2&;"O5RJDA->RS(&&#;2JD84 QOT&$F(A24<>IBKV[M'BJ'->WAX4%@!P65S\|.6G37BQ>U[5-_,7NZ'4\Z5[^V!X42>\0.'(M@A9 JM)'>%8P'^%A 20,N>14,1*]7|AA&OX$>=?'<') N+*@XZ)C|//56$[" M<\60/?(83!JN[\&FKH3(L9$;T.LK6C1^/E %30QWH.>AI Q4#!B5'6\M:!5(G;0O$67HS<); ^7.8]D" M80T=80 3RD")0TD,20H "2Y8B6Q1N-AI-9OT2!QDA@_7-1_K+DSB.R#9PPO MDN?OX2W5LBP<8 :1<*?C%UU=^!TU15PJ!8P/ 6,O3[^<GQ5%>]"YOOCT-6U& MM%BLS;(6 MP$OAGWG'YY/9]'M5AS<8=P55EFE%O%?&%I1.":2 +(0#TP5PXO=*%B|(%#$>< MK"*AGGQ;)W$FX*=/=7QS V>UF8MOQWH[>EC4##9I7M=]_=]JXK1>$S@FLS0MO M-W AP"Ul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|C|P]#I=/ #E =0:CUE?U2$>8?R^BTI1N//R<=X// 9$O?@68 M?I93>RY'|1]R/(L 50:9G3@*%)4VD88<_5V9C _]M>TI=++H\G]E3L[.|>T1 MW0FZM'=LW8R3:]+N6=T>? ^4L/M>>I1DW3U*YFH&T"]MKIZLO7SI7OWK7=D MZ,7[3A\X8LHNI"X_<_PI\T:!R0[(#L'G]63=99;$3C:DU2T* X8UX.C3YDWR MDN&UT^Y5)R/A1|\##/!*== 7EUPW KQN @["YJ"87MHH!REM)Z6[,=MFZVC/P MC-85ZT4^C":MS8)_C;; O!.1&O ME.G>G3Z0+.6Q+Z]'F"TQPI>SJ?:QDI9:9#Q7NEUJLAS(OECN-5 ^"^%,?W3 MKE9J&RL2N'TQW-M51^3#EWMFAOB^T$8E9G7:MME-&M0&4;OR^\MO^>C>]5 M7XGCE_X2W*5LSKZ.MR&N68!73T-E0'T5G*4[)=M:T!

anip:ClassCSpecialStockMember 2024-07-30 0001023024 2024-06-30 0001023024 2023-12-31 0001023024 us-gaap:ConvertiblePreferredStockMember 2024-06-30 0001023024 us-gaap:ConvertiblePreferredStockMember 2023-12-31 0001023024 us-gaap:CommonStockMember 2023-12-31 0001023024 us-gaap:CommonStockMember 2024-06-30 0001023024 anip:ClassCSpecialStockMember 2024-06-30 0001023024 anip:ClassCSpecialStockMember 2023-12-31 0001023024 2024-04-01 2024-06-30 0001023024 2023-04-01 2023-06-30 0001023024 2023-01-01 2023-06-30 0001023024 us-gaap:ConvertiblePreferredStockMember 2023-03-31 0001023024 us-gaap:CommonStockMember 2023-03-31 0001023024 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001023024 us-gaap:TreasuryStockCommonMember 2023-03-31 0001023024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001023024 us-gaap:RetainedEarningsMember 2023-03-31 0001023024 2023-03-31 0001023024 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001023024 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001023024 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001023024 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001023024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001023024 us-gaap:ConvertiblePreferredStockMember 2023-06-30 0001023024 us-gaap:CommonStockMember 2023-06-30 0001023024 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001023024 us-gaap:TreasuryStockCommonMember 2023-06-30 0001023024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001023024 us-gaap:RetainedEarningsMember 2023-06-30 0001023024 2023-06-30 0001023024 us-gaap:ConvertiblePreferredStockMember 2024-03-31 0001023024 us-gaap:CommonStockMember 2024-03-31 0001023024 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001023024 us-gaap:TreasuryStockCommonMember 2024-03-31 0001023024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001023024 us-gaap:RetainedEarningsMember 2024-03-31 0001023024 2024-03-31 0001023024 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001023024 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001023024 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001023024 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001023024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001023024 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001023024 us-gaap:TreasuryStockCommonMember 2024-06-30 0001023024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001023024 us-gaap:RetainedEarningsMember 2024-06-30 0001023024 us-gaap:ConvertiblePreferredStockMember 2022-12-31 0001023024 us-gaap:CommonStockMember 2022-12-31 0001023024 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001023024 us-gaap:TreasuryStockCommonMember 2022-12-31 0001023024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001023024 us-gaap:RetainedEarningsMember 2022-12-31 0001023024 2022-12-31 0001023024 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001023024 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-06-30 0001023024 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001023024 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001023024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001023024 us-gaap:CommonStockMember 2023-12-31 0001023024 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001023024 us-gaap:TreasuryStockCommonMember 2023-12-31 0001023024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001023024 us-gaap:RetainedEarningsMember 2023-12-31 0001023024 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001023024 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-06-30 0001023024 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001023024 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001023024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0001023024 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember anip:OakvilleOntarioFormerManufacturingFacilityMember 2024-02-16 0001023024 anip:SalesOfGenericPharmaceuticalProductsMember 2024-04-01 2024-06-30 0001023024 anip:SalesOfGenericPharmaceuticalProductsMember 2023-04-01 2023-06-30 0001023024 anip:SalesOfGenericPharmaceuticalProductsMember 2024-01-01 2024-06-30 0001023024 anip:SalesOfGenericPharmaceuticalProductsMember 2023-01-01 2023-06-30 0001023024 anip:SalesOfBrandedRoyaltiesAndOtherPharmaceuticalServicesMember 2024-04-01 2024-06-30 0001023024 anip:SalesOfBrandedRoyaltiesAndOtherPharmaceuticalServicesMember 2023-04-01 2023-06-30 0001023024 anip:SalesOfBrandedRoyaltiesAndOtherPharmaceuticalServicesMember 2024-01-01 2024-06-30 0001023024 anip:SalesOfBrandedRoyaltiesAndOtherPharmaceuticalServicesMember 2023-01-01 2023-06-30 0001023024 anip:SalesOfRareDiseasePharmaceuticalProductsMember 2024-04-01 2024-06-30 0001023024 anip:SalesOfRareDiseasePharmaceuticalProductsMember 2023-04-01 2023-06-30 0001023024 anip:SalesOfRareDiseasePharmaceuticalProductsMember 2024-01-01 2024-06-30 0001023024 anip:SalesOfRareDiseasePharmaceuticalProductsMember 2023-01-01 2023-06-30 0001023024 us-gaap:TransferredAtPointInTimeMember 2024-04-01 2024-06-30 0001023024 us-gaap:TransferredAtPointInTimeMember 2023-04-01 2023-06-30 0001023024 us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-06-30 0001023024 us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-06-30 0001023024 us-gaap:TransferredOverTimeMember 2024-04-01 2024-06-30 0001023024 us-gaap:TransferredOverTimeMember 2023-04-01 2023-06-30 0001023024 us-gaap:TransferredOverTimeMember 2024-01-01 2024-06-30 0001023024 us-gaap:TransferredOverTimeMember 2023-01-01 2023-06-30 0001023024 anip:SalesOfContractManufacturedProductsMember 2024-06-30 0001023024 anip:SalesOfContractManufacturedProductsMember 2024-06-30 0001023024 anip:ChargebacksMember 2022-12-31 0001023024 anip:GovernmentRebatesMember 2022-12-31 0001023024 anip:AllowancesForSalesReturnsMember 2022-12-31 0001023024 anip:AdministrativeFeesAndOtherRebatesMember 2022-12-31 0001023024 anip:ReservesForCashDiscountMember 2022-12-31 0001023024 anip:ChargebacksMember 2023-01-01 2023-06-30 0001023024 anip:GovernmentRebatesMember 2023-01-01 2023-06-30 0001023024 anip:AllowancesForSalesReturnsMember 2023-01-01 2023-06-30 0001023024 anip:AdministrativeFeesAndOtherRebatesMember 2023-01-01 2023-06-30 0001023024 anip:ReservesForCashDiscountMember 2023-01-01 2023-06-30 0001023024 anip:ChargebacksMember 2023-06-30 0001023024 anip:GovernmentRebatesMember 2023-06-30 0001023024 anip:AllowancesForSalesReturnsMember 2023-06-30 0001023024 anip:AdministrativeFeesAndOtherRebatesMember 2023-06-30 0001023024 anip:ReservesForCashDiscountMember 2023-06-30 0001023024 anip:ChargebacksMember 2023-12-31 0001023024 anip:GovernmentRebatesMember 2023-12-31 0001023024 anip:AllowancesForSalesReturnsMember 2023-12-31 0001023024 anip:AdministrativeFeesAndOtherRebatesMember 2023-12-31 0001023024 anip:ReservesForCashDiscountMember 2023-12-31 0001023024 anip:ChargebacksMember 2024-01-01 2024-06-30 0001023024 anip:GovernmentRebatesMember 2024-01-01 2024-06-30 0001023024 anip:AllowancesForSalesReturnsMember 2024-01-01 2024-06-30 0001023024 anip:AdministrativeFeesAndOtherRebatesMember 2024-01-01 2024-06-30 0001023024 anip:ReservesForCashDiscountMember 2024-01-01 2024-06-30 0001023024 anip:ChargebacksMember 2024-06-30 0001023024 anip:GovernmentRebatesMember 2024-06-30 0001023024 anip:AllowancesForSalesReturnsMember 2024-06-30 0001023024 anip:AdministrativeFeesAndOtherRebatesMember 2024-06-30 0001023024 anip:ReservesForCashDiscountMember 2024-06-30 0001023024 anip:FourCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001023024 anip:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001023024 anip:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001023024 anip:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001023024 anip:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001023024 anip:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001023024 anip:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001023024 anip:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001023024 anip:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001023024 anip:CustomerThreeMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001023024 anip:CustomerThreeMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001023024 anip:CustomerThreeMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001023024 anip:CustomerThreeMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001023024 anip:CustomerFourMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001023024 anip:CustomerFourMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001023024 anip:CustomerFourMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001023024 anip:CustomerFourMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001023024 anip:AlimeraSciencesIncMember 2024-06-21 0001023024 anip:AlimeraSciencesIncMember anip:MilestonePaymentsMember 2024-06-21 0001023024 anip:AlimeraSciencesIncMember anip:A2026MilestonePaymentMember 2024-06-21 2024-06-21 0001023024 anip:AlimeraSciencesIncMember anip:A2026MilestonePaymentMember 2024-06-21 0001023024 anip:AlimeraSciencesIncMember anip:A2027MilestonePaymentMember 2024-06-21 2024-06-21 0001023024 anip:AlimeraSciencesIncMember anip:A2027MilestonePaymentMember 2024-06-21 0001023024 anip:AlimeraSciencesIncMember 2024-06-21 2024-06-21 0001023024 anip:AlimeraSciencesIncMember anip:JPMorganChaseBankN.A.AndBlackstoneCreditInsuranceMember 2024-06-21 0001023024 anip:AlimeraSciencesIncMember 2024-04-01 2024-06-30 0001023024 anip:AlimeraSciencesIncMember 2024-01-01 2024-06-30 0001023024 anip:OakvilleOntarioCanadaMember 2024-04-01 2024-06-30 0001023024 anip:OakvilleOntarioCanadaMember 2024-01-01 2024-06-30 0001023024 anip:OakvilleOntarioCanadaMember 2024-06-30 0001023024 anip:OakvilleOntarioCanadaMember 2023-04-01 2023-06-30 0001023024 anip:OakvilleOntarioCanadaMember 2023-01-01 2023-06-30 0001023024 us-gaap:EmployeeSeveranceMember anip:OakvilleOntarioCanadaMember 2023-01-01 2023-06-30 0001023024 us-gaap:FacilityClosingMember anip:OakvilleOntarioCanadaMember 2023-01-01 2023-06-30 0001023024 us-gaap:OtherRestructuringMember anip:OakvilleOntarioCanadaMember 2023-01-01 2023-06-30 0001023024 anip:OakvilleOntarioCanadaMember 2023-12-31 0001023024 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember anip:OakvilleOntarioFormerManufacturingFacilityMember 2024-03-28 2024-03-28 0001023024 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember anip:OakvilleOntarioFormerManufacturingFacilityMember 2024-03-28 0001023024 anip:CreditAgreementMember anip:TermLoanMember 2021-11-19 0001023024 anip:CreditAgreementMember us-gaap:LineOfCreditMember 2021-11-19 0001023024 anip:CreditAgreementMember us-gaap:LineOfCreditMember 2024-06-30 0001023024 anip:CreditAgreementMember anip:TermLoanMember 2024-06-30 0001023024 anip:CreditAgreementMember 2021-11-19 2021-11-19 0001023024 anip:CreditAgreementMember us-gaap:LineOfCreditMember 2021-11-19 2021-11-19 0001023024 anip:TermLoanAndDelayedDrawTermLoanMember 2024-06-30 0001023024 anip:TermLoanAndDelayedDrawTermLoanMember 2023-12-31 0001023024 anip:TermLoanMember 2024-06-30 0001023024 us-gaap:InterestRateSwapMember 2021-11-21 0001023024 us-gaap:InterestRateSwapMember 2024-06-30 0001023024 us-gaap:InterestRateSwapMember 2024-01-01 2024-06-30 0001023024 us-gaap:InterestRateSwapMember 2024-04-01 2024-06-30 0001023024 us-gaap:InterestRateSwapMember 2023-04-01 2023-06-30 0001023024 us-gaap:InterestRateSwapMember 2023-01-01 2023-06-30 0001023024 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember anip:OneSupplierMember 2024-04-01 2024-06-30 0001023024 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember anip:OneSupplierMember 2024-01-01 2024-06-30 0001023024 anip:BioSantePharmaceuticalsMember 2013-01-01 2013-12-31 0001023024 anip:WellSpringPharmaServicesIncMember 2018-01-01 2018-12-31 0001023024 anip:NovitiumPharmaMember 2021-01-01 2021-12-31 0001023024 anip:AcquiredAndaIntangibleAssetsMember 2024-06-30 0001023024 anip:AcquiredAndaIntangibleAssetsMember 2023-12-31 0001023024 anip:ProductRightsMember 2024-06-30 0001023024 anip:ProductRightsMember 2023-12-31 0001023024 anip:MarketingAndDistributionRightsMember 2024-06-30 0001023024 anip:MarketingAndDistributionRightsMember 2023-12-31 0001023024 us-gaap:CustomerRelationshipsMember 2024-06-30 0001023024 us-gaap:CustomerRelationshipsMember 2023-12-31 0001023024 us-gaap:InProcessResearchAndDevelopmentMember 2024-06-30 0001023024 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0001023024 srt:MinimumMember 2024-06-30 0001023024 srt:MaximumMember 2024-06-30 0001023024 anip:ClassCSpecialStockMember 2024-06-30 0001023024 anip:ClassCSpecialStockMember 2023-12-31 0001023024 us-gaap:ConvertiblePreferredStockMember anip:PrivateInvestmentInPublicEquityMember 2021-11-19 2021-11-19 0001023024 us-gaap:ConvertiblePreferredStockMember anip:PrivateInvestmentInPublicEquityMember 2021-11-19 0001023024 us-gaap:ConvertiblePreferredStockMember anip:PrivateInvestmentInPublicEquityMember 2024-06-30 0001023024 anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2024-06-30 0001023024 anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2024-01-01 2024-06-30 0001023024 us-gaap:SellingGeneralAndAdministrativeExpensesMember anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2024-04-01 2024-06-30 0001023024 us-gaap:SellingGeneralAndAdministrativeExpensesMember anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2023-04-01 2023-06-30 0001023024 us-gaap:SellingGeneralAndAdministrativeExpensesMember anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2024-01-01 2024-06-30 0001023024 us-gaap:SellingGeneralAndAdministrativeExpensesMember anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2023-01-01 2023-06-30 0001023024 us-gaap:CostOfSalesMember anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2024-04-01 2024-06-30 0001023024 us-gaap:CostOfSalesMember anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2023-04-01 2023-06-30 0001023024 us-gaap:CostOfSalesMember anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2024-01-01 2024-06-30 0001023024 us-gaap:CostOfSalesMember anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2023-01-01 2023-06-30 0001023024 us-gaap:ResearchAndDevelopmentExpenseMember anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2024-04-01 2024-06-30 0001023024 us-gaap:ResearchAndDevelopmentExpenseMember anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2023-04-01 2023-06-30 0001023024 us-gaap:ResearchAndDevelopmentExpenseMember

anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2024-01-01 2024-06-30 0001023024 us-gaap:ResearchAndDevelopmentExpenseMember anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2023-01-01 2023-06-30 0001023024 anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2024-04-01 2024-06-30 0001023024 anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2023-04-01 2023-06-30 0001023024 anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember 2023-01-01 2023-06-30 0001023024 anip:StockIncentivePlanMember us-gaap:SubsequentEventMember 2024-07-12 2024-07-12 0001023024 anip:StockIncentivePlanMember 2024-06-30 0001023024 anip:EmployeesAndConsultantsMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001023024 srt:MinimumMember anip:NonEmployeeDirectorStockOptionMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001023024 srt:MaximumMember anip:NonEmployeeDirectorStockOptionMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001023024 anip:NonEmployeeDirectorStockOptionMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001023024 us-gaap:EmployeeStockOptionMember 2024-06-30 0001023024 anip:EmployeesAndConsultantsMember us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0001023024 anip:NonEmployeeDirectorStockOptionMember us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0001023024 anip:PerformanceBasedRestrictedStockUnitsMember 2024-01-01 2024-06-30 0001023024 anip:MarketPerformanceBasedRestrictedStockUnitsMember 2024-06-30 0001023024 anip:MarketPerformanceBasedRestrictedStockUnitsMember 2024-01-01 2024-06-30 0001023024 anip:MarketPerformanceBasedRestrictedStockUnitsMember 2023-02-28 0001023024 anip:MarketPerformanceBasedRestrictedStockUnitsMember 2023-02-28 2023-02-28 0001023024 anip:PerformanceBasedRestrictedStockUnitsMember 2024-06-30 0001023024 anip:PerformanceBasedRestrictedStockUnitsMember 2023-02-28 0001023024 anip:PerformanceBasedRestrictedStockUnitsMember 2023-02-28 2023-02-28 0001023024 us-gaap:PerformanceSharesMember 2024-02-14 2024-02-14 0001023024 srt:OfficerMember us-gaap:PerformanceSharesMember 2024-02-14 2024-02-14 0001023024 anip:MarketPerformanceBasedRestrictedStockUnitsMember 2024-02-14 2024-02-14 0001023024 anip:PerformanceBasedRestrictedStockUnitsMember 2024-02-14 2024-02-14 0001023024 us-gaap:SellingGeneralAndAdministrativeExpensesMember anip:StockIncentivePlanMember 2024-04-01 2024-06-30 0001023024 us-gaap:SellingGeneralAndAdministrativeExpensesMember anip:StockIncentivePlanMember 2023-04-01 2023-06-30 0001023024 us-gaap:CostOfSalesMember anip:StockIncentivePlanMember 2024-01-01 2024-06-30 0001023024 us-gaap:CostOfSalesMember anip:StockIncentivePlanMember 2023-01-01 2023-06-30 0001023024 us-gaap:ResearchAndDevelopmentExpenseMember anip:StockIncentivePlanMember 2024-04-01 2024-06-30 0001023024 us-gaap:ResearchAndDevelopmentExpenseMember anip:StockIncentivePlanMember 2023-04-01 2023-06-30 0001023024 us-gaap:ResearchAndDevelopmentExpenseMember anip:StockIncentivePlanMember 2024-01-01 2024-06-30 0001023024 us-gaap:ResearchAndDevelopmentExpenseMember anip:StockIncentivePlanMember 2023-01-01 2023-06-30 0001023024 us-gaap:CostOfSalesMember anip:StockIncentivePlanMember 2024-04-01 2024-06-30 0001023024 us-gaap:CostOfSalesMember anip:StockIncentivePlanMember 2023-04-01 2023-06-30 0001023024 us-gaap:SellingGeneralAndAdministrativeExpensesMember anip:StockIncentivePlanMember 2024-01-01 2024-06-30 0001023024 us-gaap:SellingGeneralAndAdministrativeExpensesMember anip:StockIncentivePlanMember 2023-01-01 2023-06-30 0001023024 anip:StockIncentivePlanMember 2024-04-01 2024-06-30 0001023024 anip:StockIncentivePlanMember 2023-04-01 2023-06-30 0001023024 anip:StockIncentivePlanMember 2024-01-01 2024-06-30 0001023024 anip:StockIncentivePlanMember 2023-01-01 2023-06-30 0001023024 us-gaap:EmployeeStockOptionMember 2022-12-31 0001023024 us-gaap:PerformanceSharesMember 2022-12-31 0001023024 us-gaap:RestrictedStockMember 2022-12-31 0001023024 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001023024 us-gaap:PerformanceSharesMember 2023-01-01 2023-06-30 0001023024 us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0001023024 us-gaap:EmployeeStockOptionMember 2023-06-30 0001023024 us-gaap:PerformanceSharesMember 2023-06-30 0001023024 us-gaap:RestrictedStockMember 2023-06-30 0001023024 us-gaap:EmployeeStockOptionMember 2023-12-31 0001023024 us-gaap:PerformanceSharesMember 2023-12-31 0001023024 us-gaap:RestrictedStockMember 2023-12-31 0001023024 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001023024 us-gaap:PerformanceSharesMember 2024-01-01 2024-06-30 0001023024 us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0001023024 us-gaap:PerformanceSharesMember 2024-06-30 0001023024 us-gaap:RestrictedStockMember 2024-06-30 0001023024 2023-04-30 0001023024 anip:UnapprovedProductsMember 2024-04-01 2024-06-30 0001023024 anip:UnapprovedProductsMember 2024-01-01 2024-06-30 0001023024 anip:UnapprovedProductsMember 2023-04-01 2023-06-30 0001023024 anip:UnapprovedProductsMember 2023-01-01 2023-06-30 0001023024 anip:AlvogenIncMember anip:ProductIntellectualPropertyMember 2023-12-27 2023-12-27 0001023024 anip:ContractCustomerMember anip:UnapprovedProductsMember 2024-01-01 2024-06-30 0001023024 anip:ContractCustomerMember anip:UnapprovedProductsMember 2024-04-01 2024-06-30 0001023024 anip:ContractCustomerMember anip:UnapprovedProductsMember 2023-04-01 2023-06-30 0001023024 anip:ContractCustomerMember anip:UnapprovedProductsMember 2023-01-01 2023-06-30 0001023024 2020-12-03 2020-12-03 0001023024 2012-01-01 2012-12-31 0001023024 2024-03-04 0001023024 2023-12-01 2023-12-31 0001023024 anip:NovitiumMember 2023-12-01 2023-12-31 0001023024 2022-09-01 2022-09-30 0001023024 2024-01-01 2024-01-31 0001023024 anip:CGOncologyMember 2024-01-24 0001023024 anip:CGOncologyMember 2024-06-30 0001023024 anip:CGOncologyMember 2024-06-28 0001023024 anip:NovitiumPharmaMember 2024-06-30 0001023024 anip:NovitiumPharmaMember 2023-12-12 2023-12-12 0001023024 anip:NovitiumPharmaMember 2024-02-22 2024-02-22 0001023024 us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember anip:ProfitBasedMilestonePaymentsMember 2024-06-30 0001023024 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001023024 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001023024 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001023024 anip:NovitiumPharmaMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001023024 anip:NovitiumPharmaMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0001023024 anip:NovitiumPharmaMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001023024 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001023024 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001023024 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001023024 anip:NovitiumPharmaMember 2023-12-31 0001023024 anip:NovitiumPharmaMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001023024 anip:NovitiumPharmaMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001023024 anip:NovitiumPharmaMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001023024 us-gaap:ConvertiblePreferredStockMember anip:PrivateInvestmentInPublicEquityMember 2021-03-08 2021-03-08 0001023024 us-gaap:ConvertiblePreferredStockMember anip:PrivateInvestmentInPublicEquityMember 2021-03-08 0001023024 anip:ScitusPharmaServicesMember us-gaap:RelatedPartyMember 2024-04-01 2024-06-30 0001023024 anip:ScitusPharmaServicesMember us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001023024 anip:ScitusPharmaServicesMember us-gaap:RelatedPartyMember 2024-01-01 2024-06-30 0001023024 anip:ScitusPharmaServicesMember us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001023024 anip:SsPharmaLlcMember us-gaap:RelatedPartyMember 2024-04-01 2024-06-30 0001023024 anip:SsPharmaLlcMember us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001023024 anip:SsPharmaLlcMember us-gaap:RelatedPartyMember 2024-01-01 2024-06-30 0001023024 anip:SsPharmaLlcMember us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001023024 anip:SThreeChemicalsPvtLtdMember us-gaap:RelatedPartyMember 2024-04-01 2024-06-30 0001023024 anip:SThreeChemicalsPvtLtdMember us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001023024 anip:SThreeChemicalsPvtLtdMember us-gaap:RelatedPartyMember 2024-01-01 2024-06-30 0001023024 anip:SThreeChemicalsPvtLtdMember us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001023024 us-gaap:RelatedPartyMember 2024-04-01 2024-06-30 0001023024 us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001023024 us-gaap:RelatedPartyMember 2024-01-01 2024-06-30 0001023024 us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001023024 anip:ScitusPharmaServicesMember us-gaap:RelatedPartyMember 2024-06-30 0001023024 anip:SThreeChemicalsPvtLtdMember us-gaap:RelatedPartyMember 2024-06-30 0001023024 anip:EsjayPharmaLlcMember us-gaap:RelatedPartyMember 2024-06-30 0001023024 anip:SsPharmaLlcMember us-gaap:RelatedPartyMember 2024-06-30 0001023024 anip:Mr.ShanmugamAndEsjayMember anip:NovitiumPharmaMember us-gaap:RelatedPartyMember 2023-12-12 2023-12-12 0001023024 anip:ChaliPropertiesLLCMember anip:NovitiumPharmaMember us-gaap:RelatedPartyMember 2023-12-12 2023-12-12 0001023024 anip:Mr.ShanmugamAndEsjayMember anip:NovitiumPharmaMember us-gaap:RelatedPartyMember 2024-02-29 2024-02-29 0001023024 anip:ChaliPropertiesLLCMember anip:NovitiumPharmaMember us-gaap:RelatedPartyMember 2024-02-29 2024-02-29 0001023024 us-gaap:OperatingSegmentsMember anip:GenericsEstablishedBrandsAndOtherMember 2024-04-01 2024-06-30 0001023024 us-gaap:OperatingSegmentsMember anip:GenericsEstablishedBrandsAndOtherMember 2023-04-01 2023-06-30 0001023024 us-gaap:OperatingSegmentsMember anip:GenericsEstablishedBrandsAndOtherMember 2024-01-01 2024-06-30 0001023024 us-gaap:OperatingSegmentsMember anip:GenericsEstablishedBrandsAndOtherMember 2023-01-01 2023-06-30 0001023024 us-gaap:OperatingSegmentsMember anip:RareDiseaseMember 2024-04-01 2024-06-30 0001023024 us-gaap:OperatingSegmentsMember anip:RareDiseaseMember 2023-04-01 2023-06-30 0001023024 us-gaap:OperatingSegmentsMember anip:RareDiseaseMember 2024-01-01 2024-06-30 0001023024 us-gaap:OperatingSegmentsMember anip:RareDiseaseMember 2023-01-01 2023-06-30 0001023024 us-gaap:CorporateNonSegmentMember 2024-04-01 2024-06-30 0001023024 us-gaap:CorporateNonSegmentMember 2023-04-01 2023-06-30 0001023024 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-06-30 0001023024 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-06-30 0001023024 country:US 2024-04-01 2024-06-30 0001023024 country:US 2023-04-01 2023-06-30 0001023024 country:US 2024-01-01 2024-06-30 0001023024 country:US 2023-01-01 2023-06-30 0001023024 country:CA 2024-04-01 2024-06-30 0001023024 country:CA 2023-04-01 2023-06-30 0001023024 country:CA 2024-01-01 2024-06-30 0001023024 country:CA 2023-01-01 2023-06-30 0001023024 country:CA 2023-12-31 0001023024 country:US 2024-06-30 0001023024 country:US 2023-12-31 0001023024 country:IN 2024-06-30 0001023024 country:IN 2023-12-31 shares iso4217:USD iso4217:USD shares anip:facility iso4217:CAD pure anip:contingentValue anip:segment anip:vote anip:tradingDay anip:installment anip:product anip:plaintiff anip:manufacturer anip:claim anip:founder 0001023024 --12-31 2024 Q2 false P7Y P1Y P3Y P3Y P3Y P3Y P3Y P3Y P3Y P3Y P3Y P3Y P3Y P3Y http://fasb.org/us-gaap/2024#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 http://fasb.org/us-gaap/2024#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 http://fasb.org/us-gaap/2024#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 http://fasb.org/us-gaap/2024#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 10-Q true 2024-06-30 false 001-31812 ANI PHARMACEUTICALS, INC DE 58-2301143 210 Main Street West Baudette MN 56623 218 634-3500 Common Stock ANIP NASDAQ Yes Yes Large Accelerated Filer false false false 21030069 10864 240110000 221121000 102784000 97262000 166091000 162079000 125448000 111196000 2867000 0 0 8020000 14001000 17400000 6943000 0 555460000 519816000 51640000 44593000 89506000 90711000 183078000 209009000 28221000 28221000 12848000 12072000 920753000 904422000 850000 850000 48681000 36683000 20357000 16276000 16111000 23786000 12324000 12168000 0 8164000 33897000 29678000 841000 12266000 6917000 5606000 139978000 145477000 284394000 284819000 11092000 11718000 4679000 4809000 44014300 44823000 0.0001 0.0001 1666667 1666667 25000 25000 25000 25000 24850000 24850000 0.0001 0.0001 33333334 33333334 21476115 21063528 20730896 20466953 2000 2000 0.0001 0.0001 781281 781281 10864 10864 10864 10864 0 0 0.0001 0.0001 1666667 1666667 0 0 0 0 0 0 0 412587 263943 20042000 10081000 532497000 514103000 -65025000 -80132000 8328000 8857000 455760000 432749000 920753000 904422000 138040000 116547000 275470000 223333000 57698000 42284000 106855000 79992000 7296000 7374000 17807000 13298000 52821000 38760000 100842000 75228000 14697000 14690000 29383000 29390000 359000 1035000 449000 1996000 0 2000 0 1132000 0 0 5347000 0 132871000 104145000 249989000 201036000 5169000 12402000 25481000 22297000 -2712000 0 6943000 0 -4656000 -7100000 -9256000 -14796000 -88000 -53000 -120000 -87000 -2287000 5249000 23048000 7414000 0 -996000 7128000 -270000 -2287000 6245000 15920000 7684000 407000 407000 813000 813000 -2694000 5838000 15107000 6871000 -0.14 0.30 0.71 0.36 -0.14 0.29 0.70 0.36 19321000 17688000 19210000 17044000 19321000 17855000 19561000 17177000 -2287000 6245000 15920000 7684000 -12000 -17000 -109000 90000 -1066000 2612000 -420000 1469000 -1078000 2595000 -529000 1559000 -3365000 8840000 15391000 9243000 24850000 25000 1000 18226000 408395000 234000 -8643000 11131000 -96252000 339482000 5249000 5249000 14000 537000 537000 40000 1289000 1289000 104000 18000 1000 2184000 80555000 80556000 407000 407000 2595000 2595000 6245000 6245000 24850000 25000 2000 20536000 495488000 248000 -9180000 13726000 -90414000 434472000 24850000 25000 2000 21373000 523628000 393000 -18742000 9406000 -62331000 476813000 7864000 7864000 20000 1300000 1300000 46000 1005000 1005000 65000 8000 407000 407000 -1078000 -1078000 -2287000 -2287000 24850000 25000 2000 21476000 532497000 413000 -20042000 8328000 -65025000 480610000 24850000 25000 1000 17644000 403900000 149000 -5094000 12167000 -97285000 338539000 9587000 9587000 99000 4086000 4086000 45000 1446000 1446000 624000 67000 28000 1000 2184000 80555000 80556000 813000 813000 1559000 1559000 7684000 7684000 24850000 25000 2000 20536000 495488000 248000 -9180000 13726000 -90414000 434472000 24850000 25000 2000 20731000 514103000 264000 -10081000 8857000 -80132000 457599000 14798000 14798000 149000 9961000 9961000 77000 3596000 3596000 606000 74000 12000 813000 813000 -529000 -529000 15920000 15920000 24850000 25000 2000 21476000 532497000 413000 -20042000 8328000 -65025000 480610000 15920000 7684000 14798000 9587000 1205000 -137000 29383000 29390000 6943000 0 750000 61000 198000 1973000 449000 1996000 5347000 0 4012000 7486000 14252000 -1032000 -1777000 -1449000 10379000 -800000 4081000 -577000 -11031000 -261000 156000 -1099000 4219000 -3601000 -6047000 2839000 35683000 42050000 0 4329000 9030000 4850000 13514000 0 4484000 -9179000 1500000 1500000 813000 813000 3596000 1446000 0 80555000 9961000 4086000 12500000 0 -21178000 75602000 18989000 108473000 221121000 53234000 240110000 161707000 221121000 48228000 0 5006000 221121000 53234000 16155000 15456000 17204000 141000 0 4499000 1618000 539000 BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS Overview
 ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, "ANI," the "Company," "we," "us," or "our") is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. The Company is focused on delivering growth by scaling up the Rare Disease business through the launch of Cortrophin Gel, strengthening its generics business with enhanced development capability, innovation in established brands and leveraging its U.S. based manufacturing capabilities. The Company<span style="background-color:#ffffff;color:#000000;font-family:'Times

New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:112%">'s three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. The Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. This action was part of ongoing initiatives to capture operational synergies following our acquisition of Novitium Pharma LLC ("Novitium") in November 2021. The Company has fully completed the transition of the products manufactured or packaged in Oakville to one of the three U.S. based manufacturing sites. In February 2024, the Company entered into an agreement for the sale of the Oakville site, for a price of $19.2 million Canadian Dollars, or approximately $14.2 million, based on the exchange rate at closing. The sale closed on March 28, 2024 (see Note 4).</div><div style="margin-top:10pt;padding-left:18pt">The Company's operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, and possible fluctuations in financial results. </div><div style="margin-top:10pt;padding-left:18pt">Basis of Presentation</div><div style="margin-top:10pt;padding-left:18pt">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company's financial position, results of operations, comprehensive (loss) income, and cash flows. The consolidated balance sheet at December 31, 2023 has been derived from audited financial statements as of that date. The unaudited interim condensed consolidated statements of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the U.S. Securities and Exchange Commission (the "SEC"). Therefore, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited financial statements and notes thereto previously distributed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"), as filed with the SEC.</div><div style="margin-top:10pt;padding-left:18pt">Principles of Consolidation</div><div style="margin-top:10pt;padding-left:18pt">The unaudited interim condensed consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</div><div style="margin-top:10pt;padding-left:18pt">Foreign Currency</div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. The Company currently has a subsidiary located in India. The Canada-based subsidiary conducted its transactions in U.S. dollars and Canadian dollars, but its functional currency was the U.S. dollar. The India-based subsidiary generally conducts its transactions in Indian rupees, which is also its functional currency. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net income. The gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the three and six months ended June 30, 2024 and 2023. Unless otherwise noted, all references to "$" or "dollar" refer to the U.S. dollar. The Company's asset and liability accounts are translated using the current exchange rate as of the balance sheet date, except for shareholders' equity accounts, which are translated using historical rates. Net revenues and expense accounts are translated using an average exchange rate over the period ended on the balance sheet date. Adjustments resulting from the translation of the financial statements of the Company's foreign subsidiaries into U.S. dollars are accumulated as a separate component of shareholders' equity within accumulated other comprehensive (loss) income, net of tax. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the condensed consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, income tax provision or benefit, deferred taxes and valuation allowance, stock-based compensation, revenue recognition, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness. Restructuring Activities The Company defines restructuring activities to include costs directly associated with exit or disposal activities. Such costs include cash employee contractual severance and other termination benefits, one-time employee termination severance and benefits, contract termination charges, impairment and acceleration of depreciation associated with long-lived assets, and other exit or disposal costs. In general, the Company records involuntary employee-related exit and disposal costs when there is a substantive plan for employee severance and related payments are probable and estimable. For one-time termination benefits, including those with a service requirement, expense is recorded when the employees are entitled to receive such benefits and the amount can be reasonably estimated. Expense related to one-time termination benefits with a service requirement is recorded over time, as the service is completed. Contract termination fees and penalties, and other exit and disposal costs are generally recorded as incurred. Restructuring activities are recognized as an operating expense in the condensed consolidated statements of operations. Investment in Equity Securities The Company accounts for its investment in equity securities with a readily determinable fair value in accordance with the guidance in ASC 321, Investments - Equity Securities. The Company presents unrealized gains and losses related to the equity securities, within Unrealized gain on investment in equity securities in its unaudited condensed consolidated statements of operations. Fair values are obtained from quoted prices on the NASDAQ Stock Market, Inc. ("NASDAQ"). Assets Held-for-Sale The Company classifies assets held-for-sale if all held-for-sale criteria is met pursuant to ASC 360-10, Property, Plant and Equipment. Criteria include management commitment to sell the disposal group in its present condition and the sale being deemed probable of being completed within one year. Assets classified as held-for-sale are not depreciated and are measured at the lower of their carrying amount or fair value less cost to sell. The Company assesses the fair value of a disposal group, less any costs to sell, each reporting period it remains classified as held-for-sale and reports any subsequent changes as an adjustment to the carrying value of the disposal group, as long as the new carrying value does not exceed the initial carrying value of the disposal group. The Company determined that the Oakville, Ontario, Canada property met the held-for-sale criteria. As of December 31, 2023, approximately $8.0 million of assets held for sale were recorded on the consolidated balance sheets. The Oakville, Ontario property was sold on March 28, 2024 (see Note 4). Recent Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies and are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures related to significant segment expenses. The guidance in this ASU is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the effect the adoption of this ASU may have on its disclosures in the notes to the consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes guidance to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. These amendments are effective for all public entities for fiscal periods beginning after December 15, 2024, with early adoption permitted. These amendments apply on a prospective basis, but entities have an option to apply it retrospectively for all periods presented. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements. Recent Securities and Exchange Commission Final Rules Issued but Not Yet Effective On March 6, 2024, the SEC adopted new rules that will require registrants to disclose certain climate-related information in their annual reports. The final rule requires disclosure of, among other things: material climate-related risks and their material impacts; activities to mitigate or adapt to such risks; information about a registrant's board of directors' oversight of climate-related risks and management's role in managing material climate-related risks; and information on any climate-related targets or goals that are material to the registrant's business, results of operations, or financial condition. In addition, certain disclosures related to severe weather events and other natural conditions will be required in a registrant'<span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-

weight:400;line-height:112%">s audited financial statements. The required information about climate-related risks will also include disclosure of a registrant's greenhouse gas emissions. The Company will be subject to the applicable requirements of the final rule in our annual reports for fiscal years beginning on January 1, 2025. In April 2024, the SEC voluntarily stayed the rules pending judicial review. The Company is currently evaluating the potential impact of these rules on its consolidated financial statements and related disclosures. 3 3 19200000 14200000 Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company's financial position, results of operations, comprehensive (loss) income, and cash flows. The consolidated balance sheet at December 31, 2023 has been derived from audited financial statements as of that date. The unaudited interim condensed consolidated statements of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the U.S. Securities and Exchange Commission (the "SEC"). Therefore, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited financial statements and notes thereto previously distributed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"), as filed with the SEC. Principles of Consolidation The unaudited interim condensed consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Foreign Currency The Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. The Company currently has a subsidiary located in India. The Canada-based subsidiary conducted its transactions in U.S. dollars and Canadian dollars, but its functional currency was the U.S. dollar. The India-based subsidiary generally conducts its transactions in Indian rupees, which is also its functional currency. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net income. The gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the three and six months ended June 30, 2024 and 2023. Unless otherwise noted, all references to "$" or "dollar" refer to the U.S. dollar. The Company's asset and liability accounts are translated using the current exchange rate as of the balance sheet date, except for shareholders' equity accounts, which are translated using historical rates. Net revenues and expense accounts are translated using an average exchange rate over the period ended on the balance sheet date. Adjustments resulting from the translation of the financial statements of the Company's foreign subsidiaries into U.S. dollars are accumulated as a separate component of shareholders' equity within accumulated other comprehensive (loss) income, net of tax. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the condensed consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, income tax provision or benefit, deferred taxes and valuation allowance, stock-based compensation, revenue recognition, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness. Restructuring Activities The Company defines restructuring activities to include costs directly associated with exit or disposal activities. Such costs include cash employee contractual severance and other termination benefits, one-time employee termination severance and benefits, contract termination charges, impairment and acceleration of depreciation associated with long-lived assets, and other exit or disposal costs. In general, the Company records involuntary employee-related exit and disposal costs when there is a substantive plan for employee severance and related payments are probable and estimable. For one-time termination benefits, including those with a service requirement, expense is recorded when the employees are entitled to receive such benefits and the amount can be reasonably estimated. Expense related to one-time termination benefits with a service requirement is recorded over time, as the service is completed. Contract termination fees and penalties, and other exit and disposal costs are generally recorded as incurred. Restructuring activities are recognized as an operating expense in the condensed consolidated statements of operations. Investment in Equity Securities The Company accounts for its investment in equity securities with a readily determinable fair value in accordance with the guidance in ASC 321, Investments – Equity Securities. The Company presents unrealized gains and losses related to the equity securities, within Unrealized gain on investment in equity securities in its unaudited condensed consolidated statements of operations. Fair values are obtained from quoted prices on the NASDAQ Stock Market, Inc. ("NASDAQ"). Assets Held-for-Sale The Company classifies assets held-for-sale if all held-for-sale criteria is met pursuant to ASC 360-10, Property, Plant and Equipment. Criteria include management commitment to sell the disposal group in its present condition and the sale being deemed probable of being completed within one year. Assets classified as held-for-sale are not depreciated and are measured at the lower of their carrying amount or fair value less cost to sell. The Company assesses the fair value of a disposal group, less any costs to sell, each reporting period it remains classified as held-for-sale and reports any subsequent changes as an adjustment to the carrying value of the disposal group, as long as the new carrying value does not exceed the initial carrying value of the disposal group. The Company determined that the Oakville, Ontario, Canada property met the held-for-sale criteria. As of December 31, 2023, approximately $8.0 million of assets held for sale were recorded on the consolidated balance sheets. The Oakville, Ontario property was sold on March 28, 2024 (see Note 4). 8000000 Recent Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies and are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures related to significant segment expenses. The guidance in this ASU is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the effect the adoption of this ASU may have on its disclosures in the notes to the consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes guidance to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. These amendments are effective for all public entities for fiscal periods beginning after December 15, 2024, with early adoption permitted. These amendments apply on a prospective basis, but entities have an option to apply it retrospectively for all periods presented. The Company does not expect that the adoption of this guidance will have a material impact on its consolidated financial statements. Recent Securities and Exchange Commission Final Rules Issued but Not Yet Effective On March 6, 2024, the SEC adopted new rules that will require registrants to disclose certain climate-related information in their annual reports. The final rule requires disclosure of, among other things: material climate-related risks and their material impacts; activities to mitigate or adapt to such risks; information about a registrant's board of directors' oversight of climate-related risks and management's role in managing material climate-related risks; and information on any climate-related targets or goals that are material to the registrant's business, results of operations, or financial condition. In addition, certain disclosures related to severe weather events and other natural conditions will be required in a registrant's audited financial statements. The required information about climate-related risks will also include disclosure of a registrant's greenhouse gas emissions. The Company will be subject to the applicable requirements of the final rule in our annual reports for fiscal years beginning on January 1, 2025. In April 2024, the SEC voluntarily stayed the rules pending judicial review. The Company is currently evaluating the potential impact of these rules on its consolidated financial statements and related disclosures. REVENUE RECOGNITION AND RELATED ALLOWANCES Revenue Recognition <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized using the following steps: •Identification of the contract, or contracts, with a customer; •Identification of the performance obligations in the contract; •Determination of the transaction price, including the identification and estimation of variable consideration; •Allocation of the transaction price to the performance obligations in the contract; and •Recognition of revenue when we satisfy a performance obligation. Revenues are primarily derived from sales of generic, rare disease, and established brand pharmaceutical products, royalties, and other pharmaceutical services. Revenue is recognized when obligations under the terms of contracts with customers are satisfied, which generally occurs when control of the products sold are transferred to the customer. Variable consideration is estimated after the consideration of applicable information that is reasonably available. The Company generally does not have incremental costs to obtain contracts that would otherwise not have been incurred. The Company does not adjust revenue for the promised amount of consideration for the effects of a significant financing component because our customers generally pay us within 100 days. All revenue recognized in the accompanying unaudited interim condensed consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:41.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:13.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Products and Services (in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Sales of generic pharmaceutical products</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">73,964 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">63,317 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">144,181 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">127,030 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,883 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,926 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45,159 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,669 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Sales of rare disease pharmaceutical products</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49,193 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,304 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">86,130 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,634 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total net revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">138,040 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">116,547 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">275,470 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">223,333 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:40.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td

style="width:12.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Timing of Revenue Recognition (in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Performance obligations transferred at a point in time</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">138,040 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">116,547 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">275,470 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">222,958 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Performance obligations transferred over time</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">375 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">138,040 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">116,547 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">275,470 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">223,333 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> In the three and six months ended June 30, 2024 and 2023, the Company did not incur, and therefore did not defer, any material incremental costs to obtain or fulfill contracts. The Company recognized a decrease of $1.5 million to net revenue from performance obligations satisfied in prior periods during the six months ended June 30, 2024, consisting primarily of revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales. The Company recognized an increase of $5.0 million to net revenue from performance obligations satisfied in prior periods during the six months ended June 30, 2023, consisting primarily of revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales. Additionally, as of June 30, 2024, and December 31, 2023, there was no deferred revenue recorded on the condensed consolidated balance sheets. As of June 30, 2024, the aggregate amount of the transaction price allocated to the remaining performance obligations for all open contract manufacturing customer contracts was $3.0 million, which consists of firm orders for contract manufactured products. The Company recognizes revenue for these performance obligations as they are satisfied, which is anticipated within six months. Variable consideration Sales of pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative and other rebates, and cash discounts. Estimates for these elements of variable consideration require significant judgment. The following table summarizes activity in the condensed consolidated balance sheets for accruals and allowances for the six months ended June 30, 2024 and 2023, respectively: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accruals for Chargebacks, Returns, and Other Allowances</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Chargebacks</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Government
Rebates</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Returns</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Administrative
Fees and Other
Rebates</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span

style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prompt
Payment
Discounts</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at December 31, 2022</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">148,562 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">10,872 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">33,399 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">9,442 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6,488 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Accruals/Adjustments</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">290,826 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,100 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,995 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,606 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,028 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Credits Taken Against Reserve</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(362,253)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10,001)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,596)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(25,177)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12,653)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at June 30, 2023 (1)</td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">77,135 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,971 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29,798 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">9,871 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,863 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at December 31, 2023</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">84,208 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">12,168 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">29,678 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">11,412 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">4,865 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Accruals/Adjustments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">267,779 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,324 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,895 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,970 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,422 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Credits Taken Against Reserve</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(262,541)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13,168)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17,676)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(29,656)

</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11,243)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at June 30, 2024 (1)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">89,446 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12,324 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">33,897 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,726 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,044 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> _____ (1)Chargebacks and Prompt Payment Discounts are included as an offset to accounts receivable in the unaudited interim condensed consolidated balance sheets. Administrative Fees and Other Rebates are included as an offset to accounts receivable or as accrued expenses and other in the unaudited interim condensed consolidated balance sheets. Returns are included in returned goods reserve in the unaudited interim condensed consolidated balance sheets. Government Rebates are included in accrued government rebates in the unaudited interim condensed consolidated balance sheets. Credit Concentration ANI’s customers are primarily wholesale distributors, chain drug stores, group purchasing organizations, and pharmaceutical companies. During the three and six months ended June 30, 2024, there were four customers that accounted for 10% or more of net revenues. During the three months ended June 30, 2023, there were four customers that accounted for 10% or more of net revenues. During the six months ended June 30, 2023, there were three customers that accounted for 10% or more of net revenues. As of June 30, 2024, accounts receivable from these customers totaled 79% of Accounts receivable, net. The four customers represent the total percentage of net revenues as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.333%"><tr><td style="width:1.0%"></td><td style="width:39.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.450%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer 1</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer 2</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer 3</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer 4</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-

color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> All revenue recognized in the accompanying unaudited interim condensed consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:41.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Products and Services (in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Sales of generic pharmaceutical products</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">73,964 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">63,317 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">144,181 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">127,030 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,883 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,926 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45,159 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,669 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Sales of rare disease pharmaceutical products</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49,193 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,304 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">86,130 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,634 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total net revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">138,040 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">116,547 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">275,470 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">223,333 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:40.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Timing of Revenue Recognition (in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman';sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Performance obligations transferred at a point in time</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">138,040 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">116,547 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">275,470 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">222,958 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Performance obligations transferred over time</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">375 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">138,040 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">116,547 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">275,470 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">223,333 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 73964000 63317000 144181000 127030000 14883000 28926000 45159000 55669000 49193000 24304000 86130000 40634000 138040000 116547000 275470000 223333000 138040000 116547000 275470000 222958000 0 0 0 375000 138040000 116547000 275470000 223333000 1500000 5000000.0 3000000.0 P6M The following table summarizes activity in the condensed consolidated balance sheets for accruals and allowances for the six months ended June 30, 2024 and 2023, respectively: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accruals for Chargebacks, Returns, and Other Allowances</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Chargebacks</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Government
Rebates</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Returns</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Administrative
Fees and Other
Rebates</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Prompt
Payment
Discounts</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at December 31, 2022</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">148,562 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">10,872 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">33,399 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">9,442 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6,488 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Accruals/Adjustments</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">290,826 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,100 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,995 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,606 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,028 </td><td style="padding:2px 1pt 2px

0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Credits Taken Against Reserve</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(362,253)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10,001)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,596)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(25,177)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12,653)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at June 30, 2023 (1)</td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">77,135 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,971 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29,798 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">9,871 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,863 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at December 31, 2023</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">84,208 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">12,168 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">29,678 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">11,412 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">4,865 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Accruals/Adjustments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">267,779 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,324 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,895 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,970 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,422 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Credits Taken Against Reserve</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(262,541)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13,168)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17,676)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(29,656)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11,243)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at June 30, 2024 (1)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">89,446 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12,324 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">33,897 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,726 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,044 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> _____ (1)Chargebacks and Prompt Payment Discounts are included as an offset to accounts receivable in the unaudited interim condensed consolidated balance sheets. Administrative Fees and Other Rebates are included as an offset to accounts receivable or as accrued expenses and other in the unaudited interim condensed consolidated balance sheets. Returns are included in returned goods reserve in the unaudited interim condensed consolidated balance sheets. Government

Rebates are included in accrued government rebates in the unaudited interim condensed consolidated balance sheets. 148562000 10872000 33399000 9442000 6488000 290826000 11100000 5995000 25606000 11028000 362253000 10001000 9596000 25177000 12653000 77135000 11971000 29798000 9871000 4863000 84208000 12168000 29678000 11412000 4865000 267779000 13324000 21895000 29970000 11422000 262541000 13168000 17676000 29656000 11243000 89446000 12324000 33897000 11726000 5044000 0.79 The four customers represent the total percentage of net revenues as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.333%"><tr><td style="width:1.0%"></td><td style="width:39.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer 1</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer 2</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer 3</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer 4</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> 0.24 0.32 0.29 0.32 0.12 0.14 0.12 0.14 0.13 0.13 0.11 0.13 0.17 0.10 0.15 0.09 PENDING MERGER AGREEMENT On June 21, 2024, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with Alimera Sciences, Inc., a Delaware corporation ("Alimera") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of the Company ("Merger Sub"), providing for the merger of Merger Sub with and into Alimera (the "Merger"), with Alimera surviving the Merger as a wholly owned indirect subsidiary of the Company. Capitalized terms used herein, but not otherwise defined, have the meanings set forth in the Merger Agreement. At the effective time of the Merger (the "Effective Time"), each outstanding share of common stock, par value $0.01 per share, of Alimera, outstanding immediately prior to the Effective Time will automatically be converted into the right to receive (i) $5.50 in cash, without interest and (ii) one contingent value right (a "CVR"), which shall represent the right to receive the Milestone Payments (as defined below) subject to the terms and conditions set forth in the CVR Agreement (as defined below) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). At or immediately prior to the Effective Time, the Company will enter into a contingent value rights agreement (the "CVR Agreement"), pursuant to which each holder of Alimera Common Stock, as well as holders of Alimera Warrants, Alimera Options, Alimera PSUs, Alimera RSAs and Alimera RSUs, may become entitled to contingent cash payments per CVR (each, a "Milestone Payment"), such payment(s) being contingent upon, and subject to, satisfaction of the Milestones (as defined below).
 When issued, each CVR will entitle the holder (the "Holder") to receive Milestone Payments for 2026 and 2027, upon satisfaction of the applicable Milestones. The Milestone Payments for each CVR will equal the product (rounded to the nearest 1/100 of $0.01) of $0.25 multiplied by a fraction (which in no case will exceed one), and (i) for 2026, equals the amount, if any, by which the 2026 Net Revenue exceeds $140.0 million, divided by $10.0 million (subject to adjustment for the exercise price of Eligible Options), and (ii) for 2027, equals the amount, if any, by which the 2027 Net Revenue exceeds $160.0 million, divided by $15.0 million (subject to adjustment for the exercise price of Eligible Options) (the occurrence of the events in clauses (i) and (ii), each, a "Milestone"). The Merger Agreement requires Alimera, as promptly as reasonably practicable, and in any event within 25 business days following the date of the Merger Agreement, to prepare and file with the SEC a proxy statement for the purpose of seeking stockholder approval to the Merger Agreement. Alimera filed their preliminary proxy statement on July 24, 2024 with the SEC. Consummation of the Merger is subject to certain conditions, including approval by Alimera's stockholders, the absence of any legal restraints restraining, enjoining, preventing, prohibiting or otherwise making illegal the consummation of the Merger, expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and any other specified required regulatory approvals that may be required will have been obtained, and each party's performance of its obligations in all material respects under the Merger Agreement. In connection with the Merger, JPMorgan Chase Bank, N.A. and Blackstone Credit & Insurance (the "Lenders") have committed to provide debt financing for the transaction in an aggregate principal amount equal to $280.0 million, on the terms and subject to the conditions set forth in a commitment letter, dated June 21, 2024 (the "Debt Commitment Letter"). The obligations of the Lenders to provide debt financing under the Debt Commitment Letter are subject to customary conditions, including, without limitation, execution and delivery of definitive

documentation consistent with the Debt Commitment Letter. During the three and six months ended June 30, 2024, the Company incurred approximately $3.5 million in transaction costs related to this pending Merger Agreement, all of which were expensed, and are included in Selling, general, and administrative on the condensed consolidated statements of operations. 0.01 5.50 1 0.01 0.25 140000000 10000000 160000000 15000000 P25D 280000000 3500000 3500000 RESTRUCTURING On March 31, 2023 the Company ceased operations at the Oakville, Ontario, Canada manufacturing plant. This action was part of ongoing initiatives to capture operational synergies following the acquisition of Novitium in November 2021. ANI has fully completed the transition of the products manufactured or packaged in Oakville to one of the Company's three U.S. based manufacturing sites. There were no restructuring activities recorded in the three or six months ended June 30, 2024 and as of June 30, 2024, there was no severance or other employee benefits accrued on the unaudited interim condensed consolidated balance sheet. For the three months ended June 30, 2023, restructuring activities resulted in an immaterial amount of expenses, and for the six months ended June 30, 2023, restructuring activities resulted in expenses of $1.1 million. This included $0.2 million of severance and other employee benefit costs and $0.7 million of accelerated depreciation costs and $0.2 million for other miscellaneous costs. In conjunction with the exit of the Canadian facility, the Company determined that the land and building at the Oakville, Ontario, Canada plant (the "Property") will be sold together and met the criteria to be classified as held for sale as of June 30, 2023. The land and building had a net carrying value of approximately $8.0 million, which was presented as assets held for sale. on the accompanying condensed consolidated balance sheet at December 31, 2023. These assets were part of the Generics, Established Brands, and Other segment. As of June 30, 2024 these assets were sold. On February 15, 2024, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement (the "Agreement") with 1540700 Ontario Limited ("Buyer") for the sale of the Property for a total purchase price of $19.2 million Canadian Dollars, or approximately $14.2 million, based on the exchange rate at closing. On March 28, 2024 the Company completed the sale of the Property. After payment of commissions, real estate taxes, and other related costs of approximately $0.7 million, the Company received a net proceeds of approximately $13.5 million at closing. The gain on the sale of the Property was approximately $5.3 million, recorded in the unaudited interim condensed consolidated statements of operations for the six months ended June 30, 2024. 3 0 0 0 0 1100000 200000 700000 200000 8000000.0 19200000 14200000 700000 13500000 5300000 INDEBTEDNESS Credit Facility On November 19, 2021, the Company completed its acquisition of Novitium pursuant to the terms of the Agreement and Plan of Merger, dated as of March 8, 2021 (the "Novitium Merger Agreement"), by and among the Company, Novitium, Nile Merger Sub LLC, a Delaware limited liability company, and certain other parties, with Novitium becoming a wholly owned subsidiary of the Company. On November 19, 2021, the Company, as borrower, entered into a credit agreement (the "Credit Agreement") with Truist Bank and other lenders, which provides for credit facilities consisting of (i) a senior secured term loan facility in an aggregate principal amount of $300.0 million (the "Term Facility") and (ii) a senior secured revolving credit facility in an aggregate commitment amount of $40.0 million, which may be used for revolving credit loans, swingline loans and letters of credit (the "Revolving Facility," and together with the Term Facility, the "Credit Facility"). The Term Facility proceeds were used to finance the cash portion of the consideration under the Novitium Merger Agreement, repay the existing credit facility, and pay fees, costs and expenses incurred in connection with the merger. The Term Facility matures in November 2027 and the Revolving Facility in November 2026. The Credit Facility has a subjective acceleration clause in case of a material adverse effect. In July 2023, the Company amended its Credit Agreement to transition from London Interbank Offered Rate ("LIBOR") to the Secured Overnight Financing Rate ("SOFR") due to the cessation of LIBOR pursuant to the terms of Amendment No.1 to the Credit Agreement ("Amendment No. 1"). SOFR was applied to the Credit Facility for the interest period (as defined in the Credit Agreement) beginning on August 1, 2023 and replaced all LIBOR terms. The Credit Facility permits both base rate borrowings ("ABR Loans") and Eurodollar rate borrowings ("Eurodollar Loans"), plus a spread as defined in the Credit Facility. As of June 30, 2024, we had not drawn on the Revolving Facility and $40.0 million remained available for borrowing subject to certain conditions. The interest rate under the Term Facility was 11.44% at June 30, 2024. The Company incurred $14.0 million in deferred debt issuance costs associated with the Credit Facility. Costs allocated to the Term Facility are classified as a direct reduction to the current and non-current portion of the borrowings, depending on their nature. Costs allocated to the Revolving Facility are classified as other current and other non-current assets, depending on their nature. A commitment fee of 0.5% per annum is assessed on any unused portion of the Revolving Facility.</div><div style="margin-top:10pt;padding-left:18pt">The Credit Facility is secured by a lien on substantially all of ANI Pharmaceuticals, Inc.'s and its principal domestic subsidiary's assets and any future domestic subsidiary guarantors' assets. The Credit Facility is subject to customary financial and nonfinancial covenants. </div><div style="margin-top:10pt;padding-left:18pt">The carrying value of the current and non-current components of the Term Facility as of June 30, 2024 and December 31, 2023 are:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Current</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Current borrowing on debt</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred financing costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,150)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,150)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Current debt, net of deferred financing costs </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">850 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px

1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">850 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:68.247%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Non-Current</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-current borrowing on debt</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">289,500 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">291,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred financing costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5,106)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6,181)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-current debt, net of deferred financing costs and current component</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">284,394 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">284,819 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of June 30, 2024, outstanding principal was $292.5 million on the Term Facility. Of the $0.6 million of unamortized deferred debt issuance costs allocated to the Revolving Facility, $0.3 million is included in other non-current assets in the unaudited interim condensed consolidated balance sheets, and $0.3 million is included in prepaid expenses and other current assets in the unaudited interim condensed consolidated balance sheets. </div><div style="margin-top:10pt;padding-left:18pt">The contractual maturity of the Term Facility is as follows for the period ending:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Term Facility</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2024 (remainder of the year)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,500 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">285,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">292,500 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt">The following table sets forth the components of total interest expense related to the Term Facility during the three and six months ended June 30, 2024 and 2023, as recognized in the accompanying unaudited interim condensed consolidated statements of operations for the three and six months ended June 30, 2024 and 2023:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contractual coupon</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,848 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,620 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,761 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">

</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14,970 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of finance fees</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">591 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">591 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,182 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,182 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Capitalized interest</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(151)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(277)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(263)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(298)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,288 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,934 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14,680 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15,854 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 300000000.0 40000000.0 40000000.0 0.1144 14000000.0 0.005 <div style="margin-top:10pt;padding-left:18pt">The carrying value of the current and non-current components of the Term Facility as of June 30, 2024 and December 31, 2023 are:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Current</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Current borrowing on debt</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred financing costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,150)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,150)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Current debt, net of deferred financing costs </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">850 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">850 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:68.247%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Non-Current</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-current borrowing on debt</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">289,500 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">291,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred financing costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5,106)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6,181)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-current debt,

net of deferred financing costs and current component</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">284,394 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">284,819 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 3000000 3000000 2150000 2150000 850000 850000 289500000 291000000 5106000 6181000 284394000 284819000 292500000 600000 300000 300000 The contractual maturity of the Term Facility is as follows for the period ending: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Term Facility</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2024 (remainder of the year)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,500 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">285,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">292,500 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1500000 3000000 3000000 285000000 292500000 The following table sets forth the components of total interest expense related to the Term Facility during the three and six months ended June 30, 2024 and 2023, as recognized in the accompanying unaudited interim condensed consolidated statements of operations for the three and six months ended June 30, 2024 and 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contractual coupon</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,848 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,620 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,761 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14,970 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of finance fees</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">591 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">591 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,182 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,182 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Capitalized interest</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(151)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(277)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(263)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(298)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,288 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,934 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman';sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14,680 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15,854 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 6848000 7620000 13761000 14970000 591000 591000 1182000 1182000 151000 277000 263000 298000 7288000 7934000 14680000 15854000 DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY In April 2020, the Company entered into an interest rate swap with Citizens Bank, N.A. to manage its exposure to changes in LIBOR-based interest rates underlying total borrowings under term facilities related to the prior credit agreement, and the interest rate swap matures in December 2026. Concurrent with the termination of the prior credit agreement and entry into the Credit Agreement with Truist Bank, the interest rate swap with a notional value of $168.6 million at origin on November 21, 2021 was novated and Truist Bank is the new counterparty. As described further below, the Company amended its Credit Agreement to transition from LIBOR to SOFR due to the cessation of LIBOR, and accordingly, the interest rate swap transitioned from LIBOR to SOFR. The swap is used to manage changes in SOFR-based interest rates underlying a portion of the borrowing under the Term Facility. The interest rate swap provides an effective fixed interest rate of 2.26% and has been designated as an effective cash flow hedge and therefore qualifies for hedge accounting. As of June 30, 2024, the notional amount of the interest rate swap was $139.4 million and decreased quarterly by approximately $4.0 million until December 2023, after which it remains static until maturity in December 2026. As of June 30, 2024, the fair value of the interest rate swap asset recorded in other non-current assets in the unaudited interim condensed consolidated balance sheets was $7.4 million. As of June 30, 2024, $8.5 million was recorded in accumulated other comprehensive (loss) income, net of tax in the unaudited interim condensed consolidated balance sheets. During the three and six months ended June 30, 2024, the loss on the fair value of the interest rate swaps, net of tax recorded in accumulated other comprehensive (loss) income in the unaudited interim condensed consolidated statements of comprehensive income was approximately $1.1 million and $0.5 million, respectively. Differences between the hedged SOFR rate and the fixed rate are recorded as interest expense in the same period that the related interest is recorded for the Term Facility based on the SOFR rate. In the three and six months ended June 30, 2024, the Company recorded a reduction in interest expense of $1.6 million and $3.2 million in relation to the interest rate swaps, respectively. In the three and six months ended June 30, 2023, the Company recorded a reduction in interest expense of $0.6 million and $1.1 million in relation to the interest rate swaps, respectively. Included in this amount for the three and six months ended June 30, 2024 are reclassifications out of accumulated other comprehensive (loss) income of $0.2 million of interest income and $0.4 million, respectively, related to terminated and de-designated cash flow hedges. Included in this amount for the three and six months ended June 30, 2023 are reclassifications out of accumulated other comprehensive (loss) income of $0.7 million of interest income and $0.7 million, respectively, related to terminated and de-designated cash flow hedges.</div><div style="margin-top:10pt;padding-left:18pt">In conjunction with the amendment of the Credit Agreement (see Note 5), the Company's derivative positions automatically transitioned to SOFR, the designated fallback terms, as determined by the International Swaps and Derivatives Association on August 1, 2023. Concurrently, the Company updated its hedge documentation to reflect the change of the benchmark index, which changed solely as a result of reference rate reform. Under ASC 848, Reference Rate Reform, hedge accounting may continue without de-designation if certain criteria are met. For cash flow hedges in which the designated hedged risk is LIBOR (or another rate that is expected to be discontinued), the guidance allows an entity to assert that it remains probable that the hedged forecasted transaction will occur. The Company applied the optional expedient within ASC 848 to conclude the updates to the hedge relationship due to reference rate reform did not have a material impact on the Company's consolidated financial statements.</div> 168600000 0.0226 139400000 4000000.0 7400000 8500000 1100000 500000 -1600000 -3200000 -600000 -1100000 200000 400000 700000 700000 EARNINGS PER SHARE<div style="margin-top:10pt;padding-left:18pt">Basic earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares of common stock outstanding during the period.</div><div style="margin-top:10pt;padding-left:18pt">For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is calculated by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options, shares to be purchased under the 2016 Employee Stock Purchase Plan ("ESPP"), and performance stock units, using the more dilutive of the treasury stock or the two-class method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share.</div><div style="margin-top:10pt;padding-left:18pt">Unvested restricted shares and Series A convertible preferred stock shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic and diluted earnings (loss) per share excludes from the numerator net income (but not net loss) attributable to the unvested restricted shares and the common shares assumed converted from the preferred shares and excludes the impact of those shares from the denominator. The Company's participating securities do not have a contractual obligation to share in the Company's losses. As such, the net loss was attributed entirely to common stockholders. As the Company has reported a net loss for the three months ended June 30, 2024, diluted net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders for this period.</div><div style="margin-top:10pt;padding-left:18pt">Earnings per share for the three and six months ended June 30, 2024 and 2023 are calculated for basic and diluted earnings per share as follows:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Basic</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Diluted</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Basic</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Diluted</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands, except per share amounts)</td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net (loss) income available to common shareholders</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(2,694)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid

#000;padding:2px 0;text-align:right;vertical-align:bottom">5,838 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(2,694)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,838 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15,107 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,871 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Earnings allocated to participating securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(589)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(589)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,499)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(716)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,474)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(716)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net (loss) income available to common shareholders</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(2,694)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,249 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(2,694)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,249 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(2,694)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,249 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,608 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,155 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,633 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,155 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic Weighted-Average Shares Outstanding</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom">19,321</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom">17,688</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom">19,321</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom">17,688</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,210 </td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom">17,044</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,210 </td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom">17,044</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Dilutive effect of common stock options, ESPP, and performance stock units</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">167</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-

color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">351 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:right;vertical-align:bottom">133</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Diluted Weighted-Average Shares Outstanding</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">19,321</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">17,855</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,561 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">17,177</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff

height:100%">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net (loss) income available to common shareholders</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(2,694)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,838 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15,107 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,871 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15,107 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,871 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Earnings allocated to participating securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(589)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(589)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,499)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(716)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,474)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(716)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net (loss) income available to common shareholders</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(2,694)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,249 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,694</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,249 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,608 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,155 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,633 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,155 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic Weighted-Average Shares Outstanding</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom">19,321</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom">17,688</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom">19,321</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom">17,688</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,210 </td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom">17,044</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,210 </td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-

align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom">17,044</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Dilutive effect of common stock options, ESPP, and performance stock units</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">167</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">351 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">133</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Diluted Weighted-Average Shares Outstanding</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">19,321</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">17,855</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,561 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">17,177</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">(Loss) earnings per share</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.14)</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.30 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.14)</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.29 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.71 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.36 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.70 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.36 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -2694000 5838000 -2694000 5838000 15107000 6871000 15107000 6871000 0 589000 0 589000 1499000 716000 1474000 716000 -2694000 5249000 -2694000 5249000 13608000 6155000 13633000 6155000 19321000 17688000 19321000 17688000 19210000 17044000 19210000 17044000 0 167000 351000 133000 19321000 17855000 19561000 17177000 -0.14 0.30 -0.14 0.29 0.71 0.36 0.70 0.36 2800000 2300000 2500000 2500000 INVENTORIES Inventories consist of the following as of: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Raw materials</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">62,584 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">62,237 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Packaging materials</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,434 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,617 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Work-in-progress</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,775 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,144 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Finished

goods</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47,655 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36,198 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Inventories</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">125,448 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">111,196 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Vendor Concentration Raw materials are sourced for products, including active pharmaceutical ingredients (“API”), from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the cost and time required to validate a second source of supply. As a result, the Company is dependent upon our current vendors to reliably supply the API required for on-going product manufacturing. During the three and six months ended June 30, 2024, approximately 27% and 24%, respectively, of our raw material purchases were from one supplier. During the three and six months ended June 30, 2023, no single vendor represented more than 10% of our raw material inventory purchases. Inventories consist of the following as of: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Raw materials</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">62,584 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">62,237 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Packaging materials</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,434 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,617 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Work-in-progress</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,775 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,144 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Finished goods</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47,655 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36,198 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Inventories</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">125,448 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">111,196 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 62584000 62237000 10434000 9617000 4775000 3144000 47655000 36198000 125448000 111196000 0.27 0.24 GOODWILL AND INTANGIBLE ASSETS Goodwill As a result of the 2013 merger with BioSante Pharmaceuticals, Inc., the Company recorded goodwill of $1.8 million. As a result of the acquisition of WellSpring Pharma Services Inc. in 2018, the Company recorded goodwill of $1.7 million. From the acquisition of Novitium in 2021, the Company recorded goodwill of $24.6 million. As of June 30, 2024, the Company has two operating segments, which were also deemed the Company’s two reporting units, Generics, Established Brands, and Other reporting unit and the Rare Disease reporting unit. All of the goodwill is recorded in the Generics, Established Brands, and Other reporting unit. Goodwill is reviewed for impairment at least annually, at October 31, or more frequently if a triggering event occurs between impairment testing dates. The Company’s impairment assessment begins with a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. Qualitative factors may include, macroeconomic conditions, industry and market considerations, cost factors, and other relevant entity and Company specific events. If, based on the qualitative test, the Company determines that it is “more likely than not” that the fair value of a reporting unit is less than its carrying value, then we evaluate goodwill for impairment by comparing the fair value of our reporting unit to its respective carrying value, including its goodwill. If it is determined that it is “not likely” that the fair value of the reporting unit is less than its carrying value, then no further testing is required. There have been no events or changes in circumstances that would have reduced the fair value of the Generics, Established Brands, and Other reporting unit below its carrying value during the three and six months ended June 30, 2024 and 2023, no impairment charges have been recognized. Intangible Assets The components of definite-lived intangible assets and indefinite-lived intangible assets, other than goodwill, are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.872%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Remaining Weighted Average
Amortization
Period(1)</td></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Carrying
Amount</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Carrying Amount </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:

height:100%">Gross Carrying
Amount</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Carrying Amount</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Definite-Lived Intangible Assets:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Acquired ANDAs intangible assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">209,780 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(112,742)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">97,038 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">209,780 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(100,660)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">109,120 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">4.8 years</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">NDAs and product rights</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">244,871 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(196,451)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,420 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">244,871 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(184,861)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,010 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">2.8 years</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Marketing and distribution rights</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,157 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,752)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,405 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,157 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,271)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,886 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">2.5 years</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Customer relationships</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,900 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,485)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,415 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,900 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,707)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,193 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">4.3 years</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total Definite-Lived Intangible Assets</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">496,708 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(333,430)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">163,278 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">496,708 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(307,499)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">189,209 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">4.1 years</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Indefinite-Lived Intangible Assets:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">In process research and development</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,800 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px

1pt;text-align:right;vertical-align:bottom">19,800 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,800 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,800 </td><td style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total Intangible Assets, net</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">516,508 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(333,430)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">183,078 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">516,508 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(307,499)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">209,009 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr></table> (1)Weighted average amortization period as of June 30, 2024. Definite-lived intangible assets arising from business combinations and other asset acquisitions include intangibles such as Abbreviated New Drug Applications (“ANDAs”), New Drug Applications (“NDAs”) and product rights, marketing and distribution rights, customer relationships, and non-compete agreements. Definite-lived intangible assets are amortized over the estimated period during which the asset is expected to contribute directly or indirectly to future cash flows. Definite-lived intangible assets are stated at cost, net of amortization, and generally amortized over their remaining estimated useful lives, ranging from seven to ten years, based on the straight-line amortization method. In the case of certain NDAs and product rights assets, an accelerated amortization method is used to better match the anticipated economic benefits expected to be provided. Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that these asset might be impaired. Amortization expense for definite-lived intangibles was $13.0 million and $12.8 million for the three months ended June 30, 2024 and 2023, respectively. Amortization expense for definite-lived intangibles was $25.9 million and $25.7 million for the six months ended June 30, 2024 and 2023, respectively. </div><div style="margin-top:10pt;padding-left:18pt">No impairment losses were recognized in the three and six months ended June 30, 2024 and 2023.</div><div style="padding-left:18pt">Indefinite-lived intangible assets other than goodwill include primarily In-Process Research & Development (“IPR&D”) projects. IPR&D intangible assets represent the fair value of technology acquired in a business combination or asset acquisition for which the technology projects are incomplete but have substance or alternative future use. When an IPR&D project is completed (generally upon receipt of regulatory approval), then the IPR&D will be accounted for as a definite-lived intangible asset. </div><div style="margin-top:10pt;padding-left:18pt">Indefinite-lived intangible assets are not amortized, and the Company tests for impairment of indefinite-lived intangible assets when events or circumstances indicate that the carrying value of the assets may not be recoverable, and the Company performs an asset impairment analysis annually, as of October 31. No impairment losses were recognized in the three and six months ended June 30, 2024 and 2023, respectively. </div><div style="margin-top:10pt;padding-left:18pt">Expected future amortization expense for definite-lived intangible assets is as follows:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2024 (remainder of the year)</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">24,896 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47,592 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,107 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,140 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,359 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2029 and thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,184 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">163,278 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1800000 1700000 24600000 2 2 The components of definite-lived intangible assets and indefinite-lived intangible assets, other than goodwill, are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.203%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.872%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Remaining

| Weighted Average
Amortization
Period(1) | (in thousands) | | |

style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">In process research and development</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,800 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,800 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,800 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,800 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:center;vertical-align:bottom">Indefinite</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total Intangible Assets, net</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">516,508 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(333,430)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">183,078 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">516,508 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(307,499)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">209,009 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr></table> (1)Weighted average amortization period as of June 30, 2024, 209780000 112742000 97038000 209780000 100660000 109120000 P4Y9M18D 244871000 196451000 48420000 244871000 184861000 60010000 P2Y9M18D 17157000 14752000 2405000 17157000 14271000 2886000 P2Y6M 24900000 9485000 15415000 24900000 7707000 17193000 P4Y3M18D 496708000 333430000 163278000 496708000 307499000 189209000 P4Y1M6D 19800000 19800000 19800000 516508000 333430000 183078000 516508000 307499000 209009000 P10Y 13000000.0 12800000 25900000 25700000 0 0 0 0 0 0 0 0 Expected future amortization expense for definite-lived intangible assets is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2024 (remainder of the year)</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">24,896 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47,592 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,107 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,140 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,359 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2029 and thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,184 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">163,278 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 24896000 47592000 34107000 25140000 18359000 13184000 163278000 MEZZANINE AND STOCKHOLDERS' EQUITY Stockholders' Equity Authorized shares The Company is authorized to issue up to 33.3 million shares of common stock with a par value of $0.0001 per share, 0.8 million shares of class C special stock with a par value of $0.0001 per share, and 1.7 million shares of undesignated preferred stock with a par value of $0.0001 per share at June 30, 2024. There were 21.5 million and 21.1 million shares of common stock issued and outstanding as of June 30, 2024, respectively, and 20.7 million and 20.5 million shares of common stock issued and outstanding as of December 31, 2023, respectively. Class C Special Stock There were 11 thousand shares of class C special stock issued and outstanding as of June 30, 2024 and December 31, 2023. Each share of class C special stock entitles its holder to one vote per share. Each share of class C special stock is exchangeable, at the option of the holder, for one share of common stock, at an exchange price of $90.00 per share, subject to adjustment upon certain capitalization events. Holders of class C special stock are not entitled to receive dividends or to participate in the distribution of our assets upon liquidation, dissolution, or winding-up the Company. The holders of class C special stock have no cumulative voting, preemptive, subscription, redemption, or sinking fund rights. Mezzanine Equity PIPE Shares Concurrently with the execution of the Novitium Merger Agreement, and as financing for a portion of the acquisition, on March 8, 2021, the Company entered into an Equity Commitment and Investment Agreement with Ampersand

2020 Limited Partnership (the "PIPE Investor"), pursuant to which the PIPE Investor purchased 25,000 shares of Series A Convertible Preferred Stock (the "PIPE Shares"), for a purchase price of $1,000 per share and an aggregate purchase price of $25.0 million on November 19, 2021. The PIPE Shares are classified as mezzanine equity because the shares are mandatorily redeemable for cash upon a change in control, an event that is not solely within the Company's control. The PIPE Shares accrue dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind, and will also participate, on a pro-rata basis, in any dividends that may be declared with respect to our common stock. The PIPE Shares are convertible into common shares at the conversion price of $41.47 (i) beginning two years after their issuance date, at the election of ANI (in which case the PIPE Investor must convert all of the PIPE Shares), if the volume-weighted average price of the common stock for any 20 trading days out of 30 consecutive trading days exceeds 170% of the conversion price, and (ii) at any time after issuance, at the election of the PIPE Investor. As of June 30, 2024, the PIPE shares are currently convertible into a maximum of 602,901 shares of common stock.</div><div style="margin-top:10pt;padding-left:18pt">In case of a liquidation event, the holder of the PIPE Shares will be entitled to receive, in preference to holders of the Company's common stock, the greater of (i) the PIPE Shares' purchase price plus any accrued and unpaid dividends thereon and (ii) the amount the holder of the PIPE Shares would have received in the liquidation event if it had converted its PIPE Shares into common stock. The PIPE Shares will have voting rights, voting as one series with the holders of common stock, on as-converted basis, and will have separate voting rights on any (i) amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the "Certificate") that adversely amends and relates solely to the terms of the PIPE Shares and (ii) issuance of additional Series A convertible preferred stock. In case of a change of control, the PIPE Shares will be redeemed at the greater of (i) the PIPE Shares' purchase price plus any accrued and unpaid dividends thereon and (ii) the change of control transaction consideration that the PIPE Investor would have received if it had converted into shares of common stock.</div><div style="margin-top:10pt;padding-left:18pt">There were 25,000 shares of Series A convertible preferred stock outstanding as of June 30, 2024.</div> 33300000 0.0001 800000 0.0001 1700000 0.0001 21500000 21100000 20700000 20500000 11000 11000 11000 1 1 90.00 25000 1000 25000000.0 0.0650 41.47 P2Y 20 30 1.70 602901 25000 STOCK-BASED COMPENSATION<div style="margin-top:10pt;padding-left:18pt">Employee Stock Purchase Plan</div><div style="margin-top:10pt;padding-left:18pt">In July 2016, the Company commenced administration of the ANI Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan. As of June 30, 2024, the Company had 0.1 million shares of common stock available under the ESPP. Under the ESPP, participants can purchase common shares of the Company's stock at a 15% discount on the lowest share price on the first day of the purchase period or the last day of the purchase period.</div><div style="margin-top:10pt;padding-left:18pt">The following table summarizes ESPP expense incurred under the 2016 Employee Stock Purchase Plan and included in our accompanying unaudited interim condensed consolidated statements of operations:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Selling, general and administrative</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">137 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">70 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">276 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">143 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of sales</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">179 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">359 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">192 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Stock Incentive Plan <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:120%">During the 2024 Annual Meeting of Stockholders held on May 21, 2024, the stockholders of the Company approved an amendment to the Amended and Restated Stock Incentive Plan (the "2022 Plan") (such amendment, the "2024 Stock Plan Amendment" and the 2022 Plan, after giving effect to the 2024 Stock Plan Amendment, the "Amended 2022 Stock Plan"). Subject to adjustment, the 2024 Stock Plan Amendment authorizes the issuance of an additional 1,610,000 shares. As of June 30, 2024, 2.0 million shares of common stock were available for issuance under the Amended 2022 Stock Plan. Stock Options Outstanding stock options to purchase shares of common stock are granted to employees and consultants generally vest over a period of four years and have 10-year contractual terms. Outstanding stock options granted to non-employee directors generally vest over a period of one to four years and have 10-year contractual terms. From time to time, stock options are granted to employees through an inducement grant outside of the Amended 2022 Stock Plan to induce prospective employees to accept employment with the Company (the "Inducement Grants"). The options are granted at an exercise price equal to the fair market value of a share of common stock on the respective grant date and are generally exercisable in four equal annual installments beginning on the first anniversary of the respective grant date. The grants are made pursuant to inducement grants outside of our stockholder approved equity plan as permitted under the Nasdaq Stock Market listing rules. Restricted Stock Awards Restricted stock awards ("RSAs") granted to employees generally vest over a period of four years and RSAs granted to non-officer directors generally vest over a period of one year. During the vesting period, the recipient of the RSAs has full voting rights as a stockholder and would receive dividends, if declared, even though the restricted stock remains subject to transfer restrictions and will generally be forfeited upon termination of the officer prior to vesting. The fair value of each RSA is based on the market value of our stock on the date of grant. Upon vesting, unrestricted shares of common stock are delivered to employees and directors. Performance-Based Restricted Stock Units February 28, 2023 Performance-Based Restricted Stock Units Grant Awards may also be issued in the form of Performance Stock Units ("PSUs"). PSUs represent the right to receive an amount of cash, a number of shares of common stock or a combination of both, contingent upon the achievement of specified performance objectives during a specified performance period. PSUs granted to date vest over a three-year performance period. On February 28, 2023, as part of the Company's equity compensation program, we granted PSUs to certain executives. Of these PSUs, 50% were market performance-based restricted stock units ("MPRSUs"), vesting of which is contingent upon the Company meeting certain total shareholder return ("TSR") levels as compared to a select peer group over the over three years starting January 1, 2023. The MPRSUs are also subject to the recipient's continued employment or service through December 31, 2025. The MPRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (83,942 shares, net of forfeitures) based on TSR performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The estimated grant date fair value per share of the MPRSUs was $68.65 and was calculated using a Monte Carlo simulation model. These MPRSUs are included at 100% of the estimate number of shares at the end of the three-year performance period and are reflected under "Granted" in the table below. The other 50% of the PSUs were performance based restricted stock units ("PRSUs"), vesting of which is contingent upon the Company meeting certain adjusted non-GAAP year-on-year EBITDA growth rates over the over three years starting January 1, 2023. The PRSUs are also subject to the recipient's continued employment or service through December 31, 2025. The PRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (83,942 shares, net of forfeitures) based on adjusted non-GAAP year-on-year EBITDA growth rates. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The Company analyzed progress on the performance goals to assess the likelihood of achievement. The estimated grant date fair value per share of the PRSUs was $41.84 based on the closing price of the stock on the date of grant. These PRSUs are included at 100% of the estimated number of shares at the end of the three-year performance period and are reflected under "Granted" in the table below. February 14, 2024 Performance-Based Restricted Stock Units Grant
 On February 14, 2024, the Company granted 73,588 PSUs to officers and employees of the Company under the 2022 Plan (66,433 to officers of the Company). PSU performance will be measured over a three-year performance period from January 1, 2024 through December 31, 2026 and will cliff-vest contingent upon the achievement of specified performance objectives. Of these PSUs, 50% were MPRSUs, vesting of which is contingent upon the Company meeting certain TSR levels as compared to a select peer group over the over three years starting January 1, 2024, and 50% of the PSUs were PRSUs, vesting of which is contingent upon the Company meeting certain adjusted non-GAAP year-on-year EBITDA growth rates over the over three years starting January 1, 2024. Both the MPRSUs and the PRSUs have a maximum potential to vest at 200%. The estimated grant date fair value per share of the MPRSUs was $85.65 and was calculated using a Monte Carlo simulation model. These MPRSUs are included at 100% of the estimate number of shares at the end of the three-year performance period and are reflected under "Granted" in the table below. The estimated grant date fair value per share of the PRSUs was $56.10 based on the closing price of the stock on the date of grant. These PRSUs are included at 100% of the estimated number of shares at the end of the three-year performance period and are reflected under "Granted" in the table below.</div><div style="margin-top:10pt;padding-left:18pt">The following table summarizes stock-based compensation expense incurred under the Amended 2022 Stock Plan and Inducement Grants included in the accompanying unaudited interim condensed consolidated statements of operations:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Selling, general, and administrative</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,069 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,766 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,301 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8,673 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">334 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">213 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">606 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td

colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">413 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of sales</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">282 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">170 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">532 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">309 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,685 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,149 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14,439 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">9,395 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> A summary of stock options (including Inducement Grants), RSA, and PSU activity under the Amended 2022 Stock Plan and Inducement Grants during the six months ended June 30, 2024 and 2023 is presented below: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Options</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">PSUs</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">RSAs</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Outstanding at December 31, 2022</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">907</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">— </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">1,141</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">3</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">85</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">624</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Options Exercised/RSAs Vested</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">(26)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">— </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">(338)</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> (1) </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(24)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">— </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(46)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Outstanding at June 30, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">860</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">85</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">1,381</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Outstanding at December 31, 2023</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">689</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">84</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,351</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">— </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">74</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">606</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Options Exercised/RSAs Vested</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">(54)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">— </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">(433)</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> (2) </td></tr><tr><td colspan="3" style="background-

color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(12)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Outstanding at June 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">635</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">158</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">1,512</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table> _____ (1)Includes 99 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $4.1 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets. (2)Includes 149 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $10.0 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets.</div> 100000 0.15 <div style="margin-top:10pt;padding-left:18pt">The following table summarizes ESPP expense incurred under the 2016 Employee Stock Purchase Plan and included in our accompanying unaudited interim condensed consolidated statements of operations:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Selling, general, and administrative</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">137 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">70 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">276 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">143 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of sales</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">179 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">359 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">192 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <div

style="margin-top:10pt;padding-left:18pt">The following table summarizes stock-based compensation expense incurred under the Amended 2022 Stock Plan and Inducement Grants included in the accompanying unaudited interim condensed consolidated statements of operations: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Selling, general, and administrative</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,069 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,766 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,301 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8,673 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">334 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">213 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">606 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">413 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of sales</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">282 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">170 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">532 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">309 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,685 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,149 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14,439 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">9,395 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 137000 70000 276000 143000 30000 18000 60000 30000 12000 12000 23000 19000 179000 100000 359000 192000 1610000 2000000.0 P4Y P10Y P4Y P10Y 4 P4Y P1Y 0.50 2 83942 68.65 1 0.50 2 83942 41.84 1 73588 66433 0.50 0.50 2 85.65 1 56.10 1 7069000 4766000 13301000 8673000 334000 213000 606000 413000 282000 170000 532000 309000 7685000 5149000 14439000 9395000 A summary of stock options (including Inducement Grants), RSA, and PSU activity under the Amended 2022 Stock Plan and Inducement Grants during the six months ended June 30, 2024 and 2023 is presented below: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Options</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">PSUs</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">RSAs</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Outstanding at December 31, 2022</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">907</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">1,141</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">3</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">85</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">624</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td

colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Options Exercised/RSAs Vested</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">(26)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">(338)</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> (1) </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(24)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(46)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Outstanding at June 30, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">860</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">85</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">1,381</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Outstanding at December 31, 2023</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">689</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">84</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,351</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">74</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">606</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Options Exercised/RSAs Vested</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">(54)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">(433)</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> (2) </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(12)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Outstanding at June 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">635</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">158</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">1,512</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table> _____ (1)Includes 99 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $4.1 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets. (2)Includes 149 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $10.0 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets. 907000 0 1141000 3000 85000 624000 26000 0 338000 24000 0 46000 860000 85000 1381000 689000 84000 1351000 0 74000 606000 54000 0 433000 0 0 12000 635000 158000 1512000 99000 4100000 149000 10000000.0 INCOME TAXES The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. As of June 30, 2024, a valuation allowance was recorded against consolidated net deferred tax assets of $0.4 million, related solely to deferred tax assets for net operating loss carryforwards in certain U.S. state jurisdictions. The Company uses a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company has not identified any uncertain income tax positions that could have a material impact on the consolidated financial statements. The Company recognizes interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense; the Company did not have any such amounts accrued as of June 30, 2024 and December 31, 2023. The Company is subject to taxation in various U.S. jurisdictions, Canada, and India and all of its income tax returns remain subject to examination by tax authorities due to the availability of NOL carryforwards. For interim periods, the Company recognizes an income tax expense (benefit) based on our estimated annual effective tax rate, calculated on a worldwide consolidated basis, expected for the entire year. The interim annual estimated effective tax rate is based on the statutory tax rates then in effect, as adjusted for estimated changes in estimated permanent differences and excludes certain discrete items whose tax effect, when material, are recognized in the interim period in which they occur. These changes in permanent differences and discrete items result in variances to the effective tax rate from period to period. The Company's estimated annual effective tax rate changes throughout the year as our on-going estimates of pre-tax income, and changes in permanent differences are revised, and as discrete items occur. Global Intangible Low-Taxed Income ("GILTI"), as defined in the Tax Cuts and Jobs Act of 2017, generated from our Canadian and Indian operations is subject to U.S. taxes, with certain defined exemptions, thresholds and credits. For financial reporting purposes the Company has elected to treat GILTI inclusions as a period cost. For the three months ended June 30, 2024, the Company recognized an income tax expense of $0.0 million. The Company's effective tax rate was 0.0% after discrete items for the three months ended June 30, 2024. The effective tax rate differed from the federal statutory rate of 21% primarily due to state taxes, stock based compensation, and non-deductible expenses related to the pending business combination. <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:400;line-height:120%">For the three months ended June 30, 2023, the Company recognized an income tax benefit of $1.0 million. The Company's effective tax rate was (19.0)% for the three months ended June 30, 2023. The effective tax rate differed from the federal statutory rate of 21% primarily due to the recognition of the U.S. federal research and development credit, permanent differences, and discrete tax benefit primarily related to remeasurement of its gross deferred assets due to change in state deferred effective tax rate. For the six months ended June 30, 2024, the Company recognized an income tax expense of $7.1 million. The Company's effective tax rate was 30.9% after discrete items for the six months ended June 30, 2024. The effective tax rate differed from the federal statutory rate of 21% primarily due to state taxes, stock based compensation, tax on the sale of the Oakville, Ontario manufacturing site, and recording of a withholding tax liability on the proceeds of the sale, and non-deductible expenses related to the pending business combination. For the six months ended June 30, 2023, the Company recognized an income tax benefit of $0.3 million. The Company's effective tax rate was (3.7)% for the six months ended June 30, 2023. The effective tax rate differed from the federal statutory rate of 21% primarily due to the recognition of the U.S. federal research and development credit, permanent differences, and discrete tax benefit primarily related to remeasurement of gross deferred assets due to change in state deferred effective tax rate. The Company does not expect that any law changes enacted during the period will have a material impact on the provision for income taxes. 400000 0 0.000 -1000000 -0.190 7100000 0.309 -300000 -0.037 COMMITMENTS AND CONTINGENCIES Operating Leases In April 2023, the Company entered into an agreement to lease additional warehouse space in East Windsor, New Jersey. The lease has a term of five years, and was classified as an operating lease. The lease was capitalized and included in other non-current assets on the accompanying unaudited condensed consolidated balance sheets. Additionally, during October 2023, the Company entered into an amendment for the Middleton, Wisconsin location which expanded the Company's square footage and also extended the termination date to December 2028. Government Regulation
 The Company's products and facilities are subject to regulation by a number of federal and state governmental agencies, such as the Drug Enforcement Administration ("DEA"), the Food and Drug Administration ("FDA"), the Centers for Medicare and Medicaid Services ("CMS"), the Central Drugs Standard Control Organization ("CDSCO"), The Narcotics Control Bureau ("NCB"), and India's Ministry of Health and Family Welfare ("MoHFW"). The FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of ANI's products. The DEA and NCB maintain oversight over products that are considered controlled substances. Unapproved Products
 Four products, Esterified Estrogens and Methyltestosterone ("EEMT"), Opium Tincture, Thyroid Tablets, and Hyoscyamine are sold without approved NDAs or ANDAs. If the FDA took enforcement action against the Company, the Company may be required to seek FDA approval for the group of products or withdraw them from the market. During the three and six months ended June 30, 2024, net revenues from commercial sales of these products for these products totaled $6.8 million and $10.9 million, respectively.
 During the three and six months ended June 30, 2023, net revenues from EEMT and Opium Tincture totaled $3.5 million and $7.2 million, respectively.
 On December 27, 2023, the Company acquired from Alvogen, Inc. the rights to Hyoscyamine for total cash consideration of $2.0 million, which product was launched commercially in February 2024. Contract manufacturing revenues for Hyoscyamine, for both the three and six months ended June 30, 2024 were less than $0.1 million. Contract manufacturing revenues for Hyoscyamine, for three and six months ended June 30, 2023 were $0.5 million and $1.1 million, respectively,
 Legal proceedings
 The Company is, and from time to time may become, involved in various disputes, governmental and/or regulatory inquiries, investigations, government reimbursement related actions and litigation. These matters are complex and subject to significant uncertainties. While we believe that we have valid claims and/or defenses in the litigation and other matters described below, litigation is inherently unpredictable, particularly where the damages sought are substantial or indeterminate or when the proceedings, investigations or inquiries are in the early stages, and the outcome of the proceedings could result in losses, including substantial damages, fines, civil or criminal penalties and injunctive or administrative remedies. We intend to vigorously prosecute and/or defend these matters, as appropriate; however, from time to time, we may settle or otherwise resolve these matters on terms and conditions that we believe are in our best interests. Resolution of any or all claims, investigations, and legal proceedings, individually or in the aggregate, could have a material adverse effect on our results of operations and/or cash flows in any given accounting period or on our overall financial condition. Some of these matters with which we are involved are described below and in our 2023 Form 10-K, and unless otherwise disclosed, we are unable to predict the outcome of the matter or to provide an estimate of the range of reasonably possible material losses. We record accruals for loss contingencies to the extent we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.
 From time to time, we are also involved in other pending proceedings for which, in our opinion based upon facts and circumstances known at the time, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to our results, and therefore remain undisclosed. If and when any reasonably possible losses associated with the resolution of such other pending proceedings, in our opinion, become material, we will disclose such matters.
 Furthermore, like many pharmaceutical manufacturers, we are periodically exposed to product liability claims. The prevalence of these claims could limit our coverage under future insurance policies or cause those policies to become more expensive, which could harm our business, financial condition, and operating results. Recent trends in the product liability and director and officer insurance markets is to exclude matters related to certain classes of drugs. Our policies have been subject to such exclusions which place further potential risk of financial loss on us. Legal fees for litigation-related matters are expensed as incurred and included in the condensed consolidated statements of operations under the selling, general, and administrative expense line item. Commercial Litigation
 On December 3, 2020, class action complaints were filed against the Company on behalf of putative classes of direct and indirect purchasers of the drug Bystolic. On December 23, 2020, six individual purchasers of Bystolic, CVS, Rite Aid, Walgreen, Kroger, Albertsons, and H-E-B, filed complaints against the Company. On March 15, 2021, the plaintiffs in these actions filed amended complaints. All amended complaints were substantively identical. The plaintiffs in these actions alleged that, beginning in 2012, Forest Laboratories, the manufacturer of Bystolic, entered into anticompetitive agreements when settling patent litigation related to Bystolic with seven potential manufacturers of a generic version of Bystolic: Hetero, Torrent, Alkem/Indchemie, Glenmark, Amerigen, Watson, and various of their corporate parents, successors, subsidiaries, and affiliates. ANI itself was not a party to patent litigation with Forest concerning Bystolic and did not settle patent litigation with Forest. The plaintiffs named the Company as a defendant based on the Company's January 8, 2020 Asset Purchase Agreement with Amerigen. Under the terms of the 2020 Asset Purchase Agreement, Amerigen agreed to indemnify ANI for certain liabilities relating to Bystolic, including liabilities that arose prior to closing of the asset purchase. The complaints alleged that the 2013 patent litigation settlement agreement between Forest and Amerigen violated federal and state antitrust laws and state consumer protection laws by delaying the market entry of generic versions of Bystolic. Plaintiffs alleged they paid higher prices as a result of delayed generic competition. Plaintiffs sought damages, trebled or otherwise multiplied under applicable law, injunctive relief, litigation costs and attorneys' fees. The complaints did not specify the amount of damages sought from the Company or other defendants and the Company. The cases were consolidated in the United States District Court for the Southern District of New York. On April 23, 2021, the Company and other defendants filed motions to dismiss the amended complaints. On January 24, 2022, the court dismissed all claims brought by the plaintiffs without prejudice. The court granted the plaintiffs until February 22, 2022 to file amended complaints, which were filed in federal court in the Southern District of New York, on that date. The newly amended complaints contained substantially similar claims. On April 19, 2022, the Company and other defendants filed motions to dismiss the newly amended complaints. After full briefing and oral argument, on February 21, 2023, the court granted the Company and the defendants' motion to dismiss all actions with prejudice. Plaintiffs filed an appeal in the Second Circuit. On May 13, 2024, the Second Circuit affirmed the district court's judgment, dismissing plaintiffs' claims with prejudice. On March 4, 2024, ANI commenced a civil action against CG Oncology, Inc. f/k/a Cold Genesys, Inc. ("CG Oncology") in the Superior Court of the State of Delaware ("Delaware Action"). ANI's complaint alleges that, under an Assignment and Technology Transfer Agreement dated as of November 15, 2010 (the "November 2010 Agreement"), CG Oncology is liable to pay ANI a running royalty of 5% of the worldwide net sales of cretostimogene made by CG Oncology or any affiliate or sublicensee thereof; and that in February 2024, CG Oncology wrongfully repudiated its royalty obligation to ANI. On April 2, 2024, CG Oncology filed an answer and counterclaim (the "CGON Answer and Counterclaim") and concurrently moved for judgment on the pleadings or, in the alternative, for partial summary judgment (the "Motion for Summary Judgment"). CG Oncology's Motion for Summary Judgment seeks judgment declaring that the November 2010 Agreement does not "oblige CGON to pay royalties after expiration of the latest-running assigned patent." CG Oncology also seeks judgment awarding compensatory damages and punitive damages on counterclaims for alleged breach of the November 2010 Agreement and for alleged misappropriation of trade secrets under federal and Delaware state law. On April 22 and 25, 2024, ANI filed its reply to CG Oncology's counterclaims, denying any liability to CG Oncology and asserting additional counterclaims against CG Oncology ("Reply Counterclaims") for alleged breach of the November 2010 Agreement and, in the alternative, for unjust enrichment. ANI's Reply Counterclaims seek judgment (i) declaring that, under Section 3.3 of the November 2010 Agreement, CG Oncology is contractually obligated to pay ANI 5% of the worldwide net sales of cretostimogene made by CG Oncology or any affiliate or sublicensee thereof; (ii) dismissing CG Oncology's counterclaims with prejudice; (iii) awarding ANI

*compensatory damages as provided by law, including damages grounded in restitution and unjust enrichment; (iv) in the event of a judgment in ANI's favor on ANI's fourth counterclaim for unjust enrichment, ordering CG Oncology to re-transfer to ANI ownership of all assets that ANI sold to CG Oncology under the November 2010 Agreement, including, without limitation, all data and documentation comprising IND 12154; and (v) in the event of a judgment in ANI's favor on ANI's fourth counterclaim for unjust enrichment, imposing a constructive trust on all fruits of CG0070-related assets that ANI sold to CG Oncology under the November 2010 Agreement including, without limitation, all data and documentation comprising IND 12154 and any other IND that CG Oncology may have for CG0070. On May 15, 2024, CG Oncology filed a reply to ANI's counterclaims, which generally maintains the positions in the CGON Answer and Counterclaim. The parties are currently engaged in pretrial discovery. On June 7, 2024, CG Oncology filed a motion to stay discovery pending a decision by the court on its Motion for Summary Judgment. The court denied CG Oncology's motion to stay discovery at the conclusion of an oral hearing held on July 11, 2024. The hearing on CG Oncology's Motion for Summary Judgment is currently scheduled for August 22, 2024. ANI intends to vigorously pursue this matter.
 On March 5, 2024, a complaint was filed against ANI by Acella Pharmaceuticals, LLC, in the United States District Court of Minnesota, asserting, among other things, false advertising under the Lanham Act, and unfair trade practices and false advertising under Minnesota law, relating to ANI's natural desiccated thyroid tablets USP. The complaint seeks injunctive relief, actual and consequential damages, disgorgement of profits, and attorneys' fees and costs. On April 16, 2024, ANI filed an answer to Acella's complaint, denying all claims, and asserting certain affirmative defenses, and counterclaims against Acella for false advertising of its thyroid product marketed as NP Thyroid® Tablets, under the Lanham Act, common law unfair competition and unfair and deceptive trade practices and false advertising under Minnesota and Georgia law. ANI seeks injunctive relief, compensatory damages, punitive damages and attorneys' fees and costs. On May 17, 2024, Acella filed a motion to dismiss ANI's counterclaims. On June 7, 2024, ANI filed an amended answer to Acella's complaint and counterclaims. Acella filed a motion to dismiss ANI's amended counterclaims on July 31, 2024. A hearing date has been set for September 11, 2024 on Acella's motion to dismiss. The case is currently in fact discovery until February 1, 2025. ANI disputes any liability in this matter and intends to defend this lawsuit vigorously.
 Patent Litigation
 On November 21, 2023, a complaint was filed against Novitium and certain other defendants in the case of Harmony Biosciences, LLC, Bioprojet Societe Civile de Recherche and Bioprojet Pharma SAS v. AET Pharma US, Inc., Annora Pharma Private Limited, Novitium Pharma LLC, Zenara Pharma Private Limited and Biophore India Pharmaceuticals Private Limited in the United States District Court for the District of Delaware, asserting, among other things, that Novitium's proposed pitolisant hydrochloride drug product, which is subject to Novitium's Abbreviated New Drug Application, infringes certain U.S. patents. The complaint seeks damages, injunctive relief, attorneys' fees and costs. On January 29, 2024, Novitium filed its answer, denying all allegations and asserting counterclaims of non-infringement and invalidity. On February 16, 2024, plaintiffs filed their answer, denying Novitium's counterclaims and asserting certain affirmative defenses against Novitium. On April 15, 2024, the court consolidated Novitium's case and two other cases brought by plaintiffs against Lupin Limited et al, and MSN Pharms. Inc. et al., into one consolidated matter filed in C.A. No. 23-1286-JLH. The case is currently in discovery. The court set a trial date of February 2026. Novitium disputes any liability in this matter. Ranitidine Related Litigation
 Federal Court Multi District Litigation
 ANI and Novitium were named as defendants, along with numerous other brand and generic pharmaceutical manufacturers, wholesale distributors, retail pharmacy chains, and repackagers of ranitidine-containing products, in In re: Zantac/Ranitidine NDMA Litigation (MDL No. 2924), filed in the United District Court for the Southern District of Florida (the "MDL Court"). Plaintiffs allege that defendants failed to disclose and/or concealed the alleged inherent presence of N-Nitrosodimethylamine (or "NDMA") in brand-name Zantac or generic ranitidine and the alleged associated risk of cancer. While ANI was initially a defendant, the lead plaintiff attorneys voluntarily dismissed ANI as a defendant in the Master Complaint. On July 8, 2021, the MDL Court dismissed all claims by all plaintiffs against the generic drug manufacturers with prejudice , on preemption grounds. The MDL Court also dismissed all claims by all plaintiffs against the brand manufacturers on summary judgment. Plaintiffs appealed the MDL Court's dismissals to the Eleventh Circuit Court of Appeals. On November 7, 2022, the Eleventh Circuit affirmed the MDL Court's dismissal of cases brought by third-party payors. The Eleventh Circuit raised questions in the appeals of the other cases about the finality of the MDL Court's judgments, which were resolved in September 2023. Plaintiffs filed opening briefs on April 10, 2024 and generics defendants filed their response on July 25, 2024.
 ANI and Novitium dispute any liability in this matter.
 State Court Personal Injury Litigation
 ANI and Novitium have also been named as defendants in various state lawsuits.
 California. The pending cases in California state court naming generic ranitidine manufacturers were transferred to an existing civil case coordination docket for pretrial proceedings (JCCP) in Alameda County. On September 21, 2023, plaintiffs filed a master complaint in the JCCP alleging strict liability, negligent failure to warn and general negligence, but not naming any generic defendants. In December 2023, the Keller Postman firm filed approximately 200 individual plaintiff short form complaints that name generic defendants. Novitium is named in 28 of the short form complaints which reference the claims for the master complaint, but has not been served. ANI is not named. On February 1, 2024, the generic defendants filed an omnibus demurrer challenging the sufficiency of the Keller Postman complaints, largely on the basis of preemption. On April 23, 2024, the California court granted the demurrer in part, dismissing all design defect claims against the generic defendants with prejudice on preemption grounds, but the court otherwise granted plaintiffs an opportunity for leave to amend their other claims against the generic defendants. Plaintiffs filed an amended master complaint on April 29, 2024. Novitium is named in one case and discovery is currently ongoing.
 Pennsylvania. In September 2022, two complaints were filed naming Novitium as a defendant in Pennsylvania state court, Philadelphia County. On February 16, 2023, the Pennsylvania plaintiffs filed a consolidated long-form complaint against the generic defendants, Plaintiffs v. Actavis, et. al. Civil Action No. 1364. The long-form complaint names Novitium as a defendant. The long form complaint asserts causes of action for negligence, failure to warn, negligent storage and transportation, breach of express warranties, breach of implied warranties, negligent misrepresentation, fraud, strict products liability, wrongful death and survivor actions, and loss of consortium. The complaint includes a prayer for punitive damages. The generic defendants filed their preliminary objections to Plaintiffs' consolidated long-form generic complaint on March 20, 2023. The court dismissed all claims related to failure to warn/design defects on preemption grounds. The court also sustained the generics' preliminary objections relating to the counts of strict liability-design defect and breach of implied warranty to the extent Pennsylvania substantive law applies, effectively dismissing the generic defendants from the case unless and until a non-resident plaintiff names a generic in a short form complaint. Out of an abundance of caution, however, the generics, including Novitium, all filed answers to the long form complaint in June 2023. In January 2024, plaintiffs filed short form complaints naming generic defendants, including Novitium in one complaint. Generic defendants filed joint preliminary objections to the short form complaints based on preemption. The deadline for filing responses to these objections has passed and no amended complaint or response has been filed by plaintiffs against Novitium.
 ANI and Novitium dispute any liability in these matters. P5Y 4 6800000 10900000 3500000 7200000 2000000.0 100000 100000 500000 1100000 6 7 0.05 0.05 200 28 2 1 FAIR VALUE DISCLOSURES Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of our funds. The fair value of short-term financial instruments (primarily accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current liabilities) approximate their carrying values because of their short-term nature. The Term Facility bears an interest rate that fluctuates with the changes in SOFR and, because the variable interest rates approximate market borrowing rates available to us, we believe the carrying values of these borrowings approximated their fair values at June 30, 2024. Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
 Money Market Funds
 Money market funds are readily convertible into cash and the net asset value of each fund on the last day of the reporting period is used to determine its fair value. Money market funds are included in Cash and cash equivalents within the Consolidated Balance Sheet, and is classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company does not adjust the quoted market price for such financial instruments. The fair value of the money market funds as of June 30, 2024 was*

approximately $166.5 million. Interest Rate Swap The fair value of the interest rate swap is estimated based on the present value of projected future cash flows using the SOFR forward rate curve (see Note 6). The model used to value the interest rate swap includes inputs of readily observable market data, a Level 2 input. As described in detail in Note 6, the fair value of the interest rate swap was $7.4 million as of June 30, 2024, and was classified as a non-current asset. CG Oncology Equity Securities The Company currently holds 219,925 shares of common stock in CG Oncology (Nasdaq: CGON). The Company accounts for its investment in CG Oncology equity securities as an equity investment with a readily determinable fair value, as the securities are publicly traded on the Nasdaq Global Select Market. The fair value of the equity securities is based on its closing price on the Nasdaq and is classified within Level 1 of the fair value hierarchy because the equity securities are valued using quoted market prices. The Company does not adjust the quoted market price for such financial instruments. The fair value of the CG Oncology equity securities as of June 30, 2024 was approximately $6.9 million based on a closing market price of $31.57 on June 28, 2024. This amount is classified on the unaudited condensed consolidated statements of operations as Unrealized gain on investment in equity securities. Between 2013 and 2023, CG Oncology securities held by the Company were valued at zero under U.S. GAAP. Contingent Consideration In connection with the acquisition of Novitium, the Company may pay up to $46.5 million in additional consideration related to the achievement of certain milestones, such as milestones on gross profit of Novitium portfolio products over a 24-month period, regulatory filings completed during this 24-month period, and a percentage of net profits on certain products that are launched in the future. The discounted cash flow method used to value this contingent consideration includes inputs which are classified as Level 3 inputs, as the inputs are not based on readily available market data. Pursuant to the terms of the Novitium Merger Agreement, on December 12, 2023, the Company paid $12.5 million of cash consideration to the Company Members, defined as the holders of Novitium ownership interests in the Novitium Merger Agreement, as the holders of Novitium ownership interests, for the achievement of the "ANDA Filing Earn-Out," as defined in the Agreement (Note 15). Furthermore, on February 22, 2024, the Company paid $12.5 million to Company Members of Novitium upon the achievement of the "Gross Profit Earn-Out," as defined in the Agreement (Note 15). The fair value of the contingent consideration was approximately $11.9 million and $24.0 million as of June 30, 2024 and December 31, 2023, respectively, and is reflected as a current and non-current accrued contingent consideration liability in the unaudited interim condensed consolidated balance sheets.</div><div style="margin-top:10pt;padding-left:18pt">The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs as of June 30, 2024:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Payment Type</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Valuation Technique</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unobservable Input</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Assumptions</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Profit-based milestone payments</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">Probability-weighted discounted cash flow</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">Discount rate</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">13%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">Projected fiscal year of payment</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">2025-2035</td></tr></table></div><div style="margin-top:10pt;padding-left:18pt">The following table presents the changes in contingent consideration balances classified as Level 3 for the three and six months ended June 30, 2024 and 2023:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"></td><td style="width:31.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Beginning balance</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,574 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">36,019 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">23,984 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">35,058 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Payment of Gross-Profit earn-out</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12,500)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Change in fair value</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">359 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,035 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">449 </td><td

style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,996 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Ending balance</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,933 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">37,054 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,933 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">37,054 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table presents our financial assets and liabilities accounted for at fair value on a recurring basis as of June 30, 2024 and December 31, 2023, by level within the fair value hierarchy: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)
Description</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value at
June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Money Market Fund</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">166,485 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">166,485 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Interest rate swap</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">7,366 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">7,366 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> CG Oncology - Investment in equity securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,943 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,943 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11,933 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11,933 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Description</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value at
December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Money Market Fund</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">191,841 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">191,841 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Interest rate swap</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6,236 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6,236 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">23,984 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis There are no financial assets or liabilities that are measured at fair value on a non-recurring basis. Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis There are no non-financial assets or liabilities that are measured at fair value on a recurring basis. Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis Long-lived assets, including property, plant, and equipment, right-of-use ("ROU") assets, intangible assets, and goodwill, are measured at fair value on a non-recurring basis, and no such fair value impairment was recognized in the three and six months ended June 30, 2024 and 2023. 166500000 7400000 219925 6900000 31.57 46500000 P24M P24M 12500000 12500000 11900000 24000000.0 The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs as of June 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Type</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Valuation Technique</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unobservable Input</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Assumptions</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Profit-based milestone payments</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">Probability-weighted discounted cash flow</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">Discount rate</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">13%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">Projected fiscal year of payment</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">2025-2035</td></tr></table> 0.13 The following table presents the changes in contingent consideration balances classified as Level 3 for the three and six months ended June 30, 2024 and 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"></td><td style="width:31.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Beginning balance</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,574 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">36,019 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">23,984 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">35,058 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Payment of Gross-Profit earn-out</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12,500)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Change in fair value</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">359 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,035 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">449 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,996 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Ending balance</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,933 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">37,054 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,933 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">37,054 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 11574000 36019000 23984000 35058000 0 0 -12500000 0 359000 1035000 449000 1996000 11933000 37054000 11933000 37054000 The following table presents our financial assets and liabilities accounted for at fair value on a recurring basis as of June 30, 2024 and December 31, 2023, by level within the fair value hierarchy: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)
Description</td><td

colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value at
June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Money Market Fund</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">166,485 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">166,485 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Interest rate swap</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">7,366 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">7,366 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> CG Oncology - Investment in equity securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,943 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,943 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11,933 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Description</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value at
December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3"

style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Money Market Fund</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">191,841 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">191,841 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Interest rate swap</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6,236 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6,236 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">23,984 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">23,984 </td></tr></table> 166485000 166485000 0 0 7366000 0 7366000 0 6943000 6943000 0 0 11933000 0 0 11933000 191841000 191841000 0 0 6236000 0 6236000 0 23984000 0 0 23984000 RELATED PARTY TRANSACTIONS PIPE Shares On March 8, 2021, the Company entered into an Equity Commitment and Investment Agreement with the PIPE Investor, pursuant to which 25,000 shares were purchased for $1,000 per share for an aggregate purchase price of $25.0 million on November 19, 2021. The Chairman of the Company's board of directors is an operating partner of Ampersand Capital Partners, an affiliate of the PIPE Investor.</div><div style="margin-top:10pt;padding-left:18pt">Novitium</div><div style="margin-top:10pt;padding-left:18pt">In connection with the acquisition of Novitium, the Company entered into employment agreements with the two executives and founders of Novitium, Muthusamy Shanmugam, Head of R&D and COO of NJ Operations of ANI, and Chad Gassert, Sr. Vice President, Corporate Development and Strategy of ANI. Both serve as executive officers of the Company and Mr. Shanmugam also serves on the Company's board of directors. Mr. Shanmugam holds a minority interest in Scitus Pharma Services ("Scitus"), which provides clinical research services to Novitium, a majority interest in SS Pharma LLC ("SS Pharma"), which acquires and supplies API to Novitium, a minority interest in Nuray Chemical Private Limited ("Nuray"), which manufactured and supplied API to Novitium in prior periods, a majority interest in Esjay Pharma LLC ("Esjay"), which provides research and development and facilities consulting services, and a minority interest in SThree Chemicals Pvt Ltd ("SThree"), which acquires and supplies API to Novitium. </div><div style="margin-top:10pt;padding-left:18pt">A summary of payments to related parties is presented below:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Scitus Pharma Services</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">580 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,188 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,081 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid

#000;padding:2px 0;text-align:right;vertical-align:bottom">1,905 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">SS Pharma LLC</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">176 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,978 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,245 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,579 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">SThree Chemicals Pvt Ltd</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">683 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,069 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,439 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,166 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,395 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,484 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table> As of June 30, 2024, the outstanding balances due to Scitus, SThree, and Esjay were $0.7 million, $2.2 million, and $46 thousand respectively. There was no outstanding balance due to SS Pharma. On December 12, 2023, the Company paid $12.5 million of cash consideration to the Company Members of Novitium for the achievement of the "ANDA Filing Earn-Out," as defined in the Novitium Merger Agreement, as discussed in Note 2. The Company paid Mr. Shanmugam and Esjay, and Mr. Gassert's company Chali Properties LLC, approximately $6.7 million and $1.9 million, respectively, for their portion of the cash consideration due to them as part of the Novitium acquisition. On February 22, 2024, the Company paid $12.5 million of cash consideration to the Company Members of Novitium for the achievement of the "Gross Profit Earn-Out," as defined in the Novitium Merger Agreement, as discussed in Note 2. The Company paid Mr. Shanmugam and Esjay, and Mr. Gassert's company Chali Properties LLC, approximately $6.7 million and $1.9 million, respectively, for their portion of the cash consideration due to them as part of the Novitium acquisition. 25000 1000 25000000.0 2 <div style="margin-top:10pt;padding-left:18pt">A summary of payments to related parties is presented below:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Scitus Pharma Services</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">580 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,188 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,081 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,905 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">SS Pharma LLC</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">176 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,978 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,245 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,579 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">SThree Chemicals Pvt Ltd</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">683 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"

style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,069 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,439 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,166 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,395 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,484 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table> 580000 1188000 1081000 1905000 176000 1978000 1245000 3579000 683000 0 1069000 0 1439000 3166000 3395000 5484000 700000 2200000 46000 0 12500000 6700000 1900000 12500000 6700000 1900000 SEGMENT REPORTING An operating segment is defined as a component of an entity that engages in business activities from which it may recognize revenues and incur expense, its operating results are regularly reviewed by the entity's chief operating decision maker ("CODM") to make decisions about resources to be allocated to the segment and assess its performance, and its discrete financial information is available. The CODM for the Company is the Chief Executive Officer. The Company is organized into two operating segments as follows: •Generics, Established Brands, and Other - Consists of operations related to the development, manufacturing, and marketing of generic and established brand pharmaceuticals, including those sold through traditional channels, contract manufactured products, product development services, royalties, and other. •Rare Disease - Consists of operations related to the development, manufacturing and marketing of pharmaceuticals used in the treatment of patients with rare conditions. The rare disease segment currently consists of operations related to Cortrophin Gel. The CODM evaluates the two operating segments based on revenues and earnings before interest, income taxes, depreciation, and amortization ("EBITDA"), exclusive of corporate expenses and other expenses not directly allocated or attributable to an operating segment. These expenses include, but are not limited to, certain management, legal, accounting, human resources, insurance, and information technology expenses. The Company does not manage assets of the Company by operating segment, and our CODM does not review asset information by operating segment. Accordingly, the Company does not present total assets by operating segment. Financial information by reportable segment is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.727%"><tr><td style="width:1.0%"></td><td style="width:36.884%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.942%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net Revenues</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Generics, Established Brands, and Other</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">88,847 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">92,243 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">189,340 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">182,699 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Rare Disease</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49,193 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,304 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">86,130 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,634 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net revenues</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">138,040 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">116,547 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">275,470 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">223,333 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Segment earnings before interest, taxes, depreciation and amortization ("EBITDA") and reconciliation to income before income taxes</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Generics, Established Brands, and Other</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">31,631 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">39,937 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">76,937 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">78,765 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Rare Disease</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,344 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,215 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,740 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,964 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,697)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,690)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(29,383)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(29,390)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Corporate and other unallocated expenses(1) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16,109)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17,060)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(26,813)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(30,042)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total operating income </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,169 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,402 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,481 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22,297 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Unrealized (loss) gain on investment in equity securities </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,712)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,943 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Interest expense, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,656)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,100)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,256)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,796)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Other expense, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">(88)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(53)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(120)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(87)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">(Loss) Income Before Income Tax Expense (Benefit)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(2,287)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,249 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">23,048 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,414 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> _____ (1)Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our unaudited interim consolidated statement of operations. This amount also includes the gain on the sale of the Oakville, Ontario site of approximately $5.3 million refer to Note 4 for further information.</div><div style="margin-top:10pt;padding-left:18pt">Geographic Information</div><div style="margin-top:10pt;padding-left:18pt">Operations are currently located in the United States and India. The Company has ceased operations at our Oakville, Ontario, Canada location as of March 31, 2023. The majority of the assets of the Company are located in the United States.</div><div style="margin-top:10pt;padding-left:18pt">The following table depicts the Company's revenue by geographic operations during the following periods:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.181%"><tr><td style="width:1.0%"></td><td style="width:35.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Location of Operations</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">United States</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">138,040 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">116,547 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">275,470 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">222,768 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Canada</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">565 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total Revenue</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">138,040 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">116,547 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">275,470 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">223,333 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table depicts the Company's property, plant and equipment, net according to geographic location, which <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:120%">excludes the land and building at the Company's Canada facility, which was classified as held for sale as of December 31, 2023. These assets had a carrying value of approximately $8.0 million. The land and building at the Canada facility was sold on March 28, 2024, refer to Note 4. The Company's property, plant and equipment are as follows: </div><div style="margin-top:10pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:62.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">United States</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">49,887 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">43,163 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">India</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,753 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,430 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total property and equipment, net</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">51,640 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">44,593 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2 2 <div style="margin-top:10pt;padding-left:18pt">Financial information by reportable segment is as follows:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.727%"><tr><td style="width:1.0%"></td><td style="width:36.884%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.942%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net Revenues</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Generics, Established Brands, and Other</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">88,847 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">92,243 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">189,340 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">182,699 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Rare Disease</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49,193 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,304 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">86,130 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,634 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net revenues</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">138,040 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">116,547 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">275,470 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">223,333 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:700;line-height:100%">Segment earnings before interest, taxes, depreciation and amortization ("EBITDA") and reconciliation to income before income taxes</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Generics, Established Brands, and Other</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">31,631 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">39,937 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">76,937 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">78,765 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Rare Disease</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,344 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,215 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,740 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,964 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,697)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,690)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(29,383)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(29,390)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Corporate and other unallocated expenses(1) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16,109)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17,060)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(26,813)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(30,042)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total operating income </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,169 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,402 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,481 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22,297 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Unrealized (loss) gain on investment in equity securities </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,712)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,943 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Interest expense, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,656)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,100)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,256)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,796)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Other expense, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(88)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(53)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(120)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(87)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">(Loss) Income Before Income Tax Expense (Benefit)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(2,287)</td><td

style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,249 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">23,048 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,414 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> _____ (1)Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our unaudited interim consolidated statement of operations. This amount also includes the gain on the sale of the Oakville, Ontario site of approximately $5.3 million refer to Note 4 for further information.</div> 88847000 92243000 189340000 182699000 49193000 24304000 86130000 40634000 138040000 116547000 275470000 223333000 31631000 39937000 76937000 78765000 4344000 4215000 4740000 2964000 -14697000 -14690000 -29383000 -29390000 -16109000 -17060000 -26813000 -30042000 5169000 12402000 25481000 22297000 -2712000 0 6943000 0 -4656000 -7100000 -9256000 -14796000 -88000 -53000 -120000 -87000 -2287000 5249000 23048000 7414000 5300000 <div style="margin-top:10pt;padding-left:18pt">The following table depicts the Company's revenue by geographic operations during the following periods:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.181%"><tr><td style="width:1.0%"></td><td style="width:35.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Location of Operations</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">United States</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">138,040 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">116,547 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">275,470 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">222,768 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Canada</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">565 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total Revenue</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">138,040 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">116,547 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">275,470 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">223,333 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 138040000 116547000 275470000 222768000 0 0 0 565000 138040000 116547000 275470000 223333000 8000000.0 The Company's property, plant and equipment are as follows: <div style="margin-top:10pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:62.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:16.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">United States</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">49,887 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">43,163 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">India</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,753 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,430 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total property and equipment, net</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">51,640 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">44,593 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 49887000 43163000 1753000 1430000 51640000 44593000 SUBSEQUENT EVENTS On July 12, 2024, the Company filed a Registration Statement on Form S-8 with the SEC, to register under the Securities Act of 1933, as amended, 1,610,000 shares of common stock which may be issued from time to time in accordance with the Company's Amended 2022 Stock Plan. 1610000 false false false false